NewCode,NewCodeDesc,SameSimCode,CPTDesc,Accuracy,Rank,Comments
0045U,"Oncology (breast ductal carcinoma in situ), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence score",81525,"Oncology (colon), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a recurrence score",90.28147664736632,2,Present in Autoproposal
0045U,"Oncology (breast ductal carcinoma in situ), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence score",81519,"Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of 21 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence score",83.87875414457994,,Present Both in MD and Autoproposal
0045U,"Oncology (breast ductal carcinoma in situ), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence score",81541,"Oncology (prostate), mRNA gene expression profiling by real-time RT-PCR of 46 genes (31 content and 15 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a disease-specific mortality risk score",76.10828137996326,,Present in Autoproposal
0045U,"Oncology (breast ductal carcinoma in situ), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence score",81520,"Oncology (breast), mRNA gene expression profiling by hybrid capture of 58 genes (50 content and 8 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a recurrence risk score",75.22593225464738,,Present in Autoproposal
0045U,"Oncology (breast ductal carcinoma in situ), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence score",81521,"Oncology (breast), mRNA, microarray gene expression profiling of 70 content genes and 465 housekeeping genes, utilizing fresh frozen or formalin-fixed paraffin-embedded tissue, algorithm reported as index related to risk of distant metastasis",60.81073254613861,,Present in Autoproposal
0045U,"Oncology (breast ductal carcinoma in situ), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence score",81493,"Coronary artery disease, mRNA, gene expression profiling by real-time RT-PCR of 23 genes, utilizing whole peripheral blood, algorithm reported as a risk score",57.96574470182744,,Present in Autoproposal
0045U,"Oncology (breast ductal carcinoma in situ), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence score",81540,"Oncology (tumor of unknown origin), mRNA, gene expression profiling by real-time RT-PCR of 92 genes (87 content and 5 housekeeping) to classify tumor into main cancer type and subtype, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a probability of a predicted main cancer type and subtype",55.5488691589743,,Present in Autoproposal
0045U,"Oncology (breast ductal carcinoma in situ), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence score",81595,"Cardiology (heart transplant), mRNA, gene expression profiling by real-time quantitative PCR of 20 genes (11 content and 9 housekeeping), utilizing subfraction of peripheral blood, algorithm reported as a rejection risk score",55.3785187613855,,Present in Autoproposal
0045U,"Oncology (breast ductal carcinoma in situ), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence score",81504,"Oncology (tissue of origin), microarray gene expression profiling of > 2000 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as tissue similarity scores",53.81803124174213,,Present in Autoproposal
0045U,"Oncology (breast ductal carcinoma in situ), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence score",0008M,"Oncology (breast), mRNA analysis of 58 genes using hybrid capture, on formalin-fixed paraffin-embedded (FFPE) tissue, prognostic algorithm reported as a risk score",48.44345804262733,,Present in Autoproposal
0046U,"FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia) internal tandem duplication (ITD) variants, quantitative",81245,"FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia), gene analysis; internal tandem duplication (ITD) variants (ie, exons 14, 15)",86.27102899397251,1,Present Both in MD and Autoproposal
0046U,"FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia) internal tandem duplication (ITD) variants, quantitative",81246,"FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia), gene analysis; tyrosine kinase domain (TKD) variants (eg, D835, I836)",65.64583988098762,,Present in Autoproposal
0046U,"FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia) internal tandem duplication (ITD) variants, quantitative",81170,"ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) (eg, acquired imatinib tyrosine kinase inhibitor resistance), gene analysis, variants in the kinase domain",33.67991772697927,,Present in Autoproposal
0046U,"FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia) internal tandem duplication (ITD) variants, quantitative",81310,"NPM1 (nucleophosmin) (eg, acute myeloid leukemia) gene analysis, exon 12 variants",32.88154800843077,,Present in Autoproposal
0046U,"FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia) internal tandem duplication (ITD) variants, quantitative",84510,Tyrosine,31.024952214392155,,Present in Autoproposal
0046U,"FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia) internal tandem duplication (ITD) variants, quantitative",81334,"RUNX1 (runt related transcription factor 1) (eg, acute myeloid leukemia, familial platelet disorder with associated myeloid malignancy), gene analysis, targeted sequence analysis (eg, exons 3-8)",29.233030623250766,,Present in Autoproposal
0046U,"FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia) internal tandem duplication (ITD) variants, quantitative",0023U,"Oncology (acute myelogenous leukemia), DNA, genotyping of internal tandem duplication, p.D835, p.I836, using mononuclear cells, reported as detection or nondetection of FLT3 mutation and indication for or against the use of midostaurin",28.37158277538665,,Present in Autoproposal
0046U,"FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia) internal tandem duplication (ITD) variants, quantitative",81218,"CEBPA (CCAAT/enhancer binding protein [C/EBP], alpha) (eg, acute myeloid leukemia), gene analysis, full gene sequence",20.684937314531908,,Present in Autoproposal
0046U,"FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia) internal tandem duplication (ITD) variants, quantitative",84220,Pyruvate kinase,17.642365834532004,,Present in Autoproposal
0046U,"FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia) internal tandem duplication (ITD) variants, quantitative",81402,"Molecular pathology procedure, Level 3 (eg, >10 SNPs, 2-10 methylated variants, or 2-10 somatic variants [typically using non-sequencing target variant analysis], immunoglobulin and T-cell receptor gene rearrangements, duplication/deletion variants of 1 exon, loss of heterozygosity [LOH], uniparental disomy [UPD]) Chromosome 1p-/19q- (eg, glial tumors), deletion analysis Chromosome 18q- (eg, D18S55, D18S58, D18S61, D18S64, and D18S69) (eg, colon cancer), allelic imbalance assessment (ie, loss of heterozygosity) COL1A1/PDGFB (t(17;22)) (eg, dermatofibrosarcoma protuberans), translocation analysis, multiple breakpoints, qualitative, and quantitative, if performed CYP21A2 (cytochrome P450, family 21, subfamily A, polypeptide 2) (eg, congenital adrenal hyperplasia, 21-hydroxylase deficiency), common variants (eg, IVS2-13G, P30L, I172N, exon 6 mutation cluster [I235N, V236E, M238K], V281L, L307FfsX6, Q318X, R356W, P453S, G110VfsX21, 30-kb deletion variant) ESR1/PGR (receptor 1/progesterone receptor) ratio (eg, breast cancer) IGH@/BCL2 (t(14;18)) (eg, follicular lymphoma), translocation analysis; major breakpoint region (MBR) and minor cluster region (mcr) breakpoints, qualitative or quantitative MEFV (Mediterranean fever) (eg, familial Mediterranean fever), common variants (eg, E148Q, P369S, F479L, M680I, I692del, M694V, M694I, K695R, V726A, A744S, R761H) MPL (myeloproliferative leukemia virus oncogene, thrombopoietin receptor, TPOR) (eg, myeloproliferative disorder), common variants (eg, W515A, W515K, W515L, W515R) TRD@ (T cell antigen receptor, delta) (eg, leukemia and lymphoma), gene rearrangement analysis, evaluation to detect abnormal clonal population Uniparental disomy (UPD) (eg, Russell-Silver syndrome, Prader-Willi/Angelman syndrome), short tandem repeat (STR) analysis",16.64070864387386,,Present in Autoproposal
0047U,"Oncology (prostate), mRNA, gene expression profiling by real-time RT-PCR of 17 genes (12 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a risk score",81525,"Oncology (colon), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a recurrence score",90.96614638583567,2,Present in Autoproposal
0047U,"Oncology (prostate), mRNA, gene expression profiling by real-time RT-PCR of 17 genes (12 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a risk score",81541,"Oncology (prostate), mRNA gene expression profiling by real-time RT-PCR of 46 genes (31 content and 15 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a disease-specific mortality risk score",85.199288802272,,Present Both in MD and Autoproposal
0047U,"Oncology (prostate), mRNA, gene expression profiling by real-time RT-PCR of 17 genes (12 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a risk score",81519,"Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of 21 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence score",81.25550033981588,,Present in Autoproposal
0047U,"Oncology (prostate), mRNA, gene expression profiling by real-time RT-PCR of 17 genes (12 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a risk score",81520,"Oncology (breast), mRNA gene expression profiling by hybrid capture of 58 genes (50 content and 8 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a recurrence risk score",75.15068473223529,,Present in Autoproposal
0047U,"Oncology (prostate), mRNA, gene expression profiling by real-time RT-PCR of 17 genes (12 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a risk score",81521,"Oncology (breast), mRNA, microarray gene expression profiling of 70 content genes and 465 housekeeping genes, utilizing fresh frozen or formalin-fixed paraffin-embedded tissue, algorithm reported as index related to risk of distant metastasis",63.88683178040845,,Present in Autoproposal
0047U,"Oncology (prostate), mRNA, gene expression profiling by real-time RT-PCR of 17 genes (12 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a risk score",81493,"Coronary artery disease, mRNA, gene expression profiling by real-time RT-PCR of 23 genes, utilizing whole peripheral blood, algorithm reported as a risk score",63.81311106577401,,Present in Autoproposal
0047U,"Oncology (prostate), mRNA, gene expression profiling by real-time RT-PCR of 17 genes (12 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a risk score",81595,"Cardiology (heart transplant), mRNA, gene expression profiling by real-time quantitative PCR of 20 genes (11 content and 9 housekeeping), utilizing subfraction of peripheral blood, algorithm reported as a rejection risk score",60.651011050347,,Present in Autoproposal
0047U,"Oncology (prostate), mRNA, gene expression profiling by real-time RT-PCR of 17 genes (12 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a risk score",81540,"Oncology (tumor of unknown origin), mRNA, gene expression profiling by real-time RT-PCR of 92 genes (87 content and 5 housekeeping) to classify tumor into main cancer type and subtype, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a probability of a predicted main cancer type and subtype",58.37385817359919,,Present in Autoproposal
0047U,"Oncology (prostate), mRNA, gene expression profiling by real-time RT-PCR of 17 genes (12 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a risk score",81504,"Oncology (tissue of origin), microarray gene expression profiling of > 2000 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as tissue similarity scores",56.55499689646235,,Present in Autoproposal
0047U,"Oncology (prostate), mRNA, gene expression profiling by real-time RT-PCR of 17 genes (12 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a risk score",81551,"Oncology (prostate), promoter methylation profiling by real-time PCR of 3 genes (GSTP1, APC, RASSF1), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a likelihood of prostate cancer detection on repeat biopsy",55.694375283619294,,Present in Autoproposal
0048U,"Oncology (solid organ neoplasia), DNA, targeted sequencing of protein-coding exons of 468 cancer-associated genes, including interrogation for somatic mutations and microsatellite instability, matched with normal specimens, utilizing formalin-fixed paraffin-embedded tumor tissue, report of clinically significant mutation(s)",0036U,"Exome (ie, somatic mutations), paired formalin-fixed paraffin-embedded tumor tissue and normal specimen, sequence analyses",39.73052545268032,10,Present in Autoproposal
0048U,"Oncology (solid organ neoplasia), DNA, targeted sequencing of protein-coding exons of 468 cancer-associated genes, including interrogation for somatic mutations and microsatellite instability, matched with normal specimens, utilizing formalin-fixed paraffin-embedded tumor tissue, report of clinically significant mutation(s)",81504,"Oncology (tissue of origin), microarray gene expression profiling of > 2000 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as tissue similarity scores",30.66413340552699,,Present in Autoproposal
0048U,"Oncology (solid organ neoplasia), DNA, targeted sequencing of protein-coding exons of 468 cancer-associated genes, including interrogation for somatic mutations and microsatellite instability, matched with normal specimens, utilizing formalin-fixed paraffin-embedded tumor tissue, report of clinically significant mutation(s)",0037U,"Targeted genomic sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden",29.815077400139256,,Present Both in MD and Autoproposal
0048U,"Oncology (solid organ neoplasia), DNA, targeted sequencing of protein-coding exons of 468 cancer-associated genes, including interrogation for somatic mutations and microsatellite instability, matched with normal specimens, utilizing formalin-fixed paraffin-embedded tumor tissue, report of clinically significant mutation(s)",81519,"Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of 21 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence score",27.70348697464464,,Present in Autoproposal
0048U,"Oncology (solid organ neoplasia), DNA, targeted sequencing of protein-coding exons of 468 cancer-associated genes, including interrogation for somatic mutations and microsatellite instability, matched with normal specimens, utilizing formalin-fixed paraffin-embedded tumor tissue, report of clinically significant mutation(s)",81525,"Oncology (colon), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a recurrence score",26.55141173622752,,Present in Autoproposal
0048U,"Oncology (solid organ neoplasia), DNA, targeted sequencing of protein-coding exons of 468 cancer-associated genes, including interrogation for somatic mutations and microsatellite instability, matched with normal specimens, utilizing formalin-fixed paraffin-embedded tumor tissue, report of clinically significant mutation(s)",81520,"Oncology (breast), mRNA gene expression profiling by hybrid capture of 58 genes (50 content and 8 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a recurrence risk score",26.380707922990677,,Present in Autoproposal
0048U,"Oncology (solid organ neoplasia), DNA, targeted sequencing of protein-coding exons of 468 cancer-associated genes, including interrogation for somatic mutations and microsatellite instability, matched with normal specimens, utilizing formalin-fixed paraffin-embedded tumor tissue, report of clinically significant mutation(s)",81521,"Oncology (breast), mRNA, microarray gene expression profiling of 70 content genes and 465 housekeeping genes, utilizing fresh frozen or formalin-fixed paraffin-embedded tissue, algorithm reported as index related to risk of distant metastasis",26.038735303784332,,Present in Autoproposal
0048U,"Oncology (solid organ neoplasia), DNA, targeted sequencing of protein-coding exons of 468 cancer-associated genes, including interrogation for somatic mutations and microsatellite instability, matched with normal specimens, utilizing formalin-fixed paraffin-embedded tumor tissue, report of clinically significant mutation(s)",81551,"Oncology (prostate), promoter methylation profiling by real-time PCR of 3 genes (GSTP1, APC, RASSF1), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a likelihood of prostate cancer detection on repeat biopsy",25.813490789861337,,Present in Autoproposal
0048U,"Oncology (solid organ neoplasia), DNA, targeted sequencing of protein-coding exons of 468 cancer-associated genes, including interrogation for somatic mutations and microsatellite instability, matched with normal specimens, utilizing formalin-fixed paraffin-embedded tumor tissue, report of clinically significant mutation(s)",0008M,"Oncology (breast), mRNA analysis of 58 genes using hybrid capture, on formalin-fixed paraffin-embedded (FFPE) tissue, prognostic algorithm reported as a risk score",25.194525403830536,,Present in Autoproposal
0048U,"Oncology (solid organ neoplasia), DNA, targeted sequencing of protein-coding exons of 468 cancer-associated genes, including interrogation for somatic mutations and microsatellite instability, matched with normal specimens, utilizing formalin-fixed paraffin-embedded tumor tissue, report of clinically significant mutation(s)",0019U,"Oncology, RNA, gene expression by whole transcriptome sequencing, formalin-fixed paraffin embedded tissue or fresh frozen tissue, predictive algorithm reported as potential targets for therapeutic agents",24.97733887680606,,Present in Autoproposal
0049U,"NPM1 (nucleophosmin) (eg, acute myeloid leukemia) gene analysis, quantitative",81310,"NPM1 (nucleophosmin) (eg, acute myeloid leukemia) gene analysis, exon 12 variants",83.48627595061149,1,Present Both in MD and Autoproposal
0049U,"NPM1 (nucleophosmin) (eg, acute myeloid leukemia) gene analysis, quantitative",81334,"RUNX1 (runt related transcription factor 1) (eg, acute myeloid leukemia, familial platelet disorder with associated myeloid malignancy), gene analysis, targeted sequence analysis (eg, exons 3-8)",45.43164374034911,,Present in Autoproposal
0049U,"NPM1 (nucleophosmin) (eg, acute myeloid leukemia) gene analysis, quantitative",81218,"CEBPA (CCAAT/enhancer binding protein [C/EBP], alpha) (eg, acute myeloid leukemia), gene analysis, full gene sequence",41.57566612234574,,Present in Autoproposal
0049U,"NPM1 (nucleophosmin) (eg, acute myeloid leukemia) gene analysis, quantitative",81245,"FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia), gene analysis; internal tandem duplication (ITD) variants (ie, exons 14, 15)",34.52504356575187,,Present in Autoproposal
0049U,"NPM1 (nucleophosmin) (eg, acute myeloid leukemia) gene analysis, quantitative",81272,"KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) (eg, gastrointestinal stromal tumor [GIST], acute myeloid leukemia, melanoma), gene analysis, targeted sequence analysis (eg, exons 8, 11, 13, 17, 18)",30.831942075910735,,Present in Autoproposal
0049U,"NPM1 (nucleophosmin) (eg, acute myeloid leukemia) gene analysis, quantitative",81246,"FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia), gene analysis; tyrosine kinase domain (TKD) variants (eg, D835, I836)",30.731045978375494,,Present in Autoproposal
0049U,"NPM1 (nucleophosmin) (eg, acute myeloid leukemia) gene analysis, quantitative",S3819,COMPLETE GENE SEQUENCE ANALYSIS; BRCA2 GENE,24.251513211111313,,Present in Autoproposal
0049U,"NPM1 (nucleophosmin) (eg, acute myeloid leukemia) gene analysis, quantitative",S3818,COMPLETE GENE SEQUENCE ANALYSIS; BRCA1 GENE,24.251513211111313,,Present in Autoproposal
0049U,"NPM1 (nucleophosmin) (eg, acute myeloid leukemia) gene analysis, quantitative",S3828,COMPLETE GENE SEQUENCE ANALYSIS; MLH1 GENE,24.198660089957954,,Present in Autoproposal
0049U,"NPM1 (nucleophosmin) (eg, acute myeloid leukemia) gene analysis, quantitative",S3829,COMPLETE GENE SEQUENCE ANALYSIS; MSH2 GENE,24.141043055858376,,Present in Autoproposal
0050U,"Targeted genomic sequence analysis panel, acute myelogenous leukemia, DNA analysis, 194 genes, interrogation for sequence variants, copy number variants or rearrangements",0022U,"Targeted genomic sequence analysis panel, non-small cell lung neoplasia, DNA and RNA analysis, 23 genes, interrogation for sequence variants and rearrangements, reported as presence/absence of variants and associated therapy(ies) to consider",61.5644352914064,5,Present in Autoproposal
0050U,"Targeted genomic sequence analysis panel, acute myelogenous leukemia, DNA analysis, 194 genes, interrogation for sequence variants, copy number variants or rearrangements",0037U,"Targeted genomic sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden",59.523473115999,,Present in Autoproposal
0050U,"Targeted genomic sequence analysis panel, acute myelogenous leukemia, DNA analysis, 194 genes, interrogation for sequence variants, copy number variants or rearrangements",81445,"Targeted genomic sequence analysis panel, solid organ neoplasm, DNA analysis, and RNA analysis when performed, 5-50 genes (eg, ALK, BRAF, CDKN2A, EGFR, ERBB2, KIT, KRAS, NRAS, MET, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and copy number variants or rearrangements, if performed",56.98695329948749,,Present in Autoproposal
0050U,"Targeted genomic sequence analysis panel, acute myelogenous leukemia, DNA analysis, 194 genes, interrogation for sequence variants, copy number variants or rearrangements",81450,"Targeted genomic sequence analysis panel, hematolymphoid neoplasm or disorder, DNA analysis, and RNA analysis when performed, 5-50 genes (eg, BRAF, CEBPA, DNMT3A, EZH2, FLT3, IDH1, IDH2, JAK2, KRAS, KIT, MLL, NRAS, NPM1, NOTCH1), interrogation for sequence variants, and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed",53.33223883853098,,Present in Autoproposal
0050U,"Targeted genomic sequence analysis panel, acute myelogenous leukemia, DNA analysis, 194 genes, interrogation for sequence variants, copy number variants or rearrangements",81455,"Targeted genomic sequence analysis panel, solid organ or hematolymphoid neoplasm, DNA analysis, and RNA analysis when performed, 51 or greater genes (eg, ALK, BRAF, CDKN2A, CEBPA, DNMT3A, EGFR, ERBB2, EZH2, FLT3, IDH1, IDH2, JAK2, KIT, KRAS, MLL, NPM1, NRAS, MET, NOTCH1, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and copy number variants or rearrangements, if performed",48.60062450808007,,Present Both in MD and Autoproposal
0050U,"Targeted genomic sequence analysis panel, acute myelogenous leukemia, DNA analysis, 194 genes, interrogation for sequence variants, copy number variants or rearrangements",0028U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, copy number variants, common variants with reflex to targeted sequence analysis",46.64875285954143,,Present in Autoproposal
0050U,"Targeted genomic sequence analysis panel, acute myelogenous leukemia, DNA analysis, 194 genes, interrogation for sequence variants, copy number variants or rearrangements",81407,"Molecular pathology procedure, Level 8 (eg, analysis of 26-50 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of >50 exons, sequence analysis of multiple genes on one platform)",36.631862927646424,,Present in Autoproposal
0050U,"Targeted genomic sequence analysis panel, acute myelogenous leukemia, DNA analysis, 194 genes, interrogation for sequence variants, copy number variants or rearrangements",81228,"Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number variants (eg, bacterial artificial chromosome [BAC] or oligo-based comparative genomic hybridization [CGH] microarray analysis)",32.9589527807549,,Present in Autoproposal
0050U,"Targeted genomic sequence analysis panel, acute myelogenous leukemia, DNA analysis, 194 genes, interrogation for sequence variants, copy number variants or rearrangements",81405,"Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25 exons, regionally targeted cytogenomic array analysis)",32.700273697484484,,Present in Autoproposal
0050U,"Targeted genomic sequence analysis panel, acute myelogenous leukemia, DNA analysis, 194 genes, interrogation for sequence variants, copy number variants or rearrangements",81229,Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for chromosomal abnormalities,32.32513077673099,,Present in Autoproposal
0051U,"Prescription drug monitoring, evaluation of drugs present by LC-MS/MS, urine, 31 drug panel, reported as quantitative results, detected or not detected, per date of service",0011U,"Prescription drug monitoring, evaluation of drugs present by LC-MS/MS, using oral fluid, reported as a comparison to an estimated steady-state range, per date of service including all drug compounds and metabolites",56.98413256496971,1,Present Both in MD and Autoproposal
0051U,"Prescription drug monitoring, evaluation of drugs present by LC-MS/MS, urine, 31 drug panel, reported as quantitative results, detected or not detected, per date of service",82542,"Column chromatography, includes mass spectrometry, if performed (eg, HPLC, LC, LC/MS, LC/MS-MS, GC, GC/MS-MS, GC/MS, HPLC/MS), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen",43.8389099029467,,Present in Autoproposal
0051U,"Prescription drug monitoring, evaluation of drugs present by LC-MS/MS, urine, 31 drug panel, reported as quantitative results, detected or not detected, per date of service",80307,"Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC-MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service",39.14616836110879,,Present Both in MD and Autoproposal
0051U,"Prescription drug monitoring, evaluation of drugs present by LC-MS/MS, urine, 31 drug panel, reported as quantitative results, detected or not detected, per date of service",0025U,"Tenofovir, by liquid chromatography with tandem mass spectrometry (LC-MS/MS), urine, quantitative",38.23492437353981,,Present in Autoproposal
0051U,"Prescription drug monitoring, evaluation of drugs present by LC-MS/MS, urine, 31 drug panel, reported as quantitative results, detected or not detected, per date of service",83789,"Mass spectrometry and tandem mass spectrometry (eg, MS, MS/MS, MALDI, MS-TOF, QTOF), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen",34.51419027047044,,Present in Autoproposal
0051U,"Prescription drug monitoring, evaluation of drugs present by LC-MS/MS, urine, 31 drug panel, reported as quantitative results, detected or not detected, per date of service",0038U,"Vitamin D, 25 hydroxy D2 and D3, by LC-MS/MS, serum microsample, quantitative",32.14716900585089,,Present in Autoproposal
0051U,"Prescription drug monitoring, evaluation of drugs present by LC-MS/MS, urine, 31 drug panel, reported as quantitative results, detected or not detected, per date of service",0002U,"Oncology (colorectal), quantitative assessment of three urine metabolites (ascorbic acid, succinic acid and carnitine) by liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring acquisition, algorithm reported as likelihood of adenomatous polyps",32.12901179651814,,Present in Autoproposal
0051U,"Prescription drug monitoring, evaluation of drugs present by LC-MS/MS, urine, 31 drug panel, reported as quantitative results, detected or not detected, per date of service",G0659,"DRUG TEST(S), DEFINITIVE, UTILIZING DRUG IDENTIFICATION METHODS ABLE TO IDENTIFY INDIVIDUAL DRUGS AND DISTINGUISH BETWEEN STRUCTURAL ISOMERS (BUT NOT NECESSARILY STEREOISOMERS), INCLUDING BUT NOT LIMITED TO GC/MS (ANY TYPE, SINGLE OR TANDEM) AND LC/MS (ANY TYPE, SINGLE OR TANDEM), EXCLUDING IMMUNOASSAYS (E.G., IA, EIA, ELISA, EMIT, FPIA) AND ENZYMATIC METHODS (E.G., ALCOHOL DEHYDROGENASE), PERFORMED WITHOUT METHOD OR DRUG-SPECIFIC CALIBRATION, WITHOUT MATRIX-MATCHED QUALITY CONTROL MATERIAL, OR WITHOUT USE OF STABLE ISOTOPE OR OTHER UNIVERSALLY RECOGNIZED INTERNAL STANDARD(S) FOR EACH DRUG, DRUG METABOLITE OR DRUG CLASS PER SPECIMEN; QUALITATIVE OR QUANTITATIVE, ALL SOURCES, INCLUDES SPECIMEN VALIDITY TESTING, PER DAY, ANY NUMBER OF DRUG CLASSES",30.787219736029513,,Present in Autoproposal
0051U,"Prescription drug monitoring, evaluation of drugs present by LC-MS/MS, urine, 31 drug panel, reported as quantitative results, detected or not detected, per date of service",83788,"Mass spectrometry and tandem mass spectrometry (MS, MS/MS), analyte not elsewhere specified; qualitative, each specimen",27.36836365881601,,Present in Autoproposal
0051U,"Prescription drug monitoring, evaluation of drugs present by LC-MS/MS, urine, 31 drug panel, reported as quantitative results, detected or not detected, per date of service",82541,"Column chromatography/mass spectrometry (eg, GC/MS, or HPLC/MS), non-drug analyte not elsewhere specified; qualitative, single stationary and mobile phase",26.056672282776596,,Present in Autoproposal
0052U,"Lipoprotein, blood, high resolution fractionation and quantitation of lipoproteins, including all five major lipoprotein classes and subclasses of HDL, LDL, and VLDL by vertical auto profile ultracentrifugation",83701,"Lipoprotein, blood; high resolution fractionation and quantitation of lipoproteins including lipoprotein subclasses when performed (eg, electrophoresis, ultracentrifugation)",69.91926888535632,1,Present Both in MD and Autoproposal
0052U,"Lipoprotein, blood, high resolution fractionation and quantitation of lipoproteins, including all five major lipoprotein classes and subclasses of HDL, LDL, and VLDL by vertical auto profile ultracentrifugation",83716,"LIPOPROTEIN, BLOOD; HIGH RESOLUTION FRACTIONATION & QUANTITATION, LIPOPROTEIN,W/WO SUBCLASSES",58.60936451807424,,Present in Autoproposal
0052U,"Lipoprotein, blood, high resolution fractionation and quantitation of lipoproteins, including all five major lipoprotein classes and subclasses of HDL, LDL, and VLDL by vertical auto profile ultracentrifugation",83695,Lipoprotein (a),40.01265060872329,,Present in Autoproposal
0052U,"Lipoprotein, blood, high resolution fractionation and quantitation of lipoproteins, including all five major lipoprotein classes and subclasses of HDL, LDL, and VLDL by vertical auto profile ultracentrifugation",83700,"Lipoprotein, blood; electrophoretic separation and quantitation",34.79856802748046,,Present in Autoproposal
0052U,"Lipoprotein, blood, high resolution fractionation and quantitation of lipoproteins, including all five major lipoprotein classes and subclasses of HDL, LDL, and VLDL by vertical auto profile ultracentrifugation",83719,"Lipoprotein, direct measurement; VLDL cholesterol",33.418200557571055,,Present in Autoproposal
0052U,"Lipoprotein, blood, high resolution fractionation and quantitation of lipoproteins, including all five major lipoprotein classes and subclasses of HDL, LDL, and VLDL by vertical auto profile ultracentrifugation",83704,"Lipoprotein, blood; quantitation of lipoprotein particle number(s) (eg, by nuclear magnetic resonance spectroscopy), includes lipoprotein particle subclass(es), when performed",32.92157650267061,,Present in Autoproposal
0052U,"Lipoprotein, blood, high resolution fractionation and quantitation of lipoproteins, including all five major lipoprotein classes and subclasses of HDL, LDL, and VLDL by vertical auto profile ultracentrifugation",83715,"LIPOPROTEIN, BLOOD; ELECTROPHORETIC SEPARATION & QUANTITATION",32.10164685555411,,Present in Autoproposal
0052U,"Lipoprotein, blood, high resolution fractionation and quantitation of lipoproteins, including all five major lipoprotein classes and subclasses of HDL, LDL, and VLDL by vertical auto profile ultracentrifugation",83721,"Lipoprotein, direct measurement; LDL cholesterol",28.83080670887433,,Present in Autoproposal
0052U,"Lipoprotein, blood, high resolution fractionation and quantitation of lipoproteins, including all five major lipoprotein classes and subclasses of HDL, LDL, and VLDL by vertical auto profile ultracentrifugation",0026T,"Lipoprotein, direct measurement, intermediate density lipoproteins (IDL) (remnant lipoproteins)",28.228343412760402,,Present in Autoproposal
0052U,"Lipoprotein, blood, high resolution fractionation and quantitation of lipoproteins, including all five major lipoprotein classes and subclasses of HDL, LDL, and VLDL by vertical auto profile ultracentrifugation",84120,"Porphyrins, urine; quantitation and fractionation",25.060060450362307,,Present in Autoproposal
0053U,"Oncology (prostate cancer), FISH analysis of 4 genes (ASAP1, HDAC9, CHD1 and PTEN), needle biopsy specimen, algorithm reported as probability of higher tumor grade",0010M,"Oncology (High-Grade Prostate Cancer), biochemical assay of four proteins (Total PSA, Free PSA, Intact PSA and human kallikrein 2 [hK2]) plus patient age, digital rectal examination status, and no history of positive prostate biopsy, utilizing plasma, prognostic algorithm reported as a probability score",34.66225468508269,4,Present in Autoproposal
0053U,"Oncology (prostate cancer), FISH analysis of 4 genes (ASAP1, HDAC9, CHD1 and PTEN), needle biopsy specimen, algorithm reported as probability of higher tumor grade",0026U,"Oncology (thyroid), DNA and mRNA of 112 genes, next-generation sequencing, fine needle aspirate of thyroid nodule, algorithmic analysis reported as a categorical result (""Positive, high probability of malignancy"" or ""Negative, low probability of malignancy"")",33.12200100911342,,Present in Autoproposal
0053U,"Oncology (prostate cancer), FISH analysis of 4 genes (ASAP1, HDAC9, CHD1 and PTEN), needle biopsy specimen, algorithm reported as probability of higher tumor grade",81539,"Oncology (high-grade prostate cancer), biochemical assay of four proteins (Total PSA, Free PSA, Intact PSA, and human kallikrein-2 [hK2]), utilizing plasma or serum, prognostic algorithm reported as a probability score",32.06829441058038,,Present in Autoproposal
0053U,"Oncology (prostate cancer), FISH analysis of 4 genes (ASAP1, HDAC9, CHD1 and PTEN), needle biopsy specimen, algorithm reported as probability of higher tumor grade",81551,"Oncology (prostate), promoter methylation profiling by real-time PCR of 3 genes (GSTP1, APC, RASSF1), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a likelihood of prostate cancer detection on repeat biopsy",31.837835235635577,,Present Both in MD and Autoproposal
0053U,"Oncology (prostate cancer), FISH analysis of 4 genes (ASAP1, HDAC9, CHD1 and PTEN), needle biopsy specimen, algorithm reported as probability of higher tumor grade",81545,"Oncology (thyroid), gene expression analysis of 142 genes, utilizing fine needle aspirate, algorithm reported as a categorical result (eg, benign or suspicious)",30.395930288959377,,Present in Autoproposal
0053U,"Oncology (prostate cancer), FISH analysis of 4 genes (ASAP1, HDAC9, CHD1 and PTEN), needle biopsy specimen, algorithm reported as probability of higher tumor grade",0011M,"Oncology, prostate cancer, mRNA expression assay of 12 genes (10 content and 2 housekeeping), RT-PCR test utilizing blood plasma and/or urine, algorithms to predict high-grade prostate cancer risk",29.88971763187648,,Present in Autoproposal
0053U,"Oncology (prostate cancer), FISH analysis of 4 genes (ASAP1, HDAC9, CHD1 and PTEN), needle biopsy specimen, algorithm reported as probability of higher tumor grade",81540,"Oncology (tumor of unknown origin), mRNA, gene expression profiling by real-time RT-PCR of 92 genes (87 content and 5 housekeeping) to classify tumor into main cancer type and subtype, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a probability of a predicted main cancer type and subtype",29.564527769302085,,Present in Autoproposal
0053U,"Oncology (prostate cancer), FISH analysis of 4 genes (ASAP1, HDAC9, CHD1 and PTEN), needle biopsy specimen, algorithm reported as probability of higher tumor grade",0007M,"Oncology (gastrointestinal neuroendocrine tumors), real-time PCR expression analysis of 51 genes, utilizing whole peripheral blood, algorithm reported as a nomogram of tumor disease index",29.468695557774748,,Present in Autoproposal
0053U,"Oncology (prostate cancer), FISH analysis of 4 genes (ASAP1, HDAC9, CHD1 and PTEN), needle biopsy specimen, algorithm reported as probability of higher tumor grade",0005U,"Oncology (prostate) gene expression profile by real-time RT-PCR of 3 genes (ERG, PCA3, and SPDEF), urine, algorithm reported as risk score",28.883162339825418,,Present in Autoproposal
0053U,"Oncology (prostate cancer), FISH analysis of 4 genes (ASAP1, HDAC9, CHD1 and PTEN), needle biopsy specimen, algorithm reported as probability of higher tumor grade",0008M,"Oncology (breast), mRNA analysis of 58 genes using hybrid capture, on formalin-fixed paraffin-embedded (FFPE) tissue, prognostic algorithm reported as a risk score",25.450899402977523,,Present in Autoproposal
0054U,"Prescription drug monitoring, 14 or more classes of drugs and substances, definitive tandem mass spectrometry with chromatography, capillary blood, quantitative report with therapeutic and toxic ranges, including steady-state range for the prescribed dose when detected, per date of service",0006U,"Detection of interacting medications, substances, supplements and foods, 120 or more analytes, definitive chromatography with mass spectrometry, urine, description and severity of each interaction identified per date of service",35.25342130541581,10,Present in Autoproposal
0054U,"Prescription drug monitoring, 14 or more classes of drugs and substances, definitive tandem mass spectrometry with chromatography, capillary blood, quantitative report with therapeutic and toxic ranges, including steady-state range for the prescribed dose when detected, per date of service",0011U,"Prescription drug monitoring, evaluation of drugs present by LC-MS/MS, using oral fluid, reported as a comparison to an estimated steady-state range, per date of service including all drug compounds and metabolites",35.05734374024783,,Present in Autoproposal
0054U,"Prescription drug monitoring, 14 or more classes of drugs and substances, definitive tandem mass spectrometry with chromatography, capillary blood, quantitative report with therapeutic and toxic ranges, including steady-state range for the prescribed dose when detected, per date of service",0025U,"Tenofovir, by liquid chromatography with tandem mass spectrometry (LC-MS/MS), urine, quantitative",26.81320956003093,,Present in Autoproposal
0054U,"Prescription drug monitoring, 14 or more classes of drugs and substances, definitive tandem mass spectrometry with chromatography, capillary blood, quantitative report with therapeutic and toxic ranges, including steady-state range for the prescribed dose when detected, per date of service",0020U,"Drug test(s), presumptive, with definitive confirmation of positive results, any number of drug classes, urine, with specimen verification including DNA authentication in comparison to buccal DNA, per date of service",24.15670361327531,,Present in Autoproposal
0054U,"Prescription drug monitoring, 14 or more classes of drugs and substances, definitive tandem mass spectrometry with chromatography, capillary blood, quantitative report with therapeutic and toxic ranges, including steady-state range for the prescribed dose when detected, per date of service",0007U,"Drug test(s), presumptive, with definitive confirmation of positive results, any number of drug classes, urine, includes specimen verification including DNA authentication in comparison to buccal DNA, per date of service",23.191265516691654,,Present in Autoproposal
0054U,"Prescription drug monitoring, 14 or more classes of drugs and substances, definitive tandem mass spectrometry with chromatography, capillary blood, quantitative report with therapeutic and toxic ranges, including steady-state range for the prescribed dose when detected, per date of service",80303,"Drug screen, any number of drug classes, presumptive, single or multiple drug class method; thin layer chromatography procedure(s) (TLC) (eg, acid, neutral, alkaloid plate), per date of service",22.758531901668196,,Present in Autoproposal
0054U,"Prescription drug monitoring, 14 or more classes of drugs and substances, definitive tandem mass spectrometry with chromatography, capillary blood, quantitative report with therapeutic and toxic ranges, including steady-state range for the prescribed dose when detected, per date of service",83788,"Mass spectrometry and tandem mass spectrometry (MS, MS/MS), analyte not elsewhere specified; qualitative, each specimen",22.66241241238144,,Present in Autoproposal
0054U,"Prescription drug monitoring, 14 or more classes of drugs and substances, definitive tandem mass spectrometry with chromatography, capillary blood, quantitative report with therapeutic and toxic ranges, including steady-state range for the prescribed dose when detected, per date of service",80377,"Drug(s) or substance(s), definitive, qualitative or quantitative, not otherwise specified; 7 or more",22.138434313323053,,Present in Autoproposal
0054U,"Prescription drug monitoring, 14 or more classes of drugs and substances, definitive tandem mass spectrometry with chromatography, capillary blood, quantitative report with therapeutic and toxic ranges, including steady-state range for the prescribed dose when detected, per date of service",83789,"Mass spectrometry and tandem mass spectrometry (eg, MS, MS/MS, MALDI, MS-TOF, QTOF), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen",21.799684692599943,,Present in Autoproposal
0054U,"Prescription drug monitoring, 14 or more classes of drugs and substances, definitive tandem mass spectrometry with chromatography, capillary blood, quantitative report with therapeutic and toxic ranges, including steady-state range for the prescribed dose when detected, per date of service",G0479,"DRUG TEST(S), PRESUMPTIVE, ANY NUMBER OF DRUG CLASSES; ANY NUMBER OF DEVICES OR PROCEDURES BY INSTRUMENTED CHEMISTRY ANALYZERS UTILIZING IMMUNOASSAY, ENZYME ASSAY, TOF, MALDI, LDTD, DESI, DART, GHPC, GC MASS SPECTROMETRY), INCLUDES SAMPLE VALIDATION WHEN PERFORMED, PER DATE OF SERVICE",21.38415188854132,,Present in Autoproposal
0055U,"Cardiology (heart transplant), cell-free DNA, PCR assay of 96 DNA target sequences (94 single nucleotide polymorphism targets and two control targets), plasma",00580,Anesthesia for heart transplant or heart/lung transplant,21.801093816981666,3,Present in Autoproposal
0055U,"Cardiology (heart transplant), cell-free DNA, PCR assay of 96 DNA target sequences (94 single nucleotide polymorphism targets and two control targets), plasma",36520,PLASMA AND/OR CELL EXCHANGE,19.18342217052323,,Present in Autoproposal
0055U,"Cardiology (heart transplant), cell-free DNA, PCR assay of 96 DNA target sequences (94 single nucleotide polymorphism targets and two control targets), plasma",81595,"Cardiology (heart transplant), mRNA, gene expression profiling by real-time quantitative PCR of 20 genes (11 content and 9 housekeeping), utilizing subfraction of peripheral blood, algorithm reported as a rejection risk score",18.86078057118969,,Present Both in MD and Autoproposal
0055U,"Cardiology (heart transplant), cell-free DNA, PCR assay of 96 DNA target sequences (94 single nucleotide polymorphism targets and two control targets), plasma",81229,Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for chromosomal abnormalities,17.267146695521337,,Present in Autoproposal
0055U,"Cardiology (heart transplant), cell-free DNA, PCR assay of 96 DNA target sequences (94 single nucleotide polymorphism targets and two control targets), plasma",0004M,"Scoliosis, DNA analysis of 53 single nucleotide polymorphisms (SNPs), using saliva, prognostic algorithm reported as a risk score",16.67164873116113,,Present in Autoproposal
0055U,"Cardiology (heart transplant), cell-free DNA, PCR assay of 96 DNA target sequences (94 single nucleotide polymorphism targets and two control targets), plasma",88182,"Flow cytometry, cell cycle or DNA analysis",16.429096154171397,,Present in Autoproposal
0055U,"Cardiology (heart transplant), cell-free DNA, PCR assay of 96 DNA target sequences (94 single nucleotide polymorphism targets and two control targets), plasma",86226,Deoxyribonucleic acid (DNA) antibody; single stranded,14.335392090757255,,Present in Autoproposal
0055U,"Cardiology (heart transplant), cell-free DNA, PCR assay of 96 DNA target sequences (94 single nucleotide polymorphism targets and two control targets), plasma",87505,"Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen (eg, Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 3-5 targets",14.25302417758607,,Present in Autoproposal
0055U,"Cardiology (heart transplant), cell-free DNA, PCR assay of 96 DNA target sequences (94 single nucleotide polymorphism targets and two control targets), plasma",83900,"Molecular diagnostics; amplification, target, multiplex, first 2 nucleic acid sequences",14.117594403277312,,Present in Autoproposal
0055U,"Cardiology (heart transplant), cell-free DNA, PCR assay of 96 DNA target sequences (94 single nucleotide polymorphism targets and two control targets), plasma",87506,"Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen (eg, Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 6-11 targets",14.073905260109786,,Present in Autoproposal
0056U,"Hematology (acute myelogenous leukemia), DNA, whole genome next-generation sequencing to detect gene rearrangement(s), blood or bone marrow, report of specific gene rearrangement(s)",0014U,"Hematology (hematolymphoid neoplasia), gene rearrangement detection by whole genome next-generation sequencing, DNA, whole blood or bone marrow, report of specific gene rearrangement(s)",80.34905047060448,1,Present Both in MD and Autoproposal
0056U,"Hematology (acute myelogenous leukemia), DNA, whole genome next-generation sequencing to detect gene rearrangement(s), blood or bone marrow, report of specific gene rearrangement(s)",0012U,"Germline disorders, gene rearrangement detection by whole genome next-generation sequencing, DNA, whole blood, report of specific gene rearrangement(s)",71.59965293569364,,Present in Autoproposal
0056U,"Hematology (acute myelogenous leukemia), DNA, whole genome next-generation sequencing to detect gene rearrangement(s), blood or bone marrow, report of specific gene rearrangement(s)",0013U,"Oncology (solid organ neoplasia), gene rearrangement detection by whole genome next-generation sequencing, DNA, fresh or frozen tissue or cells, report of specific gene rearrangement(s)",63.18580632288209,,Present in Autoproposal
0056U,"Hematology (acute myelogenous leukemia), DNA, whole genome next-generation sequencing to detect gene rearrangement(s), blood or bone marrow, report of specific gene rearrangement(s)",81342,"TRG@ (T cell antigen receptor, gamma) (eg, leukemia and lymphoma), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)",31.362376685127618,,Present in Autoproposal
0056U,"Hematology (acute myelogenous leukemia), DNA, whole genome next-generation sequencing to detect gene rearrangement(s), blood or bone marrow, report of specific gene rearrangement(s)",81264,"IGK@ (Immunoglobulin kappa light chain locus) (eg, leukemia and lymphoma, B-cell), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)",28.414134958394587,,Present Both in MD and Autoproposal
0056U,"Hematology (acute myelogenous leukemia), DNA, whole genome next-generation sequencing to detect gene rearrangement(s), blood or bone marrow, report of specific gene rearrangement(s)",78104,Bone marrow imaging; whole body,27.055244819369694,,Present in Autoproposal
0056U,"Hematology (acute myelogenous leukemia), DNA, whole genome next-generation sequencing to detect gene rearrangement(s), blood or bone marrow, report of specific gene rearrangement(s)",81341,"TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using direct probe methodology (eg, Southern blot)",26.599051606831036,,Present in Autoproposal
0056U,"Hematology (acute myelogenous leukemia), DNA, whole genome next-generation sequencing to detect gene rearrangement(s), blood or bone marrow, report of specific gene rearrangement(s)",81340,"TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using amplification methodology (eg, polymerase chain reaction)",25.909770777693232,,Present in Autoproposal
0056U,"Hematology (acute myelogenous leukemia), DNA, whole genome next-generation sequencing to detect gene rearrangement(s), blood or bone marrow, report of specific gene rearrangement(s)",S3818,COMPLETE GENE SEQUENCE ANALYSIS; BRCA1 GENE,22.51245152789477,,Present in Autoproposal
0056U,"Hematology (acute myelogenous leukemia), DNA, whole genome next-generation sequencing to detect gene rearrangement(s), blood or bone marrow, report of specific gene rearrangement(s)",S3819,COMPLETE GENE SEQUENCE ANALYSIS; BRCA2 GENE,22.51245152789477,,Present in Autoproposal
0057U,"Oncology (solid organ neoplasia), mRNA, gene expression profiling by massively parallel sequencing for analysis of 51 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a normalized percentile rank",81519,"Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of 21 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence score",63.229068224359544,1,Present Both in MD and Autoproposal
0057U,"Oncology (solid organ neoplasia), mRNA, gene expression profiling by massively parallel sequencing for analysis of 51 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a normalized percentile rank",81525,"Oncology (colon), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a recurrence score",59.586327050397806,,Present in Autoproposal
0057U,"Oncology (solid organ neoplasia), mRNA, gene expression profiling by massively parallel sequencing for analysis of 51 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a normalized percentile rank",81520,"Oncology (breast), mRNA gene expression profiling by hybrid capture of 58 genes (50 content and 8 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a recurrence risk score",59.20323581045432,,Present in Autoproposal
0057U,"Oncology (solid organ neoplasia), mRNA, gene expression profiling by massively parallel sequencing for analysis of 51 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a normalized percentile rank",81504,"Oncology (tissue of origin), microarray gene expression profiling of > 2000 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as tissue similarity scores",58.21081847561381,,Present in Autoproposal
0057U,"Oncology (solid organ neoplasia), mRNA, gene expression profiling by massively parallel sequencing for analysis of 51 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a normalized percentile rank",81541,"Oncology (prostate), mRNA gene expression profiling by real-time RT-PCR of 46 genes (31 content and 15 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a disease-specific mortality risk score",53.837046080380425,,Present in Autoproposal
0057U,"Oncology (solid organ neoplasia), mRNA, gene expression profiling by massively parallel sequencing for analysis of 51 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a normalized percentile rank",81521,"Oncology (breast), mRNA, microarray gene expression profiling of 70 content genes and 465 housekeeping genes, utilizing fresh frozen or formalin-fixed paraffin-embedded tissue, algorithm reported as index related to risk of distant metastasis",53.12626191670713,,Present in Autoproposal
0057U,"Oncology (solid organ neoplasia), mRNA, gene expression profiling by massively parallel sequencing for analysis of 51 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a normalized percentile rank",0019U,"Oncology, RNA, gene expression by whole transcriptome sequencing, formalin-fixed paraffin embedded tissue or fresh frozen tissue, predictive algorithm reported as potential targets for therapeutic agents",48.448949798909844,,Present in Autoproposal
0057U,"Oncology (solid organ neoplasia), mRNA, gene expression profiling by massively parallel sequencing for analysis of 51 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a normalized percentile rank",0008M,"Oncology (breast), mRNA analysis of 58 genes using hybrid capture, on formalin-fixed paraffin-embedded (FFPE) tissue, prognostic algorithm reported as a risk score",47.91187383750681,,Present in Autoproposal
0057U,"Oncology (solid organ neoplasia), mRNA, gene expression profiling by massively parallel sequencing for analysis of 51 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a normalized percentile rank",81551,"Oncology (prostate), promoter methylation profiling by real-time PCR of 3 genes (GSTP1, APC, RASSF1), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a likelihood of prostate cancer detection on repeat biopsy",42.28199543197784,,Present in Autoproposal
0057U,"Oncology (solid organ neoplasia), mRNA, gene expression profiling by massively parallel sequencing for analysis of 51 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a normalized percentile rank",81493,"Coronary artery disease, mRNA, gene expression profiling by real-time RT-PCR of 23 genes, utilizing whole peripheral blood, algorithm reported as a risk score",40.967581620505804,,Present in Autoproposal
0058U,"Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus oncoprotein (small T antigen), serum, quantitative",G9069,"ONCOLOGY; DISEASE STATUS; SMALL CELL LUNG CANCER, LIMITED TO SMALL CELL AND COMBINED SMALL CELL/NON-SMALL CELL; EXTENSIVE STAGE AT DIAGNOSIS, METASTATIC, LOCALLY RECURRENT, OR PROGRESSIVE (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)",40.6351295103186,10,Present in Autoproposal
0058U,"Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus oncoprotein (small T antigen), serum, quantitative",G9070,"ONCOLOGY; DISEASE STATUS; SMALL CELL LUNG CANCER, LIMITED TO SMALL CELL AND COMBINED SMALL CELL/NON-SMALL; EXTENT OF DISEASE UNKNOWN, STAGING IN PROGRESS, OR NOT LISTED (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)",36.999879655592096,,Present in Autoproposal
0058U,"Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus oncoprotein (small T antigen), serum, quantitative",G9068,"ONCOLOGY; DISEASE STATUS; LIMITED TO SMALL CELL AND COMBINED SMALL CELL/NON-SMALL CELL; EXTENT OF DISEASE INITIALLY ESTABLISHED AS LIMITED WITH NO EVIDENCE OF DISEASE PROGRESSION, RECURRENCE, OR METASTASES (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)",33.82795880580805,,Present in Autoproposal
0058U,"Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus oncoprotein (small T antigen), serum, quantitative",86356,"Mononuclear cell antigen, quantitative (eg, flow cytometry), not otherwise specified, each antigen",30.291894883135086,,Present in Autoproposal
0058U,"Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus oncoprotein (small T antigen), serum, quantitative",G9425,"PRIMARY LUNG CARCINOMA RESECTION REPORT DOES NOT DOCUMENT PT CATEGORY, PN CATEGORY AND FOR NON-SMALL CELL LUNG CANCER, HISTOLOGIC TYPE (SQUAMOUS CELL CARCINOMA, ADENOCARCINOMA)",29.13984768547345,,Present in Autoproposal
0058U,"Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus oncoprotein (small T antigen), serum, quantitative",G9422,"PRIMARY LUNG CARCINOMA RESECTION REPORT DOCUMENTS PT CATEGORY, PN CATEGORY AND FOR NON-SMALL CELL LUNG CANCER, HISTOLOGIC TYPE (SQUAMOUS CELL CARCINOMA, ADENOCARCINOMA AND NOT NSCLC-NOS)",27.978940162354178,,Present in Autoproposal
0058U,"Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus oncoprotein (small T antigen), serum, quantitative",G0267,"BONE MARROW OR PERIPHERAL STEM CELL HARVEST, MODIFICATION OR TREATMENT TO ELIMINATE CELL TYPE(S) (E.G. T-CELLS, METASTATIC CARCINOMA)",27.64790016229441,,Present in Autoproposal
0058U,"Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus oncoprotein (small T antigen), serum, quantitative",G9785,PATHOLOGY REPORT DIAGNOSING CUTANEOUS BASAL CELL CARCINOMA OR SQUAMOUS CELL CARCINOMA (TO INCLUDE IN SITU DISEASE) SENT FROM THE PATHOLOGIST/DERMATOPATHOLOGIST TO THE BIOPSYING CLINICIAN FOR REVIEW WITHIN 7 DAYS FROM THE TIME WHEN THE TISSUE SPECIMEN WAS RECEIVED BY THE PATHOLOGIST,26.650034894018503,,Present in Autoproposal
0058U,"Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus oncoprotein (small T antigen), serum, quantitative",G9098,"ONCOLOGY; DISEASE STATUS; ESOPHAGEAL CANCER, LIMITED TO ADENOCARCINOMA OR SQUAMOUS CELL CARCINOMA AS PREDOMINANT CELL TYPE; M1 AT DIAGNOSIS, METASTATIC, LOCALLY RECURRENT, OR PROGRESSIVE (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)",26.37299041441062,,Present in Autoproposal
0058U,"Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus oncoprotein (small T antigen), serum, quantitative",G9099,"ONCOLOGY; DISEASE STATUS; ESOPHAGEAL CANCER, LIMITED TO ADENOCARCINOMA OR SQUAMOUS CELL CARCINOMA AS PREDOMINANT CELL TYPE; EXTENT OF DISEASE UNKNOWN, STAGING IN PROGRESS, OR NOT LISTED (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)",26.332518881159928,,Present in Autoproposal
0059U,"Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus capsid protein (VP1), serum, reported as positive or negative",G9098,"ONCOLOGY; DISEASE STATUS; ESOPHAGEAL CANCER, LIMITED TO ADENOCARCINOMA OR SQUAMOUS CELL CARCINOMA AS PREDOMINANT CELL TYPE; M1 AT DIAGNOSIS, METASTATIC, LOCALLY RECURRENT, OR PROGRESSIVE (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)",28.17968827386428,10,Present in Autoproposal
0059U,"Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus capsid protein (VP1), serum, reported as positive or negative",G9099,"ONCOLOGY; DISEASE STATUS; ESOPHAGEAL CANCER, LIMITED TO ADENOCARCINOMA OR SQUAMOUS CELL CARCINOMA AS PREDOMINANT CELL TYPE; EXTENT OF DISEASE UNKNOWN, STAGING IN PROGRESS, OR NOT LISTED (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)",28.05325973972589,,Present in Autoproposal
0059U,"Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus capsid protein (VP1), serum, reported as positive or negative",G0267,"BONE MARROW OR PERIPHERAL STEM CELL HARVEST, MODIFICATION OR TREATMENT TO ELIMINATE CELL TYPE(S) (E.G. T-CELLS, METASTATIC CARCINOMA)",26.854051565101006,,Present in Autoproposal
0059U,"Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus capsid protein (VP1), serum, reported as positive or negative",G9069,"ONCOLOGY; DISEASE STATUS; SMALL CELL LUNG CANCER, LIMITED TO SMALL CELL AND COMBINED SMALL CELL/NON-SMALL CELL; EXTENSIVE STAGE AT DIAGNOSIS, METASTATIC, LOCALLY RECURRENT, OR PROGRESSIVE (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)",25.804558187856546,,Present in Autoproposal
0059U,"Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus capsid protein (VP1), serum, reported as positive or negative",G9097,"ONCOLOGY; DISEASE STATUS; ESOPHAGEAL CANCER, LIMITED TO ADENOCARCINOMA OR SQUAMOUS CELL CARCINOMA AS PREDOMINANT CELL TYPE; EXTENT OF DISEASE INITIALLY ESTABLISHED AS T4, ANY N, M0 (PRIOR TO NEO-ADJUVANT THERAPY, IF ANY) WITH NO EVIDENCE OF DISEASE PROGRESSION, RECURRENCE, OR METASTASES (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)",25.306788606036847,,Present in Autoproposal
0059U,"Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus capsid protein (VP1), serum, reported as positive or negative",G9785,PATHOLOGY REPORT DIAGNOSING CUTANEOUS BASAL CELL CARCINOMA OR SQUAMOUS CELL CARCINOMA (TO INCLUDE IN SITU DISEASE) SENT FROM THE PATHOLOGIST/DERMATOPATHOLOGIST TO THE BIOPSYING CLINICIAN FOR REVIEW WITHIN 7 DAYS FROM THE TIME WHEN THE TISSUE SPECIMEN WAS RECEIVED BY THE PATHOLOGIST,24.992663802919758,,Present in Autoproposal
0059U,"Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus capsid protein (VP1), serum, reported as positive or negative",G9068,"ONCOLOGY; DISEASE STATUS; LIMITED TO SMALL CELL AND COMBINED SMALL CELL/NON-SMALL CELL; EXTENT OF DISEASE INITIALLY ESTABLISHED AS LIMITED WITH NO EVIDENCE OF DISEASE PROGRESSION, RECURRENCE, OR METASTASES (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)",24.4341497464259,,Present in Autoproposal
0059U,"Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus capsid protein (VP1), serum, reported as positive or negative",G9786,PATHOLOGY REPORT DIAGNOSING CUTANEOUS BASAL CELL CARCINOMA OR SQUAMOUS CELL CARCINOMA (TO INCLUDE IN SITU DISEASE) WAS NOT SENT FROM THE PATHOLOGIST/DERMATOPATHOLOGIST TO THE BIOPSYING CLINICIAN FOR REVIEW WITHIN 7 DAYS FROM THE TIME WHEN THE TISSUE SPECIMEN WAS RECEIVED BY THE PATHOLOGIST,24.419558506998147,,Present in Autoproposal
0059U,"Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus capsid protein (VP1), serum, reported as positive or negative",G9096,"ONCOLOGY; DISEASE STATUS; ESOPHAGEAL CANCER, LIMITED TO ADENOCARCINOMA OR SQUAMOUS CELL CARCINOMA AS PREDOMINANT CELL TYPE; EXTENT OF DISEASE INITIALLY ESTABLISHED AS T1-T3, N0-N1 OR NX (PRIOR TO NEO-ADJUVANT THERAPY, IF ANY) WITH NO EVIDENCE OF DISEASE PROGRESSION, RECURRENCE, OR METASTASES (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)",24.416581162360703,,Present in Autoproposal
0059U,"Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus capsid protein (VP1), serum, reported as positive or negative",3500F,CD4+ cell count or CD4+ cell percentage documented as performed (HIV),23.76540466497329,,Present in Autoproposal
0060U,"Twin zygosity, genomic targeted sequence analysis of chromosome 2, using circulating cell-free fetal DNA in maternal blood",81422,"Fetal chromosomal microdeletion(s) genomic sequence analysis (eg, DiGeorge syndrome, Cri-du-chat syndrome), circulating cell-free fetal DNA in maternal blood",46.99723365746388,2,Present in Autoproposal
0060U,"Twin zygosity, genomic targeted sequence analysis of chromosome 2, using circulating cell-free fetal DNA in maternal blood",81420,"Fetal chromosomal aneuploidy (eg, trisomy 21, monosomy X) genomic sequence analysis panel, circulating cell-free fetal DNA in maternal blood, must include analysis of chromosomes 13, 18, and 21",46.155302932429734,,Present Both in MD and Autoproposal
0060U,"Twin zygosity, genomic targeted sequence analysis of chromosome 2, using circulating cell-free fetal DNA in maternal blood",S3711,CIRCULATING TUMOR CELL TEST,29.103634982751498,,Present in Autoproposal
0060U,"Twin zygosity, genomic targeted sequence analysis of chromosome 2, using circulating cell-free fetal DNA in maternal blood",0022U,"Targeted genomic sequence analysis panel, non-small cell lung neoplasia, DNA and RNA analysis, 23 genes, interrogation for sequence variants and rearrangements, reported as presence/absence of variants and associated therapy(ies) to consider",28.733861075047173,,Present in Autoproposal
0060U,"Twin zygosity, genomic targeted sequence analysis of chromosome 2, using circulating cell-free fetal DNA in maternal blood",S2411,FETOSCOPIC LASER THERAPY FOR TREATMENT OF TWIN-TO-TWIN TRANSFUSION SYNDROME,26.637830808392664,,Present in Autoproposal
0060U,"Twin zygosity, genomic targeted sequence analysis of chromosome 2, using circulating cell-free fetal DNA in maternal blood",86152,"Cell enumeration using immunologic selection and identification in fluid specimen (eg, circulating tumor cells in blood)",26.15953355108195,,Present in Autoproposal
0060U,"Twin zygosity, genomic targeted sequence analysis of chromosome 2, using circulating cell-free fetal DNA in maternal blood",0279T,"Cell enumeration using immunologic selection and identification in fluid specimen (eg, circulating tumor cells in blood);",26.15953355108195,,Present in Autoproposal
0060U,"Twin zygosity, genomic targeted sequence analysis of chromosome 2, using circulating cell-free fetal DNA in maternal blood",0037U,"Targeted genomic sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden",25.330633389818995,,Present in Autoproposal
0060U,"Twin zygosity, genomic targeted sequence analysis of chromosome 2, using circulating cell-free fetal DNA in maternal blood",0280T,"Cell enumeration using immunologic selection and identification in fluid specimen (eg, circulating tumor cells in blood); interpretation and report",24.897417485225613,,Present in Autoproposal
0060U,"Twin zygosity, genomic targeted sequence analysis of chromosome 2, using circulating cell-free fetal DNA in maternal blood",0009M,"Fetal aneuploidy (trisomy 21, and 18) DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy",24.83032784791675,,Present in Autoproposal
0061U,"Transcutaneous measurement of five biomarkers (tissue oxygenation [StO2], oxyhemoglobin [ctHbO2], deoxyhemoglobin [ctHbR], papillary and reticular dermal hemoglobin concentrations [ctHb1 and ctHb2]), using spatial frequency domain imaging (SFDI) and multi-spectral analysis",80321,Alcohol biomarkers; 1 or 2,22.66849367700474,2,Present in Autoproposal
0061U,"Transcutaneous measurement of five biomarkers (tissue oxygenation [StO2], oxyhemoglobin [ctHbO2], deoxyhemoglobin [ctHbR], papillary and reticular dermal hemoglobin concentrations [ctHb1 and ctHb2]), using spatial frequency domain imaging (SFDI) and multi-spectral analysis",88738,"Hemoglobin (Hgb), quantitative, transcutaneous",21.949217566185208,,Present Both in MD and Autoproposal
0061U,"Transcutaneous measurement of five biomarkers (tissue oxygenation [StO2], oxyhemoglobin [ctHbO2], deoxyhemoglobin [ctHbR], papillary and reticular dermal hemoglobin concentrations [ctHb1 and ctHb2]), using spatial frequency domain imaging (SFDI) and multi-spectral analysis",80322,Alcohol biomarkers; 3 or more,20.99427020674844,,Present in Autoproposal
0061U,"Transcutaneous measurement of five biomarkers (tissue oxygenation [StO2], oxyhemoglobin [ctHbO2], deoxyhemoglobin [ctHbR], papillary and reticular dermal hemoglobin concentrations [ctHb1 and ctHb2]), using spatial frequency domain imaging (SFDI) and multi-spectral analysis",88740,"Hemoglobin, quantitative, transcutaneous, per day; carboxyhemoglobin",19.422857101371516,,Present in Autoproposal
0061U,"Transcutaneous measurement of five biomarkers (tissue oxygenation [StO2], oxyhemoglobin [ctHbO2], deoxyhemoglobin [ctHbR], papillary and reticular dermal hemoglobin concentrations [ctHb1 and ctHb2]), using spatial frequency domain imaging (SFDI) and multi-spectral analysis",88741,"Hemoglobin, quantitative, transcutaneous, per day; methemoglobin",19.422857101371516,,Present in Autoproposal
0061U,"Transcutaneous measurement of five biomarkers (tissue oxygenation [StO2], oxyhemoglobin [ctHbO2], deoxyhemoglobin [ctHbR], papillary and reticular dermal hemoglobin concentrations [ctHb1 and ctHb2]), using spatial frequency domain imaging (SFDI) and multi-spectral analysis",0400T,Multi-spectral digital skin lesion analysis of clinically atypical cutaneous pigmented lesions for detection of melanomas and high risk melanocytic atypia; one to five lesions,19.33913041029247,,Present in Autoproposal
0061U,"Transcutaneous measurement of five biomarkers (tissue oxygenation [StO2], oxyhemoglobin [ctHbO2], deoxyhemoglobin [ctHbR], papillary and reticular dermal hemoglobin concentrations [ctHb1 and ctHb2]), using spatial frequency domain imaging (SFDI) and multi-spectral analysis",0199T,"Physiologic recording of tremor using accelerometer(s) and/or gyroscope(s) (including frequency and amplitude), including interpretation and report",18.484713717099645,,Present in Autoproposal
0061U,"Transcutaneous measurement of five biomarkers (tissue oxygenation [StO2], oxyhemoglobin [ctHbO2], deoxyhemoglobin [ctHbR], papillary and reticular dermal hemoglobin concentrations [ctHb1 and ctHb2]), using spatial frequency domain imaging (SFDI) and multi-spectral analysis",0493T,"Near-infrared spectroscopy studies of lower extremity wounds (eg, for oxyhemoglobin measurement)",18.05642849855454,,Present in Autoproposal
0061U,"Transcutaneous measurement of five biomarkers (tissue oxygenation [StO2], oxyhemoglobin [ctHbO2], deoxyhemoglobin [ctHbR], papillary and reticular dermal hemoglobin concentrations [ctHb1 and ctHb2]), using spatial frequency domain imaging (SFDI) and multi-spectral analysis",0286T,"Near-infrared spectroscopy studies of lower extremity wounds (eg, for oxyhemoglobin measurement)",18.05642849855454,,Present in Autoproposal
0061U,"Transcutaneous measurement of five biomarkers (tissue oxygenation [StO2], oxyhemoglobin [ctHbO2], deoxyhemoglobin [ctHbR], papillary and reticular dermal hemoglobin concentrations [ctHb1 and ctHb2]), using spatial frequency domain imaging (SFDI) and multi-spectral analysis",0443T,"Real-time spectral analysis of prostate tissue by fluorescence spectroscopy, including imaging guidance (List separately in addition to code for primary procedure)",17.151052139452233,,Present in Autoproposal
0062U,"Autoimmune (systemic lupus erythematosus), IgG and IgM analysis of 80 biomarkers, utilizing serum, algorithm reported with a risk score",81490,"Autoimmune (rheumatoid arthritis), analysis of 12 biomarkers using immunoassays, utilizing serum, prognostic algorithm reported as a disease activity score",53.62080040193376,10,Present Both in MD and Autoproposal
0062U,"Autoimmune (systemic lupus erythematosus), IgG and IgM analysis of 80 biomarkers, utilizing serum, algorithm reported with a risk score",81500,"Oncology (ovarian), biochemical assays of two proteins (CA-125 and HE4), utilizing serum, with menopausal status, algorithm reported as a risk score",32.353787704819716,,Present in Autoproposal
0062U,"Autoimmune (systemic lupus erythematosus), IgG and IgM analysis of 80 biomarkers, utilizing serum, algorithm reported with a risk score",81508,"Fetal congenital abnormalities, biochemical assays of two proteins (PAPP-A, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score",31.083779451911838,,Present in Autoproposal
0062U,"Autoimmune (systemic lupus erythematosus), IgG and IgM analysis of 80 biomarkers, utilizing serum, algorithm reported with a risk score",81510,"Fetal congenital abnormalities, biochemical assays of three analytes (AFP, uE3, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score",29.624687670584894,,Present in Autoproposal
0062U,"Autoimmune (systemic lupus erythematosus), IgG and IgM analysis of 80 biomarkers, utilizing serum, algorithm reported with a risk score",81509,"Fetal congenital abnormalities, biochemical assays of three proteins (PAPP-A, hCG [any form], DIA), utilizing maternal serum, algorithm reported as a risk score",29.61494115160747,,Present in Autoproposal
0062U,"Autoimmune (systemic lupus erythematosus), IgG and IgM analysis of 80 biomarkers, utilizing serum, algorithm reported with a risk score",81503,"Oncology (ovarian), biochemical assays of five proteins (CA-125, apolipoprotein A1, beta-2 microglobulin, transferrin, and pre-albumin), utilizing serum, algorithm reported as a risk score",27.90166480434056,,Present in Autoproposal
0062U,"Autoimmune (systemic lupus erythematosus), IgG and IgM analysis of 80 biomarkers, utilizing serum, algorithm reported with a risk score",80321,Alcohol biomarkers; 1 or 2,27.62593423671006,,Present in Autoproposal
0062U,"Autoimmune (systemic lupus erythematosus), IgG and IgM analysis of 80 biomarkers, utilizing serum, algorithm reported with a risk score",80322,Alcohol biomarkers; 3 or more,25.585569837298035,,Present in Autoproposal
0062U,"Autoimmune (systemic lupus erythematosus), IgG and IgM analysis of 80 biomarkers, utilizing serum, algorithm reported with a risk score",81512,"Fetal congenital abnormalities, biochemical assays of five analytes (AFP, uE3, total hCG, hyperglycosylated hCG, DIA) utilizing maternal serum, algorithm reported as a risk score",25.360493607393142,,Present in Autoproposal
0062U,"Autoimmune (systemic lupus erythematosus), IgG and IgM analysis of 80 biomarkers, utilizing serum, algorithm reported with a risk score",81493,"Coronary artery disease, mRNA, gene expression profiling by real-time RT-PCR of 23 genes, utilizing whole peripheral blood, algorithm reported as a risk score",24.95008149664403,,Present in Autoproposal
0063U,"Neurology (autism), 32 amines by LCMS/MS, using plasma, algorithm reported as metabolic signature associated with autism spectrum disorder",S3870,"COMPARATIVE GENOMIC HYBRIDIZATION (CGH) MICROARRAY TESTING FOR DEVELOPMENTAL DELAY, AUTISM SPECTRUM DISORDER AND/OR INTELLECTUAL DISABILITY",30.338285125483445,10,Present Both in MD and Autoproposal
0063U,"Neurology (autism), 32 amines by LCMS/MS, using plasma, algorithm reported as metabolic signature associated with autism spectrum disorder",82120,"Amines, vaginal fluid, qualitative",19.50927777853934,,Present in Autoproposal
0063U,"Neurology (autism), 32 amines by LCMS/MS, using plasma, algorithm reported as metabolic signature associated with autism spectrum disorder",0002U,"Oncology (colorectal), quantitative assessment of three urine metabolites (ascorbic acid, succinic acid and carnitine) by liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring acquisition, algorithm reported as likelihood of adenomatous polyps",18.02080707676195,,Present in Autoproposal
0063U,"Neurology (autism), 32 amines by LCMS/MS, using plasma, algorithm reported as metabolic signature associated with autism spectrum disorder",0011U,"Prescription drug monitoring, evaluation of drugs present by LC-MS/MS, using oral fluid, reported as a comparison to an estimated steady-state range, per date of service including all drug compounds and metabolites",16.531237480977147,,Present in Autoproposal
0063U,"Neurology (autism), 32 amines by LCMS/MS, using plasma, algorithm reported as metabolic signature associated with autism spectrum disorder",82542,"Column chromatography, includes mass spectrometry, if performed (eg, HPLC, LC, LC/MS, LC/MS-MS, GC, GC/MS-MS, GC/MS, HPLC/MS), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen",15.919793699067899,,Present in Autoproposal
0063U,"Neurology (autism), 32 amines by LCMS/MS, using plasma, algorithm reported as metabolic signature associated with autism spectrum disorder",81538,"Oncology (lung), mass spectrometric 8-protein signature, including amyloid A, utilizing serum, prognostic and predictive algorithm reported as good versus poor overall survival",15.9157131074348,,Present in Autoproposal
0063U,"Neurology (autism), 32 amines by LCMS/MS, using plasma, algorithm reported as metabolic signature associated with autism spectrum disorder",0009M,"Fetal aneuploidy (trisomy 21, and 18) DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy",15.914267504598786,,Present in Autoproposal
0063U,"Neurology (autism), 32 amines by LCMS/MS, using plasma, algorithm reported as metabolic signature associated with autism spectrum disorder",81507,"Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy",15.541908924825766,,Present in Autoproposal
0063U,"Neurology (autism), 32 amines by LCMS/MS, using plasma, algorithm reported as metabolic signature associated with autism spectrum disorder",0005M,"Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy",15.541908924825766,,Present in Autoproposal
0063U,"Neurology (autism), 32 amines by LCMS/MS, using plasma, algorithm reported as metabolic signature associated with autism spectrum disorder",80049,"METABOLIC PANEL, BASIC",14.638174519761899,,Present in Autoproposal
0064U,"Antibody, Treponema pallidum, total and rapid plasma reagin (RPR), immunoassay, qualitative",86780,Antibody; Treponema pallidum,63.50759199446474,1,Present Both in MD and Autoproposal
0064U,"Antibody, Treponema pallidum, total and rapid plasma reagin (RPR), immunoassay, qualitative",86781,"Antibody; Treponema pallidum, confirmatory test (eg, FTA-abs)",40.15408548305888,,Present in Autoproposal
0064U,"Antibody, Treponema pallidum, total and rapid plasma reagin (RPR), immunoassay, qualitative",87285,Infectious agent antigen detection by immunofluorescent technique; Treponema pallidum,38.67606789627315,,Present in Autoproposal
0064U,"Antibody, Treponema pallidum, total and rapid plasma reagin (RPR), immunoassay, qualitative",86592,"Syphilis test, non-treponemal antibody; qualitative (eg, VDRL, RPR, ART)",30.058407079785077,,Present Both in MD and Autoproposal
0064U,"Antibody, Treponema pallidum, total and rapid plasma reagin (RPR), immunoassay, qualitative",G0435,"INFECTIOUS AGENT ANTIBODY DETECTION BY RAPID ANTIBODY TEST, HIV-1 AND/OR HIV-2, SCREENING",24.962446565428785,,Present in Autoproposal
0064U,"Antibody, Treponema pallidum, total and rapid plasma reagin (RPR), immunoassay, qualitative",86318,"Immunoassay for infectious agent antibody, qualitative or semiquantitative, single step method (eg, reagent strip)",22.835831055466993,,Present in Autoproposal
0064U,"Antibody, Treponema pallidum, total and rapid plasma reagin (RPR), immunoassay, qualitative",83051,Hemoglobin; plasma,21.655623998263852,,Present in Autoproposal
0064U,"Antibody, Treponema pallidum, total and rapid plasma reagin (RPR), immunoassay, qualitative",86317,"Immunoassay for infectious agent antibody, quantitative, not otherwise specified",21.33571738767328,,Present in Autoproposal
0064U,"Antibody, Treponema pallidum, total and rapid plasma reagin (RPR), immunoassay, qualitative",36520,PLASMA AND/OR CELL EXCHANGE,20.002729758879827,,Present in Autoproposal
0064U,"Antibody, Treponema pallidum, total and rapid plasma reagin (RPR), immunoassay, qualitative",S3628,PLACENTAL ALPHA MICROGLOBULIN-1 RAPID IMMUNOASSAY FOR DETECTION OF RUPTURE OF FETAL MEMBRANES,19.90744050811874,,Present in Autoproposal
0065U,"Syphilis test, non-treponemal antibody, immunoassay, qualitative (RPR)",86592,"Syphilis test, non-treponemal antibody; qualitative (eg, VDRL, RPR, ART)",77.7977802963247,1,Present Both in MD and Autoproposal
0065U,"Syphilis test, non-treponemal antibody, immunoassay, qualitative (RPR)",86593,"Syphilis test, non-treponemal antibody; quantitative",71.33146539999056,,Present in Autoproposal
0065U,"Syphilis test, non-treponemal antibody, immunoassay, qualitative (RPR)",80055,"Obstetric panel This panel must include the following: Blood count, complete (CBC), automated and automated differential WBC count (85025 or 85027 and 85004) OR Blood count, complete (CBC), automated (85027) and appropriate manual differential WBC count (85007 or 85009) Hepatitis B surface antigen (HBsAg) (87340) Antibody, rubella (86762) Syphilis test, non-treponemal antibody; qualitative (eg, VDRL, RPR, ART) (86592) Antibody screen, RBC, each serum technique (86850) Blood typing, ABO (86900) AND Blood typing, Rh (D) (86901)",27.507424244708606,,Present in Autoproposal
0065U,"Syphilis test, non-treponemal antibody, immunoassay, qualitative (RPR)",86318,"Immunoassay for infectious agent antibody, qualitative or semiquantitative, single step method (eg, reagent strip)",25.883894450523698,,Present in Autoproposal
0065U,"Syphilis test, non-treponemal antibody, immunoassay, qualitative (RPR)",80081,"Obstetric panel (includes HIV testing) This panel must include the following: Blood count, complete (CBC), and automated differential WBC count (85025 or 85027 and 85004) OR Blood count, complete (CBC), automated (85027) and appropriate manual differential WBC count (85007 or 85009) Hepatitis B surface antigen (HBsAg) (87340) HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies, single result (87389) Antibody, rubella (86762) Syphilis test, non-treponemal antibody; qualitative (eg, VDRL, RPR, ART) (86592) Antibody screen, RBC, each serum technique (86850) Blood typing, ABO (86900) AND Blood typing, Rh (D) (86901)",25.506772522153803,,Present in Autoproposal
0065U,"Syphilis test, non-treponemal antibody, immunoassay, qualitative (RPR)",86317,"Immunoassay for infectious agent antibody, quantitative, not otherwise specified",24.183549770855706,,Present in Autoproposal
0065U,"Syphilis test, non-treponemal antibody, immunoassay, qualitative (RPR)",86694,"Antibody; herpes simplex, non-specific type test",24.058706644658812,,Present in Autoproposal
0065U,"Syphilis test, non-treponemal antibody, immunoassay, qualitative (RPR)",3512F,Syphilis screening documented as performed (HIV),23.797811220143377,,Present in Autoproposal
0065U,"Syphilis test, non-treponemal antibody, immunoassay, qualitative (RPR)",G9202,PATIENTS WITH A POSITIVE HEPATITIS C ANTIBODY TEST,22.457941834780655,,Present in Autoproposal
0065U,"Syphilis test, non-treponemal antibody, immunoassay, qualitative (RPR)",83516,"Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method",21.981976863857504,,Present in Autoproposal
0066U,"Placental alpha-micro globulin-1 (PAMG1), immunoassay with direct optical observation, cervico-vaginal fluid, each specimen",84112,"Evaluation of cervicovaginal fluid for specific amniotic fluid protein(s) (eg, placental alpha microglobulin-1 [PAMG-1], placental protein 12 [PP12], alpha-fetoprotein), qualitative, each specimen",40.87348564109586,10,Present Both in MD and Autoproposal
0066U,"Placental alpha-micro globulin-1 (PAMG1), immunoassay with direct optical observation, cervico-vaginal fluid, each specimen",87804,Infectious agent antigen detection by immunoassay with direct optical observation; Influenza,40.314710130984984,,Present in Autoproposal
0066U,"Placental alpha-micro globulin-1 (PAMG1), immunoassay with direct optical observation, cervico-vaginal fluid, each specimen",87809,Infectious agent antigen detection by immunoassay with direct optical observation; adenovirus,38.80663339880587,,Present in Autoproposal
0066U,"Placental alpha-micro globulin-1 (PAMG1), immunoassay with direct optical observation, cervico-vaginal fluid, each specimen",87899,Infectious agent antigen detection by immunoassay with direct optical observation; not otherwise specified,38.64403048975444,,Present in Autoproposal
0066U,"Placental alpha-micro globulin-1 (PAMG1), immunoassay with direct optical observation, cervico-vaginal fluid, each specimen",87802,"Infectious agent antigen detection by immunoassay with direct optical observation; Streptococcus, group B",37.287120750555616,,Present in Autoproposal
0066U,"Placental alpha-micro globulin-1 (PAMG1), immunoassay with direct optical observation, cervico-vaginal fluid, each specimen",87880,"Infectious agent antigen detection by immunoassay with direct optical observation; Streptococcus, group A",37.287120750555616,,Present in Autoproposal
0066U,"Placental alpha-micro globulin-1 (PAMG1), immunoassay with direct optical observation, cervico-vaginal fluid, each specimen",87810,Infectious agent antigen detection by immunoassay with direct optical observation; Chlamydia trachomatis,35.88645039443109,,Present in Autoproposal
0066U,"Placental alpha-micro globulin-1 (PAMG1), immunoassay with direct optical observation, cervico-vaginal fluid, each specimen",87807,Infectious agent antigen detection by immunoassay with direct optical observation; respiratory syncytial virus,35.25908397889465,,Present in Autoproposal
0066U,"Placental alpha-micro globulin-1 (PAMG1), immunoassay with direct optical observation, cervico-vaginal fluid, each specimen",87808,Infectious agent antigen detection by immunoassay with direct optical observation; Trichomonas vaginalis,34.97857917345063,,Present in Autoproposal
0066U,"Placental alpha-micro globulin-1 (PAMG1), immunoassay with direct optical observation, cervico-vaginal fluid, each specimen",87850,Infectious agent antigen detection by immunoassay with direct optical observation; Neisseria gonorrhoeae,34.96996640483167,,Present in Autoproposal
0067U,"Oncology (breast), immunohistochemistry, protein expression profiling of 4 biomarkers (matrix metalloproteinase-1 [MMP-1], carcinoembryonic antigen-related cell adhesion molecule 6 [CEACAM6], hyaluronoglucosaminidase [HYAL1], highly expressed in cancer pr",S3854,GENE EXPRESSION PROFILING PANEL FOR USE IN THE MANAGEMENT OF BREAST CANCER TREATMENT,32.058811607431096,7,Present in Autoproposal
0067U,"Oncology (breast), immunohistochemistry, protein expression profiling of 4 biomarkers (matrix metalloproteinase-1 [MMP-1], carcinoembryonic antigen-related cell adhesion molecule 6 [CEACAM6], hyaluronoglucosaminidase [HYAL1], highly expressed in cancer pr",82378,Carcinoembryonic antigen (CEA),28.68068937081576,,Present in Autoproposal
0067U,"Oncology (breast), immunohistochemistry, protein expression profiling of 4 biomarkers (matrix metalloproteinase-1 [MMP-1], carcinoembryonic antigen-related cell adhesion molecule 6 [CEACAM6], hyaluronoglucosaminidase [HYAL1], highly expressed in cancer pr",C1765,ADHESION BARRIER,22.792158376401563,,Present in Autoproposal
0067U,"Oncology (breast), immunohistochemistry, protein expression profiling of 4 biomarkers (matrix metalloproteinase-1 [MMP-1], carcinoembryonic antigen-related cell adhesion molecule 6 [CEACAM6], hyaluronoglucosaminidase [HYAL1], highly expressed in cancer pr",80321,Alcohol biomarkers; 1 or 2,22.606142399863728,,Present in Autoproposal
0067U,"Oncology (breast), immunohistochemistry, protein expression profiling of 4 biomarkers (matrix metalloproteinase-1 [MMP-1], carcinoembryonic antigen-related cell adhesion molecule 6 [CEACAM6], hyaluronoglucosaminidase [HYAL1], highly expressed in cancer pr",80322,Alcohol biomarkers; 3 or more,20.936523998346328,,Present in Autoproposal
0067U,"Oncology (breast), immunohistochemistry, protein expression profiling of 4 biomarkers (matrix metalloproteinase-1 [MMP-1], carcinoembryonic antigen-related cell adhesion molecule 6 [CEACAM6], hyaluronoglucosaminidase [HYAL1], highly expressed in cancer pr",3395F,"Quantitative non-HER2 immunohistochemistry (IHC) evaluation of breast cancer (eg, testing for estrogen or progesterone receptors [ER/PR]) performed (PATH)",20.106349311847012,,Present in Autoproposal
0067U,"Oncology (breast), immunohistochemistry, protein expression profiling of 4 biomarkers (matrix metalloproteinase-1 [MMP-1], carcinoembryonic antigen-related cell adhesion molecule 6 [CEACAM6], hyaluronoglucosaminidase [HYAL1], highly expressed in cancer pr",81519,"Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of 21 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence score",17.636752646107894,,Present Both in MD and Autoproposal
0067U,"Oncology (breast), immunohistochemistry, protein expression profiling of 4 biomarkers (matrix metalloproteinase-1 [MMP-1], carcinoembryonic antigen-related cell adhesion molecule 6 [CEACAM6], hyaluronoglucosaminidase [HYAL1], highly expressed in cancer pr",81313,"PCA3/KLK3 (prostate cancer antigen 3 [non-protein coding]/kallikrein-related peptidase 3 [prostate specific antigen]) ratio (eg, prostate cancer)",17.240070550502196,,Present in Autoproposal
0067U,"Oncology (breast), immunohistochemistry, protein expression profiling of 4 biomarkers (matrix metalloproteinase-1 [MMP-1], carcinoembryonic antigen-related cell adhesion molecule 6 [CEACAM6], hyaluronoglucosaminidase [HYAL1], highly expressed in cancer pr",81521,"Oncology (breast), mRNA, microarray gene expression profiling of 70 content genes and 465 housekeeping genes, utilizing fresh frozen or formalin-fixed paraffin-embedded tissue, algorithm reported as index related to risk of distant metastasis",16.93909015709466,,Present in Autoproposal
0067U,"Oncology (breast), immunohistochemistry, protein expression profiling of 4 biomarkers (matrix metalloproteinase-1 [MMP-1], carcinoembryonic antigen-related cell adhesion molecule 6 [CEACAM6], hyaluronoglucosaminidase [HYAL1], highly expressed in cancer pr",C8100,"ADHESION BARRIER, ADCON-L",16.881766783377135,,Present in Autoproposal
0068U,"Candida species panel (C. albicans, C. glabrata, C. parapsilosis, C. kruseii, C tropicalis, and C. auris), amplified probe technique with qualitative report of the presence or absence of each species",87481,"Infectious agent detection by nucleic acid (DNA or RNA); Candida species, amplified probe technique",55.9250290286929,10,Present Both in MD and Autoproposal
0068U,"Candida species panel (C. albicans, C. glabrata, C. parapsilosis, C. kruseii, C tropicalis, and C. auris), amplified probe technique with qualitative report of the presence or absence of each species",87480,"Infectious agent detection by nucleic acid (DNA or RNA); Candida species, direct probe technique",48.97152821315228,,Present in Autoproposal
0068U,"Candida species panel (C. albicans, C. glabrata, C. parapsilosis, C. kruseii, C tropicalis, and C. auris), amplified probe technique with qualitative report of the presence or absence of each species",87551,"Infectious agent detection by nucleic acid (DNA or RNA); Mycobacteria species, amplified probe technique",43.42778889466431,,Present in Autoproposal
0068U,"Candida species panel (C. albicans, C. glabrata, C. parapsilosis, C. kruseii, C tropicalis, and C. auris), amplified probe technique with qualitative report of the presence or absence of each species",87482,"Infectious agent detection by nucleic acid (DNA or RNA); Candida species, quantification",40.102179650891244,,Present in Autoproposal
0068U,"Candida species panel (C. albicans, C. glabrata, C. parapsilosis, C. kruseii, C tropicalis, and C. auris), amplified probe technique with qualitative report of the presence or absence of each species",87550,"Infectious agent detection by nucleic acid (DNA or RNA); Mycobacteria species, direct probe technique",36.15553076746426,,Present in Autoproposal
0068U,"Candida species panel (C. albicans, C. glabrata, C. parapsilosis, C. kruseii, C tropicalis, and C. auris), amplified probe technique with qualitative report of the presence or absence of each species",87500,"Infectious agent detection by nucleic acid (DNA or RNA); vancomycin resistance (eg, enterococcus species van A, van B), amplified probe technique",30.981665732934584,,Present in Autoproposal
0068U,"Candida species panel (C. albicans, C. glabrata, C. parapsilosis, C. kruseii, C tropicalis, and C. auris), amplified probe technique with qualitative report of the presence or absence of each species",86628,Antibody; Candida,27.656998331399805,,Present in Autoproposal
0068U,"Candida species panel (C. albicans, C. glabrata, C. parapsilosis, C. kruseii, C tropicalis, and C. auris), amplified probe technique with qualitative report of the presence or absence of each species",87552,"Infectious agent detection by nucleic acid (DNA or RNA); Mycobacteria species, quantification",26.568328196483627,,Present in Autoproposal
0068U,"Candida species panel (C. albicans, C. glabrata, C. parapsilosis, C. kruseii, C tropicalis, and C. auris), amplified probe technique with qualitative report of the presence or absence of each species",86485,Skin test; candida,25.327029078884227,,Present in Autoproposal
0068U,"Candida species panel (C. albicans, C. glabrata, C. parapsilosis, C. kruseii, C tropicalis, and C. auris), amplified probe technique with qualitative report of the presence or absence of each species",1090F,Presence or absence of urinary incontinence assessed (GER),24.452582329067575,,Present in Autoproposal
0069U,"Oncology (colorectal), microRNA, RT-PCR expression profiling of miR-31-3p, formalinfixed paraffin-embedded tissue, algorithm reported as an expression score",81519,"Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of 21 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence score",61.81302068394172,10,Present in Autoproposal
0069U,"Oncology (colorectal), microRNA, RT-PCR expression profiling of miR-31-3p, formalinfixed paraffin-embedded tissue, algorithm reported as an expression score",81541,"Oncology (prostate), mRNA gene expression profiling by real-time RT-PCR of 46 genes (31 content and 15 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a disease-specific mortality risk score",58.3115833349756,,Present in Autoproposal
0069U,"Oncology (colorectal), microRNA, RT-PCR expression profiling of miR-31-3p, formalinfixed paraffin-embedded tissue, algorithm reported as an expression score",81525,"Oncology (colon), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a recurrence score",58.251860574269344,,Present in Autoproposal
0069U,"Oncology (colorectal), microRNA, RT-PCR expression profiling of miR-31-3p, formalinfixed paraffin-embedded tissue, algorithm reported as an expression score",81504,"Oncology (tissue of origin), microarray gene expression profiling of > 2000 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as tissue similarity scores",48.24891587307862,,Present in Autoproposal
0069U,"Oncology (colorectal), microRNA, RT-PCR expression profiling of miR-31-3p, formalinfixed paraffin-embedded tissue, algorithm reported as an expression score",81493,"Coronary artery disease, mRNA, gene expression profiling by real-time RT-PCR of 23 genes, utilizing whole peripheral blood, algorithm reported as a risk score",47.36656548385703,,Present in Autoproposal
0069U,"Oncology (colorectal), microRNA, RT-PCR expression profiling of miR-31-3p, formalinfixed paraffin-embedded tissue, algorithm reported as an expression score",0018U,"Oncology (thyroid), microRNA profiling by RT-PCR of 10 microRNA sequences, utilizing fine needle aspirate, algorithm reported as a positive or negative result for moderate to high risk of malignancy",46.335490017021634,,Present in Autoproposal
0069U,"Oncology (colorectal), microRNA, RT-PCR expression profiling of miR-31-3p, formalinfixed paraffin-embedded tissue, algorithm reported as an expression score",81520,"Oncology (breast), mRNA gene expression profiling by hybrid capture of 58 genes (50 content and 8 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a recurrence risk score",46.26684043284826,,Present in Autoproposal
0069U,"Oncology (colorectal), microRNA, RT-PCR expression profiling of miR-31-3p, formalinfixed paraffin-embedded tissue, algorithm reported as an expression score",0005U,"Oncology (prostate) gene expression profile by real-time RT-PCR of 3 genes (ERG, PCA3, and SPDEF), urine, algorithm reported as risk score",43.71584704425672,,Present in Autoproposal
0069U,"Oncology (colorectal), microRNA, RT-PCR expression profiling of miR-31-3p, formalinfixed paraffin-embedded tissue, algorithm reported as an expression score",0019U,"Oncology, RNA, gene expression by whole transcriptome sequencing, formalin-fixed paraffin embedded tissue or fresh frozen tissue, predictive algorithm reported as potential targets for therapeutic agents",38.800658916133315,,Present in Autoproposal
0069U,"Oncology (colorectal), microRNA, RT-PCR expression profiling of miR-31-3p, formalinfixed paraffin-embedded tissue, algorithm reported as an expression score",81540,"Oncology (tumor of unknown origin), mRNA, gene expression profiling by real-time RT-PCR of 92 genes (87 content and 5 housekeeping) to classify tumor into main cancer type and subtype, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a probability of a predicted main cancer type and subtype",37.16890717966142,,Present in Autoproposal
0070U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, common and select rare variants (ie, *2, *3, *4, *4N, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14A, *14B, *15, *17, *29, *35, *36, *41, *57, *61, *63, *68,",81226,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *5, *6, *9, *10, *17, *19, *29, *35, *41, *1XN, *2XN, *4XN)",66.59752501313355,1,Present Both in MD and Autoproposal
0070U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, common and select rare variants (ie, *2, *3, *4, *4N, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14A, *14B, *15, *17, *29, *35, *36, *41, *57, *61, *63, *68,",81225,"CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *8, *17)",56.88915954781183,,Present in Autoproposal
0070U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, common and select rare variants (ie, *2, *3, *4, *4N, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14A, *14B, *15, *17, *29, *35, *36, *41, *57, *61, *63, *68,",81227,"CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *5, *6)",55.96206168327175,,Present in Autoproposal
0070U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, common and select rare variants (ie, *2, *3, *4, *4N, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14A, *14B, *15, *17, *29, *35, *36, *41, *57, *61, *63, *68,",0028U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, copy number variants, common variants with reflex to targeted sequence analysis",54.023294510859834,,Present in Autoproposal
0070U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, common and select rare variants (ie, *2, *3, *4, *4N, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14A, *14B, *15, *17, *29, *35, *36, *41, *57, *61, *63, *68,",81231,"CYP3A5 (cytochrome P450 family 3 subfamily A member 5) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *5, *6, *7)",49.64502536574779,,Present in Autoproposal
0070U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, common and select rare variants (ie, *2, *3, *4, *4N, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14A, *14B, *15, *17, *29, *35, *36, *41, *57, *61, *63, *68,",0031U,"CYP1A2 (cytochrome P450 family 1, subfamily A, member 2)(eg, drug metabolism) gene analysis, common variants (ie, *1F, *1K, *6, *7)",46.03801420128778,,Present in Autoproposal
0070U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, common and select rare variants (ie, *2, *3, *4, *4N, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14A, *14B, *15, *17, *29, *35, *36, *41, *57, *61, *63, *68,",81230,"CYP3A4 (cytochrome P450 family 3 subfamily A member 4) (eg, drug metabolism), gene analysis, common variant(s) (eg, *2, *22)",43.75990046114947,,Present in Autoproposal
0070U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, common and select rare variants (ie, *2, *3, *4, *4N, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14A, *14B, *15, *17, *29, *35, *36, *41, *57, *61, *63, *68,",81350,"UGT1A1 (UDP glucuronosyltransferase 1 family, polypeptide A1) (eg, irinotecan metabolism), gene analysis, common variants (eg, *28, *36, *37)",31.81071095413458,,Present in Autoproposal
0070U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, common and select rare variants (ie, *2, *3, *4, *4N, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14A, *14B, *15, *17, *29, *35, *36, *41, *57, *61, *63, *68,",81335,"TPMT (thiopurine S-methyltransferase) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3)",27.782392202185314,,Present in Autoproposal
0070U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, common and select rare variants (ie, *2, *3, *4, *4N, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14A, *14B, *15, *17, *29, *35, *36, *41, *57, *61, *63, *68,",81402,"Molecular pathology procedure, Level 3 (eg, >10 SNPs, 2-10 methylated variants, or 2-10 somatic variants [typically using non-sequencing target variant analysis], immunoglobulin and T-cell receptor gene rearrangements, duplication/deletion variants of 1 exon, loss of heterozygosity [LOH], uniparental disomy [UPD]) Chromosome 1p-/19q- (eg, glial tumors), deletion analysis Chromosome 18q- (eg, D18S55, D18S58, D18S61, D18S64, and D18S69) (eg, colon cancer), allelic imbalance assessment (ie, loss of heterozygosity) COL1A1/PDGFB (t(17;22)) (eg, dermatofibrosarcoma protuberans), translocation analysis, multiple breakpoints, qualitative, and quantitative, if performed CYP21A2 (cytochrome P450, family 21, subfamily A, polypeptide 2) (eg, congenital adrenal hyperplasia, 21-hydroxylase deficiency), common variants (eg, IVS2-13G, P30L, I172N, exon 6 mutation cluster [I235N, V236E, M238K], V281L, L307FfsX6, Q318X, R356W, P453S, G110VfsX21, 30-kb deletion variant) ESR1/PGR (receptor 1/progesterone receptor) ratio (eg, breast cancer) IGH@/BCL2 (t(14;18)) (eg, follicular lymphoma), translocation analysis; major breakpoint region (MBR) and minor cluster region (mcr) breakpoints, qualitative or quantitative MEFV (Mediterranean fever) (eg, familial Mediterranean fever), common variants (eg, E148Q, P369S, F479L, M680I, I692del, M694V, M694I, K695R, V726A, A744S, R761H) MPL (myeloproliferative leukemia virus oncogene, thrombopoietin receptor, TPOR) (eg, myeloproliferative disorder), common variants (eg, W515A, W515K, W515L, W515R) TRD@ (T cell antigen receptor, delta) (eg, leukemia and lymphoma), gene rearrangement analysis, evaluation to detect abnormal clonal population Uniparental disomy (UPD) (eg, Russell-Silver syndrome, Prader-Willi/Angelman syndrome), short tandem repeat (STR) analysis",21.919136691840784,,Present in Autoproposal
0071U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, full gene sequence (List separately in addition to code for primary procedure)",81227,"CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *5, *6)",67.7802347730701,6,Present in Autoproposal
0071U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, full gene sequence (List separately in addition to code for primary procedure)",0028U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, copy number variants, common variants with reflex to targeted sequence analysis",67.35849993867035,,Present in Autoproposal
0071U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, full gene sequence (List separately in addition to code for primary procedure)",81225,"CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *8, *17)",62.42016631180112,,Present in Autoproposal
0071U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, full gene sequence (List separately in addition to code for primary procedure)",81231,"CYP3A5 (cytochrome P450 family 3 subfamily A member 5) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *5, *6, *7)",59.34051628988084,,Present in Autoproposal
0071U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, full gene sequence (List separately in addition to code for primary procedure)",81230,"CYP3A4 (cytochrome P450 family 3 subfamily A member 4) (eg, drug metabolism), gene analysis, common variant(s) (eg, *2, *22)",57.2529425935998,,Present in Autoproposal
0071U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, full gene sequence (List separately in addition to code for primary procedure)",81226,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *5, *6, *9, *10, *17, *19, *29, *35, *41, *1XN, *2XN, *4XN)",56.72929543945966,,Present Both in MD and Autoproposal
0071U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, full gene sequence (List separately in addition to code for primary procedure)",0031U,"CYP1A2 (cytochrome P450 family 1, subfamily A, member 2)(eg, drug metabolism) gene analysis, common variants (ie, *1F, *1K, *6, *7)",50.90383390738174,,Present in Autoproposal
0071U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, full gene sequence (List separately in addition to code for primary procedure)",81406,"Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2 [S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-girdle muscular dystrophy), full gene sequence ANOS1 (anosmin-1) (eg, Kallmann syndrome 1), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+ transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Bera08, arrhythmogenic right ventricular cardiomyopathy), full gene sequence TNNT2 (troponin T, type 2 [cardiac]) (eg, familial hypertrophic cardiomyopathy), full gene sequence TRPC6 (transient receptor potential cation channel, subfamily C, member 6) (eg, focal segmental glomerulosclerosis), full gene sequence TSC1 (tuberous sclerosis 1) (eg, tuberous sclerosis), full gene sequence TSC2 (tuberous sclerosis 2) (eg, tuberous sclerosis), duplication/deletion analysis UBE3A (ubiquitin protein ligase E3A) (eg, Angelman syndrome), full gene sequence UMOD (uromodulin) (eg, glomerulocystic kidney disease with hyperuricemia and isosthenuria), full gene sequence VWF (von Willebrand factor) (von Willebrand disease type 2A), extended targeted sequence analysis (eg, exons 11-16, 24-26, 51, 52) WAS (Wiskott-Aldrich syndrome [eczema-thrombocytopenia]) (eg, Wiskott-Aldrich syndrome), full gene sequence",44.62122982011109,,Present in Autoproposal
0071U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, full gene sequence (List separately in addition to code for primary procedure)",81408,"Molecular pathology procedure, Level 9 (eg, analysis of >50 exons in a single gene by DNA sequence analysis) ABCA4 (ATP-binding cassette, sub-family A [ABC1], member 4) (eg, Stargardt disease, age-related macular degeneration), full gene sequence ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia), full gene sequence CDH23 (cadherin-related 23) (eg, Usher syndrome, type 1), full gene sequence CEP290 (centrosomal protein 290kDa) (eg, Joubert syndrome), full gene sequence COL1A1 (collagen, type I, alpha 1) (eg, osteogenesis imperfecta, type I), full gene sequence COL1A2 (collagen, type I, alpha 2) (eg, osteogenesis imperfecta, type I), full gene sequence COL4A1 (collagen, type IV, alpha 1) (eg, brain small-vessel disease with hemorrhage), full gene sequence COL4A3 (collagen, type IV, alpha 3 [Goodpasture antigen]) (eg, Alport syndrome), full gene sequence COL4A5 (collagen, type IV, alpha 5) (eg, Alport syndrome), full gene sequence DMD (dystrophin) (eg, Duchenne/Becker muscular dystrophy), full gene sequence DYSF (dysferlin, limb girdle muscular dystrophy 2B [autosomal recessive]) (eg, limb-girdle muscular dystrophy), full gene sequence FBN1 (fibrillin 1) (eg, Marfan syndrome), full gene sequence ITPR1 (inositol 1,4,5-trisphosphate receptor, type 1) (eg, spinocerebellar ataxia), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LRRK2 (leucine-rich repeat kinase 2) (eg, Parkinson disease), full gene sequence MYH11 (myosin, heavy chain 11, smooth muscle) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence NEB (nebulin) (eg, nemaline myopathy 2), full gene sequence NF1 (neurofibromin 1) (eg, neurofibromatosis, type 1), full gene sequence PKHD1 (polycystic kidney and hepatic disease 1) (eg, autosomal recessive polycystic kidney disease), full gene sequence RYR1 (ryanodine receptor 1, skeletal) (eg, malignant hyperthermia), full gene sequence RYR2 (ryanodine receptor 2 [cardiac]) (eg, cate01cholaminergic polymorphic ventricular tachycardia, arrhythmogenic right ventricular dysplasia), full gene sequence or targeted sequence analysis of > 50 exons USH2A (Usher syndrome 2A [autosomal recessive, mild]) (eg, Usher syndrome, type 2), full gene sequence VPS13B (vacuolar protein sorting 13 homolog B [yeast]) (eg, Cohen syndrome), full gene sequence VWF (von Willebrand factor) (eg, von Willebrand disease types 1 and 3), full gene sequence",41.86308114939254,,Present in Autoproposal
0071U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, full gene sequence (List separately in addition to code for primary procedure)",S3819,COMPLETE GENE SEQUENCE ANALYSIS; BRCA2 GENE,39.47822811274461,,Present in Autoproposal
0072U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, CYP2D6-2D7 hybrid gene) (List separately in addition to code for primary procedure)",0028U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, copy number variants, common variants with reflex to targeted sequence analysis",69.72194559860641,10,Present in Autoproposal
0072U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, CYP2D6-2D7 hybrid gene) (List separately in addition to code for primary procedure)",81227,"CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *5, *6)",57.00792201491542,,Present in Autoproposal
0072U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, CYP2D6-2D7 hybrid gene) (List separately in addition to code for primary procedure)",81226,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *5, *6, *9, *10, *17, *19, *29, *35, *41, *1XN, *2XN, *4XN)",54.000537590494616,,Present Both in MD and Autoproposal
0072U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, CYP2D6-2D7 hybrid gene) (List separately in addition to code for primary procedure)",81225,"CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *8, *17)",52.49972923780754,,Present in Autoproposal
0072U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, CYP2D6-2D7 hybrid gene) (List separately in addition to code for primary procedure)",81231,"CYP3A5 (cytochrome P450 family 3 subfamily A member 5) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *5, *6, *7)",50.2140362955592,,Present in Autoproposal
0072U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, CYP2D6-2D7 hybrid gene) (List separately in addition to code for primary procedure)",81230,"CYP3A4 (cytochrome P450 family 3 subfamily A member 4) (eg, drug metabolism), gene analysis, common variant(s) (eg, *2, *22)",48.44752821796455,,Present in Autoproposal
0072U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, CYP2D6-2D7 hybrid gene) (List separately in addition to code for primary procedure)",0031U,"CYP1A2 (cytochrome P450 family 1, subfamily A, member 2)(eg, drug metabolism) gene analysis, common variants (ie, *1F, *1K, *6, *7)",46.70218586161352,,Present in Autoproposal
0072U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, CYP2D6-2D7 hybrid gene) (List separately in addition to code for primary procedure)",S3818,COMPLETE GENE SEQUENCE ANALYSIS; BRCA1 GENE,35.47747405942339,,Present in Autoproposal
0072U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, CYP2D6-2D7 hybrid gene) (List separately in addition to code for primary procedure)",S3819,COMPLETE GENE SEQUENCE ANALYSIS; BRCA2 GENE,35.47747405942339,,Present in Autoproposal
0072U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, CYP2D6-2D7 hybrid gene) (List separately in addition to code for primary procedure)",S3828,COMPLETE GENE SEQUENCE ANALYSIS; MLH1 GENE,35.400155369313,,Present in Autoproposal
0073U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, CYP2D7-2D6 hybrid gene) (List separately in addition to code for primary procedure)",0028U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, copy number variants, common variants with reflex to targeted sequence analysis",69.92458616026599,6,Present in Autoproposal
0073U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, CYP2D7-2D6 hybrid gene) (List separately in addition to code for primary procedure)",81227,"CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *5, *6)",63.66410535932885,,Present in Autoproposal
0073U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, CYP2D7-2D6 hybrid gene) (List separately in addition to code for primary procedure)",81225,"CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *8, *17)",58.62954086727689,,Present in Autoproposal
0073U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, CYP2D7-2D6 hybrid gene) (List separately in addition to code for primary procedure)",81231,"CYP3A5 (cytochrome P450 family 3 subfamily A member 5) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *5, *6, *7)",56.07697288810548,,Present in Autoproposal
0073U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, CYP2D7-2D6 hybrid gene) (List separately in addition to code for primary procedure)",81230,"CYP3A4 (cytochrome P450 family 3 subfamily A member 4) (eg, drug metabolism), gene analysis, common variant(s) (eg, *2, *22)",54.10420923710508,,Present in Autoproposal
0073U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, CYP2D7-2D6 hybrid gene) (List separately in addition to code for primary procedure)",81226,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *5, *6, *9, *10, *17, *19, *29, *35, *41, *1XN, *2XN, *4XN)",52.96433744303764,,Present Both in MD and Autoproposal
0073U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, CYP2D7-2D6 hybrid gene) (List separately in addition to code for primary procedure)",0031U,"CYP1A2 (cytochrome P450 family 1, subfamily A, member 2)(eg, drug metabolism) gene analysis, common variants (ie, *1F, *1K, *6, *7)",52.15508259407889,,Present in Autoproposal
0073U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, CYP2D7-2D6 hybrid gene) (List separately in addition to code for primary procedure)",S3818,COMPLETE GENE SEQUENCE ANALYSIS; BRCA1 GENE,39.61978557666146,,Present in Autoproposal
0073U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, CYP2D7-2D6 hybrid gene) (List separately in addition to code for primary procedure)",S3819,COMPLETE GENE SEQUENCE ANALYSIS; BRCA2 GENE,39.61978557666146,,Present in Autoproposal
0073U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, CYP2D7-2D6 hybrid gene) (List separately in addition to code for primary procedure)",S3828,COMPLETE GENE SEQUENCE ANALYSIS; MLH1 GENE,39.53343923988136,,Present in Autoproposal
0074U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, non-duplicated gene when duplication/multiplication is trans) (List separately in addition to code for primary procedure)",0028U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, copy number variants, common variants with reflex to targeted sequence analysis",63.534351551182944,10,Present in Autoproposal
0074U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, non-duplicated gene when duplication/multiplication is trans) (List separately in addition to code for primary procedure)",81227,"CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *5, *6)",57.84600057296589,,Present in Autoproposal
0074U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, non-duplicated gene when duplication/multiplication is trans) (List separately in addition to code for primary procedure)",81225,"CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *8, *17)",53.27153245080925,,Present in Autoproposal
0074U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, non-duplicated gene when duplication/multiplication is trans) (List separately in addition to code for primary procedure)",81231,"CYP3A5 (cytochrome P450 family 3 subfamily A member 5) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *5, *6, *7)",50.95223733227592,,Present in Autoproposal
0074U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, non-duplicated gene when duplication/multiplication is trans) (List separately in addition to code for primary procedure)",81230,"CYP3A4 (cytochrome P450 family 3 subfamily A member 4) (eg, drug metabolism), gene analysis, common variant(s) (eg, *2, *22)",49.159759661506705,,Present in Autoproposal
0074U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, non-duplicated gene when duplication/multiplication is trans) (List separately in addition to code for primary procedure)",81226,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *5, *6, *9, *10, *17, *19, *29, *35, *41, *1XN, *2XN, *4XN)",48.12405792533095,,Present Both in MD and Autoproposal
0074U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, non-duplicated gene when duplication/multiplication is trans) (List separately in addition to code for primary procedure)",0031U,"CYP1A2 (cytochrome P450 family 1, subfamily A, member 2)(eg, drug metabolism) gene analysis, common variants (ie, *1F, *1K, *6, *7)",47.38875887114132,,Present in Autoproposal
0074U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, non-duplicated gene when duplication/multiplication is trans) (List separately in addition to code for primary procedure)",S3818,COMPLETE GENE SEQUENCE ANALYSIS; BRCA1 GENE,35.99903157725775,,Present in Autoproposal
0074U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, non-duplicated gene when duplication/multiplication is trans) (List separately in addition to code for primary procedure)",S3819,COMPLETE GENE SEQUENCE ANALYSIS; BRCA2 GENE,35.99903157725775,,Present in Autoproposal
0074U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, non-duplicated gene when duplication/multiplication is trans) (List separately in addition to code for primary procedure)",S3828,COMPLETE GENE SEQUENCE ANALYSIS; MLH1 GENE,35.92057621817177,,Present in Autoproposal
0075U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 5 gene duplication/multiplication) (List separately in addition to code for primary procedure)",0028U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, copy number variants, common variants with reflex to targeted sequence analysis",70.47699818027327,6,Present in Autoproposal
0075U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 5 gene duplication/multiplication) (List separately in addition to code for primary procedure)",81227,"CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *5, *6)",64.16705888361423,,Present in Autoproposal
0075U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 5 gene duplication/multiplication) (List separately in addition to code for primary procedure)",81225,"CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *8, *17)",59.09272077124314,,Present in Autoproposal
0075U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 5 gene duplication/multiplication) (List separately in addition to code for primary procedure)",81231,"CYP3A5 (cytochrome P450 family 3 subfamily A member 5) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *5, *6, *7)",56.51998722068961,,Present in Autoproposal
0075U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 5 gene duplication/multiplication) (List separately in addition to code for primary procedure)",81230,"CYP3A4 (cytochrome P450 family 3 subfamily A member 4) (eg, drug metabolism), gene analysis, common variant(s) (eg, *2, *22)",54.5316385170877,,Present in Autoproposal
0075U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 5 gene duplication/multiplication) (List separately in addition to code for primary procedure)",81226,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *5, *6, *9, *10, *17, *19, *29, *35, *41, *1XN, *2XN, *4XN)",53.38276160886962,,Present Both in MD and Autoproposal
0075U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 5 gene duplication/multiplication) (List separately in addition to code for primary procedure)",0031U,"CYP1A2 (cytochrome P450 family 1, subfamily A, member 2)(eg, drug metabolism) gene analysis, common variants (ie, *1F, *1K, *6, *7)",52.56711355645608,,Present in Autoproposal
0075U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 5 gene duplication/multiplication) (List separately in addition to code for primary procedure)",S3818,COMPLETE GENE SEQUENCE ANALYSIS; BRCA1 GENE,39.93278629621516,,Present in Autoproposal
0075U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 5 gene duplication/multiplication) (List separately in addition to code for primary procedure)",S3819,COMPLETE GENE SEQUENCE ANALYSIS; BRCA2 GENE,39.93278629621516,,Present in Autoproposal
0075U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 5 gene duplication/multiplication) (List separately in addition to code for primary procedure)",S3828,COMPLETE GENE SEQUENCE ANALYSIS; MLH1 GENE,39.84575781375584,,Present in Autoproposal
0076U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 3 gene duplication/ multiplication) (List separately in addition to code for primary procedure)",0028U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, copy number variants, common variants with reflex to targeted sequence analysis",70.47699818027327,10,Present in Autoproposal
0076U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 3 gene duplication/ multiplication) (List separately in addition to code for primary procedure)",81227,"CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *5, *6)",64.16705888361423,,Present in Autoproposal
0076U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 3 gene duplication/ multiplication) (List separately in addition to code for primary procedure)",81225,"CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *8, *17)",59.09272077124314,,Present in Autoproposal
0076U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 3 gene duplication/ multiplication) (List separately in addition to code for primary procedure)",81231,"CYP3A5 (cytochrome P450 family 3 subfamily A member 5) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *5, *6, *7)",56.51998722068961,,Present in Autoproposal
0076U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 3 gene duplication/ multiplication) (List separately in addition to code for primary procedure)",81230,"CYP3A4 (cytochrome P450 family 3 subfamily A member 4) (eg, drug metabolism), gene analysis, common variant(s) (eg, *2, *22)",54.5316385170877,,Present in Autoproposal
0076U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 3 gene duplication/ multiplication) (List separately in addition to code for primary procedure)",81226,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *5, *6, *9, *10, *17, *19, *29, *35, *41, *1XN, *2XN, *4XN)",53.38276160886962,,Present Both in MD and Autoproposal
0076U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 3 gene duplication/ multiplication) (List separately in addition to code for primary procedure)",0031U,"CYP1A2 (cytochrome P450 family 1, subfamily A, member 2)(eg, drug metabolism) gene analysis, common variants (ie, *1F, *1K, *6, *7)",52.56711355645608,,Present in Autoproposal
0076U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 3 gene duplication/ multiplication) (List separately in addition to code for primary procedure)",S3818,COMPLETE GENE SEQUENCE ANALYSIS; BRCA1 GENE,39.93278629621516,,Present in Autoproposal
0076U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 3 gene duplication/ multiplication) (List separately in addition to code for primary procedure)",S3819,COMPLETE GENE SEQUENCE ANALYSIS; BRCA2 GENE,39.93278629621516,,Present in Autoproposal
0076U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 3 gene duplication/ multiplication) (List separately in addition to code for primary procedure)",S3828,COMPLETE GENE SEQUENCE ANALYSIS; MLH1 GENE,39.84575781375584,,Present in Autoproposal
0077U,"Immunoglobulin paraprotein (M-protein), qualitative, immunoprecipitation and mass spectrometry, blood or urine, including isotype",83788,"Mass spectrometry and tandem mass spectrometry (MS, MS/MS), analyte not elsewhere specified; qualitative, each specimen",41.494755281125215,10,Present in Autoproposal
0077U,"Immunoglobulin paraprotein (M-protein), qualitative, immunoprecipitation and mass spectrometry, blood or urine, including isotype",84578,"Urobilinogen, urine; qualitative",33.9188074958339,,Present in Autoproposal
0077U,"Immunoglobulin paraprotein (M-protein), qualitative, immunoprecipitation and mass spectrometry, blood or urine, including isotype",83789,"Mass spectrometry and tandem mass spectrometry (eg, MS, MS/MS, MALDI, MS-TOF, QTOF), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen",33.46562693141277,,Present in Autoproposal
0077U,"Immunoglobulin paraprotein (M-protein), qualitative, immunoprecipitation and mass spectrometry, blood or urine, including isotype",84119,"Porphyrins, urine; qualitative",32.859856405375034,,Present in Autoproposal
0077U,"Immunoglobulin paraprotein (M-protein), qualitative, immunoprecipitation and mass spectrometry, blood or urine, including isotype",84106,"Porphobilinogen, urine; qualitative",31.96760141034089,,Present in Autoproposal
0077U,"Immunoglobulin paraprotein (M-protein), qualitative, immunoprecipitation and mass spectrometry, blood or urine, including isotype",83633,"Lactose, urine, qualitative",31.96760141034089,,Present in Autoproposal
0077U,"Immunoglobulin paraprotein (M-protein), qualitative, immunoprecipitation and mass spectrometry, blood or urine, including isotype",G8770,URINE PROTEIN TEST RESULT DOCUMENTED AND REVIEWED,30.95781461781123,,Present in Autoproposal
0077U,"Immunoglobulin paraprotein (M-protein), qualitative, immunoprecipitation and mass spectrometry, blood or urine, including isotype",0025U,"Tenofovir, by liquid chromatography with tandem mass spectrometry (LC-MS/MS), urine, quantitative",30.758853096538214,,Present in Autoproposal
0077U,"Immunoglobulin paraprotein (M-protein), qualitative, immunoprecipitation and mass spectrometry, blood or urine, including isotype",82787,"Gammaglobulin (immunoglobulin); immunoglobulin subclasses (eg, IgG1, 2, 3, or 4), each",30.454468600066452,,Present in Autoproposal
0077U,"Immunoglobulin paraprotein (M-protein), qualitative, immunoprecipitation and mass spectrometry, blood or urine, including isotype",84156,"Protein, total, except by refractometry; urine",28.59143807705134,,Present in Autoproposal
0078U,"Pain management (opioid-use disorder) genotyping panel, 16 common variants (ie, ABCB1, COMT, DAT1, DBH, DOR, DRD1, DRD2, DRD4, GABA, GAL, HTR2A, HTTLPR, MTHFR, MUOR, OPRK1, OPRM1), buccal swab or other germline tissue sample, algorithm reported as positiv",81265,"Comparative analysis using Short Tandem Repeat (STR) markers; patient and comparative specimen (eg, pre-transplant recipient and donor germline testing, post-transplant non-hematopoietic recipient germline [eg, buccal swab or other germline tissue sample] and donor testing, twin zygosity testing, or maternal cell contamination of fetal cells)",24.390192916109637,10,Present in Autoproposal
0078U,"Pain management (opioid-use disorder) genotyping panel, 16 common variants (ie, ABCB1, COMT, DAT1, DBH, DOR, DRD1, DRD2, DRD4, GABA, GAL, HTR2A, HTTLPR, MTHFR, MUOR, OPRK1, OPRM1), buccal swab or other germline tissue sample, algorithm reported as positiv",81291,"MTHFR (5,10-methylenetetrahydrofolate reductase) (eg, hereditary hypercoagulability) gene analysis, common variants (eg, 677T, 1298C)",17.479617074015987,,Present in Autoproposal
0078U,"Pain management (opioid-use disorder) genotyping panel, 16 common variants (ie, ABCB1, COMT, DAT1, DBH, DOR, DRD1, DRD2, DRD4, GABA, GAL, HTR2A, HTTLPR, MTHFR, MUOR, OPRK1, OPRM1), buccal swab or other germline tissue sample, algorithm reported as positiv",0033U,"HTR2A (5-hydroxytryptamine receptor 2A), HTR2C (5-hydroxytryptamine receptor 2C) (eg, citalopram metabolism) gene analysis, common variants (ie, HTR2A rs7997012 [c.614-2211T>C], HTR2C rs3813929 [c.-759C>T] and rs1414334 [c.551-3008C>G])",16.9818735090831,,Present in Autoproposal
0078U,"Pain management (opioid-use disorder) genotyping panel, 16 common variants (ie, ABCB1, COMT, DAT1, DBH, DOR, DRD1, DRD2, DRD4, GABA, GAL, HTR2A, HTTLPR, MTHFR, MUOR, OPRK1, OPRM1), buccal swab or other germline tissue sample, algorithm reported as positiv",81504,"Oncology (tissue of origin), microarray gene expression profiling of > 2000 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as tissue similarity scores",14.778418219496231,,Present in Autoproposal
0078U,"Pain management (opioid-use disorder) genotyping panel, 16 common variants (ie, ABCB1, COMT, DAT1, DBH, DOR, DRD1, DRD2, DRD4, GABA, GAL, HTR2A, HTTLPR, MTHFR, MUOR, OPRK1, OPRM1), buccal swab or other germline tissue sample, algorithm reported as positiv",80329,"Analgesics, non-opioid; 1 or 2",13.578924544687213,,Present in Autoproposal
0078U,"Pain management (opioid-use disorder) genotyping panel, 16 common variants (ie, ABCB1, COMT, DAT1, DBH, DOR, DRD1, DRD2, DRD4, GABA, GAL, HTR2A, HTTLPR, MTHFR, MUOR, OPRK1, OPRM1), buccal swab or other germline tissue sample, algorithm reported as positiv",0022U,"Targeted genomic sequence analysis panel, non-small cell lung neoplasia, DNA and RNA analysis, 23 genes, interrogation for sequence variants and rearrangements, reported as presence/absence of variants and associated therapy(ies) to consider",13.325678971867777,,Present in Autoproposal
0078U,"Pain management (opioid-use disorder) genotyping panel, 16 common variants (ie, ABCB1, COMT, DAT1, DBH, DOR, DRD1, DRD2, DRD4, GABA, GAL, HTR2A, HTTLPR, MTHFR, MUOR, OPRK1, OPRM1), buccal swab or other germline tissue sample, algorithm reported as positiv",G8512,PAIN SEVERITY QUANTIFIED; PAIN PRESENT,13.170875008852894,,Present in Autoproposal
0078U,"Pain management (opioid-use disorder) genotyping panel, 16 common variants (ie, ABCB1, COMT, DAT1, DBH, DOR, DRD1, DRD2, DRD4, GABA, GAL, HTR2A, HTTLPR, MTHFR, MUOR, OPRK1, OPRM1), buccal swab or other germline tissue sample, algorithm reported as positiv",0019U,"Oncology, RNA, gene expression by whole transcriptome sequencing, formalin-fixed paraffin embedded tissue or fresh frozen tissue, predictive algorithm reported as potential targets for therapeutic agents",13.103905602057855,,Present in Autoproposal
0078U,"Pain management (opioid-use disorder) genotyping panel, 16 common variants (ie, ABCB1, COMT, DAT1, DBH, DOR, DRD1, DRD2, DRD4, GABA, GAL, HTR2A, HTTLPR, MTHFR, MUOR, OPRK1, OPRM1), buccal swab or other germline tissue sample, algorithm reported as positiv",G9578,DOCUMENTATION OF SIGNED OPIOID TREATMENT AGREEMENT AT LEAST ONCE DURING OPIOID THERAPY,12.958384978932294,,Present in Autoproposal
0078U,"Pain management (opioid-use disorder) genotyping panel, 16 common variants (ie, ABCB1, COMT, DAT1, DBH, DOR, DRD1, DRD2, DRD4, GABA, GAL, HTR2A, HTTLPR, MTHFR, MUOR, OPRK1, OPRM1), buccal swab or other germline tissue sample, algorithm reported as positiv",0500T,"Infectious agent detection by nucleic acid (DNA or RNA), Human Papillomavirus (HPV) for five or more separately reported high-risk HPV types (eg, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) (ie, genotyping)",12.955353033330063,,Present in Autoproposal
0079U,"Comparative DNA analysis using multiple selected single-nucleotide polymorphisms (SNPs), urine and buccal DNA, for specimen identity verification",0004M,"Scoliosis, DNA analysis of 53 single nucleotide polymorphisms (SNPs), using saliva, prognostic algorithm reported as a risk score",46.42974854384342,8,Present in Autoproposal
0079U,"Comparative DNA analysis using multiple selected single-nucleotide polymorphisms (SNPs), urine and buccal DNA, for specimen identity verification",0007U,"Drug test(s), presumptive, with definitive confirmation of positive results, any number of drug classes, urine, includes specimen verification including DNA authentication in comparison to buccal DNA, per date of service",33.719376365636585,,Present in Autoproposal
0079U,"Comparative DNA analysis using multiple selected single-nucleotide polymorphisms (SNPs), urine and buccal DNA, for specimen identity verification",0020U,"Drug test(s), presumptive, with definitive confirmation of positive results, any number of drug classes, urine, with specimen verification including DNA authentication in comparison to buccal DNA, per date of service",33.66313171598267,,Present in Autoproposal
0079U,"Comparative DNA analysis using multiple selected single-nucleotide polymorphisms (SNPs), urine and buccal DNA, for specimen identity verification",S3890,"DNA ANALYSIS, FECAL, FOR COLORECTAL CANCER SCREENING",21.550246888646267,,Present in Autoproposal
0079U,"Comparative DNA analysis using multiple selected single-nucleotide polymorphisms (SNPs), urine and buccal DNA, for specimen identity verification",0009M,"Fetal aneuploidy (trisomy 21, and 18) DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy",20.58045930112454,,Present in Autoproposal
0079U,"Comparative DNA analysis using multiple selected single-nucleotide polymorphisms (SNPs), urine and buccal DNA, for specimen identity verification",0005M,"Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy",20.098922177645328,,Present in Autoproposal
0079U,"Comparative DNA analysis using multiple selected single-nucleotide polymorphisms (SNPs), urine and buccal DNA, for specimen identity verification",81507,"Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy",20.098922177645328,,Present in Autoproposal
0079U,"Comparative DNA analysis using multiple selected single-nucleotide polymorphisms (SNPs), urine and buccal DNA, for specimen identity verification",81265,"Comparative analysis using Short Tandem Repeat (STR) markers; patient and comparative specimen (eg, pre-transplant recipient and donor germline testing, post-transplant non-hematopoietic recipient germline [eg, buccal swab or other germline tissue sample] and donor testing, twin zygosity testing, or maternal cell contamination of fetal cells)",19.903300546717507,,Present Both in MD and Autoproposal
0079U,"Comparative DNA analysis using multiple selected single-nucleotide polymorphisms (SNPs), urine and buccal DNA, for specimen identity verification",88358,"Morphometric analysis; tumor (eg, DNA ploidy)",18.834381558272074,,Present in Autoproposal
0079U,"Comparative DNA analysis using multiple selected single-nucleotide polymorphisms (SNPs), urine and buccal DNA, for specimen identity verification",88182,"Flow cytometry, cell cycle or DNA analysis",18.75603917836426,,Present in Autoproposal
0505T,"Endovenous femoral-popliteal arterial revascularization, with transcatheter placement of intravascular stent graft(s) and closure by any method, including percutaneous or open vascular access, ultrasound guidance for vascular access when performed, all catheterization(s) and intraprocedural roadmapping and imaging guidance necessary to complete the intervention, all associated radiological supervision and interpretation, when performed, with crossing of the occlusive lesion in an extraluminal fashion",37191,"Insertion of intravascular vena cava filter, endovascular approach including vascular access, vessel selection, and radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance (ultrasound and fluoroscopy), when performed",51.44703468584593,10,Present in Autoproposal
0505T,"Endovenous femoral-popliteal arterial revascularization, with transcatheter placement of intravascular stent graft(s) and closure by any method, including percutaneous or open vascular access, ultrasound guidance for vascular access when performed, all catheterization(s) and intraprocedural roadmapping and imaging guidance necessary to complete the intervention, all associated radiological supervision and interpretation, when performed, with crossing of the occlusive lesion in an extraluminal fashion",37192,"Repositioning of intravascular vena cava filter, endovascular approach including vascular access, vessel selection, and radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance (ultrasound and fluoroscopy), when performed",50.82296602393433,,Present in Autoproposal
0505T,"Endovenous femoral-popliteal arterial revascularization, with transcatheter placement of intravascular stent graft(s) and closure by any method, including percutaneous or open vascular access, ultrasound guidance for vascular access when performed, all catheterization(s) and intraprocedural roadmapping and imaging guidance necessary to complete the intervention, all associated radiological supervision and interpretation, when performed, with crossing of the occlusive lesion in an extraluminal fashion",37193,"Retrieval (removal) of intravascular vena cava filter, endovascular approach including vascular access, vessel selection, and radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance (ultrasound and fluoroscopy), when performed",49.76777606040444,,Present in Autoproposal
0505T,"Endovenous femoral-popliteal arterial revascularization, with transcatheter placement of intravascular stent graft(s) and closure by any method, including percutaneous or open vascular access, ultrasound guidance for vascular access when performed, all catheterization(s) and intraprocedural roadmapping and imaging guidance necessary to complete the intervention, all associated radiological supervision and interpretation, when performed, with crossing of the occlusive lesion in an extraluminal fashion",50695,"Placement of ureteral stent, percutaneous, including diagnostic nephrostogram and/or ureterogram when performed, imaging guidance (eg, ultrasound and/or fluoroscopy), and all associated radiological supervision and interpretation; new access, with separate nephrostomy catheter",47.552629834617136,,Present in Autoproposal
0505T,"Endovenous femoral-popliteal arterial revascularization, with transcatheter placement of intravascular stent graft(s) and closure by any method, including percutaneous or open vascular access, ultrasound guidance for vascular access when performed, all catheterization(s) and intraprocedural roadmapping and imaging guidance necessary to complete the intervention, all associated radiological supervision and interpretation, when performed, with crossing of the occlusive lesion in an extraluminal fashion",37244,"Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; for arterial or venous hemorrhage or lymphatic extravasation",46.684017891030265,,Present in Autoproposal
0505T,"Endovenous femoral-popliteal arterial revascularization, with transcatheter placement of intravascular stent graft(s) and closure by any method, including percutaneous or open vascular access, ultrasound guidance for vascular access when performed, all catheterization(s) and intraprocedural roadmapping and imaging guidance necessary to complete the intervention, all associated radiological supervision and interpretation, when performed, with crossing of the occlusive lesion in an extraluminal fashion",50694,"Placement of ureteral stent, percutaneous, including diagnostic nephrostogram and/or ureterogram when performed, imaging guidance (eg, ultrasound and/or fluoroscopy), and all associated radiological supervision and interpretation; new access, without separate nephrostomy catheter",46.35415461143773,,Present in Autoproposal
0505T,"Endovenous femoral-popliteal arterial revascularization, with transcatheter placement of intravascular stent graft(s) and closure by any method, including percutaneous or open vascular access, ultrasound guidance for vascular access when performed, all catheterization(s) and intraprocedural roadmapping and imaging guidance necessary to complete the intervention, all associated radiological supervision and interpretation, when performed, with crossing of the occlusive lesion in an extraluminal fashion",50433,"Placement of nephroureteral catheter, percutaneous, including diagnostic nephrostogram and/or ureterogram when performed, imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation, new access",46.31879967552595,,Present in Autoproposal
0505T,"Endovenous femoral-popliteal arterial revascularization, with transcatheter placement of intravascular stent graft(s) and closure by any method, including percutaneous or open vascular access, ultrasound guidance for vascular access when performed, all catheterization(s) and intraprocedural roadmapping and imaging guidance necessary to complete the intervention, all associated radiological supervision and interpretation, when performed, with crossing of the occlusive lesion in an extraluminal fashion",37243,"Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; for tumors, organ ischemia, or infarction",44.80786486462359,,Present in Autoproposal
0505T,"Endovenous femoral-popliteal arterial revascularization, with transcatheter placement of intravascular stent graft(s) and closure by any method, including percutaneous or open vascular access, ultrasound guidance for vascular access when performed, all catheterization(s) and intraprocedural roadmapping and imaging guidance necessary to complete the intervention, all associated radiological supervision and interpretation, when performed, with crossing of the occlusive lesion in an extraluminal fashion",47533,"Placement of biliary drainage catheter, percutaneous, including diagnostic cholangiography when performed, imaging guidance (eg, ultrasound and/or fluoroscopy), and all associated radiological supervision and interpretation; external",43.7260978055429,,Present in Autoproposal
0505T,"Endovenous femoral-popliteal arterial revascularization, with transcatheter placement of intravascular stent graft(s) and closure by any method, including percutaneous or open vascular access, ultrasound guidance for vascular access when performed, all catheterization(s) and intraprocedural roadmapping and imaging guidance necessary to complete the intervention, all associated radiological supervision and interpretation, when performed, with crossing of the occlusive lesion in an extraluminal fashion",47531,"Injection procedure for cholangiography, percutaneous, complete diagnostic procedure including imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation; existing access",43.65413589097758,,Present in Autoproposal
0506T,"Macular pigment optical density measurement by heterochromatic flicker photometry, unilateral or bilateral, with interpretation and report",0341T,"Quantitative pupillometry with interpretation and report, unilateral or bilateral",42.1610788398358,10,Present in Autoproposal
0506T,"Macular pigment optical density measurement by heterochromatic flicker photometry, unilateral or bilateral, with interpretation and report",0330T,"Tear film imaging, unilateral or bilateral, with interpretation and report",39.49713678988442,,Present in Autoproposal
0506T,"Macular pigment optical density measurement by heterochromatic flicker photometry, unilateral or bilateral, with interpretation and report",92025,"Computerized corneal topography, unilateral or bilateral, with interpretation and report",38.03040867734295,,Present in Autoproposal
0506T,"Macular pigment optical density measurement by heterochromatic flicker photometry, unilateral or bilateral, with interpretation and report",0486T,"Optical coherence tomography (OCT) of middle ear, with interpretation and report; bilateral",37.80705399200348,,Present in Autoproposal
0506T,"Macular pigment optical density measurement by heterochromatic flicker photometry, unilateral or bilateral, with interpretation and report",0485T,"Optical coherence tomography (OCT) of middle ear, with interpretation and report; unilateral",37.48910937659081,,Present in Autoproposal
0506T,"Macular pigment optical density measurement by heterochromatic flicker photometry, unilateral or bilateral, with interpretation and report",0329T,"Monitoring of intraocular pressure for 24 hours or longer, unilateral or bilateral, with interpretation and report",35.83746833938981,,Present in Autoproposal
0506T,"Macular pigment optical density measurement by heterochromatic flicker photometry, unilateral or bilateral, with interpretation and report",76977,"Ultrasound bone density measurement and interpretation, peripheral site(s), any method",35.3981146923348,,Present in Autoproposal
0506T,"Macular pigment optical density measurement by heterochromatic flicker photometry, unilateral or bilateral, with interpretation and report",92235,"Fluorescein angiography (includes multiframe imaging) with interpretation and report, unilateral or bilateral",35.36154361344739,,Present in Autoproposal
0506T,"Macular pigment optical density measurement by heterochromatic flicker photometry, unilateral or bilateral, with interpretation and report",92145,"Corneal hysteresis determination, by air impulse stimulation, unilateral or bilateral, with interpretation and report",33.74187212567681,,Present in Autoproposal
0506T,"Macular pigment optical density measurement by heterochromatic flicker photometry, unilateral or bilateral, with interpretation and report",92132,"Scanning computerized ophthalmic diagnostic imaging, anterior segment, with interpretation and report, unilateral or bilateral",33.357646592491704,,Present in Autoproposal
0507T,"Near-infrared dual imaging (ie, simultaneous reflective and trans-illuminated light) of meibomian glands, unilateral or bilateral, with interpretation and report",0207T,"Evacuation of meibomian glands, automated, using heat and intermittent pressure, unilateral",34.902845561740634,2,Present in Autoproposal
0507T,"Near-infrared dual imaging (ie, simultaneous reflective and trans-illuminated light) of meibomian glands, unilateral or bilateral, with interpretation and report",0330T,"Tear film imaging, unilateral or bilateral, with interpretation and report",30.211626578685845,,Present Both in MD and Autoproposal
0507T,"Near-infrared dual imaging (ie, simultaneous reflective and trans-illuminated light) of meibomian glands, unilateral or bilateral, with interpretation and report",0341T,"Quantitative pupillometry with interpretation and report, unilateral or bilateral",27.614514952009294,,Present in Autoproposal
0507T,"Near-infrared dual imaging (ie, simultaneous reflective and trans-illuminated light) of meibomian glands, unilateral or bilateral, with interpretation and report",92235,"Fluorescein angiography (includes multiframe imaging) with interpretation and report, unilateral or bilateral",27.048283438332543,,Present in Autoproposal
0507T,"Near-infrared dual imaging (ie, simultaneous reflective and trans-illuminated light) of meibomian glands, unilateral or bilateral, with interpretation and report",92132,"Scanning computerized ophthalmic diagnostic imaging, anterior segment, with interpretation and report, unilateral or bilateral",25.51548907854596,,Present in Autoproposal
0507T,"Near-infrared dual imaging (ie, simultaneous reflective and trans-illuminated light) of meibomian glands, unilateral or bilateral, with interpretation and report",G8806,PERFORMANCE OF TRANS-ABDOMINAL OR TRANS-VAGINAL ULTRASOUND,25.103087430680095,,Present in Autoproposal
0507T,"Near-infrared dual imaging (ie, simultaneous reflective and trans-illuminated light) of meibomian glands, unilateral or bilateral, with interpretation and report",92025,"Computerized corneal topography, unilateral or bilateral, with interpretation and report",24.909023154768988,,Present in Autoproposal
0507T,"Near-infrared dual imaging (ie, simultaneous reflective and trans-illuminated light) of meibomian glands, unilateral or bilateral, with interpretation and report",0329T,"Monitoring of intraocular pressure for 24 hours or longer, unilateral or bilateral, with interpretation and report",24.30647415316188,,Present in Autoproposal
0507T,"Near-infrared dual imaging (ie, simultaneous reflective and trans-illuminated light) of meibomian glands, unilateral or bilateral, with interpretation and report",92240,"Indocyanine-green angiography (includes multiframe imaging) with interpretation and report, unilateral or bilateral",23.93065060553222,,Present in Autoproposal
0507T,"Near-infrared dual imaging (ie, simultaneous reflective and trans-illuminated light) of meibomian glands, unilateral or bilateral, with interpretation and report",92228,"Remote imaging for monitoring and management of active retinal disease (eg, diabetic retinopathy) with physician review, interpretation and report, unilateral or bilateral",23.599483083108545,,Present in Autoproposal
0508T,"Pulse-echo ultrasound bone density measurement resulting in indicator of axial bone mineral density, tibia",G0133,"ECHO EXAM,BONE DENSITY STUDY",53.58430092415646,2,Present in Autoproposal
0508T,"Pulse-echo ultrasound bone density measurement resulting in indicator of axial bone mineral density, tibia",76977,"Ultrasound bone density measurement and interpretation, peripheral site(s), any method",42.78770321348079,,Present Both in MD and Autoproposal
0508T,"Pulse-echo ultrasound bone density measurement resulting in indicator of axial bone mineral density, tibia",78350,"Bone density (bone mineral content) study, 1 or more sites; single photon absorptiometry",38.738805012503896,,Present in Autoproposal
0508T,"Pulse-echo ultrasound bone density measurement resulting in indicator of axial bone mineral density, tibia",77078,"Computed tomography, bone mineral density study, 1 or more sites, axial skeleton (eg, hips, pelvis, spine)",37.43678960810774,,Present in Autoproposal
0508T,"Pulse-echo ultrasound bone density measurement resulting in indicator of axial bone mineral density, tibia",G0131,"COMPUTERIZED TOMOGRAPHY BONE MINERAL DENSITY STUDY, ONE OR MORE SITES; AXIAL SKELETON (EG, HIPS, PELVIS, SPINE)",36.15198967393541,,Present in Autoproposal
0508T,"Pulse-echo ultrasound bone density measurement resulting in indicator of axial bone mineral density, tibia",78351,"Bone density (bone mineral content) study, 1 or more sites; dual photon absorptiometry, 1 or more sites",31.98302941788168,,Present in Autoproposal
0508T,"Pulse-echo ultrasound bone density measurement resulting in indicator of axial bone mineral density, tibia",77079,"Computed tomography, bone mineral density study, 1 or more sites; appendicular skeleton (peripheral) (eg, radius, wrist, heel)",28.499422166283484,,Present in Autoproposal
0508T,"Pulse-echo ultrasound bone density measurement resulting in indicator of axial bone mineral density, tibia",G9769,PATIENT HAD A BONE MINERAL DENSITY TEST IN THE PAST TWO YEARS OR RECEIVED OSTEOPOROSIS MEDICATION OR THERAPY IN THE PAST 12 MONTHS,27.772186012554133,,Present in Autoproposal
0508T,"Pulse-echo ultrasound bone density measurement resulting in indicator of axial bone mineral density, tibia",G0132,"COMPUTERIZED TOMOGRAPHY BONE MINERAL DENSITY STUDY, ONE OR MORE SITES; APPENDICULAR SKELETON (PERIPHERAL) (EG, RADIUS, WRIST, HEEL)",27.58992607609607,,Present in Autoproposal
0508T,"Pulse-echo ultrasound bone density measurement resulting in indicator of axial bone mineral density, tibia",21026,"Excision of bone (eg, for osteomyelitis or bone abscess); facial bone(s)",26.489137648228173,,Present in Autoproposal
0509T ,"Electroretinography (ERG) with interpretation and report, pattern (PERG)",92275,Electroretinography with interpretation and report,68.92732124862457,1,Present Both in MD and Autoproposal
0509T ,"Electroretinography (ERG) with interpretation and report, pattern (PERG)",93720,"Plethysmography, total body; with interpretation and report",23.523647458980005,,Present in Autoproposal
0509T ,"Electroretinography (ERG) with interpretation and report, pattern (PERG)",94777,"Pediatric home apnea monitoring event recording including respiratory rate, pattern and heart rate per 30-day period of time; review, interpretation and preparation of report only by a physician or other qualified health care professional",22.36357927013365,,Present in Autoproposal
0509T ,"Electroretinography (ERG) with interpretation and report, pattern (PERG)",83912,Molecular diagnostics; interpretation and report,22.038765661682337,,Present in Autoproposal
0509T ,"Electroretinography (ERG) with interpretation and report, pattern (PERG)",92250,Fundus photography with interpretation and report,21.853449142712876,,Present in Autoproposal
0509T ,"Electroretinography (ERG) with interpretation and report, pattern (PERG)",93040,"Rhythm ECG, 1-3 leads; with interpretation and report",21.214305014868845,,Present in Autoproposal
0509T ,"Electroretinography (ERG) with interpretation and report, pattern (PERG)",92287,Anterior segment imaging with interpretation and report; with fluorescein angiography,21.01881305984999,,Present in Autoproposal
0509T ,"Electroretinography (ERG) with interpretation and report, pattern (PERG)",0065T,"Ocular photoscreening, with interpretation and report, bilateral",20.945585626984954,,Present in Autoproposal
0509T ,"Electroretinography (ERG) with interpretation and report, pattern (PERG)",92230,Fluorescein angioscopy with interpretation and report,20.649688156594927,,Present in Autoproposal
0509T ,"Electroretinography (ERG) with interpretation and report, pattern (PERG)",G0452,MOLECULAR PATHOLOGY PROCEDURE; PHYSICIAN INTERPRETATION AND REPORT,20.39816917009693,,Present in Autoproposal
0510T ,Removal of sinus tarsi implant,27704,Removal of ankle implant,59.98286057815043,10,Present in Autoproposal
0510T ,Removal of sinus tarsi implant,65175,Removal of ocular implant,55.27288151191132,,Present in Autoproposal
0510T ,Removal of sinus tarsi implant,D6100,"IMPLANT REMOVAL, BY REPORT",55.13746071508765,,Present in Autoproposal
0510T ,Removal of sinus tarsi implant,31276,"Nasal/sinus endoscopy, surgical, with frontal sinus exploration, including removal of tissue from frontal sinus, when performed",51.8685677100617,,Present in Autoproposal
0510T ,Removal of sinus tarsi implant,19330,Removal of mammary implant material,48.44891994929713,,Present in Autoproposal
0510T ,Removal of sinus tarsi implant,31288,"Nasal/sinus endoscopy, surgical, with sphenoidotomy; with removal of tissue from the sphenoid sinus",47.615744792907584,,Present in Autoproposal
0510T ,Removal of sinus tarsi implant,31253,"Nasal/sinus endoscopy, surgical with ethmoidectomy; total (anterior and posterior), including frontal sinus exploration, with removal of tissue from frontal sinus, when performed",47.16687285917451,,Present in Autoproposal
0510T ,Removal of sinus tarsi implant,26320,Removal of implant from finger or hand,45.90943709921423,,Present in Autoproposal
0510T ,Removal of sinus tarsi implant,19328,Removal of intact mammary implant,43.38981666857228,,Present in Autoproposal
0510T ,Removal of sinus tarsi implant,31267,"Nasal/sinus endoscopy, surgical, with maxillary antrostomy; with removal of tissue from maxillary sinus",43.09680155214481,,Present in Autoproposal
0511T,Removal and reinsertion of sinus tarsi implant,11983,"Removal with reinsertion, non-biodegradable drug delivery implant",55.40351444666038,10,Present in Autoproposal
0511T,Removal and reinsertion of sinus tarsi implant,65150,Reinsertion of ocular implant; with or without conjunctival graft,49.207035832344765,,Present in Autoproposal
0511T,Removal and reinsertion of sinus tarsi implant,65155,Reinsertion of ocular implant; with use of foreign material for reinforcement and/or attachment of muscles to implant,48.345403346420504,,Present in Autoproposal
0511T,Removal and reinsertion of sinus tarsi implant,22849,Reinsertion of spinal fixation device,46.16689838260223,,Present in Autoproposal
0511T,Removal and reinsertion of sinus tarsi implant,27704,Removal of ankle implant,44.399556211818734,,Present in Autoproposal
0511T,Removal and reinsertion of sinus tarsi implant,47530,Revision and/or reinsertion of transhepatic tube,43.95517666281582,,Present in Autoproposal
0511T,Removal and reinsertion of sinus tarsi implant,11977,"Removal with reinsertion, implantable contraceptive capsules",43.687807276184344,,Present in Autoproposal
0511T,Removal and reinsertion of sinus tarsi implant,65175,Removal of ocular implant,40.91321064089496,,Present in Autoproposal
0511T,Removal and reinsertion of sinus tarsi implant,D6100,"IMPLANT REMOVAL, BY REPORT",40.812971618899866,,Present in Autoproposal
0511T,Removal and reinsertion of sinus tarsi implant,31276,"Nasal/sinus endoscopy, surgical, with frontal sinus exploration, including removal of tissue from frontal sinus, when performed",38.393323784032525,,Present in Autoproposal
0512T,"Extracorporeal shock wave for integumentary wound healing, highenergy, including topical application and dressing care; initialwound",0299T,"Extracorporeal shock wave for integumentary wound healing, high energy, including topical application and dressing care; initial wound",89.66720493874254,10,Present in Autoproposal
0512T,"Extracorporeal shock wave for integumentary wound healing, highenergy, including topical application and dressing care; initialwound",0300T,"Extracorporeal shock wave for integumentary wound healing, high energy, including topical application and dressing care; each additional wound (List separately in addition to code for primary procedure)",82.69596431266916,,Present in Autoproposal
0512T,"Extracorporeal shock wave for integumentary wound healing, highenergy, including topical application and dressing care; initialwound",50590,"Lithotripsy, extracorporeal shock wave",46.75045450267474,,Present in Autoproposal
0512T,"Extracorporeal shock wave for integumentary wound healing, highenergy, including topical application and dressing care; initialwound",0020T,EXTRACORPOREAL SHOCK WAVE THERAPY; PLANTAR FASCIA,41.712425450757785,,Present in Autoproposal
0512T,"Extracorporeal shock wave for integumentary wound healing, highenergy, including topical application and dressing care; initialwound",00872,"Anesthesia for lithotripsy, extracorporeal shock wave; with water bath",37.784927850037526,,Present in Autoproposal
0512T,"Extracorporeal shock wave for integumentary wound healing, highenergy, including topical application and dressing care; initialwound",00873,"Anesthesia for lithotripsy, extracorporeal shock wave; without water bath",37.418282882882316,,Present in Autoproposal
0512T,"Extracorporeal shock wave for integumentary wound healing, highenergy, including topical application and dressing care; initialwound",0101T,"Extracorporeal shock wave involving musculoskeletal system, not otherwise specified, high energy",33.599026348917384,,Present in Autoproposal
0512T,"Extracorporeal shock wave for integumentary wound healing, highenergy, including topical application and dressing care; initialwound",0019T,"Extracorporeal shock wave involving musculoskeletal system, not otherwise specified, low energy",33.43574891366316,,Present in Autoproposal
0512T,"Extracorporeal shock wave for integumentary wound healing, highenergy, including topical application and dressing care; initialwound",S0400,GLOBAL FEE FOR EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY TREATMENT OF KIDNEY STONE(S),31.962251310389334,,Present in Autoproposal
0512T,"Extracorporeal shock wave for integumentary wound healing, highenergy, including topical application and dressing care; initialwound",G0280,EXTRACORPOREAL SHOCK WAVE THERAPY; INVOLVING OTHER THAN ELBOW EPICONDYLITIS OR PLANTAR FASCITIS,30.933577309830874,,Present in Autoproposal
0513T,"Extracorporeal shock wave for integumentary wound healing, high energy, including topical application and dressing care; each additional wound",0299T,"Extracorporeal shock wave for integumentary wound healing, high energy, including topical application and dressing care; initial wound",95.55859245409061,6,Present in Autoproposal
0513T,"Extracorporeal shock wave for integumentary wound healing, high energy, including topical application and dressing care; each additional wound",0300T,"Extracorporeal shock wave for integumentary wound healing, high energy, including topical application and dressing care; each additional wound (List separately in addition to code for primary procedure)",92.54161647744333,,Present in Autoproposal
0513T,"Extracorporeal shock wave for integumentary wound healing, high energy, including topical application and dressing care; each additional wound",0101T,"Extracorporeal shock wave involving musculoskeletal system, not otherwise specified, high energy",42.53557816159101,,Present Both in MD and Autoproposal
0513T,"Extracorporeal shock wave for integumentary wound healing, high energy, including topical application and dressing care; each additional wound",50590,"Lithotripsy, extracorporeal shock wave",39.044145989523685,,Present in Autoproposal
0513T,"Extracorporeal shock wave for integumentary wound healing, high energy, including topical application and dressing care; each additional wound",0019T,"Extracorporeal shock wave involving musculoskeletal system, not otherwise specified, low energy",37.06376496010553,,Present in Autoproposal
0513T,"Extracorporeal shock wave for integumentary wound healing, high energy, including topical application and dressing care; each additional wound",28890,"Extracorporeal shock wave, high energy, performed by a physician or other qualified health care professional, requiring anesthesia other than local, including ultrasound guidance, involving the plantar fascia",35.45604702268604,,Present Both in MD and Autoproposal
0513T,"Extracorporeal shock wave for integumentary wound healing, high energy, including topical application and dressing care; each additional wound",A6020,COLLAGEN WOUND DRESSING,35.42376897373954,,Present in Autoproposal
0513T,"Extracorporeal shock wave for integumentary wound healing, high energy, including topical application and dressing care; each additional wound",0102T,"Extracorporeal shock wave, high energy, performed by a physician, requiring anesthesia other than local, involving lateral humeral epicondyle",35.06631508143836,,Present in Autoproposal
0513T,"Extracorporeal shock wave for integumentary wound healing, high energy, including topical application and dressing care; each additional wound",0020T,EXTRACORPOREAL SHOCK WAVE THERAPY; PLANTAR FASCIA,34.83658172314306,,Present in Autoproposal
0513T,"Extracorporeal shock wave for integumentary wound healing, high energy, including topical application and dressing care; each additional wound",97606,"Negative pressure wound therapy (eg, vacuum assisted drainage collection), utilizing durable medical equipment (DME), including topical application(s), wound assessment, and instruction(s) for ongoing care, per session; total wound(s) surface area greater than 50 square centimeters",33.293622349454175,,Present in Autoproposal
0514T,Intraoperative visual axis identification using patient fixation,0333T,"Visual evoked potential, screening of visual acuity, automated, with report",27.24969646069619,10,Present in Autoproposal
0514T,Intraoperative visual axis identification using patient fixation,77469,Intraoperative radiation treatment management,26.659914252756973,,Present in Autoproposal
0514T,Intraoperative visual axis identification using patient fixation,76998,"Ultrasonic guidance, intraoperative",26.628289978377122,,Present in Autoproposal
0514T,Intraoperative visual axis identification using patient fixation,G8317,PATIENT DOCUMENTED TO HAVE VISUAL FUNCTIONAL STATUS ASSESSED,25.694353421957345,,Present in Autoproposal
0514T,Intraoperative visual axis identification using patient fixation,G8318,PATIENT DOCUMENTED NOT TO HAVE VISUAL FUNCTIONAL STATUS ASSESSED,24.90555275521312,,Present in Autoproposal
0514T,Intraoperative visual axis identification using patient fixation,S8049,INTRAOPERATIVE RADIATION THERAPY (SINGLE ADMINISTRATION),24.163047545436044,,Present in Autoproposal
0514T,Intraoperative visual axis identification using patient fixation,38900,"Intraoperative identification (eg, mapping) of sentinel lymph node(s) includes injection of non-radioactive dye, when performed (List separately in addition to code for primary procedure)",21.299716981550933,,Present in Autoproposal
0514T,Intraoperative visual axis identification using patient fixation,1055F,Visual functional status assessed (EC),20.78979121630883,,Present in Autoproposal
0514T,Intraoperative visual axis identification using patient fixation,G8319,CLINICIAN DOCUMENTED THAT PATIENT WAS NOT AN ELIGIBLE CANDIDATE FOR ASSESSMENT OF VISUAL FUNCTIONAL STATUS,19.669090651631475,,Present in Autoproposal
0514T,Intraoperative visual axis identification using patient fixation,99173,"Screening test of visual acuity, quantitative, bilateral",19.25957600343585,,Present in Autoproposal
0515T,"Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; complete system (includes electrode and generator [transmitter and battery])",0302T,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; complete system (includes device and electrode),60.11211815927844,10,Present in Autoproposal
0515T,"Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; complete system (includes electrode and generator [transmitter and battery])",0303T,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; electrode only,52.70321710558991,,Present in Autoproposal
0515T,"Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; complete system (includes electrode and generator [transmitter and battery])",0304T,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; device only,51.25663197637489,,Present in Autoproposal
0515T,"Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; complete system (includes electrode and generator [transmitter and battery])",33224,"Insertion of pacing electrode, cardiac venous system, for left ventricular pacing, with attachment to previously placed pacemaker or implantable defibrillator pulse generator (including revision of pocket, removal, insertion, and/or replacement of existing generator)",42.30724573841919,,Present in Autoproposal
0515T,"Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; complete system (includes electrode and generator [transmitter and battery])",33226,"Repositioning of previously implanted cardiac venous system (left ventricular) electrode (including removal, insertion and/or replacement of existing generator)",39.646375986701884,,Present in Autoproposal
0515T,"Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; complete system (includes electrode and generator [transmitter and battery])",33225,"Insertion of pacing electrode, cardiac venous system, for left ventricular pacing, at time of insertion of implantable defibrillator or pacemaker pulse generator (eg, for upgrade to dual chamber system) (List separately in addition to code for primary procedure)",38.42359629397191,,Present in Autoproposal
0515T,"Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; complete system (includes electrode and generator [transmitter and battery])",G0448,"INSERTION OR REPLACEMENT OF A PERMANENT PACING CARDIOVERTER-DEFIBRILLATOR SYSTEM WITH TRANSVENOUS LEAD(S), SINGLE OR DUAL CHAMBER WITH INSERTION OF PACING ELECTRODE, CARDIAC VENOUS SYSTEM, FOR LEFT VENTRICULAR PACING",37.516540040771986,,Present in Autoproposal
0515T,"Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; complete system (includes electrode and generator [transmitter and battery])",0294T,"Insertion of left atrial hemodynamic monitor; pressure sensor lead at time of insertion of pacing cardioverter-defibrillator pulse generator including radiological supervision and interpretation and associated injection procedures, when performed (List separately in addition to code for primary procedure)",35.85090299977851,,Present in Autoproposal
0515T,"Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; complete system (includes electrode and generator [transmitter and battery])",93654,"Comprehensive electrophysiologic evaluation including insertion and repositioning of multiple electrode catheters with induction or attempted induction of an arrhythmia with right atrial pacing and recording, right ventricular pacing and recording (when necessary), and His bundle recording (when necessary) with intracardiac catheter ablation of arrhythmogenic focus; with treatment of ventricular tachycardia or focus of ventricular ectopy including intracardiac electrophysiologic 3D mapping, when performed, and left ventricular pacing and recording, when performed",35.39293192730185,,Present in Autoproposal
0515T,"Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; complete system (includes electrode and generator [transmitter and battery])",0293T,"Insertion of left atrial hemodynamic monitor; complete system, includes implanted communication module and pressure sensor lead in left atrium including transseptal access, radiological supervision and interpretation, and associated injection procedures, when performed",35.194988991882035,,Present in Autoproposal
0516T,"Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; electrode only",0303T,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; electrode only,55.938538103251176,10,Present in Autoproposal
0516T,"Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; electrode only",0304T,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; device only,54.145673215080706,,Present in Autoproposal
0516T,"Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; electrode only",0302T,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; complete system (includes device and electrode),53.294473782943484,,Present in Autoproposal
0516T,"Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; electrode only",G0448,"INSERTION OR REPLACEMENT OF A PERMANENT PACING CARDIOVERTER-DEFIBRILLATOR SYSTEM WITH TRANSVENOUS LEAD(S), SINGLE OR DUAL CHAMBER WITH INSERTION OF PACING ELECTRODE, CARDIAC VENOUS SYSTEM, FOR LEFT VENTRICULAR PACING",40.20790766718431,,Present in Autoproposal
0516T,"Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; electrode only",33990,"Insertion of ventricular assist device, percutaneous including radiological supervision and interpretation; arterial access only",38.94281437194333,,Present in Autoproposal
0516T,"Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; electrode only",0411T,"Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; ventricular electrode only",38.556428262670586,,Present in Autoproposal
0516T,"Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; electrode only",33224,"Insertion of pacing electrode, cardiac venous system, for left ventricular pacing, with attachment to previously placed pacemaker or implantable defibrillator pulse generator (including revision of pocket, removal, insertion, and/or replacement of existing generator)",38.349409567609555,,Present in Autoproposal
0516T,"Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; electrode only",93452,"Left heart catheterization including intraprocedural injection(s) for left ventriculography, imaging supervision and interpretation, when performed",38.06909590715153,,Present in Autoproposal
0516T,"Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; electrode only",93654,"Comprehensive electrophysiologic evaluation including insertion and repositioning of multiple electrode catheters with induction or attempted induction of an arrhythmia with right atrial pacing and recording, right ventricular pacing and recording (when necessary), and His bundle recording (when necessary) with intracardiac catheter ablation of arrhythmogenic focus; with treatment of ventricular tachycardia or focus of ventricular ectopy including intracardiac electrophysiologic 3D mapping, when performed, and left ventricular pacing and recording, when performed",37.60266344035132,,Present in Autoproposal
0516T,"Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; electrode only",93453,"Combined right and left heart catheterization including intraprocedural injection(s) for left ventriculography, imaging supervision and interpretation, when performed",37.50359211618111,,Present in Autoproposal
0517T,"Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; pulse generator component(s) (battery and/or transmitter) only",0304T,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; device only,50.468477809580584,10,Present in Autoproposal
0517T,"Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; pulse generator component(s) (battery and/or transmitter) only",0303T,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; electrode only,47.609662820101114,,Present in Autoproposal
0517T,"Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; pulse generator component(s) (battery and/or transmitter) only",0302T,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; complete system (includes device and electrode),46.090047140231896,,Present in Autoproposal
0517T,"Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; pulse generator component(s) (battery and/or transmitter) only",33224,"Insertion of pacing electrode, cardiac venous system, for left ventricular pacing, with attachment to previously placed pacemaker or implantable defibrillator pulse generator (including revision of pocket, removal, insertion, and/or replacement of existing generator)",41.87339777932825,,Present in Autoproposal
0517T,"Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; pulse generator component(s) (battery and/or transmitter) only",0294T,"Insertion of left atrial hemodynamic monitor; pressure sensor lead at time of insertion of pacing cardioverter-defibrillator pulse generator including radiological supervision and interpretation and associated injection procedures, when performed (List separately in addition to code for primary procedure)",39.314086004514095,,Present in Autoproposal
0517T,"Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; pulse generator component(s) (battery and/or transmitter) only",0271T,"Revision or removal of carotid sinus baroreflex activation device; pulse generator only (includes intra-operative interrogation, programming, and repositioning, when performed)",36.50061707237328,,Present in Autoproposal
0517T,"Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; pulse generator component(s) (battery and/or transmitter) only",0268T,"Implantation or replacement of carotid sinus baroreflex activation device; pulse generator only (includes intra-operative interrogation, programming, and repositioning, when performed)",36.345471488214706,,Present in Autoproposal
0517T,"Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; pulse generator component(s) (battery and/or transmitter) only",33225,"Insertion of pacing electrode, cardiac venous system, for left ventricular pacing, at time of insertion of implantable defibrillator or pacemaker pulse generator (eg, for upgrade to dual chamber system) (List separately in addition to code for primary procedure)",36.11723973634377,,Present in Autoproposal
0517T,"Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; pulse generator component(s) (battery and/or transmitter) only",0409T,"Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; pulse generator only",35.93136560836446,,Present in Autoproposal
0517T,"Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; pulse generator component(s) (battery and/or transmitter) only",33990,"Insertion of ventricular assist device, percutaneous including radiological supervision and interpretation; arterial access only",34.873482136655745,,Present in Autoproposal
0518T,Removal of only pulse generator component(s) (battery and/or transmitter) of wireless cardiac stimulator for left ventricular pacing,33224,"Insertion of pacing electrode, cardiac venous system, for left ventricular pacing, with attachment to previously placed pacemaker or implantable defibrillator pulse generator (including revision of pocket, removal, insertion, and/or replacement of existing generator)",46.1766899889662,10,Present in Autoproposal
0518T,Removal of only pulse generator component(s) (battery and/or transmitter) of wireless cardiac stimulator for left ventricular pacing,33225,"Insertion of pacing electrode, cardiac venous system, for left ventricular pacing, at time of insertion of implantable defibrillator or pacemaker pulse generator (eg, for upgrade to dual chamber system) (List separately in addition to code for primary procedure)",40.340572381622394,,Present in Autoproposal
0518T,Removal of only pulse generator component(s) (battery and/or transmitter) of wireless cardiac stimulator for left ventricular pacing,33241,Removal of implantable defibrillator pulse generator only,38.66238215521459,,Present in Autoproposal
0518T,Removal of only pulse generator component(s) (battery and/or transmitter) of wireless cardiac stimulator for left ventricular pacing,33233,Removal of permanent pacemaker pulse generator only,38.0958224684325,,Present Both in MD and Autoproposal
0518T,Removal of only pulse generator component(s) (battery and/or transmitter) of wireless cardiac stimulator for left ventricular pacing,0412T,Removal of permanent cardiac contractility modulation system; pulse generator only,36.38059590546236,,Present in Autoproposal
0518T,Removal of only pulse generator component(s) (battery and/or transmitter) of wireless cardiac stimulator for left ventricular pacing,0414T,Removal and replacement of permanent cardiac contractility modulation system pulse generator only,36.283237004314714,,Present in Autoproposal
0518T,Removal of only pulse generator component(s) (battery and/or transmitter) of wireless cardiac stimulator for left ventricular pacing,0322T,Removal of subcutaneous implantable defibrillator pulse generator only,35.894882056920366,,Present in Autoproposal
0518T,Removal of only pulse generator component(s) (battery and/or transmitter) of wireless cardiac stimulator for left ventricular pacing,33226,"Repositioning of previously implanted cardiac venous system (left ventricular) electrode (including removal, insertion and/or replacement of existing generator)",34.84989120887335,,Present in Autoproposal
0518T,Removal of only pulse generator component(s) (battery and/or transmitter) of wireless cardiac stimulator for left ventricular pacing,G0448,"INSERTION OR REPLACEMENT OF A PERMANENT PACING CARDIOVERTER-DEFIBRILLATOR SYSTEM WITH TRANSVENOUS LEAD(S), SINGLE OR DUAL CHAMBER WITH INSERTION OF PACING ELECTRODE, CARDIAC VENOUS SYSTEM, FOR LEFT VENTRICULAR PACING",34.80491111716189,,Present in Autoproposal
0518T,Removal of only pulse generator component(s) (battery and/or transmitter) of wireless cardiac stimulator for left ventricular pacing,0431T,"Removal and replacement of neurostimulator system for treatment of central sleep apnea, pulse generator only",31.96927048682258,,Present in Autoproposal
0519T,Removal and replacement of wireless cardiac stimulator for left ventricular pacing; pulse generator component(s) (battery and/or transmitter),33224,"Insertion of pacing electrode, cardiac venous system, for left ventricular pacing, with attachment to previously placed pacemaker or implantable defibrillator pulse generator (including revision of pocket, removal, insertion, and/or replacement of existing generator)",47.77643072487164,10,Present in Autoproposal
0519T,Removal and replacement of wireless cardiac stimulator for left ventricular pacing; pulse generator component(s) (battery and/or transmitter),33225,"Insertion of pacing electrode, cardiac venous system, for left ventricular pacing, at time of insertion of implantable defibrillator or pacemaker pulse generator (eg, for upgrade to dual chamber system) (List separately in addition to code for primary procedure)",38.4019448154827,,Present in Autoproposal
0519T,Removal and replacement of wireless cardiac stimulator for left ventricular pacing; pulse generator component(s) (battery and/or transmitter),33226,"Repositioning of previously implanted cardiac venous system (left ventricular) electrode (including removal, insertion and/or replacement of existing generator)",38.353443750540464,,Present in Autoproposal
0519T,Removal and replacement of wireless cardiac stimulator for left ventricular pacing; pulse generator component(s) (battery and/or transmitter),0414T,Removal and replacement of permanent cardiac contractility modulation system pulse generator only,36.64271637340464,,Present in Autoproposal
0519T,Removal and replacement of wireless cardiac stimulator for left ventricular pacing; pulse generator component(s) (battery and/or transmitter),A4638,"REPLACEMENT BATTERY FOR PATIENT-OWNED EAR PULSE GENERATOR, EACH",36.63450274664991,,Present in Autoproposal
0519T,Removal and replacement of wireless cardiac stimulator for left ventricular pacing; pulse generator component(s) (battery and/or transmitter),G0448,"INSERTION OR REPLACEMENT OF A PERMANENT PACING CARDIOVERTER-DEFIBRILLATOR SYSTEM WITH TRANSVENOUS LEAD(S), SINGLE OR DUAL CHAMBER WITH INSERTION OF PACING ELECTRODE, CARDIAC VENOUS SYSTEM, FOR LEFT VENTRICULAR PACING",36.275506304345974,,Present in Autoproposal
0519T,Removal and replacement of wireless cardiac stimulator for left ventricular pacing; pulse generator component(s) (battery and/or transmitter),33227,Removal of permanent pacemaker pulse generator with replacement of pacemaker pulse generator; single lead system,34.0345416781545,,Present Both in MD and Autoproposal
0519T,Removal and replacement of wireless cardiac stimulator for left ventricular pacing; pulse generator component(s) (battery and/or transmitter),33229,Removal of permanent pacemaker pulse generator with replacement of pacemaker pulse generator; multiple lead system,33.88389084071771,,Present in Autoproposal
0519T,Removal and replacement of wireless cardiac stimulator for left ventricular pacing; pulse generator component(s) (battery and/or transmitter),33228,Removal of permanent pacemaker pulse generator with replacement of pacemaker pulse generator; dual lead system,33.570649370764514,,Present in Autoproposal
0519T,Removal and replacement of wireless cardiac stimulator for left ventricular pacing; pulse generator component(s) (battery and/or transmitter),95978,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, battery status, electrode selectability and polarity, impedance and patient compliance measurements), complex deep brain neurostimulator pulse generator/transmitter, with initial or subsequent programming; first hour",32.44942977644739,,Present in Autoproposal
0520T,"Removal and replacement of wireless cardiac stimulator for left ventricular pacing; pulse generator component(s) (battery and/or transmitter), including placement of a new electrode",33224,"Insertion of pacing electrode, cardiac venous system, for left ventricular pacing, with attachment to previously placed pacemaker or implantable defibrillator pulse generator (including revision of pocket, removal, insertion, and/or replacement of existing generator)",50.20101620261853,10,Present Both in MD and Autoproposal
0520T,"Removal and replacement of wireless cardiac stimulator for left ventricular pacing; pulse generator component(s) (battery and/or transmitter), including placement of a new electrode",33226,"Repositioning of previously implanted cardiac venous system (left ventricular) electrode (including removal, insertion and/or replacement of existing generator)",44.53061294007323,,Present in Autoproposal
0520T,"Removal and replacement of wireless cardiac stimulator for left ventricular pacing; pulse generator component(s) (battery and/or transmitter), including placement of a new electrode",33225,"Insertion of pacing electrode, cardiac venous system, for left ventricular pacing, at time of insertion of implantable defibrillator or pacemaker pulse generator (eg, for upgrade to dual chamber system) (List separately in addition to code for primary procedure)",40.43372748385309,,Present in Autoproposal
0520T,"Removal and replacement of wireless cardiac stimulator for left ventricular pacing; pulse generator component(s) (battery and/or transmitter), including placement of a new electrode",G0448,"INSERTION OR REPLACEMENT OF A PERMANENT PACING CARDIOVERTER-DEFIBRILLATOR SYSTEM WITH TRANSVENOUS LEAD(S), SINGLE OR DUAL CHAMBER WITH INSERTION OF PACING ELECTRODE, CARDIAC VENOUS SYSTEM, FOR LEFT VENTRICULAR PACING",37.932805261204095,,Present in Autoproposal
0520T,"Removal and replacement of wireless cardiac stimulator for left ventricular pacing; pulse generator component(s) (battery and/or transmitter), including placement of a new electrode",0414T,Removal and replacement of permanent cardiac contractility modulation system pulse generator only,34.16812669205533,,Present in Autoproposal
0520T,"Removal and replacement of wireless cardiac stimulator for left ventricular pacing; pulse generator component(s) (battery and/or transmitter), including placement of a new electrode",A4638,"REPLACEMENT BATTERY FOR PATIENT-OWNED EAR PULSE GENERATOR, EACH",33.21956303463631,,Present in Autoproposal
0520T,"Removal and replacement of wireless cardiac stimulator for left ventricular pacing; pulse generator component(s) (battery and/or transmitter), including placement of a new electrode",95978,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, battery status, electrode selectability and polarity, impedance and patient compliance measurements), complex deep brain neurostimulator pulse generator/transmitter, with initial or subsequent programming; first hour",33.15746761159131,,Present in Autoproposal
0520T,"Removal and replacement of wireless cardiac stimulator for left ventricular pacing; pulse generator component(s) (battery and/or transmitter), including placement of a new electrode",33208,Insertion of new or replacement of permanent pacemaker with transvenous electrode(s); atrial and ventricular,32.79106139543843,,Present in Autoproposal
0520T,"Removal and replacement of wireless cardiac stimulator for left ventricular pacing; pulse generator component(s) (battery and/or transmitter), including placement of a new electrode",33207,Insertion of new or replacement of permanent pacemaker with transvenous electrode(s); ventricular,32.516860460168786,,Present in Autoproposal
0520T,"Removal and replacement of wireless cardiac stimulator for left ventricular pacing; pulse generator component(s) (battery and/or transmitter), including placement of a new electrode",95982,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements) gastric neurostimulator pulse generator/transmitter; subsequent, with reprogramming",32.37632408697213,,Present in Autoproposal
0521T,"Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording, and disconnection per patient encounter, wireless cardiac stimulator for left ventricular pacing",0418T,"Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording and disconnection per patient encounter, implantable cardiac contractility modulation system",71.253937872158,7,Present in Autoproposal
0521T,"Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording, and disconnection per patient encounter, wireless cardiac stimulator for left ventricular pacing",0391T,"Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording and disconnection per patient encounter, leadless pacemaker system",70.717617951118,,Present Both in MD and Autoproposal
0521T,"Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording, and disconnection per patient encounter, wireless cardiac stimulator for left ventricular pacing",0327T,"Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording and disconnection per patient encounter, implantable subcutaneous lead defibrillator system",69.66460894570861,,Present in Autoproposal
0521T,"Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording, and disconnection per patient encounter, wireless cardiac stimulator for left ventricular pacing",0463T,"Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording and disconnection per patient encounter, implantable aortic counterpulsation ventricular assist system, per day",69.14408188438271,,Present in Autoproposal
0521T,"Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording, and disconnection per patient encounter, wireless cardiac stimulator for left ventricular pacing",93292,"Interrogation device evaluation (in person) with analysis, review and report by a physician or other qualified health care professional, includes connection, recording and disconnection per patient encounter; wearable defibrillator system",63.68705160145646,,Present in Autoproposal
0521T,"Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording, and disconnection per patient encounter, wireless cardiac stimulator for left ventricular pacing",93261,"Interrogation device evaluation (in person) with analysis, review and report by a physician or other qualified health care professional, includes connection, recording and disconnection per patient encounter; implantable subcutaneous lead defibrillator system",62.5498971722311,,Present in Autoproposal
0521T,"Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording, and disconnection per patient encounter, wireless cardiac stimulator for left ventricular pacing",93288,"Interrogation device evaluation (in person) with analysis, review and report by a physician or other qualified health care professional, includes connection, recording and disconnection per patient encounter; single, dual, or multiple lead pacemaker system",61.49097752429065,,Present Both in MD and Autoproposal
0521T,"Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording, and disconnection per patient encounter, wireless cardiac stimulator for left ventricular pacing",93291,"Interrogation device evaluation (in person) with analysis, review and report by a physician or other qualified health care professional, includes connection, recording and disconnection per patient encounter; implantable loop recorder system, including heart rhythm derived data analysis",56.34510265434014,,Present in Autoproposal
0521T,"Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording, and disconnection per patient encounter, wireless cardiac stimulator for left ventricular pacing",93289,"Interrogation device evaluation (in person) with analysis, review and report by a physician or other qualified health care professional, includes connection, recording and disconnection per patient encounter; single, dual, or multiple lead transvenous implantable defibrillator system, including analysis of heart rhythm derived data elements",52.91758390026913,,Present in Autoproposal
0521T,"Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording, and disconnection per patient encounter, wireless cardiac stimulator for left ventricular pacing",93290,"Interrogation device evaluation (in person) with analysis, review and report by a physician or other qualified health care professional, includes connection, recording and disconnection per patient encounter; implantable cardiovascular monitor system, including analysis of 1 or more recorded physiologic cardiovascular data elements from all internal and external sensors",48.990713415814575,,Present in Autoproposal
0522T,"Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, including review and report, wireless cardiac stimulator for left ventricular pacing",0417T,"Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, including review and report, implantable cardiac contractility modulation system",83.85880953964464,2,Present in Autoproposal
0522T,"Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, including review and report, wireless cardiac stimulator for left ventricular pacing",0389T,"Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report, leadless pacemaker system",82.96307304620099,,Present Both in MD and Autoproposal
0522T,"Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, including review and report, wireless cardiac stimulator for left ventricular pacing",0328T,"Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, implantable subcutaneous lead defibrillator system",79.69261662642785,,Present in Autoproposal
0522T,"Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, including review and report, wireless cardiac stimulator for left ventricular pacing",93279,"Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional; single lead pacemaker system",78.72145135542843,,Present Both in MD and Autoproposal
0522T,"Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, including review and report, wireless cardiac stimulator for left ventricular pacing",93281,"Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional; multiple lead pacemaker system",78.55700486280848,,Present in Autoproposal
0522T,"Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, including review and report, wireless cardiac stimulator for left ventricular pacing",93280,"Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional; dual lead pacemaker system",78.21135179886095,,Present in Autoproposal
0522T,"Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, including review and report, wireless cardiac stimulator for left ventricular pacing",93260,"Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional; implantable subcutaneous lead defibrillator system",77.90549988788592,,Present in Autoproposal
0522T,"Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, including review and report, wireless cardiac stimulator for left ventricular pacing",93285,"Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional; implantable loop recorder system",77.4113710643958,,Present in Autoproposal
0522T,"Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, including review and report, wireless cardiac stimulator for left ventricular pacing",93282,"Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional; single lead transvenous implantable defibrillator system",76.82915978991028,,Present in Autoproposal
0522T,"Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, including review and report, wireless cardiac stimulator for left ventricular pacing",93284,"Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional; multiple lead transvenous implantable defibrillator system",76.68465982294578,,Present in Autoproposal
0523T,"Intraprocedural coronary fractional flow reserve (FFR) with 3D functional mapping of color-coded FFR values for the coronary tree, derived from coronary angiogram data, for real-time review and interpretation of possible atherosclerotic stenosis(es) intervention",0504T,"Noninvasive estimated coronary fractional flow reserve (FFR) derived from coronary computed tomography angiography data using computation fluid dynamics physiologic simulation software analysis of functional data to assess the severity of coronary artery disease; anatomical data review in comparison with estimated FFR model to reconcile discordant data, interpretation and report",46.85449333124529,5,Present in Autoproposal
0523T,"Intraprocedural coronary fractional flow reserve (FFR) with 3D functional mapping of color-coded FFR values for the coronary tree, derived from coronary angiogram data, for real-time review and interpretation of possible atherosclerotic stenosis(es) intervention",0501T,"Noninvasive estimated coronary fractional flow reserve (FFR) derived from coronary computed tomography angiography data using computation fluid dynamics physiologic simulation software analysis of functional data to assess the severity of coronary artery disease; data preparation and transmission, analysis of fluid dynamics and simulated maximal coronary hyperemia, generation of estimated FFR model, with anatomical data review in comparison with estimated FFR model to reconcile discordant data, interpretation and report",45.459237088745915,,Present Both in MD and Autoproposal
0523T,"Intraprocedural coronary fractional flow reserve (FFR) with 3D functional mapping of color-coded FFR values for the coronary tree, derived from coronary angiogram data, for real-time review and interpretation of possible atherosclerotic stenosis(es) intervention",0503T,"Noninvasive estimated coronary fractional flow reserve (FFR) derived from coronary computed tomography angiography data using computation fluid dynamics physiologic simulation software analysis of functional data to assess the severity of coronary artery disease; analysis of fluid dynamics and simulated maximal coronary hyperemia, and generation of estimated FFR model",45.15949506699918,,Present in Autoproposal
0523T,"Intraprocedural coronary fractional flow reserve (FFR) with 3D functional mapping of color-coded FFR values for the coronary tree, derived from coronary angiogram data, for real-time review and interpretation of possible atherosclerotic stenosis(es) intervention",0502T,Noninvasive estimated coronary fractional flow reserve (FFR) derived from coronary computed tomography angiography data using computation fluid dynamics physiologic simulation software analysis of functional data to assess the severity of coronary artery disease; data preparation and transmission,45.137405049635916,,Present in Autoproposal
0523T,"Intraprocedural coronary fractional flow reserve (FFR) with 3D functional mapping of color-coded FFR values for the coronary tree, derived from coronary angiogram data, for real-time review and interpretation of possible atherosclerotic stenosis(es) intervention",93454,"Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation",33.17102497170271,,Present Both in MD and Autoproposal
0523T,"Intraprocedural coronary fractional flow reserve (FFR) with 3D functional mapping of color-coded FFR values for the coronary tree, derived from coronary angiogram data, for real-time review and interpretation of possible atherosclerotic stenosis(es) intervention",93456,"Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with right heart catheterization",30.97371519721942,,Present in Autoproposal
0523T,"Intraprocedural coronary fractional flow reserve (FFR) with 3D functional mapping of color-coded FFR values for the coronary tree, derived from coronary angiogram data, for real-time review and interpretation of possible atherosclerotic stenosis(es) intervention",93571,Intravascular Doppler velocity and/or pressure derived coronary flow reserve measurement (coronary vessel or graft) during coronary angiography including pharmacologically induced stress; initial vessel (List separately in addition to code for primary procedure),29.43271640134929,,Present in Autoproposal
0523T,"Intraprocedural coronary fractional flow reserve (FFR) with 3D functional mapping of color-coded FFR values for the coronary tree, derived from coronary angiogram data, for real-time review and interpretation of possible atherosclerotic stenosis(es) intervention",93572,Intravascular Doppler velocity and/or pressure derived coronary flow reserve measurement (coronary vessel or graft) during coronary angiography including pharmacologically induced stress; each additional vessel (List separately in addition to code for primary procedure),29.318814040046938,,Present in Autoproposal
0523T,"Intraprocedural coronary fractional flow reserve (FFR) with 3D functional mapping of color-coded FFR values for the coronary tree, derived from coronary angiogram data, for real-time review and interpretation of possible atherosclerotic stenosis(es) intervention",93458,"Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed",28.68828790344404,,Present in Autoproposal
0523T,"Intraprocedural coronary fractional flow reserve (FFR) with 3D functional mapping of color-coded FFR values for the coronary tree, derived from coronary angiogram data, for real-time review and interpretation of possible atherosclerotic stenosis(es) intervention",93460,"Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with right and left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed",28.384271356987778,,Present in Autoproposal
0524T,"Endovenous catheter directed chemical ablation with balloon isolation of incompetent extremity vein, open or percutaneous, including all vascular access, catheter manipulation, diagnostic imaging, imaging guidance and monitoring",36478,"Endovenous ablation therapy of incompetent vein, extremity, inclusive of all imaging guidance and monitoring, percutaneous, laser; first vein treated",55.013004106372435,3,Present in Autoproposal
0524T,"Endovenous catheter directed chemical ablation with balloon isolation of incompetent extremity vein, open or percutaneous, including all vascular access, catheter manipulation, diagnostic imaging, imaging guidance and monitoring",36475,"Endovenous ablation therapy of incompetent vein, extremity, inclusive of all imaging guidance and monitoring, percutaneous, radiofrequency; first vein treated",54.436432283710836,,Present in Autoproposal
0524T,"Endovenous catheter directed chemical ablation with balloon isolation of incompetent extremity vein, open or percutaneous, including all vascular access, catheter manipulation, diagnostic imaging, imaging guidance and monitoring",36473,"Endovenous ablation therapy of incompetent vein, extremity, inclusive of all imaging guidance and monitoring, percutaneous, mechanochemical; first vein treated",52.91426090417419,,Present Both in MD and Autoproposal
0524T,"Endovenous catheter directed chemical ablation with balloon isolation of incompetent extremity vein, open or percutaneous, including all vascular access, catheter manipulation, diagnostic imaging, imaging guidance and monitoring",36482,"Endovenous ablation therapy of incompetent vein, extremity, by transcatheter delivery of a chemical adhesive (eg, cyanoacrylate) remote from the access site, inclusive of all imaging guidance and monitoring, percutaneous; first vein treated",52.73307673070698,,Present in Autoproposal
0524T,"Endovenous catheter directed chemical ablation with balloon isolation of incompetent extremity vein, open or percutaneous, including all vascular access, catheter manipulation, diagnostic imaging, imaging guidance and monitoring",36479,"Endovenous ablation therapy of incompetent vein, extremity, inclusive of all imaging guidance and monitoring, percutaneous, laser; subsequent vein(s) treated in a single extremity, each through separate access sites (List separately in addition to code for primary procedure)",49.62013232313169,,Present in Autoproposal
0524T,"Endovenous catheter directed chemical ablation with balloon isolation of incompetent extremity vein, open or percutaneous, including all vascular access, catheter manipulation, diagnostic imaging, imaging guidance and monitoring",36476,"Endovenous ablation therapy of incompetent vein, extremity, inclusive of all imaging guidance and monitoring, percutaneous, radiofrequency; subsequent vein(s) treated in a single extremity, each through separate access sites (List separately in addition to code for primary procedure)",49.295947234095664,,Present in Autoproposal
0524T,"Endovenous catheter directed chemical ablation with balloon isolation of incompetent extremity vein, open or percutaneous, including all vascular access, catheter manipulation, diagnostic imaging, imaging guidance and monitoring",36483,"Endovenous ablation therapy of incompetent vein, extremity, by transcatheter delivery of a chemical adhesive (eg, cyanoacrylate) remote from the access site, inclusive of all imaging guidance and monitoring, percutaneous; subsequent vein(s) treated in a single extremity, each through separate access sites (List separately in addition to code for primary procedure)",49.12430170136272,,Present in Autoproposal
0524T,"Endovenous catheter directed chemical ablation with balloon isolation of incompetent extremity vein, open or percutaneous, including all vascular access, catheter manipulation, diagnostic imaging, imaging guidance and monitoring",36474,"Endovenous ablation therapy of incompetent vein, extremity, inclusive of all imaging guidance and monitoring, percutaneous, mechanochemical; subsequent vein(s) treated in a single extremity, each through separate access sites (List separately in addition to code for primary procedure)",48.42130088568379,,Present in Autoproposal
0524T,"Endovenous catheter directed chemical ablation with balloon isolation of incompetent extremity vein, open or percutaneous, including all vascular access, catheter manipulation, diagnostic imaging, imaging guidance and monitoring",47539,"Placement of stent(s) into a bile duct, percutaneous, including diagnostic cholangiography, imaging guidance (eg, fluoroscopy and/or ultrasound), balloon dilation, catheter exchange(s) and catheter removal(s) when performed, and all associated radiological supervision and interpretation; new access, without placement of separate biliary drainage catheter",36.14909890258212,,Present in Autoproposal
0524T,"Endovenous catheter directed chemical ablation with balloon isolation of incompetent extremity vein, open or percutaneous, including all vascular access, catheter manipulation, diagnostic imaging, imaging guidance and monitoring",47538,"Placement of stent(s) into a bile duct, percutaneous, including diagnostic cholangiography, imaging guidance (eg, fluoroscopy and/or ultrasound), balloon dilation, catheter exchange(s) and catheter removal(s) when performed, and all associated radiological supervision and interpretation; existing access",35.87936128746037,,Present in Autoproposal
0525T,"Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; complete system (electrode and implantable monitor)",0302T,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; complete system (includes device and electrode),65.86544804313561,10,Present in Autoproposal
0525T,"Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; complete system (electrode and implantable monitor)",0303T,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; electrode only,59.74340306696347,,Present in Autoproposal
0525T,"Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; complete system (electrode and implantable monitor)",0304T,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; device only,56.252635606849935,,Present in Autoproposal
0525T,"Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; complete system (electrode and implantable monitor)",0306T,"Interrogation device evaluation (in person) of intracardiac ischemia monitoring system with analysis, review, and report",38.18518443942221,,Present in Autoproposal
0525T,"Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; complete system (electrode and implantable monitor)",0305T,"Programming device evaluation (in person) of intracardiac ischemia monitoring system with iterative adjustment of programmed values, with analysis, review, and report",36.91654016205583,,Present in Autoproposal
0525T,"Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; complete system (electrode and implantable monitor)",0307T,Removal of intracardiac ischemia monitoring device,36.59429929980329,,Present in Autoproposal
0525T,"Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; complete system (electrode and implantable monitor)",0293T,"Insertion of left atrial hemodynamic monitor; complete system, includes implanted communication module and pressure sensor lead in left atrium including transseptal access, radiological supervision and interpretation, and associated injection procedures, when performed",35.830070796207856,,Present in Autoproposal
0525T,"Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; complete system (electrode and implantable monitor)",0454T,"Insertion or replacement of a permanently implantable aortic counterpulsation ventricular assist system, endovascular approach, and programming of sensing and therapeutic parameters; subcutaneous electrode",35.2443918537608,,Present in Autoproposal
0525T,"Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; complete system (electrode and implantable monitor)",K0554,"RECEIVER (MONITOR), DEDICATED, FOR USE WITH THERAPEUTIC GLUCOSE CONTINUOUS MONITOR SYSTEM",34.255857826281776,,Present in Autoproposal
0525T,"Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; complete system (electrode and implantable monitor)",0424T,"Insertion or replacement of neurostimulator system for treatment of central sleep apnea; complete system (transvenous placement of right or left stimulation lead, sensing lead, implantable pulse generator)",34.19229716886315,,Present in Autoproposal
0526T,"Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; electrode only",0303T,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; electrode only,68.80056769866381,10,Present in Autoproposal
0526T,"Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; electrode only",0302T,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; complete system (includes device and electrode),67.43200743383181,,Present in Autoproposal
0526T,"Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; electrode only",0304T,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; device only,64.56726290558255,,Present in Autoproposal
0526T,"Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; electrode only",0307T,Removal of intracardiac ischemia monitoring device,44.02509608532737,,Present in Autoproposal
0526T,"Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; electrode only",0306T,"Interrogation device evaluation (in person) of intracardiac ischemia monitoring system with analysis, review, and report",41.113948313787944,,Present in Autoproposal
0526T,"Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; electrode only",0305T,"Programming device evaluation (in person) of intracardiac ischemia monitoring system with iterative adjustment of programmed values, with analysis, review, and report",40.570481029362874,,Present in Autoproposal
0526T,"Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; electrode only",0411T,"Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; ventricular electrode only",34.62604703160116,,Present Both in MD and Autoproposal
0526T,"Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; electrode only",0410T,"Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; atrial electrode only",34.40681821320294,,Present in Autoproposal
0526T,"Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; electrode only",0454T,"Insertion or replacement of a permanently implantable aortic counterpulsation ventricular assist system, endovascular approach, and programming of sensing and therapeutic parameters; subcutaneous electrode",33.403429681818054,,Present in Autoproposal
0526T,"Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; electrode only",0426T,Insertion or replacement of neurostimulator system for treatment of central sleep apnea; stimulation lead only,32.59152247233287,,Present in Autoproposal
0527T,"Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; implantable monitor only",0304T,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; device only,59.32536964741897,10,Present in Autoproposal
0527T,"Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; implantable monitor only",0303T,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; electrode only,58.68198332175163,,Present in Autoproposal
0527T,"Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; implantable monitor only",0302T,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; complete system (includes device and electrode),57.80592392471993,,Present in Autoproposal
0527T,"Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; implantable monitor only",0307T,Removal of intracardiac ischemia monitoring device,40.45091864656638,,Present in Autoproposal
0527T,"Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; implantable monitor only",0306T,"Interrogation device evaluation (in person) of intracardiac ischemia monitoring system with analysis, review, and report",37.77611240772387,,Present in Autoproposal
0527T,"Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; implantable monitor only",0305T,"Programming device evaluation (in person) of intracardiac ischemia monitoring system with iterative adjustment of programmed values, with analysis, review, and report",37.27676651494624,,Present in Autoproposal
0527T,"Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; implantable monitor only",K0554,"RECEIVER (MONITOR), DEDICATED, FOR USE WITH THERAPEUTIC GLUCOSE CONTINUOUS MONITOR SYSTEM",34.76297895162572,,Present in Autoproposal
0527T,"Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; implantable monitor only",0293T,"Insertion of left atrial hemodynamic monitor; complete system, includes implanted communication module and pressure sensor lead in left atrium including transseptal access, radiological supervision and interpretation, and associated injection procedures, when performed",32.904423768823996,,Present in Autoproposal
0527T,"Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; implantable monitor only",0294T,"Insertion of left atrial hemodynamic monitor; pressure sensor lead at time of insertion of pacing cardioverter-defibrillator pulse generator including radiological supervision and interpretation and associated injection procedures, when performed (List separately in addition to code for primary procedure)",32.130266634590896,,Present in Autoproposal
0527T,"Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; implantable monitor only",E0608,APNEA MONITOR,32.02412566194491,,Present in Autoproposal
0528T,"Programming device evaluation (in person) of intracardiac ischemia monitoring system with iterative adjustment of programmed values, with analysis, review, and report",0305T,"Programming device evaluation (in person) of intracardiac ischemia monitoring system with iterative adjustment of programmed values, with analysis, review, and report",100.00000000000003,10,Present in Autoproposal
0528T,"Programming device evaluation (in person) of intracardiac ischemia monitoring system with iterative adjustment of programmed values, with analysis, review, and report",0306T,"Interrogation device evaluation (in person) of intracardiac ischemia monitoring system with analysis, review, and report",72.66646634653395,,Present in Autoproposal
0528T,"Programming device evaluation (in person) of intracardiac ischemia monitoring system with iterative adjustment of programmed values, with analysis, review, and report",0389T,"Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report, leadless pacemaker system",62.97708738088153,,Present in Autoproposal
0528T,"Programming device evaluation (in person) of intracardiac ischemia monitoring system with iterative adjustment of programmed values, with analysis, review, and report",93279,"Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional; single lead pacemaker system",59.75728162817434,,Present Both in MD and Autoproposal
0528T,"Programming device evaluation (in person) of intracardiac ischemia monitoring system with iterative adjustment of programmed values, with analysis, review, and report",93281,"Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional; multiple lead pacemaker system",59.632450655128764,,Present in Autoproposal
0528T,"Programming device evaluation (in person) of intracardiac ischemia monitoring system with iterative adjustment of programmed values, with analysis, review, and report",93280,"Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional; dual lead pacemaker system",59.3700661699305,,Present in Autoproposal
0528T,"Programming device evaluation (in person) of intracardiac ischemia monitoring system with iterative adjustment of programmed values, with analysis, review, and report",0417T,"Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, including review and report, implantable cardiac contractility modulation system",59.35859709392422,,Present Both in MD and Autoproposal
0528T,"Programming device evaluation (in person) of intracardiac ischemia monitoring system with iterative adjustment of programmed values, with analysis, review, and report",93260,"Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional; implantable subcutaneous lead defibrillator system",57.48704374114024,,Present in Autoproposal
0528T,"Programming device evaluation (in person) of intracardiac ischemia monitoring system with iterative adjustment of programmed values, with analysis, review, and report",93285,"Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional; implantable loop recorder system",57.12242243288069,,Present in Autoproposal
0528T,"Programming device evaluation (in person) of intracardiac ischemia monitoring system with iterative adjustment of programmed values, with analysis, review, and report",93282,"Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional; single lead transvenous implantable defibrillator system",56.692804433495546,,Present in Autoproposal
0529T,"Interrogation device evaluation (in person) of intracardiac ischemia monitoring system with analysis, review, and report",0306T,"Interrogation device evaluation (in person) of intracardiac ischemia monitoring system with analysis, review, and report",100.0,10,Present in Autoproposal
0529T,"Interrogation device evaluation (in person) of intracardiac ischemia monitoring system with analysis, review, and report",0305T,"Programming device evaluation (in person) of intracardiac ischemia monitoring system with iterative adjustment of programmed values, with analysis, review, and report",72.66646634653397,,Present in Autoproposal
0529T,"Interrogation device evaluation (in person) of intracardiac ischemia monitoring system with analysis, review, and report",0307T,Removal of intracardiac ischemia monitoring device,61.67629386958471,,Present in Autoproposal
0529T,"Interrogation device evaluation (in person) of intracardiac ischemia monitoring system with analysis, review, and report",0391T,"Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording and disconnection per patient encounter, leadless pacemaker system",52.239404273403046,,Present in Autoproposal
0529T,"Interrogation device evaluation (in person) of intracardiac ischemia monitoring system with analysis, review, and report",0327T,"Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording and disconnection per patient encounter, implantable subcutaneous lead defibrillator system",51.46154205560127,,Present in Autoproposal
0529T,"Interrogation device evaluation (in person) of intracardiac ischemia monitoring system with analysis, review, and report",0418T,"Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording and disconnection per patient encounter, implantable cardiac contractility modulation system",49.386139854800184,,Present Both in MD and Autoproposal
0529T,"Interrogation device evaluation (in person) of intracardiac ischemia monitoring system with analysis, review, and report",0304T,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; device only,47.2493044325357,,Present in Autoproposal
0529T,"Interrogation device evaluation (in person) of intracardiac ischemia monitoring system with analysis, review, and report",93292,"Interrogation device evaluation (in person) with analysis, review and report by a physician or other qualified health care professional, includes connection, recording and disconnection per patient encounter; wearable defibrillator system",47.04589509631478,,Present in Autoproposal
0529T,"Interrogation device evaluation (in person) of intracardiac ischemia monitoring system with analysis, review, and report",0463T,"Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording and disconnection per patient encounter, implantable aortic counterpulsation ventricular assist system, per day",46.92457742888605,,Present in Autoproposal
0529T,"Interrogation device evaluation (in person) of intracardiac ischemia monitoring system with analysis, review, and report",0302T,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; complete system (includes device and electrode),46.9078788915427,,Present in Autoproposal
0530T,"Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; complete system (electrode and implantable monitor)",0302T,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; complete system (includes device and electrode),65.29682006939531,10,Present in Autoproposal
0530T,"Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; complete system (electrode and implantable monitor)",0303T,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; electrode only,59.39573459221423,,Present in Autoproposal
0530T,"Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; complete system (electrode and implantable monitor)",0307T,Removal of intracardiac ischemia monitoring device,55.776344886531874,,Present in Autoproposal
0530T,"Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; complete system (electrode and implantable monitor)",0304T,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; device only,54.27971803390621,,Present in Autoproposal
0530T,"Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; complete system (electrode and implantable monitor)",0306T,"Interrogation device evaluation (in person) of intracardiac ischemia monitoring system with analysis, review, and report",45.12997150051102,,Present in Autoproposal
0530T,"Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; complete system (electrode and implantable monitor)",0305T,"Programming device evaluation (in person) of intracardiac ischemia monitoring system with iterative adjustment of programmed values, with analysis, review, and report",36.752009032618396,,Present in Autoproposal
0530T,"Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; complete system (electrode and implantable monitor)",33272,Removal of subcutaneous implantable defibrillator electrode,32.041451417338585,,Present in Autoproposal
0530T,"Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; complete system (electrode and implantable monitor)",37243,"Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; for tumors, organ ischemia, or infarction",31.42416651829635,,Present in Autoproposal
0530T,"Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; complete system (electrode and implantable monitor)",93662,"Intracardiac echocardiography during therapeutic/diagnostic intervention, including imaging supervision and interpretation (List separately in addition to code for primary procedure)",30.670088440499594,,Present in Autoproposal
0530T,"Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; complete system (electrode and implantable monitor)",0458T,Removal of permanently implantable aortic counterpulsation ventricular assist system; subcutaneous electrode,29.704874057683455,,Present in Autoproposal
0531T,"Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; electrode only",0303T,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; electrode only,66.7050851064831,10,Present in Autoproposal
0531T,"Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; electrode only",0307T,Removal of intracardiac ischemia monitoring device,66.62791623369937,,Present in Autoproposal
0531T,"Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; electrode only",0302T,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; complete system (includes device and electrode),61.69058998349642,,Present in Autoproposal
0531T,"Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; electrode only",0304T,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; device only,60.54716430407425,,Present in Autoproposal
0531T,"Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; electrode only",0306T,"Interrogation device evaluation (in person) of intracardiac ischemia monitoring system with analysis, review, and report",47.245496724200684,,Present in Autoproposal
0531T,"Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; electrode only",0305T,"Programming device evaluation (in person) of intracardiac ischemia monitoring system with iterative adjustment of programmed values, with analysis, review, and report",38.59505396163304,,Present in Autoproposal
0531T,"Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; electrode only",93662,"Intracardiac echocardiography during therapeutic/diagnostic intervention, including imaging supervision and interpretation (List separately in addition to code for primary procedure)",34.98475378546381,,Present in Autoproposal
0531T,"Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; electrode only",37243,"Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; for tumors, organ ischemia, or infarction",30.836557061458496,,Present in Autoproposal
0531T,"Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; electrode only",0324T,Removal of subcutaneous defibrillator electrode,28.694413891230617,,Present in Autoproposal
0531T,"Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; electrode only",33235,Removal of transvenous pacemaker electrode(s); dual lead system,27.893299201275102,,Present in Autoproposal
0532T,"Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; implantable monitor only",0307T,Removal of intracardiac ischemia monitoring device,63.399915401927984,10,Present in Autoproposal
0532T,"Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; implantable monitor only",0304T,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; device only,57.61376479553467,,Present in Autoproposal
0532T,"Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; implantable monitor only",0303T,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; electrode only,56.988940902148734,,Present in Autoproposal
0532T,"Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; implantable monitor only",0302T,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; complete system (includes device and electrode),52.762967861616126,,Present in Autoproposal
0532T,"Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; implantable monitor only",0306T,"Interrogation device evaluation (in person) of intracardiac ischemia monitoring system with analysis, review, and report",44.95653871164266,,Present in Autoproposal
0532T,"Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; implantable monitor only",0305T,"Programming device evaluation (in person) of intracardiac ischemia monitoring system with iterative adjustment of programmed values, with analysis, review, and report",36.72519409908792,,Present in Autoproposal
0532T,"Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; implantable monitor only",93662,"Intracardiac echocardiography during therapeutic/diagnostic intervention, including imaging supervision and interpretation (List separately in addition to code for primary procedure)",33.289806371489675,,Present in Autoproposal
0532T,"Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; implantable monitor only",37243,"Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; for tumors, organ ischemia, or infarction",29.342582201218047,,Present in Autoproposal
0532T,"Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; implantable monitor only",33241,Removal of implantable defibrillator pulse generator only,28.181754152621764,,Present in Autoproposal
0532T,"Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; implantable monitor only",C1817,"SEPTAL DEFECT IMPLANT SYSTEM, INTRACARDIAC",26.3233580901851,,Present in Autoproposal
0533T,"Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; includes set-up, patient training, configuration of monitor, data upload, analysis and initial report configuration, download review, interpretation and report",0295T,"External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; includes recording, scanning analysis with report, review and interpretation",37.451003938819404,10,Present Both in MD and Autoproposal
0533T,"Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; includes set-up, patient training, configuration of monitor, data upload, analysis and initial report configuration, download review, interpretation and report",0381T,"External heart rate and 3-axis accelerometer data recording up to 14 days to assess changes in heart rate and to monitor motion analysis for the purposes of diagnosing nocturnal epilepsy seizure events; includes report, scanning analysis with report, review and interpretation by a physician or other qualified health care professional",33.239711339437186,,Present in Autoproposal
0533T,"Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; includes set-up, patient training, configuration of monitor, data upload, analysis and initial report configuration, download review, interpretation and report",0298T,External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; review and interpretation,32.66984175542018,,Present in Autoproposal
0533T,"Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; includes set-up, patient training, configuration of monitor, data upload, analysis and initial report configuration, download review, interpretation and report",0297T,External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; scanning analysis with report,31.194629991598653,,Present in Autoproposal
0533T,"Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; includes set-up, patient training, configuration of monitor, data upload, analysis and initial report configuration, download review, interpretation and report",93224,"External electrocardiographic recording up to 48 hours by continuous rhythm recording and storage; includes recording, scanning analysis with report, review and interpretation by a physician or other qualified health care professional",30.54310287961985,,Present in Autoproposal
0533T,"Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; includes set-up, patient training, configuration of monitor, data upload, analysis and initial report configuration, download review, interpretation and report",0383T,"External heart rate and 3-axis accelerometer data recording from 15 to 30 days to assess changes in heart rate and to monitor motion analysis for the purposes of diagnosing nocturnal epilepsy seizure events; includes report, scanning analysis with report, review and interpretation by a physician or other qualified health care professional",30.452667864320237,,Present in Autoproposal
0533T,"Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; includes set-up, patient training, configuration of monitor, data upload, analysis and initial report configuration, download review, interpretation and report",0385T,"External heart rate and 3-axis accelerometer data recording more than 30 days to assess changes in heart rate and to monitor motion analysis for the purposes of diagnosing nocturnal epilepsy seizure events; includes report, scanning analysis with report, review and interpretation by a physician or other qualified health care professional",30.39429011572991,,Present in Autoproposal
0533T,"Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; includes set-up, patient training, configuration of monitor, data upload, analysis and initial report configuration, download review, interpretation and report",94774,"Pediatric home apnea monitoring event recording including respiratory rate, pattern and heart rate per 30-day period of time; includes monitor attachment, download of data, review, interpretation, and preparation of a report by a physician or other qualified health care professional",29.848326418302612,,Present in Autoproposal
0533T,"Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; includes set-up, patient training, configuration of monitor, data upload, analysis and initial report configuration, download review, interpretation and report",0296T,External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; recording (includes connection and initial recording),29.781047838959353,,Present in Autoproposal
0533T,"Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; includes set-up, patient training, configuration of monitor, data upload, analysis and initial report configuration, download review, interpretation and report",0378T,"Visual field assessment, with concurrent real time data analysis and accessible data storage with patient initiated data transmitted to a remote surveillance center for up to 30 days; review and interpretation with report by a physician or other qualified health care professional",29.611589286189393,,Present in Autoproposal
0534T,"Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; set-up, patient training, configuration of monitor",0298T,External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; review and interpretation,31.653332336406383,2,Present in Autoproposal
0534T,"Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; set-up, patient training, configuration of monitor",0296T,External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; recording (includes connection and initial recording),31.50534597219935,,Present Both in MD and Autoproposal
0534T,"Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; set-up, patient training, configuration of monitor",0295T,"External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; includes recording, scanning analysis with report, review and interpretation",30.155957204100385,,Present in Autoproposal
0534T,"Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; set-up, patient training, configuration of monitor",0297T,External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; scanning analysis with report,30.06561413879112,,Present in Autoproposal
0534T,"Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; set-up, patient training, configuration of monitor",G9405,PATIENT RECEIVED FOLLOW-UP WITHIN 7 DAYS FROM DISCHARGE,28.019152983828295,,Present in Autoproposal
0534T,"Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; set-up, patient training, configuration of monitor",95249,"Ambulatory continuous glucose monitoring of interstitial tissue fluid via a subcutaneous sensor for a minimum of 72 hours; patient-provided equipment, sensor placement, hook-up, calibration of monitor, patient training, and printout of recording",27.47268234192389,,Present in Autoproposal
0534T,"Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; set-up, patient training, configuration of monitor",G9286,ANTIBIOTIC REGIMEN PRESCRIBED WITHIN 10 DAYS AFTER ONSET OF SYMPTOMS,25.949944406051838,,Present in Autoproposal
0534T,"Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; set-up, patient training, configuration of monitor",G9287,ANTIBIOTIC REGIMEN NOT PRESCRIBED WITHIN 10 DAYS AFTER ONSET OF SYMPTOMS,25.464103931915886,,Present in Autoproposal
0534T,"Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; set-up, patient training, configuration of monitor",93225,"External electrocardiographic recording up to 48 hours by continuous rhythm recording and storage; recording (includes connection, recording, and disconnection)",25.232367284739233,,Present in Autoproposal
0534T,"Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; set-up, patient training, configuration of monitor",G9505,ANTIBIOTIC REGIMEN PRESCRIBED WITHIN 10 DAYS AFTER ONSET OF SYMPTOMS FOR DOCUMENTED MEDICAL REASON,24.69562158734219,,Present in Autoproposal
0535T,"Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; data upload, analysis and initial report configuration",0295T,"External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; includes recording, scanning analysis with report, review and interpretation",36.43451729936671,2,Present in Autoproposal
0535T,"Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; data upload, analysis and initial report configuration",0297T,External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; scanning analysis with report,36.12138817482196,,Present Both in MD and Autoproposal
0535T,"Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; data upload, analysis and initial report configuration",0296T,External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; recording (includes connection and initial recording),35.545460243664024,,Present in Autoproposal
0535T,"Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; data upload, analysis and initial report configuration",0298T,External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; review and interpretation,32.417756950596385,,Present in Autoproposal
0535T,"Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; data upload, analysis and initial report configuration",0199T,"Physiologic recording of tremor using accelerometer(s) and/or gyroscope(s) (including frequency and amplitude), including interpretation and report",30.397910601955775,,Present in Autoproposal
0535T,"Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; data upload, analysis and initial report configuration",95803,"Actigraphy testing, recording, analysis, interpretation, and report (minimum of 72 hours to 14 consecutive days of recording)",29.531788066738727,,Present in Autoproposal
0535T,"Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; data upload, analysis and initial report configuration",93226,External electrocardiographic recording up to 48 hours by continuous rhythm recording and storage; scanning analysis with report,29.22502412738599,,Present in Autoproposal
0535T,"Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; data upload, analysis and initial report configuration",0378T,"Visual field assessment, with concurrent real time data analysis and accessible data storage with patient initiated data transmitted to a remote surveillance center for up to 30 days; review and interpretation with report by a physician or other qualified health care professional",29.190208237979327,,Present in Autoproposal
0535T,"Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; data upload, analysis and initial report configuration",93298,"Interrogation device evaluation(s), (remote) up to 30 days; implantable loop recorder system, including analysis of recorded heart rhythm data, analysis, review(s) and report(s) by a physician or other qualified health care professional",28.893086904471076,,Present in Autoproposal
0535T,"Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; data upload, analysis and initial report configuration",0381T,"External heart rate and 3-axis accelerometer data recording up to 14 days to assess changes in heart rate and to monitor motion analysis for the purposes of diagnosing nocturnal epilepsy seizure events; includes report, scanning analysis with report, review and interpretation by a physician or other qualified health care professional",28.086620065903578,,Present in Autoproposal
0536T,"Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; download review, interpretation and report",0295T,"External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; includes recording, scanning analysis with report, review and interpretation",41.149859194116125,2,Present in Autoproposal
0536T,"Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; download review, interpretation and report",0298T,External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; review and interpretation,41.068249818719075,,Present Both in MD and Autoproposal
0536T,"Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; download review, interpretation and report",0199T,"Physiologic recording of tremor using accelerometer(s) and/or gyroscope(s) (including frequency and amplitude), including interpretation and report",33.95548318626381,,Present in Autoproposal
0536T,"Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; download review, interpretation and report",0297T,External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; scanning analysis with report,33.63300317625146,,Present in Autoproposal
0536T,"Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; download review, interpretation and report",0296T,External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; recording (includes connection and initial recording),33.150532498097064,,Present in Autoproposal
0536T,"Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; download review, interpretation and report",93224,"External electrocardiographic recording up to 48 hours by continuous rhythm recording and storage; includes recording, scanning analysis with report, review and interpretation by a physician or other qualified health care professional",31.694106995821308,,Present in Autoproposal
0536T,"Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; download review, interpretation and report",95803,"Actigraphy testing, recording, analysis, interpretation, and report (minimum of 72 hours to 14 consecutive days of recording)",29.77373303795629,,Present in Autoproposal
0536T,"Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; download review, interpretation and report",93227,External electrocardiographic recording up to 48 hours by continuous rhythm recording and storage; review and interpretation by a physician or other qualified health care professional,29.721537631757933,,Present in Autoproposal
0536T,"Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; download review, interpretation and report",93272,"External patient and, when performed, auto activated electrocardiographic rhythm derived event recording with symptom-related memory loop with remote download capability up to 30 days, 24-hour attended monitoring; review and interpretation by a physician or other qualified health care professional",29.05274732489889,,Present in Autoproposal
0536T,"Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; download review, interpretation and report",93268,"External patient and, when performed, auto activated electrocardiographic rhythm derived event recording with symptom-related memory loop with remote download capability up to 30 days, 24-hour attended monitoring; includes transmission, review and interpretation by a physician or other qualified health care professional",28.291117055267414,,Present in Autoproposal
0537T,"Chimeric antigen receptor T-cell (CAR-T) therapy; harvesting of blood-derived T lymphocytes for development of genetically modified autologous CAR-T cells, per day",38206,"Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous",38.49747388210152,1,Present Both in MD and Autoproposal
0537T,"Chimeric antigen receptor T-cell (CAR-T) therapy; harvesting of blood-derived T lymphocytes for development of genetically modified autologous CAR-T cells, per day",Q2041,"Axicabtagene Ciloleucel, up to 200 Million Autologous Anti-CD19 CAR T Cells, Including Leukapheresis And Dose Preparation Procedures, Per Infusion",30.69604286703729,,Present Both in MD and Autoproposal
0537T,"Chimeric antigen receptor T-cell (CAR-T) therapy; harvesting of blood-derived T lymphocytes for development of genetically modified autologous CAR-T cells, per day",38205,"Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; allogeneic",29.399067750735092,,Present in Autoproposal
0537T,"Chimeric antigen receptor T-cell (CAR-T) therapy; harvesting of blood-derived T lymphocytes for development of genetically modified autologous CAR-T cells, per day",0489T,"Autologous adipose-derived regenerative cell therapy for scleroderma in the hands; adipose tissue harvesting, isolation and preparation of harvested cells including incubation with cell dissociation enzymes, removal of non-viable cells and debris, determination of concentration and dilution of regenerative cells",27.62961667360469,,Present in Autoproposal
0537T,"Chimeric antigen receptor T-cell (CAR-T) therapy; harvesting of blood-derived T lymphocytes for development of genetically modified autologous CAR-T cells, per day",0481T,"Injection(s), autologous white blood cell concentrate (autologous protein solution), any site, including image guidance, harvesting and preparation, when performed",27.626019322054606,,Present in Autoproposal
0537T,"Chimeric antigen receptor T-cell (CAR-T) therapy; harvesting of blood-derived T lymphocytes for development of genetically modified autologous CAR-T cells, per day",Q2040,"TISAGENLECLEUCEL, UP TO 250 MILLION CAR-POSITIVE VIABLE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER INFUSION",27.14305721390572,,Present Both in MD and Autoproposal
0537T,"Chimeric antigen receptor T-cell (CAR-T) therapy; harvesting of blood-derived T lymphocytes for development of genetically modified autologous CAR-T cells, per day",38232,Bone marrow harvesting for transplantation; autologous,26.03133742544273,,Present in Autoproposal
0537T,"Chimeric antigen receptor T-cell (CAR-T) therapy; harvesting of blood-derived T lymphocytes for development of genetically modified autologous CAR-T cells, per day",S2150,"BONE MARROW OR BLOOD-DERIVED STEM CELLS (PERIPHERAL OR UMBILICAL), ALLOGENEIC OR AUTOLOGOUS, HARVESTING, TRANSPLANTATION, AND RELATED COMPLICATIONS; INCLUDING: PHERESIS AND CELL PREPARATION/STORAGE; MARROW ABLATIVE THERAPY; DRUGS, SUPPLIES, HOSPITALIZATION WITH OUTPATIENT FOLLOW-UP; MEDICAL/SURGICAL, DIAGNOSTIC, EMERGENCY, AND REHABILITATIVE SERVICES; AND THE NUMBER OF DAYS OF PRE-AND POST-TRANSPLANT CARE IN THE GLOBAL DEFINITION",21.450709890532195,,Present in Autoproposal
0537T,"Chimeric antigen receptor T-cell (CAR-T) therapy; harvesting of blood-derived T lymphocytes for development of genetically modified autologous CAR-T cells, per day",0265T,"Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections, one leg, including ultrasound guidance, if performed; unilateral or bilateral bone marrow harvest only for intramuscular autologous bone marrow cell therapy",21.258922881597407,,Present in Autoproposal
0537T,"Chimeric antigen receptor T-cell (CAR-T) therapy; harvesting of blood-derived T lymphocytes for development of genetically modified autologous CAR-T cells, per day",S2112,"ARTHROSCOPY, KNEE, SURGICAL FOR HARVESTING OF CARTILAGE (CHONDROCYTE CELLS)",20.764155670313713,,Present in Autoproposal
0538T,"Chimeric antigen receptor T-cell (CAR-T) therapy; preparation of blood-derived T lymphocytes for transportation (eg, cryopreservation, storage)",38207,Transplant preparation of hematopoietic progenitor cells; cryopreservation and storage,35.691546947320944,10,Present Both in MD and Autoproposal
0538T,"Chimeric antigen receptor T-cell (CAR-T) therapy; preparation of blood-derived T lymphocytes for transportation (eg, cryopreservation, storage)",88240,"Cryopreservation, freezing and storage of cells, each cell line",35.63799381647363,,Present in Autoproposal
0538T,"Chimeric antigen receptor T-cell (CAR-T) therapy; preparation of blood-derived T lymphocytes for transportation (eg, cryopreservation, storage)",G0265,"CRYOPRESERVATION, FREEZING AND STORAGE OF CELLS FOR THERAPEUTIC USE, EACH CELL LINE",34.72535020258844,,Present in Autoproposal
0538T,"Chimeric antigen receptor T-cell (CAR-T) therapy; preparation of blood-derived T lymphocytes for transportation (eg, cryopreservation, storage)",S2142,"CORD BLOOD-DERIVED STEM-CELL TRANSPLANTATION, ALLOGENEIC",26.504367394776217,,Present in Autoproposal
0538T,"Chimeric antigen receptor T-cell (CAR-T) therapy; preparation of blood-derived T lymphocytes for transportation (eg, cryopreservation, storage)",89259,Cryopreservation; sperm,26.087126855637997,,Present in Autoproposal
0538T,"Chimeric antigen receptor T-cell (CAR-T) therapy; preparation of blood-derived T lymphocytes for transportation (eg, cryopreservation, storage)",89258,Cryopreservation; embryo(s),25.65286920108062,,Present in Autoproposal
0538T,"Chimeric antigen receptor T-cell (CAR-T) therapy; preparation of blood-derived T lymphocytes for transportation (eg, cryopreservation, storage)",0059T,Cryopreservation; oocyte(s),25.476968534341665,,Present in Autoproposal
0538T,"Chimeric antigen receptor T-cell (CAR-T) therapy; preparation of blood-derived T lymphocytes for transportation (eg, cryopreservation, storage)",38206,"Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous",23.63807542618982,,Present in Autoproposal
0538T,"Chimeric antigen receptor T-cell (CAR-T) therapy; preparation of blood-derived T lymphocytes for transportation (eg, cryopreservation, storage)",38205,"Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; allogeneic",23.447572545996742,,Present in Autoproposal
0538T,"Chimeric antigen receptor T-cell (CAR-T) therapy; preparation of blood-derived T lymphocytes for transportation (eg, cryopreservation, storage)",0001U,"Red blood cell antigen typing, DNA, human erythrocyte antigen gene analysis of 35 antigens from 11 blood groups, utilizing whole blood, common RBC alleles reported",22.558358258589173,,Present in Autoproposal
0539T,Chimeric antigen receptor T-cell (CAR-T) therapy; receipt and preparation of CAR-T cells foradministration,Q2040,"TISAGENLECLEUCEL, UP TO 250 MILLION CAR-POSITIVE VIABLE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER INFUSION",36.449838614014126,2,Present Both in MD and Autoproposal
0539T,Chimeric antigen receptor T-cell (CAR-T) therapy; receipt and preparation of CAR-T cells foradministration,Q2041,"Axicabtagene Ciloleucel, up to 200 Million Autologous Anti-CD19 CAR T Cells, Including Leukapheresis And Dose Preparation Procedures, Per Infusion",32.81636650175119,,Present Both in MD and Autoproposal
0539T,Chimeric antigen receptor T-cell (CAR-T) therapy; receipt and preparation of CAR-T cells foradministration,38212,Transplant preparation of hematopoietic progenitor cells; red blood cell removal,22.521323179191825,,Present in Autoproposal
0539T,Chimeric antigen receptor T-cell (CAR-T) therapy; receipt and preparation of CAR-T cells foradministration,94780,"Car seat/bed testing for airway integrity, neonate, with continual nursing observation and continuous recording of pulse oximetry, heart rate and respiratory rate, with interpretation and report; 60 minutes",22.44016377686606,,Present in Autoproposal
0539T,Chimeric antigen receptor T-cell (CAR-T) therapy; receipt and preparation of CAR-T cells foradministration,38211,Transplant preparation of hematopoietic progenitor cells; tumor cell depletion,22.423557449313236,,Present in Autoproposal
0539T,Chimeric antigen receptor T-cell (CAR-T) therapy; receipt and preparation of CAR-T cells foradministration,0489T,"Autologous adipose-derived regenerative cell therapy for scleroderma in the hands; adipose tissue harvesting, isolation and preparation of harvested cells including incubation with cell dissociation enzymes, removal of non-viable cells and debris, determination of concentration and dilution of regenerative cells",21.841955624987293,,Present in Autoproposal
0539T,Chimeric antigen receptor T-cell (CAR-T) therapy; receipt and preparation of CAR-T cells foradministration,94781,"Car seat/bed testing for airway integrity, neonate, with continual nursing observation and continuous recording of pulse oximetry, heart rate and respiratory rate, with interpretation and report; each additional full 30 minutes (List separately in addition to code for primary procedure)",20.822763970925667,,Present in Autoproposal
0539T,Chimeric antigen receptor T-cell (CAR-T) therapy; receipt and preparation of CAR-T cells foradministration,84238,Receptor assay; non-endocrine (specify receptor),20.132399453284986,,Present in Autoproposal
0539T,Chimeric antigen receptor T-cell (CAR-T) therapy; receipt and preparation of CAR-T cells foradministration,38210,"Transplant preparation of hematopoietic progenitor cells; specific cell depletion within harvest, T-cell depletion",19.720871957182045,,Present in Autoproposal
0539T,Chimeric antigen receptor T-cell (CAR-T) therapy; receipt and preparation of CAR-T cells foradministration,86481,"Tuberculosis test, cell mediated immunity antigen response measurement; enumeration of gamma interferon-producing T-cells in cell suspension",19.261285168202413,,Present in Autoproposal
0540T,"Chimeric antigen receptor T-cell (CAR-T) therapy; CAR-T cell administration, autologous",Q2041,"Axicabtagene Ciloleucel, up to 200 Million Autologous Anti-CD19 CAR T Cells, Including Leukapheresis And Dose Preparation Procedures, Per Infusion",28.908676302547576,5,Present Both in MD and Autoproposal
0540T,"Chimeric antigen receptor T-cell (CAR-T) therapy; CAR-T cell administration, autologous",0265T,"Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections, one leg, including ultrasound guidance, if performed; unilateral or bilateral bone marrow harvest only for intramuscular autologous bone marrow cell therapy",25.28647183005849,,Present in Autoproposal
0540T,"Chimeric antigen receptor T-cell (CAR-T) therapy; CAR-T cell administration, autologous",38241,Hematopoietic progenitor cell (HPC); autologous transplantation,24.978421541004344,,Present in Autoproposal
0540T,"Chimeric antigen receptor T-cell (CAR-T) therapy; CAR-T cell administration, autologous",0481T,"Injection(s), autologous white blood cell concentrate (autologous protein solution), any site, including image guidance, harvesting and preparation, when performed",24.59341401866835,,Present in Autoproposal
0540T,"Chimeric antigen receptor T-cell (CAR-T) therapy; CAR-T cell administration, autologous",Q2040,"TISAGENLECLEUCEL, UP TO 250 MILLION CAR-POSITIVE VIABLE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER INFUSION",24.047383152811413,,Present Both in MD and Autoproposal
0540T,"Chimeric antigen receptor T-cell (CAR-T) therapy; CAR-T cell administration, autologous",86356,"Mononuclear cell antigen, quantitative (eg, flow cytometry), not otherwise specified, each antigen",23.431845939167566,,Present in Autoproposal
0540T,"Chimeric antigen receptor T-cell (CAR-T) therapy; CAR-T cell administration, autologous",G9069,"ONCOLOGY; DISEASE STATUS; SMALL CELL LUNG CANCER, LIMITED TO SMALL CELL AND COMBINED SMALL CELL/NON-SMALL CELL; EXTENSIVE STAGE AT DIAGNOSIS, METASTATIC, LOCALLY RECURRENT, OR PROGRESSIVE (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)",22.587666013415962,,Present in Autoproposal
0540T,"Chimeric antigen receptor T-cell (CAR-T) therapy; CAR-T cell administration, autologous",88180,CELL MARKER STUDY,22.031890441289118,,Present in Autoproposal
0540T,"Chimeric antigen receptor T-cell (CAR-T) therapy; CAR-T cell administration, autologous",38206,"Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous",21.797390049117862,,Present in Autoproposal
0540T,"Chimeric antigen receptor T-cell (CAR-T) therapy; CAR-T cell administration, autologous",38204,Management of recipient hematopoietic progenitor cell donor search and cell acquisition,21.537241457355975,,Present in Autoproposal
0541T,"Myocardial imaging by magnetocardiography (MCG) for detection of cardiac ischemia, by signal acquisition using minimum 36 channel grid, generation of magnetic-field time-series images, quantitative analysis of magnetic dipoles, machine learningderived clinical scoring, and automated report generation, single study;",0477T,"Recording of fetal magnetic cardiac signal using at least 3 channels; signal extraction, technical analysis, and result",27.563343452696444,8,Present Both in MD and Autoproposal
0541T,"Myocardial imaging by magnetocardiography (MCG) for detection of cardiac ischemia, by signal acquisition using minimum 36 channel grid, generation of magnetic-field time-series images, quantitative analysis of magnetic dipoles, machine learningderived clinical scoring, and automated report generation, single study;",0478T,"Recording of fetal magnetic cardiac signal using at least 3 channels; review, interpretation, report by physician or other qualified health care professional",26.736832844952573,,Present in Autoproposal
0541T,"Myocardial imaging by magnetocardiography (MCG) for detection of cardiac ischemia, by signal acquisition using minimum 36 channel grid, generation of magnetic-field time-series images, quantitative analysis of magnetic dipoles, machine learningderived clinical scoring, and automated report generation, single study;",0475T,"Recording of fetal magnetic cardiac signal using at least 3 channels; patient recording and storage, data scanning with signal extraction, technical analysis and result, as well as supervision, review, and interpretation of report by a physician or other qualified health care professional",24.544803772546903,,Present in Autoproposal
0541T,"Myocardial imaging by magnetocardiography (MCG) for detection of cardiac ischemia, by signal acquisition using minimum 36 channel grid, generation of magnetic-field time-series images, quantitative analysis of magnetic dipoles, machine learningderived clinical scoring, and automated report generation, single study;",S8042,"MAGNETIC RESONANCE IMAGING (MRI), LOW-FIELD",22.896912082316838,,Present in Autoproposal
0541T,"Myocardial imaging by magnetocardiography (MCG) for detection of cardiac ischemia, by signal acquisition using minimum 36 channel grid, generation of magnetic-field time-series images, quantitative analysis of magnetic dipoles, machine learningderived clinical scoring, and automated report generation, single study;",S8035,MAGNETIC SOURCE IMAGING,22.673221444374683,,Present in Autoproposal
0541T,"Myocardial imaging by magnetocardiography (MCG) for detection of cardiac ischemia, by signal acquisition using minimum 36 channel grid, generation of magnetic-field time-series images, quantitative analysis of magnetic dipoles, machine learningderived clinical scoring, and automated report generation, single study;",75554,"Cardiac magnetic resonance imaging for function, with or without morphology; complete study",22.600752200244585,,Present in Autoproposal
0541T,"Myocardial imaging by magnetocardiography (MCG) for detection of cardiac ischemia, by signal acquisition using minimum 36 channel grid, generation of magnetic-field time-series images, quantitative analysis of magnetic dipoles, machine learningderived clinical scoring, and automated report generation, single study;",75555,"Cardiac magnetic resonance imaging for function, with or without morphology; limited study",22.355318574761622,,Present in Autoproposal
0541T,"Myocardial imaging by magnetocardiography (MCG) for detection of cardiac ischemia, by signal acquisition using minimum 36 channel grid, generation of magnetic-field time-series images, quantitative analysis of magnetic dipoles, machine learningderived clinical scoring, and automated report generation, single study;",0476T,"Recording of fetal magnetic cardiac signal using at least 3 channels; patient recording, data scanning, with raw electronic signal transfer of data and storage",22.012755739229238,,Present Both in MD and Autoproposal
0541T,"Myocardial imaging by magnetocardiography (MCG) for detection of cardiac ischemia, by signal acquisition using minimum 36 channel grid, generation of magnetic-field time-series images, quantitative analysis of magnetic dipoles, machine learningderived clinical scoring, and automated report generation, single study;",0380T,"Computer-aided animation and analysis of time series retinal images for the monitoring of disease progression, unilateral or bilateral, with interpretation and report",21.790863540042814,,Present in Autoproposal
0541T,"Myocardial imaging by magnetocardiography (MCG) for detection of cardiac ischemia, by signal acquisition using minimum 36 channel grid, generation of magnetic-field time-series images, quantitative analysis of magnetic dipoles, machine learningderived clinical scoring, and automated report generation, single study;",0399T,Myocardial strain imaging (quantitative assessment of myocardial mechanics using image-based analysis of local myocardial dynamics) (List separately in addition to code for primary procedure),21.00140261377916,,Present in Autoproposal
0542T,"Myocardial imaging by magnetocardiography (MCG) for detection of cardiac ischemia, by signal acquisition using minimum 36 channel grid, generation of magnetic-field time-series images, quantitative analysis of magnetic dipoles, machine learningderived clinical scoring, and automated report generation, single study; interpretation and report",0478T,"Recording of fetal magnetic cardiac signal using at least 3 channels; review, interpretation, report by physician or other qualified health care professional",30.105154003737354,10,Present in Autoproposal
0542T,"Myocardial imaging by magnetocardiography (MCG) for detection of cardiac ischemia, by signal acquisition using minimum 36 channel grid, generation of magnetic-field time-series images, quantitative analysis of magnetic dipoles, machine learningderived clinical scoring, and automated report generation, single study; interpretation and report",0475T,"Recording of fetal magnetic cardiac signal using at least 3 channels; patient recording and storage, data scanning with signal extraction, technical analysis and result, as well as supervision, review, and interpretation of report by a physician or other qualified health care professional",27.605622696584874,,Present Both in MD and Autoproposal
0542T,"Myocardial imaging by magnetocardiography (MCG) for detection of cardiac ischemia, by signal acquisition using minimum 36 channel grid, generation of magnetic-field time-series images, quantitative analysis of magnetic dipoles, machine learningderived clinical scoring, and automated report generation, single study; interpretation and report",0477T,"Recording of fetal magnetic cardiac signal using at least 3 channels; signal extraction, technical analysis, and result",27.25833447728265,,Present in Autoproposal
0542T,"Myocardial imaging by magnetocardiography (MCG) for detection of cardiac ischemia, by signal acquisition using minimum 36 channel grid, generation of magnetic-field time-series images, quantitative analysis of magnetic dipoles, machine learningderived clinical scoring, and automated report generation, single study; interpretation and report",0380T,"Computer-aided animation and analysis of time series retinal images for the monitoring of disease progression, unilateral or bilateral, with interpretation and report",26.19546551302711,,Present in Autoproposal
0542T,"Myocardial imaging by magnetocardiography (MCG) for detection of cardiac ischemia, by signal acquisition using minimum 36 channel grid, generation of magnetic-field time-series images, quantitative analysis of magnetic dipoles, machine learningderived clinical scoring, and automated report generation, single study; interpretation and report",S8042,"MAGNETIC RESONANCE IMAGING (MRI), LOW-FIELD",22.17094950040657,,Present in Autoproposal
0542T,"Myocardial imaging by magnetocardiography (MCG) for detection of cardiac ischemia, by signal acquisition using minimum 36 channel grid, generation of magnetic-field time-series images, quantitative analysis of magnetic dipoles, machine learningderived clinical scoring, and automated report generation, single study; interpretation and report",S8035,MAGNETIC SOURCE IMAGING,21.95435113029887,,Present in Autoproposal
0542T,"Myocardial imaging by magnetocardiography (MCG) for detection of cardiac ischemia, by signal acquisition using minimum 36 channel grid, generation of magnetic-field time-series images, quantitative analysis of magnetic dipoles, machine learningderived clinical scoring, and automated report generation, single study; interpretation and report",75554,"Cardiac magnetic resonance imaging for function, with or without morphology; complete study",21.884179574144706,,Present in Autoproposal
0542T,"Myocardial imaging by magnetocardiography (MCG) for detection of cardiac ischemia, by signal acquisition using minimum 36 channel grid, generation of magnetic-field time-series images, quantitative analysis of magnetic dipoles, machine learningderived clinical scoring, and automated report generation, single study; interpretation and report",0476T,"Recording of fetal magnetic cardiac signal using at least 3 channels; patient recording, data scanning, with raw electronic signal transfer of data and storage",21.78093243683204,,Present in Autoproposal
0542T,"Myocardial imaging by magnetocardiography (MCG) for detection of cardiac ischemia, by signal acquisition using minimum 36 channel grid, generation of magnetic-field time-series images, quantitative analysis of magnetic dipoles, machine learningderived clinical scoring, and automated report generation, single study; interpretation and report",75555,"Cardiac magnetic resonance imaging for function, with or without morphology; limited study",21.64652759309497,,Present in Autoproposal
0542T,"Myocardial imaging by magnetocardiography (MCG) for detection of cardiac ischemia, by signal acquisition using minimum 36 channel grid, generation of magnetic-field time-series images, quantitative analysis of magnetic dipoles, machine learningderived clinical scoring, and automated report generation, single study; interpretation and report",93317,"Transesophageal echocardiography for congenital cardiac anomalies; image acquisition, interpretation and report only",20.66261432390131,,Present in Autoproposal
10004,"Fine needle aspiration biopsy, without imaging guidance; each additional lesion (List separately in addition to code for primary procedure)",10021,Fine needle aspiration; without imaging guidance,69.0592873761698,1,Present Both in MD and Autoproposal
10004,"Fine needle aspiration biopsy, without imaging guidance; each additional lesion (List separately in addition to code for primary procedure)",10022,Fine needle aspiration; with imaging guidance,65.21674117085455,,Present in Autoproposal
10004,"Fine needle aspiration biopsy, without imaging guidance; each additional lesion (List separately in addition to code for primary procedure)",77002,"Fluoroscopic guidance for needle placement (eg, biopsy, aspiration, injection, localization device) (List separately in addition to code for primary procedure)",61.28640635814623,,Present in Autoproposal
10004,"Fine needle aspiration biopsy, without imaging guidance; each additional lesion (List separately in addition to code for primary procedure)",88170,FINE NEEDLE ASPIRATION,57.15623176026339,,Present in Autoproposal
10004,"Fine needle aspiration biopsy, without imaging guidance; each additional lesion (List separately in addition to code for primary procedure)",88171,FINE NEEDLE ASPIRATION,57.15623176026339,,Present in Autoproposal
10004,"Fine needle aspiration biopsy, without imaging guidance; each additional lesion (List separately in addition to code for primary procedure)",31633,"Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with transbronchial needle aspiration biopsy(s), each additional lobe (List separately in addition to code for primary procedure)",56.43629623305929,,Present in Autoproposal
10004,"Fine needle aspiration biopsy, without imaging guidance; each additional lesion (List separately in addition to code for primary procedure)",S2371,EACH ADDITIONAL INTERSPACE (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),55.523995642240344,,Present in Autoproposal
10004,"Fine needle aspiration biopsy, without imaging guidance; each additional lesion (List separately in addition to code for primary procedure)",19291,"Preoperative placement of needle localization wire, breast; each additional lesion (List separately in addition to code for primary procedure)",52.96706282607813,,Present in Autoproposal
10004,"Fine needle aspiration biopsy, without imaging guidance; each additional lesion (List separately in addition to code for primary procedure)",S2361,EACH ADDITIONAL CERVICAL VERTEBRAL BODY (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),50.66005149757671,,Present in Autoproposal
10004,"Fine needle aspiration biopsy, without imaging guidance; each additional lesion (List separately in addition to code for primary procedure)",56606,Biopsy of vulva or perineum (separate procedure); each separate additional lesion (List separately in addition to code for primary procedure),49.90163260285308,,Present in Autoproposal
10005,"Fine needle aspiration biopsy, including ultrasound guidance; first lesion",10022,Fine needle aspiration; with imaging guidance,68.71097156681827,1,Present Both in MD and Autoproposal
10005,"Fine needle aspiration biopsy, including ultrasound guidance; first lesion",88171,FINE NEEDLE ASPIRATION,68.29165511865685,,Present in Autoproposal
10005,"Fine needle aspiration biopsy, including ultrasound guidance; first lesion",88170,FINE NEEDLE ASPIRATION,68.29165511865685,,Present in Autoproposal
10005,"Fine needle aspiration biopsy, including ultrasound guidance; first lesion",10021,Fine needle aspiration; without imaging guidance,67.36441384013423,,Present in Autoproposal
10005,"Fine needle aspiration biopsy, including ultrasound guidance; first lesion",48100,"Biopsy of pancreas, open (eg, fine needle aspiration, needle core biopsy, wedge biopsy)",55.42498701738864,,Present in Autoproposal
10005,"Fine needle aspiration biopsy, including ultrasound guidance; first lesion",67415,Fine needle aspiration of orbital contents,50.718725960140354,,Present in Autoproposal
10005,"Fine needle aspiration biopsy, including ultrasound guidance; first lesion",45342,"Sigmoidoscopy, flexible; with transendoscopic ultrasound guided intramural or transmural fine needle aspiration/biopsy(s)",48.87293665929397,,Present in Autoproposal
10005,"Fine needle aspiration biopsy, including ultrasound guidance; first lesion",43232,"Esophagoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s)",47.091840008359654,,Present in Autoproposal
10005,"Fine needle aspiration biopsy, including ultrasound guidance; first lesion",43238,"Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s), (includes endoscopic ultrasound examination limited to the esophagus, stomach or duodenum, and adjacent structures)",39.88107624499413,,Present in Autoproposal
10005,"Fine needle aspiration biopsy, including ultrasound guidance; first lesion",77021,"Magnetic resonance guidance for needle placement (eg, for biopsy, needle aspiration, injection, or placement of localization device) radiological supervision and interpretation",37.71361368961649,,Present in Autoproposal
10006,"Fine needle aspiration biopsy, including ultrasound guidance; each additional lesion (List separately in addition to code for primary procedure)",77002,"Fluoroscopic guidance for needle placement (eg, biopsy, aspiration, injection, localization device) (List separately in addition to code for primary procedure)",60.579460185647726,3,Present in Autoproposal
10006,"Fine needle aspiration biopsy, including ultrasound guidance; each additional lesion (List separately in addition to code for primary procedure)",31633,"Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with transbronchial needle aspiration biopsy(s), each additional lobe (List separately in addition to code for primary procedure)",58.363270118461855,,Present in Autoproposal
10006,"Fine needle aspiration biopsy, including ultrasound guidance; each additional lesion (List separately in addition to code for primary procedure)",10022,Fine needle aspiration; with imaging guidance,56.84382349506101,,Present Both in MD and Autoproposal
10006,"Fine needle aspiration biopsy, including ultrasound guidance; each additional lesion (List separately in addition to code for primary procedure)",88170,FINE NEEDLE ASPIRATION,56.49692765551251,,Present in Autoproposal
10006,"Fine needle aspiration biopsy, including ultrasound guidance; each additional lesion (List separately in addition to code for primary procedure)",88171,FINE NEEDLE ASPIRATION,56.49692765551251,,Present in Autoproposal
10006,"Fine needle aspiration biopsy, including ultrasound guidance; each additional lesion (List separately in addition to code for primary procedure)",10021,Fine needle aspiration; without imaging guidance,55.729831246136044,,Present in Autoproposal
10006,"Fine needle aspiration biopsy, including ultrasound guidance; each additional lesion (List separately in addition to code for primary procedure)",S2371,EACH ADDITIONAL INTERSPACE (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),54.883519580196136,,Present in Autoproposal
10006,"Fine needle aspiration biopsy, including ultrasound guidance; each additional lesion (List separately in addition to code for primary procedure)",19291,"Preoperative placement of needle localization wire, breast; each additional lesion (List separately in addition to code for primary procedure)",52.35608129593972,,Present in Autoproposal
10006,"Fine needle aspiration biopsy, including ultrasound guidance; each additional lesion (List separately in addition to code for primary procedure)",19286,"Placement of breast localization device(s) (eg, clip, metallic pellet, wire/needle, radioactive seeds), percutaneous; each additional lesion, including ultrasound guidance (List separately in addition to code for primary procedure)",50.65606625708842,,Present in Autoproposal
10006,"Fine needle aspiration biopsy, including ultrasound guidance; each additional lesion (List separately in addition to code for primary procedure)",S2361,EACH ADDITIONAL CERVICAL VERTEBRAL BODY (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),50.07568162450079,,Present in Autoproposal
10007,"Fine needle aspiration biopsy, including fluoroscopic guidance; first lesion",10022,Fine needle aspiration; with imaging guidance,67.69101297595425,1,Present Both in MD and Autoproposal
10007,"Fine needle aspiration biopsy, including fluoroscopic guidance; first lesion",88171,FINE NEEDLE ASPIRATION,67.27792094004957,,Present in Autoproposal
10007,"Fine needle aspiration biopsy, including fluoroscopic guidance; first lesion",88170,FINE NEEDLE ASPIRATION,67.27792094004957,,Present in Autoproposal
10007,"Fine needle aspiration biopsy, including fluoroscopic guidance; first lesion",10021,Fine needle aspiration; without imaging guidance,66.36444380553868,,Present in Autoproposal
10007,"Fine needle aspiration biopsy, including fluoroscopic guidance; first lesion",48100,"Biopsy of pancreas, open (eg, fine needle aspiration, needle core biopsy, wedge biopsy)",54.602248081119356,,Present in Autoproposal
10007,"Fine needle aspiration biopsy, including fluoroscopic guidance; first lesion",67415,Fine needle aspiration of orbital contents,49.96584764855343,,Present in Autoproposal
10007,"Fine needle aspiration biopsy, including fluoroscopic guidance; first lesion",77002,"Fluoroscopic guidance for needle placement (eg, biopsy, aspiration, injection, localization device) (List separately in addition to code for primary procedure)",46.296013551144114,,Present Both in MD and Autoproposal
10007,"Fine needle aspiration biopsy, including fluoroscopic guidance; first lesion",31633,"Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with transbronchial needle aspiration biopsy(s), each additional lobe (List separately in addition to code for primary procedure)",41.22465375045789,,Present in Autoproposal
10007,"Fine needle aspiration biopsy, including fluoroscopic guidance; first lesion",45342,"Sigmoidoscopy, flexible; with transendoscopic ultrasound guided intramural or transmural fine needle aspiration/biopsy(s)",40.034264540224186,,Present in Autoproposal
10007,"Fine needle aspiration biopsy, including fluoroscopic guidance; first lesion",43232,"Esophagoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s)",38.57527927415972,,Present in Autoproposal
10008,"Fine needle aspiration biopsy, including fluoroscopic guidance; each additional lesion (List separately in addition to code for primary procedure)",77002,"Fluoroscopic guidance for needle placement (eg, biopsy, aspiration, injection, localization device) (List separately in addition to code for primary procedure)",69.48388564449381,1,Present Both in MD and Autoproposal
10008,"Fine needle aspiration biopsy, including fluoroscopic guidance; each additional lesion (List separately in addition to code for primary procedure)",31633,"Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with transbronchial needle aspiration biopsy(s), each additional lobe (List separately in addition to code for primary procedure)",65.61551131096208,,Present in Autoproposal
10008,"Fine needle aspiration biopsy, including fluoroscopic guidance; each additional lesion (List separately in addition to code for primary procedure)",10022,Fine needle aspiration; with imaging guidance,56.262250990047406,,Present Both in MD and Autoproposal
10008,"Fine needle aspiration biopsy, including fluoroscopic guidance; each additional lesion (List separately in addition to code for primary procedure)",88170,FINE NEEDLE ASPIRATION,55.918904262257776,,Present in Autoproposal
10008,"Fine needle aspiration biopsy, including fluoroscopic guidance; each additional lesion (List separately in addition to code for primary procedure)",88171,FINE NEEDLE ASPIRATION,55.918904262257776,,Present in Autoproposal
10008,"Fine needle aspiration biopsy, including fluoroscopic guidance; each additional lesion (List separately in addition to code for primary procedure)",10021,Fine needle aspiration; without imaging guidance,55.15965606141053,,Present in Autoproposal
10008,"Fine needle aspiration biopsy, including fluoroscopic guidance; each additional lesion (List separately in addition to code for primary procedure)",S2371,EACH ADDITIONAL INTERSPACE (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),54.32200305995379,,Present in Autoproposal
10008,"Fine needle aspiration biopsy, including fluoroscopic guidance; each additional lesion (List separately in addition to code for primary procedure)",31632,"Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with transbronchial lung biopsy(s), each additional lobe (List separately in addition to code for primary procedure)",52.97938906483135,,Present in Autoproposal
10008,"Fine needle aspiration biopsy, including fluoroscopic guidance; each additional lesion (List separately in addition to code for primary procedure)",19291,"Preoperative placement of needle localization wire, breast; each additional lesion (List separately in addition to code for primary procedure)",51.82042314559343,,Present in Autoproposal
10008,"Fine needle aspiration biopsy, including fluoroscopic guidance; each additional lesion (List separately in addition to code for primary procedure)",S2361,EACH ADDITIONAL CERVICAL VERTEBRAL BODY (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),49.563354377457756,,Present in Autoproposal
10009,"Fine needle aspiration biopsy, including CT guidance; first lesion",10022,Fine needle aspiration; with imaging guidance,67.97232470852322,1,Present Both in MD and Autoproposal
10009,"Fine needle aspiration biopsy, including CT guidance; first lesion",88170,FINE NEEDLE ASPIRATION,67.55751593606485,,Present in Autoproposal
10009,"Fine needle aspiration biopsy, including CT guidance; first lesion",88171,FINE NEEDLE ASPIRATION,67.55751593606485,,Present in Autoproposal
10009,"Fine needle aspiration biopsy, including CT guidance; first lesion",10021,Fine needle aspiration; without imaging guidance,66.64024255410436,,Present in Autoproposal
10009,"Fine needle aspiration biopsy, including CT guidance; first lesion",48100,"Biopsy of pancreas, open (eg, fine needle aspiration, needle core biopsy, wedge biopsy)",54.829165249803424,,Present in Autoproposal
10009,"Fine needle aspiration biopsy, including CT guidance; first lesion",67415,Fine needle aspiration of orbital contents,50.17349676700117,,Present in Autoproposal
10009,"Fine needle aspiration biopsy, including CT guidance; first lesion",45342,"Sigmoidoscopy, flexible; with transendoscopic ultrasound guided intramural or transmural fine needle aspiration/biopsy(s)",40.20063977712506,,Present in Autoproposal
10009,"Fine needle aspiration biopsy, including CT guidance; first lesion",43232,"Esophagoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s)",38.73559122946758,,Present in Autoproposal
10009,"Fine needle aspiration biopsy, including CT guidance; first lesion",77021,"Magnetic resonance guidance for needle placement (eg, for biopsy, needle aspiration, injection, or placement of localization device) radiological supervision and interpretation",37.30819019418972,,Present in Autoproposal
10009,"Fine needle aspiration biopsy, including CT guidance; first lesion",76942,"Ultrasonic guidance for needle placement (eg, biopsy, aspiration, injection, localization device), imaging supervision and interpretation",37.198746724406085,,Present in Autoproposal
10010,"Fine needle aspiration biopsy, including CT guidance; each additional lesion (List separately in addition to code for primary procedure)",77002,"Fluoroscopic guidance for needle placement (eg, biopsy, aspiration, injection, localization device) (List separately in addition to code for primary procedure)",60.1314791983245,10,Present in Autoproposal
10010,"Fine needle aspiration biopsy, including CT guidance; each additional lesion (List separately in addition to code for primary procedure)",31633,"Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with transbronchial needle aspiration biopsy(s), each additional lobe (List separately in addition to code for primary procedure)",57.9316777059353,,Present in Autoproposal
10010,"Fine needle aspiration biopsy, including CT guidance; each additional lesion (List separately in addition to code for primary procedure)",10022,Fine needle aspiration; with imaging guidance,56.42346728695835,,Present Both in MD and Autoproposal
10010,"Fine needle aspiration biopsy, including CT guidance; each additional lesion (List separately in addition to code for primary procedure)",88170,FINE NEEDLE ASPIRATION,56.079136718546685,,Present in Autoproposal
10010,"Fine needle aspiration biopsy, including CT guidance; each additional lesion (List separately in addition to code for primary procedure)",88171,FINE NEEDLE ASPIRATION,56.079136718546685,,Present in Autoproposal
10010,"Fine needle aspiration biopsy, including CT guidance; each additional lesion (List separately in addition to code for primary procedure)",10021,Fine needle aspiration; without imaging guidance,55.31771293493796,,Present in Autoproposal
10010,"Fine needle aspiration biopsy, including CT guidance; each additional lesion (List separately in addition to code for primary procedure)",S2371,EACH ADDITIONAL INTERSPACE (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),54.47765968619969,,Present in Autoproposal
10010,"Fine needle aspiration biopsy, including CT guidance; each additional lesion (List separately in addition to code for primary procedure)",19291,"Preoperative placement of needle localization wire, breast; each additional lesion (List separately in addition to code for primary procedure)",51.96891163613336,,Present in Autoproposal
10010,"Fine needle aspiration biopsy, including CT guidance; each additional lesion (List separately in addition to code for primary procedure)",S2361,EACH ADDITIONAL CERVICAL VERTEBRAL BODY (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),49.70537536514687,,Present in Autoproposal
10010,"Fine needle aspiration biopsy, including CT guidance; each additional lesion (List separately in addition to code for primary procedure)",56606,Biopsy of vulva or perineum (separate procedure); each separate additional lesion (List separately in addition to code for primary procedure),48.961248686790434,,Present in Autoproposal
10011,"Fine needle aspiration biopsy, including MR guidance; first lesion",10022,Fine needle aspiration; with imaging guidance,63.75362358196441,1,Present Both in MD and Autoproposal
10011,"Fine needle aspiration biopsy, including MR guidance; first lesion",88171,FINE NEEDLE ASPIRATION,63.36455990860602,,Present in Autoproposal
10011,"Fine needle aspiration biopsy, including MR guidance; first lesion",88170,FINE NEEDLE ASPIRATION,63.36455990860602,,Present in Autoproposal
10011,"Fine needle aspiration biopsy, including MR guidance; first lesion",10021,Fine needle aspiration; without imaging guidance,62.50421708281575,,Present in Autoproposal
10011,"Fine needle aspiration biopsy, including MR guidance; first lesion",48100,"Biopsy of pancreas, open (eg, fine needle aspiration, needle core biopsy, wedge biopsy)",51.426194081765374,,Present in Autoproposal
10011,"Fine needle aspiration biopsy, including MR guidance; first lesion",67415,Fine needle aspiration of orbital contents,47.0594795807124,,Present in Autoproposal
10011,"Fine needle aspiration biopsy, including MR guidance; first lesion",45342,"Sigmoidoscopy, flexible; with transendoscopic ultrasound guided intramural or transmural fine needle aspiration/biopsy(s)",37.705587782899585,,Present in Autoproposal
10011,"Fine needle aspiration biopsy, including MR guidance; first lesion",43232,"Esophagoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s)",36.33146744734857,,Present in Autoproposal
10011,"Fine needle aspiration biopsy, including MR guidance; first lesion",77021,"Magnetic resonance guidance for needle placement (eg, for biopsy, needle aspiration, injection, or placement of localization device) radiological supervision and interpretation",34.992658031989556,,Present Both in MD and Autoproposal
10011,"Fine needle aspiration biopsy, including MR guidance; first lesion",76942,"Ultrasonic guidance for needle placement (eg, biopsy, aspiration, injection, localization device), imaging supervision and interpretation",34.89000716921547,,Present in Autoproposal
10012,"Fine needle aspiration biopsy, including MR guidance; each additional lesion (List separately in addition to code for primary procedure)",77002,"Fluoroscopic guidance for needle placement (eg, biopsy, aspiration, injection, localization device) (List separately in addition to code for primary procedure)",57.48461226347206,10,Present in Autoproposal
10012,"Fine needle aspiration biopsy, including MR guidance; each additional lesion (List separately in addition to code for primary procedure)",31633,"Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with transbronchial needle aspiration biopsy(s), each additional lobe (List separately in addition to code for primary procedure)",55.381641614279644,,Present in Autoproposal
10012,"Fine needle aspiration biopsy, including MR guidance; each additional lesion (List separately in addition to code for primary procedure)",10022,Fine needle aspiration; with imaging guidance,53.93981958857046,,Present Both in MD and Autoproposal
10012,"Fine needle aspiration biopsy, including MR guidance; each additional lesion (List separately in addition to code for primary procedure)",88170,FINE NEEDLE ASPIRATION,53.61064576016151,,Present in Autoproposal
10012,"Fine needle aspiration biopsy, including MR guidance; each additional lesion (List separately in addition to code for primary procedure)",88171,FINE NEEDLE ASPIRATION,53.61064576016151,,Present in Autoproposal
10012,"Fine needle aspiration biopsy, including MR guidance; each additional lesion (List separately in addition to code for primary procedure)",10021,Fine needle aspiration; without imaging guidance,52.88273832211943,,Present in Autoproposal
10012,"Fine needle aspiration biopsy, including MR guidance; each additional lesion (List separately in addition to code for primary procedure)",S2371,EACH ADDITIONAL INTERSPACE (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),52.07966253006847,,Present in Autoproposal
10012,"Fine needle aspiration biopsy, including MR guidance; each additional lesion (List separately in addition to code for primary procedure)",19291,"Preoperative placement of needle localization wire, breast; each additional lesion (List separately in addition to code for primary procedure)",49.681344530121066,,Present in Autoproposal
10012,"Fine needle aspiration biopsy, including MR guidance; each additional lesion (List separately in addition to code for primary procedure)",S2361,EACH ADDITIONAL CERVICAL VERTEBRAL BODY (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),47.51744457926821,,Present in Autoproposal
10012,"Fine needle aspiration biopsy, including MR guidance; each additional lesion (List separately in addition to code for primary procedure)",56606,Biopsy of vulva or perineum (separate procedure); each separate additional lesion (List separately in addition to code for primary procedure),46.806072862647994,,Present in Autoproposal
11102,"Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); single lesion",40500,"Vermilionectomy (lip shave), with mucosal advancement",30.175652832523408,2,Present in Autoproposal
11102,"Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); single lesion",11100,"Biopsy of skin, subcutaneous tissue and/or mucous membrane (including simple closure), unless otherwise listed; single lesion",27.226854755612795,,Present Both in MD and Autoproposal
11102,"Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); single lesion",88305,"Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgical margins Breast, reduction mammoplasty Bronchus, biopsy Cell block, any source Cervix, biopsy Colon, biopsy Duodenum, biopsy Endocervix, curettings/biopsy Endometrium, curettings/biopsy Esophagus, biopsy Extremity, amputation, traumatic Fallopian tube, biopsy Fallopian tube, ectopic pregnancy Femoral head, fracture Fingers/toes, amputation, non-traumatic Gingiva/oral mucosa, biopsy Heart valve Joint, resection Kidney, biopsy Larynx, biopsy Leiomyoma(s), uterine myomectomy - without uterus Lip, biopsy/wedge resection Lung, transbronchial biopsy Lymph node, biopsy Muscle, biopsy Nasal mucosa, biopsy Nasopharynx/oropharynx, biopsy Nerve, biopsy Odontogenic/dental cyst Omentum, biopsy Ovary with or without tube, non-neoplastic Ovary, biopsy/wedge resection Parathyroid gland Peritoneum, biopsy Pituitary tumor Placenta, other than third trimester Pleura/pericardium - biopsy/tissue Polyp, cervical/endometrial Polyp, colorectal Polyp, stomach/small intestine Prostate, needle biopsy Prostate, TUR Salivary gland, biopsy Sinus, paranasal biopsy Skin, other than cyst/tag/debridement/plastic repair Small intestine, biopsy Soft tissue, other than tumor/mass/lipoma/debridement Spleen Stomach, biopsy Synovium Testis, other than tumor/biopsy/castration Thyroglossal duct/brachial cleft cyst Tongue, biopsy Tonsil, biopsy Trachea, biopsy Ureter, biopsy Urethra, biopsy Urinary bladder, biopsy Uterus, with or without tubes and ovaries, for prolapse Vagina, biopsy Vulva/labia, biopsy",26.26866703424518,,Present in Autoproposal
11102,"Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); single lesion",11301,"Shaving of epidermal or dermal lesion, single lesion, trunk, arms or legs; lesion diameter 0.6 to 1.0 cm",23.771164492022113,,Present in Autoproposal
11102,"Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); single lesion",11302,"Shaving of epidermal or dermal lesion, single lesion, trunk, arms or legs; lesion diameter 1.1 to 2.0 cm",23.771164492022113,,Present in Autoproposal
11102,"Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); single lesion",57500,"Biopsy of cervix, single or multiple, or local excision of lesion, with or without fulguration (separate procedure)",23.496285595582616,,Present in Autoproposal
11102,"Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); single lesion",11303,"Shaving of epidermal or dermal lesion, single lesion, trunk, arms or legs; lesion diameter over 2.0 cm",23.19892185959343,,Present in Autoproposal
11102,"Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); single lesion",64795,Biopsy of nerve,23.130388255405002,,Present in Autoproposal
11102,"Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); single lesion",11300,"Shaving of epidermal or dermal lesion, single lesion, trunk, arms or legs; lesion diameter 0.5 cm or less",23.03028068414217,,Present in Autoproposal
11102,"Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); single lesion",15625,SKIN GRAFT,22.937899353345035,,Present in Autoproposal
11103,"Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); each separate/additional lesion (List separately in addition to code for primary procedure)",56606,Biopsy of vulva or perineum (separate procedure); each separate additional lesion (List separately in addition to code for primary procedure),58.74579096430885,3,Present in Autoproposal
11103,"Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); each separate/additional lesion (List separately in addition to code for primary procedure)",S2371,EACH ADDITIONAL INTERSPACE (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),52.438404474649126,,Present in Autoproposal
11103,"Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); each separate/additional lesion (List separately in addition to code for primary procedure)",11101,"Biopsy of skin, subcutaneous tissue and/or mucous membrane (including simple closure), unless otherwise listed; each separate/additional lesion (List separately in addition to code for primary procedure)",49.60096087328459,,Present Both in MD and Autoproposal
11103,"Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); each separate/additional lesion (List separately in addition to code for primary procedure)",S2361,EACH ADDITIONAL CERVICAL VERTEBRAL BODY (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),47.84476045732383,,Present in Autoproposal
11103,"Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); each separate/additional lesion (List separately in addition to code for primary procedure)",64837,"Suture of each additional nerve, hand or foot (List separately in addition to code for primary procedure)",45.24345378174522,,Present in Autoproposal
11103,"Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); each separate/additional lesion (List separately in addition to code for primary procedure)",16036,Escharotomy; each additional incision (List separately in addition to code for primary procedure),44.90383395238631,,Present in Autoproposal
11103,"Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); each separate/additional lesion (List separately in addition to code for primary procedure)",64859,Suture of each additional major peripheral nerve (List separately in addition to code for primary procedure),44.191621802013856,,Present in Autoproposal
11103,"Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); each separate/additional lesion (List separately in addition to code for primary procedure)",19291,"Preoperative placement of needle localization wire, breast; each additional lesion (List separately in addition to code for primary procedure)",43.488218817241666,,Present in Autoproposal
11103,"Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); each separate/additional lesion (List separately in addition to code for primary procedure)",13102,"Repair, complex, trunk; each additional 5 cm or less (List separately in addition to code for primary procedure)",43.407316930325706,,Present in Autoproposal
11103,"Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); each separate/additional lesion (List separately in addition to code for primary procedure)",G0346,"EACH ADDITIONAL HOUR, UP TO EIGHT (8) HOURS (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE)",43.182889461118116,,Present in Autoproposal
11104,"Punch biopsy of skin (including simple closure, when performed); single lesion",11100,"Biopsy of skin, subcutaneous tissue and/or mucous membrane (including simple closure), unless otherwise listed; single lesion",47.98353868563904,1,Present Both in MD and Autoproposal
11104,"Punch biopsy of skin (including simple closure, when performed); single lesion",55700,"Biopsy, prostate; needle or punch, single or multiple, any approach",42.3258772223856,,Present in Autoproposal
11104,"Punch biopsy of skin (including simple closure, when performed); single lesion",15775,Punch graft for hair transplant; 1 to 15 punch grafts,39.6457437008862,,Present in Autoproposal
11104,"Punch biopsy of skin (including simple closure, when performed); single lesion",15776,Punch graft for hair transplant; more than 15 punch grafts,38.55092650599877,,Present in Autoproposal
11104,"Punch biopsy of skin (including simple closure, when performed); single lesion",11101,"Biopsy of skin, subcutaneous tissue and/or mucous membrane (including simple closure), unless otherwise listed; each separate/additional lesion (List separately in addition to code for primary procedure)",37.02687310085506,,Present in Autoproposal
11104,"Punch biopsy of skin (including simple closure, when performed); single lesion",67840,Excision of lesion of eyelid (except chalazion) without closure or with simple direct closure,36.33073717173062,,Present in Autoproposal
11104,"Punch biopsy of skin (including simple closure, when performed); single lesion",42106,"Excision, lesion of palate, uvula; with simple primary closure",34.26211940981621,,Present in Autoproposal
11104,"Punch biopsy of skin (including simple closure, when performed); single lesion",19083,"Biopsy, breast, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; first lesion, including ultrasound guidance",32.985950190480665,,Present in Autoproposal
11104,"Punch biopsy of skin (including simple closure, when performed); single lesion",19081,"Biopsy, breast, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; first lesion, including stereotactic guidance",32.71951945073644,,Present in Autoproposal
11104,"Punch biopsy of skin (including simple closure, when performed); single lesion",19085,"Biopsy, breast, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; first lesion, including magnetic resonance guidance",32.290441683954306,,Present in Autoproposal
11105,"Punch biopsy of skin (including simple closure, when performed); each separate/additional lesion (List separately in addition to code for primary procedure)",11101,"Biopsy of skin, subcutaneous tissue and/or mucous membrane (including simple closure), unless otherwise listed; each separate/additional lesion (List separately in addition to code for primary procedure)",63.60733881419751,1,Present Both in MD and Autoproposal
11105,"Punch biopsy of skin (including simple closure, when performed); each separate/additional lesion (List separately in addition to code for primary procedure)",56606,Biopsy of vulva or perineum (separate procedure); each separate additional lesion (List separately in addition to code for primary procedure),57.93319661633689,,Present in Autoproposal
11105,"Punch biopsy of skin (including simple closure, when performed); each separate/additional lesion (List separately in addition to code for primary procedure)",S2371,EACH ADDITIONAL INTERSPACE (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),51.713056319601634,,Present in Autoproposal
11105,"Punch biopsy of skin (including simple closure, when performed); each separate/additional lesion (List separately in addition to code for primary procedure)",19084,"Biopsy, breast, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; each additional lesion, including ultrasound guidance (List separately in addition to code for primary procedure)",47.856772453154974,,Present in Autoproposal
11105,"Punch biopsy of skin (including simple closure, when performed); each separate/additional lesion (List separately in addition to code for primary procedure)",19082,"Biopsy, breast, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; each additional lesion, including stereotactic guidance (List separately in addition to code for primary procedure)",47.51837180530713,,Present in Autoproposal
11105,"Punch biopsy of skin (including simple closure, when performed); each separate/additional lesion (List separately in addition to code for primary procedure)",S2361,EACH ADDITIONAL CERVICAL VERTEBRAL BODY (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),47.18295335098469,,Present in Autoproposal
11105,"Punch biopsy of skin (including simple closure, when performed); each separate/additional lesion (List separately in addition to code for primary procedure)",19086,"Biopsy, breast, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; each additional lesion, including magnetic resonance guidance (List separately in addition to code for primary procedure)",46.971230470057506,,Present in Autoproposal
11105,"Punch biopsy of skin (including simple closure, when performed); each separate/additional lesion (List separately in addition to code for primary procedure)",31632,"Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with transbronchial lung biopsy(s), each additional lobe (List separately in addition to code for primary procedure)",44.93310160269398,,Present in Autoproposal
11105,"Punch biopsy of skin (including simple closure, when performed); each separate/additional lesion (List separately in addition to code for primary procedure)",64837,"Suture of each additional nerve, hand or foot (List separately in addition to code for primary procedure)",44.61762894864162,,Present in Autoproposal
11105,"Punch biopsy of skin (including simple closure, when performed); each separate/additional lesion (List separately in addition to code for primary procedure)",16036,Escharotomy; each additional incision (List separately in addition to code for primary procedure),44.28270687122829,,Present in Autoproposal
11106,"Incisional biopsy of skin (eg, wedge) (including simple closure, when performed); single lesion",11100,"Biopsy of skin, subcutaneous tissue and/or mucous membrane (including simple closure), unless otherwise listed; single lesion",45.360277214194234,1,Present Both in MD and Autoproposal
11106,"Incisional biopsy of skin (eg, wedge) (including simple closure, when performed); single lesion",47100,"Biopsy of liver, wedge",38.88983455801843,,Present in Autoproposal
11106,"Incisional biopsy of skin (eg, wedge) (including simple closure, when performed); single lesion",19101,"Biopsy of breast; open, incisional",38.45365979919767,,Present in Autoproposal
11106,"Incisional biopsy of skin (eg, wedge) (including simple closure, when performed); single lesion",32096,"Thoracotomy, with diagnostic biopsy(ies) of lung infiltrate(s) (eg, wedge, incisional), unilateral",38.30404651685562,,Present in Autoproposal
11106,"Incisional biopsy of skin (eg, wedge) (including simple closure, when performed); single lesion",32607,"Thoracoscopy; with diagnostic biopsy(ies) of lung infiltrate(s) (eg, wedge, incisional), unilateral",38.16551931917908,,Present in Autoproposal
11106,"Incisional biopsy of skin (eg, wedge) (including simple closure, when performed); single lesion",67810,Incisional biopsy of eyelid skin including lid margin,37.230054451196175,,Present in Autoproposal
11106,"Incisional biopsy of skin (eg, wedge) (including simple closure, when performed); single lesion",11101,"Biopsy of skin, subcutaneous tissue and/or mucous membrane (including simple closure), unless otherwise listed; each separate/additional lesion (List separately in addition to code for primary procedure)",35.0026128592356,,Present in Autoproposal
11106,"Incisional biopsy of skin (eg, wedge) (including simple closure, when performed); single lesion",D7286,INCISIONAL BIOPSY OF ORAL TISSUE-SOFT,34.987469201239044,,Present in Autoproposal
11106,"Incisional biopsy of skin (eg, wedge) (including simple closure, when performed); single lesion",32097,"Thoracotomy, with diagnostic biopsy(ies) of lung nodule(s) or mass(es) (eg, wedge, incisional), unilateral",34.885274360163535,,Present in Autoproposal
11106,"Incisional biopsy of skin (eg, wedge) (including simple closure, when performed); single lesion",32608,"Thoracoscopy; with diagnostic biopsy(ies) of lung nodule(s) or mass(es) (eg, wedge, incisional), unilateral",34.78053038856177,,Present in Autoproposal
11107,"Incisional biopsy of skin (eg, wedge) (including simple closure, when performed); each separate/additional lesion (List separately in addition to code for primary procedure)",11101,"Biopsy of skin, subcutaneous tissue and/or mucous membrane (including simple closure), unless otherwise listed; each separate/additional lesion (List separately in addition to code for primary procedure)",61.31559768136938,1,Present Both in MD and Autoproposal
11107,"Incisional biopsy of skin (eg, wedge) (including simple closure, when performed); each separate/additional lesion (List separately in addition to code for primary procedure)",56606,Biopsy of vulva or perineum (separate procedure); each separate additional lesion (List separately in addition to code for primary procedure),55.845892036126344,,Present in Autoproposal
11107,"Incisional biopsy of skin (eg, wedge) (including simple closure, when performed); each separate/additional lesion (List separately in addition to code for primary procedure)",S2371,EACH ADDITIONAL INTERSPACE (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),49.8498603349673,,Present in Autoproposal
11107,"Incisional biopsy of skin (eg, wedge) (including simple closure, when performed); each separate/additional lesion (List separately in addition to code for primary procedure)",19084,"Biopsy, breast, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; each additional lesion, including ultrasound guidance (List separately in addition to code for primary procedure)",47.94240901088472,,Present in Autoproposal
11107,"Incisional biopsy of skin (eg, wedge) (including simple closure, when performed); each separate/additional lesion (List separately in addition to code for primary procedure)",19082,"Biopsy, breast, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; each additional lesion, including stereotactic guidance (List separately in addition to code for primary procedure)",47.60340281725663,,Present in Autoproposal
11107,"Incisional biopsy of skin (eg, wedge) (including simple closure, when performed); each separate/additional lesion (List separately in addition to code for primary procedure)",19086,"Biopsy, breast, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; each additional lesion, including magnetic resonance guidance (List separately in addition to code for primary procedure)",47.05528240844769,,Present in Autoproposal
11107,"Incisional biopsy of skin (eg, wedge) (including simple closure, when performed); each separate/additional lesion (List separately in addition to code for primary procedure)",S2361,EACH ADDITIONAL CERVICAL VERTEBRAL BODY (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),45.482974748222794,,Present in Autoproposal
11107,"Incisional biopsy of skin (eg, wedge) (including simple closure, when performed); each separate/additional lesion (List separately in addition to code for primary procedure)",31632,"Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with transbronchial lung biopsy(s), each additional lobe (List separately in addition to code for primary procedure)",43.31418405185542,,Present in Autoproposal
11107,"Incisional biopsy of skin (eg, wedge) (including simple closure, when performed); each separate/additional lesion (List separately in addition to code for primary procedure)",64837,"Suture of each additional nerve, hand or foot (List separately in addition to code for primary procedure)",43.01007772236643,,Present in Autoproposal
11107,"Incisional biopsy of skin (eg, wedge) (including simple closure, when performed); each separate/additional lesion (List separately in addition to code for primary procedure)",16036,Escharotomy; each additional incision (List separately in addition to code for primary procedure),42.68722272267416,,Present in Autoproposal
20932,"Allograft, includes templating, cutting, placement and internal fixation, when performed; osteoarticular, including articular surface and contiguous bone (List separately in addition to code for primary procedure)",61316,Incision and subcutaneous placement of cranial bone graft (List separately in addition to code for primary procedure),43.762697436385416,10,Present in Autoproposal
20932,"Allograft, includes templating, cutting, placement and internal fixation, when performed; osteoarticular, including articular surface and contiguous bone (List separately in addition to code for primary procedure)",20931,"Allograft, structural, for spine surgery only (List separately in addition to code for primary procedure)",38.05605456640887,,Present in Autoproposal
20932,"Allograft, includes templating, cutting, placement and internal fixation, when performed; osteoarticular, including articular surface and contiguous bone (List separately in addition to code for primary procedure)",27358,Excision or curettage of bone cyst or benign tumor of femur; with internal fixation (List in addition to code for primary procedure),36.61053201027876,,Present in Autoproposal
20932,"Allograft, includes templating, cutting, placement and internal fixation, when performed; osteoarticular, including articular surface and contiguous bone (List separately in addition to code for primary procedure)",90863,"Pharmacologic management, including prescription and review of medication, when performed with psychotherapy services (List separately in addition to the code for primary procedure)",35.88507381307224,,Present in Autoproposal
20932,"Allograft, includes templating, cutting, placement and internal fixation, when performed; osteoarticular, including articular surface and contiguous bone (List separately in addition to code for primary procedure)",37239,"Transcatheter placement of an intravascular stent(s), open or percutaneous, including radiological supervision and interpretation and including angioplasty within the same vessel, when performed; each additional vein (List separately in addition to code for primary procedure)",35.733616110501686,,Present in Autoproposal
20932,"Allograft, includes templating, cutting, placement and internal fixation, when performed; osteoarticular, including articular surface and contiguous bone (List separately in addition to code for primary procedure)",20930,"Allograft, morselized, or placement of osteopromotive material, for spine surgery only (List separately in addition to code for primary procedure)",35.554609675097026,,Present Both in MD and Autoproposal
20932,"Allograft, includes templating, cutting, placement and internal fixation, when performed; osteoarticular, including articular surface and contiguous bone (List separately in addition to code for primary procedure)",43635,Vagotomy when performed with partial distal gastrectomy (List separately in addition to code[s] for primary procedure),35.45660049161874,,Present in Autoproposal
20932,"Allograft, includes templating, cutting, placement and internal fixation, when performed; osteoarticular, including articular surface and contiguous bone (List separately in addition to code for primary procedure)",S2371,EACH ADDITIONAL INTERSPACE (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),35.278807496000624,,Present in Autoproposal
20932,"Allograft, includes templating, cutting, placement and internal fixation, when performed; osteoarticular, including articular surface and contiguous bone (List separately in addition to code for primary procedure)",90833,"Psychotherapy, 30 minutes with patient when performed with an evaluation and management service (List separately in addition to the code for primary procedure)",35.125256719717235,,Present in Autoproposal
20932,"Allograft, includes templating, cutting, placement and internal fixation, when performed; osteoarticular, including articular surface and contiguous bone (List separately in addition to code for primary procedure)",22841,Internal spinal fixation by wiring of spinous processes (List separately in addition to code for primary procedure),34.69724915295193,,Present in Autoproposal
20933,"Allograft, includes templating, cutting, placement and internal fixation, when performed; hemicortical intercalary, partial (ie, hemicylindrical) (List separately in addition to code for primary procedure)",43635,Vagotomy when performed with partial distal gastrectomy (List separately in addition to code[s] for primary procedure),47.436417950718614,2,Present in Autoproposal
20933,"Allograft, includes templating, cutting, placement and internal fixation, when performed; hemicortical intercalary, partial (ie, hemicylindrical) (List separately in addition to code for primary procedure)",20931,"Allograft, structural, for spine surgery only (List separately in addition to code for primary procedure)",43.91673486480746,,Present Both in MD and Autoproposal
20933,"Allograft, includes templating, cutting, placement and internal fixation, when performed; hemicortical intercalary, partial (ie, hemicylindrical) (List separately in addition to code for primary procedure)",61316,Incision and subcutaneous placement of cranial bone graft (List separately in addition to code for primary procedure),42.133239640704204,,Present in Autoproposal
20933,"Allograft, includes templating, cutting, placement and internal fixation, when performed; hemicortical intercalary, partial (ie, hemicylindrical) (List separately in addition to code for primary procedure)",20930,"Allograft, morselized, or placement of osteopromotive material, for spine surgery only (List separately in addition to code for primary procedure)",41.03006431205827,,Present in Autoproposal
20933,"Allograft, includes templating, cutting, placement and internal fixation, when performed; hemicortical intercalary, partial (ie, hemicylindrical) (List separately in addition to code for primary procedure)",S2371,EACH ADDITIONAL INTERSPACE (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),40.71178825027219,,Present in Autoproposal
20933,"Allograft, includes templating, cutting, placement and internal fixation, when performed; hemicortical intercalary, partial (ie, hemicylindrical) (List separately in addition to code for primary procedure)",22841,Internal spinal fixation by wiring of spinous processes (List separately in addition to code for primary procedure),40.04066919047796,,Present in Autoproposal
20933,"Allograft, includes templating, cutting, placement and internal fixation, when performed; hemicortical intercalary, partial (ie, hemicylindrical) (List separately in addition to code for primary procedure)",26863,"Arthrodesis, interphalangeal joint, with or without internal fixation; with autograft (includes obtaining graft), each additional joint (List separately in addition to code for primary procedure)",39.51321568282218,,Present in Autoproposal
20933,"Allograft, includes templating, cutting, placement and internal fixation, when performed; hemicortical intercalary, partial (ie, hemicylindrical) (List separately in addition to code for primary procedure)",34808,Endovascular placement of iliac artery occlusion device (List separately in addition to code for primary procedure),39.37603172964466,,Present in Autoproposal
20933,"Allograft, includes templating, cutting, placement and internal fixation, when performed; hemicortical intercalary, partial (ie, hemicylindrical) (List separately in addition to code for primary procedure)",90833,"Psychotherapy, 30 minutes with patient when performed with an evaluation and management service (List separately in addition to the code for primary procedure)",38.9843567017855,,Present in Autoproposal
20933,"Allograft, includes templating, cutting, placement and internal fixation, when performed; hemicortical intercalary, partial (ie, hemicylindrical) (List separately in addition to code for primary procedure)",64913,"Nerve repair; with nerve allograft, each additional strand (List separately in addition to code for primary procedure)",38.69710633336196,,Present in Autoproposal
20934,"Allograft, includes templating, cutting, placement and internal fixation, when performed; intercalary, complete (ie, cylindrical) (List separately in addition to code for primary procedure)",20931,"Allograft, structural, for spine surgery only (List separately in addition to code for primary procedure)",43.92362327944971,1,Present Both in MD and Autoproposal
20934,"Allograft, includes templating, cutting, placement and internal fixation, when performed; intercalary, complete (ie, cylindrical) (List separately in addition to code for primary procedure)",61316,Incision and subcutaneous placement of cranial bone graft (List separately in addition to code for primary procedure),42.139848311083725,,Present in Autoproposal
20934,"Allograft, includes templating, cutting, placement and internal fixation, when performed; intercalary, complete (ie, cylindrical) (List separately in addition to code for primary procedure)",20930,"Allograft, morselized, or placement of osteopromotive material, for spine surgery only (List separately in addition to code for primary procedure)",41.03649994750907,,Present in Autoproposal
20934,"Allograft, includes templating, cutting, placement and internal fixation, when performed; intercalary, complete (ie, cylindrical) (List separately in addition to code for primary procedure)",43635,Vagotomy when performed with partial distal gastrectomy (List separately in addition to code[s] for primary procedure),40.92337948607197,,Present in Autoproposal
20934,"Allograft, includes templating, cutting, placement and internal fixation, when performed; intercalary, complete (ie, cylindrical) (List separately in addition to code for primary procedure)",S2371,EACH ADDITIONAL INTERSPACE (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),40.71817396358076,,Present in Autoproposal
20934,"Allograft, includes templating, cutting, placement and internal fixation, when performed; intercalary, complete (ie, cylindrical) (List separately in addition to code for primary procedure)",22841,Internal spinal fixation by wiring of spinous processes (List separately in addition to code for primary procedure),40.04694963761926,,Present in Autoproposal
20934,"Allograft, includes templating, cutting, placement and internal fixation, when performed; intercalary, complete (ie, cylindrical) (List separately in addition to code for primary procedure)",26863,"Arthrodesis, interphalangeal joint, with or without internal fixation; with autograft (includes obtaining graft), each additional joint (List separately in addition to code for primary procedure)",39.519413397982696,,Present in Autoproposal
20934,"Allograft, includes templating, cutting, placement and internal fixation, when performed; intercalary, complete (ie, cylindrical) (List separately in addition to code for primary procedure)",34808,Endovascular placement of iliac artery occlusion device (List separately in addition to code for primary procedure),39.38220792726852,,Present in Autoproposal
20934,"Allograft, includes templating, cutting, placement and internal fixation, when performed; intercalary, complete (ie, cylindrical) (List separately in addition to code for primary procedure)",90833,"Psychotherapy, 30 minutes with patient when performed with an evaluation and management service (List separately in addition to the code for primary procedure)",38.99047146451433,,Present in Autoproposal
20934,"Allograft, includes templating, cutting, placement and internal fixation, when performed; intercalary, complete (ie, cylindrical) (List separately in addition to code for primary procedure)",64913,"Nerve repair; with nerve allograft, each additional strand (List separately in addition to code for primary procedure)",38.70317604038138,,Present in Autoproposal
27369,Injection procedure for contrast knee arthrography or contrast enhanced CT/MRI knee arthrography,27370,Injection of contrast for knee arthrography,82.45866612757074,1,Present Both in MD and Autoproposal
27369,Injection procedure for contrast knee arthrography or contrast enhanced CT/MRI knee arthrography,23350,Injection procedure for shoulder arthrography or enhanced CT/MRI shoulder arthrography,72.30974082147685,,Present in Autoproposal
27369,Injection procedure for contrast knee arthrography or contrast enhanced CT/MRI knee arthrography,24220,Injection procedure for elbow arthrography,54.420419845707144,,Present in Autoproposal
27369,Injection procedure for contrast knee arthrography or contrast enhanced CT/MRI knee arthrography,25246,Injection procedure for wrist arthrography,54.192658649456895,,Present in Autoproposal
27369,Injection procedure for contrast knee arthrography or contrast enhanced CT/MRI knee arthrography,27648,Injection procedure for ankle arthrography,53.881496207010784,,Present in Autoproposal
27369,Injection procedure for contrast knee arthrography or contrast enhanced CT/MRI knee arthrography,27095,Injection procedure for hip arthrography; with anesthesia,48.287286063314944,,Present in Autoproposal
27369,Injection procedure for contrast knee arthrography or contrast enhanced CT/MRI knee arthrography,27093,Injection procedure for hip arthrography; without anesthesia,47.201660163597346,,Present in Autoproposal
27369,Injection procedure for contrast knee arthrography or contrast enhanced CT/MRI knee arthrography,G9455,"PATIENT UNDERWENT ABDOMINAL IMAGING WITH ULTRASOUND, CONTRAST ENHANCED CT OR CONTRAST MRI FOR HCC",46.433309071953644,,Present in Autoproposal
27369,Injection procedure for contrast knee arthrography or contrast enhanced CT/MRI knee arthrography,G0259,INJECTION PROCEDURE FOR SACROILIAC JOINT; ARTHROGRAPHY,46.29085957654521,,Present in Autoproposal
27369,Injection procedure for contrast knee arthrography or contrast enhanced CT/MRI knee arthrography,21116,Injection procedure for temporomandibular joint arthrography,45.790781475626225,,Present in Autoproposal
33274,"Transcatheter insertion or replacement of permanent leadless pacemaker, right ventricular, including imaging guidance (eg, fluoroscopy, venous ultrasound, ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed",0387T,"Transcatheter insertion or replacement of permanent leadless pacemaker, ventricular",57.005198281017044,1,Present Both in MD and Autoproposal
33274,"Transcatheter insertion or replacement of permanent leadless pacemaker, right ventricular, including imaging guidance (eg, fluoroscopy, venous ultrasound, ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed",0388T,"Transcatheter removal of permanent leadless pacemaker, ventricular",48.23942071879721,,Present in Autoproposal
33274,"Transcatheter insertion or replacement of permanent leadless pacemaker, right ventricular, including imaging guidance (eg, fluoroscopy, venous ultrasound, ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed",0304T,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; device only,36.477358654336825,,Present in Autoproposal
33274,"Transcatheter insertion or replacement of permanent leadless pacemaker, right ventricular, including imaging guidance (eg, fluoroscopy, venous ultrasound, ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed",37197,"Transcatheter retrieval, percutaneous, of intravascular foreign body (eg, fractured venous or arterial catheter), includes radiological supervision and interpretation, and imaging guidance (ultrasound or fluoroscopy), when performed",36.31697205591949,,Present in Autoproposal
33274,"Transcatheter insertion or replacement of permanent leadless pacemaker, right ventricular, including imaging guidance (eg, fluoroscopy, venous ultrasound, ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed",0303T,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; electrode only,33.776164927721844,,Present in Autoproposal
33274,"Transcatheter insertion or replacement of permanent leadless pacemaker, right ventricular, including imaging guidance (eg, fluoroscopy, venous ultrasound, ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed",0302T,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; complete system (includes device and electrode),33.747494309107026,,Present in Autoproposal
33274,"Transcatheter insertion or replacement of permanent leadless pacemaker, right ventricular, including imaging guidance (eg, fluoroscopy, venous ultrasound, ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed",33207,Insertion of new or replacement of permanent pacemaker with transvenous electrode(s); ventricular,32.805448364881585,,Present Both in MD and Autoproposal
33274,"Transcatheter insertion or replacement of permanent leadless pacemaker, right ventricular, including imaging guidance (eg, fluoroscopy, venous ultrasound, ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed",33208,Insertion of new or replacement of permanent pacemaker with transvenous electrode(s); atrial and ventricular,31.62083490528952,,Present in Autoproposal
33274,"Transcatheter insertion or replacement of permanent leadless pacemaker, right ventricular, including imaging guidance (eg, fluoroscopy, venous ultrasound, ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed",0411T,"Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; ventricular electrode only",30.443801098058536,,Present in Autoproposal
33274,"Transcatheter insertion or replacement of permanent leadless pacemaker, right ventricular, including imaging guidance (eg, fluoroscopy, venous ultrasound, ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed",47533,"Placement of biliary drainage catheter, percutaneous, including diagnostic cholangiography when performed, imaging guidance (eg, ultrasound and/or fluoroscopy), and all associated radiological supervision and interpretation; external",30.194057604249565,,Present in Autoproposal
33275,"Transcatheter removal of permanent leadless pacemaker, right ventricular",0388T,"Transcatheter removal of permanent leadless pacemaker, ventricular",91.79214804180256,1,Present Both in MD and Autoproposal
33275,"Transcatheter removal of permanent leadless pacemaker, right ventricular",0387T,"Transcatheter insertion or replacement of permanent leadless pacemaker, ventricular",78.9740217039753,,Present in Autoproposal
33275,"Transcatheter removal of permanent leadless pacemaker, right ventricular",93603,Right ventricular recording,43.59558729411819,,Present in Autoproposal
33275,"Transcatheter removal of permanent leadless pacemaker, right ventricular",33233,Removal of permanent pacemaker pulse generator only,40.74943100607099,,Present Both in MD and Autoproposal
33275,"Transcatheter removal of permanent leadless pacemaker, right ventricular",33215,Repositioning of previously implanted transvenous pacemaker or implantable defibrillator (right atrial or right ventricular) electrode,38.4011412549019,,Present in Autoproposal
33275,"Transcatheter removal of permanent leadless pacemaker, right ventricular",33207,Insertion of new or replacement of permanent pacemaker with transvenous electrode(s); ventricular,37.68339579710902,,Present in Autoproposal
33275,"Transcatheter removal of permanent leadless pacemaker, right ventricular",33236,"Removal of permanent epicardial pacemaker and electrodes by thoracotomy; single lead system, atrial or ventricular",35.960150375151784,,Present in Autoproposal
33275,"Transcatheter removal of permanent leadless pacemaker, right ventricular",33208,Insertion of new or replacement of permanent pacemaker with transvenous electrode(s); atrial and ventricular,34.999640060349336,,Present in Autoproposal
33275,"Transcatheter removal of permanent leadless pacemaker, right ventricular",93542,Injection procedure during cardiac catheterization; for selective right ventricular or right atrial angiography,33.36017657341764,,Present in Autoproposal
33275,"Transcatheter removal of permanent leadless pacemaker, right ventricular",33227,Removal of permanent pacemaker pulse generator with replacement of pacemaker pulse generator; single lead system,31.97501453055696,,Present in Autoproposal
33285,"Insertion, subcutaneous cardiac rhythm monitor, including programming",0319T,Insertion or replacement of subcutaneous implantable defibrillator system with subcutaneous electrode,31.562492755571935,10,Present in Autoproposal
33285,"Insertion, subcutaneous cardiac rhythm monitor, including programming",0320T,Insertion of subcutaneous defibrillator electrode,31.13597897303698,,Present in Autoproposal
33285,"Insertion, subcutaneous cardiac rhythm monitor, including programming",E0608,APNEA MONITOR,29.507032098234042,,Present in Autoproposal
33285,"Insertion, subcutaneous cardiac rhythm monitor, including programming",33271,Insertion of subcutaneous implantable defibrillator electrode,28.162211625017562,,Present in Autoproposal
33285,"Insertion, subcutaneous cardiac rhythm monitor, including programming",0321T,Insertion of subcutaneous implantable defibrillator pulse generator only with existing subcutaneous electrode,27.54013311515353,,Present in Autoproposal
33285,"Insertion, subcutaneous cardiac rhythm monitor, including programming",K0554,"RECEIVER (MONITOR), DEDICATED, FOR USE WITH THERAPEUTIC GLUCOSE CONTINUOUS MONITOR SYSTEM",26.312304574761274,,Present in Autoproposal
33285,"Insertion, subcutaneous cardiac rhythm monitor, including programming",0411T,"Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; ventricular electrode only",25.242774073719975,,Present in Autoproposal
33285,"Insertion, subcutaneous cardiac rhythm monitor, including programming",0409T,"Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; pulse generator only",25.152743807270117,,Present in Autoproposal
33285,"Insertion, subcutaneous cardiac rhythm monitor, including programming",0410T,"Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; atrial electrode only",25.08295382255979,,Present in Autoproposal
33285,"Insertion, subcutaneous cardiac rhythm monitor, including programming",E0607,HOME BLOOD GLUCOSE MONITOR,24.55261096135814,,Present in Autoproposal
33286,"Removal, subcutaneous cardiac rhythm monitor",E0608,APNEA MONITOR,34.19494472179875,10,Present in Autoproposal
33286,"Removal, subcutaneous cardiac rhythm monitor",0324T,Removal of subcutaneous defibrillator electrode,33.222813738305156,,Present in Autoproposal
33286,"Removal, subcutaneous cardiac rhythm monitor",28190,"Removal of foreign body, foot; subcutaneous",31.55004104907132,,Present in Autoproposal
33286,"Removal, subcutaneous cardiac rhythm monitor",23330,"Removal of foreign body, shoulder; subcutaneous",31.264938147629906,,Present in Autoproposal
33286,"Removal, subcutaneous cardiac rhythm monitor",K0554,"RECEIVER (MONITOR), DEDICATED, FOR USE WITH THERAPEUTIC GLUCOSE CONTINUOUS MONITOR SYSTEM",30.492656714564763,,Present in Autoproposal
33286,"Removal, subcutaneous cardiac rhythm monitor",33272,Removal of subcutaneous implantable defibrillator electrode,29.933084077051625,,Present Both in MD and Autoproposal
33286,"Removal, subcutaneous cardiac rhythm monitor",E0607,HOME BLOOD GLUCOSE MONITOR,28.453392798177056,,Present in Autoproposal
33286,"Removal, subcutaneous cardiac rhythm monitor",S9007,ULTRAFILTRATION MONITOR,28.119549981522397,,Present in Autoproposal
33286,"Removal, subcutaneous cardiac rhythm monitor",A4670,AUTOMATIC BLOOD PRESSURE MONITOR,26.71941145944364,,Present in Autoproposal
33286,"Removal, subcutaneous cardiac rhythm monitor",93040,"Rhythm ECG, 1-3 leads; with interpretation and report",26.648811440953263,,Present in Autoproposal
33289,"Transcatheter implantation of wireless pulmonary artery pressure sensor for long-term hemodynamic monitoring, including deployment and calibration of the sensor, right heart catheterization, selective pulmonary catheterization, radiological supervision and interpretation, and pulmonary artery angiography, when performed",C9741,"RIGHT HEART CATHETERIZATION WITH IMPLANTATION OF WIRELESS PRESSURE SENSOR IN THE PULMONARY ARTERY, INCLUDING ANY TYPE OF MEASUREMENT, ANGIOGRAPHY, IMAGING SUPERVISION, INTERPRETATION, AND REPORT",68.40549106799078,10,Present Both in MD and Autoproposal
33289,"Transcatheter implantation of wireless pulmonary artery pressure sensor for long-term hemodynamic monitoring, including deployment and calibration of the sensor, right heart catheterization, selective pulmonary catheterization, radiological supervision and interpretation, and pulmonary artery angiography, when performed",C2624,"IMPLANTABLE WIRELESS PULMONARY ARTERY PRESSURE SENSOR WITH DELIVERY CATHETER, INCLUDING ALL SYSTEM COMPONENTS",46.622007119315064,,Present in Autoproposal
33289,"Transcatheter implantation of wireless pulmonary artery pressure sensor for long-term hemodynamic monitoring, including deployment and calibration of the sensor, right heart catheterization, selective pulmonary catheterization, radiological supervision and interpretation, and pulmonary artery angiography, when performed",75741,"Angiography, pulmonary, unilateral, selective, radiological supervision and interpretation",45.5276128986304,,Present Both in MD and Autoproposal
33289,"Transcatheter implantation of wireless pulmonary artery pressure sensor for long-term hemodynamic monitoring, including deployment and calibration of the sensor, right heart catheterization, selective pulmonary catheterization, radiological supervision and interpretation, and pulmonary artery angiography, when performed",75743,"Angiography, pulmonary, bilateral, selective, radiological supervision and interpretation",45.386827506735145,,Present in Autoproposal
33289,"Transcatheter implantation of wireless pulmonary artery pressure sensor for long-term hemodynamic monitoring, including deployment and calibration of the sensor, right heart catheterization, selective pulmonary catheterization, radiological supervision and interpretation, and pulmonary artery angiography, when performed",36014,"Selective catheter placement, left or right pulmonary artery",38.649519570448604,,Present Both in MD and Autoproposal
33289,"Transcatheter implantation of wireless pulmonary artery pressure sensor for long-term hemodynamic monitoring, including deployment and calibration of the sensor, right heart catheterization, selective pulmonary catheterization, radiological supervision and interpretation, and pulmonary artery angiography, when performed",93541,Injection procedure during cardiac catheterization; for pulmonary angiography,38.580114045560684,,Present in Autoproposal
33289,"Transcatheter implantation of wireless pulmonary artery pressure sensor for long-term hemodynamic monitoring, including deployment and calibration of the sensor, right heart catheterization, selective pulmonary catheterization, radiological supervision and interpretation, and pulmonary artery angiography, when performed",33471,"Valvotomy, pulmonary valve, closed heart; via pulmonary artery",37.43135621867051,,Present in Autoproposal
33289,"Transcatheter implantation of wireless pulmonary artery pressure sensor for long-term hemodynamic monitoring, including deployment and calibration of the sensor, right heart catheterization, selective pulmonary catheterization, radiological supervision and interpretation, and pulmonary artery angiography, when performed",34806,"Transcatheter placement of wireless physiologic sensor in aneurysmal sac during endovascular repair, including radiological supervision and interpretation, instrument calibration, and collection of pressure data (List separately in addition to code for primary procedure)",35.71293847851012,,Present in Autoproposal
33289,"Transcatheter implantation of wireless pulmonary artery pressure sensor for long-term hemodynamic monitoring, including deployment and calibration of the sensor, right heart catheterization, selective pulmonary catheterization, radiological supervision and interpretation, and pulmonary artery angiography, when performed",93501,Right heart catheterization,35.44917842138634,,Present in Autoproposal
33289,"Transcatheter implantation of wireless pulmonary artery pressure sensor for long-term hemodynamic monitoring, including deployment and calibration of the sensor, right heart catheterization, selective pulmonary catheterization, radiological supervision and interpretation, and pulmonary artery angiography, when performed",0153T,"Transcatheter placement of wireless physiologic sensor in aneurysmal sac during endovascular repair, including radiological supervision and interpretation and instrument calibration (List separately in addition to code for primary procedure)",35.22343032951194,,Present in Autoproposal
33440,"Replacement, aortic valve; by translocation of autologous pulmonary valve and transventricular aortic annulus enlargement of the left ventricular outflow tract with valved conduit replacement of pulmonary valve (Ross-Konno procedure)",33413,"Replacement, aortic valve; by translocation of autologous pulmonary valve with allograft replacement of pulmonary valve (Ross procedure)",73.6352899821561,1,Present Both in MD and Autoproposal
33440,"Replacement, aortic valve; by translocation of autologous pulmonary valve and transventricular aortic annulus enlargement of the left ventricular outflow tract with valved conduit replacement of pulmonary valve (Ross-Konno procedure)",33412,"Replacement, aortic valve; with transventricular aortic annulus enlargement (Konno procedure)",67.64605774302517,,Present Both in MD and Autoproposal
33440,"Replacement, aortic valve; by translocation of autologous pulmonary valve and transventricular aortic annulus enlargement of the left ventricular outflow tract with valved conduit replacement of pulmonary valve (Ross-Konno procedure)",33475,"Replacement, pulmonary valve",56.83966285571794,,Present in Autoproposal
33440,"Replacement, aortic valve; by translocation of autologous pulmonary valve and transventricular aortic annulus enlargement of the left ventricular outflow tract with valved conduit replacement of pulmonary valve (Ross-Konno procedure)",33411,"Replacement, aortic valve; with aortic annulus enlargement, noncoronary sinus",51.65364809031872,,Present in Autoproposal
33440,"Replacement, aortic valve; by translocation of autologous pulmonary valve and transventricular aortic annulus enlargement of the left ventricular outflow tract with valved conduit replacement of pulmonary valve (Ross-Konno procedure)",33410,"Replacement, aortic valve, open, with cardiopulmonary bypass; with stentless tissue valve",40.83520761839729,,Present in Autoproposal
33440,"Replacement, aortic valve; by translocation of autologous pulmonary valve and transventricular aortic annulus enlargement of the left ventricular outflow tract with valved conduit replacement of pulmonary valve (Ross-Konno procedure)",33405,"Replacement, aortic valve, open, with cardiopulmonary bypass; with prosthetic valve other than homograft or stentless valve",40.429811638853735,,Present in Autoproposal
33440,"Replacement, aortic valve; by translocation of autologous pulmonary valve and transventricular aortic annulus enlargement of the left ventricular outflow tract with valved conduit replacement of pulmonary valve (Ross-Konno procedure)",33406,"Replacement, aortic valve, open, with cardiopulmonary bypass; with allograft valve (freehand)",39.72835378146984,,Present in Autoproposal
33440,"Replacement, aortic valve; by translocation of autologous pulmonary valve and transventricular aortic annulus enlargement of the left ventricular outflow tract with valved conduit replacement of pulmonary valve (Ross-Konno procedure)",33470,"Valvotomy, pulmonary valve, closed heart; transventricular",37.68321642330601,,Present in Autoproposal
33440,"Replacement, aortic valve; by translocation of autologous pulmonary valve and transventricular aortic annulus enlargement of the left ventricular outflow tract with valved conduit replacement of pulmonary valve (Ross-Konno procedure)",33602,Closure of semilunar valve (aortic or pulmonary) by suture or patch,36.71986743343197,,Present in Autoproposal
33440,"Replacement, aortic valve; by translocation of autologous pulmonary valve and transventricular aortic annulus enlargement of the left ventricular outflow tract with valved conduit replacement of pulmonary valve (Ross-Konno procedure)",33414,Repair of left ventricular outflow tract obstruction by patch enlargement of the outflow tract,36.548471426155984,,Present in Autoproposal
33866,"Aortic hemiarch graft including isolation and control of the arch vessels, beveled open distal aortic anastomosis extending under one or more of the arch vessels, and total circulatory arrest or isolated cerebral perfusion (List separately in addition to code for primary procedure)",35400,Angioscopy (noncoronary vessels or grafts) during therapeutic intervention (List separately in addition to code for primary procedure),27.995985817115116,10,Present in Autoproposal
33866,"Aortic hemiarch graft including isolation and control of the arch vessels, beveled open distal aortic anastomosis extending under one or more of the arch vessels, and total circulatory arrest or isolated cerebral perfusion (List separately in addition to code for primary procedure)",35685,"Placement of vein patch or cuff at distal anastomosis of bypass graft, synthetic conduit (List separately in addition to code for primary procedure)",26.92558212139748,,Present in Autoproposal
33866,"Aortic hemiarch graft including isolation and control of the arch vessels, beveled open distal aortic anastomosis extending under one or more of the arch vessels, and total circulatory arrest or isolated cerebral perfusion (List separately in addition to code for primary procedure)",00563,"Anesthesia for procedures on heart, pericardial sac, and great vessels of chest; with pump oxygenator with hypothermic circulatory arrest",26.538442479295902,,Present in Autoproposal
33866,"Aortic hemiarch graft including isolation and control of the arch vessels, beveled open distal aortic anastomosis extending under one or more of the arch vessels, and total circulatory arrest or isolated cerebral perfusion (List separately in addition to code for primary procedure)",33368,"Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; cardiopulmonary bypass support with open peripheral arterial and venous cannulation (eg, femoral, iliac, axillary vessels) (List separately in addition to code for primary procedure)",26.435116354731967,,Present in Autoproposal
33866,"Aortic hemiarch graft including isolation and control of the arch vessels, beveled open distal aortic anastomosis extending under one or more of the arch vessels, and total circulatory arrest or isolated cerebral perfusion (List separately in addition to code for primary procedure)",0081T,"Placement of visceral extension prosthesis for endovascular repair of abdominal aortic aneurysm involving visceral vessels, each visceral branch, radiological supervision and interpretation (List separately in addition to code for primary procedure)",25.97521271352446,,Present in Autoproposal
33866,"Aortic hemiarch graft including isolation and control of the arch vessels, beveled open distal aortic anastomosis extending under one or more of the arch vessels, and total circulatory arrest or isolated cerebral perfusion (List separately in addition to code for primary procedure)",0079T,"Placement of visceral extension prosthesis for endovascular repair of abdominal aortic aneurysm involving visceral vessels, each visceral branch (List separately in addition to code for primary procedure)",25.866218508806305,,Present in Autoproposal
33866,"Aortic hemiarch graft including isolation and control of the arch vessels, beveled open distal aortic anastomosis extending under one or more of the arch vessels, and total circulatory arrest or isolated cerebral perfusion (List separately in addition to code for primary procedure)",33367,"Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; cardiopulmonary bypass support with percutaneous peripheral arterial and venous cannulation (eg, femoral vessels) (List separately in addition to code for primary procedure)",25.765292848338504,,Present in Autoproposal
33866,"Aortic hemiarch graft including isolation and control of the arch vessels, beveled open distal aortic anastomosis extending under one or more of the arch vessels, and total circulatory arrest or isolated cerebral perfusion (List separately in addition to code for primary procedure)",34813,Placement of femoral-femoral prosthetic graft during endovascular aortic aneurysm repair (List separately in addition to code for primary procedure),25.584134106918537,,Present in Autoproposal
33866,"Aortic hemiarch graft including isolation and control of the arch vessels, beveled open distal aortic anastomosis extending under one or more of the arch vessels, and total circulatory arrest or isolated cerebral perfusion (List separately in addition to code for primary procedure)",36221,"Non-selective catheter placement, thoracic aorta, with angiography of the extracranial carotid, vertebral, and/or intracranial vessels, unilateral or bilateral, and all associated radiological supervision and interpretation, includes angiography of the cervicocerebral arch, when performed",25.450083417244052,,Present in Autoproposal
33866,"Aortic hemiarch graft including isolation and control of the arch vessels, beveled open distal aortic anastomosis extending under one or more of the arch vessels, and total circulatory arrest or isolated cerebral perfusion (List separately in addition to code for primary procedure)",90785,Interactive complexity (List separately in addition to the code for primary procedure),25.264429937222683,,Present in Autoproposal
36572,"Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, including all imaging guidance, image documentation, and all associated radiological supervision and interpretation required to perform the insertion; younger than 5 years of age",36568,"Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump; younger than 5 years of age",75.21220240666258,1,Present Both in MD and Autoproposal
36572,"Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, including all imaging guidance, image documentation, and all associated radiological supervision and interpretation required to perform the insertion; younger than 5 years of age",36569,"Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump; age 5 years or older",67.98903052654796,,Present in Autoproposal
36572,"Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, including all imaging guidance, image documentation, and all associated radiological supervision and interpretation required to perform the insertion; younger than 5 years of age",36570,"Insertion of peripherally inserted central venous access device, with subcutaneous port; younger than 5 years of age",61.711805932540784,,Present in Autoproposal
36572,"Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, including all imaging guidance, image documentation, and all associated radiological supervision and interpretation required to perform the insertion; younger than 5 years of age",36557,"Insertion of tunneled centrally inserted central venous catheter, without subcutaneous port or pump; younger than 5 years of age",59.12346012022215,,Present in Autoproposal
36572,"Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, including all imaging guidance, image documentation, and all associated radiological supervision and interpretation required to perform the insertion; younger than 5 years of age",S9527,"INSERTION OF A PERIPHERALLY INSERTED CENTRAL VENOUS CATHETER (PICC), INCLUDING NURSING SERVICES AND ALL SUPPLIES",59.09061251503649,,Present in Autoproposal
36572,"Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, including all imaging guidance, image documentation, and all associated radiological supervision and interpretation required to perform the insertion; younger than 5 years of age",36571,"Insertion of peripherally inserted central venous access device, with subcutaneous port; age 5 years or older",54.30896272858303,,Present in Autoproposal
36572,"Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, including all imaging guidance, image documentation, and all associated radiological supervision and interpretation required to perform the insertion; younger than 5 years of age",36584,"Replacement, complete, of a peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, through same venous access",52.5370938029695,,Present in Autoproposal
36572,"Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, including all imaging guidance, image documentation, and all associated radiological supervision and interpretation required to perform the insertion; younger than 5 years of age",36558,"Insertion of tunneled centrally inserted central venous catheter, without subcutaneous port or pump; age 5 years or older",51.55951219876547,,Present in Autoproposal
36572,"Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, including all imaging guidance, image documentation, and all associated radiological supervision and interpretation required to perform the insertion; younger than 5 years of age",36560,"Insertion of tunneled centrally inserted central venous access device, with subcutaneous port; younger than 5 years of age",50.277709276738136,,Present in Autoproposal
36572,"Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, including all imaging guidance, image documentation, and all associated radiological supervision and interpretation required to perform the insertion; younger than 5 years of age",S5520,"HOME INFUSION THERAPY, ALL SUPPLIES (INCLUDING CATHETER) NECESSARY FOR A PERIPHERALLY INSERTED CENTRAL VENOUS CATHETER (PICC) LINE INSERTION",49.697013833286825,,Present in Autoproposal
36573,"Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, including all imaging guidance, image documentation, and all associated radiological supervision and interpretation required to perform the insertion; age 5 years or older",36569,"Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump; age 5 years or older",74.76201620789142,10,Present Both in MD and Autoproposal
36573,"Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, including all imaging guidance, image documentation, and all associated radiological supervision and interpretation required to perform the insertion; age 5 years or older",36568,"Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump; younger than 5 years of age",67.49203689381694,,Present in Autoproposal
36573,"Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, including all imaging guidance, image documentation, and all associated radiological supervision and interpretation required to perform the insertion; age 5 years or older",36571,"Insertion of peripherally inserted central venous access device, with subcutaneous port; age 5 years or older",60.88188425856455,,Present in Autoproposal
36573,"Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, including all imaging guidance, image documentation, and all associated radiological supervision and interpretation required to perform the insertion; age 5 years or older",S9527,"INSERTION OF A PERIPHERALLY INSERTED CENTRAL VENOUS CATHETER (PICC), INCLUDING NURSING SERVICES AND ALL SUPPLIES",58.854246344509775,,Present in Autoproposal
36573,"Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, including all imaging guidance, image documentation, and all associated radiological supervision and interpretation required to perform the insertion; age 5 years or older",36558,"Insertion of tunneled centrally inserted central venous catheter, without subcutaneous port or pump; age 5 years or older",58.296086063863086,,Present in Autoproposal
36573,"Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, including all imaging guidance, image documentation, and all associated radiological supervision and interpretation required to perform the insertion; age 5 years or older",36584,"Replacement, complete, of a peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, through same venous access",52.93317887674878,,Present in Autoproposal
36573,"Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, including all imaging guidance, image documentation, and all associated radiological supervision and interpretation required to perform the insertion; age 5 years or older",36570,"Insertion of peripherally inserted central venous access device, with subcutaneous port; younger than 5 years of age",52.60758314175435,,Present in Autoproposal
36573,"Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, including all imaging guidance, image documentation, and all associated radiological supervision and interpretation required to perform the insertion; age 5 years or older",36557,"Insertion of tunneled centrally inserted central venous catheter, without subcutaneous port or pump; younger than 5 years of age",51.160192282863505,,Present in Autoproposal
36573,"Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, including all imaging guidance, image documentation, and all associated radiological supervision and interpretation required to perform the insertion; age 5 years or older",S5520,"HOME INFUSION THERAPY, ALL SUPPLIES (INCLUDING CATHETER) NECESSARY FOR A PERIPHERALLY INSERTED CENTRAL VENOUS CATHETER (PICC) LINE INSERTION",50.08370323514596,,Present in Autoproposal
36573,"Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, including all imaging guidance, image documentation, and all associated radiological supervision and interpretation required to perform the insertion; age 5 years or older",36561,"Insertion of tunneled centrally inserted central venous access device, with subcutaneous port; age 5 years or older",49.055146061749056,,Present in Autoproposal
38531,"Biopsy or excision of lymph node(s); open, inguinofemoral node(s)",38510,"Biopsy or excision of lymph node(s); open, deep cervical node(s)",81.46677247668234,4,Present in Autoproposal
38531,"Biopsy or excision of lymph node(s); open, inguinofemoral node(s)",38530,"Biopsy or excision of lymph node(s); open, internal mammary node(s)",80.19466824168204,,Present in Autoproposal
38531,"Biopsy or excision of lymph node(s); open, inguinofemoral node(s)",38525,"Biopsy or excision of lymph node(s); open, deep axillary node(s)",79.32429654398446,,Present in Autoproposal
38531,"Biopsy or excision of lymph node(s); open, inguinofemoral node(s)",38500,"Biopsy or excision of lymph node(s); open, superficial",75.47688654943727,,Present Both in MD and Autoproposal
38531,"Biopsy or excision of lymph node(s); open, inguinofemoral node(s)",38520,"Biopsy or excision of lymph node(s); open, deep cervical node(s) with excision scalene fat pad",66.83386503201525,,Present in Autoproposal
38531,"Biopsy or excision of lymph node(s); open, inguinofemoral node(s)",G8878,SENTINEL LYMPH NODE BIOPSY PROCEDURE PERFORMED,56.66698626026865,,Present in Autoproposal
38531,"Biopsy or excision of lymph node(s); open, inguinofemoral node(s)",38505,"Biopsy or excision of lymph node(s); by needle, superficial (eg, cervical, inguinal, axillary)",50.66275710632101,,Present in Autoproposal
38531,"Biopsy or excision of lymph node(s); open, inguinofemoral node(s)",38570,"Laparoscopy, surgical; with retroperitoneal lymph node sampling (biopsy), single or multiple",48.02730900879671,,Present in Autoproposal
38531,"Biopsy or excision of lymph node(s); open, inguinofemoral node(s)",56311,LAPAROSCOPIC LYMPH NODE BIOP,46.36100974065781,,Present in Autoproposal
38531,"Biopsy or excision of lymph node(s); open, inguinofemoral node(s)",G8882,"SENTINEL LYMPH NODE BIOPSY PROCEDURE NOT PERFORMED, REASON NOT GIVEN",45.98470819958549,,Present in Autoproposal
43762,"Replacement of gastrostomy tube, percutaneous, includes removal, when performed, without imaging or endoscopic guidance; not requiring revision of gastrostomy tract",43760,"Change of gastrostomy tube, percutaneous, without imaging or endoscopic guidance",69.59493495342602,1,Present Both in MD and Autoproposal
43762,"Replacement of gastrostomy tube, percutaneous, includes removal, when performed, without imaging or endoscopic guidance; not requiring revision of gastrostomy tract",43750,Percutaneous placement of gastrostomy tube,59.64551815043404,,Present in Autoproposal
43762,"Replacement of gastrostomy tube, percutaneous, includes removal, when performed, without imaging or endoscopic guidance; not requiring revision of gastrostomy tract",74350,"Percutaneous placement of gastrostomy tube, radiological supervision and interpretation",47.889043538782545,,Present in Autoproposal
43762,"Replacement of gastrostomy tube, percutaneous, includes removal, when performed, without imaging or endoscopic guidance; not requiring revision of gastrostomy tract",43870,"Closure of gastrostomy, surgical",46.05079948755309,,Present in Autoproposal
43762,"Replacement of gastrostomy tube, percutaneous, includes removal, when performed, without imaging or endoscopic guidance; not requiring revision of gastrostomy tract",56346,LAPAROSCOPIC GASTROSTOMY,43.27472146423696,,Present in Autoproposal
43762,"Replacement of gastrostomy tube, percutaneous, includes removal, when performed, without imaging or endoscopic guidance; not requiring revision of gastrostomy tract",49440,"Insertion of gastrostomy tube, percutaneous, under fluoroscopic guidance including contrast injection(s), image documentation and report",41.536957766617114,,Present in Autoproposal
43762,"Replacement of gastrostomy tube, percutaneous, includes removal, when performed, without imaging or endoscopic guidance; not requiring revision of gastrostomy tract",49450,"Replacement of gastrostomy or cecostomy (or other colonic) tube, percutaneous, under fluoroscopic guidance including contrast injection(s), image documentation and report",40.1433865478722,,Present in Autoproposal
43762,"Replacement of gastrostomy tube, percutaneous, includes removal, when performed, without imaging or endoscopic guidance; not requiring revision of gastrostomy tract",43246,"Esophagogastroduodenoscopy, flexible, transoral; with directed placement of percutaneous gastrostomy tube",39.061023363437464,,Present in Autoproposal
43762,"Replacement of gastrostomy tube, percutaneous, includes removal, when performed, without imaging or endoscopic guidance; not requiring revision of gastrostomy tract",49446,"Conversion of gastrostomy tube to gastro-jejunostomy tube, percutaneous, under fluoroscopic guidance including contrast injection(s), image documentation and report",36.18896204956322,,Present in Autoproposal
43762,"Replacement of gastrostomy tube, percutaneous, includes removal, when performed, without imaging or endoscopic guidance; not requiring revision of gastrostomy tract",B4084,GASTROSTOMY/JEJUNOSTOMY TUBING,35.230927963511185,,Present in Autoproposal
43763,"Replacement of gastrostomy tube, percutaneous, includes removal, when performed, without imaging or endoscopic guidance; requiring revision of gastrostomy tract",43760,"Change of gastrostomy tube, percutaneous, without imaging or endoscopic guidance",70.40650035892868,1,Present Both in MD and Autoproposal
43763,"Replacement of gastrostomy tube, percutaneous, includes removal, when performed, without imaging or endoscopic guidance; requiring revision of gastrostomy tract",43750,Percutaneous placement of gastrostomy tube,60.341060709049366,,Present in Autoproposal
43763,"Replacement of gastrostomy tube, percutaneous, includes removal, when performed, without imaging or endoscopic guidance; requiring revision of gastrostomy tract",74350,"Percutaneous placement of gastrostomy tube, radiological supervision and interpretation",48.447490659463035,,Present in Autoproposal
43763,"Replacement of gastrostomy tube, percutaneous, includes removal, when performed, without imaging or endoscopic guidance; requiring revision of gastrostomy tract",43870,"Closure of gastrostomy, surgical",46.58781034595605,,Present in Autoproposal
43763,"Replacement of gastrostomy tube, percutaneous, includes removal, when performed, without imaging or endoscopic guidance; requiring revision of gastrostomy tract",56346,LAPAROSCOPIC GASTROSTOMY,43.77935972414252,,Present in Autoproposal
43763,"Replacement of gastrostomy tube, percutaneous, includes removal, when performed, without imaging or endoscopic guidance; requiring revision of gastrostomy tract",49440,"Insertion of gastrostomy tube, percutaneous, under fluoroscopic guidance including contrast injection(s), image documentation and report",42.02133149289145,,Present in Autoproposal
43763,"Replacement of gastrostomy tube, percutaneous, includes removal, when performed, without imaging or endoscopic guidance; requiring revision of gastrostomy tract",49450,"Replacement of gastrostomy or cecostomy (or other colonic) tube, percutaneous, under fluoroscopic guidance including contrast injection(s), image documentation and report",40.61150946233107,,Present in Autoproposal
43763,"Replacement of gastrostomy tube, percutaneous, includes removal, when performed, without imaging or endoscopic guidance; requiring revision of gastrostomy tract",43246,"Esophagogastroduodenoscopy, flexible, transoral; with directed placement of percutaneous gastrostomy tube",39.516524547345625,,Present in Autoproposal
43763,"Replacement of gastrostomy tube, percutaneous, includes removal, when performed, without imaging or endoscopic guidance; requiring revision of gastrostomy tract",49446,"Conversion of gastrostomy tube to gastro-jejunostomy tube, percutaneous, under fluoroscopic guidance including contrast injection(s), image documentation and report",36.6109713477992,,Present in Autoproposal
43763,"Replacement of gastrostomy tube, percutaneous, includes removal, when performed, without imaging or endoscopic guidance; requiring revision of gastrostomy tract",B4084,GASTROSTOMY/JEJUNOSTOMY TUBING,35.64176536652156,,Present in Autoproposal
50436,"Dilation of existing tract, percutaneous, for an endourologic procedure including imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation, with postprocedure tube placement, when performed",50693,"Placement of ureteral stent, percutaneous, including diagnostic nephrostogram and/or ureterogram when performed, imaging guidance (eg, ultrasound and/or fluoroscopy), and all associated radiological supervision and interpretation; pre-existing nephrostomy tract",71.56599978772273,10,Present in Autoproposal
50436,"Dilation of existing tract, percutaneous, for an endourologic procedure including imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation, with postprocedure tube placement, when performed",47531,"Injection procedure for cholangiography, percutaneous, complete diagnostic procedure including imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation; existing access",70.23102307821951,,Present in Autoproposal
50436,"Dilation of existing tract, percutaneous, for an endourologic procedure including imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation, with postprocedure tube placement, when performed",47533,"Placement of biliary drainage catheter, percutaneous, including diagnostic cholangiography when performed, imaging guidance (eg, ultrasound and/or fluoroscopy), and all associated radiological supervision and interpretation; external",67.85857360360039,,Present in Autoproposal
50436,"Dilation of existing tract, percutaneous, for an endourologic procedure including imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation, with postprocedure tube placement, when performed",50432,"Placement of nephrostomy catheter, percutaneous, including diagnostic nephrostogram and/or ureterogram when performed, imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation",66.4951005835084,,Present in Autoproposal
50436,"Dilation of existing tract, percutaneous, for an endourologic procedure including imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation, with postprocedure tube placement, when performed",47534,"Placement of biliary drainage catheter, percutaneous, including diagnostic cholangiography when performed, imaging guidance (eg, ultrasound and/or fluoroscopy), and all associated radiological supervision and interpretation; internal-external",66.3614013241636,,Present in Autoproposal
50436,"Dilation of existing tract, percutaneous, for an endourologic procedure including imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation, with postprocedure tube placement, when performed",47538,"Placement of stent(s) into a bile duct, percutaneous, including diagnostic cholangiography, imaging guidance (eg, fluoroscopy and/or ultrasound), balloon dilation, catheter exchange(s) and catheter removal(s) when performed, and all associated radiological supervision and interpretation; existing access",65.26393620697566,,Present in Autoproposal
50436,"Dilation of existing tract, percutaneous, for an endourologic procedure including imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation, with postprocedure tube placement, when performed",50706,"Balloon dilation, ureteral stricture, including imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation (List separately in addition to code for primary procedure)",62.46137214701385,,Present in Autoproposal
50436,"Dilation of existing tract, percutaneous, for an endourologic procedure including imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation, with postprocedure tube placement, when performed",50433,"Placement of nephroureteral catheter, percutaneous, including diagnostic nephrostogram and/or ureterogram when performed, imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation, new access",62.25879069245962,,Present in Autoproposal
50436,"Dilation of existing tract, percutaneous, for an endourologic procedure including imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation, with postprocedure tube placement, when performed",50431,"Injection procedure for antegrade nephrostogram and/or ureterogram, complete diagnostic procedure including imaging guidance (eg, ultrasound and fluoroscopy) and all associated radiological supervision and interpretation; existing access",61.41416031778585,,Present in Autoproposal
50436,"Dilation of existing tract, percutaneous, for an endourologic procedure including imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation, with postprocedure tube placement, when performed",50435,"Exchange nephrostomy catheter, percutaneous, including diagnostic nephrostogram and/or ureterogram when performed, imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation",61.18708313444525,,Present in Autoproposal
50437,"Dilation of existing tract, percutaneous, for an endourologic procedure including imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation, with postprocedure tube placement, when performed; including new access into the renal collecting system",47531,"Injection procedure for cholangiography, percutaneous, complete diagnostic procedure including imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation; existing access",64.28693481183005,10,Present in Autoproposal
50437,"Dilation of existing tract, percutaneous, for an endourologic procedure including imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation, with postprocedure tube placement, when performed; including new access into the renal collecting system",47538,"Placement of stent(s) into a bile duct, percutaneous, including diagnostic cholangiography, imaging guidance (eg, fluoroscopy and/or ultrasound), balloon dilation, catheter exchange(s) and catheter removal(s) when performed, and all associated radiological supervision and interpretation; existing access",62.6693503747199,,Present in Autoproposal
50437,"Dilation of existing tract, percutaneous, for an endourologic procedure including imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation, with postprocedure tube placement, when performed; including new access into the renal collecting system",50433,"Placement of nephroureteral catheter, percutaneous, including diagnostic nephrostogram and/or ureterogram when performed, imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation, new access",60.96022893743758,,Present in Autoproposal
50437,"Dilation of existing tract, percutaneous, for an endourologic procedure including imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation, with postprocedure tube placement, when performed; including new access into the renal collecting system",50693,"Placement of ureteral stent, percutaneous, including diagnostic nephrostogram and/or ureterogram when performed, imaging guidance (eg, ultrasound and/or fluoroscopy), and all associated radiological supervision and interpretation; pre-existing nephrostomy tract",60.194341428596054,,Present in Autoproposal
50437,"Dilation of existing tract, percutaneous, for an endourologic procedure including imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation, with postprocedure tube placement, when performed; including new access into the renal collecting system",50695,"Placement of ureteral stent, percutaneous, including diagnostic nephrostogram and/or ureterogram when performed, imaging guidance (eg, ultrasound and/or fluoroscopy), and all associated radiological supervision and interpretation; new access, with separate nephrostomy catheter",59.10873389233955,,Present in Autoproposal
50437,"Dilation of existing tract, percutaneous, for an endourologic procedure including imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation, with postprocedure tube placement, when performed; including new access into the renal collecting system",47541,"Placement of access through the biliary tree and into small bowel to assist with an endoscopic biliary procedure (eg, rendezvous procedure), percutaneous, including diagnostic cholangiography when performed, imaging guidance (eg, ultrasound and/or fluoroscopy), and all associated radiological supervision and interpretation, new access",58.90066031319742,,Present in Autoproposal
50437,"Dilation of existing tract, percutaneous, for an endourologic procedure including imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation, with postprocedure tube placement, when performed; including new access into the renal collecting system",50694,"Placement of ureteral stent, percutaneous, including diagnostic nephrostogram and/or ureterogram when performed, imaging guidance (eg, ultrasound and/or fluoroscopy), and all associated radiological supervision and interpretation; new access, without separate nephrostomy catheter",58.14684685112683,,Present in Autoproposal
50437,"Dilation of existing tract, percutaneous, for an endourologic procedure including imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation, with postprocedure tube placement, when performed; including new access into the renal collecting system",47533,"Placement of biliary drainage catheter, percutaneous, including diagnostic cholangiography when performed, imaging guidance (eg, ultrasound and/or fluoroscopy), and all associated radiological supervision and interpretation; external",57.43446898309159,,Present in Autoproposal
50437,"Dilation of existing tract, percutaneous, for an endourologic procedure including imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation, with postprocedure tube placement, when performed; including new access into the renal collecting system",47532,"Injection procedure for cholangiography, percutaneous, complete diagnostic procedure including imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation; new access (eg, percutaneous transhepatic cholangiogram)",57.08391289515239,,Present in Autoproposal
50437,"Dilation of existing tract, percutaneous, for an endourologic procedure including imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation, with postprocedure tube placement, when performed; including new access into the renal collecting system",47539,"Placement of stent(s) into a bile duct, percutaneous, including diagnostic cholangiography, imaging guidance (eg, fluoroscopy and/or ultrasound), balloon dilation, catheter exchange(s) and catheter removal(s) when performed, and all associated radiological supervision and interpretation; new access, without placement of separate biliary drainage catheter",56.92578802436786,,Present in Autoproposal
53854,Transurethral destruction of prostate tissue; by radiofrequency generated water vapor thermotherapy,53852,Transurethral destruction of prostate tissue; by radiofrequency thermotherapy,77.53202232043137,1,Present Both in MD and Autoproposal
53854,Transurethral destruction of prostate tissue; by radiofrequency generated water vapor thermotherapy,53853,Transurethral destruction of prostate tissue; by water-induced thermotherapy,70.8669127277755,,Present in Autoproposal
53854,Transurethral destruction of prostate tissue; by radiofrequency generated water vapor thermotherapy,53850,Transurethral destruction of prostate tissue; by microwave thermotherapy,61.34253931004503,,Present Both in MD and Autoproposal
53854,Transurethral destruction of prostate tissue; by radiofrequency generated water vapor thermotherapy,C9700,WATER INDUCED THERMOTHERAPY,40.8692874396016,,Present in Autoproposal
53854,Transurethral destruction of prostate tissue; by radiofrequency generated water vapor thermotherapy,52450,Transurethral incision of prostate,39.32619887956036,,Present in Autoproposal
53854,Transurethral destruction of prostate tissue; by radiofrequency generated water vapor thermotherapy,00914,Anesthesia for transurethral procedures (including urethrocystoscopy); transurethral resection of prostate,33.09004922258373,,Present in Autoproposal
53854,Transurethral destruction of prostate tissue; by radiofrequency generated water vapor thermotherapy,E1405,OXYGEN AND WATER VAPOR ENRICHING SYSTEM WITH HEATED DELIVERY,29.121167624968287,,Present in Autoproposal
53854,Transurethral destruction of prostate tissue; by radiofrequency generated water vapor thermotherapy,E1406,OXYGEN AND WATER VAPOR ENRICHING SYSTEM WITHOUT HEATED DELIVERY,28.851828371392497,,Present in Autoproposal
53854,Transurethral destruction of prostate tissue; by radiofrequency generated water vapor thermotherapy,77620,Hyperthermia generated by intracavitary probe(s),24.299947757604144,,Present in Autoproposal
53854,Transurethral destruction of prostate tissue; by radiofrequency generated water vapor thermotherapy,00912,Anesthesia for transurethral procedures (including urethrocystoscopy); transurethral resection of bladder tumor(s),23.893113010247287,,Present in Autoproposal
76391,"Magnetic resonance (eg, vibration) elastography",91200,"Liver elastography, mechanically induced shear wave (eg, vibration), without imaging, with interpretation and report",47.47793430878281,1,Present Both in MD and Autoproposal
76391,"Magnetic resonance (eg, vibration) elastography",76390,Magnetic resonance spectroscopy,38.10174491281614,,Present in Autoproposal
76391,"Magnetic resonance (eg, vibration) elastography",0346T,"Ultrasound, elastography (List separately in addition to code for primary procedure)",36.7908515429039,,Present Both in MD and Autoproposal
76391,"Magnetic resonance (eg, vibration) elastography",76498,"Unlisted magnetic resonance procedure (eg, diagnostic, interventional)",35.733159614326595,,Present in Autoproposal
76391,"Magnetic resonance (eg, vibration) elastography",70336,"Magnetic resonance (eg, proton) imaging, temporomandibular joint(s)",34.424728114226774,,Present in Autoproposal
76391,"Magnetic resonance (eg, vibration) elastography",C8900,"MAGNETIC RESONANCE ANGIOGRAPHY WITH CONTRAST, ABDOMEN",33.392528663489315,,Present in Autoproposal
76391,"Magnetic resonance (eg, vibration) elastography",74182,"Magnetic resonance (eg, proton) imaging, abdomen; with contrast material(s)",33.38884206741024,,Present in Autoproposal
76391,"Magnetic resonance (eg, vibration) elastography",72196,"Magnetic resonance (eg, proton) imaging, pelvis; with contrast material(s)",32.95043977137006,,Present in Autoproposal
76391,"Magnetic resonance (eg, vibration) elastography",74181,"Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s)",32.90138718104521,,Present in Autoproposal
76391,"Magnetic resonance (eg, vibration) elastography",C8918,"MAGNETIC RESONANCE ANGIOGRAPHY WITH CONTRAST, PELVIS",32.78333130354326,,Present in Autoproposal
76978,"Ultrasound, targeted dynamic microbubble sonographic contrast characterization (non-cardiac); initial lesion",C9744,"ULTRASOUND, ABDOMINAL, WITH CONTRAST",28.774320329913728,10,Present Both in MD and Autoproposal
76978,"Ultrasound, targeted dynamic microbubble sonographic contrast characterization (non-cardiac); initial lesion",C1723,"CATHETER, ABLATION, NON-CARDIAC",24.223919519892277,,Present in Autoproposal
76978,"Ultrasound, targeted dynamic microbubble sonographic contrast characterization (non-cardiac); initial lesion",C8921,"TRANSTHORACIC ECHOCARDIOGRAPHY WITH CONTRAST, OR WITHOUT CONTRAST FOLLOWED BY WITH CONTRAST, FOR CONGENITAL CARDIAC ANOMALIES; COMPLETE",22.50042559835092,,Present in Autoproposal
76978,"Ultrasound, targeted dynamic microbubble sonographic contrast characterization (non-cardiac); initial lesion",G8265,PATIENT DOCUMENTED TO HAVE RECEIVED CHARACTERIZATION OF URINARY INCONTINENCE,21.985921791260033,,Present in Autoproposal
76978,"Ultrasound, targeted dynamic microbubble sonographic contrast characterization (non-cardiac); initial lesion",G8266,PATIENT NOT DOCUMENTED TO HAVE RECEIVED CHARACTERIZATION OF URINARY INCONTINENCE,21.407498186901574,,Present in Autoproposal
76978,"Ultrasound, targeted dynamic microbubble sonographic contrast characterization (non-cardiac); initial lesion",C8922,"TRANSTHORACIC ECHOCARDIOGRAPHY WITH CONTRAST, OR WITHOUT CONTRAST FOLLOWED BY WITH CONTRAST, FOR CONGENITAL CARDIAC ANOMALIES; FOLLOW-UP OR LIMITED STUDY",20.783369243745607,,Present in Autoproposal
76978,"Ultrasound, targeted dynamic microbubble sonographic contrast characterization (non-cardiac); initial lesion",G9828,HER2-TARGETED THERAPIES ADMINISTERED DURING THE INITIAL COURSE OF TREATMENT,20.6224584447216,,Present in Autoproposal
76978,"Ultrasound, targeted dynamic microbubble sonographic contrast characterization (non-cardiac); initial lesion",G9827,HER2-TARGETED THERAPIES NOT ADMINISTERED DURING THE INITIAL COURSE OF TREATMENT,20.23565982094229,,Present in Autoproposal
76978,"Ultrasound, targeted dynamic microbubble sonographic contrast characterization (non-cardiac); initial lesion",T2023,TARGETED CASE MANAGEMENT; PER MONTH,19.950371562506966,,Present in Autoproposal
76978,"Ultrasound, targeted dynamic microbubble sonographic contrast characterization (non-cardiac); initial lesion",93893,Transcranial Doppler study of the intracranial arteries; emboli detection with intravenous microbubble injection,19.265941234190727,,Present in Autoproposal
76979,"Ultrasound, targeted dynamic microbubble sonographic contrast characterization (non-cardiac); each additional lesion with separate injection (List separately in addition to code for primary procedure)",56606,Biopsy of vulva or perineum (separate procedure); each separate additional lesion (List separately in addition to code for primary procedure),44.8584950363845,10,Present in Autoproposal
76979,"Ultrasound, targeted dynamic microbubble sonographic contrast characterization (non-cardiac); each additional lesion with separate injection (List separately in addition to code for primary procedure)",S2371,EACH ADDITIONAL INTERSPACE (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),44.76015196367803,,Present in Autoproposal
76979,"Ultrasound, targeted dynamic microbubble sonographic contrast characterization (non-cardiac); each additional lesion with separate injection (List separately in addition to code for primary procedure)",S2361,EACH ADDITIONAL CERVICAL VERTEBRAL BODY (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),40.839128691852096,,Present in Autoproposal
76979,"Ultrasound, targeted dynamic microbubble sonographic contrast characterization (non-cardiac); each additional lesion with separate injection (List separately in addition to code for primary procedure)",0346T,"Ultrasound, elastography (List separately in addition to code for primary procedure)",39.68551493075818,,Present in Autoproposal
76979,"Ultrasound, targeted dynamic microbubble sonographic contrast characterization (non-cardiac); each additional lesion with separate injection (List separately in addition to code for primary procedure)",16036,Escharotomy; each additional incision (List separately in addition to code for primary procedure),38.32882505859318,,Present in Autoproposal
76979,"Ultrasound, targeted dynamic microbubble sonographic contrast characterization (non-cardiac); each additional lesion with separate injection (List separately in addition to code for primary procedure)",64837,"Suture of each additional nerve, hand or foot (List separately in addition to code for primary procedure)",37.47608609078185,,Present in Autoproposal
76979,"Ultrasound, targeted dynamic microbubble sonographic contrast characterization (non-cardiac); each additional lesion with separate injection (List separately in addition to code for primary procedure)",13102,"Repair, complex, trunk; each additional 5 cm or less (List separately in addition to code for primary procedure)",37.05143437528117,,Present in Autoproposal
76979,"Ultrasound, targeted dynamic microbubble sonographic contrast characterization (non-cardiac); each additional lesion with separate injection (List separately in addition to code for primary procedure)",G0346,"EACH ADDITIONAL HOUR, UP TO EIGHT (8) HOURS (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE)",36.85986852336033,,Present in Autoproposal
76979,"Ultrasound, targeted dynamic microbubble sonographic contrast characterization (non-cardiac); each additional lesion with separate injection (List separately in addition to code for primary procedure)",64859,Suture of each additional major peripheral nerve (List separately in addition to code for primary procedure),36.60483196381786,,Present in Autoproposal
76979,"Ultrasound, targeted dynamic microbubble sonographic contrast characterization (non-cardiac); each additional lesion with separate injection (List separately in addition to code for primary procedure)",15787,Abrasion; each additional 4 lesions or less (List separately in addition to code for primary procedure),36.44354145753737,,Present in Autoproposal
76981,"Ultrasound, elastography; parenchyma (eg, organ)",0346T,"Ultrasound, elastography (List separately in addition to code for primary procedure)",56.295851997013166,3,Present Both in MD and Autoproposal
76981,"Ultrasound, elastography; parenchyma (eg, organ)",76705,"Ultrasound, abdominal, real time with image documentation; limited (eg, single organ, quadrant, follow-up)",35.65794501307178,,Present in Autoproposal
76981,"Ultrasound, elastography; parenchyma (eg, organ)",91200,"Liver elastography, mechanically induced shear wave (eg, vibration), without imaging, with interpretation and report",31.179110838074614,,Present Both in MD and Autoproposal
76981,"Ultrasound, elastography; parenchyma (eg, organ)",36500,Venous catheterization for selective organ blood sampling,26.083263822092174,,Present in Autoproposal
76981,"Ultrasound, elastography; parenchyma (eg, organ)",76999,"Unlisted ultrasound procedure (eg, diagnostic, interventional)",23.901822152782888,,Present in Autoproposal
76981,"Ultrasound, elastography; parenchyma (eg, organ)",C9744,"ULTRASOUND, ABDOMINAL, WITH CONTRAST",22.761755253928385,,Present in Autoproposal
76981,"Ultrasound, elastography; parenchyma (eg, organ)",88037,"Necropsy (autopsy), limited, gross and/or microscopic; single organ",22.530759101305318,,Present in Autoproposal
76981,"Ultrasound, elastography; parenchyma (eg, organ)",C1001,"CATHETER, DIAGNOSTIC ULTRASOUND, ACUNAV DIAGNOSTIC ULTRASOUND CATHETER",22.364805341508436,,Present in Autoproposal
76981,"Ultrasound, elastography; parenchyma (eg, organ)",C1753,"CATHETER, INTRAVASCULAR ULTRASOUND",22.322986335118873,,Present in Autoproposal
76981,"Ultrasound, elastography; parenchyma (eg, organ)",76830,"Ultrasound, transvaginal",22.315159582534346,,Present in Autoproposal
76982,"Ultrasound, elastography; first target lesion",0346T,"Ultrasound, elastography (List separately in addition to code for primary procedure)",51.662435747195424,4,Present Both in MD and Autoproposal
76982,"Ultrasound, elastography; first target lesion",17100,"DESTRUCTION, BENIGN LESION, FIRST LESION",37.082229240700656,,Present in Autoproposal
76982,"Ultrasound, elastography; first target lesion",83900,"Molecular diagnostics; amplification, target, multiplex, first 2 nucleic acid sequences",25.692276465986218,,Present in Autoproposal
76982,"Ultrasound, elastography; first target lesion",91200,"Liver elastography, mechanically induced shear wave (eg, vibration), without imaging, with interpretation and report",25.07413303700171,,Present Both in MD and Autoproposal
76982,"Ultrasound, elastography; first target lesion",19285,"Placement of breast localization device(s) (eg, clip, metallic pellet, wire/needle, radioactive seeds), percutaneous; first lesion, including ultrasound guidance",22.349613593103463,,Present in Autoproposal
76982,"Ultrasound, elastography; first target lesion",76936,"Ultrasound guided compression repair of arterial pseudoaneurysm or arteriovenous fistulae (includes diagnostic ultrasound evaluation, compression of lesion and imaging)",21.88995812889094,,Present in Autoproposal
76982,"Ultrasound, elastography; first target lesion",C9744,"ULTRASOUND, ABDOMINAL, WITH CONTRAST",20.88835458715241,,Present in Autoproposal
76982,"Ultrasound, elastography; first target lesion",C1001,"CATHETER, DIAGNOSTIC ULTRASOUND, ACUNAV DIAGNOSTIC ULTRASOUND CATHETER",20.52407553962439,,Present in Autoproposal
76982,"Ultrasound, elastography; first target lesion",C1753,"CATHETER, INTRAVASCULAR ULTRASOUND",20.485698436268233,,Present in Autoproposal
76982,"Ultrasound, elastography; first target lesion",76830,"Ultrasound, transvaginal",20.47851586262979,,Present in Autoproposal
76983,"Ultrasound, elastography; each additional target lesion (List separately in addition to code for primary procedure)",0346T,"Ultrasound, elastography (List separately in addition to code for primary procedure)",82.70605912406975,10,Present Both in MD and Autoproposal
76983,"Ultrasound, elastography; each additional target lesion (List separately in addition to code for primary procedure)",S2371,EACH ADDITIONAL INTERSPACE (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),58.56634387405033,,Present in Autoproposal
76983,"Ultrasound, elastography; each additional target lesion (List separately in addition to code for primary procedure)",S2361,EACH ADDITIONAL CERVICAL VERTEBRAL BODY (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),53.43588771603148,,Present in Autoproposal
76983,"Ultrasound, elastography; each additional target lesion (List separately in addition to code for primary procedure)",16036,Escharotomy; each additional incision (List separately in addition to code for primary procedure),50.15128524343437,,Present in Autoproposal
76983,"Ultrasound, elastography; each additional target lesion (List separately in addition to code for primary procedure)",64837,"Suture of each additional nerve, hand or foot (List separately in addition to code for primary procedure)",49.03552040724328,,Present in Autoproposal
76983,"Ultrasound, elastography; each additional target lesion (List separately in addition to code for primary procedure)",13102,"Repair, complex, trunk; each additional 5 cm or less (List separately in addition to code for primary procedure)",48.47988560026364,,Present in Autoproposal
76983,"Ultrasound, elastography; each additional target lesion (List separately in addition to code for primary procedure)",G0346,"EACH ADDITIONAL HOUR, UP TO EIGHT (8) HOURS (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE)",48.22923159070564,,Present in Autoproposal
76983,"Ultrasound, elastography; each additional target lesion (List separately in addition to code for primary procedure)",64859,Suture of each additional major peripheral nerve (List separately in addition to code for primary procedure),47.89552944289479,,Present in Autoproposal
76983,"Ultrasound, elastography; each additional target lesion (List separately in addition to code for primary procedure)",15787,Abrasion; each additional 4 lesions or less (List separately in addition to code for primary procedure),47.684489157282975,,Present in Autoproposal
76983,"Ultrasound, elastography; each additional target lesion (List separately in addition to code for primary procedure)",G0354,EACH ADDITIONAL SEQUENTIAL INTRAVENOUS PUSH (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),47.53812593734257,,Present in Autoproposal
77046,"Magnetic resonance imaging, breast, without contrast material; unilateral",77058,"Magnetic resonance imaging, breast, without and/or with contrast material(s); unilateral",96.10709761523239,1,Present Both in MD and Autoproposal
77046,"Magnetic resonance imaging, breast, without contrast material; unilateral",C8904,"MAGNETIC RESONANCE IMAGING WITHOUT CONTRAST, BREAST; UNILATERAL",94.06183925988364,,Present in Autoproposal
77046,"Magnetic resonance imaging, breast, without contrast material; unilateral",C8903,"MAGNETIC RESONANCE IMAGING WITH CONTRAST, BREAST; UNILATERAL",88.9094163021444,,Present in Autoproposal
77046,"Magnetic resonance imaging, breast, without contrast material; unilateral",77059,"Magnetic resonance imaging, breast, without and/or with contrast material(s); bilateral",83.70571810630601,,Present in Autoproposal
77046,"Magnetic resonance imaging, breast, without contrast material; unilateral",C8905,"MAGNETIC RESONANCE IMAGING WITHOUT CONTRAST FOLLOWED BY WITH CONTRAST, BREAST; UNILATERAL",81.03478586879737,,Present in Autoproposal
77046,"Magnetic resonance imaging, breast, without contrast material; unilateral",C8907,"MAGNETIC RESONANCE IMAGING WITHOUT CONTRAST, BREAST; BILATERAL",80.3273009868332,,Present in Autoproposal
77046,"Magnetic resonance imaging, breast, without contrast material; unilateral",C8906,"MAGNETIC RESONANCE IMAGING WITH CONTRAST, BREAST; BILATERAL",74.9187159632987,,Present in Autoproposal
77046,"Magnetic resonance imaging, breast, without contrast material; unilateral",C8908,"MAGNETIC RESONANCE IMAGING WITHOUT CONTRAST FOLLOWED BY WITH CONTRAST, BREAST; BILATERAL",70.77910874646614,,Present in Autoproposal
77046,"Magnetic resonance imaging, breast, without contrast material; unilateral",75552,Cardiac magnetic resonance imaging for morphology; without contrast material,67.47736653330696,,Present in Autoproposal
77046,"Magnetic resonance imaging, breast, without contrast material; unilateral",74181,"Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s)",67.23031612188358,,Present in Autoproposal
77047,"Magnetic resonance imaging, breast, without contrast material; bilateral",77059,"Magnetic resonance imaging, breast, without and/or with contrast material(s); bilateral",96.12972264170047,1,Present Both in MD and Autoproposal
77047,"Magnetic resonance imaging, breast, without contrast material; bilateral",C8907,"MAGNETIC RESONANCE IMAGING WITHOUT CONTRAST, BREAST; BILATERAL",94.09959690836982,,Present in Autoproposal
77047,"Magnetic resonance imaging, breast, without contrast material; bilateral",C8906,"MAGNETIC RESONANCE IMAGING WITH CONTRAST, BREAST; BILATERAL",88.98157610722355,,Present in Autoproposal
77047,"Magnetic resonance imaging, breast, without contrast material; bilateral",77058,"Magnetic resonance imaging, breast, without and/or with contrast material(s); unilateral",83.6860171851378,,Present in Autoproposal
77047,"Magnetic resonance imaging, breast, without contrast material; bilateral",C8908,"MAGNETIC RESONANCE IMAGING WITHOUT CONTRAST FOLLOWED BY WITH CONTRAST, BREAST; BILATERAL",81.11833715729895,,Present in Autoproposal
77047,"Magnetic resonance imaging, breast, without contrast material; bilateral",C8904,"MAGNETIC RESONANCE IMAGING WITHOUT CONTRAST, BREAST; UNILATERAL",80.35954541261063,,Present in Autoproposal
77047,"Magnetic resonance imaging, breast, without contrast material; bilateral",C8903,"MAGNETIC RESONANCE IMAGING WITH CONTRAST, BREAST; UNILATERAL",74.95915645948796,,Present in Autoproposal
77047,"Magnetic resonance imaging, breast, without contrast material; bilateral",C8905,"MAGNETIC RESONANCE IMAGING WITHOUT CONTRAST FOLLOWED BY WITH CONTRAST, BREAST; UNILATERAL",70.70029616950406,,Present in Autoproposal
77047,"Magnetic resonance imaging, breast, without contrast material; bilateral",75552,Cardiac magnetic resonance imaging for morphology; without contrast material,67.26904099144076,,Present in Autoproposal
77047,"Magnetic resonance imaging, breast, without contrast material; bilateral",74181,"Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s)",67.02275330852137,,Present in Autoproposal
77048,"Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; unilateral",77058,"Magnetic resonance imaging, breast, without and/or with contrast material(s); unilateral",53.07770209361728,1,Present Both in MD and Autoproposal
77048,"Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; unilateral",77065,"Diagnostic mammography, including computer-aided detection (CAD) when performed; unilateral",53.02067427092976,,Present in Autoproposal
77048,"Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; unilateral",G0206,"DIAGNOSTIC MAMMOGRAPHY, INCLUDING COMPUTER-AIDED DETECTION (CAD) WHEN PERFORMED; UNILATERAL",53.02067427092976,,Present in Autoproposal
77048,"Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; unilateral",0159T,"Computer-aided detection, including computer algorithm analysis of MRI image data for lesion detection/characterization, pharmacokinetic analysis, with further physician review for interpretation, breast MRI (List separately in addition to code for primary procedure)",52.345112513231214,,Present in Autoproposal
77048,"Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; unilateral",G0204,"DIAGNOSTIC MAMMOGRAPHY, INCLUDING COMPUTER-AIDED DETECTION (CAD) WHEN PERFORMED; BILATERAL",47.761349792665975,,Present in Autoproposal
77048,"Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; unilateral",77066,"Diagnostic mammography, including computer-aided detection (CAD) when performed; bilateral",47.761349792665975,,Present in Autoproposal
77048,"Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; unilateral",C8904,"MAGNETIC RESONANCE IMAGING WITHOUT CONTRAST, BREAST; UNILATERAL",47.61150199938718,,Present in Autoproposal
77048,"Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; unilateral",77059,"Magnetic resonance imaging, breast, without and/or with contrast material(s); bilateral",46.787826766135076,,Present in Autoproposal
77048,"Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; unilateral",C8903,"MAGNETIC RESONANCE IMAGING WITH CONTRAST, BREAST; UNILATERAL",46.69284028241972,,Present in Autoproposal
77048,"Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; unilateral",G0202,"SCREENING MAMMOGRAPHY, BILATERAL (2-VIEW STUDY OF EACH BREAST), INCLUDING COMPUTER-AIDED DETECTION (CAD) WHEN PERFORMED",45.11905982473217,,Present in Autoproposal
77049,"Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; bilateral",77059,"Magnetic resonance imaging, breast, without and/or with contrast material(s); bilateral",53.18495533723574,1,Present Both in MD and Autoproposal
77049,"Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; bilateral",G0204,"DIAGNOSTIC MAMMOGRAPHY, INCLUDING COMPUTER-AIDED DETECTION (CAD) WHEN PERFORMED; BILATERAL",53.124537924774884,,Present in Autoproposal
77049,"Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; bilateral",77066,"Diagnostic mammography, including computer-aided detection (CAD) when performed; bilateral",53.124537924774884,,Present in Autoproposal
77049,"Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; bilateral",0159T,"Computer-aided detection, including computer algorithm analysis of MRI image data for lesion detection/characterization, pharmacokinetic analysis, with further physician review for interpretation, breast MRI (List separately in addition to code for primary procedure)",52.303564056131435,,Present in Autoproposal
77049,"Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; bilateral",77067,"Screening mammography, bilateral (2-view study of each breast), including computer-aided detection (CAD) when performed",49.616227203810794,,Present in Autoproposal
77049,"Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; bilateral",G0202,"SCREENING MAMMOGRAPHY, BILATERAL (2-VIEW STUDY OF EACH BREAST), INCLUDING COMPUTER-AIDED DETECTION (CAD) WHEN PERFORMED",49.616227203810794,,Present in Autoproposal
77049,"Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; bilateral",G0206,"DIAGNOSTIC MAMMOGRAPHY, INCLUDING COMPUTER-AIDED DETECTION (CAD) WHEN PERFORMED; UNILATERAL",47.81952048050597,,Present in Autoproposal
77049,"Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; bilateral",77065,"Diagnostic mammography, including computer-aided detection (CAD) when performed; unilateral",47.81952048050597,,Present in Autoproposal
77049,"Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; bilateral",C8907,"MAGNETIC RESONANCE IMAGING WITHOUT CONTRAST, BREAST; BILATERAL",47.74019771040584,,Present in Autoproposal
77049,"Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; bilateral",77058,"Magnetic resonance imaging, breast, without and/or with contrast material(s); unilateral",46.884434311395665,,Present in Autoproposal
81163,"BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis",81162,"BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis and full duplication/deletion analysis",68.47245134684793,10,Present Both in MD and Autoproposal
81163,"BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis",S3820,COMPLETE BRCA1 AND BRCA2 GENE SEQUENCE ANALYSIS FOR SUSCEPTIBILITY TO BREAST AND OVARIAN CANCER,66.34301695442055,,Present in Autoproposal
81163,"BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis",81216,"BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis",63.98802793387848,,Present in Autoproposal
81163,"BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis",81213,"BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary breast and ovarian cancer) gene analysis; uncommon duplication/deletion variants",58.05258424058536,,Present in Autoproposal
81163,"BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis",81212,"BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary breast and ovarian cancer) gene analysis; 185delAG, 5385insC, 6174delT variants",55.03080895413789,,Present in Autoproposal
81163,"BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis",81215,"BRCA1 (breast cancer 1) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant",50.149356680099835,,Present in Autoproposal
81163,"BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis",81217,"BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant",50.149356680099835,,Present in Autoproposal
81163,"BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis",S3823,THREE-MUTATION BRCA1 AND BRCA2 ANALYSIS FOR SUSCEPTIBILITY TO BREAST AND OVARIAN CANCER IN ASHKENAZI INDIVIDUALS,49.03364983294334,,Present in Autoproposal
81163,"BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis",S3819,COMPLETE GENE SEQUENCE ANALYSIS; BRCA2 GENE,47.33059544165947,,Present in Autoproposal
81163,"BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis",S3818,COMPLETE GENE SEQUENCE ANALYSIS; BRCA1 GENE,47.33059544165947,,Present in Autoproposal
81164,"BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)",81162,"BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis and full duplication/deletion analysis",67.93621325775356,10,Present Both in MD and Autoproposal
81164,"BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)",81213,"BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary breast and ovarian cancer) gene analysis; uncommon duplication/deletion variants",63.32058108942977,,Present Both in MD and Autoproposal
81164,"BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)",S3820,COMPLETE BRCA1 AND BRCA2 GENE SEQUENCE ANALYSIS FOR SUSCEPTIBILITY TO BREAST AND OVARIAN CANCER,57.63653879258518,,Present in Autoproposal
81164,"BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)",81216,"BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis",55.68640656399081,,Present in Autoproposal
81164,"BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)",81212,"BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary breast and ovarian cancer) gene analysis; 185delAG, 5385insC, 6174delT variants",51.30058864743712,,Present Both in MD and Autoproposal
81164,"BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)",81215,"BRCA1 (breast cancer 1) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant",47.5164477504003,,Present in Autoproposal
81164,"BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)",81217,"BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant",47.5164477504003,,Present in Autoproposal
81164,"BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)",S3819,COMPLETE GENE SEQUENCE ANALYSIS; BRCA2 GENE,45.40339944759515,,Present in Autoproposal
81164,"BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)",S3818,COMPLETE GENE SEQUENCE ANALYSIS; BRCA1 GENE,45.40339944759515,,Present in Autoproposal
81164,"BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)",81433,"Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer); duplication/deletion analysis panel, must include analyses for BRCA1, BRCA2, MLH1, MSH2, and STK11",45.02028434243763,,Present in Autoproposal
81165,"BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis",81162,"BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis and full duplication/deletion analysis",74.92856631532086,1,Present Both in MD and Autoproposal
81165,"BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis",81215,"BRCA1 (breast cancer 1) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant",66.01334588402761,,Present in Autoproposal
81165,"BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis",81216,"BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis",64.4364273557763,,Present in Autoproposal
81165,"BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis",S3820,COMPLETE BRCA1 AND BRCA2 GENE SEQUENCE ANALYSIS FOR SUSCEPTIBILITY TO BREAST AND OVARIAN CANCER,64.41165825614613,,Present in Autoproposal
81165,"BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis",S3818,COMPLETE GENE SEQUENCE ANALYSIS; BRCA1 GENE,62.30291223311117,,Present in Autoproposal
81165,"BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis",81213,"BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary breast and ovarian cancer) gene analysis; uncommon duplication/deletion variants",59.1409000373028,,Present in Autoproposal
81165,"BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis",81212,"BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary breast and ovarian cancer) gene analysis; 185delAG, 5385insC, 6174delT variants",56.0624753213529,,Present in Autoproposal
81165,"BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis",81433,"Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer); duplication/deletion analysis panel, must include analyses for BRCA1, BRCA2, MLH1, MSH2, and STK11",48.452040650844744,,Present in Autoproposal
81165,"BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis",81217,"BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant",46.44724467274596,,Present in Autoproposal
81165,"BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis",81432,"Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer); genomic sequence analysis panel, must include sequencing of at least 10 genes, always including BRCA1, BRCA2, CDH1, MLH1, MSH2, MSH6, PALB2, PTEN, STK11, and TP53",45.39317863281253,,Present in Autoproposal
81166,"BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)",81162,"BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis and full duplication/deletion analysis",70.5243708641041,10,Present Both in MD and Autoproposal
81166,"BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)",81213,"BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary breast and ovarian cancer) gene analysis; uncommon duplication/deletion variants",63.18880228120658,,Present Both in MD and Autoproposal
81166,"BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)",81215,"BRCA1 (breast cancer 1) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant",58.04092497803186,,Present in Autoproposal
81166,"BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)",S3818,COMPLETE GENE SEQUENCE ANALYSIS; BRCA1 GENE,55.45985497333989,,Present in Autoproposal
81166,"BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)",81216,"BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis",51.80073752258531,,Present in Autoproposal
81166,"BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)",S3820,COMPLETE BRCA1 AND BRCA2 GENE SEQUENCE ANALYSIS FOR SUSCEPTIBILITY TO BREAST AND OVARIAN CANCER,51.622229318259016,,Present in Autoproposal
81166,"BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)",81212,"BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary breast and ovarian cancer) gene analysis; 185delAG, 5385insC, 6174delT variants",49.243378418383294,,Present Both in MD and Autoproposal
81166,"BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)",81433,"Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer); duplication/deletion analysis panel, must include analyses for BRCA1, BRCA2, MLH1, MSH2, and STK11",46.47075698203367,,Present in Autoproposal
81166,"BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)",81217,"BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant",42.007338008464664,,Present in Autoproposal
81166,"BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)",S3823,THREE-MUTATION BRCA1 AND BRCA2 ANALYSIS FOR SUSCEPTIBILITY TO BREAST AND OVARIAN CANCER IN ASHKENAZI INDIVIDUALS,36.650030478647885,,Present in Autoproposal
81167,"BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)",81162,"BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis and full duplication/deletion analysis",70.5243708641041,7,Present in Autoproposal
81167,"BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)",81216,"BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis",68.02045815071564,,Present Both in MD and Autoproposal
81167,"BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)",81213,"BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary breast and ovarian cancer) gene analysis; uncommon duplication/deletion variants",63.18880228120658,,Present Both in MD and Autoproposal
81167,"BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)",81217,"BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant",58.04092497803186,,Present in Autoproposal
81167,"BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)",S3819,COMPLETE GENE SEQUENCE ANALYSIS; BRCA2 GENE,55.45985497333989,,Present in Autoproposal
81167,"BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)",S3820,COMPLETE BRCA1 AND BRCA2 GENE SEQUENCE ANALYSIS FOR SUSCEPTIBILITY TO BREAST AND OVARIAN CANCER,51.622229318259016,,Present in Autoproposal
81167,"BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)",81212,"BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary breast and ovarian cancer) gene analysis; 185delAG, 5385insC, 6174delT variants",49.243378418383294,,Present Both in MD and Autoproposal
81167,"BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)",81433,"Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer); duplication/deletion analysis panel, must include analyses for BRCA1, BRCA2, MLH1, MSH2, and STK11",46.47075698203367,,Present in Autoproposal
81167,"BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)",81215,"BRCA1 (breast cancer 1) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant",42.007338008464664,,Present in Autoproposal
81167,"BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements)",S3823,THREE-MUTATION BRCA1 AND BRCA2 ANALYSIS FOR SUSCEPTIBILITY TO BREAST AND OVARIAN CANCER IN ASHKENAZI INDIVIDUALS,36.650030478647885,,Present in Autoproposal
81171,"AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental retardation 2 [FRAXE]) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",81243,"FMR1 (fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",85.62236959784198,10,Present Both in MD and Autoproposal
81171,"AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental retardation 2 [FRAXE]) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",81244,"FMR1 (Fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; characterization of alleles (eg, expanded size and methylation status)",67.74853151359468,,Present in Autoproposal
81171,"AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental retardation 2 [FRAXE]) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",81342,"TRG@ (T cell antigen receptor, gamma) (eg, leukemia and lymphoma), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)",32.33173387860163,,Present in Autoproposal
81171,"AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental retardation 2 [FRAXE]) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",81264,"IGK@ (Immunoglobulin kappa light chain locus) (eg, leukemia and lymphoma, B-cell), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)",29.292367064168722,,Present in Autoproposal
81171,"AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental retardation 2 [FRAXE]) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",81231,"CYP3A5 (cytochrome P450 family 3 subfamily A member 5) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *5, *6, *7)",28.194332239335495,,Present in Autoproposal
81171,"AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental retardation 2 [FRAXE]) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",81341,"TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using direct probe methodology (eg, Southern blot)",27.76880094591751,,Present in Autoproposal
81171,"AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental retardation 2 [FRAXE]) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",81230,"CYP3A4 (cytochrome P450 family 3 subfamily A member 4) (eg, drug metabolism), gene analysis, common variant(s) (eg, *2, *22)",27.202467826165872,,Present in Autoproposal
81171,"AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental retardation 2 [FRAXE]) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",81340,"TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using amplification methodology (eg, polymerase chain reaction)",27.04920753999137,,Present in Autoproposal
81171,"AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental retardation 2 [FRAXE]) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",81262,"IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); direct probe methodology (eg, Southern blot)",26.241075406609266,,Present in Autoproposal
81171,"AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental retardation 2 [FRAXE]) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",81261,"IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); amplified methodology (eg, polymerase chain reaction)",24.852559039633,,Present in Autoproposal
81172,"AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental retardation 2 [FRAXE]) gene analysis; characterization of alleles (eg, expanded size and methylation status)",81244,"FMR1 (Fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; characterization of alleles (eg, expanded size and methylation status)",86.10302107855942,1,Present Both in MD and Autoproposal
81172,"AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental retardation 2 [FRAXE]) gene analysis; characterization of alleles (eg, expanded size and methylation status)",81243,"FMR1 (fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",66.61963393031785,,Present in Autoproposal
81172,"AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental retardation 2 [FRAXE]) gene analysis; characterization of alleles (eg, expanded size and methylation status)",81231,"CYP3A5 (cytochrome P450 family 3 subfamily A member 5) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *5, *6, *7)",27.2238950059976,,Present in Autoproposal
81172,"AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental retardation 2 [FRAXE]) gene analysis; characterization of alleles (eg, expanded size and methylation status)",81230,"CYP3A4 (cytochrome P450 family 3 subfamily A member 4) (eg, drug metabolism), gene analysis, common variant(s) (eg, *2, *22)",26.266170154949602,,Present in Autoproposal
81172,"AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental retardation 2 [FRAXE]) gene analysis; characterization of alleles (eg, expanded size and methylation status)",81327,"SEPT9 (Septin9) (eg, colorectal cancer) methylation analysis",22.636123284854143,,Present in Autoproposal
81172,"AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental retardation 2 [FRAXE]) gene analysis; characterization of alleles (eg, expanded size and methylation status)",81328,"SLCO1B1 (solute carrier organic anion transporter family, member 1B1) (eg, adverse drug reaction), gene analysis, common variant(s) (eg, *5)",21.46639975758502,,Present in Autoproposal
81172,"AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental retardation 2 [FRAXE]) gene analysis; characterization of alleles (eg, expanded size and methylation status)",0031U,"CYP1A2 (cytochrome P450 family 1, subfamily A, member 2)(eg, drug metabolism) gene analysis, common variants (ie, *1F, *1K, *6, *7)",20.86961934417258,,Present in Autoproposal
81172,"AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental retardation 2 [FRAXE]) gene analysis; characterization of alleles (eg, expanded size and methylation status)",G8364,PATIENT DOCUMENTED TO HAVE MENTAL STATUS ASSESSED,20.792231498619913,,Present in Autoproposal
81172,"AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental retardation 2 [FRAXE]) gene analysis; characterization of alleles (eg, expanded size and methylation status)",G8365,PATIENT NOT DOCUMENTED TO HAVE MENTAL STATUS ASSESSED,20.058684877507687,,Present in Autoproposal
81172,"AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental retardation 2 [FRAXE]) gene analysis; characterization of alleles (eg, expanded size and methylation status)",81288,"MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; promoter methylation analysis",19.981038733156225,,Present in Autoproposal
81173,"AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; full gene sequence",81408,"Molecular pathology procedure, Level 9 (eg, analysis of >50 exons in a single gene by DNA sequence analysis) ABCA4 (ATP-binding cassette, sub-family A [ABC1], member 4) (eg, Stargardt disease, age-related macular degeneration), full gene sequence ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia), full gene sequence CDH23 (cadherin-related 23) (eg, Usher syndrome, type 1), full gene sequence CEP290 (centrosomal protein 290kDa) (eg, Joubert syndrome), full gene sequence COL1A1 (collagen, type I, alpha 1) (eg, osteogenesis imperfecta, type I), full gene sequence COL1A2 (collagen, type I, alpha 2) (eg, osteogenesis imperfecta, type I), full gene sequence COL4A1 (collagen, type IV, alpha 1) (eg, brain small-vessel disease with hemorrhage), full gene sequence COL4A3 (collagen, type IV, alpha 3 [Goodpasture antigen]) (eg, Alport syndrome), full gene sequence COL4A5 (collagen, type IV, alpha 5) (eg, Alport syndrome), full gene sequence DMD (dystrophin) (eg, Duchenne/Becker muscular dystrophy), full gene sequence DYSF (dysferlin, limb girdle muscular dystrophy 2B [autosomal recessive]) (eg, limb-girdle muscular dystrophy), full gene sequence FBN1 (fibrillin 1) (eg, Marfan syndrome), full gene sequence ITPR1 (inositol 1,4,5-trisphosphate receptor, type 1) (eg, spinocerebellar ataxia), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LRRK2 (leucine-rich repeat kinase 2) (eg, Parkinson disease), full gene sequence MYH11 (myosin, heavy chain 11, smooth muscle) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence NEB (nebulin) (eg, nemaline myopathy 2), full gene sequence NF1 (neurofibromin 1) (eg, neurofibromatosis, type 1), full gene sequence PKHD1 (polycystic kidney and hepatic disease 1) (eg, autosomal recessive polycystic kidney disease), full gene sequence RYR1 (ryanodine receptor 1, skeletal) (eg, malignant hyperthermia), full gene sequence RYR2 (ryanodine receptor 2 [cardiac]) (eg, cate01cholaminergic polymorphic ventricular tachycardia, arrhythmogenic right ventricular dysplasia), full gene sequence or targeted sequence analysis of > 50 exons USH2A (Usher syndrome 2A [autosomal recessive, mild]) (eg, Usher syndrome, type 2), full gene sequence VPS13B (vacuolar protein sorting 13 homolog B [yeast]) (eg, Cohen syndrome), full gene sequence VWF (von Willebrand factor) (eg, von Willebrand disease types 1 and 3), full gene sequence",54.405643731630335,10,Present in Autoproposal
81173,"AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; full gene sequence",81406,"Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2 [S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-girdle muscular dystrophy), full gene sequence ANOS1 (anosmin-1) (eg, Kallmann syndrome 1), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+ transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Bera08, arrhythmogenic right ventricular cardiomyopathy), full gene sequence TNNT2 (troponin T, type 2 [cardiac]) (eg, familial hypertrophic cardiomyopathy), full gene sequence TRPC6 (transient receptor potential cation channel, subfamily C, member 6) (eg, focal segmental glomerulosclerosis), full gene sequence TSC1 (tuberous sclerosis 1) (eg, tuberous sclerosis), full gene sequence TSC2 (tuberous sclerosis 2) (eg, tuberous sclerosis), duplication/deletion analysis UBE3A (ubiquitin protein ligase E3A) (eg, Angelman syndrome), full gene sequence UMOD (uromodulin) (eg, glomerulocystic kidney disease with hyperuricemia and isosthenuria), full gene sequence VWF (von Willebrand factor) (von Willebrand disease type 2A), extended targeted sequence analysis (eg, exons 11-16, 24-26, 51, 52) WAS (Wiskott-Aldrich syndrome [eczema-thrombocytopenia]) (eg, Wiskott-Aldrich syndrome), full gene sequence",50.05119413873559,,Present in Autoproposal
81173,"AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; full gene sequence",S3819,COMPLETE GENE SEQUENCE ANALYSIS; BRCA2 GENE,44.682505730724465,,Present in Autoproposal
81173,"AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; full gene sequence",S3818,COMPLETE GENE SEQUENCE ANALYSIS; BRCA1 GENE,44.682505730724465,,Present in Autoproposal
81173,"AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; full gene sequence",S3828,COMPLETE GENE SEQUENCE ANALYSIS; MLH1 GENE,44.58512583247796,,Present in Autoproposal
81173,"AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; full gene sequence",S3829,COMPLETE GENE SEQUENCE ANALYSIS; MSH2 GENE,44.478968602867965,,Present in Autoproposal
81173,"AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; full gene sequence",81249,"G6PD (glucose-6-phosphate dehydrogenase) (eg, hemolytic anemia, jaundice), gene analysis; full gene sequence",35.22584475647071,,Present in Autoproposal
81173,"AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; full gene sequence",81162,"BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis and full duplication/deletion analysis",32.29715902254042,,Present in Autoproposal
81173,"AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; full gene sequence",81216,"BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis",31.565061423483844,,Present in Autoproposal
81173,"AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; full gene sequence",81252,"GJB2 (gap junction protein, beta 2, 26kDa, connexin 26) (eg, nonsyndromic hearing loss) gene analysis; full gene sequence",30.31215427224051,,Present Both in MD and Autoproposal
81174,"AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; known familial variant",81217,"BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant",35.73863595010168,10,Present in Autoproposal
81174,"AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; known familial variant",81215,"BRCA1 (breast cancer 1) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant",35.73863595010168,,Present in Autoproposal
81174,"AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; known familial variant",81248,"G6PD (glucose-6-phosphate dehydrogenase) (eg, hemolytic anemia, jaundice), gene analysis; known familial variant(s)",33.59250120977861,,Present in Autoproposal
81174,"AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; known familial variant",81303,"MECP2 (methyl CpG binding protein 2) (eg, Rett syndrome) gene analysis; known familial variant",32.96189801175514,,Present in Autoproposal
81174,"AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; known familial variant",81322,"PTEN (phosphatase and tensin homolog) (eg, Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; known familial variant",27.41816667458178,,Present in Autoproposal
81174,"AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; known familial variant",81326,"PMP22 (peripheral myelin protein 22) (eg, Charcot-Marie-Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; known familial variant",27.019305869567205,,Present in Autoproposal
81174,"AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; known familial variant",81202,"APC (adenomatous polyposis coli) (eg, familial adenomatosis polyposis [FAP], attenuated FAP) gene analysis; known familial variants",24.772720807563825,,Present in Autoproposal
81174,"AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; known familial variant",81258,"HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis; known familial variant",24.21142405836289,,Present in Autoproposal
81174,"AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; known familial variant",81402,"Molecular pathology procedure, Level 3 (eg, >10 SNPs, 2-10 methylated variants, or 2-10 somatic variants [typically using non-sequencing target variant analysis], immunoglobulin and T-cell receptor gene rearrangements, duplication/deletion variants of 1 exon, loss of heterozygosity [LOH], uniparental disomy [UPD]) Chromosome 1p-/19q- (eg, glial tumors), deletion analysis Chromosome 18q- (eg, D18S55, D18S58, D18S61, D18S64, and D18S69) (eg, colon cancer), allelic imbalance assessment (ie, loss of heterozygosity) COL1A1/PDGFB (t(17;22)) (eg, dermatofibrosarcoma protuberans), translocation analysis, multiple breakpoints, qualitative, and quantitative, if performed CYP21A2 (cytochrome P450, family 21, subfamily A, polypeptide 2) (eg, congenital adrenal hyperplasia, 21-hydroxylase deficiency), common variants (eg, IVS2-13G, P30L, I172N, exon 6 mutation cluster [I235N, V236E, M238K], V281L, L307FfsX6, Q318X, R356W, P453S, G110VfsX21, 30-kb deletion variant) ESR1/PGR (receptor 1/progesterone receptor) ratio (eg, breast cancer) IGH@/BCL2 (t(14;18)) (eg, follicular lymphoma), translocation analysis; major breakpoint region (MBR) and minor cluster region (mcr) breakpoints, qualitative or quantitative MEFV (Mediterranean fever) (eg, familial Mediterranean fever), common variants (eg, E148Q, P369S, F479L, M680I, I692del, M694V, M694I, K695R, V726A, A744S, R761H) MPL (myeloproliferative leukemia virus oncogene, thrombopoietin receptor, TPOR) (eg, myeloproliferative disorder), common variants (eg, W515A, W515K, W515L, W515R) TRD@ (T cell antigen receptor, delta) (eg, leukemia and lymphoma), gene rearrangement analysis, evaluation to detect abnormal clonal population Uniparental disomy (UPD) (eg, Russell-Silver syndrome, Prader-Willi/Angelman syndrome), short tandem repeat (STR) analysis",24.15148383582701,,Present in Autoproposal
81174,"AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; known familial variant",81299,"MSH6 (mutS homolog 6 [E. coli]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; known familial variants",24.074084102078714,,Present in Autoproposal
81177,"ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81243,"FMR1 (fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",48.012319602547485,10,Present Both in MD and Autoproposal
81177,"ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81342,"TRG@ (T cell antigen receptor, gamma) (eg, leukemia and lymphoma), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)",39.12958141758766,,Present in Autoproposal
81177,"ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81264,"IGK@ (Immunoglobulin kappa light chain locus) (eg, leukemia and lymphoma, B-cell), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)",35.45117828369391,,Present in Autoproposal
81177,"ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81341,"TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using direct probe methodology (eg, Southern blot)",33.607277653649284,,Present in Autoproposal
81177,"ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81340,"TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using amplification methodology (eg, polymerase chain reaction)",32.73638749754226,,Present in Autoproposal
81177,"ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81262,"IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); direct probe methodology (eg, Southern blot)",31.75834307134239,,Present in Autoproposal
81177,"ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81261,"IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); amplified methodology (eg, polymerase chain reaction)",30.077886822529525,,Present in Autoproposal
81177,"ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81244,"FMR1 (Fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; characterization of alleles (eg, expanded size and methylation status)",27.38466839485615,,Present in Autoproposal
81177,"ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",S3819,COMPLETE GENE SEQUENCE ANALYSIS; BRCA2 GENE,23.54139360548389,,Present in Autoproposal
81177,"ATN1 (atrophin 1) (eg, dentatorubral-pallidoluysian atrophy) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",S3818,COMPLETE GENE SEQUENCE ANALYSIS; BRCA1 GENE,23.54139360548389,,Present in Autoproposal
81178,"ATXN1 (ataxin 1) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81243,"FMR1 (fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",44.40812219820924,1,Present Both in MD and Autoproposal
81178,"ATXN1 (ataxin 1) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81342,"TRG@ (T cell antigen receptor, gamma) (eg, leukemia and lymphoma), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)",36.1921949937368,,Present in Autoproposal
81178,"ATXN1 (ataxin 1) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81264,"IGK@ (Immunoglobulin kappa light chain locus) (eg, leukemia and lymphoma, B-cell), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)",32.78992288490159,,Present in Autoproposal
81178,"ATXN1 (ataxin 1) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81341,"TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using direct probe methodology (eg, Southern blot)",31.084440517496205,,Present in Autoproposal
81178,"ATXN1 (ataxin 1) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81340,"TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using amplification methodology (eg, polymerase chain reaction)",30.278926499557237,,Present in Autoproposal
81178,"ATXN1 (ataxin 1) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81262,"IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); direct probe methodology (eg, Southern blot)",29.374302087458283,,Present in Autoproposal
81178,"ATXN1 (ataxin 1) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81261,"IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); amplified methodology (eg, polymerase chain reaction)",27.81999462921029,,Present in Autoproposal
81178,"ATXN1 (ataxin 1) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81244,"FMR1 (Fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; characterization of alleles (eg, expanded size and methylation status)",25.328951204675505,,Present in Autoproposal
81178,"ATXN1 (ataxin 1) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81408,"Molecular pathology procedure, Level 9 (eg, analysis of >50 exons in a single gene by DNA sequence analysis) ABCA4 (ATP-binding cassette, sub-family A [ABC1], member 4) (eg, Stargardt disease, age-related macular degeneration), full gene sequence ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia), full gene sequence CDH23 (cadherin-related 23) (eg, Usher syndrome, type 1), full gene sequence CEP290 (centrosomal protein 290kDa) (eg, Joubert syndrome), full gene sequence COL1A1 (collagen, type I, alpha 1) (eg, osteogenesis imperfecta, type I), full gene sequence COL1A2 (collagen, type I, alpha 2) (eg, osteogenesis imperfecta, type I), full gene sequence COL4A1 (collagen, type IV, alpha 1) (eg, brain small-vessel disease with hemorrhage), full gene sequence COL4A3 (collagen, type IV, alpha 3 [Goodpasture antigen]) (eg, Alport syndrome), full gene sequence COL4A5 (collagen, type IV, alpha 5) (eg, Alport syndrome), full gene sequence DMD (dystrophin) (eg, Duchenne/Becker muscular dystrophy), full gene sequence DYSF (dysferlin, limb girdle muscular dystrophy 2B [autosomal recessive]) (eg, limb-girdle muscular dystrophy), full gene sequence FBN1 (fibrillin 1) (eg, Marfan syndrome), full gene sequence ITPR1 (inositol 1,4,5-trisphosphate receptor, type 1) (eg, spinocerebellar ataxia), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LRRK2 (leucine-rich repeat kinase 2) (eg, Parkinson disease), full gene sequence MYH11 (myosin, heavy chain 11, smooth muscle) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence NEB (nebulin) (eg, nemaline myopathy 2), full gene sequence NF1 (neurofibromin 1) (eg, neurofibromatosis, type 1), full gene sequence PKHD1 (polycystic kidney and hepatic disease 1) (eg, autosomal recessive polycystic kidney disease), full gene sequence RYR1 (ryanodine receptor 1, skeletal) (eg, malignant hyperthermia), full gene sequence RYR2 (ryanodine receptor 2 [cardiac]) (eg, cate01cholaminergic polymorphic ventricular tachycardia, arrhythmogenic right ventricular dysplasia), full gene sequence or targeted sequence analysis of > 50 exons USH2A (Usher syndrome 2A [autosomal recessive, mild]) (eg, Usher syndrome, type 2), full gene sequence VPS13B (vacuolar protein sorting 13 homolog B [yeast]) (eg, Cohen syndrome), full gene sequence VWF (von Willebrand factor) (eg, von Willebrand disease types 1 and 3), full gene sequence",24.400122395214368,,Present in Autoproposal
81178,"ATXN1 (ataxin 1) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81406,"Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2 [S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-girdle muscular dystrophy), full gene sequence ANOS1 (anosmin-1) (eg, Kallmann syndrome 1), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+ transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Bera08, arrhythmogenic right ventricular cardiomyopathy), full gene sequence TNNT2 (troponin T, type 2 [cardiac]) (eg, familial hypertrophic cardiomyopathy), full gene sequence TRPC6 (transient receptor potential cation channel, subfamily C, member 6) (eg, focal segmental glomerulosclerosis), full gene sequence TSC1 (tuberous sclerosis 1) (eg, tuberous sclerosis), full gene sequence TSC2 (tuberous sclerosis 2) (eg, tuberous sclerosis), duplication/deletion analysis UBE3A (ubiquitin protein ligase E3A) (eg, Angelman syndrome), full gene sequence UMOD (uromodulin) (eg, glomerulocystic kidney disease with hyperuricemia and isosthenuria), full gene sequence VWF (von Willebrand factor) (von Willebrand disease type 2A), extended targeted sequence analysis (eg, exons 11-16, 24-26, 51, 52) WAS (Wiskott-Aldrich syndrome [eczema-thrombocytopenia]) (eg, Wiskott-Aldrich syndrome), full gene sequence",22.85724389533324,,Present in Autoproposal
81179,"ATXN2 (ataxin 2) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81243,"FMR1 (fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",44.40812219820924,1,Present Both in MD and Autoproposal
81179,"ATXN2 (ataxin 2) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81342,"TRG@ (T cell antigen receptor, gamma) (eg, leukemia and lymphoma), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)",36.1921949937368,,Present in Autoproposal
81179,"ATXN2 (ataxin 2) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81264,"IGK@ (Immunoglobulin kappa light chain locus) (eg, leukemia and lymphoma, B-cell), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)",32.78992288490159,,Present in Autoproposal
81179,"ATXN2 (ataxin 2) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81341,"TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using direct probe methodology (eg, Southern blot)",31.084440517496205,,Present in Autoproposal
81179,"ATXN2 (ataxin 2) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81340,"TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using amplification methodology (eg, polymerase chain reaction)",30.278926499557237,,Present in Autoproposal
81179,"ATXN2 (ataxin 2) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81262,"IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); direct probe methodology (eg, Southern blot)",29.374302087458283,,Present in Autoproposal
81179,"ATXN2 (ataxin 2) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81261,"IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); amplified methodology (eg, polymerase chain reaction)",27.81999462921029,,Present in Autoproposal
81179,"ATXN2 (ataxin 2) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81244,"FMR1 (Fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; characterization of alleles (eg, expanded size and methylation status)",25.328951204675505,,Present in Autoproposal
81179,"ATXN2 (ataxin 2) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81408,"Molecular pathology procedure, Level 9 (eg, analysis of >50 exons in a single gene by DNA sequence analysis) ABCA4 (ATP-binding cassette, sub-family A [ABC1], member 4) (eg, Stargardt disease, age-related macular degeneration), full gene sequence ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia), full gene sequence CDH23 (cadherin-related 23) (eg, Usher syndrome, type 1), full gene sequence CEP290 (centrosomal protein 290kDa) (eg, Joubert syndrome), full gene sequence COL1A1 (collagen, type I, alpha 1) (eg, osteogenesis imperfecta, type I), full gene sequence COL1A2 (collagen, type I, alpha 2) (eg, osteogenesis imperfecta, type I), full gene sequence COL4A1 (collagen, type IV, alpha 1) (eg, brain small-vessel disease with hemorrhage), full gene sequence COL4A3 (collagen, type IV, alpha 3 [Goodpasture antigen]) (eg, Alport syndrome), full gene sequence COL4A5 (collagen, type IV, alpha 5) (eg, Alport syndrome), full gene sequence DMD (dystrophin) (eg, Duchenne/Becker muscular dystrophy), full gene sequence DYSF (dysferlin, limb girdle muscular dystrophy 2B [autosomal recessive]) (eg, limb-girdle muscular dystrophy), full gene sequence FBN1 (fibrillin 1) (eg, Marfan syndrome), full gene sequence ITPR1 (inositol 1,4,5-trisphosphate receptor, type 1) (eg, spinocerebellar ataxia), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LRRK2 (leucine-rich repeat kinase 2) (eg, Parkinson disease), full gene sequence MYH11 (myosin, heavy chain 11, smooth muscle) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence NEB (nebulin) (eg, nemaline myopathy 2), full gene sequence NF1 (neurofibromin 1) (eg, neurofibromatosis, type 1), full gene sequence PKHD1 (polycystic kidney and hepatic disease 1) (eg, autosomal recessive polycystic kidney disease), full gene sequence RYR1 (ryanodine receptor 1, skeletal) (eg, malignant hyperthermia), full gene sequence RYR2 (ryanodine receptor 2 [cardiac]) (eg, cate01cholaminergic polymorphic ventricular tachycardia, arrhythmogenic right ventricular dysplasia), full gene sequence or targeted sequence analysis of > 50 exons USH2A (Usher syndrome 2A [autosomal recessive, mild]) (eg, Usher syndrome, type 2), full gene sequence VPS13B (vacuolar protein sorting 13 homolog B [yeast]) (eg, Cohen syndrome), full gene sequence VWF (von Willebrand factor) (eg, von Willebrand disease types 1 and 3), full gene sequence",24.400122395214368,,Present in Autoproposal
81179,"ATXN2 (ataxin 2) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81406,"Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2 [S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-girdle muscular dystrophy), full gene sequence ANOS1 (anosmin-1) (eg, Kallmann syndrome 1), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+ transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Bera08, arrhythmogenic right ventricular cardiomyopathy), full gene sequence TNNT2 (troponin T, type 2 [cardiac]) (eg, familial hypertrophic cardiomyopathy), full gene sequence TRPC6 (transient receptor potential cation channel, subfamily C, member 6) (eg, focal segmental glomerulosclerosis), full gene sequence TSC1 (tuberous sclerosis 1) (eg, tuberous sclerosis), full gene sequence TSC2 (tuberous sclerosis 2) (eg, tuberous sclerosis), duplication/deletion analysis UBE3A (ubiquitin protein ligase E3A) (eg, Angelman syndrome), full gene sequence UMOD (uromodulin) (eg, glomerulocystic kidney disease with hyperuricemia and isosthenuria), full gene sequence VWF (von Willebrand factor) (von Willebrand disease type 2A), extended targeted sequence analysis (eg, exons 11-16, 24-26, 51, 52) WAS (Wiskott-Aldrich syndrome [eczema-thrombocytopenia]) (eg, Wiskott-Aldrich syndrome), full gene sequence",22.85724389533324,,Present in Autoproposal
81180,"ATXN3 (ataxin 3) (eg, spinocerebellar ataxia, Machado-Joseph disease) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81243,"FMR1 (fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",43.41450742648198,10,Present Both in MD and Autoproposal
81180,"ATXN3 (ataxin 3) (eg, spinocerebellar ataxia, Machado-Joseph disease) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81342,"TRG@ (T cell antigen receptor, gamma) (eg, leukemia and lymphoma), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)",35.382408454992756,,Present in Autoproposal
81180,"ATXN3 (ataxin 3) (eg, spinocerebellar ataxia, Machado-Joseph disease) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81264,"IGK@ (Immunoglobulin kappa light chain locus) (eg, leukemia and lymphoma, B-cell), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)",32.056260885035506,,Present in Autoproposal
81180,"ATXN3 (ataxin 3) (eg, spinocerebellar ataxia, Machado-Joseph disease) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81341,"TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using direct probe methodology (eg, Southern blot)",30.388938034162035,,Present in Autoproposal
81180,"ATXN3 (ataxin 3) (eg, spinocerebellar ataxia, Machado-Joseph disease) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81340,"TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using amplification methodology (eg, polymerase chain reaction)",29.60144708469431,,Present in Autoproposal
81180,"ATXN3 (ataxin 3) (eg, spinocerebellar ataxia, Machado-Joseph disease) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81262,"IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); direct probe methodology (eg, Southern blot)",28.717063298278976,,Present in Autoproposal
81180,"ATXN3 (ataxin 3) (eg, spinocerebellar ataxia, Machado-Joseph disease) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81261,"IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); amplified methodology (eg, polymerase chain reaction)",27.197532875714415,,Present in Autoproposal
81180,"ATXN3 (ataxin 3) (eg, spinocerebellar ataxia, Machado-Joseph disease) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81408,"Molecular pathology procedure, Level 9 (eg, analysis of >50 exons in a single gene by DNA sequence analysis) ABCA4 (ATP-binding cassette, sub-family A [ABC1], member 4) (eg, Stargardt disease, age-related macular degeneration), full gene sequence ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia), full gene sequence CDH23 (cadherin-related 23) (eg, Usher syndrome, type 1), full gene sequence CEP290 (centrosomal protein 290kDa) (eg, Joubert syndrome), full gene sequence COL1A1 (collagen, type I, alpha 1) (eg, osteogenesis imperfecta, type I), full gene sequence COL1A2 (collagen, type I, alpha 2) (eg, osteogenesis imperfecta, type I), full gene sequence COL4A1 (collagen, type IV, alpha 1) (eg, brain small-vessel disease with hemorrhage), full gene sequence COL4A3 (collagen, type IV, alpha 3 [Goodpasture antigen]) (eg, Alport syndrome), full gene sequence COL4A5 (collagen, type IV, alpha 5) (eg, Alport syndrome), full gene sequence DMD (dystrophin) (eg, Duchenne/Becker muscular dystrophy), full gene sequence DYSF (dysferlin, limb girdle muscular dystrophy 2B [autosomal recessive]) (eg, limb-girdle muscular dystrophy), full gene sequence FBN1 (fibrillin 1) (eg, Marfan syndrome), full gene sequence ITPR1 (inositol 1,4,5-trisphosphate receptor, type 1) (eg, spinocerebellar ataxia), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LRRK2 (leucine-rich repeat kinase 2) (eg, Parkinson disease), full gene sequence MYH11 (myosin, heavy chain 11, smooth muscle) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence NEB (nebulin) (eg, nemaline myopathy 2), full gene sequence NF1 (neurofibromin 1) (eg, neurofibromatosis, type 1), full gene sequence PKHD1 (polycystic kidney and hepatic disease 1) (eg, autosomal recessive polycystic kidney disease), full gene sequence RYR1 (ryanodine receptor 1, skeletal) (eg, malignant hyperthermia), full gene sequence RYR2 (ryanodine receptor 2 [cardiac]) (eg, cate01cholaminergic polymorphic ventricular tachycardia, arrhythmogenic right ventricular dysplasia), full gene sequence or targeted sequence analysis of > 50 exons USH2A (Usher syndrome 2A [autosomal recessive, mild]) (eg, Usher syndrome, type 2), full gene sequence VPS13B (vacuolar protein sorting 13 homolog B [yeast]) (eg, Cohen syndrome), full gene sequence VWF (von Willebrand factor) (eg, von Willebrand disease types 1 and 3), full gene sequence",25.87273869660504,,Present in Autoproposal
81180,"ATXN3 (ataxin 3) (eg, spinocerebellar ataxia, Machado-Joseph disease) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81244,"FMR1 (Fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; characterization of alleles (eg, expanded size and methylation status)",24.76222559630607,,Present in Autoproposal
81180,"ATXN3 (ataxin 3) (eg, spinocerebellar ataxia, Machado-Joseph disease) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81406,"Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2 [S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-girdle muscular dystrophy), full gene sequence ANOS1 (anosmin-1) (eg, Kallmann syndrome 1), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+ transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Bera08, arrhythmogenic right ventricular cardiomyopathy), full gene sequence TNNT2 (troponin T, type 2 [cardiac]) (eg, familial hypertrophic cardiomyopathy), full gene sequence TRPC6 (transient receptor potential cation channel, subfamily C, member 6) (eg, focal segmental glomerulosclerosis), full gene sequence TSC1 (tuberous sclerosis 1) (eg, tuberous sclerosis), full gene sequence TSC2 (tuberous sclerosis 2) (eg, tuberous sclerosis), duplication/deletion analysis UBE3A (ubiquitin protein ligase E3A) (eg, Angelman syndrome), full gene sequence UMOD (uromodulin) (eg, glomerulocystic kidney disease with hyperuricemia and isosthenuria), full gene sequence VWF (von Willebrand factor) (von Willebrand disease type 2A), extended targeted sequence analysis (eg, exons 11-16, 24-26, 51, 52) WAS (Wiskott-Aldrich syndrome [eczema-thrombocytopenia]) (eg, Wiskott-Aldrich syndrome), full gene sequence",23.929806956119904,,Present in Autoproposal
81181,"ATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81243,"FMR1 (fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",44.40812219820924,1,Present Both in MD and Autoproposal
81181,"ATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81342,"TRG@ (T cell antigen receptor, gamma) (eg, leukemia and lymphoma), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)",36.1921949937368,,Present in Autoproposal
81181,"ATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81264,"IGK@ (Immunoglobulin kappa light chain locus) (eg, leukemia and lymphoma, B-cell), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)",32.78992288490159,,Present in Autoproposal
81181,"ATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81341,"TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using direct probe methodology (eg, Southern blot)",31.084440517496205,,Present in Autoproposal
81181,"ATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81340,"TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using amplification methodology (eg, polymerase chain reaction)",30.278926499557237,,Present in Autoproposal
81181,"ATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81262,"IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); direct probe methodology (eg, Southern blot)",29.374302087458283,,Present in Autoproposal
81181,"ATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81261,"IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); amplified methodology (eg, polymerase chain reaction)",27.81999462921029,,Present in Autoproposal
81181,"ATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81244,"FMR1 (Fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; characterization of alleles (eg, expanded size and methylation status)",25.328951204675505,,Present in Autoproposal
81181,"ATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81408,"Molecular pathology procedure, Level 9 (eg, analysis of >50 exons in a single gene by DNA sequence analysis) ABCA4 (ATP-binding cassette, sub-family A [ABC1], member 4) (eg, Stargardt disease, age-related macular degeneration), full gene sequence ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia), full gene sequence CDH23 (cadherin-related 23) (eg, Usher syndrome, type 1), full gene sequence CEP290 (centrosomal protein 290kDa) (eg, Joubert syndrome), full gene sequence COL1A1 (collagen, type I, alpha 1) (eg, osteogenesis imperfecta, type I), full gene sequence COL1A2 (collagen, type I, alpha 2) (eg, osteogenesis imperfecta, type I), full gene sequence COL4A1 (collagen, type IV, alpha 1) (eg, brain small-vessel disease with hemorrhage), full gene sequence COL4A3 (collagen, type IV, alpha 3 [Goodpasture antigen]) (eg, Alport syndrome), full gene sequence COL4A5 (collagen, type IV, alpha 5) (eg, Alport syndrome), full gene sequence DMD (dystrophin) (eg, Duchenne/Becker muscular dystrophy), full gene sequence DYSF (dysferlin, limb girdle muscular dystrophy 2B [autosomal recessive]) (eg, limb-girdle muscular dystrophy), full gene sequence FBN1 (fibrillin 1) (eg, Marfan syndrome), full gene sequence ITPR1 (inositol 1,4,5-trisphosphate receptor, type 1) (eg, spinocerebellar ataxia), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LRRK2 (leucine-rich repeat kinase 2) (eg, Parkinson disease), full gene sequence MYH11 (myosin, heavy chain 11, smooth muscle) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence NEB (nebulin) (eg, nemaline myopathy 2), full gene sequence NF1 (neurofibromin 1) (eg, neurofibromatosis, type 1), full gene sequence PKHD1 (polycystic kidney and hepatic disease 1) (eg, autosomal recessive polycystic kidney disease), full gene sequence RYR1 (ryanodine receptor 1, skeletal) (eg, malignant hyperthermia), full gene sequence RYR2 (ryanodine receptor 2 [cardiac]) (eg, cate01cholaminergic polymorphic ventricular tachycardia, arrhythmogenic right ventricular dysplasia), full gene sequence or targeted sequence analysis of > 50 exons USH2A (Usher syndrome 2A [autosomal recessive, mild]) (eg, Usher syndrome, type 2), full gene sequence VPS13B (vacuolar protein sorting 13 homolog B [yeast]) (eg, Cohen syndrome), full gene sequence VWF (von Willebrand factor) (eg, von Willebrand disease types 1 and 3), full gene sequence",24.400122395214368,,Present in Autoproposal
81181,"ATXN7 (ataxin 7) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81406,"Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2 [S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-girdle muscular dystrophy), full gene sequence ANOS1 (anosmin-1) (eg, Kallmann syndrome 1), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+ transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Bera08, arrhythmogenic right ventricular cardiomyopathy), full gene sequence TNNT2 (troponin T, type 2 [cardiac]) (eg, familial hypertrophic cardiomyopathy), full gene sequence TRPC6 (transient receptor potential cation channel, subfamily C, member 6) (eg, focal segmental glomerulosclerosis), full gene sequence TSC1 (tuberous sclerosis 1) (eg, tuberous sclerosis), full gene sequence TSC2 (tuberous sclerosis 2) (eg, tuberous sclerosis), duplication/deletion analysis UBE3A (ubiquitin protein ligase E3A) (eg, Angelman syndrome), full gene sequence UMOD (uromodulin) (eg, glomerulocystic kidney disease with hyperuricemia and isosthenuria), full gene sequence VWF (von Willebrand factor) (von Willebrand disease type 2A), extended targeted sequence analysis (eg, exons 11-16, 24-26, 51, 52) WAS (Wiskott-Aldrich syndrome [eczema-thrombocytopenia]) (eg, Wiskott-Aldrich syndrome), full gene sequence",22.85724389533324,,Present in Autoproposal
81182,"ATXN8OS (ATXN8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81243,"FMR1 (fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",38.098717012791624,10,Present Both in MD and Autoproposal
81182,"ATXN8OS (ATXN8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81342,"TRG@ (T cell antigen receptor, gamma) (eg, leukemia and lymphoma), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)",31.050090093513454,,Present in Autoproposal
81182,"ATXN8OS (ATXN8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81264,"IGK@ (Immunoglobulin kappa light chain locus) (eg, leukemia and lymphoma, B-cell), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)",28.131205081972638,,Present in Autoproposal
81182,"ATXN8OS (ATXN8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81341,"TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using direct probe methodology (eg, Southern blot)",26.668033777496625,,Present in Autoproposal
81182,"ATXN8OS (ATXN8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81340,"TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using amplification methodology (eg, polymerase chain reaction)",25.976965362527004,,Present in Autoproposal
81182,"ATXN8OS (ATXN8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81262,"IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); direct probe methodology (eg, Southern blot)",25.20086793319659,,Present in Autoproposal
81182,"ATXN8OS (ATXN8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81261,"IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); amplified methodology (eg, polymerase chain reaction)",23.86739294998621,,Present in Autoproposal
81182,"ATXN8OS (ATXN8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81408,"Molecular pathology procedure, Level 9 (eg, analysis of >50 exons in a single gene by DNA sequence analysis) ABCA4 (ATP-binding cassette, sub-family A [ABC1], member 4) (eg, Stargardt disease, age-related macular degeneration), full gene sequence ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia), full gene sequence CDH23 (cadherin-related 23) (eg, Usher syndrome, type 1), full gene sequence CEP290 (centrosomal protein 290kDa) (eg, Joubert syndrome), full gene sequence COL1A1 (collagen, type I, alpha 1) (eg, osteogenesis imperfecta, type I), full gene sequence COL1A2 (collagen, type I, alpha 2) (eg, osteogenesis imperfecta, type I), full gene sequence COL4A1 (collagen, type IV, alpha 1) (eg, brain small-vessel disease with hemorrhage), full gene sequence COL4A3 (collagen, type IV, alpha 3 [Goodpasture antigen]) (eg, Alport syndrome), full gene sequence COL4A5 (collagen, type IV, alpha 5) (eg, Alport syndrome), full gene sequence DMD (dystrophin) (eg, Duchenne/Becker muscular dystrophy), full gene sequence DYSF (dysferlin, limb girdle muscular dystrophy 2B [autosomal recessive]) (eg, limb-girdle muscular dystrophy), full gene sequence FBN1 (fibrillin 1) (eg, Marfan syndrome), full gene sequence ITPR1 (inositol 1,4,5-trisphosphate receptor, type 1) (eg, spinocerebellar ataxia), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LRRK2 (leucine-rich repeat kinase 2) (eg, Parkinson disease), full gene sequence MYH11 (myosin, heavy chain 11, smooth muscle) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence NEB (nebulin) (eg, nemaline myopathy 2), full gene sequence NF1 (neurofibromin 1) (eg, neurofibromatosis, type 1), full gene sequence PKHD1 (polycystic kidney and hepatic disease 1) (eg, autosomal recessive polycystic kidney disease), full gene sequence RYR1 (ryanodine receptor 1, skeletal) (eg, malignant hyperthermia), full gene sequence RYR2 (ryanodine receptor 2 [cardiac]) (eg, cate01cholaminergic polymorphic ventricular tachycardia, arrhythmogenic right ventricular dysplasia), full gene sequence or targeted sequence analysis of > 50 exons USH2A (Usher syndrome 2A [autosomal recessive, mild]) (eg, Usher syndrome, type 2), full gene sequence VPS13B (vacuolar protein sorting 13 homolog B [yeast]) (eg, Cohen syndrome), full gene sequence VWF (von Willebrand factor) (eg, von Willebrand disease types 1 and 3), full gene sequence",21.845070894253823,,Present in Autoproposal
81182,"ATXN8OS (ATXN8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81244,"FMR1 (Fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; characterization of alleles (eg, expanded size and methylation status)",21.73027131997608,,Present in Autoproposal
81182,"ATXN8OS (ATXN8 opposite strand [non-protein coding]) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81406,"Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2 [S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-girdle muscular dystrophy), full gene sequence ANOS1 (anosmin-1) (eg, Kallmann syndrome 1), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+ transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Bera08, arrhythmogenic right ventricular cardiomyopathy), full gene sequence TNNT2 (troponin T, type 2 [cardiac]) (eg, familial hypertrophic cardiomyopathy), full gene sequence TRPC6 (transient receptor potential cation channel, subfamily C, member 6) (eg, focal segmental glomerulosclerosis), full gene sequence TSC1 (tuberous sclerosis 1) (eg, tuberous sclerosis), full gene sequence TSC2 (tuberous sclerosis 2) (eg, tuberous sclerosis), duplication/deletion analysis UBE3A (ubiquitin protein ligase E3A) (eg, Angelman syndrome), full gene sequence UMOD (uromodulin) (eg, glomerulocystic kidney disease with hyperuricemia and isosthenuria), full gene sequence VWF (von Willebrand factor) (von Willebrand disease type 2A), extended targeted sequence analysis (eg, exons 11-16, 24-26, 51, 52) WAS (Wiskott-Aldrich syndrome [eczema-thrombocytopenia]) (eg, Wiskott-Aldrich syndrome), full gene sequence",20.897442738220263,,Present in Autoproposal
81183,"ATXN10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81243,"FMR1 (fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",43.4430618667983,1,Present Both in MD and Autoproposal
81183,"ATXN10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81342,"TRG@ (T cell antigen receptor, gamma) (eg, leukemia and lymphoma), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)",35.40568005083399,,Present in Autoproposal
81183,"ATXN10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81264,"IGK@ (Immunoglobulin kappa light chain locus) (eg, leukemia and lymphoma, B-cell), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)",32.07734481855141,,Present in Autoproposal
81183,"ATXN10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81341,"TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using direct probe methodology (eg, Southern blot)",30.40892534183429,,Present in Autoproposal
81183,"ATXN10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81340,"TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using amplification methodology (eg, polymerase chain reaction)",29.620916446531197,,Present in Autoproposal
81183,"ATXN10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81262,"IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); direct probe methodology (eg, Southern blot)",28.735950986257453,,Present in Autoproposal
81183,"ATXN10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81261,"IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); amplified methodology (eg, polymerase chain reaction)",27.215421143376222,,Present in Autoproposal
81183,"ATXN10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81244,"FMR1 (Fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; characterization of alleles (eg, expanded size and methylation status)",24.77851212205063,,Present in Autoproposal
81183,"ATXN10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81408,"Molecular pathology procedure, Level 9 (eg, analysis of >50 exons in a single gene by DNA sequence analysis) ABCA4 (ATP-binding cassette, sub-family A [ABC1], member 4) (eg, Stargardt disease, age-related macular degeneration), full gene sequence ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia), full gene sequence CDH23 (cadherin-related 23) (eg, Usher syndrome, type 1), full gene sequence CEP290 (centrosomal protein 290kDa) (eg, Joubert syndrome), full gene sequence COL1A1 (collagen, type I, alpha 1) (eg, osteogenesis imperfecta, type I), full gene sequence COL1A2 (collagen, type I, alpha 2) (eg, osteogenesis imperfecta, type I), full gene sequence COL4A1 (collagen, type IV, alpha 1) (eg, brain small-vessel disease with hemorrhage), full gene sequence COL4A3 (collagen, type IV, alpha 3 [Goodpasture antigen]) (eg, Alport syndrome), full gene sequence COL4A5 (collagen, type IV, alpha 5) (eg, Alport syndrome), full gene sequence DMD (dystrophin) (eg, Duchenne/Becker muscular dystrophy), full gene sequence DYSF (dysferlin, limb girdle muscular dystrophy 2B [autosomal recessive]) (eg, limb-girdle muscular dystrophy), full gene sequence FBN1 (fibrillin 1) (eg, Marfan syndrome), full gene sequence ITPR1 (inositol 1,4,5-trisphosphate receptor, type 1) (eg, spinocerebellar ataxia), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LRRK2 (leucine-rich repeat kinase 2) (eg, Parkinson disease), full gene sequence MYH11 (myosin, heavy chain 11, smooth muscle) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence NEB (nebulin) (eg, nemaline myopathy 2), full gene sequence NF1 (neurofibromin 1) (eg, neurofibromatosis, type 1), full gene sequence PKHD1 (polycystic kidney and hepatic disease 1) (eg, autosomal recessive polycystic kidney disease), full gene sequence RYR1 (ryanodine receptor 1, skeletal) (eg, malignant hyperthermia), full gene sequence RYR2 (ryanodine receptor 2 [cardiac]) (eg, cate01cholaminergic polymorphic ventricular tachycardia, arrhythmogenic right ventricular dysplasia), full gene sequence or targeted sequence analysis of > 50 exons USH2A (Usher syndrome 2A [autosomal recessive, mild]) (eg, Usher syndrome, type 2), full gene sequence VPS13B (vacuolar protein sorting 13 homolog B [yeast]) (eg, Cohen syndrome), full gene sequence VWF (von Willebrand factor) (eg, von Willebrand disease types 1 and 3), full gene sequence",23.869868265123216,,Present in Autoproposal
81183,"ATXN10 (ataxin 10) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81406,"Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2 [S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-girdle muscular dystrophy), full gene sequence ANOS1 (anosmin-1) (eg, Kallmann syndrome 1), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+ transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Bera08, arrhythmogenic right ventricular cardiomyopathy), full gene sequence TNNT2 (troponin T, type 2 [cardiac]) (eg, familial hypertrophic cardiomyopathy), full gene sequence TRPC6 (transient receptor potential cation channel, subfamily C, member 6) (eg, focal segmental glomerulosclerosis), full gene sequence TSC1 (tuberous sclerosis 1) (eg, tuberous sclerosis), full gene sequence TSC2 (tuberous sclerosis 2) (eg, tuberous sclerosis), duplication/deletion analysis UBE3A (ubiquitin protein ligase E3A) (eg, Angelman syndrome), full gene sequence UMOD (uromodulin) (eg, glomerulocystic kidney disease with hyperuricemia and isosthenuria), full gene sequence VWF (von Willebrand factor) (von Willebrand disease type 2A), extended targeted sequence analysis (eg, exons 11-16, 24-26, 51, 52) WAS (Wiskott-Aldrich syndrome [eczema-thrombocytopenia]) (eg, Wiskott-Aldrich syndrome), full gene sequence",22.360519010855676,,Present in Autoproposal
81184,"CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",81243,"FMR1 (fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",35.10483068965463,1,Present Both in MD and Autoproposal
81184,"CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",S3861,"GENETIC TESTING, SODIUM CHANNEL, VOLTAGE-GATED, TYPE V, ALPHA SUBUNIT (SCN5A) AND VARIANTS FOR SUSPECTED BRUGADA SYNDROME",33.03075508224665,,Present in Autoproposal
81184,"CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",81342,"TRG@ (T cell antigen receptor, gamma) (eg, leukemia and lymphoma), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)",28.61010136549592,,Present in Autoproposal
81184,"CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",81264,"IGK@ (Immunoglobulin kappa light chain locus) (eg, leukemia and lymphoma, B-cell), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)",25.920589167531144,,Present in Autoproposal
81184,"CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",81341,"TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using direct probe methodology (eg, Southern blot)",24.572397287569785,,Present in Autoproposal
81184,"CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",81340,"TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using amplification methodology (eg, polymerase chain reaction)",23.93563464555401,,Present in Autoproposal
81184,"CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",81262,"IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); direct probe methodology (eg, Southern blot)",23.220524768069872,,Present in Autoproposal
81184,"CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",81261,"IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); amplified methodology (eg, polymerase chain reaction)",21.991837368996205,,Present in Autoproposal
81184,"CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",82331,Calcium; after calcium infusion test,20.292201621823878,,Present in Autoproposal
81184,"CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",82310,Calcium; total,20.062563694203998,,Present in Autoproposal
81185,"CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; full gene sequence",81408,"Molecular pathology procedure, Level 9 (eg, analysis of >50 exons in a single gene by DNA sequence analysis) ABCA4 (ATP-binding cassette, sub-family A [ABC1], member 4) (eg, Stargardt disease, age-related macular degeneration), full gene sequence ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia), full gene sequence CDH23 (cadherin-related 23) (eg, Usher syndrome, type 1), full gene sequence CEP290 (centrosomal protein 290kDa) (eg, Joubert syndrome), full gene sequence COL1A1 (collagen, type I, alpha 1) (eg, osteogenesis imperfecta, type I), full gene sequence COL1A2 (collagen, type I, alpha 2) (eg, osteogenesis imperfecta, type I), full gene sequence COL4A1 (collagen, type IV, alpha 1) (eg, brain small-vessel disease with hemorrhage), full gene sequence COL4A3 (collagen, type IV, alpha 3 [Goodpasture antigen]) (eg, Alport syndrome), full gene sequence COL4A5 (collagen, type IV, alpha 5) (eg, Alport syndrome), full gene sequence DMD (dystrophin) (eg, Duchenne/Becker muscular dystrophy), full gene sequence DYSF (dysferlin, limb girdle muscular dystrophy 2B [autosomal recessive]) (eg, limb-girdle muscular dystrophy), full gene sequence FBN1 (fibrillin 1) (eg, Marfan syndrome), full gene sequence ITPR1 (inositol 1,4,5-trisphosphate receptor, type 1) (eg, spinocerebellar ataxia), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LRRK2 (leucine-rich repeat kinase 2) (eg, Parkinson disease), full gene sequence MYH11 (myosin, heavy chain 11, smooth muscle) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence NEB (nebulin) (eg, nemaline myopathy 2), full gene sequence NF1 (neurofibromin 1) (eg, neurofibromatosis, type 1), full gene sequence PKHD1 (polycystic kidney and hepatic disease 1) (eg, autosomal recessive polycystic kidney disease), full gene sequence RYR1 (ryanodine receptor 1, skeletal) (eg, malignant hyperthermia), full gene sequence RYR2 (ryanodine receptor 2 [cardiac]) (eg, cate01cholaminergic polymorphic ventricular tachycardia, arrhythmogenic right ventricular dysplasia), full gene sequence or targeted sequence analysis of > 50 exons USH2A (Usher syndrome 2A [autosomal recessive, mild]) (eg, Usher syndrome, type 2), full gene sequence VPS13B (vacuolar protein sorting 13 homolog B [yeast]) (eg, Cohen syndrome), full gene sequence VWF (von Willebrand factor) (eg, von Willebrand disease types 1 and 3), full gene sequence",47.53852575228535,10,Present in Autoproposal
81185,"CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; full gene sequence",81406,"Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2 [S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-girdle muscular dystrophy), full gene sequence ANOS1 (anosmin-1) (eg, Kallmann syndrome 1), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+ transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Bera08, arrhythmogenic right ventricular cardiomyopathy), full gene sequence TNNT2 (troponin T, type 2 [cardiac]) (eg, familial hypertrophic cardiomyopathy), full gene sequence TRPC6 (transient receptor potential cation channel, subfamily C, member 6) (eg, focal segmental glomerulosclerosis), full gene sequence TSC1 (tuberous sclerosis 1) (eg, tuberous sclerosis), full gene sequence TSC2 (tuberous sclerosis 2) (eg, tuberous sclerosis), duplication/deletion analysis UBE3A (ubiquitin protein ligase E3A) (eg, Angelman syndrome), full gene sequence UMOD (uromodulin) (eg, glomerulocystic kidney disease with hyperuricemia and isosthenuria), full gene sequence VWF (von Willebrand factor) (von Willebrand disease type 2A), extended targeted sequence analysis (eg, exons 11-16, 24-26, 51, 52) WAS (Wiskott-Aldrich syndrome [eczema-thrombocytopenia]) (eg, Wiskott-Aldrich syndrome), full gene sequence",46.03191994427993,,Present in Autoproposal
81185,"CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; full gene sequence",S3818,COMPLETE GENE SEQUENCE ANALYSIS; BRCA1 GENE,41.84237524644373,,Present in Autoproposal
81185,"CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; full gene sequence",S3819,COMPLETE GENE SEQUENCE ANALYSIS; BRCA2 GENE,41.84237524644373,,Present in Autoproposal
81185,"CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; full gene sequence",S3828,COMPLETE GENE SEQUENCE ANALYSIS; MLH1 GENE,41.75118505517634,,Present in Autoproposal
81185,"CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; full gene sequence",S3829,COMPLETE GENE SEQUENCE ANALYSIS; MSH2 GENE,41.6517754414176,,Present in Autoproposal
81185,"CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; full gene sequence",S3861,"GENETIC TESTING, SODIUM CHANNEL, VOLTAGE-GATED, TYPE V, ALPHA SUBUNIT (SCN5A) AND VARIANTS FOR SUSPECTED BRUGADA SYNDROME",36.30100708349749,,Present in Autoproposal
81185,"CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; full gene sequence",81249,"G6PD (glucose-6-phosphate dehydrogenase) (eg, hemolytic anemia, jaundice), gene analysis; full gene sequence",32.98680301314699,,Present in Autoproposal
81185,"CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; full gene sequence",81216,"BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis",28.596440401709124,,Present in Autoproposal
81185,"CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; full gene sequence",81252,"GJB2 (gap junction protein, beta 2, 26kDa, connexin 26) (eg, nonsyndromic hearing loss) gene analysis; full gene sequence",28.38543883887542,,Present in Autoproposal
81186,"CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; known familial variant",S3861,"GENETIC TESTING, SODIUM CHANNEL, VOLTAGE-GATED, TYPE V, ALPHA SUBUNIT (SCN5A) AND VARIANTS FOR SUSPECTED BRUGADA SYNDROME",36.709333147489254,10,Present in Autoproposal
81186,"CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; known familial variant",81217,"BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant",32.45189718139123,,Present in Autoproposal
81186,"CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; known familial variant",81215,"BRCA1 (breast cancer 1) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant",32.45189718139123,,Present in Autoproposal
81186,"CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; known familial variant",81248,"G6PD (glucose-6-phosphate dehydrogenase) (eg, hemolytic anemia, jaundice), gene analysis; known familial variant(s)",31.407294116865835,,Present in Autoproposal
81186,"CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; known familial variant",81303,"MECP2 (methyl CpG binding protein 2) (eg, Rett syndrome) gene analysis; known familial variant",30.817711936376284,,Present in Autoproposal
81186,"CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; known familial variant",81362,"HBB (hemoglobin, subunit beta) (eg, sickle cell anemia, beta thalassemia, hemoglobinopathy); known familial variant(s)",29.330280311257134,,Present in Autoproposal
81186,"CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; known familial variant",81326,"PMP22 (peripheral myelin protein 22) (eg, Charcot-Marie-Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; known familial variant",25.261688046974974,,Present in Autoproposal
81186,"CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; known familial variant",81322,"PTEN (phosphatase and tensin homolog) (eg, Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; known familial variant",24.896628037736946,,Present in Autoproposal
81186,"CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; known familial variant",81202,"APC (adenomatous polyposis coli) (eg, familial adenomatosis polyposis [FAP], attenuated FAP) gene analysis; known familial variants",23.161244339009635,,Present in Autoproposal
81186,"CACNA1A (calcium voltage-gated channel subunit alpha1 A) (eg, spinocerebellar ataxia) gene analysis; known familial variant",82331,Calcium; after calcium infusion test,22.552109020115314,,Present in Autoproposal
81187,"CNBP (CCHC-type zinc finger nucleic acid binding protein) (eg, myotonic dystrophy type 2) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81243,"FMR1 (fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",34.526265225129464,1,Present Both in MD and Autoproposal
81187,"CNBP (CCHC-type zinc finger nucleic acid binding protein) (eg, myotonic dystrophy type 2) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",S3853,GENETIC TESTING FOR MYOTONIC MUSCULAR DYSTROPHY,30.886444636349953,,Present Both in MD and Autoproposal
81187,"CNBP (CCHC-type zinc finger nucleic acid binding protein) (eg, myotonic dystrophy type 2) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",84630,Zinc,28.508809998245567,,Present in Autoproposal
81187,"CNBP (CCHC-type zinc finger nucleic acid binding protein) (eg, myotonic dystrophy type 2) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81342,"TRG@ (T cell antigen receptor, gamma) (eg, leukemia and lymphoma), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)",28.138576043725372,,Present in Autoproposal
81187,"CNBP (CCHC-type zinc finger nucleic acid binding protein) (eg, myotonic dystrophy type 2) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81302,"MECP2 (methyl CpG binding protein 2) (eg, Rett syndrome) gene analysis; full sequence analysis",26.10308572738882,,Present in Autoproposal
81187,"CNBP (CCHC-type zinc finger nucleic acid binding protein) (eg, myotonic dystrophy type 2) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81264,"IGK@ (Immunoglobulin kappa light chain locus) (eg, leukemia and lymphoma, B-cell), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)",25.493389906977583,,Present in Autoproposal
81187,"CNBP (CCHC-type zinc finger nucleic acid binding protein) (eg, myotonic dystrophy type 2) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81408,"Molecular pathology procedure, Level 9 (eg, analysis of >50 exons in a single gene by DNA sequence analysis) ABCA4 (ATP-binding cassette, sub-family A [ABC1], member 4) (eg, Stargardt disease, age-related macular degeneration), full gene sequence ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia), full gene sequence CDH23 (cadherin-related 23) (eg, Usher syndrome, type 1), full gene sequence CEP290 (centrosomal protein 290kDa) (eg, Joubert syndrome), full gene sequence COL1A1 (collagen, type I, alpha 1) (eg, osteogenesis imperfecta, type I), full gene sequence COL1A2 (collagen, type I, alpha 2) (eg, osteogenesis imperfecta, type I), full gene sequence COL4A1 (collagen, type IV, alpha 1) (eg, brain small-vessel disease with hemorrhage), full gene sequence COL4A3 (collagen, type IV, alpha 3 [Goodpasture antigen]) (eg, Alport syndrome), full gene sequence COL4A5 (collagen, type IV, alpha 5) (eg, Alport syndrome), full gene sequence DMD (dystrophin) (eg, Duchenne/Becker muscular dystrophy), full gene sequence DYSF (dysferlin, limb girdle muscular dystrophy 2B [autosomal recessive]) (eg, limb-girdle muscular dystrophy), full gene sequence FBN1 (fibrillin 1) (eg, Marfan syndrome), full gene sequence ITPR1 (inositol 1,4,5-trisphosphate receptor, type 1) (eg, spinocerebellar ataxia), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LRRK2 (leucine-rich repeat kinase 2) (eg, Parkinson disease), full gene sequence MYH11 (myosin, heavy chain 11, smooth muscle) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence NEB (nebulin) (eg, nemaline myopathy 2), full gene sequence NF1 (neurofibromin 1) (eg, neurofibromatosis, type 1), full gene sequence PKHD1 (polycystic kidney and hepatic disease 1) (eg, autosomal recessive polycystic kidney disease), full gene sequence RYR1 (ryanodine receptor 1, skeletal) (eg, malignant hyperthermia), full gene sequence RYR2 (ryanodine receptor 2 [cardiac]) (eg, cate01cholaminergic polymorphic ventricular tachycardia, arrhythmogenic right ventricular dysplasia), full gene sequence or targeted sequence analysis of > 50 exons USH2A (Usher syndrome 2A [autosomal recessive, mild]) (eg, Usher syndrome, type 2), full gene sequence VPS13B (vacuolar protein sorting 13 homolog B [yeast]) (eg, Cohen syndrome), full gene sequence VWF (von Willebrand factor) (eg, von Willebrand disease types 1 and 3), full gene sequence",24.85929101028358,,Present in Autoproposal
81187,"CNBP (CCHC-type zinc finger nucleic acid binding protein) (eg, myotonic dystrophy type 2) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81341,"TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using direct probe methodology (eg, Southern blot)",24.167417683000174,,Present in Autoproposal
81187,"CNBP (CCHC-type zinc finger nucleic acid binding protein) (eg, myotonic dystrophy type 2) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81340,"TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using amplification methodology (eg, polymerase chain reaction)",23.541149575968117,,Present in Autoproposal
81187,"CNBP (CCHC-type zinc finger nucleic acid binding protein) (eg, myotonic dystrophy type 2) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81218,"CEBPA (CCAAT/enhancer binding protein [C/EBP], alpha) (eg, acute myeloid leukemia), gene analysis, full gene sequence",23.422249933210665,,Present in Autoproposal
81188,"CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",81243,"FMR1 (fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",46.42392824957985,10,Present Both in MD and Autoproposal
81188,"CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",82610,Cystatin C,43.56757701019523,,Present in Autoproposal
81188,"CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",81342,"TRG@ (T cell antigen receptor, gamma) (eg, leukemia and lymphoma), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)",37.83505765194894,,Present in Autoproposal
81188,"CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",81264,"IGK@ (Immunoglobulin kappa light chain locus) (eg, leukemia and lymphoma, B-cell), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)",34.27834711235126,,Present in Autoproposal
81188,"CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",81341,"TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using direct probe methodology (eg, Southern blot)",32.49544823853794,,Present in Autoproposal
81188,"CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",81340,"TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using amplification methodology (eg, polymerase chain reaction)",31.65336973753937,,Present in Autoproposal
81188,"CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",81262,"IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); direct probe methodology (eg, Southern blot)",30.707681950682357,,Present in Autoproposal
81188,"CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",81261,"IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); amplified methodology (eg, polymerase chain reaction)",29.08282022837334,,Present in Autoproposal
81188,"CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",81244,"FMR1 (Fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; characterization of alleles (eg, expanded size and methylation status)",26.478701533801434,,Present in Autoproposal
81188,"CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",81406,"Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2 [S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-girdle muscular dystrophy), full gene sequence ANOS1 (anosmin-1) (eg, Kallmann syndrome 1), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+ transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Bera08, arrhythmogenic right ventricular cardiomyopathy), full gene sequence TNNT2 (troponin T, type 2 [cardiac]) (eg, familial hypertrophic cardiomyopathy), full gene sequence TRPC6 (transient receptor potential cation channel, subfamily C, member 6) (eg, focal segmental glomerulosclerosis), full gene sequence TSC1 (tuberous sclerosis 1) (eg, tuberous sclerosis), full gene sequence TSC2 (tuberous sclerosis 2) (eg, tuberous sclerosis), duplication/deletion analysis UBE3A (ubiquitin protein ligase E3A) (eg, Angelman syndrome), full gene sequence UMOD (uromodulin) (eg, glomerulocystic kidney disease with hyperuricemia and isosthenuria), full gene sequence VWF (von Willebrand factor) (von Willebrand disease type 2A), extended targeted sequence analysis (eg, exons 11-16, 24-26, 51, 52) WAS (Wiskott-Aldrich syndrome [eczema-thrombocytopenia]) (eg, Wiskott-Aldrich syndrome), full gene sequence",23.357315892318386,,Present in Autoproposal
81189,"CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; full gene sequence",81408,"Molecular pathology procedure, Level 9 (eg, analysis of >50 exons in a single gene by DNA sequence analysis) ABCA4 (ATP-binding cassette, sub-family A [ABC1], member 4) (eg, Stargardt disease, age-related macular degeneration), full gene sequence ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia), full gene sequence CDH23 (cadherin-related 23) (eg, Usher syndrome, type 1), full gene sequence CEP290 (centrosomal protein 290kDa) (eg, Joubert syndrome), full gene sequence COL1A1 (collagen, type I, alpha 1) (eg, osteogenesis imperfecta, type I), full gene sequence COL1A2 (collagen, type I, alpha 2) (eg, osteogenesis imperfecta, type I), full gene sequence COL4A1 (collagen, type IV, alpha 1) (eg, brain small-vessel disease with hemorrhage), full gene sequence COL4A3 (collagen, type IV, alpha 3 [Goodpasture antigen]) (eg, Alport syndrome), full gene sequence COL4A5 (collagen, type IV, alpha 5) (eg, Alport syndrome), full gene sequence DMD (dystrophin) (eg, Duchenne/Becker muscular dystrophy), full gene sequence DYSF (dysferlin, limb girdle muscular dystrophy 2B [autosomal recessive]) (eg, limb-girdle muscular dystrophy), full gene sequence FBN1 (fibrillin 1) (eg, Marfan syndrome), full gene sequence ITPR1 (inositol 1,4,5-trisphosphate receptor, type 1) (eg, spinocerebellar ataxia), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LRRK2 (leucine-rich repeat kinase 2) (eg, Parkinson disease), full gene sequence MYH11 (myosin, heavy chain 11, smooth muscle) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence NEB (nebulin) (eg, nemaline myopathy 2), full gene sequence NF1 (neurofibromin 1) (eg, neurofibromatosis, type 1), full gene sequence PKHD1 (polycystic kidney and hepatic disease 1) (eg, autosomal recessive polycystic kidney disease), full gene sequence RYR1 (ryanodine receptor 1, skeletal) (eg, malignant hyperthermia), full gene sequence RYR2 (ryanodine receptor 2 [cardiac]) (eg, cate01cholaminergic polymorphic ventricular tachycardia, arrhythmogenic right ventricular dysplasia), full gene sequence or targeted sequence analysis of > 50 exons USH2A (Usher syndrome 2A [autosomal recessive, mild]) (eg, Usher syndrome, type 2), full gene sequence VPS13B (vacuolar protein sorting 13 homolog B [yeast]) (eg, Cohen syndrome), full gene sequence VWF (von Willebrand factor) (eg, von Willebrand disease types 1 and 3), full gene sequence",65.47685441412455,10,Present in Autoproposal
81189,"CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; full gene sequence",81406,"Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2 [S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-girdle muscular dystrophy), full gene sequence ANOS1 (anosmin-1) (eg, Kallmann syndrome 1), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+ transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Bera08, arrhythmogenic right ventricular cardiomyopathy), full gene sequence TNNT2 (troponin T, type 2 [cardiac]) (eg, familial hypertrophic cardiomyopathy), full gene sequence TRPC6 (transient receptor potential cation channel, subfamily C, member 6) (eg, focal segmental glomerulosclerosis), full gene sequence TSC1 (tuberous sclerosis 1) (eg, tuberous sclerosis), full gene sequence TSC2 (tuberous sclerosis 2) (eg, tuberous sclerosis), duplication/deletion analysis UBE3A (ubiquitin protein ligase E3A) (eg, Angelman syndrome), full gene sequence UMOD (uromodulin) (eg, glomerulocystic kidney disease with hyperuricemia and isosthenuria), full gene sequence VWF (von Willebrand factor) (von Willebrand disease type 2A), extended targeted sequence analysis (eg, exons 11-16, 24-26, 51, 52) WAS (Wiskott-Aldrich syndrome [eczema-thrombocytopenia]) (eg, Wiskott-Aldrich syndrome), full gene sequence",64.6571589458446,,Present in Autoproposal
81189,"CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; full gene sequence",S3819,COMPLETE GENE SEQUENCE ANALYSIS; BRCA2 GENE,60.21744941397845,,Present in Autoproposal
81189,"CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; full gene sequence",S3818,COMPLETE GENE SEQUENCE ANALYSIS; BRCA1 GENE,60.21744941397845,,Present in Autoproposal
81189,"CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; full gene sequence",S3828,COMPLETE GENE SEQUENCE ANALYSIS; MLH1 GENE,60.086213060942754,,Present in Autoproposal
81189,"CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; full gene sequence",S3829,COMPLETE GENE SEQUENCE ANALYSIS; MSH2 GENE,59.94314772699546,,Present in Autoproposal
81189,"CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; full gene sequence",82610,Cystatin C,52.106823928115,,Present in Autoproposal
81189,"CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; full gene sequence",81249,"G6PD (glucose-6-phosphate dehydrogenase) (eg, hemolytic anemia, jaundice), gene analysis; full gene sequence",47.47295367611517,,Present in Autoproposal
81189,"CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; full gene sequence",81216,"BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis",41.15456384030506,,Present in Autoproposal
81189,"CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; full gene sequence",81252,"GJB2 (gap junction protein, beta 2, 26kDa, connexin 26) (eg, nonsyndromic hearing loss) gene analysis; full gene sequence",40.85090096597317,,Present Both in MD and Autoproposal
81190,"CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; known familial variant(s)",82610,Cystatin C,53.34323359857972,10,Present in Autoproposal
81190,"CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; known familial variant(s)",81215,"BRCA1 (breast cancer 1) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant",47.27951712344382,,Present in Autoproposal
81190,"CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; known familial variant(s)",81217,"BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant",47.27951712344382,,Present in Autoproposal
81190,"CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; known familial variant(s)",81248,"G6PD (glucose-6-phosphate dehydrogenase) (eg, hemolytic anemia, jaundice), gene analysis; known familial variant(s)",45.75762371301015,,Present in Autoproposal
81190,"CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; known familial variant(s)",81303,"MECP2 (methyl CpG binding protein 2) (eg, Rett syndrome) gene analysis; known familial variant",44.898655109654726,,Present in Autoproposal
81190,"CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; known familial variant(s)",81326,"PMP22 (peripheral myelin protein 22) (eg, Charcot-Marie-Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; known familial variant",36.80402430428403,,Present in Autoproposal
81190,"CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; known familial variant(s)",81322,"PTEN (phosphatase and tensin homolog) (eg, Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; known familial variant",36.27216446073223,,Present in Autoproposal
81190,"CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; known familial variant(s)",81202,"APC (adenomatous polyposis coli) (eg, familial adenomatosis polyposis [FAP], attenuated FAP) gene analysis; known familial variants",33.74386533414768,,Present in Autoproposal
81190,"CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; known familial variant(s)",81299,"MSH6 (mutS homolog 6 [E. coli]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; known familial variants",32.79222570237238,,Present in Autoproposal
81190,"CSTB (cystatin B) (eg, Unverricht-Lundborg disease) gene analysis; known familial variant(s)",81258,"HBA1/HBA2 (alpha globin 1 and alpha globin 2) (eg, alpha thalassemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis; known familial variant",32.127939803997535,,Present in Autoproposal
81204,"AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; characterization of alleles (eg, expanded size or methylation status)",81244,"FMR1 (Fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; characterization of alleles (eg, expanded size and methylation status)",39.93232127761709,1,Present Both in MD and Autoproposal
81204,"AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; characterization of alleles (eg, expanded size or methylation status)",81408,"Molecular pathology procedure, Level 9 (eg, analysis of >50 exons in a single gene by DNA sequence analysis) ABCA4 (ATP-binding cassette, sub-family A [ABC1], member 4) (eg, Stargardt disease, age-related macular degeneration), full gene sequence ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia), full gene sequence CDH23 (cadherin-related 23) (eg, Usher syndrome, type 1), full gene sequence CEP290 (centrosomal protein 290kDa) (eg, Joubert syndrome), full gene sequence COL1A1 (collagen, type I, alpha 1) (eg, osteogenesis imperfecta, type I), full gene sequence COL1A2 (collagen, type I, alpha 2) (eg, osteogenesis imperfecta, type I), full gene sequence COL4A1 (collagen, type IV, alpha 1) (eg, brain small-vessel disease with hemorrhage), full gene sequence COL4A3 (collagen, type IV, alpha 3 [Goodpasture antigen]) (eg, Alport syndrome), full gene sequence COL4A5 (collagen, type IV, alpha 5) (eg, Alport syndrome), full gene sequence DMD (dystrophin) (eg, Duchenne/Becker muscular dystrophy), full gene sequence DYSF (dysferlin, limb girdle muscular dystrophy 2B [autosomal recessive]) (eg, limb-girdle muscular dystrophy), full gene sequence FBN1 (fibrillin 1) (eg, Marfan syndrome), full gene sequence ITPR1 (inositol 1,4,5-trisphosphate receptor, type 1) (eg, spinocerebellar ataxia), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LRRK2 (leucine-rich repeat kinase 2) (eg, Parkinson disease), full gene sequence MYH11 (myosin, heavy chain 11, smooth muscle) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence NEB (nebulin) (eg, nemaline myopathy 2), full gene sequence NF1 (neurofibromin 1) (eg, neurofibromatosis, type 1), full gene sequence PKHD1 (polycystic kidney and hepatic disease 1) (eg, autosomal recessive polycystic kidney disease), full gene sequence RYR1 (ryanodine receptor 1, skeletal) (eg, malignant hyperthermia), full gene sequence RYR2 (ryanodine receptor 2 [cardiac]) (eg, cate01cholaminergic polymorphic ventricular tachycardia, arrhythmogenic right ventricular dysplasia), full gene sequence or targeted sequence analysis of > 50 exons USH2A (Usher syndrome 2A [autosomal recessive, mild]) (eg, Usher syndrome, type 2), full gene sequence VPS13B (vacuolar protein sorting 13 homolog B [yeast]) (eg, Cohen syndrome), full gene sequence VWF (von Willebrand factor) (eg, von Willebrand disease types 1 and 3), full gene sequence",23.089884486993512,,Present in Autoproposal
81204,"AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; characterization of alleles (eg, expanded size or methylation status)",81402,"Molecular pathology procedure, Level 3 (eg, >10 SNPs, 2-10 methylated variants, or 2-10 somatic variants [typically using non-sequencing target variant analysis], immunoglobulin and T-cell receptor gene rearrangements, duplication/deletion variants of 1 exon, loss of heterozygosity [LOH], uniparental disomy [UPD]) Chromosome 1p-/19q- (eg, glial tumors), deletion analysis Chromosome 18q- (eg, D18S55, D18S58, D18S61, D18S64, and D18S69) (eg, colon cancer), allelic imbalance assessment (ie, loss of heterozygosity) COL1A1/PDGFB (t(17;22)) (eg, dermatofibrosarcoma protuberans), translocation analysis, multiple breakpoints, qualitative, and quantitative, if performed CYP21A2 (cytochrome P450, family 21, subfamily A, polypeptide 2) (eg, congenital adrenal hyperplasia, 21-hydroxylase deficiency), common variants (eg, IVS2-13G, P30L, I172N, exon 6 mutation cluster [I235N, V236E, M238K], V281L, L307FfsX6, Q318X, R356W, P453S, G110VfsX21, 30-kb deletion variant) ESR1/PGR (receptor 1/progesterone receptor) ratio (eg, breast cancer) IGH@/BCL2 (t(14;18)) (eg, follicular lymphoma), translocation analysis; major breakpoint region (MBR) and minor cluster region (mcr) breakpoints, qualitative or quantitative MEFV (Mediterranean fever) (eg, familial Mediterranean fever), common variants (eg, E148Q, P369S, F479L, M680I, I692del, M694V, M694I, K695R, V726A, A744S, R761H) MPL (myeloproliferative leukemia virus oncogene, thrombopoietin receptor, TPOR) (eg, myeloproliferative disorder), common variants (eg, W515A, W515K, W515L, W515R) TRD@ (T cell antigen receptor, delta) (eg, leukemia and lymphoma), gene rearrangement analysis, evaluation to detect abnormal clonal population Uniparental disomy (UPD) (eg, Russell-Silver syndrome, Prader-Willi/Angelman syndrome), short tandem repeat (STR) analysis",22.309023898710826,,Present in Autoproposal
81204,"AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; characterization of alleles (eg, expanded size or methylation status)",81327,"SEPT9 (Septin9) (eg, colorectal cancer) methylation analysis",21.25115377222662,,Present in Autoproposal
81204,"AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; characterization of alleles (eg, expanded size or methylation status)",81243,"FMR1 (fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",20.888829198134978,,Present in Autoproposal
81204,"AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; characterization of alleles (eg, expanded size or methylation status)",81406,"Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2 [S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-girdle muscular dystrophy), full gene sequence ANOS1 (anosmin-1) (eg, Kallmann syndrome 1), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+ transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Bera08, arrhythmogenic right ventricular cardiomyopathy), full gene sequence TNNT2 (troponin T, type 2 [cardiac]) (eg, familial hypertrophic cardiomyopathy), full gene sequence TRPC6 (transient receptor potential cation channel, subfamily C, member 6) (eg, focal segmental glomerulosclerosis), full gene sequence TSC1 (tuberous sclerosis 1) (eg, tuberous sclerosis), full gene sequence TSC2 (tuberous sclerosis 2) (eg, tuberous sclerosis), duplication/deletion analysis UBE3A (ubiquitin protein ligase E3A) (eg, Angelman syndrome), full gene sequence UMOD (uromodulin) (eg, glomerulocystic kidney disease with hyperuricemia and isosthenuria), full gene sequence VWF (von Willebrand factor) (von Willebrand disease type 2A), extended targeted sequence analysis (eg, exons 11-16, 24-26, 51, 52) WAS (Wiskott-Aldrich syndrome [eczema-thrombocytopenia]) (eg, Wiskott-Aldrich syndrome), full gene sequence",20.048223580918222,,Present in Autoproposal
81204,"AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; characterization of alleles (eg, expanded size or methylation status)",G9132,"ONCOLOGY; DISEASE STATUS; PROSTATE CANCER, LIMITED TO ADENOCARCINOMA; HORMONE-REFRACTORY/ANDROGEN-INDEPENDENT (E.G., RISING PSA ON ANTI-ANDROGEN THERAPY OR POST-ORCHIECTOMY); CLINICAL METASTASES (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)",20.01371391898547,,Present in Autoproposal
81204,"AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; characterization of alleles (eg, expanded size or methylation status)",81161,"DMD (dystrophin) (eg, Duchenne/Becker muscular dystrophy) deletion analysis, and duplication analysis, if performed",19.076128940257668,,Present in Autoproposal
81204,"AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; characterization of alleles (eg, expanded size or methylation status)",81288,"MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; promoter methylation analysis",18.758518024649256,,Present in Autoproposal
81204,"AR (androgen receptor) (eg, spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis; characterization of alleles (eg, expanded size or methylation status)",88289,Chromosome analysis; additional high resolution study,18.65401641858303,,Present in Autoproposal
81233,"BTK (Bruton's tyrosine kinase) (eg, chronic lymphocytic leukemia) gene analysis, common variants (eg, C481S, C481R, C481F)",81246,"FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia), gene analysis; tyrosine kinase domain (TKD) variants (eg, D835, I836)",56.989218352887235,1,Present Both in MD and Autoproposal
81233,"BTK (Bruton's tyrosine kinase) (eg, chronic lymphocytic leukemia) gene analysis, common variants (eg, C481S, C481R, C481F)",81170,"ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) (eg, acquired imatinib tyrosine kinase inhibitor resistance), gene analysis, variants in the kinase domain",50.62535838925088,,Present in Autoproposal
81233,"BTK (Bruton's tyrosine kinase) (eg, chronic lymphocytic leukemia) gene analysis, common variants (eg, C481S, C481R, C481F)",81245,"FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia), gene analysis; internal tandem duplication (ITD) variants (ie, exons 14, 15)",44.0861370491944,,Present in Autoproposal
81233,"BTK (Bruton's tyrosine kinase) (eg, chronic lymphocytic leukemia) gene analysis, common variants (eg, C481S, C481R, C481F)",84510,Tyrosine,40.04878418142533,,Present in Autoproposal
81233,"BTK (Bruton's tyrosine kinase) (eg, chronic lymphocytic leukemia) gene analysis, common variants (eg, C481S, C481R, C481F)",81335,"TPMT (thiopurine S-methyltransferase) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3)",36.20612254834108,,Present in Autoproposal
81233,"BTK (Bruton's tyrosine kinase) (eg, chronic lymphocytic leukemia) gene analysis, common variants (eg, C481S, C481R, C481F)",81260,"IKBKAP (inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-associated protein) (eg, familial dysautonomia) gene analysis, common variants (eg, 2507+6T>C, R696P)",34.2280345616094,,Present in Autoproposal
81233,"BTK (Bruton's tyrosine kinase) (eg, chronic lymphocytic leukemia) gene analysis, common variants (eg, C481S, C481R, C481F)",G8375,CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENT WITH NO DOCUMENTATION OF BASELINE FLOW CYTOMETRY PERFORMED,33.73516179100295,,Present in Autoproposal
81233,"BTK (Bruton's tyrosine kinase) (eg, chronic lymphocytic leukemia) gene analysis, common variants (eg, C481S, C481R, C481F)",81310,"NPM1 (nucleophosmin) (eg, acute myeloid leukemia) gene analysis, exon 12 variants",33.12340144072189,,Present in Autoproposal
81233,"BTK (Bruton's tyrosine kinase) (eg, chronic lymphocytic leukemia) gene analysis, common variants (eg, C481S, C481R, C481F)",81231,"CYP3A5 (cytochrome P450 family 3 subfamily A member 5) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *5, *6, *7)",32.502399937361474,,Present in Autoproposal
81233,"BTK (Bruton's tyrosine kinase) (eg, chronic lymphocytic leukemia) gene analysis, common variants (eg, C481S, C481R, C481F)",81227,"CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *5, *6)",32.39240168511846,,Present in Autoproposal
81234,"DMPK (DM1 protein kinase) (eg, myotonic dystrophy type 1) gene analysis; evaluation to detect abnormal (expanded) alleles",81243,"FMR1 (fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",38.535753690093344,2,Present Both in MD and Autoproposal
81234,"DMPK (DM1 protein kinase) (eg, myotonic dystrophy type 1) gene analysis; evaluation to detect abnormal (expanded) alleles",S3853,GENETIC TESTING FOR MYOTONIC MUSCULAR DYSTROPHY,36.875931262356985,,Present Both in MD and Autoproposal
81234,"DMPK (DM1 protein kinase) (eg, myotonic dystrophy type 1) gene analysis; evaluation to detect abnormal (expanded) alleles",81342,"TRG@ (T cell antigen receptor, gamma) (eg, leukemia and lymphoma), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)",31.84015722644747,,Present in Autoproposal
81234,"DMPK (DM1 protein kinase) (eg, myotonic dystrophy type 1) gene analysis; evaluation to detect abnormal (expanded) alleles",81264,"IGK@ (Immunoglobulin kappa light chain locus) (eg, leukemia and lymphoma, B-cell), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)",28.847001412294265,,Present in Autoproposal
81234,"DMPK (DM1 protein kinase) (eg, myotonic dystrophy type 1) gene analysis; evaluation to detect abnormal (expanded) alleles",81341,"TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using direct probe methodology (eg, Southern blot)",25.87698531134747,,Present in Autoproposal
81234,"DMPK (DM1 protein kinase) (eg, myotonic dystrophy type 1) gene analysis; evaluation to detect abnormal (expanded) alleles",81340,"TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using amplification methodology (eg, polymerase chain reaction)",25.206415918324016,,Present in Autoproposal
81234,"DMPK (DM1 protein kinase) (eg, myotonic dystrophy type 1) gene analysis; evaluation to detect abnormal (expanded) alleles",81262,"IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); direct probe methodology (eg, Southern blot)",24.453339709312147,,Present in Autoproposal
81234,"DMPK (DM1 protein kinase) (eg, myotonic dystrophy type 1) gene analysis; evaluation to detect abnormal (expanded) alleles",81170,"ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) (eg, acquired imatinib tyrosine kinase inhibitor resistance), gene analysis, variants in the kinase domain",24.17944974236589,,Present in Autoproposal
81234,"DMPK (DM1 protein kinase) (eg, myotonic dystrophy type 1) gene analysis; evaluation to detect abnormal (expanded) alleles",81261,"IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); amplified methodology (eg, polymerase chain reaction)",23.159419323524197,,Present in Autoproposal
81234,"DMPK (DM1 protein kinase) (eg, myotonic dystrophy type 1) gene analysis; evaluation to detect abnormal (expanded) alleles",81408,"Molecular pathology procedure, Level 9 (eg, analysis of >50 exons in a single gene by DNA sequence analysis) ABCA4 (ATP-binding cassette, sub-family A [ABC1], member 4) (eg, Stargardt disease, age-related macular degeneration), full gene sequence ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia), full gene sequence CDH23 (cadherin-related 23) (eg, Usher syndrome, type 1), full gene sequence CEP290 (centrosomal protein 290kDa) (eg, Joubert syndrome), full gene sequence COL1A1 (collagen, type I, alpha 1) (eg, osteogenesis imperfecta, type I), full gene sequence COL1A2 (collagen, type I, alpha 2) (eg, osteogenesis imperfecta, type I), full gene sequence COL4A1 (collagen, type IV, alpha 1) (eg, brain small-vessel disease with hemorrhage), full gene sequence COL4A3 (collagen, type IV, alpha 3 [Goodpasture antigen]) (eg, Alport syndrome), full gene sequence COL4A5 (collagen, type IV, alpha 5) (eg, Alport syndrome), full gene sequence DMD (dystrophin) (eg, Duchenne/Becker muscular dystrophy), full gene sequence DYSF (dysferlin, limb girdle muscular dystrophy 2B [autosomal recessive]) (eg, limb-girdle muscular dystrophy), full gene sequence FBN1 (fibrillin 1) (eg, Marfan syndrome), full gene sequence ITPR1 (inositol 1,4,5-trisphosphate receptor, type 1) (eg, spinocerebellar ataxia), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LRRK2 (leucine-rich repeat kinase 2) (eg, Parkinson disease), full gene sequence MYH11 (myosin, heavy chain 11, smooth muscle) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence NEB (nebulin) (eg, nemaline myopathy 2), full gene sequence NF1 (neurofibromin 1) (eg, neurofibromatosis, type 1), full gene sequence PKHD1 (polycystic kidney and hepatic disease 1) (eg, autosomal recessive polycystic kidney disease), full gene sequence RYR1 (ryanodine receptor 1, skeletal) (eg, malignant hyperthermia), full gene sequence RYR2 (ryanodine receptor 2 [cardiac]) (eg, cate01cholaminergic polymorphic ventricular tachycardia, arrhythmogenic right ventricular dysplasia), full gene sequence or targeted sequence analysis of > 50 exons USH2A (Usher syndrome 2A [autosomal recessive, mild]) (eg, Usher syndrome, type 2), full gene sequence VPS13B (vacuolar protein sorting 13 homolog B [yeast]) (eg, Cohen syndrome), full gene sequence VWF (von Willebrand factor) (eg, von Willebrand disease types 1 and 3), full gene sequence",22.9979144594231,,Present in Autoproposal
81236,"EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (eg, myelodysplastic syndrome, myeloproliferative neoplasms) gene analysis, full gene sequence",81175,"ASXL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; full gene sequence",52.940853378119435,10,Present Both in MD and Autoproposal
81236,"EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (eg, myelodysplastic syndrome, myeloproliferative neoplasms) gene analysis, full gene sequence",81406,"Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2 [S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-girdle muscular dystrophy), full gene sequence ANOS1 (anosmin-1) (eg, Kallmann syndrome 1), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+ transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Bera08, arrhythmogenic right ventricular cardiomyopathy), full gene sequence TNNT2 (troponin T, type 2 [cardiac]) (eg, familial hypertrophic cardiomyopathy), full gene sequence TRPC6 (transient receptor potential cation channel, subfamily C, member 6) (eg, focal segmental glomerulosclerosis), full gene sequence TSC1 (tuberous sclerosis 1) (eg, tuberous sclerosis), full gene sequence TSC2 (tuberous sclerosis 2) (eg, tuberous sclerosis), duplication/deletion analysis UBE3A (ubiquitin protein ligase E3A) (eg, Angelman syndrome), full gene sequence UMOD (uromodulin) (eg, glomerulocystic kidney disease with hyperuricemia and isosthenuria), full gene sequence VWF (von Willebrand factor) (von Willebrand disease type 2A), extended targeted sequence analysis (eg, exons 11-16, 24-26, 51, 52) WAS (Wiskott-Aldrich syndrome [eczema-thrombocytopenia]) (eg, Wiskott-Aldrich syndrome), full gene sequence",46.35378289501135,,Present in Autoproposal
81236,"EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (eg, myelodysplastic syndrome, myeloproliferative neoplasms) gene analysis, full gene sequence",81408,"Molecular pathology procedure, Level 9 (eg, analysis of >50 exons in a single gene by DNA sequence analysis) ABCA4 (ATP-binding cassette, sub-family A [ABC1], member 4) (eg, Stargardt disease, age-related macular degeneration), full gene sequence ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia), full gene sequence CDH23 (cadherin-related 23) (eg, Usher syndrome, type 1), full gene sequence CEP290 (centrosomal protein 290kDa) (eg, Joubert syndrome), full gene sequence COL1A1 (collagen, type I, alpha 1) (eg, osteogenesis imperfecta, type I), full gene sequence COL1A2 (collagen, type I, alpha 2) (eg, osteogenesis imperfecta, type I), full gene sequence COL4A1 (collagen, type IV, alpha 1) (eg, brain small-vessel disease with hemorrhage), full gene sequence COL4A3 (collagen, type IV, alpha 3 [Goodpasture antigen]) (eg, Alport syndrome), full gene sequence COL4A5 (collagen, type IV, alpha 5) (eg, Alport syndrome), full gene sequence DMD (dystrophin) (eg, Duchenne/Becker muscular dystrophy), full gene sequence DYSF (dysferlin, limb girdle muscular dystrophy 2B [autosomal recessive]) (eg, limb-girdle muscular dystrophy), full gene sequence FBN1 (fibrillin 1) (eg, Marfan syndrome), full gene sequence ITPR1 (inositol 1,4,5-trisphosphate receptor, type 1) (eg, spinocerebellar ataxia), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LRRK2 (leucine-rich repeat kinase 2) (eg, Parkinson disease), full gene sequence MYH11 (myosin, heavy chain 11, smooth muscle) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence NEB (nebulin) (eg, nemaline myopathy 2), full gene sequence NF1 (neurofibromin 1) (eg, neurofibromatosis, type 1), full gene sequence PKHD1 (polycystic kidney and hepatic disease 1) (eg, autosomal recessive polycystic kidney disease), full gene sequence RYR1 (ryanodine receptor 1, skeletal) (eg, malignant hyperthermia), full gene sequence RYR2 (ryanodine receptor 2 [cardiac]) (eg, cate01cholaminergic polymorphic ventricular tachycardia, arrhythmogenic right ventricular dysplasia), full gene sequence or targeted sequence analysis of > 50 exons USH2A (Usher syndrome 2A [autosomal recessive, mild]) (eg, Usher syndrome, type 2), full gene sequence VPS13B (vacuolar protein sorting 13 homolog B [yeast]) (eg, Cohen syndrome), full gene sequence VWF (von Willebrand factor) (eg, von Willebrand disease types 1 and 3), full gene sequence",45.887589483657216,,Present in Autoproposal
81236,"EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (eg, myelodysplastic syndrome, myeloproliferative neoplasms) gene analysis, full gene sequence",81176,"ASXL1 (additional sex combs like 1, transcriptional regulator) (eg, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myelomonocytic leukemia), gene analysis; targeted sequence analysis (eg, exon 12)",44.386189850366165,,Present in Autoproposal
81236,"EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (eg, myelodysplastic syndrome, myeloproliferative neoplasms) gene analysis, full gene sequence",S3818,COMPLETE GENE SEQUENCE ANALYSIS; BRCA1 GENE,40.32243450241345,,Present in Autoproposal
81236,"EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (eg, myelodysplastic syndrome, myeloproliferative neoplasms) gene analysis, full gene sequence",S3819,COMPLETE GENE SEQUENCE ANALYSIS; BRCA2 GENE,40.32243450241345,,Present in Autoproposal
81236,"EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (eg, myelodysplastic syndrome, myeloproliferative neoplasms) gene analysis, full gene sequence",S3828,COMPLETE GENE SEQUENCE ANALYSIS; MLH1 GENE,40.23455683072333,,Present in Autoproposal
81236,"EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (eg, myelodysplastic syndrome, myeloproliferative neoplasms) gene analysis, full gene sequence",S3829,COMPLETE GENE SEQUENCE ANALYSIS; MSH2 GENE,40.13875831029785,,Present in Autoproposal
81236,"EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (eg, myelodysplastic syndrome, myeloproliferative neoplasms) gene analysis, full gene sequence",81218,"CEBPA (CCAAT/enhancer binding protein [C/EBP], alpha) (eg, acute myeloid leukemia), gene analysis, full gene sequence",37.706318597531116,,Present in Autoproposal
81236,"EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (eg, myelodysplastic syndrome, myeloproliferative neoplasms) gene analysis, full gene sequence",81249,"G6PD (glucose-6-phosphate dehydrogenase) (eg, hemolytic anemia, jaundice), gene analysis; full gene sequence",31.788544414783974,,Present in Autoproposal
81237,"EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (eg, diffuse large B-cell lymphoma) gene analysis, common variant(s) (eg, codon 646)",81276,"KRAS (Kirsten rat sarcoma viral oncogene homolog) (eg, carcinoma) gene analysis; additional variant(s) (eg, codon 61, codon 146)",33.88021588336293,10,Present in Autoproposal
81237,"EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (eg, diffuse large B-cell lymphoma) gene analysis, common variant(s) (eg, codon 646)",G9121,"ONCOLOGY; DISEASE STATUS; NON-HODGKIN'S LYMPHOMA, LIMITED TO FOLLICULAR LYMPHOMA, MANTLE CELL LYMPHOMA, DIFFUSE LARGE B-CELL LYMPHOMA, SMALL LYMPHOCYTIC LYMPHOMA; RELAPSED/REFRACTORY (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)",33.64586783609626,,Present in Autoproposal
81237,"EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (eg, diffuse large B-cell lymphoma) gene analysis, common variant(s) (eg, codon 646)",G9120,ONCOLOGY; DISEASE STATUS; NON-HODGKIN'S LYMPHOMA; TRANSFORMED FROM FOLLICULAR LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT),33.18978314528498,,Present in Autoproposal
81237,"EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (eg, diffuse large B-cell lymphoma) gene analysis, common variant(s) (eg, codon 646)",81355,"VKORC1 (vitamin K epoxide reductase complex, subunit 1) (eg, warfarin metabolism), gene analysis, common variant(s) (eg, -1639G>A, c.173+1000C>T)",32.8047958509666,,Present in Autoproposal
81237,"EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (eg, diffuse large B-cell lymphoma) gene analysis, common variant(s) (eg, codon 646)",G9119,"ONCOLOGY; DISEASE STATUS; NON-HODGKIN'S LYMPHOMA, LIMITED TO FOLLICULAR LYMPHOMA, MANTLE CELL LYMPHOMA, DIFFUSE LARGE B-CELL LYMPHOMA, SMALL LYMPHOCYTIC LYMPHOMA; STAGE III, IV NOT RELAPSED, NOT REFRACTORY (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)",32.49040508735639,,Present in Autoproposal
81237,"EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (eg, diffuse large B-cell lymphoma) gene analysis, common variant(s) (eg, codon 646)",G9118,"ONCOLOGY; DISEASE STATUS; NON-HODGKIN'S LYMPHOMA, LIMITED TO FOLLICULAR LYMPHOMA, MANTLE CELL LYMPHOMA, DIFFUSE LARGE B-CELL LYMPHOMA, SMALL LYMPHOCYTIC LYMPHOMA; STAGE I, II AT DIAGNOSIS, NOT RELAPSED, NOT REFRACTORY (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)",32.45097106998072,,Present in Autoproposal
81237,"EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (eg, diffuse large B-cell lymphoma) gene analysis, common variant(s) (eg, codon 646)",G9122,"ONCOLOGY; DISEASE STATUS; NON-HODGKIN'S LYMPHOMA, LIMITED TO FOLLICULAR LYMPHOMA, MANTLE CELL LYMPHOMA, DIFFUSE LARGE B-CELL LYMPHOMA, SMALL LYMPHOCYTIC LYMPHOMA; DIAGNOSTIC EVALUATION, STAGE NOT DETERMINED, EVALUATION OF POSSIBLE RELAPSE OR NON-RESPONSE TO THERAPY, OR NOT LISTED  (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)",30.86824926783862,,Present in Autoproposal
81237,"EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (eg, diffuse large B-cell lymphoma) gene analysis, common variant(s) (eg, codon 646)",81260,"IKBKAP (inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-associated protein) (eg, familial dysautonomia) gene analysis, common variants (eg, 2507+6T>C, R696P)",29.89851174519026,,Present in Autoproposal
81237,"EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (eg, diffuse large B-cell lymphoma) gene analysis, common variant(s) (eg, codon 646)",81247,"G6PD (glucose-6-phosphate dehydrogenase) (eg, hemolytic anemia, jaundice), gene analysis; common variant(s) (eg, A, A-)",27.45809939095862,,Present in Autoproposal
81237,"EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (eg, diffuse large B-cell lymphoma) gene analysis, common variant(s) (eg, codon 646)",81346,"TYMS (thymidylate synthetase) (eg, 5-fluorouracil/5-FU drug metabolism), gene analysis, common variant(s) (eg, tandem repeat variant)",27.44230253378244,,Present in Autoproposal
81239,"DMPK (DM1 protein kinase) (eg, myotonic dystrophy type 1) gene analysis; characterization of alleles (eg, expanded size)",S3853,GENETIC TESTING FOR MYOTONIC MUSCULAR DYSTROPHY,37.40711830619553,1,Present Both in MD and Autoproposal
81239,"DMPK (DM1 protein kinase) (eg, myotonic dystrophy type 1) gene analysis; characterization of alleles (eg, expanded size)",81244,"FMR1 (Fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; characterization of alleles (eg, expanded size and methylation status)",35.1139820557408,,Present Both in MD and Autoproposal
81239,"DMPK (DM1 protein kinase) (eg, myotonic dystrophy type 1) gene analysis; characterization of alleles (eg, expanded size)",81408,"Molecular pathology procedure, Level 9 (eg, analysis of >50 exons in a single gene by DNA sequence analysis) ABCA4 (ATP-binding cassette, sub-family A [ABC1], member 4) (eg, Stargardt disease, age-related macular degeneration), full gene sequence ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia), full gene sequence CDH23 (cadherin-related 23) (eg, Usher syndrome, type 1), full gene sequence CEP290 (centrosomal protein 290kDa) (eg, Joubert syndrome), full gene sequence COL1A1 (collagen, type I, alpha 1) (eg, osteogenesis imperfecta, type I), full gene sequence COL1A2 (collagen, type I, alpha 2) (eg, osteogenesis imperfecta, type I), full gene sequence COL4A1 (collagen, type IV, alpha 1) (eg, brain small-vessel disease with hemorrhage), full gene sequence COL4A3 (collagen, type IV, alpha 3 [Goodpasture antigen]) (eg, Alport syndrome), full gene sequence COL4A5 (collagen, type IV, alpha 5) (eg, Alport syndrome), full gene sequence DMD (dystrophin) (eg, Duchenne/Becker muscular dystrophy), full gene sequence DYSF (dysferlin, limb girdle muscular dystrophy 2B [autosomal recessive]) (eg, limb-girdle muscular dystrophy), full gene sequence FBN1 (fibrillin 1) (eg, Marfan syndrome), full gene sequence ITPR1 (inositol 1,4,5-trisphosphate receptor, type 1) (eg, spinocerebellar ataxia), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LRRK2 (leucine-rich repeat kinase 2) (eg, Parkinson disease), full gene sequence MYH11 (myosin, heavy chain 11, smooth muscle) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence NEB (nebulin) (eg, nemaline myopathy 2), full gene sequence NF1 (neurofibromin 1) (eg, neurofibromatosis, type 1), full gene sequence PKHD1 (polycystic kidney and hepatic disease 1) (eg, autosomal recessive polycystic kidney disease), full gene sequence RYR1 (ryanodine receptor 1, skeletal) (eg, malignant hyperthermia), full gene sequence RYR2 (ryanodine receptor 2 [cardiac]) (eg, cate01cholaminergic polymorphic ventricular tachycardia, arrhythmogenic right ventricular dysplasia), full gene sequence or targeted sequence analysis of > 50 exons USH2A (Usher syndrome 2A [autosomal recessive, mild]) (eg, Usher syndrome, type 2), full gene sequence VPS13B (vacuolar protein sorting 13 homolog B [yeast]) (eg, Cohen syndrome), full gene sequence VWF (von Willebrand factor) (eg, von Willebrand disease types 1 and 3), full gene sequence",27.41060698584163,,Present in Autoproposal
81239,"DMPK (DM1 protein kinase) (eg, myotonic dystrophy type 1) gene analysis; characterization of alleles (eg, expanded size)",81260,"IKBKAP (inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-associated protein) (eg, familial dysautonomia) gene analysis, common variants (eg, 2507+6T>C, R696P)",26.49424347113103,,Present Both in MD and Autoproposal
81239,"DMPK (DM1 protein kinase) (eg, myotonic dystrophy type 1) gene analysis; characterization of alleles (eg, expanded size)",81406,"Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2 [S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-girdle muscular dystrophy), full gene sequence ANOS1 (anosmin-1) (eg, Kallmann syndrome 1), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+ transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Bera08, arrhythmogenic right ventricular cardiomyopathy), full gene sequence TNNT2 (troponin T, type 2 [cardiac]) (eg, familial hypertrophic cardiomyopathy), full gene sequence TRPC6 (transient receptor potential cation channel, subfamily C, member 6) (eg, focal segmental glomerulosclerosis), full gene sequence TSC1 (tuberous sclerosis 1) (eg, tuberous sclerosis), full gene sequence TSC2 (tuberous sclerosis 2) (eg, tuberous sclerosis), duplication/deletion analysis UBE3A (ubiquitin protein ligase E3A) (eg, Angelman syndrome), full gene sequence UMOD (uromodulin) (eg, glomerulocystic kidney disease with hyperuricemia and isosthenuria), full gene sequence VWF (von Willebrand factor) (von Willebrand disease type 2A), extended targeted sequence analysis (eg, exons 11-16, 24-26, 51, 52) WAS (Wiskott-Aldrich syndrome [eczema-thrombocytopenia]) (eg, Wiskott-Aldrich syndrome), full gene sequence",25.793695880099715,,Present in Autoproposal
81239,"DMPK (DM1 protein kinase) (eg, myotonic dystrophy type 1) gene analysis; characterization of alleles (eg, expanded size)",81170,"ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) (eg, acquired imatinib tyrosine kinase inhibitor resistance), gene analysis, variants in the kinase domain",25.73879907741481,,Present in Autoproposal
81239,"DMPK (DM1 protein kinase) (eg, myotonic dystrophy type 1) gene analysis; characterization of alleles (eg, expanded size)",0027U,"JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) gene analysis, targeted sequence analysis exons 12-15",24.70131096732187,,Present in Autoproposal
81239,"DMPK (DM1 protein kinase) (eg, myotonic dystrophy type 1) gene analysis; characterization of alleles (eg, expanded size)",81243,"FMR1 (fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",24.28872077312519,,Present in Autoproposal
81239,"DMPK (DM1 protein kinase) (eg, myotonic dystrophy type 1) gene analysis; characterization of alleles (eg, expanded size)",81246,"FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia), gene analysis; tyrosine kinase domain (TKD) variants (eg, D835, I836)",24.09010805189405,,Present in Autoproposal
81239,"DMPK (DM1 protein kinase) (eg, myotonic dystrophy type 1) gene analysis; characterization of alleles (eg, expanded size)",81270,"JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) gene analysis, p.Val617Phe (V617F) variant",22.083315062150415,,Present in Autoproposal
81271,"HTT (huntingtin) (eg, Huntington disease) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",81243,"FMR1 (fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",51.576201284157584,10,Present Both in MD and Autoproposal
81271,"HTT (huntingtin) (eg, Huntington disease) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",81342,"TRG@ (T cell antigen receptor, gamma) (eg, leukemia and lymphoma), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)",42.03411091288436,,Present in Autoproposal
81271,"HTT (huntingtin) (eg, Huntington disease) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",81264,"IGK@ (Immunoglobulin kappa light chain locus) (eg, leukemia and lymphoma, B-cell), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)",38.08266549203214,,Present in Autoproposal
81271,"HTT (huntingtin) (eg, Huntington disease) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",81341,"TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using direct probe methodology (eg, Southern blot)",36.10189491417985,,Present in Autoproposal
81271,"HTT (huntingtin) (eg, Huntington disease) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",81340,"TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using amplification methodology (eg, polymerase chain reaction)",35.16635990234126,,Present in Autoproposal
81271,"HTT (huntingtin) (eg, Huntington disease) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",81262,"IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); direct probe methodology (eg, Southern blot)",34.115716721422,,Present in Autoproposal
81271,"HTT (huntingtin) (eg, Huntington disease) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",81261,"IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); amplified methodology (eg, polymerase chain reaction)",32.3105227533848,,Present in Autoproposal
81271,"HTT (huntingtin) (eg, Huntington disease) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",81244,"FMR1 (Fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; characterization of alleles (eg, expanded size and methylation status)",29.41739080563125,,Present in Autoproposal
81271,"HTT (huntingtin) (eg, Huntington disease) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",81406,"Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2 [S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-girdle muscular dystrophy), full gene sequence ANOS1 (anosmin-1) (eg, Kallmann syndrome 1), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+ transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Bera08, arrhythmogenic right ventricular cardiomyopathy), full gene sequence TNNT2 (troponin T, type 2 [cardiac]) (eg, familial hypertrophic cardiomyopathy), full gene sequence TRPC6 (transient receptor potential cation channel, subfamily C, member 6) (eg, focal segmental glomerulosclerosis), full gene sequence TSC1 (tuberous sclerosis 1) (eg, tuberous sclerosis), full gene sequence TSC2 (tuberous sclerosis 2) (eg, tuberous sclerosis), duplication/deletion analysis UBE3A (ubiquitin protein ligase E3A) (eg, Angelman syndrome), full gene sequence UMOD (uromodulin) (eg, glomerulocystic kidney disease with hyperuricemia and isosthenuria), full gene sequence VWF (von Willebrand factor) (von Willebrand disease type 2A), extended targeted sequence analysis (eg, exons 11-16, 24-26, 51, 52) WAS (Wiskott-Aldrich syndrome [eczema-thrombocytopenia]) (eg, Wiskott-Aldrich syndrome), full gene sequence",25.949584004252564,,Present in Autoproposal
81271,"HTT (huntingtin) (eg, Huntington disease) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",81408,"Molecular pathology procedure, Level 9 (eg, analysis of >50 exons in a single gene by DNA sequence analysis) ABCA4 (ATP-binding cassette, sub-family A [ABC1], member 4) (eg, Stargardt disease, age-related macular degeneration), full gene sequence ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia), full gene sequence CDH23 (cadherin-related 23) (eg, Usher syndrome, type 1), full gene sequence CEP290 (centrosomal protein 290kDa) (eg, Joubert syndrome), full gene sequence COL1A1 (collagen, type I, alpha 1) (eg, osteogenesis imperfecta, type I), full gene sequence COL1A2 (collagen, type I, alpha 2) (eg, osteogenesis imperfecta, type I), full gene sequence COL4A1 (collagen, type IV, alpha 1) (eg, brain small-vessel disease with hemorrhage), full gene sequence COL4A3 (collagen, type IV, alpha 3 [Goodpasture antigen]) (eg, Alport syndrome), full gene sequence COL4A5 (collagen, type IV, alpha 5) (eg, Alport syndrome), full gene sequence DMD (dystrophin) (eg, Duchenne/Becker muscular dystrophy), full gene sequence DYSF (dysferlin, limb girdle muscular dystrophy 2B [autosomal recessive]) (eg, limb-girdle muscular dystrophy), full gene sequence FBN1 (fibrillin 1) (eg, Marfan syndrome), full gene sequence ITPR1 (inositol 1,4,5-trisphosphate receptor, type 1) (eg, spinocerebellar ataxia), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LRRK2 (leucine-rich repeat kinase 2) (eg, Parkinson disease), full gene sequence MYH11 (myosin, heavy chain 11, smooth muscle) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence NEB (nebulin) (eg, nemaline myopathy 2), full gene sequence NF1 (neurofibromin 1) (eg, neurofibromatosis, type 1), full gene sequence PKHD1 (polycystic kidney and hepatic disease 1) (eg, autosomal recessive polycystic kidney disease), full gene sequence RYR1 (ryanodine receptor 1, skeletal) (eg, malignant hyperthermia), full gene sequence RYR2 (ryanodine receptor 2 [cardiac]) (eg, cate01cholaminergic polymorphic ventricular tachycardia, arrhythmogenic right ventricular dysplasia), full gene sequence or targeted sequence analysis of > 50 exons USH2A (Usher syndrome 2A [autosomal recessive, mild]) (eg, Usher syndrome, type 2), full gene sequence VPS13B (vacuolar protein sorting 13 homolog B [yeast]) (eg, Cohen syndrome), full gene sequence VWF (von Willebrand factor) (eg, von Willebrand disease types 1 and 3), full gene sequence",25.609287731810326,,Present in Autoproposal
81274,"HTT (huntingtin) (eg, Huntington disease) gene analysis; characterization of alleles (eg, expanded size)",81244,"FMR1 (Fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; characterization of alleles (eg, expanded size and methylation status)",46.588648744634874,10,Present Both in MD and Autoproposal
81274,"HTT (huntingtin) (eg, Huntington disease) gene analysis; characterization of alleles (eg, expanded size)",81243,"FMR1 (fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",32.2258716986114,,Present in Autoproposal
81274,"HTT (huntingtin) (eg, Huntington disease) gene analysis; characterization of alleles (eg, expanded size)",81406,"Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2 [S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-girdle muscular dystrophy), full gene sequence ANOS1 (anosmin-1) (eg, Kallmann syndrome 1), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+ transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Bera08, arrhythmogenic right ventricular cardiomyopathy), full gene sequence TNNT2 (troponin T, type 2 [cardiac]) (eg, familial hypertrophic cardiomyopathy), full gene sequence TRPC6 (transient receptor potential cation channel, subfamily C, member 6) (eg, focal segmental glomerulosclerosis), full gene sequence TSC1 (tuberous sclerosis 1) (eg, tuberous sclerosis), full gene sequence TSC2 (tuberous sclerosis 2) (eg, tuberous sclerosis), duplication/deletion analysis UBE3A (ubiquitin protein ligase E3A) (eg, Angelman syndrome), full gene sequence UMOD (uromodulin) (eg, glomerulocystic kidney disease with hyperuricemia and isosthenuria), full gene sequence VWF (von Willebrand factor) (von Willebrand disease type 2A), extended targeted sequence analysis (eg, exons 11-16, 24-26, 51, 52) WAS (Wiskott-Aldrich syndrome [eczema-thrombocytopenia]) (eg, Wiskott-Aldrich syndrome), full gene sequence",28.06278772620525,,Present in Autoproposal
81274,"HTT (huntingtin) (eg, Huntington disease) gene analysis; characterization of alleles (eg, expanded size)",81408,"Molecular pathology procedure, Level 9 (eg, analysis of >50 exons in a single gene by DNA sequence analysis) ABCA4 (ATP-binding cassette, sub-family A [ABC1], member 4) (eg, Stargardt disease, age-related macular degeneration), full gene sequence ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia), full gene sequence CDH23 (cadherin-related 23) (eg, Usher syndrome, type 1), full gene sequence CEP290 (centrosomal protein 290kDa) (eg, Joubert syndrome), full gene sequence COL1A1 (collagen, type I, alpha 1) (eg, osteogenesis imperfecta, type I), full gene sequence COL1A2 (collagen, type I, alpha 2) (eg, osteogenesis imperfecta, type I), full gene sequence COL4A1 (collagen, type IV, alpha 1) (eg, brain small-vessel disease with hemorrhage), full gene sequence COL4A3 (collagen, type IV, alpha 3 [Goodpasture antigen]) (eg, Alport syndrome), full gene sequence COL4A5 (collagen, type IV, alpha 5) (eg, Alport syndrome), full gene sequence DMD (dystrophin) (eg, Duchenne/Becker muscular dystrophy), full gene sequence DYSF (dysferlin, limb girdle muscular dystrophy 2B [autosomal recessive]) (eg, limb-girdle muscular dystrophy), full gene sequence FBN1 (fibrillin 1) (eg, Marfan syndrome), full gene sequence ITPR1 (inositol 1,4,5-trisphosphate receptor, type 1) (eg, spinocerebellar ataxia), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LRRK2 (leucine-rich repeat kinase 2) (eg, Parkinson disease), full gene sequence MYH11 (myosin, heavy chain 11, smooth muscle) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence NEB (nebulin) (eg, nemaline myopathy 2), full gene sequence NF1 (neurofibromin 1) (eg, neurofibromatosis, type 1), full gene sequence PKHD1 (polycystic kidney and hepatic disease 1) (eg, autosomal recessive polycystic kidney disease), full gene sequence RYR1 (ryanodine receptor 1, skeletal) (eg, malignant hyperthermia), full gene sequence RYR2 (ryanodine receptor 2 [cardiac]) (eg, cate01cholaminergic polymorphic ventricular tachycardia, arrhythmogenic right ventricular dysplasia), full gene sequence or targeted sequence analysis of > 50 exons USH2A (Usher syndrome 2A [autosomal recessive, mild]) (eg, Usher syndrome, type 2), full gene sequence VPS13B (vacuolar protein sorting 13 homolog B [yeast]) (eg, Cohen syndrome), full gene sequence VWF (von Willebrand factor) (eg, von Willebrand disease types 1 and 3), full gene sequence",27.705974292043116,,Present in Autoproposal
81274,"HTT (huntingtin) (eg, Huntington disease) gene analysis; characterization of alleles (eg, expanded size)",S3818,COMPLETE GENE SEQUENCE ANALYSIS; BRCA1 GENE,27.202915230385482,,Present in Autoproposal
81274,"HTT (huntingtin) (eg, Huntington disease) gene analysis; characterization of alleles (eg, expanded size)",S3819,COMPLETE GENE SEQUENCE ANALYSIS; BRCA2 GENE,27.202915230385482,,Present in Autoproposal
81274,"HTT (huntingtin) (eg, Huntington disease) gene analysis; characterization of alleles (eg, expanded size)",S3828,COMPLETE GENE SEQUENCE ANALYSIS; MLH1 GENE,27.14362989994526,,Present in Autoproposal
81274,"HTT (huntingtin) (eg, Huntington disease) gene analysis; characterization of alleles (eg, expanded size)",S3829,COMPLETE GENE SEQUENCE ANALYSIS; MSH2 GENE,27.079000889755537,,Present in Autoproposal
81274,"HTT (huntingtin) (eg, Huntington disease) gene analysis; characterization of alleles (eg, expanded size)",81200,"ASPA (aspartoacylase) (eg, Canavan disease) gene analysis, common variants (eg, E285A, Y231X)",26.495352549031338,,Present in Autoproposal
81274,"HTT (huntingtin) (eg, Huntington disease) gene analysis; characterization of alleles (eg, expanded size)",G8265,PATIENT DOCUMENTED TO HAVE RECEIVED CHARACTERIZATION OF URINARY INCONTINENCE,25.625196547062647,,Present in Autoproposal
81284,"FXN (frataxin) (eg, Friedreich ataxia) gene analysis; evaluation to detect abnormal (expanded) alleles",81243,"FMR1 (fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",47.26042050996085,10,Present Both in MD and Autoproposal
81284,"FXN (frataxin) (eg, Friedreich ataxia) gene analysis; evaluation to detect abnormal (expanded) alleles",81342,"TRG@ (T cell antigen receptor, gamma) (eg, leukemia and lymphoma), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)",39.048911089859395,,Present in Autoproposal
81284,"FXN (frataxin) (eg, Friedreich ataxia) gene analysis; evaluation to detect abnormal (expanded) alleles",81264,"IGK@ (Immunoglobulin kappa light chain locus) (eg, leukemia and lymphoma, B-cell), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)",35.378091425442655,,Present in Autoproposal
81284,"FXN (frataxin) (eg, Friedreich ataxia) gene analysis; evaluation to detect abnormal (expanded) alleles",81341,"TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using direct probe methodology (eg, Southern blot)",31.73565040869451,,Present in Autoproposal
81284,"FXN (frataxin) (eg, Friedreich ataxia) gene analysis; evaluation to detect abnormal (expanded) alleles",81340,"TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using amplification methodology (eg, polymerase chain reaction)",30.9132611088702,,Present in Autoproposal
81284,"FXN (frataxin) (eg, Friedreich ataxia) gene analysis; evaluation to detect abnormal (expanded) alleles",81262,"IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); direct probe methodology (eg, Southern blot)",29.989685081262945,,Present in Autoproposal
81284,"FXN (frataxin) (eg, Friedreich ataxia) gene analysis; evaluation to detect abnormal (expanded) alleles",81261,"IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); amplified methodology (eg, polymerase chain reaction)",28.40281533867193,,Present in Autoproposal
81284,"FXN (frataxin) (eg, Friedreich ataxia) gene analysis; evaluation to detect abnormal (expanded) alleles",81244,"FMR1 (Fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; characterization of alleles (eg, expanded size and methylation status)",25.6001164624982,,Present in Autoproposal
81284,"FXN (frataxin) (eg, Friedreich ataxia) gene analysis; evaluation to detect abnormal (expanded) alleles",S3819,COMPLETE GENE SEQUENCE ANALYSIS; BRCA2 GENE,24.787794347981503,,Present in Autoproposal
81284,"FXN (frataxin) (eg, Friedreich ataxia) gene analysis; evaluation to detect abnormal (expanded) alleles",S3818,COMPLETE GENE SEQUENCE ANALYSIS; BRCA1 GENE,24.787794347981503,,Present in Autoproposal
81285,"FXN (frataxin) (eg, Friedreich ataxia) gene analysis; characterization of alleles (eg, expanded size)",81244,"FMR1 (Fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; characterization of alleles (eg, expanded size and methylation status)",43.38237924760706,10,Present Both in MD and Autoproposal
81285,"FXN (frataxin) (eg, Friedreich ataxia) gene analysis; characterization of alleles (eg, expanded size)",81243,"FMR1 (fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",30.008060445730006,,Present in Autoproposal
81285,"FXN (frataxin) (eg, Friedreich ataxia) gene analysis; characterization of alleles (eg, expanded size)",81408,"Molecular pathology procedure, Level 9 (eg, analysis of >50 exons in a single gene by DNA sequence analysis) ABCA4 (ATP-binding cassette, sub-family A [ABC1], member 4) (eg, Stargardt disease, age-related macular degeneration), full gene sequence ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia), full gene sequence CDH23 (cadherin-related 23) (eg, Usher syndrome, type 1), full gene sequence CEP290 (centrosomal protein 290kDa) (eg, Joubert syndrome), full gene sequence COL1A1 (collagen, type I, alpha 1) (eg, osteogenesis imperfecta, type I), full gene sequence COL1A2 (collagen, type I, alpha 2) (eg, osteogenesis imperfecta, type I), full gene sequence COL4A1 (collagen, type IV, alpha 1) (eg, brain small-vessel disease with hemorrhage), full gene sequence COL4A3 (collagen, type IV, alpha 3 [Goodpasture antigen]) (eg, Alport syndrome), full gene sequence COL4A5 (collagen, type IV, alpha 5) (eg, Alport syndrome), full gene sequence DMD (dystrophin) (eg, Duchenne/Becker muscular dystrophy), full gene sequence DYSF (dysferlin, limb girdle muscular dystrophy 2B [autosomal recessive]) (eg, limb-girdle muscular dystrophy), full gene sequence FBN1 (fibrillin 1) (eg, Marfan syndrome), full gene sequence ITPR1 (inositol 1,4,5-trisphosphate receptor, type 1) (eg, spinocerebellar ataxia), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LRRK2 (leucine-rich repeat kinase 2) (eg, Parkinson disease), full gene sequence MYH11 (myosin, heavy chain 11, smooth muscle) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence NEB (nebulin) (eg, nemaline myopathy 2), full gene sequence NF1 (neurofibromin 1) (eg, neurofibromatosis, type 1), full gene sequence PKHD1 (polycystic kidney and hepatic disease 1) (eg, autosomal recessive polycystic kidney disease), full gene sequence RYR1 (ryanodine receptor 1, skeletal) (eg, malignant hyperthermia), full gene sequence RYR2 (ryanodine receptor 2 [cardiac]) (eg, cate01cholaminergic polymorphic ventricular tachycardia, arrhythmogenic right ventricular dysplasia), full gene sequence or targeted sequence analysis of > 50 exons USH2A (Usher syndrome 2A [autosomal recessive, mild]) (eg, Usher syndrome, type 2), full gene sequence VPS13B (vacuolar protein sorting 13 homolog B [yeast]) (eg, Cohen syndrome), full gene sequence VWF (von Willebrand factor) (eg, von Willebrand disease types 1 and 3), full gene sequence",27.145752558931168,,Present in Autoproposal
81285,"FXN (frataxin) (eg, Friedreich ataxia) gene analysis; characterization of alleles (eg, expanded size)",81406,"Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2 [S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-girdle muscular dystrophy), full gene sequence ANOS1 (anosmin-1) (eg, Kallmann syndrome 1), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+ transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Bera08, arrhythmogenic right ventricular cardiomyopathy), full gene sequence TNNT2 (troponin T, type 2 [cardiac]) (eg, familial hypertrophic cardiomyopathy), full gene sequence TRPC6 (transient receptor potential cation channel, subfamily C, member 6) (eg, focal segmental glomerulosclerosis), full gene sequence TSC1 (tuberous sclerosis 1) (eg, tuberous sclerosis), full gene sequence TSC2 (tuberous sclerosis 2) (eg, tuberous sclerosis), duplication/deletion analysis UBE3A (ubiquitin protein ligase E3A) (eg, Angelman syndrome), full gene sequence UMOD (uromodulin) (eg, glomerulocystic kidney disease with hyperuricemia and isosthenuria), full gene sequence VWF (von Willebrand factor) (von Willebrand disease type 2A), extended targeted sequence analysis (eg, exons 11-16, 24-26, 51, 52) WAS (Wiskott-Aldrich syndrome [eczema-thrombocytopenia]) (eg, Wiskott-Aldrich syndrome), full gene sequence",25.423204237112216,,Present in Autoproposal
81285,"FXN (frataxin) (eg, Friedreich ataxia) gene analysis; characterization of alleles (eg, expanded size)",S3818,COMPLETE GENE SEQUENCE ANALYSIS; BRCA1 GENE,25.33078801305633,,Present in Autoproposal
81285,"FXN (frataxin) (eg, Friedreich ataxia) gene analysis; characterization of alleles (eg, expanded size)",S3819,COMPLETE GENE SEQUENCE ANALYSIS; BRCA2 GENE,25.33078801305633,,Present in Autoproposal
81285,"FXN (frataxin) (eg, Friedreich ataxia) gene analysis; characterization of alleles (eg, expanded size)",S3828,COMPLETE GENE SEQUENCE ANALYSIS; MLH1 GENE,25.275582748291626,,Present in Autoproposal
81285,"FXN (frataxin) (eg, Friedreich ataxia) gene analysis; characterization of alleles (eg, expanded size)",S3829,COMPLETE GENE SEQUENCE ANALYSIS; MSH2 GENE,25.215401560255547,,Present in Autoproposal
81285,"FXN (frataxin) (eg, Friedreich ataxia) gene analysis; characterization of alleles (eg, expanded size)",G8265,PATIENT DOCUMENTED TO HAVE RECEIVED CHARACTERIZATION OF URINARY INCONTINENCE,23.86164923976601,,Present in Autoproposal
81285,"FXN (frataxin) (eg, Friedreich ataxia) gene analysis; characterization of alleles (eg, expanded size)",G8266,PATIENT NOT DOCUMENTED TO HAVE RECEIVED CHARACTERIZATION OF URINARY INCONTINENCE,23.233877464252394,,Present in Autoproposal
81286,"FXN (frataxin) (eg, Friedreich ataxia) gene analysis; full gene sequence",81408,"Molecular pathology procedure, Level 9 (eg, analysis of >50 exons in a single gene by DNA sequence analysis) ABCA4 (ATP-binding cassette, sub-family A [ABC1], member 4) (eg, Stargardt disease, age-related macular degeneration), full gene sequence ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia), full gene sequence CDH23 (cadherin-related 23) (eg, Usher syndrome, type 1), full gene sequence CEP290 (centrosomal protein 290kDa) (eg, Joubert syndrome), full gene sequence COL1A1 (collagen, type I, alpha 1) (eg, osteogenesis imperfecta, type I), full gene sequence COL1A2 (collagen, type I, alpha 2) (eg, osteogenesis imperfecta, type I), full gene sequence COL4A1 (collagen, type IV, alpha 1) (eg, brain small-vessel disease with hemorrhage), full gene sequence COL4A3 (collagen, type IV, alpha 3 [Goodpasture antigen]) (eg, Alport syndrome), full gene sequence COL4A5 (collagen, type IV, alpha 5) (eg, Alport syndrome), full gene sequence DMD (dystrophin) (eg, Duchenne/Becker muscular dystrophy), full gene sequence DYSF (dysferlin, limb girdle muscular dystrophy 2B [autosomal recessive]) (eg, limb-girdle muscular dystrophy), full gene sequence FBN1 (fibrillin 1) (eg, Marfan syndrome), full gene sequence ITPR1 (inositol 1,4,5-trisphosphate receptor, type 1) (eg, spinocerebellar ataxia), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LRRK2 (leucine-rich repeat kinase 2) (eg, Parkinson disease), full gene sequence MYH11 (myosin, heavy chain 11, smooth muscle) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence NEB (nebulin) (eg, nemaline myopathy 2), full gene sequence NF1 (neurofibromin 1) (eg, neurofibromatosis, type 1), full gene sequence PKHD1 (polycystic kidney and hepatic disease 1) (eg, autosomal recessive polycystic kidney disease), full gene sequence RYR1 (ryanodine receptor 1, skeletal) (eg, malignant hyperthermia), full gene sequence RYR2 (ryanodine receptor 2 [cardiac]) (eg, cate01cholaminergic polymorphic ventricular tachycardia, arrhythmogenic right ventricular dysplasia), full gene sequence or targeted sequence analysis of > 50 exons USH2A (Usher syndrome 2A [autosomal recessive, mild]) (eg, Usher syndrome, type 2), full gene sequence VPS13B (vacuolar protein sorting 13 homolog B [yeast]) (eg, Cohen syndrome), full gene sequence VWF (von Willebrand factor) (eg, von Willebrand disease types 1 and 3), full gene sequence",71.26020725749372,10,Present in Autoproposal
81286,"FXN (frataxin) (eg, Friedreich ataxia) gene analysis; full gene sequence",81406,"Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2 [S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-girdle muscular dystrophy), full gene sequence ANOS1 (anosmin-1) (eg, Kallmann syndrome 1), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+ transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Bera08, arrhythmogenic right ventricular cardiomyopathy), full gene sequence TNNT2 (troponin T, type 2 [cardiac]) (eg, familial hypertrophic cardiomyopathy), full gene sequence TRPC6 (transient receptor potential cation channel, subfamily C, member 6) (eg, focal segmental glomerulosclerosis), full gene sequence TSC1 (tuberous sclerosis 1) (eg, tuberous sclerosis), full gene sequence TSC2 (tuberous sclerosis 2) (eg, tuberous sclerosis), duplication/deletion analysis UBE3A (ubiquitin protein ligase E3A) (eg, Angelman syndrome), full gene sequence UMOD (uromodulin) (eg, glomerulocystic kidney disease with hyperuricemia and isosthenuria), full gene sequence VWF (von Willebrand factor) (von Willebrand disease type 2A), extended targeted sequence analysis (eg, exons 11-16, 24-26, 51, 52) WAS (Wiskott-Aldrich syndrome [eczema-thrombocytopenia]) (eg, Wiskott-Aldrich syndrome), full gene sequence",68.03593045300597,,Present in Autoproposal
81286,"FXN (frataxin) (eg, Friedreich ataxia) gene analysis; full gene sequence",S3819,COMPLETE GENE SEQUENCE ANALYSIS; BRCA2 GENE,64.1190982777584,,Present in Autoproposal
81286,"FXN (frataxin) (eg, Friedreich ataxia) gene analysis; full gene sequence",S3818,COMPLETE GENE SEQUENCE ANALYSIS; BRCA1 GENE,64.1190982777584,,Present in Autoproposal
81286,"FXN (frataxin) (eg, Friedreich ataxia) gene analysis; full gene sequence",S3828,COMPLETE GENE SEQUENCE ANALYSIS; MLH1 GENE,63.97935877202041,,Present in Autoproposal
81286,"FXN (frataxin) (eg, Friedreich ataxia) gene analysis; full gene sequence",S3829,COMPLETE GENE SEQUENCE ANALYSIS; MSH2 GENE,63.827023854205436,,Present in Autoproposal
81286,"FXN (frataxin) (eg, Friedreich ataxia) gene analysis; full gene sequence",81249,"G6PD (glucose-6-phosphate dehydrogenase) (eg, hemolytic anemia, jaundice), gene analysis; full gene sequence",50.54885273150917,,Present in Autoproposal
81286,"FXN (frataxin) (eg, Friedreich ataxia) gene analysis; full gene sequence",81216,"BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis",43.82107759685769,,Present in Autoproposal
81286,"FXN (frataxin) (eg, Friedreich ataxia) gene analysis; full gene sequence",81252,"GJB2 (gap junction protein, beta 2, 26kDa, connexin 26) (eg, nonsyndromic hearing loss) gene analysis; full gene sequence",43.497739596459525,,Present Both in MD and Autoproposal
81286,"FXN (frataxin) (eg, Friedreich ataxia) gene analysis; full gene sequence",81218,"CEBPA (CCAAT/enhancer binding protein [C/EBP], alpha) (eg, acute myeloid leukemia), gene analysis, full gene sequence",43.377592444343364,,Present in Autoproposal
81289,"FXN (frataxin) (eg, Friedreich ataxia) gene analysis; known familial variant(s)",81215,"BRCA1 (breast cancer 1) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant",50.50537381825491,10,Present in Autoproposal
81289,"FXN (frataxin) (eg, Friedreich ataxia) gene analysis; known familial variant(s)",81217,"BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant",50.50537381825491,,Present in Autoproposal
81289,"FXN (frataxin) (eg, Friedreich ataxia) gene analysis; known familial variant(s)",81248,"G6PD (glucose-6-phosphate dehydrogenase) (eg, hemolytic anemia, jaundice), gene analysis; known familial variant(s)",48.87964241738623,,Present in Autoproposal
81289,"FXN (frataxin) (eg, Friedreich ataxia) gene analysis; known familial variant(s)",81303,"MECP2 (methyl CpG binding protein 2) (eg, Rett syndrome) gene analysis; known familial variant",47.96206683603373,,Present in Autoproposal
81289,"FXN (frataxin) (eg, Friedreich ataxia) gene analysis; known familial variant(s)",81326,"PMP22 (peripheral myelin protein 22) (eg, Charcot-Marie-Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; known familial variant",39.315143609669114,,Present in Autoproposal
81289,"FXN (frataxin) (eg, Friedreich ataxia) gene analysis; known familial variant(s)",81322,"PTEN (phosphatase and tensin homolog) (eg, Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; known familial variant",38.746995247506966,,Present in Autoproposal
81289,"FXN (frataxin) (eg, Friedreich ataxia) gene analysis; known familial variant(s)",81202,"APC (adenomatous polyposis coli) (eg, familial adenomatosis polyposis [FAP], attenuated FAP) gene analysis; known familial variants",36.0461915954916,,Present in Autoproposal
81289,"FXN (frataxin) (eg, Friedreich ataxia) gene analysis; known familial variant(s)",81299,"MSH6 (mutS homolog 6 [E. coli]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; known familial variants",35.02962208997849,,Present in Autoproposal
81289,"FXN (frataxin) (eg, Friedreich ataxia) gene analysis; known familial variant(s)",81362,"HBB (hemoglobin, subunit beta) (eg, sickle cell anemia, beta thalassemia, hemoglobinopathy); known familial variant(s)",32.956887375200736,,Present in Autoproposal
81289,"FXN (frataxin) (eg, Friedreich ataxia) gene analysis; known familial variant(s)",81253,"GJB2 (gap junction protein, beta 2, 26kDa, connexin 26) (eg, nonsyndromic hearing loss) gene analysis; known familial variants",32.79871712574336,,Present Both in MD and Autoproposal
81305,"MYD88 (myeloid differentiation primary response 88) (eg, Waldenstrom's macroglobulinemia, lymphoplasmacytic leukemia) gene analysis, p.Leu265Pro (L265P) variant",81334,"RUNX1 (runt related transcription factor 1) (eg, acute myeloid leukemia, familial platelet disorder with associated myeloid malignancy), gene analysis, targeted sequence analysis (eg, exons 3-8)",42.508842664309036,10,Present in Autoproposal
81305,"MYD88 (myeloid differentiation primary response 88) (eg, Waldenstrom's macroglobulinemia, lymphoplasmacytic leukemia) gene analysis, p.Leu265Pro (L265P) variant",81310,"NPM1 (nucleophosmin) (eg, acute myeloid leukemia) gene analysis, exon 12 variants",41.43337913408679,,Present in Autoproposal
81305,"MYD88 (myeloid differentiation primary response 88) (eg, Waldenstrom's macroglobulinemia, lymphoplasmacytic leukemia) gene analysis, p.Leu265Pro (L265P) variant",81218,"CEBPA (CCAAT/enhancer binding protein [C/EBP], alpha) (eg, acute myeloid leukemia), gene analysis, full gene sequence",37.39292308548185,,Present in Autoproposal
81305,"MYD88 (myeloid differentiation primary response 88) (eg, Waldenstrom's macroglobulinemia, lymphoplasmacytic leukemia) gene analysis, p.Leu265Pro (L265P) variant",81283,"IFNL3 (interferon, lambda 3) (eg, drug response), gene analysis, rs12979860 variant",35.094219065790526,,Present in Autoproposal
81305,"MYD88 (myeloid differentiation primary response 88) (eg, Waldenstrom's macroglobulinemia, lymphoplasmacytic leukemia) gene analysis, p.Leu265Pro (L265P) variant",81245,"FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia), gene analysis; internal tandem duplication (ITD) variants (ie, exons 14, 15)",30.291724146739895,,Present in Autoproposal
81305,"MYD88 (myeloid differentiation primary response 88) (eg, Waldenstrom's macroglobulinemia, lymphoplasmacytic leukemia) gene analysis, p.Leu265Pro (L265P) variant",81272,"KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) (eg, gastrointestinal stromal tumor [GIST], acute myeloid leukemia, melanoma), gene analysis, targeted sequence analysis (eg, exons 8, 11, 13, 17, 18)",27.775095404075095,,Present in Autoproposal
81305,"MYD88 (myeloid differentiation primary response 88) (eg, Waldenstrom's macroglobulinemia, lymphoplasmacytic leukemia) gene analysis, p.Leu265Pro (L265P) variant",81346,"TYMS (thymidylate synthetase) (eg, 5-fluorouracil/5-FU drug metabolism), gene analysis, common variant(s) (eg, tandem repeat variant)",27.730907152143136,,Present in Autoproposal
81305,"MYD88 (myeloid differentiation primary response 88) (eg, Waldenstrom's macroglobulinemia, lymphoplasmacytic leukemia) gene analysis, p.Leu265Pro (L265P) variant",81246,"FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia), gene analysis; tyrosine kinase domain (TKD) variants (eg, D835, I836)",27.249904793156688,,Present in Autoproposal
81305,"MYD88 (myeloid differentiation primary response 88) (eg, Waldenstrom's macroglobulinemia, lymphoplasmacytic leukemia) gene analysis, p.Leu265Pro (L265P) variant",S3818,COMPLETE GENE SEQUENCE ANALYSIS; BRCA1 GENE,25.737963775131213,,Present in Autoproposal
81305,"MYD88 (myeloid differentiation primary response 88) (eg, Waldenstrom's macroglobulinemia, lymphoplasmacytic leukemia) gene analysis, p.Leu265Pro (L265P) variant",S3819,COMPLETE GENE SEQUENCE ANALYSIS; BRCA2 GENE,25.737963775131213,,Present in Autoproposal
81306,"NUDT15 (nudix hydrolase 15) (eg, drug metabolism) gene analysis, common variant(s) (eg, *2, *3, *4, *5, *6)",0034U,"TPMT (thiopurine S-methyltransferase), NUDT15 (nudix hydroxylase 15)(eg, thiopurine metabolism), gene analysis, common variants (ie, TPMT *2, *3A, *3B, *3C, *4, *5, *6, *8, *12; NUDT15 *3, *4, *5)",50.15958719703675,1,Present Both in MD and Autoproposal
81306,"NUDT15 (nudix hydrolase 15) (eg, drug metabolism) gene analysis, common variant(s) (eg, *2, *3, *4, *5, *6)",81230,"CYP3A4 (cytochrome P450 family 3 subfamily A member 4) (eg, drug metabolism), gene analysis, common variant(s) (eg, *2, *22)",46.58879721354868,,Present in Autoproposal
81306,"NUDT15 (nudix hydrolase 15) (eg, drug metabolism) gene analysis, common variant(s) (eg, *2, *3, *4, *5, *6)",81346,"TYMS (thymidylate synthetase) (eg, 5-fluorouracil/5-FU drug metabolism), gene analysis, common variant(s) (eg, tandem repeat variant)",45.97942508089741,,Present in Autoproposal
81306,"NUDT15 (nudix hydrolase 15) (eg, drug metabolism) gene analysis, common variant(s) (eg, *2, *3, *4, *5, *6)",81335,"TPMT (thiopurine S-methyltransferase) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3)",44.46533472061826,,Present Both in MD and Autoproposal
81306,"NUDT15 (nudix hydrolase 15) (eg, drug metabolism) gene analysis, common variant(s) (eg, *2, *3, *4, *5, *6)",81232,"DPYD (dihydropyrimidine dehydrogenase) (eg, 5-fluorouracil/5-FU and capecitabine drug metabolism), gene analysis, common variant(s) (eg, *2A, *4, *5, *6)",42.253293800881444,,Present in Autoproposal
81306,"NUDT15 (nudix hydrolase 15) (eg, drug metabolism) gene analysis, common variant(s) (eg, *2, *3, *4, *5, *6)",81231,"CYP3A5 (cytochrome P450 family 3 subfamily A member 5) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *5, *6, *7)",39.91673205294386,,Present in Autoproposal
81306,"NUDT15 (nudix hydrolase 15) (eg, drug metabolism) gene analysis, common variant(s) (eg, *2, *3, *4, *5, *6)",81227,"CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *5, *6)",39.781641389807035,,Present in Autoproposal
81306,"NUDT15 (nudix hydrolase 15) (eg, drug metabolism) gene analysis, common variant(s) (eg, *2, *3, *4, *5, *6)",81225,"CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *8, *17)",36.635704789485054,,Present in Autoproposal
81306,"NUDT15 (nudix hydrolase 15) (eg, drug metabolism) gene analysis, common variant(s) (eg, *2, *3, *4, *5, *6)",81355,"VKORC1 (vitamin K epoxide reductase complex, subunit 1) (eg, warfarin metabolism), gene analysis, common variant(s) (eg, -1639G>A, c.173+1000C>T)",35.02482458736223,,Present in Autoproposal
81306,"NUDT15 (nudix hydrolase 15) (eg, drug metabolism) gene analysis, common variant(s) (eg, *2, *3, *4, *5, *6)",81247,"G6PD (glucose-6-phosphate dehydrogenase) (eg, hemolytic anemia, jaundice), gene analysis; common variant(s) (eg, A, A-)",34.102881874714775,,Present in Autoproposal
81312,"PABPN1 (poly[A] binding protein nuclear 1) (eg, oculopharyngeal muscular dystrophy) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81243,"FMR1 (fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",37.474622127738,10,Present Both in MD and Autoproposal
81312,"PABPN1 (poly[A] binding protein nuclear 1) (eg, oculopharyngeal muscular dystrophy) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81342,"TRG@ (T cell antigen receptor, gamma) (eg, leukemia and lymphoma), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)",30.541458729331044,,Present in Autoproposal
81312,"PABPN1 (poly[A] binding protein nuclear 1) (eg, oculopharyngeal muscular dystrophy) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",S3853,GENETIC TESTING FOR MYOTONIC MUSCULAR DYSTROPHY,29.806715094255342,,Present in Autoproposal
81312,"PABPN1 (poly[A] binding protein nuclear 1) (eg, oculopharyngeal muscular dystrophy) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81161,"DMD (dystrophin) (eg, Duchenne/Becker muscular dystrophy) deletion analysis, and duplication analysis, if performed",29.10951090629567,,Present Both in MD and Autoproposal
81312,"PABPN1 (poly[A] binding protein nuclear 1) (eg, oculopharyngeal muscular dystrophy) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81302,"MECP2 (methyl CpG binding protein 2) (eg, Rett syndrome) gene analysis; full sequence analysis",28.33214851428168,,Present in Autoproposal
81312,"PABPN1 (poly[A] binding protein nuclear 1) (eg, oculopharyngeal muscular dystrophy) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81264,"IGK@ (Immunoglobulin kappa light chain locus) (eg, leukemia and lymphoma, B-cell), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)",27.67038795796925,,Present in Autoproposal
81312,"PABPN1 (poly[A] binding protein nuclear 1) (eg, oculopharyngeal muscular dystrophy) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81341,"TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using direct probe methodology (eg, Southern blot)",26.231184855014934,,Present in Autoproposal
81312,"PABPN1 (poly[A] binding protein nuclear 1) (eg, oculopharyngeal muscular dystrophy) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81340,"TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using amplification methodology (eg, polymerase chain reaction)",25.55143682815339,,Present in Autoproposal
81312,"PABPN1 (poly[A] binding protein nuclear 1) (eg, oculopharyngeal muscular dystrophy) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81408,"Molecular pathology procedure, Level 9 (eg, analysis of >50 exons in a single gene by DNA sequence analysis) ABCA4 (ATP-binding cassette, sub-family A [ABC1], member 4) (eg, Stargardt disease, age-related macular degeneration), full gene sequence ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia), full gene sequence CDH23 (cadherin-related 23) (eg, Usher syndrome, type 1), full gene sequence CEP290 (centrosomal protein 290kDa) (eg, Joubert syndrome), full gene sequence COL1A1 (collagen, type I, alpha 1) (eg, osteogenesis imperfecta, type I), full gene sequence COL1A2 (collagen, type I, alpha 2) (eg, osteogenesis imperfecta, type I), full gene sequence COL4A1 (collagen, type IV, alpha 1) (eg, brain small-vessel disease with hemorrhage), full gene sequence COL4A3 (collagen, type IV, alpha 3 [Goodpasture antigen]) (eg, Alport syndrome), full gene sequence COL4A5 (collagen, type IV, alpha 5) (eg, Alport syndrome), full gene sequence DMD (dystrophin) (eg, Duchenne/Becker muscular dystrophy), full gene sequence DYSF (dysferlin, limb girdle muscular dystrophy 2B [autosomal recessive]) (eg, limb-girdle muscular dystrophy), full gene sequence FBN1 (fibrillin 1) (eg, Marfan syndrome), full gene sequence ITPR1 (inositol 1,4,5-trisphosphate receptor, type 1) (eg, spinocerebellar ataxia), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LRRK2 (leucine-rich repeat kinase 2) (eg, Parkinson disease), full gene sequence MYH11 (myosin, heavy chain 11, smooth muscle) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence NEB (nebulin) (eg, nemaline myopathy 2), full gene sequence NF1 (neurofibromin 1) (eg, neurofibromatosis, type 1), full gene sequence PKHD1 (polycystic kidney and hepatic disease 1) (eg, autosomal recessive polycystic kidney disease), full gene sequence RYR1 (ryanodine receptor 1, skeletal) (eg, malignant hyperthermia), full gene sequence RYR2 (ryanodine receptor 2 [cardiac]) (eg, cate01cholaminergic polymorphic ventricular tachycardia, arrhythmogenic right ventricular dysplasia), full gene sequence or targeted sequence analysis of > 50 exons USH2A (Usher syndrome 2A [autosomal recessive, mild]) (eg, Usher syndrome, type 2), full gene sequence VPS13B (vacuolar protein sorting 13 homolog B [yeast]) (eg, Cohen syndrome), full gene sequence VWF (von Willebrand factor) (eg, von Willebrand disease types 1 and 3), full gene sequence",25.470796114782157,,Present in Autoproposal
81312,"PABPN1 (poly[A] binding protein nuclear 1) (eg, oculopharyngeal muscular dystrophy) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81218,"CEBPA (CCAAT/enhancer binding protein [C/EBP], alpha) (eg, acute myeloid leukemia), gene analysis, full gene sequence",25.422383796949322,,Present in Autoproposal
81320,"PLCG2 (phospholipase C gamma 2) (eg, chronic lymphocytic leukemia) gene analysis, common variants (eg, R665W, S707F, L845F)",81335,"TPMT (thiopurine S-methyltransferase) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3)",36.276813493637455,10,Present in Autoproposal
81320,"PLCG2 (phospholipase C gamma 2) (eg, chronic lymphocytic leukemia) gene analysis, common variants (eg, R665W, S707F, L845F)",G8375,CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENT WITH NO DOCUMENTATION OF BASELINE FLOW CYTOMETRY PERFORMED,33.801028288403984,,Present in Autoproposal
81320,"PLCG2 (phospholipase C gamma 2) (eg, chronic lymphocytic leukemia) gene analysis, common variants (eg, R665W, S707F, L845F)",81310,"NPM1 (nucleophosmin) (eg, acute myeloid leukemia) gene analysis, exon 12 variants",33.18807350153562,,Present in Autoproposal
81320,"PLCG2 (phospholipase C gamma 2) (eg, chronic lymphocytic leukemia) gene analysis, common variants (eg, R665W, S707F, L845F)",81231,"CYP3A5 (cytochrome P450 family 3 subfamily A member 5) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *5, *6, *7)",32.565859518621664,,Present in Autoproposal
81320,"PLCG2 (phospholipase C gamma 2) (eg, chronic lymphocytic leukemia) gene analysis, common variants (eg, R665W, S707F, L845F)",81227,"CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *5, *6)",32.45564649937559,,Present in Autoproposal
81320,"PLCG2 (phospholipase C gamma 2) (eg, chronic lymphocytic leukemia) gene analysis, common variants (eg, R665W, S707F, L845F)",81200,"ASPA (aspartoacylase) (eg, Canavan disease) gene analysis, common variants (eg, E285A, Y231X)",32.10508372218263,,Present in Autoproposal
81320,"PLCG2 (phospholipase C gamma 2) (eg, chronic lymphocytic leukemia) gene analysis, common variants (eg, R665W, S707F, L845F)",81402,"Molecular pathology procedure, Level 3 (eg, >10 SNPs, 2-10 methylated variants, or 2-10 somatic variants [typically using non-sequencing target variant analysis], immunoglobulin and T-cell receptor gene rearrangements, duplication/deletion variants of 1 exon, loss of heterozygosity [LOH], uniparental disomy [UPD]) Chromosome 1p-/19q- (eg, glial tumors), deletion analysis Chromosome 18q- (eg, D18S55, D18S58, D18S61, D18S64, and D18S69) (eg, colon cancer), allelic imbalance assessment (ie, loss of heterozygosity) COL1A1/PDGFB (t(17;22)) (eg, dermatofibrosarcoma protuberans), translocation analysis, multiple breakpoints, qualitative, and quantitative, if performed CYP21A2 (cytochrome P450, family 21, subfamily A, polypeptide 2) (eg, congenital adrenal hyperplasia, 21-hydroxylase deficiency), common variants (eg, IVS2-13G, P30L, I172N, exon 6 mutation cluster [I235N, V236E, M238K], V281L, L307FfsX6, Q318X, R356W, P453S, G110VfsX21, 30-kb deletion variant) ESR1/PGR (receptor 1/progesterone receptor) ratio (eg, breast cancer) IGH@/BCL2 (t(14;18)) (eg, follicular lymphoma), translocation analysis; major breakpoint region (MBR) and minor cluster region (mcr) breakpoints, qualitative or quantitative MEFV (Mediterranean fever) (eg, familial Mediterranean fever), common variants (eg, E148Q, P369S, F479L, M680I, I692del, M694V, M694I, K695R, V726A, A744S, R761H) MPL (myeloproliferative leukemia virus oncogene, thrombopoietin receptor, TPOR) (eg, myeloproliferative disorder), common variants (eg, W515A, W515K, W515L, W515R) TRD@ (T cell antigen receptor, delta) (eg, leukemia and lymphoma), gene rearrangement analysis, evaluation to detect abnormal clonal population Uniparental disomy (UPD) (eg, Russell-Silver syndrome, Prader-Willi/Angelman syndrome), short tandem repeat (STR) analysis",31.30108600027603,,Present in Autoproposal
81320,"PLCG2 (phospholipase C gamma 2) (eg, chronic lymphocytic leukemia) gene analysis, common variants (eg, R665W, S707F, L845F)",81219,"CALR (calreticulin) (eg, myeloproliferative disorders), gene analysis, common variants in exon 9",30.774678612658374,,Present in Autoproposal
81320,"PLCG2 (phospholipase C gamma 2) (eg, chronic lymphocytic leukemia) gene analysis, common variants (eg, R665W, S707F, L845F)",0028U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, copy number variants, common variants with reflex to targeted sequence analysis",30.382431921093588,,Present in Autoproposal
81320,"PLCG2 (phospholipase C gamma 2) (eg, chronic lymphocytic leukemia) gene analysis, common variants (eg, R665W, S707F, L845F)",81225,"CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *8, *17)",29.889050385127298,,Present in Autoproposal
81329,"SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; dosage/deletion analysis (eg, carrier testing), includes SMN2 (survival of motor neuron 2, centromeric) analysis, if performed",81161,"DMD (dystrophin) (eg, Duchenne/Becker muscular dystrophy) deletion analysis, and duplication analysis, if performed",34.260842708173215,10,Present Both in MD and Autoproposal
81329,"SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; dosage/deletion analysis (eg, carrier testing), includes SMN2 (survival of motor neuron 2, centromeric) analysis, if performed",78191,Platelet survival study,32.978191526051184,,Present in Autoproposal
81329,"SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; dosage/deletion analysis (eg, carrier testing), includes SMN2 (survival of motor neuron 2, centromeric) analysis, if performed",78130,Red cell survival study,29.840073930272943,,Present in Autoproposal
81329,"SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; dosage/deletion analysis (eg, carrier testing), includes SMN2 (survival of motor neuron 2, centromeric) analysis, if performed",81162,"BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis and full duplication/deletion analysis",26.894810960492688,,Present in Autoproposal
81329,"SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; dosage/deletion analysis (eg, carrier testing), includes SMN2 (survival of motor neuron 2, centromeric) analysis, if performed",G9261,DOCUMENTATION OF PATIENT SURVIVAL AND ABSENCE OF STROKE FOLLOWING CEA,24.762429911034562,,Present in Autoproposal
81329,"SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; dosage/deletion analysis (eg, carrier testing), includes SMN2 (survival of motor neuron 2, centromeric) analysis, if performed",95929,Central motor evoked potential study (transcranial motor stimulation); lower limbs,24.60310263275401,,Present in Autoproposal
81329,"SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; dosage/deletion analysis (eg, carrier testing), includes SMN2 (survival of motor neuron 2, centromeric) analysis, if performed",95928,Central motor evoked potential study (transcranial motor stimulation); upper limbs,24.526181800664478,,Present in Autoproposal
81329,"SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; dosage/deletion analysis (eg, carrier testing), includes SMN2 (survival of motor neuron 2, centromeric) analysis, if performed",64836,Suture of 1 nerve; ulnar motor,24.46737502328317,,Present in Autoproposal
81329,"SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; dosage/deletion analysis (eg, carrier testing), includes SMN2 (survival of motor neuron 2, centromeric) analysis, if performed",G9259,DOCUMENTATION OF PATIENT SURVIVAL AND ABSENCE OF STROKE FOLLOWING CAS,24.32032799547392,,Present in Autoproposal
81329,"SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; dosage/deletion analysis (eg, carrier testing), includes SMN2 (survival of motor neuron 2, centromeric) analysis, if performed",95939,Central motor evoked potential study (transcranial motor stimulation); in upper and lower limbs,23.658176217895253,,Present in Autoproposal
81333,"TGFBI (transforming growth factor beta-induced) (eg, corneal dystrophy) gene analysis, common variants (eg, R124H, R124C, R124L, R555W, R555Q)",81335,"TPMT (thiopurine S-methyltransferase) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3)",36.710067499239535,10,Present in Autoproposal
81333,"TGFBI (transforming growth factor beta-induced) (eg, corneal dystrophy) gene analysis, common variants (eg, R124H, R124C, R124L, R555W, R555Q)",81235,"EGFR (epidermal growth factor receptor) (eg, non-small cell lung cancer) gene analysis, common variants (eg, exon 19 LREA deletion, L858R, T790M, G719A, G719S, L861Q)",33.45254431695061,,Present in Autoproposal
81333,"TGFBI (transforming growth factor beta-induced) (eg, corneal dystrophy) gene analysis, common variants (eg, R124H, R124C, R124L, R555W, R555Q)",81231,"CYP3A5 (cytochrome P450 family 3 subfamily A member 5) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *5, *6, *7)",32.95479359864476,,Present in Autoproposal
81333,"TGFBI (transforming growth factor beta-induced) (eg, corneal dystrophy) gene analysis, common variants (eg, R124H, R124C, R124L, R555W, R555Q)",81227,"CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *5, *6)",32.843264305242855,,Present in Autoproposal
81333,"TGFBI (transforming growth factor beta-induced) (eg, corneal dystrophy) gene analysis, common variants (eg, R124H, R124C, R124L, R555W, R555Q)",81200,"ASPA (aspartoacylase) (eg, Canavan disease) gene analysis, common variants (eg, E285A, Y231X)",32.48851475658882,,Present in Autoproposal
81333,"TGFBI (transforming growth factor beta-induced) (eg, corneal dystrophy) gene analysis, common variants (eg, R124H, R124C, R124L, R555W, R555Q)",81251,"GBA (glucosidase, beta, acid) (eg, Gaucher disease) gene analysis, common variants (eg, N370S, 84GG, L444P, IVS2+1G>A)",32.485458259586096,,Present in Autoproposal
81333,"TGFBI (transforming growth factor beta-induced) (eg, corneal dystrophy) gene analysis, common variants (eg, R124H, R124C, R124L, R555W, R555Q)",81219,"CALR (calreticulin) (eg, myeloproliferative disorders), gene analysis, common variants in exon 9",31.142220618032944,,Present in Autoproposal
81333,"TGFBI (transforming growth factor beta-induced) (eg, corneal dystrophy) gene analysis, common variants (eg, R124H, R124C, R124L, R555W, R555Q)",0028U,"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, copy number variants, common variants with reflex to targeted sequence analysis",30.745289323992413,,Present in Autoproposal
81333,"TGFBI (transforming growth factor beta-induced) (eg, corneal dystrophy) gene analysis, common variants (eg, R124H, R124C, R124L, R555W, R555Q)",81225,"CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *8, *17)",30.24601533204222,,Present in Autoproposal
81333,"TGFBI (transforming growth factor beta-induced) (eg, corneal dystrophy) gene analysis, common variants (eg, R124H, R124C, R124L, R555W, R555Q)",81291,"MTHFR (5,10-methylenetetrahydrofolate reductase) (eg, hereditary hypercoagulability) gene analysis, common variants (eg, 677T, 1298C)",29.59350696665607,,Present in Autoproposal
81336,"SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; full gene sequence",81408,"Molecular pathology procedure, Level 9 (eg, analysis of >50 exons in a single gene by DNA sequence analysis) ABCA4 (ATP-binding cassette, sub-family A [ABC1], member 4) (eg, Stargardt disease, age-related macular degeneration), full gene sequence ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia), full gene sequence CDH23 (cadherin-related 23) (eg, Usher syndrome, type 1), full gene sequence CEP290 (centrosomal protein 290kDa) (eg, Joubert syndrome), full gene sequence COL1A1 (collagen, type I, alpha 1) (eg, osteogenesis imperfecta, type I), full gene sequence COL1A2 (collagen, type I, alpha 2) (eg, osteogenesis imperfecta, type I), full gene sequence COL4A1 (collagen, type IV, alpha 1) (eg, brain small-vessel disease with hemorrhage), full gene sequence COL4A3 (collagen, type IV, alpha 3 [Goodpasture antigen]) (eg, Alport syndrome), full gene sequence COL4A5 (collagen, type IV, alpha 5) (eg, Alport syndrome), full gene sequence DMD (dystrophin) (eg, Duchenne/Becker muscular dystrophy), full gene sequence DYSF (dysferlin, limb girdle muscular dystrophy 2B [autosomal recessive]) (eg, limb-girdle muscular dystrophy), full gene sequence FBN1 (fibrillin 1) (eg, Marfan syndrome), full gene sequence ITPR1 (inositol 1,4,5-trisphosphate receptor, type 1) (eg, spinocerebellar ataxia), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LRRK2 (leucine-rich repeat kinase 2) (eg, Parkinson disease), full gene sequence MYH11 (myosin, heavy chain 11, smooth muscle) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence NEB (nebulin) (eg, nemaline myopathy 2), full gene sequence NF1 (neurofibromin 1) (eg, neurofibromatosis, type 1), full gene sequence PKHD1 (polycystic kidney and hepatic disease 1) (eg, autosomal recessive polycystic kidney disease), full gene sequence RYR1 (ryanodine receptor 1, skeletal) (eg, malignant hyperthermia), full gene sequence RYR2 (ryanodine receptor 2 [cardiac]) (eg, cate01cholaminergic polymorphic ventricular tachycardia, arrhythmogenic right ventricular dysplasia), full gene sequence or targeted sequence analysis of > 50 exons USH2A (Usher syndrome 2A [autosomal recessive, mild]) (eg, Usher syndrome, type 2), full gene sequence VPS13B (vacuolar protein sorting 13 homolog B [yeast]) (eg, Cohen syndrome), full gene sequence VWF (von Willebrand factor) (eg, von Willebrand disease types 1 and 3), full gene sequence",54.357274618803416,9,Present in Autoproposal
81336,"SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; full gene sequence",81406,"Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2 [S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-girdle muscular dystrophy), full gene sequence ANOS1 (anosmin-1) (eg, Kallmann syndrome 1), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+ transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Bera08, arrhythmogenic right ventricular cardiomyopathy), full gene sequence TNNT2 (troponin T, type 2 [cardiac]) (eg, familial hypertrophic cardiomyopathy), full gene sequence TRPC6 (transient receptor potential cation channel, subfamily C, member 6) (eg, focal segmental glomerulosclerosis), full gene sequence TSC1 (tuberous sclerosis 1) (eg, tuberous sclerosis), full gene sequence TSC2 (tuberous sclerosis 2) (eg, tuberous sclerosis), duplication/deletion analysis UBE3A (ubiquitin protein ligase E3A) (eg, Angelman syndrome), full gene sequence UMOD (uromodulin) (eg, glomerulocystic kidney disease with hyperuricemia and isosthenuria), full gene sequence VWF (von Willebrand factor) (von Willebrand disease type 2A), extended targeted sequence analysis (eg, exons 11-16, 24-26, 51, 52) WAS (Wiskott-Aldrich syndrome [eczema-thrombocytopenia]) (eg, Wiskott-Aldrich syndrome), full gene sequence",50.99147530214473,,Present in Autoproposal
81336,"SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; full gene sequence",S3819,COMPLETE GENE SEQUENCE ANALYSIS; BRCA2 GENE,47.979895640733055,,Present in Autoproposal
81336,"SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; full gene sequence",S3818,COMPLETE GENE SEQUENCE ANALYSIS; BRCA1 GENE,47.979895640733055,,Present in Autoproposal
81336,"SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; full gene sequence",S3828,COMPLETE GENE SEQUENCE ANALYSIS; MLH1 GENE,47.87532949613208,,Present in Autoproposal
81336,"SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; full gene sequence",S3829,COMPLETE GENE SEQUENCE ANALYSIS; MSH2 GENE,47.761338288277905,,Present in Autoproposal
81336,"SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; full gene sequence",81249,"G6PD (glucose-6-phosphate dehydrogenase) (eg, hemolytic anemia, jaundice), gene analysis; full gene sequence",37.825370973095715,,Present in Autoproposal
81336,"SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; full gene sequence",81216,"BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis",32.791021496492604,,Present in Autoproposal
81336,"SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; full gene sequence",81252,"GJB2 (gap junction protein, beta 2, 26kDa, connexin 26) (eg, nonsyndromic hearing loss) gene analysis; full gene sequence",32.54906981700106,,Present Both in MD and Autoproposal
81336,"SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; full gene sequence",81218,"CEBPA (CCAAT/enhancer binding protein [C/EBP], alpha) (eg, acute myeloid leukemia), gene analysis, full gene sequence",32.45916450056798,,Present in Autoproposal
81337,"SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; known familial sequence variant(s)",81215,"BRCA1 (breast cancer 1) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant",36.04257185103199,10,Present in Autoproposal
81337,"SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; known familial sequence variant(s)",81217,"BRCA2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; known familial variant",36.04257185103199,,Present in Autoproposal
81337,"SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; known familial sequence variant(s)",81248,"G6PD (glucose-6-phosphate dehydrogenase) (eg, hemolytic anemia, jaundice), gene analysis; known familial variant(s)",34.88238756970884,,Present in Autoproposal
81337,"SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; known familial sequence variant(s)",81303,"MECP2 (methyl CpG binding protein 2) (eg, Rett syndrome) gene analysis; known familial variant",34.22757044195805,,Present in Autoproposal
81337,"SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; known familial sequence variant(s)",81408,"Molecular pathology procedure, Level 9 (eg, analysis of >50 exons in a single gene by DNA sequence analysis) ABCA4 (ATP-binding cassette, sub-family A [ABC1], member 4) (eg, Stargardt disease, age-related macular degeneration), full gene sequence ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia), full gene sequence CDH23 (cadherin-related 23) (eg, Usher syndrome, type 1), full gene sequence CEP290 (centrosomal protein 290kDa) (eg, Joubert syndrome), full gene sequence COL1A1 (collagen, type I, alpha 1) (eg, osteogenesis imperfecta, type I), full gene sequence COL1A2 (collagen, type I, alpha 2) (eg, osteogenesis imperfecta, type I), full gene sequence COL4A1 (collagen, type IV, alpha 1) (eg, brain small-vessel disease with hemorrhage), full gene sequence COL4A3 (collagen, type IV, alpha 3 [Goodpasture antigen]) (eg, Alport syndrome), full gene sequence COL4A5 (collagen, type IV, alpha 5) (eg, Alport syndrome), full gene sequence DMD (dystrophin) (eg, Duchenne/Becker muscular dystrophy), full gene sequence DYSF (dysferlin, limb girdle muscular dystrophy 2B [autosomal recessive]) (eg, limb-girdle muscular dystrophy), full gene sequence FBN1 (fibrillin 1) (eg, Marfan syndrome), full gene sequence ITPR1 (inositol 1,4,5-trisphosphate receptor, type 1) (eg, spinocerebellar ataxia), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LRRK2 (leucine-rich repeat kinase 2) (eg, Parkinson disease), full gene sequence MYH11 (myosin, heavy chain 11, smooth muscle) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence NEB (nebulin) (eg, nemaline myopathy 2), full gene sequence NF1 (neurofibromin 1) (eg, neurofibromatosis, type 1), full gene sequence PKHD1 (polycystic kidney and hepatic disease 1) (eg, autosomal recessive polycystic kidney disease), full gene sequence RYR1 (ryanodine receptor 1, skeletal) (eg, malignant hyperthermia), full gene sequence RYR2 (ryanodine receptor 2 [cardiac]) (eg, cate01cholaminergic polymorphic ventricular tachycardia, arrhythmogenic right ventricular dysplasia), full gene sequence or targeted sequence analysis of > 50 exons USH2A (Usher syndrome 2A [autosomal recessive, mild]) (eg, Usher syndrome, type 2), full gene sequence VPS13B (vacuolar protein sorting 13 homolog B [yeast]) (eg, Cohen syndrome), full gene sequence VWF (von Willebrand factor) (eg, von Willebrand disease types 1 and 3), full gene sequence",33.12818810940591,,Present in Autoproposal
81337,"SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; known familial sequence variant(s)",81406,"Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2 [S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-girdle muscular dystrophy), full gene sequence ANOS1 (anosmin-1) (eg, Kallmann syndrome 1), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+ transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Bera08, arrhythmogenic right ventricular cardiomyopathy), full gene sequence TNNT2 (troponin T, type 2 [cardiac]) (eg, familial hypertrophic cardiomyopathy), full gene sequence TRPC6 (transient receptor potential cation channel, subfamily C, member 6) (eg, focal segmental glomerulosclerosis), full gene sequence TSC1 (tuberous sclerosis 1) (eg, tuberous sclerosis), full gene sequence TSC2 (tuberous sclerosis 2) (eg, tuberous sclerosis), duplication/deletion analysis UBE3A (ubiquitin protein ligase E3A) (eg, Angelman syndrome), full gene sequence UMOD (uromodulin) (eg, glomerulocystic kidney disease with hyperuricemia and isosthenuria), full gene sequence VWF (von Willebrand factor) (von Willebrand disease type 2A), extended targeted sequence analysis (eg, exons 11-16, 24-26, 51, 52) WAS (Wiskott-Aldrich syndrome [eczema-thrombocytopenia]) (eg, Wiskott-Aldrich syndrome), full gene sequence",31.49053531430815,,Present in Autoproposal
81337,"SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; known familial sequence variant(s)",S3819,COMPLETE GENE SEQUENCE ANALYSIS; BRCA2 GENE,31.154685974761875,,Present in Autoproposal
81337,"SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; known familial sequence variant(s)",S3818,COMPLETE GENE SEQUENCE ANALYSIS; BRCA1 GENE,31.154685974761875,,Present in Autoproposal
81337,"SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; known familial sequence variant(s)",S3828,COMPLETE GENE SEQUENCE ANALYSIS; MLH1 GENE,31.086788257288124,,Present in Autoproposal
81337,"SMN1 (survival of motor neuron 1, telomeric) (eg, spinal muscular atrophy) gene analysis; known familial sequence variant(s)",S3829,COMPLETE GENE SEQUENCE ANALYSIS; MSH2 GENE,31.012770583069464,,Present in Autoproposal
81343,"PPP2R2B (protein phosphatase 2 regulatory subunit Bbeta) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81243,"FMR1 (fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",38.95701291082396,10,Present Both in MD and Autoproposal
81343,"PPP2R2B (protein phosphatase 2 regulatory subunit Bbeta) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81342,"TRG@ (T cell antigen receptor, gamma) (eg, leukemia and lymphoma), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)",31.74959304401568,,Present in Autoproposal
81343,"PPP2R2B (protein phosphatase 2 regulatory subunit Bbeta) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81264,"IGK@ (Immunoglobulin kappa light chain locus) (eg, leukemia and lymphoma, B-cell), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)",28.764950777935493,,Present in Autoproposal
81343,"PPP2R2B (protein phosphatase 2 regulatory subunit Bbeta) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81341,"TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using direct probe methodology (eg, Southern blot)",27.268816843029462,,Present in Autoproposal
81343,"PPP2R2B (protein phosphatase 2 regulatory subunit Bbeta) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81340,"TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using amplification methodology (eg, polymerase chain reaction)",26.562179893675108,,Present in Autoproposal
81343,"PPP2R2B (protein phosphatase 2 regulatory subunit Bbeta) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81262,"IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); direct probe methodology (eg, Southern blot)",25.76859837846736,,Present in Autoproposal
81343,"PPP2R2B (protein phosphatase 2 regulatory subunit Bbeta) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81261,"IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); amplified methodology (eg, polymerase chain reaction)",24.40508259079015,,Present in Autoproposal
81343,"PPP2R2B (protein phosphatase 2 regulatory subunit Bbeta) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81250,"G6PC (glucose-6-phosphatase, catalytic subunit) (eg, Glycogen storage disease, type 1a, von Gierke disease) gene analysis, common variants (eg, R83C, Q347X)",24.36311961675239,,Present in Autoproposal
81343,"PPP2R2B (protein phosphatase 2 regulatory subunit Bbeta) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81408,"Molecular pathology procedure, Level 9 (eg, analysis of >50 exons in a single gene by DNA sequence analysis) ABCA4 (ATP-binding cassette, sub-family A [ABC1], member 4) (eg, Stargardt disease, age-related macular degeneration), full gene sequence ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia), full gene sequence CDH23 (cadherin-related 23) (eg, Usher syndrome, type 1), full gene sequence CEP290 (centrosomal protein 290kDa) (eg, Joubert syndrome), full gene sequence COL1A1 (collagen, type I, alpha 1) (eg, osteogenesis imperfecta, type I), full gene sequence COL1A2 (collagen, type I, alpha 2) (eg, osteogenesis imperfecta, type I), full gene sequence COL4A1 (collagen, type IV, alpha 1) (eg, brain small-vessel disease with hemorrhage), full gene sequence COL4A3 (collagen, type IV, alpha 3 [Goodpasture antigen]) (eg, Alport syndrome), full gene sequence COL4A5 (collagen, type IV, alpha 5) (eg, Alport syndrome), full gene sequence DMD (dystrophin) (eg, Duchenne/Becker muscular dystrophy), full gene sequence DYSF (dysferlin, limb girdle muscular dystrophy 2B [autosomal recessive]) (eg, limb-girdle muscular dystrophy), full gene sequence FBN1 (fibrillin 1) (eg, Marfan syndrome), full gene sequence ITPR1 (inositol 1,4,5-trisphosphate receptor, type 1) (eg, spinocerebellar ataxia), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LRRK2 (leucine-rich repeat kinase 2) (eg, Parkinson disease), full gene sequence MYH11 (myosin, heavy chain 11, smooth muscle) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence NEB (nebulin) (eg, nemaline myopathy 2), full gene sequence NF1 (neurofibromin 1) (eg, neurofibromatosis, type 1), full gene sequence PKHD1 (polycystic kidney and hepatic disease 1) (eg, autosomal recessive polycystic kidney disease), full gene sequence RYR1 (ryanodine receptor 1, skeletal) (eg, malignant hyperthermia), full gene sequence RYR2 (ryanodine receptor 2 [cardiac]) (eg, cate01cholaminergic polymorphic ventricular tachycardia, arrhythmogenic right ventricular dysplasia), full gene sequence or targeted sequence analysis of > 50 exons USH2A (Usher syndrome 2A [autosomal recessive, mild]) (eg, Usher syndrome, type 2), full gene sequence VPS13B (vacuolar protein sorting 13 homolog B [yeast]) (eg, Cohen syndrome), full gene sequence VWF (von Willebrand factor) (eg, von Willebrand disease types 1 and 3), full gene sequence",22.33720123907537,,Present in Autoproposal
81343,"PPP2R2B (protein phosphatase 2 regulatory subunit Bbeta) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81244,"FMR1 (Fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; characterization of alleles (eg, expanded size and methylation status)",22.21981543587907,,Present in Autoproposal
81344,"TBP (TATA box binding protein) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81243,"FMR1 (fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; evaluation to detect abnormal (eg, expanded) alleles",38.800460900453224,10,Present Both in MD and Autoproposal
81344,"TBP (TATA box binding protein) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81342,"TRG@ (T cell antigen receptor, gamma) (eg, leukemia and lymphoma), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)",31.622004652398715,,Present in Autoproposal
81344,"TBP (TATA box binding protein) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81302,"MECP2 (methyl CpG binding protein 2) (eg, Rett syndrome) gene analysis; full sequence analysis",29.334529829469286,,Present in Autoproposal
81344,"TBP (TATA box binding protein) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81264,"IGK@ (Immunoglobulin kappa light chain locus) (eg, leukemia and lymphoma, B-cell), gene rearrangement analysis, evaluation to detect abnormal clonal population(s)",28.64935642056499,,Present in Autoproposal
81344,"TBP (TATA box binding protein) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81341,"TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using direct probe methodology (eg, Southern blot)",27.15923482484496,,Present in Autoproposal
81344,"TBP (TATA box binding protein) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81340,"TRB@ (T cell antigen receptor, beta) (eg, leukemia and lymphoma), gene rearrangement analysis to detect abnormal clonal population(s); using amplification methodology (eg, polymerase chain reaction)",26.45543755509533,,Present in Autoproposal
81344,"TBP (TATA box binding protein) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81218,"CEBPA (CCAAT/enhancer binding protein [C/EBP], alpha) (eg, acute myeloid leukemia), gene analysis, full gene sequence",26.321818673649368,,Present in Autoproposal
81344,"TBP (TATA box binding protein) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81304,"MECP2 (methyl CpG binding protein 2) (eg, Rett syndrome) gene analysis; duplication/deletion variants",26.047415070277207,,Present in Autoproposal
81344,"TBP (TATA box binding protein) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81303,"MECP2 (methyl CpG binding protein 2) (eg, Rett syndrome) gene analysis; known familial variant",25.947374250049283,,Present in Autoproposal
81344,"TBP (TATA box binding protein) (eg, spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (eg, expanded) alleles",81262,"IGH@ (Immunoglobulin heavy chain locus) (eg, leukemias and lymphomas, B-cell), gene rearrangement analysis to detect abnormal clonal population(s); direct probe methodology (eg, Southern blot)",25.665045113492464,,Present in Autoproposal
81345,"TERT (telomerase reverse transcriptase) (eg, thyroid carcinoma, glioblastoma multiforme) gene analysis, targeted sequence analysis (eg, promoter region)",81287,"MGMT (O-6-methylguanine-DNA methyltransferase) (eg, glioblastoma multiforme), methylation analysis",37.381295553521745,10,Present Both in MD and Autoproposal
81345,"TERT (telomerase reverse transcriptase) (eg, thyroid carcinoma, glioblastoma multiforme) gene analysis, targeted sequence analysis (eg, promoter region)",0027U,"JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) gene analysis, targeted sequence analysis exons 12-15",31.11010700021622,,Present in Autoproposal
81345,"TERT (telomerase reverse transcriptase) (eg, thyroid carcinoma, glioblastoma multiforme) gene analysis, targeted sequence analysis (eg, promoter region)",S3818,COMPLETE GENE SEQUENCE ANALYSIS; BRCA1 GENE,30.37775138040398,,Present in Autoproposal
81345,"TERT (telomerase reverse transcriptase) (eg, thyroid carcinoma, glioblastoma multiforme) gene analysis, targeted sequence analysis (eg, promoter region)",S3819,COMPLETE GENE SEQUENCE ANALYSIS; BRCA2 GENE,30.37775138040398,,Present in Autoproposal
81345,"TERT (telomerase reverse transcriptase) (eg, thyroid carcinoma, glioblastoma multiforme) gene analysis, targeted sequence analysis (eg, promoter region)",S3828,COMPLETE GENE SEQUENCE ANALYSIS; MLH1 GENE,30.311546894106623,,Present in Autoproposal
81345,"TERT (telomerase reverse transcriptase) (eg, thyroid carcinoma, glioblastoma multiforme) gene analysis, targeted sequence analysis (eg, promoter region)",S3829,COMPLETE GENE SEQUENCE ANALYSIS; MSH2 GENE,30.2393750703562,,Present in Autoproposal
81345,"TERT (telomerase reverse transcriptase) (eg, thyroid carcinoma, glioblastoma multiforme) gene analysis, targeted sequence analysis (eg, promoter region)",81406,"Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia) ACADVL (acyl-CoA dehydrogenase, very long chain) (eg, very long chain acyl-coenzyme A dehydrogenase deficiency), full gene sequence ACTN4 (actinin, alpha 4) (eg, focal segmental glomerulosclerosis), full gene sequence AFG3L2 (AFG3 ATPase family gene 3-like 2 [S. cerevisiae]) (eg, spinocerebellar ataxia), full gene sequence AIRE (autoimmune regulator) (eg, autoimmune polyendocrinopathy syndrome type 1), full gene sequence ALDH7A1 (aldehyde dehydrogenase 7 family, member A1) (eg, pyridoxine-dependent epilepsy), full gene sequence ANO5 (anoctamin 5) (eg, limb-girdle muscular dystrophy), full gene sequence ANOS1 (anosmin-1) (eg, Kallmann syndrome 1), full gene sequence APP (amyloid beta [A4] precursor protein) (eg, Alzheimer disease), full gene sequence ASS1 (argininosuccinate synthase 1) (eg, citrullinemia type I), full gene sequence ATL1 (atlastin GTPase 1) (eg, spastic paraplegia), full gene sequence ATP1A2 (ATPase, Na+/K+ transporting, alpha 2 polypeptide) (eg, familial hemiplegic migraine), full gene sequence ATP7B (ATPase, Cu++ transporting, beta polypeptide) (eg, Wilson disease), full gene sequence BBS1 (Bardet-Biedl syndrome 1) (eg, Bardet-Biedl syndrome), full gene sequence BBS2 (Bardet-Biedl syndrome 2) (eg, Bardet-Biedl syndrome), full gene sequence BCKDHB (branched-chain keto acid dehydrogenase E1, beta polypeptide) (eg, maple syrup urine disease, type 1B), full gene sequence BEST1 (bestrophin 1) (eg, vitelliform macular dystrophy), full gene sequence BMPR2 (bone morphogenetic protein receptor, type II [serine/threonine kinase]) (eg, heritable pulmonary arterial hypertension), full gene sequence BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, Noonan syndrome), full gene sequence BSCL2 (Berardinelli-Seip congenital lipodystrophy 2 [seipin]) (eg, Bera08, arrhythmogenic right ventricular cardiomyopathy), full gene sequence TNNT2 (troponin T, type 2 [cardiac]) (eg, familial hypertrophic cardiomyopathy), full gene sequence TRPC6 (transient receptor potential cation channel, subfamily C, member 6) (eg, focal segmental glomerulosclerosis), full gene sequence TSC1 (tuberous sclerosis 1) (eg, tuberous sclerosis), full gene sequence TSC2 (tuberous sclerosis 2) (eg, tuberous sclerosis), duplication/deletion analysis UBE3A (ubiquitin protein ligase E3A) (eg, Angelman syndrome), full gene sequence UMOD (uromodulin) (eg, glomerulocystic kidney disease with hyperuricemia and isosthenuria), full gene sequence VWF (von Willebrand factor) (von Willebrand disease type 2A), extended targeted sequence analysis (eg, exons 11-16, 24-26, 51, 52) WAS (Wiskott-Aldrich syndrome [eczema-thrombocytopenia]) (eg, Wiskott-Aldrich syndrome), full gene sequence",29.506569370808737,,Present in Autoproposal
81345,"TERT (telomerase reverse transcriptase) (eg, thyroid carcinoma, glioblastoma multiforme) gene analysis, targeted sequence analysis (eg, promoter region)",81408,"Molecular pathology procedure, Level 9 (eg, analysis of >50 exons in a single gene by DNA sequence analysis) ABCA4 (ATP-binding cassette, sub-family A [ABC1], member 4) (eg, Stargardt disease, age-related macular degeneration), full gene sequence ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia), full gene sequence CDH23 (cadherin-related 23) (eg, Usher syndrome, type 1), full gene sequence CEP290 (centrosomal protein 290kDa) (eg, Joubert syndrome), full gene sequence COL1A1 (collagen, type I, alpha 1) (eg, osteogenesis imperfecta, type I), full gene sequence COL1A2 (collagen, type I, alpha 2) (eg, osteogenesis imperfecta, type I), full gene sequence COL4A1 (collagen, type IV, alpha 1) (eg, brain small-vessel disease with hemorrhage), full gene sequence COL4A3 (collagen, type IV, alpha 3 [Goodpasture antigen]) (eg, Alport syndrome), full gene sequence COL4A5 (collagen, type IV, alpha 5) (eg, Alport syndrome), full gene sequence DMD (dystrophin) (eg, Duchenne/Becker muscular dystrophy), full gene sequence DYSF (dysferlin, limb girdle muscular dystrophy 2B [autosomal recessive]) (eg, limb-girdle muscular dystrophy), full gene sequence FBN1 (fibrillin 1) (eg, Marfan syndrome), full gene sequence ITPR1 (inositol 1,4,5-trisphosphate receptor, type 1) (eg, spinocerebellar ataxia), full gene sequence LAMA2 (laminin, alpha 2) (eg, congenital muscular dystrophy), full gene sequence LRRK2 (leucine-rich repeat kinase 2) (eg, Parkinson disease), full gene sequence MYH11 (myosin, heavy chain 11, smooth muscle) (eg, thoracic aortic aneurysms and aortic dissections), full gene sequence NEB (nebulin) (eg, nemaline myopathy 2), full gene sequence NF1 (neurofibromin 1) (eg, neurofibromatosis, type 1), full gene sequence PKHD1 (polycystic kidney and hepatic disease 1) (eg, autosomal recessive polycystic kidney disease), full gene sequence RYR1 (ryanodine receptor 1, skeletal) (eg, malignant hyperthermia), full gene sequence RYR2 (ryanodine receptor 2 [cardiac]) (eg, cate01cholaminergic polymorphic ventricular tachycardia, arrhythmogenic right ventricular dysplasia), full gene sequence or targeted sequence analysis of > 50 exons USH2A (Usher syndrome 2A [autosomal recessive, mild]) (eg, Usher syndrome, type 2), full gene sequence VPS13B (vacuolar protein sorting 13 homolog B [yeast]) (eg, Cohen syndrome), full gene sequence VWF (von Willebrand factor) (eg, von Willebrand disease types 1 and 3), full gene sequence",28.788619178409995,,Present in Autoproposal
81345,"TERT (telomerase reverse transcriptase) (eg, thyroid carcinoma, glioblastoma multiforme) gene analysis, targeted sequence analysis (eg, promoter region)",79030,"THYROID ABLATION, CARCINOMA",28.54443339152405,,Present in Autoproposal
81345,"TERT (telomerase reverse transcriptase) (eg, thyroid carcinoma, glioblastoma multiforme) gene analysis, targeted sequence analysis (eg, promoter region)",81314,"PDGFRA (platelet-derived growth factor receptor, alpha polypeptide) (eg, gastrointestinal stromal tumor [GIST]), gene analysis, targeted sequence analysis (eg, exons 12, 18)",27.71313464859778,,Present in Autoproposal
81443,"Genetic testing for severe inherited conditions (eg, cystic fibrosis, Ashkenazi Jewish-associated disorders [eg, Bloom syndrome, Canavan disease, Fanconi anemia type C, mucolipidosis type VI, Gaucher disease, Tay-Sachs disease], beta hemoglobinopathies, phenylketonuria, galactosemia), genomic sequence analysis panel, must include sequencing of at least 15 genes (eg, ACADM, ARSA, ASPA, ATP7B, BCKDHA, BCKDHB, BLM, CFTR, DHCR7, FANCC, G6PC, GAA, GALT, GBA, GBE1, HBB, HEXA, IKBKAP, MCOLN1, PAH)",81412,"Ashkenazi Jewish associated disorders (eg, Bloom syndrome, Canavan disease, cystic fibrosis, familial dysautonomia, Fanconi anemia group C, Gaucher disease, Tay-Sachs disease), genomic sequence analysis panel, must include sequencing of at least 9 genes, including ASPA, BLM, CFTR, FANCC, GBA, HEXA, IKBKAP, MCOLN1, and SMPD1",77.90611309028772,1,Present Both in MD and Autoproposal
81443,"Genetic testing for severe inherited conditions (eg, cystic fibrosis, Ashkenazi Jewish-associated disorders [eg, Bloom syndrome, Canavan disease, Fanconi anemia type C, mucolipidosis type VI, Gaucher disease, Tay-Sachs disease], beta hemoglobinopathies, phenylketonuria, galactosemia), genomic sequence analysis panel, must include sequencing of at least 15 genes (eg, ACADM, ARSA, ASPA, ATP7B, BCKDHA, BCKDHB, BLM, CFTR, DHCR7, FANCC, G6PC, GAA, GALT, GBA, GBE1, HBB, HEXA, IKBKAP, MCOLN1, PAH)",S3847,GENETIC TESTING FOR TAY-SACHS DISEASE,33.67879964394848,,Present in Autoproposal
81443,"Genetic testing for severe inherited conditions (eg, cystic fibrosis, Ashkenazi Jewish-associated disorders [eg, Bloom syndrome, Canavan disease, Fanconi anemia type C, mucolipidosis type VI, Gaucher disease, Tay-Sachs disease], beta hemoglobinopathies, phenylketonuria, galactosemia), genomic sequence analysis panel, must include sequencing of at least 15 genes (eg, ACADM, ARSA, ASPA, ATP7B, BCKDHA, BCKDHB, BLM, CFTR, DHCR7, FANCC, G6PC, GAA, GALT, GBA, GBE1, HBB, HEXA, IKBKAP, MCOLN1, PAH)",S3848,GENETIC TESTING FOR GAUCHER DISEASE,30.103299646130427,,Present in Autoproposal
81443,"Genetic testing for severe inherited conditions (eg, cystic fibrosis, Ashkenazi Jewish-associated disorders [eg, Bloom syndrome, Canavan disease, Fanconi anemia type C, mucolipidosis type VI, Gaucher disease, Tay-Sachs disease], beta hemoglobinopathies, phenylketonuria, galactosemia), genomic sequence analysis panel, must include sequencing of at least 15 genes (eg, ACADM, ARSA, ASPA, ATP7B, BCKDHA, BCKDHB, BLM, CFTR, DHCR7, FANCC, G6PC, GAA, GALT, GBA, GBE1, HBB, HEXA, IKBKAP, MCOLN1, PAH)",S3851,GENETIC TESTING FOR CANAVAN DISEASE,30.103299646130427,,Present in Autoproposal
81443,"Genetic testing for severe inherited conditions (eg, cystic fibrosis, Ashkenazi Jewish-associated disorders [eg, Bloom syndrome, Canavan disease, Fanconi anemia type C, mucolipidosis type VI, Gaucher disease, Tay-Sachs disease], beta hemoglobinopathies, phenylketonuria, galactosemia), genomic sequence analysis panel, must include sequencing of at least 15 genes (eg, ACADM, ARSA, ASPA, ATP7B, BCKDHA, BCKDHB, BLM, CFTR, DHCR7, FANCC, G6PC, GAA, GALT, GBA, GBE1, HBB, HEXA, IKBKAP, MCOLN1, PAH)",S3835,COMPLETE GENE SEQUENCE ANALYSIS FOR CYSTIC FIBROSIS GENETIC TESTING,25.87200301236523,,Present in Autoproposal
81443,"Genetic testing for severe inherited conditions (eg, cystic fibrosis, Ashkenazi Jewish-associated disorders [eg, Bloom syndrome, Canavan disease, Fanconi anemia type C, mucolipidosis type VI, Gaucher disease, Tay-Sachs disease], beta hemoglobinopathies, phenylketonuria, galactosemia), genomic sequence analysis panel, must include sequencing of at least 15 genes (eg, ACADM, ARSA, ASPA, ATP7B, BCKDHA, BCKDHB, BLM, CFTR, DHCR7, FANCC, G6PC, GAA, GALT, GBA, GBE1, HBB, HEXA, IKBKAP, MCOLN1, PAH)",81242,"FANCC (Fanconi anemia, complementation group C) (eg, Fanconi anemia, type C) gene analysis, common variant (eg, IVS4+4A>T)",25.157413287671282,,Present in Autoproposal
81443,"Genetic testing for severe inherited conditions (eg, cystic fibrosis, Ashkenazi Jewish-associated disorders [eg, Bloom syndrome, Canavan disease, Fanconi anemia type C, mucolipidosis type VI, Gaucher disease, Tay-Sachs disease], beta hemoglobinopathies, phenylketonuria, galactosemia), genomic sequence analysis panel, must include sequencing of at least 15 genes (eg, ACADM, ARSA, ASPA, ATP7B, BCKDHA, BCKDHB, BLM, CFTR, DHCR7, FANCC, G6PC, GAA, GALT, GBA, GBE1, HBB, HEXA, IKBKAP, MCOLN1, PAH)",81255,"HEXA (hexosaminidase A [alpha polypeptide]) (eg, Tay-Sachs disease) gene analysis, common variants (eg, 1278insTATC, 1421+1G>C, G269S)",22.589613937232027,,Present in Autoproposal
81443,"Genetic testing for severe inherited conditions (eg, cystic fibrosis, Ashkenazi Jewish-associated disorders [eg, Bloom syndrome, Canavan disease, Fanconi anemia type C, mucolipidosis type VI, Gaucher disease, Tay-Sachs disease], beta hemoglobinopathies, phenylketonuria, galactosemia), genomic sequence analysis panel, must include sequencing of at least 15 genes (eg, ACADM, ARSA, ASPA, ATP7B, BCKDHA, BCKDHB, BLM, CFTR, DHCR7, FANCC, G6PC, GAA, GALT, GBA, GBE1, HBB, HEXA, IKBKAP, MCOLN1, PAH)",81200,"ASPA (aspartoacylase) (eg, Canavan disease) gene analysis, common variants (eg, E285A, Y231X)",22.562687440448602,,Present in Autoproposal
81443,"Genetic testing for severe inherited conditions (eg, cystic fibrosis, Ashkenazi Jewish-associated disorders [eg, Bloom syndrome, Canavan disease, Fanconi anemia type C, mucolipidosis type VI, Gaucher disease, Tay-Sachs disease], beta hemoglobinopathies, phenylketonuria, galactosemia), genomic sequence analysis panel, must include sequencing of at least 15 genes (eg, ACADM, ARSA, ASPA, ATP7B, BCKDHA, BCKDHB, BLM, CFTR, DHCR7, FANCC, G6PC, GAA, GALT, GBA, GBE1, HBB, HEXA, IKBKAP, MCOLN1, PAH)",81223,"CFTR (cystic fibrosis transmembrane conductance regulator) (eg, cystic fibrosis) gene analysis; full gene sequence",22.559601731732577,,Present in Autoproposal
81443,"Genetic testing for severe inherited conditions (eg, cystic fibrosis, Ashkenazi Jewish-associated disorders [eg, Bloom syndrome, Canavan disease, Fanconi anemia type C, mucolipidosis type VI, Gaucher disease, Tay-Sachs disease], beta hemoglobinopathies, phenylketonuria, galactosemia), genomic sequence analysis panel, must include sequencing of at least 15 genes (eg, ACADM, ARSA, ASPA, ATP7B, BCKDHA, BCKDHB, BLM, CFTR, DHCR7, FANCC, G6PC, GAA, GALT, GBA, GBE1, HBB, HEXA, IKBKAP, MCOLN1, PAH)",81224,"CFTR (cystic fibrosis transmembrane conductance regulator) (eg, cystic fibrosis) gene analysis; intron 8 poly-T analysis (eg, male infertility)",21.177929888789823,,Present in Autoproposal
81518,"Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of 11 genes (7 content and 4 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithms reported as percentage risk for metastatic recurrence and likelihood of benefit from extended endocrine therapy",81525,"Oncology (colon), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a recurrence score",72.54046444465469,2,Present in Autoproposal
81518,"Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of 11 genes (7 content and 4 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithms reported as percentage risk for metastatic recurrence and likelihood of benefit from extended endocrine therapy",81519,"Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of 21 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence score",68.15822377655007,,Present Both in MD and Autoproposal
81518,"Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of 11 genes (7 content and 4 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithms reported as percentage risk for metastatic recurrence and likelihood of benefit from extended endocrine therapy",81541,"Oncology (prostate), mRNA gene expression profiling by real-time RT-PCR of 46 genes (31 content and 15 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a disease-specific mortality risk score",64.5234756311192,,Present in Autoproposal
81518,"Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of 11 genes (7 content and 4 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithms reported as percentage risk for metastatic recurrence and likelihood of benefit from extended endocrine therapy",81520,"Oncology (breast), mRNA gene expression profiling by hybrid capture of 58 genes (50 content and 8 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a recurrence risk score",63.477830523427556,,Present Both in MD and Autoproposal
81518,"Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of 11 genes (7 content and 4 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithms reported as percentage risk for metastatic recurrence and likelihood of benefit from extended endocrine therapy",81521,"Oncology (breast), mRNA, microarray gene expression profiling of 70 content genes and 465 housekeeping genes, utilizing fresh frozen or formalin-fixed paraffin-embedded tissue, algorithm reported as index related to risk of distant metastasis",53.7629777523685,,Present in Autoproposal
81518,"Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of 11 genes (7 content and 4 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithms reported as percentage risk for metastatic recurrence and likelihood of benefit from extended endocrine therapy",81595,"Cardiology (heart transplant), mRNA, gene expression profiling by real-time quantitative PCR of 20 genes (11 content and 9 housekeeping), utilizing subfraction of peripheral blood, algorithm reported as a rejection risk score",49.11513440854253,,Present in Autoproposal
81518,"Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of 11 genes (7 content and 4 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithms reported as percentage risk for metastatic recurrence and likelihood of benefit from extended endocrine therapy",81540,"Oncology (tumor of unknown origin), mRNA, gene expression profiling by real-time RT-PCR of 92 genes (87 content and 5 housekeeping) to classify tumor into main cancer type and subtype, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a probability of a predicted main cancer type and subtype",48.47298818901511,,Present in Autoproposal
81518,"Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of 11 genes (7 content and 4 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithms reported as percentage risk for metastatic recurrence and likelihood of benefit from extended endocrine therapy",81493,"Coronary artery disease, mRNA, gene expression profiling by real-time RT-PCR of 23 genes, utilizing whole peripheral blood, algorithm reported as a risk score",47.332152066706534,,Present in Autoproposal
81518,"Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of 11 genes (7 content and 4 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithms reported as percentage risk for metastatic recurrence and likelihood of benefit from extended endocrine therapy",81504,"Oncology (tissue of origin), microarray gene expression profiling of > 2000 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as tissue similarity scores",44.97209964408675,,Present in Autoproposal
81518,"Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of 11 genes (7 content and 4 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithms reported as percentage risk for metastatic recurrence and likelihood of benefit from extended endocrine therapy",81551,"Oncology (prostate), promoter methylation profiling by real-time PCR of 3 genes (GSTP1, APC, RASSF1), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a likelihood of prostate cancer detection on repeat biopsy",44.927035695326815,,Present in Autoproposal
81596,"Infectious disease, chronic hepatitis C virus (HCV) infection, six biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, and haptoglobin) utilizing serum, prognostic algorithm reported as scores for fibrosis and necroinflammatory activity in liver",0001M,"Infectious disease, chronic hepatitis C virus (HCV) infection, six biochemical assays (ALT, A2 macroglobulin, apolipoprotein A-1, total bilirubin, GGT, and haptoglobin) utilizing serum, prognostic algorithm reported as scores for fibrosis and necroinflammatory activity in liver",100.0,1,Present Both in MD and Autoproposal
81596,"Infectious disease, chronic hepatitis C virus (HCV) infection, six biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, and haptoglobin) utilizing serum, prognostic algorithm reported as scores for fibrosis and necroinflammatory activity in liver",0002M,"Liver disease, ten biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, haptoglobin, AST, glucose, total cholesterol and triglycerides) utilizing serum, prognostic algorithm reported as quantitative scores for fibrosis, steatosis and alcoholic steatohepatitis (ASH)",65.86236418738702,,Present in Autoproposal
81596,"Infectious disease, chronic hepatitis C virus (HCV) infection, six biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, and haptoglobin) utilizing serum, prognostic algorithm reported as scores for fibrosis and necroinflammatory activity in liver",0003M,"Liver disease, ten biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, haptoglobin, AST, glucose, total cholesterol and triglycerides) utilizing serum, prognostic algorithm reported as quantitative scores for fibrosis, steatosis and nonalcoholic steatohepatitis (NASH)",65.73986623583608,,Present in Autoproposal
81596,"Infectious disease, chronic hepatitis C virus (HCV) infection, six biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, and haptoglobin) utilizing serum, prognostic algorithm reported as scores for fibrosis and necroinflammatory activity in liver",81503,"Oncology (ovarian), biochemical assays of five proteins (CA-125, apolipoprotein A1, beta-2 microglobulin, transferrin, and pre-albumin), utilizing serum, algorithm reported as a risk score",29.1609660933024,,Present in Autoproposal
81596,"Infectious disease, chronic hepatitis C virus (HCV) infection, six biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, and haptoglobin) utilizing serum, prognostic algorithm reported as scores for fibrosis and necroinflammatory activity in liver",81490,"Autoimmune (rheumatoid arthritis), analysis of 12 biomarkers using immunoassays, utilizing serum, prognostic algorithm reported as a disease activity score",28.546662686438236,,Present in Autoproposal
81596,"Infectious disease, chronic hepatitis C virus (HCV) infection, six biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, and haptoglobin) utilizing serum, prognostic algorithm reported as scores for fibrosis and necroinflammatory activity in liver",0003U,"Oncology (ovarian) biochemical assays of five proteins (apolipoprotein A-1, CA 125 II, follicle stimulating hormone, human epididymis protein 4, transferrin), utilizing serum, algorithm reported as a likelihood score",26.85156723436688,,Present in Autoproposal
81596,"Infectious disease, chronic hepatitis C virus (HCV) infection, six biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, and haptoglobin) utilizing serum, prognostic algorithm reported as scores for fibrosis and necroinflammatory activity in liver",81500,"Oncology (ovarian), biochemical assays of two proteins (CA-125 and HE4), utilizing serum, with menopausal status, algorithm reported as a risk score",26.837646380408707,,Present in Autoproposal
81596,"Infectious disease, chronic hepatitis C virus (HCV) infection, six biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, and haptoglobin) utilizing serum, prognostic algorithm reported as scores for fibrosis and necroinflammatory activity in liver",81508,"Fetal congenital abnormalities, biochemical assays of two proteins (PAPP-A, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score",26.07620914354139,,Present in Autoproposal
81596,"Infectious disease, chronic hepatitis C virus (HCV) infection, six biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, and haptoglobin) utilizing serum, prognostic algorithm reported as scores for fibrosis and necroinflammatory activity in liver",81510,"Fetal congenital abnormalities, biochemical assays of three analytes (AFP, uE3, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score",24.85217580138088,,Present in Autoproposal
81596,"Infectious disease, chronic hepatitis C virus (HCV) infection, six biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, and haptoglobin) utilizing serum, prognostic algorithm reported as scores for fibrosis and necroinflammatory activity in liver",81509,"Fetal congenital abnormalities, biochemical assays of three proteins (PAPP-A, hCG [any form], DIA), utilizing maternal serum, algorithm reported as a risk score",24.843999438282243,,Present in Autoproposal
82642,Dihydrotestosterone (DHT),82651,Dihydrotestosterone (DHT),100.0,10,Present in Autoproposal
82642,Dihydrotestosterone (DHT),G6047,DIHYDROTESTOSTERONE,69.29490142762354,,Present in Autoproposal
82642,Dihydrotestosterone (DHT),C9100,"SUPPLY OF RADIOPHARMACEUTICAL DIAGNOSTIC IMAGING AGENT, IODINATED I-131 ALBUMIN, PER MCI",0.0,,Present in Autoproposal
82642,Dihydrotestosterone (DHT),C9110,"INJECTION, ALEMTUZUMAB, PER 10 MG/ ML",0.0,,Present in Autoproposal
82642,Dihydrotestosterone (DHT),C9109,"INJECTION, TIROFIBAN HYDROCHLORIDE, 6.25 MG",0.0,,Present in Autoproposal
82642,Dihydrotestosterone (DHT),C9108,"INJECTION, THYROTROPIN ALPHA, 1.1 MG",0.0,,Present in Autoproposal
82642,Dihydrotestosterone (DHT),C9107,"INJECTION, TINZAPARIN SODIUM, PER 2ML VIAL",0.0,,Present in Autoproposal
82642,Dihydrotestosterone (DHT),C9106,"SIROLIMUS, PER 1 MG/ML",0.0,,Present in Autoproposal
82642,Dihydrotestosterone (DHT),C9105,"INJECTION, HEPATITIS B IMMUNE GLOBULIN, PER 1 ML",0.0,,Present in Autoproposal
82642,Dihydrotestosterone (DHT),C9104,"ANTI-THYMOCYTE GLOBULIN, PER 25 MG",0.0,,Present in Autoproposal
83722,"Lipoprotein, direct measurement; small dense LDL cholesterol",83721,"Lipoprotein, direct measurement; LDL cholesterol",81.01260357337331,1,Present Both in MD and Autoproposal
83722,"Lipoprotein, direct measurement; small dense LDL cholesterol",83719,"Lipoprotein, direct measurement; VLDL cholesterol",57.56550120514756,,Present in Autoproposal
83722,"Lipoprotein, direct measurement; small dense LDL cholesterol",83718,"Lipoprotein, direct measurement; high density cholesterol (HDL cholesterol)",57.03251894919718,,Present in Autoproposal
83722,"Lipoprotein, direct measurement; small dense LDL cholesterol",80061,"Lipid panel This panel must include the following: Cholesterol, serum, total (82465) Lipoprotein, direct measurement, high density cholesterol (HDL cholesterol) (83718) Triglycerides (84478)",41.08643630516974,,Present in Autoproposal
83722,"Lipoprotein, direct measurement; small dense LDL cholesterol",83695,Lipoprotein (a),39.53592492844108,,Present in Autoproposal
83722,"Lipoprotein, direct measurement; small dense LDL cholesterol",S2120,LOW DENSITY LIPOPROTEIN (LDL) APHERESIS USING HEPARIN-INDUCED EXTRACORPOREAL LDL PRECIPITATION,32.838329720052464,,Present in Autoproposal
83722,"Lipoprotein, direct measurement; small dense LDL cholesterol",G8725,"FASTING LIPID PROFILE PERFORMED (TRIGLYCERIDES, LDL-C, HDL-C AND TOTAL CHOLESTEROL)",28.773142475006118,,Present in Autoproposal
83722,"Lipoprotein, direct measurement; small dense LDL cholesterol",G8596,LDL-C WAS NOT PERFORMED,26.66664773871053,,Present in Autoproposal
83722,"Lipoprotein, direct measurement; small dense LDL cholesterol",G8767,"LIPID PANEL RESULTS DOCUMENTED AND REVIEWED (MUST INCLUDE TOTAL CHOLESTEROL, HDL-C, TRIGLYCERIDES AND CALCULATED LDL-C)",25.046262530467807,,Present in Autoproposal
83722,"Lipoprotein, direct measurement; small dense LDL cholesterol",G8593,"LIPID PROFILE RESULTS DOCUMENTED AND REVIEWED (MUST INCLUDE TOTAL CHOLESTEROL, HDL-C, TRIGLYCERIDES AND CALCULATED LDL-C)",24.776138164813922,,Present in Autoproposal
90689,"Influenza virus vaccine quadrivalent (IIV4), inactivated, adjuvanted, preservative free, 0.25mL dosage, for intramuscular use",90686,"Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use",78.01115554030365,6,Present in Autoproposal
90689,"Influenza virus vaccine quadrivalent (IIV4), inactivated, adjuvanted, preservative free, 0.25mL dosage, for intramuscular use",90685,"Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL dosage, for intramuscular use",76.11840564526577,,Present in Autoproposal
90689,"Influenza virus vaccine quadrivalent (IIV4), inactivated, adjuvanted, preservative free, 0.25mL dosage, for intramuscular use",90688,"Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use",68.96051476440961,,Present in Autoproposal
90689,"Influenza virus vaccine quadrivalent (IIV4), inactivated, adjuvanted, preservative free, 0.25mL dosage, for intramuscular use",90630,"Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, for intradermal use",68.15099971439498,,Present Both in MD and Autoproposal
90689,"Influenza virus vaccine quadrivalent (IIV4), inactivated, adjuvanted, preservative free, 0.25mL dosage, for intramuscular use",90687,"Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.25 mL dosage, for intramuscular use",67.03934313767076,,Present in Autoproposal
90689,"Influenza virus vaccine quadrivalent (IIV4), inactivated, adjuvanted, preservative free, 0.25mL dosage, for intramuscular use",90653,"Influenza vaccine, inactivated (IIV), subunit, adjuvanted, for intramuscular use",56.818694638863164,,Present Both in MD and Autoproposal
90689,"Influenza virus vaccine quadrivalent (IIV4), inactivated, adjuvanted, preservative free, 0.25mL dosage, for intramuscular use",90656,"Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use",54.9081057603266,,Present in Autoproposal
90689,"Influenza virus vaccine quadrivalent (IIV4), inactivated, adjuvanted, preservative free, 0.25mL dosage, for intramuscular use",90655,"Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.25 mL dosage, for intramuscular use",53.589473999111526,,Present in Autoproposal
90689,"Influenza virus vaccine quadrivalent (IIV4), inactivated, adjuvanted, preservative free, 0.25mL dosage, for intramuscular use",90674,"Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use",53.55106018812785,,Present in Autoproposal
90689,"Influenza virus vaccine quadrivalent (IIV4), inactivated, adjuvanted, preservative free, 0.25mL dosage, for intramuscular use",90666,"Influenza virus vaccine (IIV), pandemic formulation, split virus, preservative free, for intramuscular use",47.9023975290455,,Present in Autoproposal
92273,"Electroretinography (ERG), with interpretation and report; full field (ie, ffERG, flash ERG, Ganzfeld ERG)",92275,Electroretinography with interpretation and report,35.02421649266655,1,Present Both in MD and Autoproposal
92273,"Electroretinography (ERG), with interpretation and report; full field (ie, ffERG, flash ERG, Ganzfeld ERG)",0005U,"Oncology (prostate) gene expression profile by real-time RT-PCR of 3 genes (ERG, PCA3, and SPDEF), urine, algorithm reported as risk score",27.07668327088933,,Present in Autoproposal
92273,"Electroretinography (ERG), with interpretation and report; full field (ie, ffERG, flash ERG, Ganzfeld ERG)",95930,"Visual evoked potential (VEP) checkerboard or flash testing, central nervous system except glaucoma, with interpretation and report",15.70736741220534,,Present in Autoproposal
92273,"Electroretinography (ERG), with interpretation and report; full field (ie, ffERG, flash ERG, Ganzfeld ERG)",D0365,CONE BEAM CT CAPTURE AND INTERPRETATION WITH FIELD OF VIEW OF ONE FULL DENTAL ARCH  MANDIBLE,13.522769096455347,,Present in Autoproposal
92273,"Electroretinography (ERG), with interpretation and report; full field (ie, ffERG, flash ERG, Ganzfeld ERG)",D0366,"CONE BEAM CT CAPTURE AND INTERPRETATION WITH FIELD OF VIEW OF ONE FULL DENTAL ARCH  MAXILLA, WITH OR WITHOUT CRANIUM",13.03493126971755,,Present in Autoproposal
92273,"Electroretinography (ERG), with interpretation and report; full field (ie, ffERG, flash ERG, Ganzfeld ERG)",S8075,"COMPUTER ANALYSIS OF FULL-FIELD DIGITAL MAMMOGRAM AND FURTHER PHYSICIAN REVIEW FOR INTERPRETATION, MAMMOGRAPHY (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE)",12.521948023414996,,Present in Autoproposal
92273,"Electroretinography (ERG), with interpretation and report; full field (ie, ffERG, flash ERG, Ganzfeld ERG)",93720,"Plethysmography, total body; with interpretation and report",11.95313130374875,,Present in Autoproposal
92273,"Electroretinography (ERG), with interpretation and report; full field (ie, ffERG, flash ERG, Ganzfeld ERG)",83912,Molecular diagnostics; interpretation and report,11.198614508485782,,Present in Autoproposal
92273,"Electroretinography (ERG), with interpretation and report; full field (ie, ffERG, flash ERG, Ganzfeld ERG)",92250,Fundus photography with interpretation and report,11.104449150504701,,Present in Autoproposal
92273,"Electroretinography (ERG), with interpretation and report; full field (ie, ffERG, flash ERG, Ganzfeld ERG)",93040,"Rhythm ECG, 1-3 leads; with interpretation and report",10.779679205900585,,Present in Autoproposal
92274,"Electroretinography (ERG), with interpretation and report; multifocal (mfERG)",92275,Electroretinography with interpretation and report,67.90956738702714,10,Present Both in MD and Autoproposal
92274,"Electroretinography (ERG), with interpretation and report; multifocal (mfERG)",92353,Fitting of spectacle prosthesis for aphakia; multifocal,26.45296860589605,,Present in Autoproposal
92274,"Electroretinography (ERG), with interpretation and report; multifocal (mfERG)",V2786,"SPECIALTY OCCUPATIONAL MULTIFOCAL LENS, PER LENS",24.510315787332864,,Present in Autoproposal
92274,"Electroretinography (ERG), with interpretation and report; multifocal (mfERG)",93720,"Plethysmography, total body; with interpretation and report",23.17630648291224,,Present in Autoproposal
92274,"Electroretinography (ERG), with interpretation and report; multifocal (mfERG)",92342,"Fitting of spectacles, except for aphakia; multifocal, other than bifocal",22.987420251712713,,Present in Autoproposal
92274,"Electroretinography (ERG), with interpretation and report; multifocal (mfERG)",83912,Molecular diagnostics; interpretation and report,21.713349869356506,,Present in Autoproposal
92274,"Electroretinography (ERG), with interpretation and report; multifocal (mfERG)",92250,Fundus photography with interpretation and report,21.530769661611426,,Present in Autoproposal
92274,"Electroretinography (ERG), with interpretation and report; multifocal (mfERG)",93040,"Rhythm ECG, 1-3 leads; with interpretation and report",20.90106288592974,,Present in Autoproposal
92274,"Electroretinography (ERG), with interpretation and report; multifocal (mfERG)",92287,Anterior segment imaging with interpretation and report; with fluorescein angiography,20.7084574886434,,Present in Autoproposal
92274,"Electroretinography (ERG), with interpretation and report; multifocal (mfERG)",0065T,"Ocular photoscreening, with interpretation and report, bilateral",20.636311303405908,,Present in Autoproposal
93264,"Remote monitoring of a wireless pulmonary artery pressure sensor for up to 30 days, including at least weekly downloads of pulmonary artery pressure recordings, interpretation(s), trend analysis, and report(s) by a physician or other qualified health care professional",C2624,"IMPLANTABLE WIRELESS PULMONARY ARTERY PRESSURE SENSOR WITH DELIVERY CATHETER, INCLUDING ALL SYSTEM COMPONENTS",45.429094477804846,8,Present in Autoproposal
93264,"Remote monitoring of a wireless pulmonary artery pressure sensor for up to 30 days, including at least weekly downloads of pulmonary artery pressure recordings, interpretation(s), trend analysis, and report(s) by a physician or other qualified health care professional",C9741,"RIGHT HEART CATHETERIZATION WITH IMPLANTATION OF WIRELESS PRESSURE SENSOR IN THE PULMONARY ARTERY, INCLUDING ANY TYPE OF MEASUREMENT, ANGIOGRAPHY, IMAGING SUPERVISION, INTERPRETATION, AND REPORT",43.5623255390353,,Present in Autoproposal
93264,"Remote monitoring of a wireless pulmonary artery pressure sensor for up to 30 days, including at least weekly downloads of pulmonary artery pressure recordings, interpretation(s), trend analysis, and report(s) by a physician or other qualified health care professional",0496T,"Initiation and monitoring marginal (extended) cadaver donor lung(s) organ perfusion system by physician or qualified health care professional, including physiological and laboratory assessment (eg, pulmonary artery flow, pulmonary artery pressure, left atrial pressure, pulmonary vascular resistance, mean/peak and plateau airway pressure, dynamic compliance and perfusate gas analysis), including bronchoscopy and X ray when performed; each additional hour (List separately in addition to code for primary procedure)",40.72898078582984,,Present in Autoproposal
93264,"Remote monitoring of a wireless pulmonary artery pressure sensor for up to 30 days, including at least weekly downloads of pulmonary artery pressure recordings, interpretation(s), trend analysis, and report(s) by a physician or other qualified health care professional",0495T,"Initiation and monitoring marginal (extended) cadaver donor lung(s) organ perfusion system by physician or qualified health care professional, including physiological and laboratory assessment (eg, pulmonary artery flow, pulmonary artery pressure, left atrial pressure, pulmonary vascular resistance, mean/peak and plateau airway pressure, dynamic compliance and perfusate gas analysis), including bronchoscopy and X ray when performed; first two hours in sterile field",39.84181751682743,,Present in Autoproposal
93264,"Remote monitoring of a wireless pulmonary artery pressure sensor for up to 30 days, including at least weekly downloads of pulmonary artery pressure recordings, interpretation(s), trend analysis, and report(s) by a physician or other qualified health care professional",93298,"Interrogation device evaluation(s), (remote) up to 30 days; implantable loop recorder system, including analysis of recorded heart rhythm data, analysis, review(s) and report(s) by a physician or other qualified health care professional",37.067852499529515,,Present in Autoproposal
93264,"Remote monitoring of a wireless pulmonary artery pressure sensor for up to 30 days, including at least weekly downloads of pulmonary artery pressure recordings, interpretation(s), trend analysis, and report(s) by a physician or other qualified health care professional",93294,"Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead pacemaker system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional",34.214912754794454,,Present in Autoproposal
93264,"Remote monitoring of a wireless pulmonary artery pressure sensor for up to 30 days, including at least weekly downloads of pulmonary artery pressure recordings, interpretation(s), trend analysis, and report(s) by a physician or other qualified health care professional",33506,Repair of anomalous coronary artery from pulmonary artery origin; by translocation from pulmonary artery to aorta,33.64167704310329,,Present in Autoproposal
93264,"Remote monitoring of a wireless pulmonary artery pressure sensor for up to 30 days, including at least weekly downloads of pulmonary artery pressure recordings, interpretation(s), trend analysis, and report(s) by a physician or other qualified health care professional",93295,"Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead implantable defibrillator system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional",33.45626943817833,,Present Both in MD and Autoproposal
93264,"Remote monitoring of a wireless pulmonary artery pressure sensor for up to 30 days, including at least weekly downloads of pulmonary artery pressure recordings, interpretation(s), trend analysis, and report(s) by a physician or other qualified health care professional",0498T,"External patient-activated, physician- or other qualified health care professional-prescribed, electrocardiographic rhythm derived event recorder without 24 hour attended monitoring; review and interpretation by a physician or other qualified health care professional per 30 days with at least one patient-generated triggered event",32.90071267325682,,Present in Autoproposal
93264,"Remote monitoring of a wireless pulmonary artery pressure sensor for up to 30 days, including at least weekly downloads of pulmonary artery pressure recordings, interpretation(s), trend analysis, and report(s) by a physician or other qualified health care professional",33690,Banding of pulmonary artery,32.017589208848875,,Present in Autoproposal
95836,"Electrocorticogram from an implanted brain neurostimulator pulse generator/transmitter, including recording, with interpretation and written report, up to 30 days",95979,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, battery status, electrode selectability and polarity, impedance and patient compliance measurements), complex deep brain neurostimulator pulse generator/transmitter, with initial or subsequent programming; each additional 30 minutes after first hour (List separately in addition to code for primary procedure)",40.679774822176825,10,Present in Autoproposal
95836,"Electrocorticogram from an implanted brain neurostimulator pulse generator/transmitter, including recording, with interpretation and written report, up to 30 days",95978,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, battery status, electrode selectability and polarity, impedance and patient compliance measurements), complex deep brain neurostimulator pulse generator/transmitter, with initial or subsequent programming; first hour",40.09387310960018,,Present in Autoproposal
95836,"Electrocorticogram from an implanted brain neurostimulator pulse generator/transmitter, including recording, with interpretation and written report, up to 30 days",E0756,IMPLANTABLE NEUROSTIMULATOR PULSE GENERATOR,37.16177163099547,,Present in Autoproposal
95836,"Electrocorticogram from an implanted brain neurostimulator pulse generator/transmitter, including recording, with interpretation and written report, up to 30 days",95982,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements) gastric neurostimulator pulse generator/transmitter; subsequent, with reprogramming",35.51523172768273,,Present in Autoproposal
95836,"Electrocorticogram from an implanted brain neurostimulator pulse generator/transmitter, including recording, with interpretation and written report, up to 30 days",95980,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements) gastric neurostimulator pulse generator/transmitter; intraoperative, with programming",35.49201296349056,,Present in Autoproposal
95836,"Electrocorticogram from an implanted brain neurostimulator pulse generator/transmitter, including recording, with interpretation and written report, up to 30 days",95975,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude, pulse duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); complex cranial nerve neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming, each additional 30 minutes after first hour (List separately in addition to code for primary procedure)",35.23746258761279,,Present in Autoproposal
95836,"Electrocorticogram from an implanted brain neurostimulator pulse generator/transmitter, including recording, with interpretation and written report, up to 30 days",95981,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements) gastric neurostimulator pulse generator/transmitter; subsequent, without reprogramming",34.82085998286551,,Present in Autoproposal
95836,"Electrocorticogram from an implanted brain neurostimulator pulse generator/transmitter, including recording, with interpretation and written report, up to 30 days",63688,Revision or removal of implanted spinal neurostimulator pulse generator or receiver,34.33390282400195,,Present in Autoproposal
95836,"Electrocorticogram from an implanted brain neurostimulator pulse generator/transmitter, including recording, with interpretation and written report, up to 30 days",95970,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude, pulse duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); simple or complex brain, spinal cord, or peripheral (ie, cranial nerve, peripheral nerve, sacral nerve, neuromuscular) neurostimulator pulse generator/transmitter, without reprogramming",33.36662516576805,,Present in Autoproposal
95836,"Electrocorticogram from an implanted brain neurostimulator pulse generator/transmitter, including recording, with interpretation and written report, up to 30 days",95974,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude, pulse duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); complex cranial nerve neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming, with or without nerve interface testing, first hour",33.30010719318583,,Present in Autoproposal
95976,"Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with simple cranial nerve neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional",95974,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude, pulse duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); complex cranial nerve neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming, with or without nerve interface testing, first hour",45.14173708376461,1,Present Both in MD and Autoproposal
95976,"Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with simple cranial nerve neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional",95980,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements) gastric neurostimulator pulse generator/transmitter; intraoperative, with programming",43.646777636316436,,Present in Autoproposal
95976,"Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with simple cranial nerve neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional",95971,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude, pulse duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); simple spinal cord, or peripheral (ie, peripheral nerve, sacral nerve, neuromuscular) neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming",43.39735173140991,,Present in Autoproposal
95976,"Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with simple cranial nerve neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional",95975,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude, pulse duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); complex cranial nerve neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming, each additional 30 minutes after first hour (List separately in addition to code for primary procedure)",43.22881579138229,,Present Both in MD and Autoproposal
95976,"Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with simple cranial nerve neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional",95972,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude, pulse duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); complex spinal cord, or peripheral (ie, peripheral nerve, sacral nerve, neuromuscular) (except cranial nerve) neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming",42.81896613604208,,Present in Autoproposal
95976,"Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with simple cranial nerve neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional",95970,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude, pulse duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); simple or complex brain, spinal cord, or peripheral (ie, cranial nerve, peripheral nerve, sacral nerve, neuromuscular) neurostimulator pulse generator/transmitter, without reprogramming",42.50906388453829,,Present in Autoproposal
95976,"Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with simple cranial nerve neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional",95982,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements) gastric neurostimulator pulse generator/transmitter; subsequent, with reprogramming",41.88931505468286,,Present in Autoproposal
95976,"Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with simple cranial nerve neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional",95981,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements) gastric neurostimulator pulse generator/transmitter; subsequent, without reprogramming",41.53295360288626,,Present in Autoproposal
95976,"Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with simple cranial nerve neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional",95978,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, battery status, electrode selectability and polarity, impedance and patient compliance measurements), complex deep brain neurostimulator pulse generator/transmitter, with initial or subsequent programming; first hour",41.409447828909066,,Present in Autoproposal
95976,"Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with simple cranial nerve neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional",95973,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude, pulse duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); complex spinal cord, or peripheral (ie, peripheral nerve, sacral nerve, neuromuscular) (except cranial nerve) neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming, each additional 30 minutes after first hour (List separately in addition to code for primary procedure)",40.659626103238175,,Present in Autoproposal
95977,"Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with complex cranial nerve neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional",95974,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude, pulse duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); complex cranial nerve neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming, with or without nerve interface testing, first hour",46.33353764584923,10,Present Both in MD and Autoproposal
95977,"Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with complex cranial nerve neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional",95975,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude, pulse duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); complex cranial nerve neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming, each additional 30 minutes after first hour (List separately in addition to code for primary procedure)",44.40928986554483,,Present Both in MD and Autoproposal
95977,"Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with complex cranial nerve neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional",95972,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude, pulse duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); complex spinal cord, or peripheral (ie, peripheral nerve, sacral nerve, neuromuscular) (except cranial nerve) neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming",43.93192498631441,,Present in Autoproposal
95977,"Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with complex cranial nerve neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional",95980,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements) gastric neurostimulator pulse generator/transmitter; intraoperative, with programming",43.6509307465129,,Present in Autoproposal
95977,"Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with complex cranial nerve neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional",95978,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, battery status, electrode selectability and polarity, impedance and patient compliance measurements), complex deep brain neurostimulator pulse generator/transmitter, with initial or subsequent programming; first hour",42.80694002016384,,Present in Autoproposal
95977,"Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with complex cranial nerve neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional",95970,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude, pulse duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); simple or complex brain, spinal cord, or peripheral (ie, cranial nerve, peripheral nerve, sacral nerve, neuromuscular) neurostimulator pulse generator/transmitter, without reprogramming",42.492175686694964,,Present in Autoproposal
95977,"Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with complex cranial nerve neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional",95971,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude, pulse duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); simple spinal cord, or peripheral (ie, peripheral nerve, sacral nerve, neuromuscular) neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming",42.2267221828888,,Present in Autoproposal
95977,"Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with complex cranial nerve neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional",95982,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements) gastric neurostimulator pulse generator/transmitter; subsequent, with reprogramming",41.893300937510794,,Present in Autoproposal
95977,"Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with complex cranial nerve neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional",95973,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude, pulse duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); complex spinal cord, or peripheral (ie, peripheral nerve, sacral nerve, neuromuscular) (except cranial nerve) neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming, each additional 30 minutes after first hour (List separately in addition to code for primary procedure)",41.71645896969713,,Present in Autoproposal
95977,"Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with complex cranial nerve neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional",95981,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements) gastric neurostimulator pulse generator/transmitter; subsequent, without reprogramming",41.53690557694801,,Present in Autoproposal
95983,"Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with brain neurostimulator pulse generator/transmitter programming, first 15 minutes face-to-face time with physician or other qualified health care professional",95978,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, battery status, electrode selectability and polarity, impedance and patient compliance measurements), complex deep brain neurostimulator pulse generator/transmitter, with initial or subsequent programming; first hour",43.698431652180474,1,Present Both in MD and Autoproposal
95983,"Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with brain neurostimulator pulse generator/transmitter programming, first 15 minutes face-to-face time with physician or other qualified health care professional",95980,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements) gastric neurostimulator pulse generator/transmitter; intraoperative, with programming",43.02533029317379,,Present in Autoproposal
95983,"Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with brain neurostimulator pulse generator/transmitter programming, first 15 minutes face-to-face time with physician or other qualified health care professional",95974,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude, pulse duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); complex cranial nerve neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming, with or without nerve interface testing, first hour",42.44952379143279,,Present in Autoproposal
95983,"Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with brain neurostimulator pulse generator/transmitter programming, first 15 minutes face-to-face time with physician or other qualified health care professional",95975,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude, pulse duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); complex cranial nerve neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming, each additional 30 minutes after first hour (List separately in addition to code for primary procedure)",42.32324697078935,,Present in Autoproposal
95983,"Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with brain neurostimulator pulse generator/transmitter programming, first 15 minutes face-to-face time with physician or other qualified health care professional",95979,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, battery status, electrode selectability and polarity, impedance and patient compliance measurements), complex deep brain neurostimulator pulse generator/transmitter, with initial or subsequent programming; each additional 30 minutes after first hour (List separately in addition to code for primary procedure)",42.12934830610176,,Present Both in MD and Autoproposal
95983,"Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with brain neurostimulator pulse generator/transmitter programming, first 15 minutes face-to-face time with physician or other qualified health care professional",95982,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements) gastric neurostimulator pulse generator/transmitter; subsequent, with reprogramming",41.30376433583012,,Present in Autoproposal
95983,"Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with brain neurostimulator pulse generator/transmitter programming, first 15 minutes face-to-face time with physician or other qualified health care professional",95981,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements) gastric neurostimulator pulse generator/transmitter; subsequent, without reprogramming",40.68874063561768,,Present in Autoproposal
95983,"Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with brain neurostimulator pulse generator/transmitter programming, first 15 minutes face-to-face time with physician or other qualified health care professional",95971,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude, pulse duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); simple spinal cord, or peripheral (ie, peripheral nerve, sacral nerve, neuromuscular) neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming",39.7872933022429,,Present in Autoproposal
95983,"Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with brain neurostimulator pulse generator/transmitter programming, first 15 minutes face-to-face time with physician or other qualified health care professional",95972,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude, pulse duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); complex spinal cord, or peripheral (ie, peripheral nerve, sacral nerve, neuromuscular) (except cranial nerve) neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming",38.261853542247145,,Present in Autoproposal
95983,"Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with brain neurostimulator pulse generator/transmitter programming, first 15 minutes face-to-face time with physician or other qualified health care professional",95973,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude, pulse duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); complex spinal cord, or peripheral (ie, peripheral nerve, sacral nerve, neuromuscular) (except cranial nerve) neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming, each additional 30 minutes after first hour (List separately in addition to code for primary procedure)",38.167606690307885,,Present in Autoproposal
95984,"Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with brain neurostimulator pulse generator/transmitter programming, each additional 15 minutes face-to-face time with physician or other qualified health care professional (List separately in addition to code for primary procedure)",95979,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, battery status, electrode selectability and polarity, impedance and patient compliance measurements), complex deep brain neurostimulator pulse generator/transmitter, with initial or subsequent programming; each additional 30 minutes after first hour (List separately in addition to code for primary procedure)",45.98213253443544,10,Present Both in MD and Autoproposal
95984,"Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with brain neurostimulator pulse generator/transmitter programming, each additional 15 minutes face-to-face time with physician or other qualified health care professional (List separately in addition to code for primary procedure)",95975,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude, pulse duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); complex cranial nerve neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming, each additional 30 minutes after first hour (List separately in addition to code for primary procedure)",45.704160244812485,,Present in Autoproposal
95984,"Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with brain neurostimulator pulse generator/transmitter programming, each additional 15 minutes face-to-face time with physician or other qualified health care professional (List separately in addition to code for primary procedure)",95980,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements) gastric neurostimulator pulse generator/transmitter; intraoperative, with programming",42.16852730533509,,Present in Autoproposal
95984,"Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with brain neurostimulator pulse generator/transmitter programming, each additional 15 minutes face-to-face time with physician or other qualified health care professional (List separately in addition to code for primary procedure)",95978,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, battery status, electrode selectability and polarity, impedance and patient compliance measurements), complex deep brain neurostimulator pulse generator/transmitter, with initial or subsequent programming; first hour",41.65404056557643,,Present Both in MD and Autoproposal
95984,"Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with brain neurostimulator pulse generator/transmitter programming, each additional 15 minutes face-to-face time with physician or other qualified health care professional (List separately in addition to code for primary procedure)",95973,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude, pulse duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); complex spinal cord, or peripheral (ie, peripheral nerve, sacral nerve, neuromuscular) (except cranial nerve) neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming, each additional 30 minutes after first hour (List separately in addition to code for primary procedure)",41.18821781017321,,Present in Autoproposal
95984,"Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with brain neurostimulator pulse generator/transmitter programming, each additional 15 minutes face-to-face time with physician or other qualified health care professional (List separately in addition to code for primary procedure)",95974,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude, pulse duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); complex cranial nerve neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming, with or without nerve interface testing, first hour",40.603614979203215,,Present in Autoproposal
95984,"Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with brain neurostimulator pulse generator/transmitter programming, each additional 15 minutes face-to-face time with physician or other qualified health care professional (List separately in addition to code for primary procedure)",95982,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements) gastric neurostimulator pulse generator/transmitter; subsequent, with reprogramming",40.48124447483697,,Present in Autoproposal
95984,"Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with brain neurostimulator pulse generator/transmitter programming, each additional 15 minutes face-to-face time with physician or other qualified health care professional (List separately in addition to code for primary procedure)",0363T,"Exposure behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by physician or other qualified health care professional with the assistance of one or more technicians; each additional 30 minutes of technician(s) time, face-to-face with the patient (List separately in addition to code for primary procedure)",40.19104897344712,,Present in Autoproposal
95984,"Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with brain neurostimulator pulse generator/transmitter programming, each additional 15 minutes face-to-face time with physician or other qualified health care professional (List separately in addition to code for primary procedure)",95981,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements) gastric neurostimulator pulse generator/transmitter; subsequent, without reprogramming",39.87846830742309,,Present in Autoproposal
95984,"Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with brain neurostimulator pulse generator/transmitter programming, each additional 15 minutes face-to-face time with physician or other qualified health care professional (List separately in addition to code for primary procedure)",95971,"Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude, pulse duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); simple spinal cord, or peripheral (ie, peripheral nerve, sacral nerve, neuromuscular) neurostimulator pulse generator/transmitter, with intraoperative or subsequent programming",38.99497232417976,,Present in Autoproposal
96112,"Developmental test administration (including assessment of fine and/or gross motor, language, cognitive level, social, memory and/or executive functions by standardized developmental instruments when performed), by physician or other qualified health care professional, with interpretation and report; first hour",96111,"Developmental testing, (includes assessment of motor, language, social, adaptive, and/or cognitive functioning by standardized developmental instruments) with interpretation and report",65.24743914356085,1,Present Both in MD and Autoproposal
96112,"Developmental test administration (including assessment of fine and/or gross motor, language, cognitive level, social, memory and/or executive functions by standardized developmental instruments when performed), by physician or other qualified health care professional, with interpretation and report; first hour",96110,"Developmental screening (eg, developmental milestone survey, speech and language delay screen), with scoring and documentation, per standardized instrument",34.344234356948064,,Present Both in MD and Autoproposal
96112,"Developmental test administration (including assessment of fine and/or gross motor, language, cognitive level, social, memory and/or executive functions by standardized developmental instruments when performed), by physician or other qualified health care professional, with interpretation and report; first hour",G9966,"CHILDREN WHO WERE SCREENED FOR RISK OF DEVELOPMENTAL, BEHAVIORAL AND SOCIAL DELAYS USING A STANDARDIZED TOOL WITH INTERPRETATION AND REPORT",32.61649664112159,,Present Both in MD and Autoproposal
96112,"Developmental test administration (including assessment of fine and/or gross motor, language, cognitive level, social, memory and/or executive functions by standardized developmental instruments when performed), by physician or other qualified health care professional, with interpretation and report; first hour",G9967,"CHILDREN WHO WERE NOT SCREENED FOR RISK OF DEVELOPMENTAL, BEHAVIORAL AND SOCIAL DELAYS USING A STANDARDIZED TOOL WITH INTERPRETATION AND REPORT",32.285005181111316,,Present in Autoproposal
96112,"Developmental test administration (including assessment of fine and/or gross motor, language, cognitive level, social, memory and/or executive functions by standardized developmental instruments when performed), by physician or other qualified health care professional, with interpretation and report; first hour",0362T,"Exposure behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by physician or other qualified health care professional with the assistance of one or more technicians; first 30 minutes of technician(s) time, face-to-face with the patient",31.869780704454016,,Present in Autoproposal
96112,"Developmental test administration (including assessment of fine and/or gross motor, language, cognitive level, social, memory and/or executive functions by standardized developmental instruments when performed), by physician or other qualified health care professional, with interpretation and report; first hour",94452,"High altitude simulation test (HAST), with interpretation and report by a physician or other qualified health care professional",30.821671049788524,,Present in Autoproposal
96112,"Developmental test administration (including assessment of fine and/or gross motor, language, cognitive level, social, memory and/or executive functions by standardized developmental instruments when performed), by physician or other qualified health care professional, with interpretation and report; first hour",90935,Hemodialysis procedure with single evaluation by a physician or other qualified health care professional,29.455083243314277,,Present in Autoproposal
96112,"Developmental test administration (including assessment of fine and/or gross motor, language, cognitive level, social, memory and/or executive functions by standardized developmental instruments when performed), by physician or other qualified health care professional, with interpretation and report; first hour",0359T,"Behavior identification assessment, by the physician or other qualified health care professional, face-to-face with patient and caregiver(s), includes administration of standardized and non-standardized tests, detailed behavioral history, patient observation and caregiver interview, interpretation of test results, discussion of findings and recommendations with the primary guardian(s)/caregiver(s), and preparation of report",29.212948032729024,,Present in Autoproposal
96112,"Developmental test administration (including assessment of fine and/or gross motor, language, cognitive level, social, memory and/or executive functions by standardized developmental instruments when performed), by physician or other qualified health care professional, with interpretation and report; first hour",0363T,"Exposure behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by physician or other qualified health care professional with the assistance of one or more technicians; each additional 30 minutes of technician(s) time, face-to-face with the patient (List separately in addition to code for primary procedure)",28.635767879707853,,Present in Autoproposal
96112,"Developmental test administration (including assessment of fine and/or gross motor, language, cognitive level, social, memory and/or executive functions by standardized developmental instruments when performed), by physician or other qualified health care professional, with interpretation and report; first hour",90460,"Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered",26.741248163055513,,Present in Autoproposal
96113,"Developmental test administration (including assessment of fine and/or gross motor, language, cognitive level, social, memory and/or executive functions by standardized developmental instruments when performed), by physician or other qualified health care professional, with interpretation and report; each additional 30 minutes (List separately in addition to code for primary procedure)",96111,"Developmental testing, (includes assessment of motor, language, social, adaptive, and/or cognitive functioning by standardized developmental instruments) with interpretation and report",62.38217104110089,8,Present Both in MD and Autoproposal
96113,"Developmental test administration (including assessment of fine and/or gross motor, language, cognitive level, social, memory and/or executive functions by standardized developmental instruments when performed), by physician or other qualified health care professional, with interpretation and report; each additional 30 minutes (List separately in addition to code for primary procedure)",0363T,"Exposure behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by physician or other qualified health care professional with the assistance of one or more technicians; each additional 30 minutes of technician(s) time, face-to-face with the patient (List separately in addition to code for primary procedure)",40.095094431674035,,Present in Autoproposal
96113,"Developmental test administration (including assessment of fine and/or gross motor, language, cognitive level, social, memory and/or executive functions by standardized developmental instruments when performed), by physician or other qualified health care professional, with interpretation and report; each additional 30 minutes (List separately in addition to code for primary procedure)",0361T,"Observational behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by one technician; each additional 30 minutes of technician time, face-to-face with the patient (List separately in addition to code for primary service)",33.8970768657327,,Present in Autoproposal
96113,"Developmental test administration (including assessment of fine and/or gross motor, language, cognitive level, social, memory and/or executive functions by standardized developmental instruments when performed), by physician or other qualified health care professional, with interpretation and report; each additional 30 minutes (List separately in addition to code for primary procedure)",0369T,Adaptive behavior treatment with protocol modification administered by physician or other qualified health care professional with one patient; each additional 30 minutes of patient face-to-face time (List separately in addition to code for primary procedure),33.35739470524855,,Present in Autoproposal
96113,"Developmental test administration (including assessment of fine and/or gross motor, language, cognitive level, social, memory and/or executive functions by standardized developmental instruments when performed), by physician or other qualified health care professional, with interpretation and report; each additional 30 minutes (List separately in addition to code for primary procedure)",90461,"Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; each additional vaccine or toxoid component administered (List separately in addition to code for primary procedure)",33.35052712255508,,Present in Autoproposal
96113,"Developmental test administration (including assessment of fine and/or gross motor, language, cognitive level, social, memory and/or executive functions by standardized developmental instruments when performed), by physician or other qualified health care professional, with interpretation and report; each additional 30 minutes (List separately in addition to code for primary procedure)",96110,"Developmental screening (eg, developmental milestone survey, speech and language delay screen), with scoring and documentation, per standardized instrument",32.836045828815074,,Present Both in MD and Autoproposal
96113,"Developmental test administration (including assessment of fine and/or gross motor, language, cognitive level, social, memory and/or executive functions by standardized developmental instruments when performed), by physician or other qualified health care professional, with interpretation and report; each additional 30 minutes (List separately in addition to code for primary procedure)",0362T,"Exposure behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by physician or other qualified health care professional with the assistance of one or more technicians; first 30 minutes of technician(s) time, face-to-face with the patient",32.17907826054376,,Present in Autoproposal
96113,"Developmental test administration (including assessment of fine and/or gross motor, language, cognitive level, social, memory and/or executive functions by standardized developmental instruments when performed), by physician or other qualified health care professional, with interpretation and report; each additional 30 minutes (List separately in addition to code for primary procedure)",G9966,"CHILDREN WHO WERE SCREENED FOR RISK OF DEVELOPMENTAL, BEHAVIORAL AND SOCIAL DELAYS USING A STANDARDIZED TOOL WITH INTERPRETATION AND REPORT",31.830338497704574,,Present Both in MD and Autoproposal
96113,"Developmental test administration (including assessment of fine and/or gross motor, language, cognitive level, social, memory and/or executive functions by standardized developmental instruments when performed), by physician or other qualified health care professional, with interpretation and report; each additional 30 minutes (List separately in addition to code for primary procedure)",G9967,"CHILDREN WHO WERE NOT SCREENED FOR RISK OF DEVELOPMENTAL, BEHAVIORAL AND SOCIAL DELAYS USING A STANDARDIZED TOOL WITH INTERPRETATION AND REPORT",31.506837004048677,,Present in Autoproposal
96113,"Developmental test administration (including assessment of fine and/or gross motor, language, cognitive level, social, memory and/or executive functions by standardized developmental instruments when performed), by physician or other qualified health care professional, with interpretation and report; each additional 30 minutes (List separately in addition to code for primary procedure)",99494,"Initial or subsequent psychiatric collaborative care management, each additional 30 minutes in a calendar month of behavioral health care manager activities, in consultation with a psychiatric consultant, and directed by the treating physician or other qualified health care professional (List separately in addition to code for primary procedure)",31.492868413236707,,Present in Autoproposal
96121,"Neurobehavioral status exam (clinical assessment of thinking, reasoning and judgment, [eg, acquired knowledge, attention, language, memory, planning and problem solving, and visual spatial abilities]), by physician or other qualified health care professional, both face-to-face time with the patient and time interpreting test results and preparing the report; each additional hour (List separately in addition to code for primary procedure)",96116,"Neurobehavioral status exam (clinical assessment of thinking, reasoning and judgment, eg, acquired knowledge, attention, language, memory, planning and problem solving, and visual spatial abilities), per hour of the psychologist's or physician's time, both face-to-face time with the patient and time interpreting test results and preparing the report",91.07099612735887,1,Present Both in MD and Autoproposal
96121,"Neurobehavioral status exam (clinical assessment of thinking, reasoning and judgment, [eg, acquired knowledge, attention, language, memory, planning and problem solving, and visual spatial abilities]), by physician or other qualified health care professional, both face-to-face time with the patient and time interpreting test results and preparing the report; each additional hour (List separately in addition to code for primary procedure)",96125,"Standardized cognitive performance testing (eg, Ross Information Processing Assessment) per hour of a qualified health care professional's time, both face-to-face time administering tests to the patient and time interpreting these test results and preparing the report",47.25736762508844,,Present in Autoproposal
96121,"Neurobehavioral status exam (clinical assessment of thinking, reasoning and judgment, [eg, acquired knowledge, attention, language, memory, planning and problem solving, and visual spatial abilities]), by physician or other qualified health care professional, both face-to-face time with the patient and time interpreting test results and preparing the report; each additional hour (List separately in addition to code for primary procedure)",96101,"Psychological testing (includes psychodiagnostic assessment of emotionality, intellectual abilities, personality and psychopathology, eg, MMPI, Rorschach, WAIS), per hour of the psychologist's or physician's time, both face-to-face time administering tests to the patient and time interpreting these test results and preparing the report",43.27114611337139,,Present in Autoproposal
96121,"Neurobehavioral status exam (clinical assessment of thinking, reasoning and judgment, [eg, acquired knowledge, attention, language, memory, planning and problem solving, and visual spatial abilities]), by physician or other qualified health care professional, both face-to-face time with the patient and time interpreting test results and preparing the report; each additional hour (List separately in addition to code for primary procedure)",0363T,"Exposure behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by physician or other qualified health care professional with the assistance of one or more technicians; each additional 30 minutes of technician(s) time, face-to-face with the patient (List separately in addition to code for primary procedure)",41.154531720658596,,Present in Autoproposal
96121,"Neurobehavioral status exam (clinical assessment of thinking, reasoning and judgment, [eg, acquired knowledge, attention, language, memory, planning and problem solving, and visual spatial abilities]), by physician or other qualified health care professional, both face-to-face time with the patient and time interpreting test results and preparing the report; each additional hour (List separately in addition to code for primary procedure)",96118,"Neuropsychological testing (eg, Halstead-Reitan Neuropsychological Battery, Wechsler Memory Scales and Wisconsin Card Sorting Test), per hour of the psychologist's or physician's time, both face-to-face time administering tests to the patient and time interpreting these test results and preparing the report",40.39582954488941,,Present Both in MD and Autoproposal
96121,"Neurobehavioral status exam (clinical assessment of thinking, reasoning and judgment, [eg, acquired knowledge, attention, language, memory, planning and problem solving, and visual spatial abilities]), by physician or other qualified health care professional, both face-to-face time with the patient and time interpreting test results and preparing the report; each additional hour (List separately in addition to code for primary procedure)",0369T,Adaptive behavior treatment with protocol modification administered by physician or other qualified health care professional with one patient; each additional 30 minutes of patient face-to-face time (List separately in addition to code for primary procedure),37.30819230578768,,Present in Autoproposal
96121,"Neurobehavioral status exam (clinical assessment of thinking, reasoning and judgment, [eg, acquired knowledge, attention, language, memory, planning and problem solving, and visual spatial abilities]), by physician or other qualified health care professional, both face-to-face time with the patient and time interpreting test results and preparing the report; each additional hour (List separately in addition to code for primary procedure)",0361T,"Observational behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by one technician; each additional 30 minutes of technician time, face-to-face with the patient (List separately in addition to code for primary service)",36.78398646152846,,Present in Autoproposal
96121,"Neurobehavioral status exam (clinical assessment of thinking, reasoning and judgment, [eg, acquired knowledge, attention, language, memory, planning and problem solving, and visual spatial abilities]), by physician or other qualified health care professional, both face-to-face time with the patient and time interpreting test results and preparing the report; each additional hour (List separately in addition to code for primary procedure)",0362T,"Exposure behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by physician or other qualified health care professional with the assistance of one or more technicians; first 30 minutes of technician(s) time, face-to-face with the patient",34.28141478164628,,Present in Autoproposal
96121,"Neurobehavioral status exam (clinical assessment of thinking, reasoning and judgment, [eg, acquired knowledge, attention, language, memory, planning and problem solving, and visual spatial abilities]), by physician or other qualified health care professional, both face-to-face time with the patient and time interpreting test results and preparing the report; each additional hour (List separately in addition to code for primary procedure)",0359T,"Behavior identification assessment, by the physician or other qualified health care professional, face-to-face with patient and caregiver(s), includes administration of standardized and non-standardized tests, detailed behavioral history, patient observation and caregiver interview, interpretation of test results, discussion of findings and recommendations with the primary guardian(s)/caregiver(s), and preparation of report",30.880685696673282,,Present in Autoproposal
96121,"Neurobehavioral status exam (clinical assessment of thinking, reasoning and judgment, [eg, acquired knowledge, attention, language, memory, planning and problem solving, and visual spatial abilities]), by physician or other qualified health care professional, both face-to-face time with the patient and time interpreting test results and preparing the report; each additional hour (List separately in addition to code for primary procedure)",96102,"Psychological testing (includes psychodiagnostic assessment of emotionality, intellectual abilities, personality and psychopathology, eg, MMPI and WAIS), with qualified health care professional interpretation and report, administered by technician, per hour of technician time, face-to-face",30.542232296996275,,Present in Autoproposal
96130,"Psychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; first hour",0359T,"Behavior identification assessment, by the physician or other qualified health care professional, face-to-face with patient and caregiver(s), includes administration of standardized and non-standardized tests, detailed behavioral history, patient observation and caregiver interview, interpretation of test results, discussion of findings and recommendations with the primary guardian(s)/caregiver(s), and preparation of report",40.77306343047227,4,Present in Autoproposal
96130,"Psychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; first hour",0378T,"Visual field assessment, with concurrent real time data analysis and accessible data storage with patient initiated data transmitted to a remote surveillance center for up to 30 days; review and interpretation with report by a physician or other qualified health care professional",35.96603845593516,,Present in Autoproposal
96130,"Psychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; first hour",99091,"Collection and interpretation of physiologic data (eg, ECG, blood pressure, glucose monitoring) digitally stored and/or transmitted by the patient and/or caregiver to the physician or other qualified health care professional, qualified by education, training, licensure/regulation (when applicable) requiring a minimum of 30 minutes of time",35.208005684992614,,Present in Autoproposal
96130,"Psychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; first hour",99483,"Assessment of and care planning for a patient with cognitive impairment, requiring an independent historian, in the office or other outpatient, home or domiciliary or rest home, with all of the following required elements: Cognition-focused evaluation including a pertinent history and examination; Medical decision making of moderate or high complexity; Functional assessment (eg, basic and instrumental activities of daily living), including decision-making capacity; Use of standardized instruments for staging of dementia (eg, functional assessment staging test [FAST], clinical dementia rating [CDR]); Medication reconciliation and review for high-risk medications; Evaluation for neuropsychiatric and behavioral symptoms, including depression, including use of standardized screening instrument(s); Evaluation of safety (eg, home), including motor vehicle operation; Identification of caregiver(s), caregiver knowledge, caregiver needs, social supports, and the willingness of caregiver to take on caregiving tasks; Development, updating or revision, or review of an Advance Care Plan; Creation of a written care plan, including initial plans to address any neuropsychiatric symptoms, neuro-cognitive symptoms, functional limitations, and referral to community resources as needed (eg, rehabilitation services, adult day programs, support groups) shared with the patient and/or caregiver with initial education and support. Typically, 50 minutes are spent face-to-face with the patient and/or family or caregiver.",34.15762230217872,,Present Both in MD and Autoproposal
96130,"Psychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; first hour",0379T,"Visual field assessment, with concurrent real time data analysis and accessible data storage with patient initiated data transmitted to a remote surveillance center for up to 30 days; technical support and patient instructions, surveillance, analysis, and transmission of daily and emergent data reports as prescribed by a physician or other qualified health care professional",33.62975864785455,,Present in Autoproposal
96130,"Psychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; first hour",99378,"Supervision of a hospice patient (patient not present) requiring complex and multidisciplinary care modalities involving regular development and/or revision of care plans by that individual, review of subsequent reports of patient status, review of related laboratory and other studies, communication (including telephone calls) for purposes of assessment or care decisions with health care professional(s), family member(s), surrogate decision maker(s) (eg, legal guardian) and/or key caregiver(s) involved in patient's care, integration of new information into the medical treatment plan and/or adjustment of medical therapy, within a calendar month; 30 minutes or more",32.88033241036389,,Present in Autoproposal
96130,"Psychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; first hour",99380,"Supervision of a nursing facility patient (patient not present) requiring complex and multidisciplinary care modalities involving regular development and/or revision of care plans by that individual, review of subsequent reports of patient status, review of related laboratory and other studies, communication (including telephone calls) for purposes of assessment or care decisions with health care professional(s), family member(s), surrogate decision maker(s) (eg, legal guardian) and/or key caregiver(s) involved in patient's care, integration of new information into the medical treatment plan and/or adjustment of medical therapy, within a calendar month; 30 minutes or more",32.731671452480036,,Present in Autoproposal
96130,"Psychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; first hour",99340,"Individual physician supervision of a patient (patient not present) in home, domiciliary or rest home (eg, assisted living facility) requiring complex and multidisciplinary care modalities involving regular physician development and/or revision of care plans, review of subsequent reports of patient status, review of related laboratory and other studies, communication (including telephone calls) for purposes of assessment or care decisions with health care professional(s), family member(s), surrogate decision maker(s) (eg, legal guardian) and/or key caregiver(s) involved in patient's care, integration of new information into the medical treatment plan and/or adjustment of medical therapy, within a calendar month; 30 minutes or more",32.705802904426676,,Present in Autoproposal
96130,"Psychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; first hour",99377,"Supervision of a hospice patient (patient not present) requiring complex and multidisciplinary care modalities involving regular development and/or revision of care plans by that individual, review of subsequent reports of patient status, review of related laboratory and other studies, communication (including telephone calls) for purposes of assessment or care decisions with health care professional(s), family member(s), surrogate decision maker(s) (eg, legal guardian) and/or key caregiver(s) involved in patient's care, integration of new information into the medical treatment plan and/or adjustment of medical therapy, within a calendar month; 15-29 minutes",32.47010608407926,,Present in Autoproposal
96130,"Psychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; first hour",99339,"Individual physician supervision of a patient (patient not present) in home, domiciliary or rest home (eg, assisted living facility) requiring complex and multidisciplinary care modalities involving regular physician development and/or revision of care plans, review of subsequent reports of patient status, review of related laboratory and other studies, communication (including telephone calls) for purposes of assessment or care decisions with health care professional(s), family member(s), surrogate decision maker(s) (eg, legal guardian) and/or key caregiver(s) involved in patient's care, integration of new information into the medical treatment plan and/or adjustment of medical therapy, within a calendar month; 15-29 minutes",32.3553475639829,,Present in Autoproposal
96131,"Psychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; each additional hour (List separately in addition to code for primary procedure)",0359T,"Behavior identification assessment, by the physician or other qualified health care professional, face-to-face with patient and caregiver(s), includes administration of standardized and non-standardized tests, detailed behavioral history, patient observation and caregiver interview, interpretation of test results, discussion of findings and recommendations with the primary guardian(s)/caregiver(s), and preparation of report",40.34529159937652,10,Present in Autoproposal
96131,"Psychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; each additional hour (List separately in addition to code for primary procedure)",0363T,"Exposure behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by physician or other qualified health care professional with the assistance of one or more technicians; each additional 30 minutes of technician(s) time, face-to-face with the patient (List separately in addition to code for primary procedure)",38.0729588158616,,Present in Autoproposal
96131,"Psychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; each additional hour (List separately in addition to code for primary procedure)",0378T,"Visual field assessment, with concurrent real time data analysis and accessible data storage with patient initiated data transmitted to a remote surveillance center for up to 30 days; review and interpretation with report by a physician or other qualified health care professional",35.81471832614424,,Present in Autoproposal
96131,"Psychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; each additional hour (List separately in addition to code for primary procedure)",0369T,Adaptive behavior treatment with protocol modification administered by physician or other qualified health care professional with one patient; each additional 30 minutes of patient face-to-face time (List separately in addition to code for primary procedure),34.79555664233361,,Present in Autoproposal
96131,"Psychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; each additional hour (List separately in addition to code for primary procedure)",99483,"Assessment of and care planning for a patient with cognitive impairment, requiring an independent historian, in the office or other outpatient, home or domiciliary or rest home, with all of the following required elements: Cognition-focused evaluation including a pertinent history and examination; Medical decision making of moderate or high complexity; Functional assessment (eg, basic and instrumental activities of daily living), including decision-making capacity; Use of standardized instruments for staging of dementia (eg, functional assessment staging test [FAST], clinical dementia rating [CDR]); Medication reconciliation and review for high-risk medications; Evaluation for neuropsychiatric and behavioral symptoms, including depression, including use of standardized screening instrument(s); Evaluation of safety (eg, home), including motor vehicle operation; Identification of caregiver(s), caregiver knowledge, caregiver needs, social supports, and the willingness of caregiver to take on caregiving tasks; Development, updating or revision, or review of an Advance Care Plan; Creation of a written care plan, including initial plans to address any neuropsychiatric symptoms, neuro-cognitive symptoms, functional limitations, and referral to community resources as needed (eg, rehabilitation services, adult day programs, support groups) shared with the patient and/or caregiver with initial education and support. Typically, 50 minutes are spent face-to-face with the patient and/or family or caregiver.",34.16633566044408,,Present Both in MD and Autoproposal
96131,"Psychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; each additional hour (List separately in addition to code for primary procedure)",99091,"Collection and interpretation of physiologic data (eg, ECG, blood pressure, glucose monitoring) digitally stored and/or transmitted by the patient and/or caregiver to the physician or other qualified health care professional, qualified by education, training, licensure/regulation (when applicable) requiring a minimum of 30 minutes of time",34.11489526431858,,Present in Autoproposal
96131,"Psychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; each additional hour (List separately in addition to code for primary procedure)",99489,"Complex chronic care management services, with the following required elements: multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient, chronic conditions place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline, establishment or substantial revision of a comprehensive care plan, moderate or high complexity medical decision making; 60 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month.; each additional 30 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month (List separately in addition to code for primary procedure)",33.8004588809627,,Present in Autoproposal
96131,"Psychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; each additional hour (List separately in addition to code for primary procedure)",0379T,"Visual field assessment, with concurrent real time data analysis and accessible data storage with patient initiated data transmitted to a remote surveillance center for up to 30 days; technical support and patient instructions, surveillance, analysis, and transmission of daily and emergent data reports as prescribed by a physician or other qualified health care professional",33.23986006190192,,Present in Autoproposal
96131,"Psychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; each additional hour (List separately in addition to code for primary procedure)",99157,Moderate sedation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports; each additional 15 minutes intraservice time (List separately in addition to code for primary service),32.72214215091005,,Present in Autoproposal
96131,"Psychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; each additional hour (List separately in addition to code for primary procedure)",99340,"Individual physician supervision of a patient (patient not present) in home, domiciliary or rest home (eg, assisted living facility) requiring complex and multidisciplinary care modalities involving regular physician development and/or revision of care plans, review of subsequent reports of patient status, review of related laboratory and other studies, communication (including telephone calls) for purposes of assessment or care decisions with health care professional(s), family member(s), surrogate decision maker(s) (eg, legal guardian) and/or key caregiver(s) involved in patient's care, integration of new information into the medical treatment plan and/or adjustment of medical therapy, within a calendar month; 30 minutes or more",32.40074890588705,,Present in Autoproposal
96132,"Neuropsychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; first hour",0359T,"Behavior identification assessment, by the physician or other qualified health care professional, face-to-face with patient and caregiver(s), includes administration of standardized and non-standardized tests, detailed behavioral history, patient observation and caregiver interview, interpretation of test results, discussion of findings and recommendations with the primary guardian(s)/caregiver(s), and preparation of report",40.69475700963758,10,Present in Autoproposal
96132,"Neuropsychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; first hour",0378T,"Visual field assessment, with concurrent real time data analysis and accessible data storage with patient initiated data transmitted to a remote surveillance center for up to 30 days; review and interpretation with report by a physician or other qualified health care professional",35.89696413318064,,Present in Autoproposal
96132,"Neuropsychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; first hour",99091,"Collection and interpretation of physiologic data (eg, ECG, blood pressure, glucose monitoring) digitally stored and/or transmitted by the patient and/or caregiver to the physician or other qualified health care professional, qualified by education, training, licensure/regulation (when applicable) requiring a minimum of 30 minutes of time",35.140387196756606,,Present in Autoproposal
96132,"Neuropsychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; first hour",99483,"Assessment of and care planning for a patient with cognitive impairment, requiring an independent historian, in the office or other outpatient, home or domiciliary or rest home, with all of the following required elements: Cognition-focused evaluation including a pertinent history and examination; Medical decision making of moderate or high complexity; Functional assessment (eg, basic and instrumental activities of daily living), including decision-making capacity; Use of standardized instruments for staging of dementia (eg, functional assessment staging test [FAST], clinical dementia rating [CDR]); Medication reconciliation and review for high-risk medications; Evaluation for neuropsychiatric and behavioral symptoms, including depression, including use of standardized screening instrument(s); Evaluation of safety (eg, home), including motor vehicle operation; Identification of caregiver(s), caregiver knowledge, caregiver needs, social supports, and the willingness of caregiver to take on caregiving tasks; Development, updating or revision, or review of an Advance Care Plan; Creation of a written care plan, including initial plans to address any neuropsychiatric symptoms, neuro-cognitive symptoms, functional limitations, and referral to community resources as needed (eg, rehabilitation services, adult day programs, support groups) shared with the patient and/or caregiver with initial education and support. Typically, 50 minutes are spent face-to-face with the patient and/or family or caregiver.",34.09202112037722,,Present in Autoproposal
96132,"Neuropsychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; first hour",0379T,"Visual field assessment, with concurrent real time data analysis and accessible data storage with patient initiated data transmitted to a remote surveillance center for up to 30 days; technical support and patient instructions, surveillance, analysis, and transmission of daily and emergent data reports as prescribed by a physician or other qualified health care professional",33.565171250889925,,Present in Autoproposal
96132,"Neuropsychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; first hour",99378,"Supervision of a hospice patient (patient not present) requiring complex and multidisciplinary care modalities involving regular development and/or revision of care plans by that individual, review of subsequent reports of patient status, review of related laboratory and other studies, communication (including telephone calls) for purposes of assessment or care decisions with health care professional(s), family member(s), surrogate decision maker(s) (eg, legal guardian) and/or key caregiver(s) involved in patient's care, integration of new information into the medical treatment plan and/or adjustment of medical therapy, within a calendar month; 30 minutes or more",32.81718431870036,,Present in Autoproposal
96132,"Neuropsychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; first hour",99380,"Supervision of a nursing facility patient (patient not present) requiring complex and multidisciplinary care modalities involving regular development and/or revision of care plans by that individual, review of subsequent reports of patient status, review of related laboratory and other studies, communication (including telephone calls) for purposes of assessment or care decisions with health care professional(s), family member(s), surrogate decision maker(s) (eg, legal guardian) and/or key caregiver(s) involved in patient's care, integration of new information into the medical treatment plan and/or adjustment of medical therapy, within a calendar month; 30 minutes or more",32.6688088705759,,Present in Autoproposal
96132,"Neuropsychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; first hour",96120,"Neuropsychological testing (eg, Wisconsin Card Sorting Test), administered by a computer, with qualified health care professional interpretation and report",32.647662519727696,,Present in Autoproposal
96132,"Neuropsychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; first hour",99340,"Individual physician supervision of a patient (patient not present) in home, domiciliary or rest home (eg, assisted living facility) requiring complex and multidisciplinary care modalities involving regular physician development and/or revision of care plans, review of subsequent reports of patient status, review of related laboratory and other studies, communication (including telephone calls) for purposes of assessment or care decisions with health care professional(s), family member(s), surrogate decision maker(s) (eg, legal guardian) and/or key caregiver(s) involved in patient's care, integration of new information into the medical treatment plan and/or adjustment of medical therapy, within a calendar month; 30 minutes or more",32.64299000418096,,Present in Autoproposal
96132,"Neuropsychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; first hour",99377,"Supervision of a hospice patient (patient not present) requiring complex and multidisciplinary care modalities involving regular development and/or revision of care plans by that individual, review of subsequent reports of patient status, review of related laboratory and other studies, communication (including telephone calls) for purposes of assessment or care decisions with health care professional(s), family member(s), surrogate decision maker(s) (eg, legal guardian) and/or key caregiver(s) involved in patient's care, integration of new information into the medical treatment plan and/or adjustment of medical therapy, within a calendar month; 15-29 minutes",32.4077458497078,,Present in Autoproposal
96133,"Neuropsychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; each additional hour (List separately in addition to code for primary procedure)",0359T,"Behavior identification assessment, by the physician or other qualified health care professional, face-to-face with patient and caregiver(s), includes administration of standardized and non-standardized tests, detailed behavioral history, patient observation and caregiver interview, interpretation of test results, discussion of findings and recommendations with the primary guardian(s)/caregiver(s), and preparation of report",40.27471058794502,10,Present in Autoproposal
96133,"Neuropsychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; each additional hour (List separately in addition to code for primary procedure)",0363T,"Exposure behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by physician or other qualified health care professional with the assistance of one or more technicians; each additional 30 minutes of technician(s) time, face-to-face with the patient (List separately in addition to code for primary procedure)",38.00635307737549,,Present in Autoproposal
96133,"Neuropsychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; each additional hour (List separately in addition to code for primary procedure)",0378T,"Visual field assessment, with concurrent real time data analysis and accessible data storage with patient initiated data transmitted to a remote surveillance center for up to 30 days; review and interpretation with report by a physician or other qualified health care professional",35.75206320721005,,Present in Autoproposal
96133,"Neuropsychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; each additional hour (List separately in addition to code for primary procedure)",0369T,Adaptive behavior treatment with protocol modification administered by physician or other qualified health care professional with one patient; each additional 30 minutes of patient face-to-face time (List separately in addition to code for primary procedure),34.73468446905686,,Present in Autoproposal
96133,"Neuropsychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; each additional hour (List separately in addition to code for primary procedure)",99483,"Assessment of and care planning for a patient with cognitive impairment, requiring an independent historian, in the office or other outpatient, home or domiciliary or rest home, with all of the following required elements: Cognition-focused evaluation including a pertinent history and examination; Medical decision making of moderate or high complexity; Functional assessment (eg, basic and instrumental activities of daily living), including decision-making capacity; Use of standardized instruments for staging of dementia (eg, functional assessment staging test [FAST], clinical dementia rating [CDR]); Medication reconciliation and review for high-risk medications; Evaluation for neuropsychiatric and behavioral symptoms, including depression, including use of standardized screening instrument(s); Evaluation of safety (eg, home), including motor vehicle operation; Identification of caregiver(s), caregiver knowledge, caregiver needs, social supports, and the willingness of caregiver to take on caregiving tasks; Development, updating or revision, or review of an Advance Care Plan; Creation of a written care plan, including initial plans to address any neuropsychiatric symptoms, neuro-cognitive symptoms, functional limitations, and referral to community resources as needed (eg, rehabilitation services, adult day programs, support groups) shared with the patient and/or caregiver with initial education and support. Typically, 50 minutes are spent face-to-face with the patient and/or family or caregiver.",34.10656426129872,,Present in Autoproposal
96133,"Neuropsychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; each additional hour (List separately in addition to code for primary procedure)",99091,"Collection and interpretation of physiologic data (eg, ECG, blood pressure, glucose monitoring) digitally stored and/or transmitted by the patient and/or caregiver to the physician or other qualified health care professional, qualified by education, training, licensure/regulation (when applicable) requiring a minimum of 30 minutes of time",34.05521385622404,,Present in Autoproposal
96133,"Neuropsychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; each additional hour (List separately in addition to code for primary procedure)",99489,"Complex chronic care management services, with the following required elements: multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient, chronic conditions place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline, establishment or substantial revision of a comprehensive care plan, moderate or high complexity medical decision making; 60 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month.; each additional 30 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month (List separately in addition to code for primary procedure)",33.74132755534591,,Present in Autoproposal
96133,"Neuropsychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; each additional hour (List separately in addition to code for primary procedure)",0379T,"Visual field assessment, with concurrent real time data analysis and accessible data storage with patient initiated data transmitted to a remote surveillance center for up to 30 days; technical support and patient instructions, surveillance, analysis, and transmission of daily and emergent data reports as prescribed by a physician or other qualified health care professional",33.181709461174904,,Present in Autoproposal
96133,"Neuropsychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; each additional hour (List separately in addition to code for primary procedure)",99157,Moderate sedation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports; each additional 15 minutes intraservice time (List separately in addition to code for primary service),32.66489725819371,,Present in Autoproposal
96133,"Neuropsychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; each additional hour (List separately in addition to code for primary procedure)",99340,"Individual physician supervision of a patient (patient not present) in home, domiciliary or rest home (eg, assisted living facility) requiring complex and multidisciplinary care modalities involving regular physician development and/or revision of care plans, review of subsequent reports of patient status, review of related laboratory and other studies, communication (including telephone calls) for purposes of assessment or care decisions with health care professional(s), family member(s), surrogate decision maker(s) (eg, legal guardian) and/or key caregiver(s) involved in patient's care, integration of new information into the medical treatment plan and/or adjustment of medical therapy, within a calendar month; 30 minutes or more",32.34406626614748,,Present in Autoproposal
96136,"Psychological or neuropsychological test administration and scoring by physician or other qualified health care professional, two or more tests, any method; first 30 minutes",0362T,"Exposure behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by physician or other qualified health care professional with the assistance of one or more technicians; first 30 minutes of technician(s) time, face-to-face with the patient",41.547610558358166,10,Present in Autoproposal
96136,"Psychological or neuropsychological test administration and scoring by physician or other qualified health care professional, two or more tests, any method; first 30 minutes",90935,Hemodialysis procedure with single evaluation by a physician or other qualified health care professional,38.36216578593414,,Present in Autoproposal
96136,"Psychological or neuropsychological test administration and scoring by physician or other qualified health care professional, two or more tests, any method; first 30 minutes",90460,"Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered",37.096470899011464,,Present in Autoproposal
96136,"Psychological or neuropsychological test administration and scoring by physician or other qualified health care professional, two or more tests, any method; first 30 minutes",0363T,"Exposure behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by physician or other qualified health care professional with the assistance of one or more technicians; each additional 30 minutes of technician(s) time, face-to-face with the patient (List separately in addition to code for primary procedure)",37.03429895590534,,Present in Autoproposal
96136,"Psychological or neuropsychological test administration and scoring by physician or other qualified health care professional, two or more tests, any method; first 30 minutes",99156,"Moderate sedation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports; initial 15 minutes of intraservice time, patient age 5 years or older",35.103225139472805,,Present in Autoproposal
96136,"Psychological or neuropsychological test administration and scoring by physician or other qualified health care professional, two or more tests, any method; first 30 minutes",76001,"Fluoroscopy, physician or other qualified health care professional time more than 1 hour, assisting a nonradiologic physician or other qualified health care professional (eg, nephrostolithotomy, ERCP, bronchoscopy, transbronchial biopsy)",34.991437012355554,,Present in Autoproposal
96136,"Psychological or neuropsychological test administration and scoring by physician or other qualified health care professional, two or more tests, any method; first 30 minutes",96120,"Neuropsychological testing (eg, Wisconsin Card Sorting Test), administered by a computer, with qualified health care professional interpretation and report",33.54389194556794,,Present in Autoproposal
96136,"Psychological or neuropsychological test administration and scoring by physician or other qualified health care professional, two or more tests, any method; first 30 minutes",99155,"Moderate sedation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports; initial 15 minutes of intraservice time, patient younger than 5 years of age",33.49147929998174,,Present in Autoproposal
96136,"Psychological or neuropsychological test administration and scoring by physician or other qualified health care professional, two or more tests, any method; first 30 minutes",99157,Moderate sedation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports; each additional 15 minutes intraservice time (List separately in addition to code for primary service),33.32624836482251,,Present in Autoproposal
96136,"Psychological or neuropsychological test administration and scoring by physician or other qualified health care professional, two or more tests, any method; first 30 minutes",0368T,Adaptive behavior treatment with protocol modification administered by physician or other qualified health care professional with one patient; first 30 minutes of patient face-to-face time,33.0413441441817,,Present in Autoproposal
96137,"Psychological or neuropsychological test administration and scoring by physician or other qualified health care professional, two or more tests, any method; each additional 30 minutes (List separately in addition to code for primary procedure)",0363T,"Exposure behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by physician or other qualified health care professional with the assistance of one or more technicians; each additional 30 minutes of technician(s) time, face-to-face with the patient (List separately in addition to code for primary procedure)",47.96014745133593,10,Present in Autoproposal
96137,"Psychological or neuropsychological test administration and scoring by physician or other qualified health care professional, two or more tests, any method; each additional 30 minutes (List separately in addition to code for primary procedure)",90461,"Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; each additional vaccine or toxoid component administered (List separately in addition to code for primary procedure)",45.73682753086902,,Present in Autoproposal
96137,"Psychological or neuropsychological test administration and scoring by physician or other qualified health care professional, two or more tests, any method; each additional 30 minutes (List separately in addition to code for primary procedure)",0369T,Adaptive behavior treatment with protocol modification administered by physician or other qualified health care professional with one patient; each additional 30 minutes of patient face-to-face time (List separately in addition to code for primary procedure),43.42518463653015,,Present in Autoproposal
96137,"Psychological or neuropsychological test administration and scoring by physician or other qualified health care professional, two or more tests, any method; each additional 30 minutes (List separately in addition to code for primary procedure)",99157,Moderate sedation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports; each additional 15 minutes intraservice time (List separately in addition to code for primary service),42.66341189414909,,Present in Autoproposal
96137,"Psychological or neuropsychological test administration and scoring by physician or other qualified health care professional, two or more tests, any method; each additional 30 minutes (List separately in addition to code for primary procedure)",99494,"Initial or subsequent psychiatric collaborative care management, each additional 30 minutes in a calendar month of behavioral health care manager activities, in consultation with a psychiatric consultant, and directed by the treating physician or other qualified health care professional (List separately in addition to code for primary procedure)",41.14807735567534,,Present in Autoproposal
96137,"Psychological or neuropsychological test administration and scoring by physician or other qualified health care professional, two or more tests, any method; each additional 30 minutes (List separately in addition to code for primary procedure)",90935,Hemodialysis procedure with single evaluation by a physician or other qualified health care professional,38.239118751550414,,Present in Autoproposal
96137,"Psychological or neuropsychological test administration and scoring by physician or other qualified health care professional, two or more tests, any method; each additional 30 minutes (List separately in addition to code for primary procedure)",S2371,EACH ADDITIONAL INTERSPACE (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),37.92946539051364,,Present in Autoproposal
96137,"Psychological or neuropsychological test administration and scoring by physician or other qualified health care professional, two or more tests, any method; each additional 30 minutes (List separately in addition to code for primary procedure)",G0504,"INITIAL OR SUBSEQUENT PSYCHIATRIC COLLABORATIVE CARE MANAGEMENT, EACH ADDITIONAL 30 MINUTES IN A CALENDAR MONTH OF BEHAVIORAL HEALTH CARE MANAGER ACTIVITIES, IN CONSULTATION WITH A PSYCHIATRIC CONSULTANT, AND DIRECTED BY THE TREATING PHYSICIAN OR OTHER QUALIFIED HEALTH CARE PROFESSIONAL (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE);  (USE G0504 IN CONJUNCTION WITH G0502, G0503)",37.114463271332326,,Present in Autoproposal
96137,"Psychological or neuropsychological test administration and scoring by physician or other qualified health care professional, two or more tests, any method; each additional 30 minutes (List separately in addition to code for primary procedure)",92996,"Percutaneous transluminal coronary atherectomy, by mechanical or other method, with or without balloon angioplasty; each additional vessel (List separately in addition to code for primary procedure)",36.68248120396765,,Present in Autoproposal
96137,"Psychological or neuropsychological test administration and scoring by physician or other qualified health care professional, two or more tests, any method; each additional 30 minutes (List separately in addition to code for primary procedure)",0361T,"Observational behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by one technician; each additional 30 minutes of technician time, face-to-face with the patient (List separately in addition to code for primary service)",36.66018343176576,,Present in Autoproposal
96138,"Psychological or neuropsychological test administration and scoring by technician, two or more tests, any method; first 30 minutes",0366T,"Group adaptive behavior treatment by protocol, administered by technician, face-to-face with two or more patients; first 30 minutes of technician time",39.15748831476182,10,Present in Autoproposal
96138,"Psychological or neuropsychological test administration and scoring by technician, two or more tests, any method; first 30 minutes",0367T,"Group adaptive behavior treatment by protocol, administered by technician, face-to-face with two or more patients; each additional 30 minutes of technician time (List separately in addition to code for primary procedure)",32.48391869962932,,Present in Autoproposal
96138,"Psychological or neuropsychological test administration and scoring by technician, two or more tests, any method; first 30 minutes",96119,"Neuropsychological testing (eg, Halstead-Reitan Neuropsychological Battery, Wechsler Memory Scales and Wisconsin Card Sorting Test), with qualified health care professional interpretation and report, administered by technician, per hour of technician time, face-to-face",32.39035247629442,,Present Both in MD and Autoproposal
96138,"Psychological or neuropsychological test administration and scoring by technician, two or more tests, any method; first 30 minutes",0364T,"Adaptive behavior treatment by protocol, administered by technician, face-to-face with one patient; first 30 minutes of technician time",32.03557190218497,,Present in Autoproposal
96138,"Psychological or neuropsychological test administration and scoring by technician, two or more tests, any method; first 30 minutes",0360T,"Observational behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by one technician; first 30 minutes of technician time, face-to-face with the patient",27.760762892266992,,Present in Autoproposal
96138,"Psychological or neuropsychological test administration and scoring by technician, two or more tests, any method; first 30 minutes",11721,Debridement of nail(s) by any method(s); 6 or more,27.244143021633406,,Present in Autoproposal
96138,"Psychological or neuropsychological test administration and scoring by technician, two or more tests, any method; first 30 minutes",0365T,"Adaptive behavior treatment by protocol, administered by technician, face-to-face with one patient; each additional 30 minutes of technician time (List separately in addition to code for primary procedure)",25.502349721137957,,Present in Autoproposal
96138,"Psychological or neuropsychological test administration and scoring by technician, two or more tests, any method; first 30 minutes",96118,"Neuropsychological testing (eg, Halstead-Reitan Neuropsychological Battery, Wechsler Memory Scales and Wisconsin Card Sorting Test), per hour of the psychologist's or physician's time, both face-to-face time administering tests to the patient and time interpreting these test results and preparing the report",24.760743268403257,,Present in Autoproposal
96138,"Psychological or neuropsychological test administration and scoring by technician, two or more tests, any method; first 30 minutes",96102,"Psychological testing (includes psychodiagnostic assessment of emotionality, intellectual abilities, personality and psychopathology, eg, MMPI and WAIS), with qualified health care professional interpretation and report, administered by technician, per hour of technician time, face-to-face",23.288321189368023,,Present Both in MD and Autoproposal
96138,"Psychological or neuropsychological test administration and scoring by technician, two or more tests, any method; first 30 minutes",0361T,"Observational behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by one technician; each additional 30 minutes of technician time, face-to-face with the patient (List separately in addition to code for primary service)",22.451741608376146,,Present in Autoproposal
96139,"Psychological or neuropsychological test administration and scoring by technician, two or more tests, any method; each additional 30 minutes (List separately in addition to code for primary procedure)",0367T,"Group adaptive behavior treatment by protocol, administered by technician, face-to-face with two or more patients; each additional 30 minutes of technician time (List separately in addition to code for primary procedure)",48.65104045243499,10,Present in Autoproposal
96139,"Psychological or neuropsychological test administration and scoring by technician, two or more tests, any method; each additional 30 minutes (List separately in addition to code for primary procedure)",0365T,"Adaptive behavior treatment by protocol, administered by technician, face-to-face with one patient; each additional 30 minutes of technician time (List separately in addition to code for primary procedure)",43.12860198745307,,Present in Autoproposal
96139,"Psychological or neuropsychological test administration and scoring by technician, two or more tests, any method; each additional 30 minutes (List separately in addition to code for primary procedure)",S2371,EACH ADDITIONAL INTERSPACE (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),40.47122076570794,,Present in Autoproposal
96139,"Psychological or neuropsychological test administration and scoring by technician, two or more tests, any method; each additional 30 minutes (List separately in addition to code for primary procedure)",90840,Psychotherapy for crisis; each additional 30 minutes (List separately in addition to code for primary service),38.91978609964191,,Present in Autoproposal
96139,"Psychological or neuropsychological test administration and scoring by technician, two or more tests, any method; each additional 30 minutes (List separately in addition to code for primary procedure)",96415,"Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)",37.24413759809755,,Present in Autoproposal
96139,"Psychological or neuropsychological test administration and scoring by technician, two or more tests, any method; each additional 30 minutes (List separately in addition to code for primary procedure)",S2361,EACH ADDITIONAL CERVICAL VERTEBRAL BODY (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),36.92591112086315,,Present in Autoproposal
96139,"Psychological or neuropsychological test administration and scoring by technician, two or more tests, any method; each additional 30 minutes (List separately in addition to code for primary procedure)",G0241,EACH ADDITIONAL 30 MINUTES (LIST SEPARATELY IN ADDITION TO G0240),36.62865009292605,,Present in Autoproposal
96139,"Psychological or neuropsychological test administration and scoring by technician, two or more tests, any method; each additional 30 minutes (List separately in addition to code for primary procedure)",0361T,"Observational behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by one technician; each additional 30 minutes of technician time, face-to-face with the patient (List separately in addition to code for primary service)",36.37517763646013,,Present in Autoproposal
96139,"Psychological or neuropsychological test administration and scoring by technician, two or more tests, any method; each additional 30 minutes (List separately in addition to code for primary procedure)",64837,"Suture of each additional nerve, hand or foot (List separately in addition to code for primary procedure)",35.90526386841118,,Present in Autoproposal
96139,"Psychological or neuropsychological test administration and scoring by technician, two or more tests, any method; each additional 30 minutes (List separately in addition to code for primary procedure)",96423,"Chemotherapy administration, intra-arterial; infusion technique, each additional hour (List separately in addition to code for primary procedure)",35.61608469323211,,Present in Autoproposal
96146,"Psychological or neuropsychological test administration, with single automated, standardized instrument via electronic platform, with automated result only",85024,AUTOMATED HEMOGRAM,28.135703048193562,10,Present in Autoproposal
96146,"Psychological or neuropsychological test administration, with single automated, standardized instrument via electronic platform, with automated result only",85023,AUTOMATED HEMOGRAM,28.135703048193562,,Present in Autoproposal
96146,"Psychological or neuropsychological test administration, with single automated, standardized instrument via electronic platform, with automated result only",85022,AUTOMATED HEMOGRAM,28.135703048193562,,Present in Autoproposal
96146,"Psychological or neuropsychological test administration, with single automated, standardized instrument via electronic platform, with automated result only",85021,AUTOMATED HEMOGRAM,28.135703048193562,,Present in Autoproposal
96146,"Psychological or neuropsychological test administration, with single automated, standardized instrument via electronic platform, with automated result only",S9015,AUTOMATED EEG MONITORING,27.06663445310651,,Present in Autoproposal
96146,"Psychological or neuropsychological test administration, with single automated, standardized instrument via electronic platform, with automated result only",85595,"PLATELET COUNT, AUTOMATED",26.66773853742051,,Present in Autoproposal
96146,"Psychological or neuropsychological test administration, with single automated, standardized instrument via electronic platform, with automated result only",96160,"Administration of patient-focused health risk assessment instrument (eg, health hazard appraisal) with scoring and documentation, per standardized instrument",25.02985094678514,,Present in Autoproposal
96146,"Psychological or neuropsychological test administration, with single automated, standardized instrument via electronic platform, with automated result only",99177,"Instrument-based ocular screening (eg, photoscreening, automated-refraction), bilateral; with on-site analysis",24.60141324784467,,Present in Autoproposal
96146,"Psychological or neuropsychological test administration, with single automated, standardized instrument via electronic platform, with automated result only",K0609,"REPLACEMENT ELECTRODES FOR USE WITH AUTOMATED EXTERNAL DEFIBRILLATOR, GARMENT TYPE ONLY, EACH",24.558624548529114,,Present in Autoproposal
96146,"Psychological or neuropsychological test administration, with single automated, standardized instrument via electronic platform, with automated result only",85049,"Blood count; platelet, automated",24.46481929571562,,Present in Autoproposal
97151,"Behavior identification assessment, administered by a physician or other qualified health care professional, each 15 minutes of the physician's or other qualified health care professional's time face-to-face with patient and/or guardian(s)/caregiver(s) administering assessments and discussing findings and recommendations, and non-face-to-face analyzing past data, scoring/interpreting the assessment, and preparing the report/treatment plan",0359T,"Behavior identification assessment, by the physician or other qualified health care professional, face-to-face with patient and caregiver(s), includes administration of standardized and non-standardized tests, detailed behavioral history, patient observation and caregiver interview, interpretation of test results, discussion of findings and recommendations with the primary guardian(s)/caregiver(s), and preparation of report",57.04965066301653,1,Present Both in MD and Autoproposal
97151,"Behavior identification assessment, administered by a physician or other qualified health care professional, each 15 minutes of the physician's or other qualified health care professional's time face-to-face with patient and/or guardian(s)/caregiver(s) administering assessments and discussing findings and recommendations, and non-face-to-face analyzing past data, scoring/interpreting the assessment, and preparing the report/treatment plan",0362T,"Exposure behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by physician or other qualified health care professional with the assistance of one or more technicians; first 30 minutes of technician(s) time, face-to-face with the patient",56.69550853644881,,Present in Autoproposal
97151,"Behavior identification assessment, administered by a physician or other qualified health care professional, each 15 minutes of the physician's or other qualified health care professional's time face-to-face with patient and/or guardian(s)/caregiver(s) administering assessments and discussing findings and recommendations, and non-face-to-face analyzing past data, scoring/interpreting the assessment, and preparing the report/treatment plan",0363T,"Exposure behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by physician or other qualified health care professional with the assistance of one or more technicians; each additional 30 minutes of technician(s) time, face-to-face with the patient (List separately in addition to code for primary procedure)",55.60192470672435,,Present in Autoproposal
97151,"Behavior identification assessment, administered by a physician or other qualified health care professional, each 15 minutes of the physician's or other qualified health care professional's time face-to-face with patient and/or guardian(s)/caregiver(s) administering assessments and discussing findings and recommendations, and non-face-to-face analyzing past data, scoring/interpreting the assessment, and preparing the report/treatment plan",0368T,Adaptive behavior treatment with protocol modification administered by physician or other qualified health care professional with one patient; first 30 minutes of patient face-to-face time,51.630307472090884,,Present in Autoproposal
97151,"Behavior identification assessment, administered by a physician or other qualified health care professional, each 15 minutes of the physician's or other qualified health care professional's time face-to-face with patient and/or guardian(s)/caregiver(s) administering assessments and discussing findings and recommendations, and non-face-to-face analyzing past data, scoring/interpreting the assessment, and preparing the report/treatment plan",96125,"Standardized cognitive performance testing (eg, Ross Information Processing Assessment) per hour of a qualified health care professional's time, both face-to-face time administering tests to the patient and time interpreting these test results and preparing the report",49.46002789592004,,Present in Autoproposal
97151,"Behavior identification assessment, administered by a physician or other qualified health care professional, each 15 minutes of the physician's or other qualified health care professional's time face-to-face with patient and/or guardian(s)/caregiver(s) administering assessments and discussing findings and recommendations, and non-face-to-face analyzing past data, scoring/interpreting the assessment, and preparing the report/treatment plan",0372T,"Adaptive behavior treatment social skills group, administered by physician or other qualified health care professional face-to-face with multiple patients",49.37974269064742,,Present in Autoproposal
97151,"Behavior identification assessment, administered by a physician or other qualified health care professional, each 15 minutes of the physician's or other qualified health care professional's time face-to-face with patient and/or guardian(s)/caregiver(s) administering assessments and discussing findings and recommendations, and non-face-to-face analyzing past data, scoring/interpreting the assessment, and preparing the report/treatment plan",0369T,Adaptive behavior treatment with protocol modification administered by physician or other qualified health care professional with one patient; each additional 30 minutes of patient face-to-face time (List separately in addition to code for primary procedure),49.22385119430107,,Present in Autoproposal
97151,"Behavior identification assessment, administered by a physician or other qualified health care professional, each 15 minutes of the physician's or other qualified health care professional's time face-to-face with patient and/or guardian(s)/caregiver(s) administering assessments and discussing findings and recommendations, and non-face-to-face analyzing past data, scoring/interpreting the assessment, and preparing the report/treatment plan",0360T,"Observational behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by one technician; first 30 minutes of technician time, face-to-face with the patient",47.46014428734506,,Present Both in MD and Autoproposal
97151,"Behavior identification assessment, administered by a physician or other qualified health care professional, each 15 minutes of the physician's or other qualified health care professional's time face-to-face with patient and/or guardian(s)/caregiver(s) administering assessments and discussing findings and recommendations, and non-face-to-face analyzing past data, scoring/interpreting the assessment, and preparing the report/treatment plan",96154,"Health and behavior intervention, each 15 minutes, face-to-face; family (with the patient present)",47.09064723233078,,Present in Autoproposal
97151,"Behavior identification assessment, administered by a physician or other qualified health care professional, each 15 minutes of the physician's or other qualified health care professional's time face-to-face with patient and/or guardian(s)/caregiver(s) administering assessments and discussing findings and recommendations, and non-face-to-face analyzing past data, scoring/interpreting the assessment, and preparing the report/treatment plan",96152,"Health and behavior intervention, each 15 minutes, face-to-face; individual",46.053371557803736,,Present in Autoproposal
97152,"Behavior identification-supporting assessment, administered by one technician under the direction of a physician or other qualified health care professional, face-to-face with the patient, each 15 minutes",0360T,"Observational behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by one technician; first 30 minutes of technician time, face-to-face with the patient",64.63920841736412,3,Present Both in MD and Autoproposal
97152,"Behavior identification-supporting assessment, administered by one technician under the direction of a physician or other qualified health care professional, face-to-face with the patient, each 15 minutes",0362T,"Exposure behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by physician or other qualified health care professional with the assistance of one or more technicians; first 30 minutes of technician(s) time, face-to-face with the patient",64.53652892387564,,Present in Autoproposal
97152,"Behavior identification-supporting assessment, administered by one technician under the direction of a physician or other qualified health care professional, face-to-face with the patient, each 15 minutes",0363T,"Exposure behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by physician or other qualified health care professional with the assistance of one or more technicians; each additional 30 minutes of technician(s) time, face-to-face with the patient (List separately in addition to code for primary procedure)",63.472887614772674,,Present Both in MD and Autoproposal
97152,"Behavior identification-supporting assessment, administered by one technician under the direction of a physician or other qualified health care professional, face-to-face with the patient, each 15 minutes",0361T,"Observational behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by one technician; each additional 30 minutes of technician time, face-to-face with the patient (List separately in addition to code for primary service)",62.338549541085854,,Present in Autoproposal
97152,"Behavior identification-supporting assessment, administered by one technician under the direction of a physician or other qualified health care professional, face-to-face with the patient, each 15 minutes",0368T,Adaptive behavior treatment with protocol modification administered by physician or other qualified health care professional with one patient; first 30 minutes of patient face-to-face time,56.44123666800432,,Present in Autoproposal
97152,"Behavior identification-supporting assessment, administered by one technician under the direction of a physician or other qualified health care professional, face-to-face with the patient, each 15 minutes",0369T,Adaptive behavior treatment with protocol modification administered by physician or other qualified health care professional with one patient; each additional 30 minutes of patient face-to-face time (List separately in addition to code for primary procedure),54.14260360232355,,Present in Autoproposal
97152,"Behavior identification-supporting assessment, administered by one technician under the direction of a physician or other qualified health care professional, face-to-face with the patient, each 15 minutes",0364T,"Adaptive behavior treatment by protocol, administered by technician, face-to-face with one patient; first 30 minutes of technician time",51.66030314419948,,Present in Autoproposal
97152,"Behavior identification-supporting assessment, administered by one technician under the direction of a physician or other qualified health care professional, face-to-face with the patient, each 15 minutes",96154,"Health and behavior intervention, each 15 minutes, face-to-face; family (with the patient present)",51.484931575187765,,Present in Autoproposal
97152,"Behavior identification-supporting assessment, administered by one technician under the direction of a physician or other qualified health care professional, face-to-face with the patient, each 15 minutes",96155,"Health and behavior intervention, each 15 minutes, face-to-face; family (without the patient present)",49.9022411525561,,Present in Autoproposal
97152,"Behavior identification-supporting assessment, administered by one technician under the direction of a physician or other qualified health care professional, face-to-face with the patient, each 15 minutes",0365T,"Adaptive behavior treatment by protocol, administered by technician, face-to-face with one patient; each additional 30 minutes of technician time (List separately in addition to code for primary procedure)",49.8420614047893,,Present in Autoproposal
97153,"Adaptive behavior treatment by protocol, administered by technician under the direction of a physician or other qualified health care professional, face-to-face with one patient, each 15 minutes",0368T,Adaptive behavior treatment with protocol modification administered by physician or other qualified health care professional with one patient; first 30 minutes of patient face-to-face time,77.05771864788812,4,Present in Autoproposal
97153,"Adaptive behavior treatment by protocol, administered by technician under the direction of a physician or other qualified health care professional, face-to-face with one patient, each 15 minutes",0364T,"Adaptive behavior treatment by protocol, administered by technician, face-to-face with one patient; first 30 minutes of technician time",73.65911214916763,,Present Both in MD and Autoproposal
97153,"Adaptive behavior treatment by protocol, administered by technician under the direction of a physician or other qualified health care professional, face-to-face with one patient, each 15 minutes",0369T,Adaptive behavior treatment with protocol modification administered by physician or other qualified health care professional with one patient; each additional 30 minutes of patient face-to-face time (List separately in addition to code for primary procedure),73.07250430083265,,Present in Autoproposal
97153,"Adaptive behavior treatment by protocol, administered by technician under the direction of a physician or other qualified health care professional, face-to-face with one patient, each 15 minutes",0365T,"Adaptive behavior treatment by protocol, administered by technician, face-to-face with one patient; each additional 30 minutes of technician time (List separately in addition to code for primary procedure)",70.08873239046065,,Present Both in MD and Autoproposal
97153,"Adaptive behavior treatment by protocol, administered by technician under the direction of a physician or other qualified health care professional, face-to-face with one patient, each 15 minutes",0366T,"Group adaptive behavior treatment by protocol, administered by technician, face-to-face with two or more patients; first 30 minutes of technician time",66.07225772497684,,Present in Autoproposal
97153,"Adaptive behavior treatment by protocol, administered by technician under the direction of a physician or other qualified health care professional, face-to-face with one patient, each 15 minutes",0367T,"Group adaptive behavior treatment by protocol, administered by technician, face-to-face with two or more patients; each additional 30 minutes of technician time (List separately in addition to code for primary procedure)",63.46711670089945,,Present in Autoproposal
97153,"Adaptive behavior treatment by protocol, administered by technician under the direction of a physician or other qualified health care professional, face-to-face with one patient, each 15 minutes",0360T,"Observational behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by one technician; first 30 minutes of technician time, face-to-face with the patient",62.565772780070816,,Present in Autoproposal
97153,"Adaptive behavior treatment by protocol, administered by technician under the direction of a physician or other qualified health care professional, face-to-face with one patient, each 15 minutes",0372T,"Adaptive behavior treatment social skills group, administered by physician or other qualified health care professional face-to-face with multiple patients",62.55037871839462,,Present in Autoproposal
97153,"Adaptive behavior treatment by protocol, administered by technician under the direction of a physician or other qualified health care professional, face-to-face with one patient, each 15 minutes",0362T,"Exposure behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by physician or other qualified health care professional with the assistance of one or more technicians; first 30 minutes of technician(s) time, face-to-face with the patient",61.84890741540294,,Present in Autoproposal
97153,"Adaptive behavior treatment by protocol, administered by technician under the direction of a physician or other qualified health care professional, face-to-face with one patient, each 15 minutes",0363T,"Exposure behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by physician or other qualified health care professional with the assistance of one or more technicians; each additional 30 minutes of technician(s) time, face-to-face with the patient (List separately in addition to code for primary procedure)",60.91679128806917,,Present in Autoproposal
97154,"Group adaptive behavior treatment by protocol, administered by technician under the direction of a physician or other qualified health care professional, face-to-face with two or more patients, each 15 minutes",0366T,"Group adaptive behavior treatment by protocol, administered by technician, face-to-face with two or more patients; first 30 minutes of technician time",76.26113204499906,2,Present Both in MD and Autoproposal
97154,"Group adaptive behavior treatment by protocol, administered by technician under the direction of a physician or other qualified health care professional, face-to-face with two or more patients, each 15 minutes",0367T,"Group adaptive behavior treatment by protocol, administered by technician, face-to-face with two or more patients; each additional 30 minutes of technician time (List separately in addition to code for primary procedure)",72.78686521956803,,Present Both in MD and Autoproposal
97154,"Group adaptive behavior treatment by protocol, administered by technician under the direction of a physician or other qualified health care professional, face-to-face with two or more patients, each 15 minutes",0372T,"Adaptive behavior treatment social skills group, administered by physician or other qualified health care professional face-to-face with multiple patients",67.97968609307317,,Present in Autoproposal
97154,"Group adaptive behavior treatment by protocol, administered by technician under the direction of a physician or other qualified health care professional, face-to-face with two or more patients, each 15 minutes",0368T,Adaptive behavior treatment with protocol modification administered by physician or other qualified health care professional with one patient; first 30 minutes of patient face-to-face time,67.47766868674853,,Present in Autoproposal
97154,"Group adaptive behavior treatment by protocol, administered by technician under the direction of a physician or other qualified health care professional, face-to-face with two or more patients, each 15 minutes",0364T,"Adaptive behavior treatment by protocol, administered by technician, face-to-face with one patient; first 30 minutes of technician time",65.28908172993525,,Present in Autoproposal
97154,"Group adaptive behavior treatment by protocol, administered by technician under the direction of a physician or other qualified health care professional, face-to-face with two or more patients, each 15 minutes",0369T,Adaptive behavior treatment with protocol modification administered by physician or other qualified health care professional with one patient; each additional 30 minutes of patient face-to-face time (List separately in addition to code for primary procedure),64.16076736661809,,Present in Autoproposal
97154,"Group adaptive behavior treatment by protocol, administered by technician under the direction of a physician or other qualified health care professional, face-to-face with two or more patients, each 15 minutes",0365T,"Adaptive behavior treatment by protocol, administered by technician, face-to-face with one patient; each additional 30 minutes of technician time (List separately in addition to code for primary procedure)",62.2697500842414,,Present in Autoproposal
97154,"Group adaptive behavior treatment by protocol, administered by technician under the direction of a physician or other qualified health care professional, face-to-face with two or more patients, each 15 minutes",96153,"Health and behavior intervention, each 15 minutes, face-to-face; group (2 or more patients)",58.81456576771318,,Present in Autoproposal
97154,"Group adaptive behavior treatment by protocol, administered by technician under the direction of a physician or other qualified health care professional, face-to-face with two or more patients, each 15 minutes",0362T,"Exposure behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by physician or other qualified health care professional with the assistance of one or more technicians; first 30 minutes of technician(s) time, face-to-face with the patient",58.43430068458878,,Present in Autoproposal
97154,"Group adaptive behavior treatment by protocol, administered by technician under the direction of a physician or other qualified health care professional, face-to-face with two or more patients, each 15 minutes",0363T,"Exposure behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by physician or other qualified health care professional with the assistance of one or more technicians; each additional 30 minutes of technician(s) time, face-to-face with the patient (List separately in addition to code for primary procedure)",57.55901137975323,,Present in Autoproposal
97155,"Adaptive behavior treatment with protocol modification, administered by physician or other qualified health care professional, which may include simultaneous direction of technician, face-to-face with one patient, each 15 minutes",0368T,Adaptive behavior treatment with protocol modification administered by physician or other qualified health care professional with one patient; first 30 minutes of patient face-to-face time,76.68571153442622,2,Present Both in MD and Autoproposal
97155,"Adaptive behavior treatment with protocol modification, administered by physician or other qualified health care professional, which may include simultaneous direction of technician, face-to-face with one patient, each 15 minutes",0369T,Adaptive behavior treatment with protocol modification administered by physician or other qualified health care professional with one patient; each additional 30 minutes of patient face-to-face time (List separately in addition to code for primary procedure),72.54294916751478,,Present Both in MD and Autoproposal
97155,"Adaptive behavior treatment with protocol modification, administered by physician or other qualified health care professional, which may include simultaneous direction of technician, face-to-face with one patient, each 15 minutes",0364T,"Adaptive behavior treatment by protocol, administered by technician, face-to-face with one patient; first 30 minutes of technician time",65.43600186995775,,Present in Autoproposal
97155,"Adaptive behavior treatment with protocol modification, administered by physician or other qualified health care professional, which may include simultaneous direction of technician, face-to-face with one patient, each 15 minutes",0365T,"Adaptive behavior treatment by protocol, administered by technician, face-to-face with one patient; each additional 30 minutes of technician time (List separately in addition to code for primary procedure)",62.342193559556755,,Present in Autoproposal
97155,"Adaptive behavior treatment with protocol modification, administered by physician or other qualified health care professional, which may include simultaneous direction of technician, face-to-face with one patient, each 15 minutes",0366T,"Group adaptive behavior treatment by protocol, administered by technician, face-to-face with two or more patients; first 30 minutes of technician time",58.56455006023559,,Present in Autoproposal
97155,"Adaptive behavior treatment with protocol modification, administered by physician or other qualified health care professional, which may include simultaneous direction of technician, face-to-face with one patient, each 15 minutes",0372T,"Adaptive behavior treatment social skills group, administered by physician or other qualified health care professional face-to-face with multiple patients",56.71815014446457,,Present in Autoproposal
97155,"Adaptive behavior treatment with protocol modification, administered by physician or other qualified health care professional, which may include simultaneous direction of technician, face-to-face with one patient, each 15 minutes",0360T,"Observational behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by one technician; first 30 minutes of technician time, face-to-face with the patient",56.40615089847909,,Present in Autoproposal
97155,"Adaptive behavior treatment with protocol modification, administered by physician or other qualified health care professional, which may include simultaneous direction of technician, face-to-face with one patient, each 15 minutes",0367T,"Group adaptive behavior treatment by protocol, administered by technician, face-to-face with two or more patients; each additional 30 minutes of technician time (List separately in addition to code for primary procedure)",56.33466477559191,,Present in Autoproposal
97155,"Adaptive behavior treatment with protocol modification, administered by physician or other qualified health care professional, which may include simultaneous direction of technician, face-to-face with one patient, each 15 minutes",0362T,"Exposure behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by physician or other qualified health care professional with the assistance of one or more technicians; first 30 minutes of technician(s) time, face-to-face with the patient",55.522984097174685,,Present in Autoproposal
97155,"Adaptive behavior treatment with protocol modification, administered by physician or other qualified health care professional, which may include simultaneous direction of technician, face-to-face with one patient, each 15 minutes",0363T,"Exposure behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by physician or other qualified health care professional with the assistance of one or more technicians; each additional 30 minutes of technician(s) time, face-to-face with the patient (List separately in addition to code for primary procedure)",54.72759866964344,,Present in Autoproposal
97156,"Family adaptive behavior treatment guidance, administered by physician or other qualified health care professional (with or without the patient present), face-to-face with guardian(s)/caregiver(s), each 15 minutes",0370T,"Family adaptive behavior treatment guidance, administered by physician or other qualified health care professional (without the patient present)",76.98661605304756,1,Present Both in MD and Autoproposal
97156,"Family adaptive behavior treatment guidance, administered by physician or other qualified health care professional (with or without the patient present), face-to-face with guardian(s)/caregiver(s), each 15 minutes",0371T,"Multiple-family group adaptive behavior treatment guidance, administered by physician or other qualified health care professional (without the patient present)",72.7321483346825,,Present Both in MD and Autoproposal
97156,"Family adaptive behavior treatment guidance, administered by physician or other qualified health care professional (with or without the patient present), face-to-face with guardian(s)/caregiver(s), each 15 minutes",0368T,Adaptive behavior treatment with protocol modification administered by physician or other qualified health care professional with one patient; first 30 minutes of patient face-to-face time,66.6128029428191,,Present in Autoproposal
97156,"Family adaptive behavior treatment guidance, administered by physician or other qualified health care professional (with or without the patient present), face-to-face with guardian(s)/caregiver(s), each 15 minutes",96154,"Health and behavior intervention, each 15 minutes, face-to-face; family (with the patient present)",65.35388955044095,,Present in Autoproposal
97156,"Family adaptive behavior treatment guidance, administered by physician or other qualified health care professional (with or without the patient present), face-to-face with guardian(s)/caregiver(s), each 15 minutes",96155,"Health and behavior intervention, each 15 minutes, face-to-face; family (without the patient present)",64.8932774276359,,Present in Autoproposal
97156,"Family adaptive behavior treatment guidance, administered by physician or other qualified health care professional (with or without the patient present), face-to-face with guardian(s)/caregiver(s), each 15 minutes",0369T,Adaptive behavior treatment with protocol modification administered by physician or other qualified health care professional with one patient; each additional 30 minutes of patient face-to-face time (List separately in addition to code for primary procedure),63.53728174869603,,Present in Autoproposal
97156,"Family adaptive behavior treatment guidance, administered by physician or other qualified health care professional (with or without the patient present), face-to-face with guardian(s)/caregiver(s), each 15 minutes",0372T,"Adaptive behavior treatment social skills group, administered by physician or other qualified health care professional face-to-face with multiple patients",63.36697833342654,,Present in Autoproposal
97156,"Family adaptive behavior treatment guidance, administered by physician or other qualified health care professional (with or without the patient present), face-to-face with guardian(s)/caregiver(s), each 15 minutes",0362T,"Exposure behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by physician or other qualified health care professional with the assistance of one or more technicians; first 30 minutes of technician(s) time, face-to-face with the patient",51.368763579520284,,Present in Autoproposal
97156,"Family adaptive behavior treatment guidance, administered by physician or other qualified health care professional (with or without the patient present), face-to-face with guardian(s)/caregiver(s), each 15 minutes",0363T,"Exposure behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by physician or other qualified health care professional with the assistance of one or more technicians; each additional 30 minutes of technician(s) time, face-to-face with the patient (List separately in addition to code for primary procedure)",50.92419123650299,,Present in Autoproposal
97156,"Family adaptive behavior treatment guidance, administered by physician or other qualified health care professional (with or without the patient present), face-to-face with guardian(s)/caregiver(s), each 15 minutes",96152,"Health and behavior intervention, each 15 minutes, face-to-face; individual",49.92382829620101,,Present in Autoproposal
97157,"Multiple-family group adaptive behavior treatment guidance, administered by physician or other qualified health care professional (without the patient present), face-to-face with multiple sets of guardians/caregivers, each 15 minutes",0371T,"Multiple-family group adaptive behavior treatment guidance, administered by physician or other qualified health care professional (without the patient present)",84.91991003370508,2,Present Both in MD and Autoproposal
97157,"Multiple-family group adaptive behavior treatment guidance, administered by physician or other qualified health care professional (without the patient present), face-to-face with multiple sets of guardians/caregivers, each 15 minutes",0370T,"Family adaptive behavior treatment guidance, administered by physician or other qualified health care professional (without the patient present)",76.67437030350051,,Present Both in MD and Autoproposal
97157,"Multiple-family group adaptive behavior treatment guidance, administered by physician or other qualified health care professional (without the patient present), face-to-face with multiple sets of guardians/caregivers, each 15 minutes",0372T,"Adaptive behavior treatment social skills group, administered by physician or other qualified health care professional face-to-face with multiple patients",73.2033278654108,,Present in Autoproposal
97157,"Multiple-family group adaptive behavior treatment guidance, administered by physician or other qualified health care professional (without the patient present), face-to-face with multiple sets of guardians/caregivers, each 15 minutes",0368T,Adaptive behavior treatment with protocol modification administered by physician or other qualified health care professional with one patient; first 30 minutes of patient face-to-face time,65.31020719326747,,Present in Autoproposal
97157,"Multiple-family group adaptive behavior treatment guidance, administered by physician or other qualified health care professional (without the patient present), face-to-face with multiple sets of guardians/caregivers, each 15 minutes",96155,"Health and behavior intervention, each 15 minutes, face-to-face; family (without the patient present)",65.29377838708295,,Present in Autoproposal
97157,"Multiple-family group adaptive behavior treatment guidance, administered by physician or other qualified health care professional (without the patient present), face-to-face with multiple sets of guardians/caregivers, each 15 minutes",96154,"Health and behavior intervention, each 15 minutes, face-to-face; family (with the patient present)",64.57870932454222,,Present in Autoproposal
97157,"Multiple-family group adaptive behavior treatment guidance, administered by physician or other qualified health care professional (without the patient present), face-to-face with multiple sets of guardians/caregivers, each 15 minutes",0369T,Adaptive behavior treatment with protocol modification administered by physician or other qualified health care professional with one patient; each additional 30 minutes of patient face-to-face time (List separately in addition to code for primary procedure),62.35759413972606,,Present in Autoproposal
97157,"Multiple-family group adaptive behavior treatment guidance, administered by physician or other qualified health care professional (without the patient present), face-to-face with multiple sets of guardians/caregivers, each 15 minutes",96153,"Health and behavior intervention, each 15 minutes, face-to-face; group (2 or more patients)",53.1366282152713,,Present in Autoproposal
97157,"Multiple-family group adaptive behavior treatment guidance, administered by physician or other qualified health care professional (without the patient present), face-to-face with multiple sets of guardians/caregivers, each 15 minutes",96152,"Health and behavior intervention, each 15 minutes, face-to-face; individual",50.23194250963699,,Present in Autoproposal
97157,"Multiple-family group adaptive behavior treatment guidance, administered by physician or other qualified health care professional (without the patient present), face-to-face with multiple sets of guardians/caregivers, each 15 minutes",0362T,"Exposure behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by physician or other qualified health care professional with the assistance of one or more technicians; first 30 minutes of technician(s) time, face-to-face with the patient",49.46101526505574,,Present in Autoproposal
97158,"Group adaptive behavior treatment with protocol modification, administered by physician or other qualified health care professional, face-to-face with multiple patients, each 15 minutes",0368T,Adaptive behavior treatment with protocol modification administered by physician or other qualified health care professional with one patient; first 30 minutes of patient face-to-face time,80.66136022477242,4,Present in Autoproposal
97158,"Group adaptive behavior treatment with protocol modification, administered by physician or other qualified health care professional, face-to-face with multiple patients, each 15 minutes",0372T,"Adaptive behavior treatment social skills group, administered by physician or other qualified health care professional face-to-face with multiple patients",77.66318752713097,,Present Both in MD and Autoproposal
97158,"Group adaptive behavior treatment with protocol modification, administered by physician or other qualified health care professional, face-to-face with multiple patients, each 15 minutes",0369T,Adaptive behavior treatment with protocol modification administered by physician or other qualified health care professional with one patient; each additional 30 minutes of patient face-to-face time (List separately in addition to code for primary procedure),76.51928391347545,,Present in Autoproposal
97158,"Group adaptive behavior treatment with protocol modification, administered by physician or other qualified health care professional, face-to-face with multiple patients, each 15 minutes",0371T,"Multiple-family group adaptive behavior treatment guidance, administered by physician or other qualified health care professional (without the patient present)",61.02359212481379,,Present Both in MD and Autoproposal
97158,"Group adaptive behavior treatment with protocol modification, administered by physician or other qualified health care professional, face-to-face with multiple patients, each 15 minutes",96153,"Health and behavior intervention, each 15 minutes, face-to-face; group (2 or more patients)",60.721201160967354,,Present in Autoproposal
97158,"Group adaptive behavior treatment with protocol modification, administered by physician or other qualified health care professional, face-to-face with multiple patients, each 15 minutes",0366T,"Group adaptive behavior treatment by protocol, administered by technician, face-to-face with two or more patients; first 30 minutes of technician time",59.985433982913406,,Present in Autoproposal
97158,"Group adaptive behavior treatment with protocol modification, administered by physician or other qualified health care professional, face-to-face with multiple patients, each 15 minutes",0367T,"Group adaptive behavior treatment by protocol, administered by technician, face-to-face with two or more patients; each additional 30 minutes of technician time (List separately in addition to code for primary procedure)",57.96278185058073,,Present in Autoproposal
97158,"Group adaptive behavior treatment with protocol modification, administered by physician or other qualified health care professional, face-to-face with multiple patients, each 15 minutes",0370T,"Family adaptive behavior treatment guidance, administered by physician or other qualified health care professional (without the patient present)",55.05393679525837,,Present in Autoproposal
97158,"Group adaptive behavior treatment with protocol modification, administered by physician or other qualified health care professional, face-to-face with multiple patients, each 15 minutes",0364T,"Adaptive behavior treatment by protocol, administered by technician, face-to-face with one patient; first 30 minutes of technician time",54.20758574766927,,Present in Autoproposal
97158,"Group adaptive behavior treatment with protocol modification, administered by physician or other qualified health care professional, face-to-face with multiple patients, each 15 minutes",0365T,"Adaptive behavior treatment by protocol, administered by technician, face-to-face with one patient; each additional 30 minutes of technician time (List separately in addition to code for primary procedure)",52.343924038926694,,Present in Autoproposal
99451,"Interprofessional telephone/Internet/electronic health record assessment and management service provided by a consultative physician, including a written report to the patient's treating/requesting physician or other qualified health care professional, 5 minutes or more of medical consultative time",99446,Interprofessional telephone/Internet assessment and management service provided by a consultative physician including a verbal and written report to the patient's treating/requesting physician or other qualified health care professional; 5-10 minutes of medical consultative discussion and review,86.93787651929222,1,Present Both in MD and Autoproposal
99451,"Interprofessional telephone/Internet/electronic health record assessment and management service provided by a consultative physician, including a written report to the patient's treating/requesting physician or other qualified health care professional, 5 minutes or more of medical consultative time",99449,Interprofessional telephone/Internet assessment and management service provided by a consultative physician including a verbal and written report to the patient's treating/requesting physician or other qualified health care professional; 31 minutes or more of medical consultative discussion and review,86.75903817837836,,Present Both in MD and Autoproposal
99451,"Interprofessional telephone/Internet/electronic health record assessment and management service provided by a consultative physician, including a written report to the patient's treating/requesting physician or other qualified health care professional, 5 minutes or more of medical consultative time",99447,Interprofessional telephone/Internet assessment and management service provided by a consultative physician including a verbal and written report to the patient's treating/requesting physician or other qualified health care professional; 11-20 minutes of medical consultative discussion and review,85.43060716704134,,Present Both in MD and Autoproposal
99451,"Interprofessional telephone/Internet/electronic health record assessment and management service provided by a consultative physician, including a written report to the patient's treating/requesting physician or other qualified health care professional, 5 minutes or more of medical consultative time",99448,Interprofessional telephone/Internet assessment and management service provided by a consultative physician including a verbal and written report to the patient's treating/requesting physician or other qualified health care professional; 21-30 minutes of medical consultative discussion and review,85.23353469665243,,Present Both in MD and Autoproposal
99451,"Interprofessional telephone/Internet/electronic health record assessment and management service provided by a consultative physician, including a written report to the patient's treating/requesting physician or other qualified health care professional, 5 minutes or more of medical consultative time",0362T,"Exposure behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by physician or other qualified health care professional with the assistance of one or more technicians; first 30 minutes of technician(s) time, face-to-face with the patient",40.14624892539561,,Present in Autoproposal
99451,"Interprofessional telephone/Internet/electronic health record assessment and management service provided by a consultative physician, including a written report to the patient's treating/requesting physician or other qualified health care professional, 5 minutes or more of medical consultative time",99157,Moderate sedation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports; each additional 15 minutes intraservice time (List separately in addition to code for primary service),39.04671380449775,,Present in Autoproposal
99451,"Interprofessional telephone/Internet/electronic health record assessment and management service provided by a consultative physician, including a written report to the patient's treating/requesting physician or other qualified health care professional, 5 minutes or more of medical consultative time",99156,"Moderate sedation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports; initial 15 minutes of intraservice time, patient age 5 years or older",38.9575654439299,,Present in Autoproposal
99451,"Interprofessional telephone/Internet/electronic health record assessment and management service provided by a consultative physician, including a written report to the patient's treating/requesting physician or other qualified health care professional, 5 minutes or more of medical consultative time",0363T,"Exposure behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by physician or other qualified health care professional with the assistance of one or more technicians; each additional 30 minutes of technician(s) time, face-to-face with the patient (List separately in addition to code for primary procedure)",38.93918329940359,,Present in Autoproposal
99451,"Interprofessional telephone/Internet/electronic health record assessment and management service provided by a consultative physician, including a written report to the patient's treating/requesting physician or other qualified health care professional, 5 minutes or more of medical consultative time",99444,"Online evaluation and management service provided by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient or guardian, not originating from a related E/M service provided within the previous 7 days, using the Internet or similar electronic communications network",38.66987371402483,,Present in Autoproposal
99451,"Interprofessional telephone/Internet/electronic health record assessment and management service provided by a consultative physician, including a written report to the patient's treating/requesting physician or other qualified health care professional, 5 minutes or more of medical consultative time",99155,"Moderate sedation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports; initial 15 minutes of intraservice time, patient younger than 5 years of age",38.286226639141844,,Present in Autoproposal
99452,"Interprofessional telephone/Internet/electronic health record referral service(s) provided by a treating/requesting physician or other qualified health care professional, 30 minutes",99448,Interprofessional telephone/Internet assessment and management service provided by a consultative physician including a verbal and written report to the patient's treating/requesting physician or other qualified health care professional; 21-30 minutes of medical consultative discussion and review,59.4670532130137,1,Present Both in MD and Autoproposal
99452,"Interprofessional telephone/Internet/electronic health record referral service(s) provided by a treating/requesting physician or other qualified health care professional, 30 minutes",99446,Interprofessional telephone/Internet assessment and management service provided by a consultative physician including a verbal and written report to the patient's treating/requesting physician or other qualified health care professional; 5-10 minutes of medical consultative discussion and review,58.16749107073772,,Present in Autoproposal
99452,"Interprofessional telephone/Internet/electronic health record referral service(s) provided by a treating/requesting physician or other qualified health care professional, 30 minutes",99447,Interprofessional telephone/Internet assessment and management service provided by a consultative physician including a verbal and written report to the patient's treating/requesting physician or other qualified health care professional; 11-20 minutes of medical consultative discussion and review,57.15902295421091,,Present in Autoproposal
99452,"Interprofessional telephone/Internet/electronic health record referral service(s) provided by a treating/requesting physician or other qualified health care professional, 30 minutes",99449,Interprofessional telephone/Internet assessment and management service provided by a consultative physician including a verbal and written report to the patient's treating/requesting physician or other qualified health care professional; 31 minutes or more of medical consultative discussion and review,57.013625794962664,,Present Both in MD and Autoproposal
99452,"Interprofessional telephone/Internet/electronic health record referral service(s) provided by a treating/requesting physician or other qualified health care professional, 30 minutes",99157,Moderate sedation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports; each additional 15 minutes intraservice time (List separately in addition to code for primary service),39.86620173475315,,Present in Autoproposal
99452,"Interprofessional telephone/Internet/electronic health record referral service(s) provided by a treating/requesting physician or other qualified health care professional, 30 minutes",90935,Hemodialysis procedure with single evaluation by a physician or other qualified health care professional,38.98152674323917,,Present in Autoproposal
99452,"Interprofessional telephone/Internet/electronic health record referral service(s) provided by a treating/requesting physician or other qualified health care professional, 30 minutes",99156,"Moderate sedation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports; initial 15 minutes of intraservice time, patient age 5 years or older",38.40239768645515,,Present in Autoproposal
99452,"Interprofessional telephone/Internet/electronic health record referral service(s) provided by a treating/requesting physician or other qualified health care professional, 30 minutes",99155,"Moderate sedation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports; initial 15 minutes of intraservice time, patient younger than 5 years of age",37.63818072456886,,Present in Autoproposal
99452,"Interprofessional telephone/Internet/electronic health record referral service(s) provided by a treating/requesting physician or other qualified health care professional, 30 minutes",99444,"Online evaluation and management service provided by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient or guardian, not originating from a related E/M service provided within the previous 7 days, using the Internet or similar electronic communications network",36.215347441152474,,Present in Autoproposal
99452,"Interprofessional telephone/Internet/electronic health record referral service(s) provided by a treating/requesting physician or other qualified health care professional, 30 minutes",99149,"Moderate sedation services (other than those services described by codes 00100-01999), provided by a physician or other qualified health care professional other than the health care professional performing the diagnostic or therapeutic service that the sedation supports; age 5 years or older, first 30 minutes intra-service time",35.93422711848887,,Present in Autoproposal
99453,"Remote monitoring of physiologic parameter(s) (eg, weight, blood pressure, pulse oximetry, respiratory flow rate), initial; set-up and patient education on use of equipment",2010F,"Vital signs (temperature, pulse, respiratory rate, and blood pressure) documented and reviewed (CAP) (EM)",27.054422592166144,10,Present in Autoproposal
99453,"Remote monitoring of physiologic parameter(s) (eg, weight, blood pressure, pulse oximetry, respiratory flow rate), initial; set-up and patient education on use of equipment",94780,"Car seat/bed testing for airway integrity, neonate, with continual nursing observation and continuous recording of pulse oximetry, heart rate and respiratory rate, with interpretation and report; 60 minutes",26.10607765989606,,Present in Autoproposal
99453,"Remote monitoring of physiologic parameter(s) (eg, weight, blood pressure, pulse oximetry, respiratory flow rate), initial; set-up and patient education on use of equipment",Q0092,SET-UP PORTABLE X-RAY EQUIPMENT,25.828040182765914,,Present in Autoproposal
99453,"Remote monitoring of physiologic parameter(s) (eg, weight, blood pressure, pulse oximetry, respiratory flow rate), initial; set-up and patient education on use of equipment",94781,"Car seat/bed testing for airway integrity, neonate, with continual nursing observation and continuous recording of pulse oximetry, heart rate and respiratory rate, with interpretation and report; each additional full 30 minutes (List separately in addition to code for primary procedure)",24.224453026455997,,Present in Autoproposal
99453,"Remote monitoring of physiologic parameter(s) (eg, weight, blood pressure, pulse oximetry, respiratory flow rate), initial; set-up and patient education on use of equipment",99091,"Collection and interpretation of physiologic data (eg, ECG, blood pressure, glucose monitoring) digitally stored and/or transmitted by the patient and/or caregiver to the physician or other qualified health care professional, qualified by education, training, licensure/regulation (when applicable) requiring a minimum of 30 minutes of time",23.321820748407763,,Present in Autoproposal
99453,"Remote monitoring of physiologic parameter(s) (eg, weight, blood pressure, pulse oximetry, respiratory flow rate), initial; set-up and patient education on use of equipment",94776,"Pediatric home apnea monitoring event recording including respiratory rate, pattern and heart rate per 30-day period of time; monitoring, download of information, receipt of transmission(s) and analyses by computer only",22.26179857488109,,Present in Autoproposal
99453,"Remote monitoring of physiologic parameter(s) (eg, weight, blood pressure, pulse oximetry, respiratory flow rate), initial; set-up and patient education on use of equipment",94375,Respiratory flow volume loop,22.08611734182389,,Present in Autoproposal
99453,"Remote monitoring of physiologic parameter(s) (eg, weight, blood pressure, pulse oximetry, respiratory flow rate), initial; set-up and patient education on use of equipment",94775,"Pediatric home apnea monitoring event recording including respiratory rate, pattern and heart rate per 30-day period of time; monitor attachment only (includes hook-up, initiation of recording and disconnection)",21.385648401368588,,Present in Autoproposal
99453,"Remote monitoring of physiologic parameter(s) (eg, weight, blood pressure, pulse oximetry, respiratory flow rate), initial; set-up and patient education on use of equipment",82810,"Gases, blood, O2 saturation only, by direct measurement, except pulse oximetry",20.97296941512692,,Present in Autoproposal
99453,"Remote monitoring of physiologic parameter(s) (eg, weight, blood pressure, pulse oximetry, respiratory flow rate), initial; set-up and patient education on use of equipment",94762,Noninvasive ear or pulse oximetry for oxygen saturation; by continuous overnight monitoring (separate procedure),20.936689605674808,,Present in Autoproposal
99454,"Remote monitoring of physiologic parameter(s) (eg, weight, blood pressure, pulse oximetry, respiratory flow rate), initial; device(s) supply with daily recording(s) or programmed alert(s) transmission, each 30 days",94776,"Pediatric home apnea monitoring event recording including respiratory rate, pattern and heart rate per 30-day period of time; monitoring, download of information, receipt of transmission(s) and analyses by computer only",27.553482258379606,10,Present in Autoproposal
99454,"Remote monitoring of physiologic parameter(s) (eg, weight, blood pressure, pulse oximetry, respiratory flow rate), initial; device(s) supply with daily recording(s) or programmed alert(s) transmission, each 30 days",94781,"Car seat/bed testing for airway integrity, neonate, with continual nursing observation and continuous recording of pulse oximetry, heart rate and respiratory rate, with interpretation and report; each additional full 30 minutes (List separately in addition to code for primary procedure)",26.611195779854352,,Present in Autoproposal
99454,"Remote monitoring of physiologic parameter(s) (eg, weight, blood pressure, pulse oximetry, respiratory flow rate), initial; device(s) supply with daily recording(s) or programmed alert(s) transmission, each 30 days",94780,"Car seat/bed testing for airway integrity, neonate, with continual nursing observation and continuous recording of pulse oximetry, heart rate and respiratory rate, with interpretation and report; 60 minutes",25.046175029345335,,Present in Autoproposal
99454,"Remote monitoring of physiologic parameter(s) (eg, weight, blood pressure, pulse oximetry, respiratory flow rate), initial; device(s) supply with daily recording(s) or programmed alert(s) transmission, each 30 days",A9280,"ALERT OR ALARM DEVICE, NOT OTHERWISE CLASSIFIED",23.231215356997346,,Present in Autoproposal
99454,"Remote monitoring of physiologic parameter(s) (eg, weight, blood pressure, pulse oximetry, respiratory flow rate), initial; device(s) supply with daily recording(s) or programmed alert(s) transmission, each 30 days",94775,"Pediatric home apnea monitoring event recording including respiratory rate, pattern and heart rate per 30-day period of time; monitor attachment only (includes hook-up, initiation of recording and disconnection)",23.17401035416323,,Present in Autoproposal
99454,"Remote monitoring of physiologic parameter(s) (eg, weight, blood pressure, pulse oximetry, respiratory flow rate), initial; device(s) supply with daily recording(s) or programmed alert(s) transmission, each 30 days",2010F,"Vital signs (temperature, pulse, respiratory rate, and blood pressure) documented and reviewed (CAP) (EM)",22.325421402749924,,Present in Autoproposal
99454,"Remote monitoring of physiologic parameter(s) (eg, weight, blood pressure, pulse oximetry, respiratory flow rate), initial; device(s) supply with daily recording(s) or programmed alert(s) transmission, each 30 days",94777,"Pediatric home apnea monitoring event recording including respiratory rate, pattern and heart rate per 30-day period of time; review, interpretation and preparation of report only by a physician or other qualified health care professional",21.84828235627442,,Present in Autoproposal
99454,"Remote monitoring of physiologic parameter(s) (eg, weight, blood pressure, pulse oximetry, respiratory flow rate), initial; device(s) supply with daily recording(s) or programmed alert(s) transmission, each 30 days",93271,"External patient and, when performed, auto activated electrocardiographic rhythm derived event recording with symptom-related memory loop with remote download capability up to 30 days, 24-hour attended monitoring; transmission and analysis",21.22918168210584,,Present in Autoproposal
99454,"Remote monitoring of physiologic parameter(s) (eg, weight, blood pressure, pulse oximetry, respiratory flow rate), initial; device(s) supply with daily recording(s) or programmed alert(s) transmission, each 30 days",94774,"Pediatric home apnea monitoring event recording including respiratory rate, pattern and heart rate per 30-day period of time; includes monitor attachment, download of data, review, interpretation, and preparation of a report by a physician or other qualified health care professional",20.15922666748701,,Present in Autoproposal
99454,"Remote monitoring of physiologic parameter(s) (eg, weight, blood pressure, pulse oximetry, respiratory flow rate), initial; device(s) supply with daily recording(s) or programmed alert(s) transmission, each 30 days",93268,"External patient and, when performed, auto activated electrocardiographic rhythm derived event recording with symptom-related memory loop with remote download capability up to 30 days, 24-hour attended monitoring; includes transmission, review and interpretation by a physician or other qualified health care professional",20.00517091998098,,Present in Autoproposal
99457,"Remote physiologic monitoring treatment management services, 20 minutes or more of clinical staff/physician/other qualified health care professional time in a calendar month requiring interactive communication with the patient/caregiver during the month",99489,"Complex chronic care management services, with the following required elements: multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient, chronic conditions place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline, establishment or substantial revision of a comprehensive care plan, moderate or high complexity medical decision making; 60 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month.; each additional 30 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month (List separately in addition to code for primary procedure)",48.03289136465697,7,Present in Autoproposal
99457,"Remote physiologic monitoring treatment management services, 20 minutes or more of clinical staff/physician/other qualified health care professional time in a calendar month requiring interactive communication with the patient/caregiver during the month",99488,"Complex chronic care coordination services; first hour of clinical staff time directed by a physician or other qualified health care professional with one face-to-face visit, per calendar month",46.97084211387478,,Present in Autoproposal
99457,"Remote physiologic monitoring treatment management services, 20 minutes or more of clinical staff/physician/other qualified health care professional time in a calendar month requiring interactive communication with the patient/caregiver during the month",99484,"Care management services for behavioral health conditions, at least 20 minutes of clinical staff time, directed by a physician or other qualified health care professional, per calendar month, with the following required elements: initial assessment or follow-up monitoring, including the use of applicable validated rating scales; behavioral health care planning in relation to behavioral/psychiatric health problems, including revision for patients who are not progressing or whose status changes; facilitating and coordinating treatment such as psychotherapy, pharmacotherapy, counseling and/or psychiatric consultation; and continuity of care with a designated member of the care team.",38.686520227335855,,Present in Autoproposal
99457,"Remote physiologic monitoring treatment management services, 20 minutes or more of clinical staff/physician/other qualified health care professional time in a calendar month requiring interactive communication with the patient/caregiver during the month",G0507,"CARE MANAGEMENT SERVICES FOR BEHAVIORAL HEALTH CONDITIONS, AT LEAST 20 MINUTES OF CLINICAL STAFF TIME, DIRECTED BY A PHYSICIAN OR OTHER QUALIFIED HEALTH CARE PROFESSIONAL, PER CALENDAR MONTH, WITH THE FOLLOWING REQUIRED ELEMENTS: INITIAL ASSESSMENT OR FOLLOW-UP MONITORING, INCLUDING THE USE OF APPLICABLE VALIDATED RATING SCALES; BEHAVIORAL HEALTH CARE PLANNING IN RELATION TO BEHAVIORAL/PSYCHIATRIC HEALTH PROBLEMS, INCLUDING REVISION FOR PATIENTS WHO ARE NOT PROGRESSING OR WHOSE STATUS CHANGES; FACILITATING AND COORDINATING TREATMENT SUCH AS PSYCHOTHERAPY, PHARMACOTHERAPY, COUNSELING AND/OR PSYCHIATRIC CONSULTATION; AND CONTINUITY OF CARE WITH A DESIGNATED MEMBER OF THE CARE TEAM",38.686520227335855,,Present in Autoproposal
99457,"Remote physiologic monitoring treatment management services, 20 minutes or more of clinical staff/physician/other qualified health care professional time in a calendar month requiring interactive communication with the patient/caregiver during the month",G0511,"RURAL HEALTH CLINIC OR FEDERALLY QUALIFIED HEALTH CENTER (RHC OR FQHC) ONLY, GENERAL CARE MANAGEMENT, 20 MINUTES OR MORE OF CLINICAL STAFF TIME FOR CHRONIC CARE MANAGEMENT SERVICES OR BEHAVIORAL HEALTH INTEGRATION SERVICES DIRECTED BY AN RHC OR FQHC PRACTITIONER (PHYSICIAN, NP, PA, OR CNM), PER CALENDAR MONTH",38.36822005207541,,Present in Autoproposal
99457,"Remote physiologic monitoring treatment management services, 20 minutes or more of clinical staff/physician/other qualified health care professional time in a calendar month requiring interactive communication with the patient/caregiver during the month",99490,"Chronic care management services, at least 20 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month, with the following required elements: multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient; chronic conditions place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline; comprehensive care plan established, implemented, revised, or monitored.",37.33290913915223,,Present in Autoproposal
99457,"Remote physiologic monitoring treatment management services, 20 minutes or more of clinical staff/physician/other qualified health care professional time in a calendar month requiring interactive communication with the patient/caregiver during the month",99091,"Collection and interpretation of physiologic data (eg, ECG, blood pressure, glucose monitoring) digitally stored and/or transmitted by the patient and/or caregiver to the physician or other qualified health care professional, qualified by education, training, licensure/regulation (when applicable) requiring a minimum of 30 minutes of time",36.63241349147533,,Present Both in MD and Autoproposal
99457,"Remote physiologic monitoring treatment management services, 20 minutes or more of clinical staff/physician/other qualified health care professional time in a calendar month requiring interactive communication with the patient/caregiver during the month",99487,"Complex chronic care management services, with the following required elements: multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient, chronic conditions place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline, establishment or substantial revision of a comprehensive care plan, moderate or high complexity medical decision making; 60 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month.",36.03301867484518,,Present in Autoproposal
99457,"Remote physiologic monitoring treatment management services, 20 minutes or more of clinical staff/physician/other qualified health care professional time in a calendar month requiring interactive communication with the patient/caregiver during the month",99156,"Moderate sedation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports; initial 15 minutes of intraservice time, patient age 5 years or older",35.97061691508775,,Present in Autoproposal
99457,"Remote physiologic monitoring treatment management services, 20 minutes or more of clinical staff/physician/other qualified health care professional time in a calendar month requiring interactive communication with the patient/caregiver during the month",99155,"Moderate sedation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports; initial 15 minutes of intraservice time, patient younger than 5 years of age",35.63353283995976,,Present in Autoproposal
99491,"Chronic care management services, provided personally by a physician or other qualified health care professional, at least 30 minutes of physician or other qualified health care professional time, per calendar month, with the following required elements: multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient; chronic conditions place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline; comprehensive care plan established, implemented, revised, or monitored.",99490,"Chronic care management services, at least 20 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month, with the following required elements: multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient; chronic conditions place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline; comprehensive care plan established, implemented, revised, or monitored.",95.09459348621822,2,Present Both in MD and Autoproposal
99491,"Chronic care management services, provided personally by a physician or other qualified health care professional, at least 30 minutes of physician or other qualified health care professional time, per calendar month, with the following required elements: multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient; chronic conditions place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline; comprehensive care plan established, implemented, revised, or monitored.",99487,"Complex chronic care management services, with the following required elements: multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient, chronic conditions place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline, establishment or substantial revision of a comprehensive care plan, moderate or high complexity medical decision making; 60 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month.",84.81848310833273,,Present Both in MD and Autoproposal
99491,"Chronic care management services, provided personally by a physician or other qualified health care professional, at least 30 minutes of physician or other qualified health care professional time, per calendar month, with the following required elements: multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient; chronic conditions place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline; comprehensive care plan established, implemented, revised, or monitored.",99489,"Complex chronic care management services, with the following required elements: multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient, chronic conditions place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline, establishment or substantial revision of a comprehensive care plan, moderate or high complexity medical decision making; 60 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month.; each additional 30 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month (List separately in addition to code for primary procedure)",81.60318113727142,,Present in Autoproposal
99491,"Chronic care management services, provided personally by a physician or other qualified health care professional, at least 30 minutes of physician or other qualified health care professional time, per calendar month, with the following required elements: multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient; chronic conditions place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline; comprehensive care plan established, implemented, revised, or monitored.",99156,"Moderate sedation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports; initial 15 minutes of intraservice time, patient age 5 years or older",41.16331108746605,,Present in Autoproposal
99491,"Chronic care management services, provided personally by a physician or other qualified health care professional, at least 30 minutes of physician or other qualified health care professional time, per calendar month, with the following required elements: multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient; chronic conditions place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline; comprehensive care plan established, implemented, revised, or monitored.",99155,"Moderate sedation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports; initial 15 minutes of intraservice time, patient younger than 5 years of age",40.24035102541759,,Present in Autoproposal
99491,"Chronic care management services, provided personally by a physician or other qualified health care professional, at least 30 minutes of physician or other qualified health care professional time, per calendar month, with the following required elements: multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient; chronic conditions place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline; comprehensive care plan established, implemented, revised, or monitored.",0362T,"Exposure behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by physician or other qualified health care professional with the assistance of one or more technicians; first 30 minutes of technician(s) time, face-to-face with the patient",39.95067116870542,,Present in Autoproposal
99491,"Chronic care management services, provided personally by a physician or other qualified health care professional, at least 30 minutes of physician or other qualified health care professional time, per calendar month, with the following required elements: multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient; chronic conditions place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline; comprehensive care plan established, implemented, revised, or monitored.",G0507,"CARE MANAGEMENT SERVICES FOR BEHAVIORAL HEALTH CONDITIONS, AT LEAST 20 MINUTES OF CLINICAL STAFF TIME, DIRECTED BY A PHYSICIAN OR OTHER QUALIFIED HEALTH CARE PROFESSIONAL, PER CALENDAR MONTH, WITH THE FOLLOWING REQUIRED ELEMENTS: INITIAL ASSESSMENT OR FOLLOW-UP MONITORING, INCLUDING THE USE OF APPLICABLE VALIDATED RATING SCALES; BEHAVIORAL HEALTH CARE PLANNING IN RELATION TO BEHAVIORAL/PSYCHIATRIC HEALTH PROBLEMS, INCLUDING REVISION FOR PATIENTS WHO ARE NOT PROGRESSING OR WHOSE STATUS CHANGES; FACILITATING AND COORDINATING TREATMENT SUCH AS PSYCHOTHERAPY, PHARMACOTHERAPY, COUNSELING AND/OR PSYCHIATRIC CONSULTATION; AND CONTINUITY OF CARE WITH A DESIGNATED MEMBER OF THE CARE TEAM",39.52182901747206,,Present in Autoproposal
99491,"Chronic care management services, provided personally by a physician or other qualified health care professional, at least 30 minutes of physician or other qualified health care professional time, per calendar month, with the following required elements: multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient; chronic conditions place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline; comprehensive care plan established, implemented, revised, or monitored.",99484,"Care management services for behavioral health conditions, at least 20 minutes of clinical staff time, directed by a physician or other qualified health care professional, per calendar month, with the following required elements: initial assessment or follow-up monitoring, including the use of applicable validated rating scales; behavioral health care planning in relation to behavioral/psychiatric health problems, including revision for patients who are not progressing or whose status changes; facilitating and coordinating treatment such as psychotherapy, pharmacotherapy, counseling and/or psychiatric consultation; and continuity of care with a designated member of the care team.",39.52182901747206,,Present in Autoproposal
99491,"Chronic care management services, provided personally by a physician or other qualified health care professional, at least 30 minutes of physician or other qualified health care professional time, per calendar month, with the following required elements: multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient; chronic conditions place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline; comprehensive care plan established, implemented, revised, or monitored.",99488,"Complex chronic care coordination services; first hour of clinical staff time directed by a physician or other qualified health care professional with one face-to-face visit, per calendar month",39.33965675179003,,Present in Autoproposal
99491,"Chronic care management services, provided personally by a physician or other qualified health care professional, at least 30 minutes of physician or other qualified health care professional time, per calendar month, with the following required elements: multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient; chronic conditions place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline; comprehensive care plan established, implemented, revised, or monitored.",0363T,"Exposure behavioral follow-up assessment, includes physician or other qualified health care professional direction with interpretation and report, administered by physician or other qualified health care professional with the assistance of one or more technicians; each additional 30 minutes of technician(s) time, face-to-face with the patient (List separately in addition to code for primary procedure)",38.53367403923444,,Present in Autoproposal
A4563,"Rectal control system for vaginal insertion, for long term use, includes pump and all supplies and accessories, any type each",A4459,"MANUAL PUMP-OPERATED ENEMA SYSTEM, INCLUDES BALLOON, CATHETER AND ALL ACCESSORIES, REUSABLE, ANY TYPE",38.55201525108787,10,Present Both in MD and Autoproposal
A4563,"Rectal control system for vaginal insertion, for long term use, includes pump and all supplies and accessories, any type each",A9274,"EXTERNAL AMBULATORY INSULIN DELIVERY SYSTEM, DISPOSABLE, EACH, INCLUDES ALL SUPPLIES AND ACCESSORIES",37.838141057317316,,Present in Autoproposal
A4563,"Rectal control system for vaginal insertion, for long term use, includes pump and all supplies and accessories, any type each",A9272,"WOUND SUCTION, DISPOSABLE, INCLUDES DRESSING, ALL ACCESSORIES AND COMPONENTS, ANY TYPE, EACH",35.981339207728205,,Present in Autoproposal
A4563,"Rectal control system for vaginal insertion, for long term use, includes pump and all supplies and accessories, any type each",E0446,"TOPICAL OXYGEN DELIVERY SYSTEM, NOT OTHERWISE SPECIFIED, INCLUDES ALL SUPPLIES AND ACCESSORIES",35.88737317577485,,Present in Autoproposal
A4563,"Rectal control system for vaginal insertion, for long term use, includes pump and all supplies and accessories, any type each",A6550,"WOUND CARE SET, FOR NEGATIVE PRESSURE WOUND THERAPY ELECTRICAL PUMP, INCLUDES ALL SUPPLIES AND ACCESSORIES",34.72887396290778,,Present in Autoproposal
A4563,"Rectal control system for vaginal insertion, for long term use, includes pump and all supplies and accessories, any type each",E0766,"ELECTRICAL STIMULATION DEVICE USED FOR CANCER TREATMENT, INCLUDES ALL ACCESSORIES, ANY TYPE",34.56313311533303,,Present in Autoproposal
A4563,"Rectal control system for vaginal insertion, for long term use, includes pump and all supplies and accessories, any type each",E0640,"PATIENT LIFT, FIXED SYSTEM, INCLUDES ALL COMPONENTS/ACCESSORIES",30.312887682830507,,Present in Autoproposal
A4563,"Rectal control system for vaginal insertion, for long term use, includes pump and all supplies and accessories, any type each",A4337,"INCONTINENCE SUPPLY, RECTAL INSERT, ANY TYPE, EACH",30.072191987332843,,Present Both in MD and Autoproposal
A4563,"Rectal control system for vaginal insertion, for long term use, includes pump and all supplies and accessories, any type each",4144F,Alternative long-term control medication prescribed (Asthma),29.60183163969211,,Present in Autoproposal
A4563,"Rectal control system for vaginal insertion, for long term use, includes pump and all supplies and accessories, any type each",A4632,"REPLACEMENT BATTERY FOR EXTERNAL INFUSION PUMP, ANY TYPE, EACH",29.338440164044332,,Present in Autoproposal
A5514,"For diabetics only, multiple density insert, made by direct carving with cam technology from a rectified cad model created from a digitized scan of the patient, total contact with patient's foot, including arch, base layer minimum of 3/16 inch material of shore a 35 durometer (or higher), includes arch filler and other shaping material, custom fabricated, each",K0903,"For Diabetics Only, Multiple Density Insert, Made By Direct Carving With CAM Technology From A Rectified CAD Model Created From A Digitized Scan Of The Patient, Total Contact With Patient's Foot, Including Arch, Base Layer Minimum Of 3/16 Inch Material Of Shore A 35 Durometer (Or Higher), Includes Arch Filler And Other Shaping Material, Custom Fabricated, Each",100.00000000000003,1,Present Both in MD and Autoproposal
A5514,"For diabetics only, multiple density insert, made by direct carving with cam technology from a rectified cad model created from a digitized scan of the patient, total contact with patient's foot, including arch, base layer minimum of 3/16 inch material of shore a 35 durometer (or higher), includes arch filler and other shaping material, custom fabricated, each",K0629,"FOR DIABETICS ONLY, MULTIPLE DENSITY INSERT, CUSTOM MOLDED FROM MODEL OF PATIENT'S FOOT, TOTAL CONTACT WITH PATIENT'S FOOT, INCLUDING ARCH, BASE LAYER MINIMUM OF 3/16 INCH MATERIAL OF SHORE A 35 DUROMETER OR HIGHER, INCLUDES ARCH FILLER AND OTHER SHAPING MATERIAL, CUSTOM FABRICATED, EACH",80.80594807001884,,Present in Autoproposal
A5514,"For diabetics only, multiple density insert, made by direct carving with cam technology from a rectified cad model created from a digitized scan of the patient, total contact with patient's foot, including arch, base layer minimum of 3/16 inch material of shore a 35 durometer (or higher), includes arch filler and other shaping material, custom fabricated, each",A5513,"FOR DIABETICS ONLY, MULTIPLE DENSITY INSERT, CUSTOM MOLDED FROM MODEL OF PATIENT'S FOOT, TOTAL CONTACT WITH PATIENT'S FOOT, INCLUDING ARCH, BASE LAYER MINIMUM OF 3/16 INCH MATERIAL OF SHORE A 35 DUROMETER OR HIGHER), INCLUDES ARCH FILLER AND OTHER SHAPING MATERIAL, CUSTOM FABRICATED, EACH",80.80594807001884,,Present Both in MD and Autoproposal
A5514,"For diabetics only, multiple density insert, made by direct carving with cam technology from a rectified cad model created from a digitized scan of the patient, total contact with patient's foot, including arch, base layer minimum of 3/16 inch material of shore a 35 durometer (or higher), includes arch filler and other shaping material, custom fabricated, each",A5512,"FOR DIABETICS ONLY, MULTIPLE DENSITY INSERT, DIRECT FORMED, MOLDED TO FOOT AFTER EXTERNAL HEAT SOURCE OF 230 DEGREES FAHRENHEIT OR HIGHER, TOTAL CONTACT WITH PATIENT'S FOOT, INCLUDING ARCH, BASE LAYER MINIMUM OF 1/4 INCH MATERIAL OF SHORE A 35 DUROMETER OR 3/16 INCH MATERIAL OF SHORE A 40 DUROMETER (OR HIGHER), PREFABRICATED, EACH",60.0703522788117,,Present in Autoproposal
A5514,"For diabetics only, multiple density insert, made by direct carving with cam technology from a rectified cad model created from a digitized scan of the patient, total contact with patient's foot, including arch, base layer minimum of 3/16 inch material of shore a 35 durometer (or higher), includes arch filler and other shaping material, custom fabricated, each",K0628,"FOR DIABETICS ONLY, MULTIPLE DENSITY INSERT, DIRECT FORMED, MOLDED TO FOOT AFTER EXTERNAL HEAT SOURCE OF 230 DEGREES FAHRENHEIT OR HIGHER, TOTAL CONTACT WITH PATIENT'S FOOT, INCLUDING ARCH, BASE LAYER MINIMUM OF 1/4 INCH MATERIAL OF SHORE A 35 DUROMETER OR 3/16 INCH MATERIAL OF SHORE A 40 DUROMETER (OR HIGHER), PREFABRICATED, EACH",60.0703522788117,,Present in Autoproposal
A5514,"For diabetics only, multiple density insert, made by direct carving with cam technology from a rectified cad model created from a digitized scan of the patient, total contact with patient's foot, including arch, base layer minimum of 3/16 inch material of shore a 35 durometer (or higher), includes arch filler and other shaping material, custom fabricated, each",A5511,"FOR DIABETICS ONLY, CUSTOM-MOLDED FROM MODEL OF PATIENT'S FOOT, MULTIPLE DENSITY INSERT(S), CUSTOM-FABRICATED, PER SHOE",40.0910338016999,,Present in Autoproposal
A5514,"For diabetics only, multiple density insert, made by direct carving with cam technology from a rectified cad model created from a digitized scan of the patient, total contact with patient's foot, including arch, base layer minimum of 3/16 inch material of shore a 35 durometer (or higher), includes arch filler and other shaping material, custom fabricated, each",A5502,"FOR DIABETICS ONLY, MULTIPLE DENSITY INSERT(S), PER SHOE",26.595536724496522,,Present in Autoproposal
A5514,"For diabetics only, multiple density insert, made by direct carving with cam technology from a rectified cad model created from a digitized scan of the patient, total contact with patient's foot, including arch, base layer minimum of 3/16 inch material of shore a 35 durometer (or higher), includes arch filler and other shaping material, custom fabricated, each",L5000,"PARTIAL FOOT, SHOE INSERT WITH LONGITUDINAL ARCH, TOE FILLER",25.470397461868117,,Present in Autoproposal
A5514,"For diabetics only, multiple density insert, made by direct carving with cam technology from a rectified cad model created from a digitized scan of the patient, total contact with patient's foot, including arch, base layer minimum of 3/16 inch material of shore a 35 durometer (or higher), includes arch filler and other shaping material, custom fabricated, each",L3010,"FOOT, INSERT, REMOVABLE, MOLDED TO PATIENT MODEL, LONGITUDINAL ARCH SUPPORT, EACH",25.378922131942122,,Present in Autoproposal
A5514,"For diabetics only, multiple density insert, made by direct carving with cam technology from a rectified cad model created from a digitized scan of the patient, total contact with patient's foot, including arch, base layer minimum of 3/16 inch material of shore a 35 durometer (or higher), includes arch filler and other shaping material, custom fabricated, each",A5510,"FOR DIABETICS ONLY, DIRECT FORMED, COMPRESSION MOLDED TO PATIENT'S FOOT WITHOUT EXTERNAL HEAT SOURCE, MULTIPLE-DENSITY INSERT(S) PREFABRICATED, PER SHOE",23.83028660828565,,Present in Autoproposal
A6460,"Synthetic resorbable wound dressing, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing",A6209,"FOAM DRESSING, WOUND COVER, STERILE, PAD SIZE 16 SQ. IN. OR LESS, WITHOUT ADHESIVE BORDER, EACH DRESSING",82.16241611809275,8,Present in Autoproposal
A6460,"Synthetic resorbable wound dressing, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing",A6242,"HYDROGEL DRESSING, WOUND COVER, STERILE, PAD SIZE 16 SQ. IN. OR LESS, WITHOUT ADHESIVE BORDER, EACH DRESSING",81.70971992043197,,Present in Autoproposal
A6460,"Synthetic resorbable wound dressing, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing",A6234,"HYDROCOLLOID DRESSING, WOUND COVER, STERILE, PAD SIZE 16 SQ. IN. OR LESS, WITHOUT ADHESIVE BORDER, EACH DRESSING",81.0183160493809,,Present in Autoproposal
A6460,"Synthetic resorbable wound dressing, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing",A6200,"COMPOSITE DRESSING, PAD SIZE 16 SQ. IN. OR LESS, WITHOUT ADHESIVE BORDER, EACH DRESSING",79.01193512843591,,Present in Autoproposal
A6460,"Synthetic resorbable wound dressing, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing",A6212,"FOAM DRESSING, WOUND COVER, STERILE, PAD SIZE 16 SQ. IN. OR LESS, WITH ANY SIZE ADHESIVE BORDER, EACH DRESSING",78.5496193871055,,Present in Autoproposal
A6460,"Synthetic resorbable wound dressing, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing",A6203,"COMPOSITE DRESSING, STERILE, PAD SIZE 16 SQ. IN. OR LESS, WITH ANY SIZE ADHESIVE BORDER, EACH DRESSING",78.19430916328184,,Present in Autoproposal
A6460,"Synthetic resorbable wound dressing, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing",A6245,"HYDROGEL DRESSING, WOUND COVER, STERILE, PAD SIZE 16 SQ. IN. OR LESS, WITH ANY SIZE ADHESIVE BORDER, EACH DRESSING",78.17556577146983,,Present in Autoproposal
A6460,"Synthetic resorbable wound dressing, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing",A6251,"SPECIALTY ABSORPTIVE DRESSING, WOUND COVER, STERILE, PAD SIZE 16 SQ. IN. OR LESS, WITHOUT ADHESIVE BORDER, EACH DRESSING",77.86670586308747,,Present Both in MD and Autoproposal
A6460,"Synthetic resorbable wound dressing, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing",A6237,"HYDROCOLLOID DRESSING, WOUND COVER, STERILE, PAD SIZE 16 SQ. IN. OR LESS, WITH ANY SIZE ADHESIVE BORDER, EACH DRESSING",77.60264701625358,,Present in Autoproposal
A6460,"Synthetic resorbable wound dressing, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing",A6254,"SPECIALTY ABSORPTIVE DRESSING, WOUND COVER, STERILE, PAD SIZE 16 SQ. IN. OR LESS, WITH ANY SIZE ADHESIVE BORDER, EACH DRESSING",74.96637941649507,,Present in Autoproposal
A6461,"Synthetic resorbable wound dressing, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing",A6210,"FOAM DRESSING, WOUND COVER, STERILE, PAD SIZE MORE THAN 16 SQ. IN. BUT LESS THAN OR EQUAL TO 48 SQ. IN., WITHOUT ADHESIVE BORDER, EACH DRESSING",88.36557001351872,8,Present in Autoproposal
A6461,"Synthetic resorbable wound dressing, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing",A6243,"HYDROGEL DRESSING, WOUND COVER, STERILE, PAD SIZE MORE THAN 16 SQ. IN. BUT LESS THAN OR EQUAL TO 48 SQ. IN., WITHOUT ADHESIVE BORDER, EACH DRESSING",88.05032631999585,,Present in Autoproposal
A6461,"Synthetic resorbable wound dressing, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing",A6235,"HYDROCOLLOID DRESSING, WOUND COVER, STERILE, PAD SIZE MORE THAN 16 SQ. IN. BUT LESS THAN OR EQUAL TO 48 SQ. IN., WITHOUT ADHESIVE BORDER, EACH DRESSING",87.56528252121865,,Present in Autoproposal
A6461,"Synthetic resorbable wound dressing, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing",A6201,"COMPOSITE DRESSING, PAD SIZE MORE THAN 16 SQ. IN. BUT LESS THAN OR EQUAL TO 48 SQ. IN. , WITHOUT ADHESIVE BORDER, EACH DRESSING",86.64742796802375,,Present in Autoproposal
A6461,"Synthetic resorbable wound dressing, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing",A6204,"COMPOSITE DRESSING, STERILE, PAD SIZE MORE THAN 16 SQ. IN. BUT LESS THAN OR EQUAL TO 48 SQ. IN., WITH ANY SIZE ADHESIVE BORDER, EACH DRESSING",85.71213962619716,,Present in Autoproposal
A6461,"Synthetic resorbable wound dressing, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing",A6213,"FOAM DRESSING, WOUND COVER, STERILE, PAD SIZE MORE THAN 16 SQ. IN. BUT LESS THAN OR EQUAL TO 48 SQ. IN., WITH ANY SIZE ADHESIVE BORDER, EACH DRESSING",85.64428461074465,,Present in Autoproposal
A6461,"Synthetic resorbable wound dressing, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing",A6246,"HYDROGEL DRESSING, WOUND COVER, STERILE, PAD SIZE MORE THAN 16 SQ. IN. BUT LESS THAN OR EQUAL TO 48 SQ. IN., WITH ANY SIZE ADHESIVE BORDER, EACH DRESSING",85.36694682458818,,Present in Autoproposal
A6461,"Synthetic resorbable wound dressing, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing",A6252,"SPECIALTY ABSORPTIVE DRESSING, WOUND COVER, STERILE, PAD SIZE MORE THAN 16 SQ. IN. BUT LESS THAN OR EQUAL TO 48 SQ. IN., WITHOUT ADHESIVE BORDER, EACH DRESSING",85.2989207424391,,Present Both in MD and Autoproposal
A6461,"Synthetic resorbable wound dressing, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing",A6238,"HYDROCOLLOID DRESSING, WOUND COVER, STERILE, PAD SIZE MORE THAN 16 SQ. IN. BUT LESS THAN OR EQUAL TO 48 SQ. IN., WITH ANY SIZE ADHESIVE BORDER, EACH DRESSING",84.9396901207187,,Present in Autoproposal
A6461,"Synthetic resorbable wound dressing, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing",A6255,"SPECIALTY ABSORPTIVE DRESSING, WOUND COVER, STERILE, PAD SIZE MORE THAN 16 SQ. IN. BUT LESS THAN OR EQUAL TO 48 SQ. IN., WITH ANY SIZE ADHESIVE BORDER, EACH DRESSING",82.93478046883553,,Present in Autoproposal
C1823,"Generator, neurostimulator (implantable), non-rechargeable, with transvenous sensing and stimulation leads",C1767,"GENERATOR, NEUROSTIMULATOR (IMPLANTABLE), NON-RECHARGEABLE",68.60710299473905,1,Present Both in MD and Autoproposal
C1823,"Generator, neurostimulator (implantable), non-rechargeable, with transvenous sensing and stimulation leads",L8686,"IMPLANTABLE NEUROSTIMULATOR PULSE GENERATOR, SINGLE ARRAY, NON-RECHARGEABLE, INCLUDES EXTENSION",51.315514771049685,,Present Both in MD and Autoproposal
C1823,"Generator, neurostimulator (implantable), non-rechargeable, with transvenous sensing and stimulation leads",C1820,"GENERATOR, NEUROSTIMULATOR (IMPLANTABLE), WITH RECHARGEABLE BATTERY AND CHARGING SYSTEM",50.27120864231039,,Present in Autoproposal
C1823,"Generator, neurostimulator (implantable), non-rechargeable, with transvenous sensing and stimulation leads",L8688,"IMPLANTABLE NEUROSTIMULATOR PULSE GENERATOR, DUAL ARRAY, NON-RECHARGEABLE, INCLUDES EXTENSION",50.10087268724433,,Present in Autoproposal
C1823,"Generator, neurostimulator (implantable), non-rechargeable, with transvenous sensing and stimulation leads",L8685,"IMPLANTABLE NEUROSTIMULATOR PULSE GENERATOR, SINGLE ARRAY, RECHARGEABLE, INCLUDES EXTENSION",47.40075638651241,,Present in Autoproposal
C1823,"Generator, neurostimulator (implantable), non-rechargeable, with transvenous sensing and stimulation leads",L8687,"IMPLANTABLE NEUROSTIMULATOR PULSE GENERATOR, DUAL ARRAY, RECHARGEABLE, INCLUDES EXTENSION",46.21245571733867,,Present in Autoproposal
C1823,"Generator, neurostimulator (implantable), non-rechargeable, with transvenous sensing and stimulation leads",C1822,"GENERATOR, NEUROSTIMULATOR (IMPLANTABLE), HIGH FREQUENCY, WITH RECHARGEABLE BATTERY AND CHARGING SYSTEM",44.564203599421944,,Present in Autoproposal
C1823,"Generator, neurostimulator (implantable), non-rechargeable, with transvenous sensing and stimulation leads",E0756,IMPLANTABLE NEUROSTIMULATOR PULSE GENERATOR,43.205780557946326,,Present in Autoproposal
C1823,"Generator, neurostimulator (implantable), non-rechargeable, with transvenous sensing and stimulation leads",0424T,"Insertion or replacement of neurostimulator system for treatment of central sleep apnea; complete system (transvenous placement of right or left stimulation lead, sensing lead, implantable pulse generator)",41.32415283921205,,Present in Autoproposal
C1823,"Generator, neurostimulator (implantable), non-rechargeable, with transvenous sensing and stimulation leads",L8679,"IMPLANTABLE NEUROSTIMULATOR, PULSE GENERATOR, ANY TYPE",38.338881858895014,,Present in Autoproposal
C8937,"Computer-aided detection, including computer algorithm analysis of breast mri image data for lesion detection/characterization, pharmacokinetic analysis, with further physician review for interpretation (list separately in addition to code for primary procedure)",0159T,"Computer-aided detection, including computer algorithm analysis of MRI image data for lesion detection/characterization, pharmacokinetic analysis, with further physician review for interpretation, breast MRI (List separately in addition to code for primary procedure)",98.05386217483544,10,Present Both in MD and Autoproposal
C8937,"Computer-aided detection, including computer algorithm analysis of breast mri image data for lesion detection/characterization, pharmacokinetic analysis, with further physician review for interpretation (list separately in addition to code for primary procedure)",77051,"Computer-aided detection (computer algorithm analysis of digital image data for lesion detection) with further review for interpretation, with or without digitization of film radiographic images; diagnostic mammography (List separately in addition to code for primary procedure)",70.16015193465563,,Present in Autoproposal
C8937,"Computer-aided detection, including computer algorithm analysis of breast mri image data for lesion detection/characterization, pharmacokinetic analysis, with further physician review for interpretation (list separately in addition to code for primary procedure)",77052,"Computer-aided detection (computer algorithm analysis of digital image data for lesion detection) with further review for interpretation, with or without digitization of film radiographic images; screening mammography (List separately in addition to code for primary procedure)",69.91904542928864,,Present in Autoproposal
C8937,"Computer-aided detection, including computer algorithm analysis of breast mri image data for lesion detection/characterization, pharmacokinetic analysis, with further physician review for interpretation (list separately in addition to code for primary procedure)",0174T,"Computer-aided detection (CAD) (computer algorithm analysis of digital image data for lesion detection) with further physician review for interpretation and report, with or without digitization of film radiographic images, chest radiograph(s), performed concurrent with primary interpretation (List separately in addition to code for primary procedure)",66.5718012064679,,Present in Autoproposal
C8937,"Computer-aided detection, including computer algorithm analysis of breast mri image data for lesion detection/characterization, pharmacokinetic analysis, with further physician review for interpretation (list separately in addition to code for primary procedure)",G0236,"DIGITIZATION OF FILM RADIOGRAPHIC IMAGES WITH COMPUTER ANALYSIS FOR LESION DETECTION, OR COMPUTER ANALYSIS OF DIGITAL MAMMOGRAM FOR LESION DETECTION, AND FURTHER PHYSICIAN REVIEW FOR INTERPRETATION, DIAGNOSTIC MAMMOGRAPHY (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE)",62.68156965218422,,Present in Autoproposal
C8937,"Computer-aided detection, including computer algorithm analysis of breast mri image data for lesion detection/characterization, pharmacokinetic analysis, with further physician review for interpretation (list separately in addition to code for primary procedure)",0175T,"Computer-aided detection (CAD) (computer algorithm analysis of digital image data for lesion detection) with further physician review for interpretation and report, with or without digitization of film radiographic images, chest radiograph(s), performed remote from primary interpretation",60.264085888838736,,Present in Autoproposal
C8937,"Computer-aided detection, including computer algorithm analysis of breast mri image data for lesion detection/characterization, pharmacokinetic analysis, with further physician review for interpretation (list separately in addition to code for primary procedure)",S8075,"COMPUTER ANALYSIS OF FULL-FIELD DIGITAL MAMMOGRAM AND FURTHER PHYSICIAN REVIEW FOR INTERPRETATION, MAMMOGRAPHY (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE)",50.299889488106096,,Present in Autoproposal
C8937,"Computer-aided detection, including computer algorithm analysis of breast mri image data for lesion detection/characterization, pharmacokinetic analysis, with further physician review for interpretation (list separately in addition to code for primary procedure)",20985,"Computer-assisted surgical navigational procedure for musculoskeletal procedures, image-less (List separately in addition to code for primary procedure)",37.34434329356125,,Present in Autoproposal
C8937,"Computer-aided detection, including computer algorithm analysis of breast mri image data for lesion detection/characterization, pharmacokinetic analysis, with further physician review for interpretation (list separately in addition to code for primary procedure)",0055T,"Computer-assisted musculoskeletal surgical navigational orthopedic procedure, with image-guidance based on CT/MRI images (List separately in addition to code for primary procedure)",35.85654859008642,,Present in Autoproposal
C8937,"Computer-aided detection, including computer algorithm analysis of breast mri image data for lesion detection/characterization, pharmacokinetic analysis, with further physician review for interpretation (list separately in addition to code for primary procedure)",61783,Stereotactic computer-assisted (navigational) procedure; spinal (List separately in addition to code for primary procedure),34.62276464004949,,Present in Autoproposal
C9015,"INJECTION, C-1 ESTERASE INHIBITOR (HUMAN), HAEGARDA, 10 UNITS",C9251,"INJECTION, C1 ESTERASE INHIBITOR (HUMAN), 10 UNITS",88.09831409958694,10,Present in Autoproposal
C9015,"INJECTION, C-1 ESTERASE INHIBITOR (HUMAN), HAEGARDA, 10 UNITS",J0597,"INJECTION, C-1 ESTERASE INHIBITOR (HUMAN), BERINERT, 10 UNITS",85.10157254654143,,Present in Autoproposal
C9015,"INJECTION, C-1 ESTERASE INHIBITOR (HUMAN), HAEGARDA, 10 UNITS",C9269,"INJECTION, C-1 ESTERASE INHIBITOR (HUMAN), BERINERT, 10 UNITS",85.10157254654143,,Present in Autoproposal
C9015,"INJECTION, C-1 ESTERASE INHIBITOR (HUMAN), HAEGARDA, 10 UNITS",J0598,"INJECTION, C-1 ESTERASE INHIBITOR (HUMAN), CINRYZE, 10 UNITS",84.14902634397725,,Present in Autoproposal
C9015,"INJECTION, C-1 ESTERASE INHIBITOR (HUMAN), HAEGARDA, 10 UNITS",C9445,"INJECTION, C-1 ESTERASE INHIBITOR (RECOMBINANT), RUCONEST, 10 UNITS",71.09294481139679,,Present in Autoproposal
C9015,"INJECTION, C-1 ESTERASE INHIBITOR (HUMAN), HAEGARDA, 10 UNITS",J0596,"INJECTION, C1 ESTERASE INHIBITOR (RECOMBINANT), RUCONEST, 10 UNITS",64.82959256505981,,Present in Autoproposal
C9015,"INJECTION, C-1 ESTERASE INHIBITOR (HUMAN), HAEGARDA, 10 UNITS",J0256,"INJECTION, ALPHA 1 PROTEINASE INHIBITOR (HUMAN), NOT OTHERWISE SPECIFIED, 10 MG",42.812443352148534,,Present in Autoproposal
C9015,"INJECTION, C-1 ESTERASE INHIBITOR (HUMAN), HAEGARDA, 10 UNITS",J0257,"INJECTION, ALPHA 1 PROTEINASE INHIBITOR (HUMAN), (GLASSIA), 10 MG",41.346903444950414,,Present in Autoproposal
C9015,"INJECTION, C-1 ESTERASE INHIBITOR (HUMAN), HAEGARDA, 10 UNITS",J1786,"INJECTION, IMIGLUCERASE, 10 UNITS",39.75158562595242,,Present in Autoproposal
C9015,"INJECTION, C-1 ESTERASE INHIBITOR (HUMAN), HAEGARDA, 10 UNITS",C9293,"INJECTION, GLUCARPIDASE, 10 UNITS",38.30645420129501,,Present in Autoproposal
C9016,"INJECTION, TRIPTORELIN EXTENDED RELEASE, 3.75 MG",J3315,"INJECTION, TRIPTORELIN PAMOATE, 3.75 MG",67.0061417214346,10,Present in Autoproposal
C9016,"INJECTION, TRIPTORELIN EXTENDED RELEASE, 3.75 MG",C9486,"INJECTION, GRANISETRON EXTENDED RELEASE, 0.1 MG",52.26529875400029,,Present in Autoproposal
C9016,"INJECTION, TRIPTORELIN EXTENDED RELEASE, 3.75 MG",J1627,"INJECTION, GRANISETRON, EXTENDED-RELEASE, 0.1 MG",52.26529875400029,,Present in Autoproposal
C9016,"INJECTION, TRIPTORELIN EXTENDED RELEASE, 3.75 MG",J0401,"INJECTION, ARIPIPRAZOLE, EXTENDED RELEASE, 1 MG",51.524647857564496,,Present in Autoproposal
C9016,"INJECTION, TRIPTORELIN EXTENDED RELEASE, 3.75 MG",J2426,"INJECTION, PALIPERIDONE PALMITATE EXTENDED RELEASE, 1 MG",42.15151377156684,,Present in Autoproposal
C9016,"INJECTION, TRIPTORELIN EXTENDED RELEASE, 3.75 MG",J9600,"INJECTION, PORFIMER SODIUM, 75 MG",33.44411894505548,,Present in Autoproposal
C9016,"INJECTION, TRIPTORELIN EXTENDED RELEASE, 3.75 MG",Q9993,"Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg",33.042910050085716,,Present in Autoproposal
C9016,"INJECTION, TRIPTORELIN EXTENDED RELEASE, 3.75 MG",C9469,"Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg",33.042910050085716,,Present in Autoproposal
C9016,"INJECTION, TRIPTORELIN EXTENDED RELEASE, 3.75 MG",J7508,"TACROLIMUS, EXTENDED RELEASE, (ASTAGRAF XL), ORAL, 0.1 MG",33.00410873100541,,Present in Autoproposal
C9016,"INJECTION, TRIPTORELIN EXTENDED RELEASE, 3.75 MG",J7512,"PREDNISONE, IMMEDIATE RELEASE OR DELAYED RELEASE, ORAL, 1 MG",31.8558208048838,,Present in Autoproposal
C9029,"INJECTION, GUSELKUMAB, 1 MG",J9267,"INJECTION, PACLITAXEL, 1 MG",52.950885430632866,10,Present in Autoproposal
C9029,"INJECTION, GUSELKUMAB, 1 MG",J9280,"INJECTION, MITOMYCIN, 5 MG",52.950885430632866,,Present in Autoproposal
C9029,"INJECTION, GUSELKUMAB, 1 MG",Q2046,"INJECTION, AFLIBERCEPT, 1 MG",52.316794577196156,,Present in Autoproposal
C9029,"INJECTION, GUSELKUMAB, 1 MG",J0202,"INJECTION, ALEMTUZUMAB, 1 MG",52.316794577196156,,Present in Autoproposal
C9029,"INJECTION, GUSELKUMAB, 1 MG",J0178,"INJECTION, AFLIBERCEPT, 1 MG",52.316794577196156,,Present in Autoproposal
C9029,"INJECTION, GUSELKUMAB, 1 MG",J3396,"INJECTION, VERTEPORFIN, 0.1 MG",52.316794577196156,,Present in Autoproposal
C9029,"INJECTION, GUSELKUMAB, 1 MG",C9261,"INJECTION, USTEKINUMAB, 1 MG",52.316794577196156,,Present in Autoproposal
C9029,"INJECTION, GUSELKUMAB, 1 MG",J1325,"INJECTION, EPOPROSTENOL, 0.5 MG",52.316794577196156,,Present in Autoproposal
C9029,"INJECTION, GUSELKUMAB, 1 MG",Q9979,"INJECTION, ALEMTUZUMAB, 1 MG",52.316794577196156,,Present in Autoproposal
C9029,"INJECTION, GUSELKUMAB, 1 MG",J2505,"INJECTION, PEGFILGRASTIM, 6 MG",51.58259659366726,,Present in Autoproposal
C9030,"Injection, copanlisib, 1 mg",J9267,"INJECTION, PACLITAXEL, 1 MG",52.950885430632866,10,Present in Autoproposal
C9030,"Injection, copanlisib, 1 mg",J9280,"INJECTION, MITOMYCIN, 5 MG",52.950885430632866,,Present in Autoproposal
C9030,"Injection, copanlisib, 1 mg",Q2046,"INJECTION, AFLIBERCEPT, 1 MG",52.316794577196156,,Present in Autoproposal
C9030,"Injection, copanlisib, 1 mg",J0202,"INJECTION, ALEMTUZUMAB, 1 MG",52.316794577196156,,Present in Autoproposal
C9030,"Injection, copanlisib, 1 mg",J0178,"INJECTION, AFLIBERCEPT, 1 MG",52.316794577196156,,Present in Autoproposal
C9030,"Injection, copanlisib, 1 mg",J3396,"INJECTION, VERTEPORFIN, 0.1 MG",52.316794577196156,,Present in Autoproposal
C9030,"Injection, copanlisib, 1 mg",C9261,"INJECTION, USTEKINUMAB, 1 MG",52.316794577196156,,Present in Autoproposal
C9030,"Injection, copanlisib, 1 mg",J1325,"INJECTION, EPOPROSTENOL, 0.5 MG",52.316794577196156,,Present in Autoproposal
C9030,"Injection, copanlisib, 1 mg",Q9979,"INJECTION, ALEMTUZUMAB, 1 MG",52.316794577196156,,Present in Autoproposal
C9030,"Injection, copanlisib, 1 mg",J2505,"INJECTION, PEGFILGRASTIM, 6 MG",51.58259659366726,,Present in Autoproposal
C9031,"Lutetium Lu 177, dotatate, therapeutic, 1 mCi",A9587,"GALLIUM GA-68, DOTATATE, DIAGNOSTIC, 0.1 MILLICURIE",36.34459133759684,10,Present in Autoproposal
C9031,"Lutetium Lu 177, dotatate, therapeutic, 1 mCi",A9603,I-131SODIUMIODIDECAP PER MCI,30.08987560263958,,Present in Autoproposal
C9031,"Lutetium Lu 177, dotatate, therapeutic, 1 mCi",C1348,"SUPPLY OF RADIOPHARMACEUTICAL THERAPEUTIC IMAGING AGENT, SODIUM IODIDE I-131, SOLUTION, PER INITIAL 1-6 MCI",28.78242297374346,,Present in Autoproposal
C9031,"Lutetium Lu 177, dotatate, therapeutic, 1 mCi",C1064,"SUPPLY OF RADIOPHARMACEUTICAL THERAPEUTIC IMAGING AGENT, SODIUM IODIDE I-131, CAPSULE, EACH ADDITIONAL MCI",28.245055309532713,,Present in Autoproposal
C9031,"Lutetium Lu 177, dotatate, therapeutic, 1 mCi",C1188,"SUPPLY OF RADIOPHARMACEUTICAL THERAPEUTIC IMAGING AGENT, SODIUM IODIDE I-131, CAPSULE, PER INITIAL 1-5 MCI",28.151547629097983,,Present in Autoproposal
C9031,"Lutetium Lu 177, dotatate, therapeutic, 1 mCi",C1089,"CO 57, 0.5 MCI",27.532615629079388,,Present in Autoproposal
C9031,"Lutetium Lu 177, dotatate, therapeutic, 1 mCi",A9523,"SUPPLY OF RADIOPHARMACEUTICAL THERAPEUTIC IMAGING AGENT, YTTRIUM 90 IBRITUMOMAB TIUXETAN, PER MCI",27.26071003570253,,Present in Autoproposal
C9031,"Lutetium Lu 177, dotatate, therapeutic, 1 mCi",C1065,"SUPPLY OF RADIOPHARMACUETICAL THERAPEUTIC IMAGING AGENT, SODIUM IODIDE I-131, SOLUTION, EACH ADDITIONAL MCI",27.06226861981378,,Present in Autoproposal
C9031,"Lutetium Lu 177, dotatate, therapeutic, 1 mCi",C9401,"SUPPLY OF THERAPEUTIC RADIOPHARMACEUTICAL, STRONTIUM-89 CHLORIDE, BRAND NAME, PER MCI",27.030118513370173,,Present in Autoproposal
C9031,"Lutetium Lu 177, dotatate, therapeutic, 1 mCi",C9402,"SUPPLY OF RADIOPHARMACEUTICAL THERAPEUTIC IMAGING AGENT, I-131 SODIUM IODIDE CAPSULE, BRAND NAME, PER MCI",26.197763324166118,,Present in Autoproposal
C9032,"Injection, voretigene neparvovec-rzyl, 1 billion vector genome",C1732,"CATHETER, ELECTROPHYSIOLOGY, DIAGNOSTIC/ABLATION, 3D OR VECTOR MAPPING",35.28557271593263,10,Present in Autoproposal
C9032,"Injection, voretigene neparvovec-rzyl, 1 billion vector genome",81426,"Genome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis, each comparator genome (eg, parents, siblings) (List separately in addition to code for primary procedure)",32.1683589809139,,Present in Autoproposal
C9032,"Injection, voretigene neparvovec-rzyl, 1 billion vector genome",81427,"Genome (eg, unexplained constitutional or heritable disorder or syndrome); re-evaluation of previously obtained genome sequence (eg, updated knowledge or unrelated condition/syndrome)",29.314512779729178,,Present in Autoproposal
C9032,"Injection, voretigene neparvovec-rzyl, 1 billion vector genome",C2630,"CATHETER, ELECTROPHYSIOLOGY, DIAGNOSTIC/ABLATION, OTHER THAN 3D OR VECTOR MAPPING, COOL-TIP",28.772178648393247,,Present in Autoproposal
C9032,"Injection, voretigene neparvovec-rzyl, 1 billion vector genome",C1733,"CATHETER, ELECTROPHYSIOLOGY, DIAGNOSTIC/ABLATION, OTHER THAN 3D OR VECTOR MAPPING, OTHER THAN COOL-TIP",26.23070802421217,,Present in Autoproposal
C9032,"Injection, voretigene neparvovec-rzyl, 1 billion vector genome",81425,"Genome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis",24.401238438677645,,Present in Autoproposal
C9032,"Injection, voretigene neparvovec-rzyl, 1 billion vector genome",81460,"Whole mitochondrial genome (eg, Leigh syndrome, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes [MELAS], myoclonic epilepsy with ragged-red fibers [MERFF], neuropathy, ataxia, and retinitis pigmentosa [NARP], Leber hereditary optic neuropathy [LHON]), genomic sequence, must include sequence analysis of entire mitochondrial genome with heteroplasmy detection",17.18562375036031,,Present in Autoproposal
C9032,"Injection, voretigene neparvovec-rzyl, 1 billion vector genome",81465,"Whole mitochondrial genome large deletion analysis panel (eg, Kearns-Sayre syndrome, chronic progressive external ophthalmoplegia), including heteroplasmy detection, if performed",16.69180815175585,,Present in Autoproposal
C9032,"Injection, voretigene neparvovec-rzyl, 1 billion vector genome",0012U,"Germline disorders, gene rearrangement detection by whole genome next-generation sequencing, DNA, whole blood, report of specific gene rearrangement(s)",16.174354323254164,,Present in Autoproposal
C9032,"Injection, voretigene neparvovec-rzyl, 1 billion vector genome",0010U,"Infectious disease (bacterial), strain typing by whole genome sequencing, phylogenetic-based report of strain relatedness, per submitted isolate",15.60428265338564,,Present in Autoproposal
C9033,"Injection, fosnetupitant 235 mg and palonosetron 0.25 mg",Q9978,NETUPITANT 300 MG AND PALONOSETRON 0.5 MG,64.05208411016878,10,Present in Autoproposal
C9033,"Injection, fosnetupitant 235 mg and palonosetron 0.25 mg",J8655,NETUPITANT 300 MG AND PALONOSETRON 0.5 MG,64.05208411016878,,Present in Autoproposal
C9033,"Injection, fosnetupitant 235 mg and palonosetron 0.25 mg",C9448,"NETUPITANT 300 MG AND PALONOSETRON 0.5 MG, ORAL",60.79858330895031,,Present in Autoproposal
C9033,"Injection, fosnetupitant 235 mg and palonosetron 0.25 mg",J2469,"INJECTION, PALONOSETRON HCL, 25 MCG",60.562306701369415,,Present in Autoproposal
C9033,"Injection, fosnetupitant 235 mg and palonosetron 0.25 mg",Q2024,"INJECTION, BEVACIZUMAB, 0. 25 MG",47.22998849294521,,Present in Autoproposal
C9033,"Injection, fosnetupitant 235 mg and palonosetron 0.25 mg",C9257,"INJECTION, BEVACIZUMAB, 0.25 MG",47.22998849294521,,Present in Autoproposal
C9033,"Injection, fosnetupitant 235 mg and palonosetron 0.25 mg",J0695,"INJECTION, CEFTOLOZANE 50 MG AND TAZOBACTAM 25 MG",46.358922349901235,,Present in Autoproposal
C9033,"Injection, fosnetupitant 235 mg and palonosetron 0.25 mg",C9452,"INJECTION, CEFTOLOZANE 50 MG AND TAZOBACTAM 25 MG",46.358922349901235,,Present in Autoproposal
C9033,"Injection, fosnetupitant 235 mg and palonosetron 0.25 mg",S0107,"INJECTION, OMALIZUMAB, 25 MG",46.102051220505544,,Present in Autoproposal
C9033,"Injection, fosnetupitant 235 mg and palonosetron 0.25 mg",J2324,"INJECTION, NESIRITIDE, 0.25 MG",46.102051220505544,,Present in Autoproposal
C9034,"Injection, dexamethasone 9%, intraocular, 1 mcg",J1094,"INJECTION, DEXAMETHASONE ACETATE, 1 MG",49.87855885970082,10,Present in Autoproposal
C9034,"Injection, dexamethasone 9%, intraocular, 1 mcg",J1095,"INJECTION, DEXAMETHASONE ACETATE, PER 8 MG",47.88850130504275,,Present in Autoproposal
C9034,"Injection, dexamethasone 9%, intraocular, 1 mcg",J1100,"INJECTION, DEXAMETHASONE SODIUM PHOSPHATE, 1 MG",44.676961730427436,,Present in Autoproposal
C9034,"Injection, dexamethasone 9%, intraocular, 1 mcg",J7312,"INJECTION, DEXAMETHASONE, INTRAVITREAL IMPLANT, 0.1 MG",43.14413321348959,,Present in Autoproposal
C9034,"Injection, dexamethasone 9%, intraocular, 1 mcg",C9256,"INJECTION, DEXAMETHASONE INTRAVITREAL IMPLANT, 0.1 MG",43.14413321348959,,Present in Autoproposal
C9034,"Injection, dexamethasone 9%, intraocular, 1 mcg",J8540,"DEXAMETHASONE, ORAL, 0.25 MG",41.680191101511795,,Present in Autoproposal
C9034,"Injection, dexamethasone 9%, intraocular, 1 mcg",J2501,"INJECTION, PARICALCITOL, 1 MCG",37.79126683893201,,Present in Autoproposal
C9034,"Injection, dexamethasone 9%, intraocular, 1 mcg",J2500,"INJECTION, PARICALCITOL, 5 MCG",37.79126683893201,,Present in Autoproposal
C9034,"Injection, dexamethasone 9%, intraocular, 1 mcg",J0636,"INJECTION, CALCITRIOL, 0.1 MCG",37.79126683893201,,Present in Autoproposal
C9034,"Injection, dexamethasone 9%, intraocular, 1 mcg",C9449,"INJECTION, BLINATUMOMAB, 1 MCG",37.79126683893201,,Present in Autoproposal
C9035,"Injection, aripiprazole lauroxil (aristada initio), 1 mg",J1942,"INJECTION, ARIPIPRAZOLE LAUROXIL, 1 MG",100.0,3,Present in Autoproposal
C9035,"Injection, aripiprazole lauroxil (aristada initio), 1 mg",C9470,"INJECTION, ARIPIPRAZOLE LAUROXIL, 1 MG",100.0,,Present in Autoproposal
C9035,"Injection, aripiprazole lauroxil (aristada initio), 1 mg",J0400,"INJECTION, ARIPIPRAZOLE, INTRAMUSCULAR, 0.25 MG",58.84641353566033,,Present Both in MD and Autoproposal
C9035,"Injection, aripiprazole lauroxil (aristada initio), 1 mg",J0401,"INJECTION, ARIPIPRAZOLE, EXTENDED RELEASE, 1 MG",55.13193108933406,,Present in Autoproposal
C9035,"Injection, aripiprazole lauroxil (aristada initio), 1 mg",J9280,"INJECTION, MITOMYCIN, 5 MG",20.274587255394135,,Present in Autoproposal
C9035,"Injection, aripiprazole lauroxil (aristada initio), 1 mg",J9267,"INJECTION, PACLITAXEL, 1 MG",20.274587255394135,,Present in Autoproposal
C9035,"Injection, aripiprazole lauroxil (aristada initio), 1 mg",Q2046,"INJECTION, AFLIBERCEPT, 1 MG",20.03179754127894,,Present in Autoproposal
C9035,"Injection, aripiprazole lauroxil (aristada initio), 1 mg",J0202,"INJECTION, ALEMTUZUMAB, 1 MG",20.03179754127894,,Present in Autoproposal
C9035,"Injection, aripiprazole lauroxil (aristada initio), 1 mg",J0178,"INJECTION, AFLIBERCEPT, 1 MG",20.03179754127894,,Present in Autoproposal
C9035,"Injection, aripiprazole lauroxil (aristada initio), 1 mg",J3396,"INJECTION, VERTEPORFIN, 0.1 MG",20.03179754127894,,Present in Autoproposal
C9036,"Injection, patisiran, 0.1 mg",J9267,"INJECTION, PACLITAXEL, 1 MG",52.950885430632866,10,Present in Autoproposal
C9036,"Injection, patisiran, 0.1 mg",J9280,"INJECTION, MITOMYCIN, 5 MG",52.950885430632866,,Present in Autoproposal
C9036,"Injection, patisiran, 0.1 mg",Q2046,"INJECTION, AFLIBERCEPT, 1 MG",52.316794577196156,,Present in Autoproposal
C9036,"Injection, patisiran, 0.1 mg",J0202,"INJECTION, ALEMTUZUMAB, 1 MG",52.316794577196156,,Present in Autoproposal
C9036,"Injection, patisiran, 0.1 mg",J0178,"INJECTION, AFLIBERCEPT, 1 MG",52.316794577196156,,Present in Autoproposal
C9036,"Injection, patisiran, 0.1 mg",J3396,"INJECTION, VERTEPORFIN, 0.1 MG",52.316794577196156,,Present in Autoproposal
C9036,"Injection, patisiran, 0.1 mg",C9261,"INJECTION, USTEKINUMAB, 1 MG",52.316794577196156,,Present in Autoproposal
C9036,"Injection, patisiran, 0.1 mg",J1325,"INJECTION, EPOPROSTENOL, 0.5 MG",52.316794577196156,,Present in Autoproposal
C9036,"Injection, patisiran, 0.1 mg",Q9979,"INJECTION, ALEMTUZUMAB, 1 MG",52.316794577196156,,Present in Autoproposal
C9036,"Injection, patisiran, 0.1 mg",J2505,"INJECTION, PEGFILGRASTIM, 6 MG",51.58259659366726,,Present in Autoproposal
C9037,"Injection, risperidone (perseris), 0.5 mg",C9125,"INJECTION, RISPERIDONE, PER 12.5 MG",85.39949108154674,2,Present in Autoproposal
C9037,"Injection, risperidone (perseris), 0.5 mg",J2794,"INJECTION, RISPERIDONE, LONG ACTING, 0.5 MG",72.824499215805,,Present Both in MD and Autoproposal
C9037,"Injection, risperidone (perseris), 0.5 mg",S0163,"INJECTION, RISPERIDONE, LONG ACTING, 12.5 MG",68.22832337910145,,Present in Autoproposal
C9037,"Injection, risperidone (perseris), 0.5 mg",J9267,"INJECTION, PACLITAXEL, 1 MG",26.8496608620037,,Present in Autoproposal
C9037,"Injection, risperidone (perseris), 0.5 mg",J9280,"INJECTION, MITOMYCIN, 5 MG",26.8496608620037,,Present in Autoproposal
C9037,"Injection, risperidone (perseris), 0.5 mg",C9261,"INJECTION, USTEKINUMAB, 1 MG",26.528134144706826,,Present in Autoproposal
C9037,"Injection, risperidone (perseris), 0.5 mg",Q2046,"INJECTION, AFLIBERCEPT, 1 MG",26.528134144706826,,Present in Autoproposal
C9037,"Injection, risperidone (perseris), 0.5 mg",Q9979,"INJECTION, ALEMTUZUMAB, 1 MG",26.528134144706826,,Present in Autoproposal
C9037,"Injection, risperidone (perseris), 0.5 mg",J1325,"INJECTION, EPOPROSTENOL, 0.5 MG",26.528134144706826,,Present in Autoproposal
C9037,"Injection, risperidone (perseris), 0.5 mg",J0202,"INJECTION, ALEMTUZUMAB, 1 MG",26.528134144706826,,Present in Autoproposal
C9038,"Injection, mogamulizumab-kpkc, 1 mg",J9267,"INJECTION, PACLITAXEL, 1 MG",52.950885430632866,10,Present in Autoproposal
C9038,"Injection, mogamulizumab-kpkc, 1 mg",J9280,"INJECTION, MITOMYCIN, 5 MG",52.950885430632866,,Present in Autoproposal
C9038,"Injection, mogamulizumab-kpkc, 1 mg",Q2046,"INJECTION, AFLIBERCEPT, 1 MG",52.316794577196156,,Present in Autoproposal
C9038,"Injection, mogamulizumab-kpkc, 1 mg",J0202,"INJECTION, ALEMTUZUMAB, 1 MG",52.316794577196156,,Present in Autoproposal
C9038,"Injection, mogamulizumab-kpkc, 1 mg",J0178,"INJECTION, AFLIBERCEPT, 1 MG",52.316794577196156,,Present in Autoproposal
C9038,"Injection, mogamulizumab-kpkc, 1 mg",J3396,"INJECTION, VERTEPORFIN, 0.1 MG",52.316794577196156,,Present in Autoproposal
C9038,"Injection, mogamulizumab-kpkc, 1 mg",C9261,"INJECTION, USTEKINUMAB, 1 MG",52.316794577196156,,Present in Autoproposal
C9038,"Injection, mogamulizumab-kpkc, 1 mg",J1325,"INJECTION, EPOPROSTENOL, 0.5 MG",52.316794577196156,,Present in Autoproposal
C9038,"Injection, mogamulizumab-kpkc, 1 mg",Q9979,"INJECTION, ALEMTUZUMAB, 1 MG",52.316794577196156,,Present in Autoproposal
C9038,"Injection, mogamulizumab-kpkc, 1 mg",J2505,"INJECTION, PEGFILGRASTIM, 6 MG",51.58259659366726,,Present in Autoproposal
C9039,"Injection, plazomicin, 5 mg",J9267,"INJECTION, PACLITAXEL, 1 MG",52.950885430632866,10,Present in Autoproposal
C9039,"Injection, plazomicin, 5 mg",J9280,"INJECTION, MITOMYCIN, 5 MG",52.950885430632866,,Present in Autoproposal
C9039,"Injection, plazomicin, 5 mg",Q2046,"INJECTION, AFLIBERCEPT, 1 MG",52.316794577196156,,Present in Autoproposal
C9039,"Injection, plazomicin, 5 mg",J0202,"INJECTION, ALEMTUZUMAB, 1 MG",52.316794577196156,,Present in Autoproposal
C9039,"Injection, plazomicin, 5 mg",J0178,"INJECTION, AFLIBERCEPT, 1 MG",52.316794577196156,,Present in Autoproposal
C9039,"Injection, plazomicin, 5 mg",J3396,"INJECTION, VERTEPORFIN, 0.1 MG",52.316794577196156,,Present in Autoproposal
C9039,"Injection, plazomicin, 5 mg",C9261,"INJECTION, USTEKINUMAB, 1 MG",52.316794577196156,,Present in Autoproposal
C9039,"Injection, plazomicin, 5 mg",J1325,"INJECTION, EPOPROSTENOL, 0.5 MG",52.316794577196156,,Present in Autoproposal
C9039,"Injection, plazomicin, 5 mg",Q9979,"INJECTION, ALEMTUZUMAB, 1 MG",52.316794577196156,,Present in Autoproposal
C9039,"Injection, plazomicin, 5 mg",J2505,"INJECTION, PEGFILGRASTIM, 6 MG",51.58259659366726,,Present in Autoproposal
C9407,"Iodine i-131 iobenguane, diagnostic, 1 millicurie",A9508,"IODINE I-131 IOBENGUANE SULFATE, DIAGNOSTIC, PER 0.5 MILLICURIE",90.3230700627568,1,Present Both in MD and Autoproposal
C9407,"Iodine i-131 iobenguane, diagnostic, 1 millicurie",A9529,"IODINE I-131 SODIUM IODIDE SOLUTION, DIAGNOSTIC, PER MILLICURIE",61.399214002465264,,Present in Autoproposal
C9407,"Iodine i-131 iobenguane, diagnostic, 1 millicurie",A9528,"IODINE I-131 SODIUM IODIDE CAPSULE(S), DIAGNOSTIC, PER MILLICURIE",59.633611111622486,,Present in Autoproposal
C9407,"Iodine i-131 iobenguane, diagnostic, 1 millicurie",A9530,"IODINE I-131 SODIUM IODIDE SOLUTION, THERAPEUTIC, PER MILLICURIE",53.05924791173402,,Present in Autoproposal
C9407,"Iodine i-131 iobenguane, diagnostic, 1 millicurie",A9517,"IODINE I-131 SODIUM IODIDE CAPSULE(S), THERAPEUTIC, PER MILLICURIE",51.55597894774713,,Present in Autoproposal
C9407,"Iodine i-131 iobenguane, diagnostic, 1 millicurie",A9582,"IODINE I-123 IOBENGUANE, DIAGNOSTIC, PER STUDY DOSE, UP TO 15 MILLICURIES",47.43620366027351,,Present in Autoproposal
C9407,"Iodine i-131 iobenguane, diagnostic, 1 millicurie",A9544,"IODINE I-131 TOSITUMOMAB, DIAGNOSTIC, PER STUDY DOSE",46.63919131410731,,Present in Autoproposal
C9407,"Iodine i-131 iobenguane, diagnostic, 1 millicurie",A9533,"SUPPLY OF RADIOPHARMACEUTICAL DIAGNOSTIC IMAGING AGENT, I-131 TOSITUMOMAB, PER MILLICURIE",43.818711540575315,,Present in Autoproposal
C9407,"Iodine i-131 iobenguane, diagnostic, 1 millicurie",A9509,"IODINE I-123 SODIUM IODIDE, DIAGNOSTIC, PER MILLICURIE",43.704187163850406,,Present in Autoproposal
C9407,"Iodine i-131 iobenguane, diagnostic, 1 millicurie",A9545,"IODINE I-131 TOSITUMOMAB, THERAPEUTIC, PER TREATMENT DOSE",38.437039806989844,,Present in Autoproposal
C9408,"Iodine i-131 iobenguane, therapeutic, 1 millicurie",A9508,"IODINE I-131 IOBENGUANE SULFATE, DIAGNOSTIC, PER 0.5 MILLICURIE",81.66468153968731,1,Present Both in MD and Autoproposal
C9408,"Iodine i-131 iobenguane, therapeutic, 1 millicurie",A9530,"IODINE I-131 SODIUM IODIDE SOLUTION, THERAPEUTIC, PER MILLICURIE",62.048227812725955,,Present in Autoproposal
C9408,"Iodine i-131 iobenguane, therapeutic, 1 millicurie",A9517,"IODINE I-131 SODIUM IODIDE CAPSULE(S), THERAPEUTIC, PER MILLICURIE",60.2902840270088,,Present in Autoproposal
C9408,"Iodine i-131 iobenguane, therapeutic, 1 millicurie",A9529,"IODINE I-131 SODIUM IODIDE SOLUTION, DIAGNOSTIC, PER MILLICURIE",52.9722219161952,,Present in Autoproposal
C9408,"Iodine i-131 iobenguane, therapeutic, 1 millicurie",A9528,"IODINE I-131 SODIUM IODIDE CAPSULE(S), DIAGNOSTIC, PER MILLICURIE",51.44894658329201,,Present in Autoproposal
C9408,"Iodine i-131 iobenguane, therapeutic, 1 millicurie",A9545,"IODINE I-131 TOSITUMOMAB, THERAPEUTIC, PER TREATMENT DOSE",48.62484568554575,,Present in Autoproposal
C9408,"Iodine i-131 iobenguane, therapeutic, 1 millicurie",A9534,"SUPPLY OF RADIOPHARMACEUTICAL THERAPEUTIC IMAGING AGENT, I-131 TOSITUMOMAB, PER MILLICURIE",44.73585859768915,,Present in Autoproposal
C9408,"Iodine i-131 iobenguane, therapeutic, 1 millicurie",A9527,"IODINE I-125, SODIUM IODIDE SOLUTION, THERAPEUTIC, PER MILLICURIE",43.98063907457816,,Present in Autoproposal
C9408,"Iodine i-131 iobenguane, therapeutic, 1 millicurie",A9582,"IODINE I-123 IOBENGUANE, DIAGNOSTIC, PER STUDY DOSE, UP TO 15 MILLICURIES",40.03043223161431,,Present in Autoproposal
C9408,"Iodine i-131 iobenguane, therapeutic, 1 millicurie",C9405,"SUPPLY OF RADIOPHARMACEUTICAL THERAPEUTIC AGENT, I-131 SODIUM IODIDE SOLUTION, BRAND NAME, PER MILLICURIE",38.12816173701879,,Present in Autoproposal
C9488,"INJECTION, CONIVAPTAN HYDROCHLORIDE, 1 MG",J0592,"INJECTION, BUPRENORPHINE HYDROCHLORIDE, 0.1 MG",71.02180022641626,10,Present in Autoproposal
C9488,"INJECTION, CONIVAPTAN HYDROCHLORIDE, 1 MG",J1610,"INJECTION, GLUCAGON HYDROCHLORIDE, PER 1 MG",68.51374178794302,,Present in Autoproposal
C9488,"INJECTION, CONIVAPTAN HYDROCHLORIDE, 1 MG",C1167,"INJECTION, EPIRUBICIN HYDROCHLORIDE, 2 MG",67.89652939720932,,Present in Autoproposal
C9488,"INJECTION, CONIVAPTAN HYDROCHLORIDE, 1 MG",J0364,"INJECTION, APOMORPHINE HYDROCHLORIDE, 1 MG",66.82480681706915,,Present in Autoproposal
C9488,"INJECTION, CONIVAPTAN HYDROCHLORIDE, 1 MG",S0167,"INJECTION, APOMORPHINE HYDROCHLORIDE, 1 MG",66.82480681706915,,Present in Autoproposal
C9488,"INJECTION, CONIVAPTAN HYDROCHLORIDE, 1 MG",J9211,"INJECTION, IDARUBICIN HYDROCHLORIDE, 5 MG",66.82480681706915,,Present in Autoproposal
C9488,"INJECTION, CONIVAPTAN HYDROCHLORIDE, 1 MG",J2405,"INJECTION, ONDANSETRON HYDROCHLORIDE, PER 1 MG",66.74514300019008,,Present in Autoproposal
C9488,"INJECTION, CONIVAPTAN HYDROCHLORIDE, 1 MG",J2310,"INJECTION, NALOXONE HYDROCHLORIDE, PER 1 MG",66.74514300019008,,Present in Autoproposal
C9488,"INJECTION, CONIVAPTAN HYDROCHLORIDE, 1 MG",C9482,"INJECTION, SOTALOL HYDROCHLORIDE, 1 MG",65.34852468403945,,Present in Autoproposal
C9488,"INJECTION, CONIVAPTAN HYDROCHLORIDE, 1 MG",J2265,"INJECTION, MINOCYCLINE HYDROCHLORIDE, 1 MG",65.34852468403945,,Present in Autoproposal
C9738,ADJUNCTIVE BLUE LIGHT CYSTOSCOPY WITH FLUORESCENT IMAGING AGENT  (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),S2371,EACH ADDITIONAL INTERSPACE (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),37.157898349092456,10,Present in Autoproposal
C9738,ADJUNCTIVE BLUE LIGHT CYSTOSCOPY WITH FLUORESCENT IMAGING AGENT  (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),61517,Implantation of brain intracavitary chemotherapy agent (List separately in addition to code for primary procedure),36.045765640652675,,Present in Autoproposal
C9738,ADJUNCTIVE BLUE LIGHT CYSTOSCOPY WITH FLUORESCENT IMAGING AGENT  (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),90785,Interactive complexity (List separately in addition to the code for primary procedure),35.09008686407851,,Present in Autoproposal
C9738,ADJUNCTIVE BLUE LIGHT CYSTOSCOPY WITH FLUORESCENT IMAGING AGENT  (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),48400,Injection procedure for intraoperative pancreatography (List separately in addition to code for primary procedure),34.323241415693154,,Present in Autoproposal
C9738,ADJUNCTIVE BLUE LIGHT CYSTOSCOPY WITH FLUORESCENT IMAGING AGENT  (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),0346T,"Ultrasound, elastography (List separately in addition to code for primary procedure)",34.03739098424822,,Present in Autoproposal
C9738,ADJUNCTIVE BLUE LIGHT CYSTOSCOPY WITH FLUORESCENT IMAGING AGENT  (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),S2361,EACH ADDITIONAL CERVICAL VERTEBRAL BODY (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),33.90283826178167,,Present in Autoproposal
C9738,ADJUNCTIVE BLUE LIGHT CYSTOSCOPY WITH FLUORESCENT IMAGING AGENT  (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),92547,Use of vertical electrodes (List separately in addition to code for primary procedure),33.387387145240154,,Present in Autoproposal
C9738,ADJUNCTIVE BLUE LIGHT CYSTOSCOPY WITH FLUORESCENT IMAGING AGENT  (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),93568,"Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for pulmonary angiography (List separately in addition to code for primary procedure)",32.77619344920898,,Present in Autoproposal
C9738,ADJUNCTIVE BLUE LIGHT CYSTOSCOPY WITH FLUORESCENT IMAGING AGENT  (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),66990,Use of ophthalmic endoscope (List separately in addition to code for primary procedure),32.353239619794714,,Present in Autoproposal
C9738,ADJUNCTIVE BLUE LIGHT CYSTOSCOPY WITH FLUORESCENT IMAGING AGENT  (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),95873,Electrical stimulation for guidance in conjunction with chemodenervation (List separately in addition to code for primary procedure),32.09555925324362,,Present in Autoproposal
C9745,"NASAL ENDOSCOPY, SURGICAL; BALLOON DILATION OF EUSTACHIAN TUBE",31296,"Nasal/sinus endoscopy, surgical; with dilation of frontal sinus ostium (eg, balloon dilation)",51.155638918384774,10,Present in Autoproposal
C9745,"NASAL ENDOSCOPY, SURGICAL; BALLOON DILATION OF EUSTACHIAN TUBE",31297,"Nasal/sinus endoscopy, surgical; with dilation of sphenoid sinus ostium (eg, balloon dilation)",50.44108090926699,,Present in Autoproposal
C9745,"NASAL ENDOSCOPY, SURGICAL; BALLOON DILATION OF EUSTACHIAN TUBE",31298,"Nasal/sinus endoscopy, surgical; with dilation of frontal and sphenoid sinus ostia (eg, balloon dilation)",47.64981832877383,,Present in Autoproposal
C9745,"NASAL ENDOSCOPY, SURGICAL; BALLOON DILATION OF EUSTACHIAN TUBE",31238,"Nasal/sinus endoscopy, surgical; with control of nasal hemorrhage",45.28415552515664,,Present in Autoproposal
C9745,"NASAL ENDOSCOPY, SURGICAL; BALLOON DILATION OF EUSTACHIAN TUBE",31295,"Nasal/sinus endoscopy, surgical; with dilation of maxillary sinus ostium (eg, balloon dilation), transnasal or via canine fossa",42.7987074585949,,Present in Autoproposal
C9745,"NASAL ENDOSCOPY, SURGICAL; BALLOON DILATION OF EUSTACHIAN TUBE",69405,"Eustachian tube catheterization, transtympanic",41.69547276589054,,Present in Autoproposal
C9745,"NASAL ENDOSCOPY, SURGICAL; BALLOON DILATION OF EUSTACHIAN TUBE",31287,"Nasal/sinus endoscopy, surgical, with sphenoidotomy",38.44873189494563,,Present in Autoproposal
C9745,"NASAL ENDOSCOPY, SURGICAL; BALLOON DILATION OF EUSTACHIAN TUBE",69400,"Eustachian tube inflation, transnasal; with catheterization",37.9678284161197,,Present in Autoproposal
C9745,"NASAL ENDOSCOPY, SURGICAL; BALLOON DILATION OF EUSTACHIAN TUBE",31239,"Nasal/sinus endoscopy, surgical; with dacryocystorhinostomy",37.702324118092,,Present in Autoproposal
C9745,"NASAL ENDOSCOPY, SURGICAL; BALLOON DILATION OF EUSTACHIAN TUBE",69401,"Eustachian tube inflation, transnasal; without catheterization",37.506277311855754,,Present in Autoproposal
C9746,"TRANSPERINEAL IMPLANTATION OF PERMANENT ADJUSTABLE BALLOON CONTINENCE DEVICE, WITH CYSTOURETHROSCOPY, WHEN PERFORMED AND/OR FLUOROSCOPY, WHEN PERFORMED",63663,"Revision including replacement, when performed, of spinal neurostimulator electrode percutaneous array(s), including fluoroscopy, when performed",39.335941979343424,10,Present in Autoproposal
C9746,"TRANSPERINEAL IMPLANTATION OF PERMANENT ADJUSTABLE BALLOON CONTINENCE DEVICE, WITH CYSTOURETHROSCOPY, WHEN PERFORMED AND/OR FLUOROSCOPY, WHEN PERFORMED",0499T,"Cystourethroscopy, with mechanical dilation and urethral therapeutic drug delivery for urethral stricture or stenosis, including fluoroscopy, when performed",32.333710509087574,,Present in Autoproposal
C9746,"TRANSPERINEAL IMPLANTATION OF PERMANENT ADJUSTABLE BALLOON CONTINENCE DEVICE, WITH CYSTOURETHROSCOPY, WHEN PERFORMED AND/OR FLUOROSCOPY, WHEN PERFORMED",63664,"Revision including replacement, when performed, of spinal neurostimulator electrode plate/paddle(s) placed via laminotomy or laminectomy, including fluoroscopy, when performed",32.255662565135154,,Present in Autoproposal
C9746,"TRANSPERINEAL IMPLANTATION OF PERMANENT ADJUSTABLE BALLOON CONTINENCE DEVICE, WITH CYSTOURETHROSCOPY, WHEN PERFORMED AND/OR FLUOROSCOPY, WHEN PERFORMED",0304T,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; device only,32.023910691492055,,Present in Autoproposal
C9746,"TRANSPERINEAL IMPLANTATION OF PERMANENT ADJUSTABLE BALLOON CONTINENCE DEVICE, WITH CYSTOURETHROSCOPY, WHEN PERFORMED AND/OR FLUOROSCOPY, WHEN PERFORMED",0283T,"Percutaneous or open implantation of neurostimulator electrode array(s), subcutaneous (peripheral subcutaneous field stimulation), including imaging guidance, when performed, cervical, thoracic or lumbar; permanent, with implantation of a pulse generator",31.773398958936937,,Present in Autoproposal
C9746,"TRANSPERINEAL IMPLANTATION OF PERMANENT ADJUSTABLE BALLOON CONTINENCE DEVICE, WITH CYSTOURETHROSCOPY, WHEN PERFORMED AND/OR FLUOROSCOPY, WHEN PERFORMED",31622,"Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; diagnostic, with cell washing, when performed (separate procedure)",31.741979614237952,,Present in Autoproposal
C9746,"TRANSPERINEAL IMPLANTATION OF PERMANENT ADJUSTABLE BALLOON CONTINENCE DEVICE, WITH CYSTOURETHROSCOPY, WHEN PERFORMED AND/OR FLUOROSCOPY, WHEN PERFORMED",55874,"Transperineal placement of biodegradable material, peri-prostatic, single or multiple injection(s), including image guidance, when performed",31.487481696226766,,Present in Autoproposal
C9746,"TRANSPERINEAL IMPLANTATION OF PERMANENT ADJUSTABLE BALLOON CONTINENCE DEVICE, WITH CYSTOURETHROSCOPY, WHEN PERFORMED AND/OR FLUOROSCOPY, WHEN PERFORMED",31647,"Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with balloon occlusion, when performed, assessment of air leak, airway sizing, and insertion of bronchial valve(s), initial lobe",31.26102261063807,,Present in Autoproposal
C9746,"TRANSPERINEAL IMPLANTATION OF PERMANENT ADJUSTABLE BALLOON CONTINENCE DEVICE, WITH CYSTOURETHROSCOPY, WHEN PERFORMED AND/OR FLUOROSCOPY, WHEN PERFORMED",0200T,"Percutaneous sacral augmentation (sacroplasty), unilateral injection(s), including the use of a balloon or mechanical device, when used, 1 or more needles, includes imaging guidance and bone biopsy, when performed",31.23129155799097,,Present in Autoproposal
C9746,"TRANSPERINEAL IMPLANTATION OF PERMANENT ADJUSTABLE BALLOON CONTINENCE DEVICE, WITH CYSTOURETHROSCOPY, WHEN PERFORMED AND/OR FLUOROSCOPY, WHEN PERFORMED",63661,"Removal of spinal neurostimulator electrode percutaneous array(s), including fluoroscopy, when performed",31.149645388015152,,Present in Autoproposal
C9747,"ABLATION OF PROSTATE, TRANSRECTAL, HIGH INTENSITY FOCUSED ULTRASOUND (HIFU), INCLUDING IMAGING GUIDANCE",76872,"Ultrasound, transrectal",53.49720670576822,10,Present in Autoproposal
C9747,"ABLATION OF PROSTATE, TRANSRECTAL, HIGH INTENSITY FOCUSED ULTRASOUND (HIFU), INCLUDING IMAGING GUIDANCE",76873,"Ultrasound, transrectal; prostate volume study for brachytherapy treatment planning (separate procedure)",39.77814709528319,,Present in Autoproposal
C9747,"ABLATION OF PROSTATE, TRANSRECTAL, HIGH INTENSITY FOCUSED ULTRASOUND (HIFU), INCLUDING IMAGING GUIDANCE",0398T,"Magnetic resonance image guided high intensity focused ultrasound (MRgFUS), stereotactic ablation lesion, intracranial for movement disorder including stereotactic navigation and frame placement when performed",34.15003297969442,,Present in Autoproposal
C9747,"ABLATION OF PROSTATE, TRANSRECTAL, HIGH INTENSITY FOCUSED ULTRASOUND (HIFU), INCLUDING IMAGING GUIDANCE",45000,Transrectal drainage of pelvic abscess,31.516505667790817,,Present in Autoproposal
C9747,"ABLATION OF PROSTATE, TRANSRECTAL, HIGH INTENSITY FOCUSED ULTRASOUND (HIFU), INCLUDING IMAGING GUIDANCE",55873,Cryosurgical ablation of the prostate (includes ultrasonic guidance and monitoring),31.177838348828946,,Present in Autoproposal
C9747,"ABLATION OF PROSTATE, TRANSRECTAL, HIGH INTENSITY FOCUSED ULTRASOUND (HIFU), INCLUDING IMAGING GUIDANCE",76940,"Ultrasound guidance for, and monitoring of, parenchymal tissue ablation",31.17609683754816,,Present in Autoproposal
C9747,"ABLATION OF PROSTATE, TRANSRECTAL, HIGH INTENSITY FOCUSED ULTRASOUND (HIFU), INCLUDING IMAGING GUIDANCE",C9734,"FOCUSED ULTRASOUND ABLATION/THERAPEUTIC INTERVENTION, OTHER THAN UTERINE LEIOMYOMATA, WITH MAGNETIC RESONANCE (MR) GUIDANCE",31.06670365550982,,Present in Autoproposal
C9747,"ABLATION OF PROSTATE, TRANSRECTAL, HIGH INTENSITY FOCUSED ULTRASOUND (HIFU), INCLUDING IMAGING GUIDANCE",G8465,HIGH OR VERY HIGH RISK OF RECURRENCE OF PROSTATE CANCER,29.588072680060474,,Present in Autoproposal
C9747,"ABLATION OF PROSTATE, TRANSRECTAL, HIGH INTENSITY FOCUSED ULTRASOUND (HIFU), INCLUDING IMAGING GUIDANCE",0071T,"Focused ultrasound ablation of uterine leiomyomata, including MR guidance; total leiomyomata volume less than 200 cc of tissue",28.527257847444666,,Present in Autoproposal
C9747,"ABLATION OF PROSTATE, TRANSRECTAL, HIGH INTENSITY FOCUSED ULTRASOUND (HIFU), INCLUDING IMAGING GUIDANCE",50542,"Laparoscopy, surgical; ablation of renal mass lesion(s), including intraoperative ultrasound guidance and monitoring, when performed",28.24170093266908,,Present in Autoproposal
C9748,TRANSURETHRAL DESTRUCTION OF PROSTATE TISSUE; BY RADIOFREQUENCY WATER VAPOR (STEAM) THERMAL THERAPY,53852,Transurethral destruction of prostate tissue; by radiofrequency thermotherapy,62.39008221006226,10,Present in Autoproposal
C9748,TRANSURETHRAL DESTRUCTION OF PROSTATE TISSUE; BY RADIOFREQUENCY WATER VAPOR (STEAM) THERMAL THERAPY,53853,Transurethral destruction of prostate tissue; by water-induced thermotherapy,56.7045120118127,,Present in Autoproposal
C9748,TRANSURETHRAL DESTRUCTION OF PROSTATE TISSUE; BY RADIOFREQUENCY WATER VAPOR (STEAM) THERMAL THERAPY,53850,Transurethral destruction of prostate tissue; by microwave thermotherapy,46.04858682282272,,Present in Autoproposal
C9748,TRANSURETHRAL DESTRUCTION OF PROSTATE TISSUE; BY RADIOFREQUENCY WATER VAPOR (STEAM) THERMAL THERAPY,52450,Transurethral incision of prostate,41.78963264715742,,Present in Autoproposal
C9748,TRANSURETHRAL DESTRUCTION OF PROSTATE TISSUE; BY RADIOFREQUENCY WATER VAPOR (STEAM) THERMAL THERAPY,46930,"Destruction of internal hemorrhoid(s) by thermal energy (eg, infrared coagulation, cautery, radiofrequency)",35.74342237933198,,Present in Autoproposal
C9748,TRANSURETHRAL DESTRUCTION OF PROSTATE TISSUE; BY RADIOFREQUENCY WATER VAPOR (STEAM) THERMAL THERAPY,00914,Anesthesia for transurethral procedures (including urethrocystoscopy); transurethral resection of prostate,35.16284412645959,,Present in Autoproposal
C9748,TRANSURETHRAL DESTRUCTION OF PROSTATE TISSUE; BY RADIOFREQUENCY WATER VAPOR (STEAM) THERMAL THERAPY,C9716,CREATIONS OF THERMAL ANAL LESIONS BY RADIOFREQUENCY ENERGY,32.70539765203593,,Present in Autoproposal
C9748,TRANSURETHRAL DESTRUCTION OF PROSTATE TISSUE; BY RADIOFREQUENCY WATER VAPOR (STEAM) THERMAL THERAPY,E1405,OXYGEN AND WATER VAPOR ENRICHING SYSTEM WITH HEATED DELIVERY,30.94534768109078,,Present in Autoproposal
C9748,TRANSURETHRAL DESTRUCTION OF PROSTATE TISSUE; BY RADIOFREQUENCY WATER VAPOR (STEAM) THERMAL THERAPY,E1406,OXYGEN AND WATER VAPOR ENRICHING SYSTEM WITHOUT HEATED DELIVERY,30.659136738129757,,Present in Autoproposal
C9748,TRANSURETHRAL DESTRUCTION OF PROSTATE TISSUE; BY RADIOFREQUENCY WATER VAPOR (STEAM) THERMAL THERAPY,61790,"Creation of lesion by stereotactic method, percutaneous, by neurolytic agent (eg, alcohol, thermal, electrical, radiofrequency); gasserian ganglion",27.23846280619371,,Present in Autoproposal
C9750,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation and peri-operative interrogation and programming; complete system (includes device and electrode),0302T,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; complete system (includes device and electrode),87.02411342786237,10,Present in Autoproposal
C9750,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation and peri-operative interrogation and programming; complete system (includes device and electrode),0303T,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; electrode only,78.98337965030545,,Present in Autoproposal
C9750,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation and peri-operative interrogation and programming; complete system (includes device and electrode),0304T,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; device only,77.71207992288316,,Present in Autoproposal
C9750,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation and peri-operative interrogation and programming; complete system (includes device and electrode),0306T,"Interrogation device evaluation (in person) of intracardiac ischemia monitoring system with analysis, review, and report",50.19251569420765,,Present in Autoproposal
C9750,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation and peri-operative interrogation and programming; complete system (includes device and electrode),0307T,Removal of intracardiac ischemia monitoring device,48.67553746176318,,Present in Autoproposal
C9750,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation and peri-operative interrogation and programming; complete system (includes device and electrode),0305T,"Programming device evaluation (in person) of intracardiac ischemia monitoring system with iterative adjustment of programmed values, with analysis, review, and report",39.993094179044505,,Present in Autoproposal
C9750,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation and peri-operative interrogation and programming; complete system (includes device and electrode),0390T,"Peri-procedural device evaluation (in person) and programming of device system parameters before or after a surgery, procedure or test with analysis, review and report, leadless pacemaker system",34.80134026178479,,Present in Autoproposal
C9750,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation and peri-operative interrogation and programming; complete system (includes device and electrode),0266T,"Implantation or replacement of carotid sinus baroreflex activation device; total system (includes generator placement, unilateral or bilateral lead placement, intra-operative interrogation, programming, and repositioning, when performed)",32.726638534451254,,Present in Autoproposal
C9750,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation and peri-operative interrogation and programming; complete system (includes device and electrode),0454T,"Insertion or replacement of a permanently implantable aortic counterpulsation ventricular assist system, endovascular approach, and programming of sensing and therapeutic parameters; subcutaneous electrode",32.54586641920695,,Present in Autoproposal
C9750,Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation and peri-operative interrogation and programming; complete system (includes device and electrode),0269T,"Revision or removal of carotid sinus baroreflex activation device; total system (includes generator placement, unilateral or bilateral lead placement, intra-operative interrogation, programming, and repositioning, when performed)",32.48973514068298,,Present in Autoproposal
C9751,"Bronchoscopy, rigid or flexible, transbronchial ablation of lesion(s) by microwave energy, including  fluoroscopic guidance, when performed, with computed tomography acquisition(s) and 3-d rendering, computer-assisted, image-guided navigation, and endobronchial ultrasound (ebus) guided transtracheal and/or transbronchial sampling (eg, aspiration[s]/biopsy[ies]) and all mediastinal and/or hilar lymph node stations or structures and therapeutic intervention(s)",31653,"Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with endobronchial ultrasound (EBUS) guided transtracheal and/or transbronchial sampling (eg, aspiration[s]/biopsy[ies]), 3 or more mediastinal and/or hilar lymph node stations or structures",78.87105552583192,10,Present in Autoproposal
C9751,"Bronchoscopy, rigid or flexible, transbronchial ablation of lesion(s) by microwave energy, including  fluoroscopic guidance, when performed, with computed tomography acquisition(s) and 3-d rendering, computer-assisted, image-guided navigation, and endobronchial ultrasound (ebus) guided transtracheal and/or transbronchial sampling (eg, aspiration[s]/biopsy[ies]) and all mediastinal and/or hilar lymph node stations or structures and therapeutic intervention(s)",31652,"Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with endobronchial ultrasound (EBUS) guided transtracheal and/or transbronchial sampling (eg, aspiration[s]/biopsy[ies]), one or two mediastinal and/or hilar lymph node stations or structures",77.82797205020584,,Present Both in MD and Autoproposal
C9751,"Bronchoscopy, rigid or flexible, transbronchial ablation of lesion(s) by microwave energy, including  fluoroscopic guidance, when performed, with computed tomography acquisition(s) and 3-d rendering, computer-assisted, image-guided navigation, and endobronchial ultrasound (ebus) guided transtracheal and/or transbronchial sampling (eg, aspiration[s]/biopsy[ies]) and all mediastinal and/or hilar lymph node stations or structures and therapeutic intervention(s)",31627,"Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with computer-assisted, image-guided navigation (List separately in addition to code for primary procedure[s])",44.37566474122044,,Present Both in MD and Autoproposal
C9751,"Bronchoscopy, rigid or flexible, transbronchial ablation of lesion(s) by microwave energy, including  fluoroscopic guidance, when performed, with computed tomography acquisition(s) and 3-d rendering, computer-assisted, image-guided navigation, and endobronchial ultrasound (ebus) guided transtracheal and/or transbronchial sampling (eg, aspiration[s]/biopsy[ies]) and all mediastinal and/or hilar lymph node stations or structures and therapeutic intervention(s)",31628,"Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with transbronchial lung biopsy(s), single lobe",39.18547412151454,,Present in Autoproposal
C9751,"Bronchoscopy, rigid or flexible, transbronchial ablation of lesion(s) by microwave energy, including  fluoroscopic guidance, when performed, with computed tomography acquisition(s) and 3-d rendering, computer-assisted, image-guided navigation, and endobronchial ultrasound (ebus) guided transtracheal and/or transbronchial sampling (eg, aspiration[s]/biopsy[ies]) and all mediastinal and/or hilar lymph node stations or structures and therapeutic intervention(s)",31654,"Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with transendoscopic endobronchial ultrasound (EBUS) during bronchoscopic diagnostic or therapeutic intervention(s) for peripheral lesion(s) (List separately in addition to code for primary procedure[s])",36.2468231165216,,Present in Autoproposal
C9751,"Bronchoscopy, rigid or flexible, transbronchial ablation of lesion(s) by microwave energy, including  fluoroscopic guidance, when performed, with computed tomography acquisition(s) and 3-d rendering, computer-assisted, image-guided navigation, and endobronchial ultrasound (ebus) guided transtracheal and/or transbronchial sampling (eg, aspiration[s]/biopsy[ies]) and all mediastinal and/or hilar lymph node stations or structures and therapeutic intervention(s)",31633,"Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with transbronchial needle aspiration biopsy(s), each additional lobe (List separately in addition to code for primary procedure)",36.20771056516657,,Present in Autoproposal
C9751,"Bronchoscopy, rigid or flexible, transbronchial ablation of lesion(s) by microwave energy, including  fluoroscopic guidance, when performed, with computed tomography acquisition(s) and 3-d rendering, computer-assisted, image-guided navigation, and endobronchial ultrasound (ebus) guided transtracheal and/or transbronchial sampling (eg, aspiration[s]/biopsy[ies]) and all mediastinal and/or hilar lymph node stations or structures and therapeutic intervention(s)",31629,"Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with transbronchial needle aspiration biopsy(s), trachea, main stem and/or lobar bronchus(i)",35.98554621214336,,Present in Autoproposal
C9751,"Bronchoscopy, rigid or flexible, transbronchial ablation of lesion(s) by microwave energy, including  fluoroscopic guidance, when performed, with computed tomography acquisition(s) and 3-d rendering, computer-assisted, image-guided navigation, and endobronchial ultrasound (ebus) guided transtracheal and/or transbronchial sampling (eg, aspiration[s]/biopsy[ies]) and all mediastinal and/or hilar lymph node stations or structures and therapeutic intervention(s)",31632,"Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with transbronchial lung biopsy(s), each additional lobe (List separately in addition to code for primary procedure)",34.13653640015739,,Present in Autoproposal
C9751,"Bronchoscopy, rigid or flexible, transbronchial ablation of lesion(s) by microwave energy, including  fluoroscopic guidance, when performed, with computed tomography acquisition(s) and 3-d rendering, computer-assisted, image-guided navigation, and endobronchial ultrasound (ebus) guided transtracheal and/or transbronchial sampling (eg, aspiration[s]/biopsy[ies]) and all mediastinal and/or hilar lymph node stations or structures and therapeutic intervention(s)",31625,"Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial or endobronchial biopsy(s), single or multiple sites",33.53157776213598,,Present in Autoproposal
C9751,"Bronchoscopy, rigid or flexible, transbronchial ablation of lesion(s) by microwave energy, including  fluoroscopic guidance, when performed, with computed tomography acquisition(s) and 3-d rendering, computer-assisted, image-guided navigation, and endobronchial ultrasound (ebus) guided transtracheal and/or transbronchial sampling (eg, aspiration[s]/biopsy[ies]) and all mediastinal and/or hilar lymph node stations or structures and therapeutic intervention(s)",31640,"Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with excision of tumor",29.692526144866655,,Present in Autoproposal
C9752,"Destruction of intraosseous basivertebral nerve, first two vertebral bodies, including imaging guidance (e.g., fluoroscopy), lumbar/sacrum",36680,Placement of needle for intraosseous infusion,31.93002721465331,1,Present Both in MD and Autoproposal
C9752,"Destruction of intraosseous basivertebral nerve, first two vertebral bodies, including imaging guidance (e.g., fluoroscopy), lumbar/sacrum",64635,"Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); lumbar or sacral, single facet joint",28.61662746814413,,Present Both in MD and Autoproposal
C9752,"Destruction of intraosseous basivertebral nerve, first two vertebral bodies, including imaging guidance (e.g., fluoroscopy), lumbar/sacrum",64636,"Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); lumbar or sacral, each additional facet joint (List separately in addition to code for primary procedure)",26.278422536393965,,Present in Autoproposal
C9752,"Destruction of intraosseous basivertebral nerve, first two vertebral bodies, including imaging guidance (e.g., fluoroscopy), lumbar/sacrum",72292,"Radiological supervision and interpretation, percutaneous vertebroplasty, vertebral augmentation, or sacral augmentation (sacroplasty), including cavity creation, per vertebral body or sacrum; under CT guidance",24.14438342351232,,Present in Autoproposal
C9752,"Destruction of intraosseous basivertebral nerve, first two vertebral bodies, including imaging guidance (e.g., fluoroscopy), lumbar/sacrum",72291,"Radiological supervision and interpretation, percutaneous vertebroplasty, vertebral augmentation, or sacral augmentation (sacroplasty), including cavity creation, per vertebral body or sacrum; under fluoroscopic guidance",24.11450663794981,,Present in Autoproposal
C9752,"Destruction of intraosseous basivertebral nerve, first two vertebral bodies, including imaging guidance (e.g., fluoroscopy), lumbar/sacrum",64633,"Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); cervical or thoracic, single facet joint",23.870101225837224,,Present in Autoproposal
C9752,"Destruction of intraosseous basivertebral nerve, first two vertebral bodies, including imaging guidance (e.g., fluoroscopy), lumbar/sacrum",0202T,"Posterior vertebral joint(s) arthroplasty (eg, facet joint[s] replacement), including facetectomy, laminectomy, foraminotomy, and vertebral column fixation, injection of bone cement, when performed, including fluoroscopy, single level, lumbar spine",23.60308914320499,,Present in Autoproposal
C9752,"Destruction of intraosseous basivertebral nerve, first two vertebral bodies, including imaging guidance (e.g., fluoroscopy), lumbar/sacrum",22114,"Partial excision of vertebral body, for intrinsic bony lesion, without decompression of spinal cord or nerve root(s), single vertebral segment; lumbar",23.297946241217655,,Present in Autoproposal
C9752,"Destruction of intraosseous basivertebral nerve, first two vertebral bodies, including imaging guidance (e.g., fluoroscopy), lumbar/sacrum",22515,"Percutaneous vertebral augmentation, including cavity creation (fracture reduction and bone biopsy included when performed) using mechanical device (eg, kyphoplasty), 1 vertebral body, unilateral or bilateral cannulation, inclusive of all imaging guidance; each additional thoracic or lumbar vertebral body (List separately in addition to code for primary procedure)",22.759342036222975,,Present in Autoproposal
C9752,"Destruction of intraosseous basivertebral nerve, first two vertebral bodies, including imaging guidance (e.g., fluoroscopy), lumbar/sacrum",22514,"Percutaneous vertebral augmentation, including cavity creation (fracture reduction and bone biopsy included when performed) using mechanical device (eg, kyphoplasty), 1 vertebral body, unilateral or bilateral cannulation, inclusive of all imaging guidance; lumbar",22.603294824351018,,Present in Autoproposal
C9753,"Destruction of intraosseous basivertebral nerve, each additional vertebral body, including imaging guidance (e.g., fluoroscopy), lumbar/sacrum (list separately in addition to code for primary procedure)",S2361,EACH ADDITIONAL CERVICAL VERTEBRAL BODY (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),57.65963775228282,10,Present in Autoproposal
C9753,"Destruction of intraosseous basivertebral nerve, each additional vertebral body, including imaging guidance (e.g., fluoroscopy), lumbar/sacrum (list separately in addition to code for primary procedure)",S2363,"KYPHOPLASTY, ONE VERTEBRAL BODY, UNILATERAL OR BILATERAL INJECTION; EACH ADDITIONAL VERTEBRAL BODY (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE)",48.434834974424916,,Present in Autoproposal
C9753,"Destruction of intraosseous basivertebral nerve, each additional vertebral body, including imaging guidance (e.g., fluoroscopy), lumbar/sacrum (list separately in addition to code for primary procedure)",C9719,"KYPHOPLASTY, ONE VERTEBRAL BODY, UNILATERAL OR BILATERAL INJECTION; EACH ADDITIONAL VERTEBRAL BODY (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE)",48.434834974424916,,Present in Autoproposal
C9753,"Destruction of intraosseous basivertebral nerve, each additional vertebral body, including imaging guidance (e.g., fluoroscopy), lumbar/sacrum (list separately in addition to code for primary procedure)",64636,"Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); lumbar or sacral, each additional facet joint (List separately in addition to code for primary procedure)",47.19395886843319,,Present Both in MD and Autoproposal
C9753,"Destruction of intraosseous basivertebral nerve, each additional vertebral body, including imaging guidance (e.g., fluoroscopy), lumbar/sacrum (list separately in addition to code for primary procedure)",64837,"Suture of each additional nerve, hand or foot (List separately in addition to code for primary procedure)",46.32544518378086,,Present in Autoproposal
C9753,"Destruction of intraosseous basivertebral nerve, each additional vertebral body, including imaging guidance (e.g., fluoroscopy), lumbar/sacrum (list separately in addition to code for primary procedure)",22522,"Percutaneous vertebroplasty (bone biopsy included when performed), 1 vertebral body, unilateral or bilateral injection; each additional thoracic or lumbar vertebral body (List separately in addition to code for primary procedure)",46.14306395617458,,Present in Autoproposal
C9753,"Destruction of intraosseous basivertebral nerve, each additional vertebral body, including imaging guidance (e.g., fluoroscopy), lumbar/sacrum (list separately in addition to code for primary procedure)",S2371,EACH ADDITIONAL INTERSPACE (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE),45.99997435692356,,Present in Autoproposal
C9753,"Destruction of intraosseous basivertebral nerve, each additional vertebral body, including imaging guidance (e.g., fluoroscopy), lumbar/sacrum (list separately in addition to code for primary procedure)",64901,"Nerve graft, each additional nerve; single strand (List separately in addition to code for primary procedure)",45.609427757549774,,Present in Autoproposal
C9753,"Destruction of intraosseous basivertebral nerve, each additional vertebral body, including imaging guidance (e.g., fluoroscopy), lumbar/sacrum (list separately in addition to code for primary procedure)",64859,Suture of each additional major peripheral nerve (List separately in addition to code for primary procedure),45.24845877698155,,Present in Autoproposal
C9753,"Destruction of intraosseous basivertebral nerve, each additional vertebral body, including imaging guidance (e.g., fluoroscopy), lumbar/sacrum (list separately in addition to code for primary procedure)",64623,"Destruction by neurolytic agent, paravertebral facet joint nerve; lumbar or sacral, each additional level (List separately in addition to code for primary procedure)",44.94714321520748,,Present in Autoproposal
D0412,BLOOD GLUCOSE LEVEL TEST  IN-OFFICE USING A GLUCOSE METER,82950,Glucose; post glucose dose (includes glucose),59.109049252391,8,Present in Autoproposal
D0412,BLOOD GLUCOSE LEVEL TEST  IN-OFFICE USING A GLUCOSE METER,82951,"Glucose; tolerance test (GTT), 3 specimens (includes glucose)",47.23530494156634,,Present in Autoproposal
D0412,BLOOD GLUCOSE LEVEL TEST  IN-OFFICE USING A GLUCOSE METER,E0607,HOME BLOOD GLUCOSE MONITOR,46.85483078260535,,Present in Autoproposal
D0412,BLOOD GLUCOSE LEVEL TEST  IN-OFFICE USING A GLUCOSE METER,A4253,"BLOOD GLUCOSE TEST OR REAGENT STRIPS FOR HOME BLOOD GLUCOSE MONITOR, PER 50 STRIPS",44.56077894333603,,Present in Autoproposal
D0412,BLOOD GLUCOSE LEVEL TEST  IN-OFFICE USING A GLUCOSE METER,82945,"Glucose, body fluid, other than blood",43.22611416080624,,Present in Autoproposal
D0412,BLOOD GLUCOSE LEVEL TEST  IN-OFFICE USING A GLUCOSE METER,A4772,"BLOOD GLUCOSE TEST STRIPS, FOR DIALYSIS, PER 50",43.04751690012916,,Present in Autoproposal
D0412,BLOOD GLUCOSE LEVEL TEST  IN-OFFICE USING A GLUCOSE METER,82962,"Glucose, blood by glucose monitoring device(s) cleared by the FDA specifically for home use",40.339031890779985,,Present Both in MD and Autoproposal
D0412,BLOOD GLUCOSE LEVEL TEST  IN-OFFICE USING A GLUCOSE METER,82948,"Glucose; blood, reagent strip",40.067323415045166,,Present Both in MD and Autoproposal
D0412,BLOOD GLUCOSE LEVEL TEST  IN-OFFICE USING A GLUCOSE METER,S1034,"ARTIFICIAL PANCREAS DEVICE SYSTEM (E.G., LOW GLUCOSE SUSPEND (LGS) FEATURE) INCLUDING CONTINUOUS GLUCOSE MONITOR, BLOOD GLUCOSE DEVICE, INSULIN PUMP AND COMPUTER ALGORITHM THAT COMMUNICATES WITH ALL OF THE DEVICES",38.175716468029094,,Present in Autoproposal
D0412,BLOOD GLUCOSE LEVEL TEST  IN-OFFICE USING A GLUCOSE METER,82953,Glucose; tolbutamide tolerance test,36.512163101913565,,Present in Autoproposal
D1516,"SPACE MAINTAINER  FIXED  BILATERAL, MAXILLARY",D1515,SPACE MAINTAINER - FIXED - BILATERAL,89.40333692375813,1,Present Both in MD and Autoproposal
D1516,"SPACE MAINTAINER  FIXED  BILATERAL, MAXILLARY",D1555,REMOVAL OF FIXED SPACE MAINTAINER,76.24291629056911,,Present in Autoproposal
D1516,"SPACE MAINTAINER  FIXED  BILATERAL, MAXILLARY",D1510,SPACE MAINTAINER - FIXED - UNILATERAL,75.82035219545378,,Present in Autoproposal
D1516,"SPACE MAINTAINER  FIXED  BILATERAL, MAXILLARY",D1525,SPACE MAINTAINER - REMOVABLE - BILATERAL,70.12509628958253,,Present in Autoproposal
D1516,"SPACE MAINTAINER  FIXED  BILATERAL, MAXILLARY",D1575,DISTAL SHOE SPACE MAINTAINER  FIXED  UNILATERAL,63.60769478420772,,Present in Autoproposal
D1516,"SPACE MAINTAINER  FIXED  BILATERAL, MAXILLARY",D1520,SPACE MAINTAINER - REMOVABLE - UNILATERAL,56.76792995507027,,Present in Autoproposal
D1516,"SPACE MAINTAINER  FIXED  BILATERAL, MAXILLARY",D1550,RE-CEMENT OR RE-BOND SPACE MAINTAINER,37.256863167995114,,Present in Autoproposal
D1516,"SPACE MAINTAINER  FIXED  BILATERAL, MAXILLARY",D6114,IMPLANT /ABUTMENT SUPPORTED FIXED DENTURE FOR EDENTULOUS ARCH  MAXILLARY,28.81681499003925,,Present in Autoproposal
D1516,"SPACE MAINTAINER  FIXED  BILATERAL, MAXILLARY",D5110,COMPLETE DENTURE - MAXILLARY,28.70639647995199,,Present in Autoproposal
D1516,"SPACE MAINTAINER  FIXED  BILATERAL, MAXILLARY",D6119,IMPLANT/ABUTMENT SUPPORTED INTERIM FIXED DENTURE FOR EDENTULOUS ARCH  MAXILLARY,26.799177872070025,,Present in Autoproposal
D1517,"SPACE MAINTAINER  FIXED  BILATERAL, MANDIBULAR",D1515,SPACE MAINTAINER - FIXED - BILATERAL,89.96648253730126,1,Present Both in MD and Autoproposal
D1517,"SPACE MAINTAINER  FIXED  BILATERAL, MANDIBULAR",D1555,REMOVAL OF FIXED SPACE MAINTAINER,76.72316529860541,,Present in Autoproposal
D1517,"SPACE MAINTAINER  FIXED  BILATERAL, MANDIBULAR",D1510,SPACE MAINTAINER - FIXED - UNILATERAL,76.29793950064105,,Present in Autoproposal
D1517,"SPACE MAINTAINER  FIXED  BILATERAL, MANDIBULAR",D1525,SPACE MAINTAINER - REMOVABLE - BILATERAL,70.56680956040199,,Present in Autoproposal
D1517,"SPACE MAINTAINER  FIXED  BILATERAL, MANDIBULAR",D1575,DISTAL SHOE SPACE MAINTAINER  FIXED  UNILATERAL,64.00835538075643,,Present in Autoproposal
D1517,"SPACE MAINTAINER  FIXED  BILATERAL, MANDIBULAR",D1520,SPACE MAINTAINER - REMOVABLE - UNILATERAL,57.12550733242683,,Present in Autoproposal
D1517,"SPACE MAINTAINER  FIXED  BILATERAL, MANDIBULAR",D1550,RE-CEMENT OR RE-BOND SPACE MAINTAINER,37.49154164633117,,Present in Autoproposal
D1517,"SPACE MAINTAINER  FIXED  BILATERAL, MANDIBULAR",D6115,IMPLANT /ABUTMENT SUPPORTED FIXED DENTURE FOR EDENTULOUS ARCH  MANDIBULAR,28.103490556639933,,Present in Autoproposal
D1517,"SPACE MAINTAINER  FIXED  BILATERAL, MANDIBULAR",D5120,COMPLETE DENTURE - MANDIBULAR,27.443588032822362,,Present in Autoproposal
D1517,"SPACE MAINTAINER  FIXED  BILATERAL, MANDIBULAR",D6118,IMPLANT/ABUTMENT SUPPORTED INTERIM FIXED DENTURE FOR EDENTULOUS ARCH  MANDIBULAR,26.121494974032466,,Present in Autoproposal
D1526,"SPACE MAINTAINER  REMOVABLE  BILATERAL, MAXILLARY",D1525,SPACE MAINTAINER - REMOVABLE - BILATERAL,89.79507214162811,1,Present Both in MD and Autoproposal
D1526,"SPACE MAINTAINER  REMOVABLE  BILATERAL, MAXILLARY",D1520,SPACE MAINTAINER - REMOVABLE - UNILATERAL,76.74638967983262,,Present in Autoproposal
D1526,"SPACE MAINTAINER  REMOVABLE  BILATERAL, MAXILLARY",D1515,SPACE MAINTAINER - FIXED - BILATERAL,70.4323607700636,,Present in Autoproposal
D1526,"SPACE MAINTAINER  REMOVABLE  BILATERAL, MAXILLARY",D1555,REMOVAL OF FIXED SPACE MAINTAINER,57.343507110867776,,Present in Autoproposal
D1526,"SPACE MAINTAINER  REMOVABLE  BILATERAL, MAXILLARY",D1510,SPACE MAINTAINER - FIXED - UNILATERAL,57.02568994998302,,Present in Autoproposal
D1526,"SPACE MAINTAINER  REMOVABLE  BILATERAL, MAXILLARY",D1575,DISTAL SHOE SPACE MAINTAINER  FIXED  UNILATERAL,47.840356529165184,,Present in Autoproposal
D1526,"SPACE MAINTAINER  REMOVABLE  BILATERAL, MAXILLARY",D1550,RE-CEMENT OR RE-BOND SPACE MAINTAINER,36.599516336427065,,Present in Autoproposal
D1526,"SPACE MAINTAINER  REMOVABLE  BILATERAL, MAXILLARY",D9932,"CLEANING AND INSPECTION OF REMOVABLE COMPLETE DENTURE, MAXILLARY",34.17189040433105,,Present in Autoproposal
D1526,"SPACE MAINTAINER  REMOVABLE  BILATERAL, MAXILLARY",D9934,"CLEANING AND INSPECTION OF REMOVABLE PARTIAL DENTURE, MAXILLARY",34.164070895457364,,Present in Autoproposal
D1526,"SPACE MAINTAINER  REMOVABLE  BILATERAL, MAXILLARY",D6110,IMPLANT /ABUTMENT SUPPORTED REMOVABLE DENTURE FOR EDENTULOUS ARCH  MAXILLARY,30.8086525913087,,Present in Autoproposal
D1527,"SPACE MAINTAINER  REMOVABLE  BILATERAL, MANDIBULAR",D1525,SPACE MAINTAINER - REMOVABLE - BILATERAL,90.34072169880747,1,Present Both in MD and Autoproposal
D1527,"SPACE MAINTAINER  REMOVABLE  BILATERAL, MANDIBULAR",D1520,SPACE MAINTAINER - REMOVABLE - UNILATERAL,77.21274749374322,,Present in Autoproposal
D1527,"SPACE MAINTAINER  REMOVABLE  BILATERAL, MANDIBULAR",D1515,SPACE MAINTAINER - FIXED - BILATERAL,70.86035069811517,,Present in Autoproposal
D1527,"SPACE MAINTAINER  REMOVABLE  BILATERAL, MANDIBULAR",D1555,REMOVAL OF FIXED SPACE MAINTAINER,57.69196119098483,,Present in Autoproposal
D1527,"SPACE MAINTAINER  REMOVABLE  BILATERAL, MANDIBULAR",D1510,SPACE MAINTAINER - FIXED - UNILATERAL,57.372212779431585,,Present in Autoproposal
D1527,"SPACE MAINTAINER  REMOVABLE  BILATERAL, MANDIBULAR",D1575,DISTAL SHOE SPACE MAINTAINER  FIXED  UNILATERAL,48.13106367748474,,Present in Autoproposal
D1527,"SPACE MAINTAINER  REMOVABLE  BILATERAL, MANDIBULAR",D1550,RE-CEMENT OR RE-BOND SPACE MAINTAINER,36.82191729235538,,Present in Autoproposal
D1527,"SPACE MAINTAINER  REMOVABLE  BILATERAL, MANDIBULAR",D9933,"CLEANING AND INSPECTION OF REMOVABLE COMPLETE DENTURE, MANDIBULAR",33.45610591174923,,Present in Autoproposal
D1527,"SPACE MAINTAINER  REMOVABLE  BILATERAL, MANDIBULAR",D9935,"CLEANING AND INSPECTION OF REMOVABLE PARTIAL DENTURE, MANDIBULAR",33.448375493460524,,Present in Autoproposal
D1527,"SPACE MAINTAINER  REMOVABLE  BILATERAL, MANDIBULAR",D6111,IMPLANT /ABUTMENT SUPPORTED REMOVABLE DENTURE FOR EDENTULOUS ARCH  MANDIBULAR,30.135802619319207,,Present in Autoproposal
D5282,"REMOVABLE UNILATERAL PARTIAL DENTURE  ONE PIECE CAST METAL (INCLUDING CLASPS AND TEETH), MAXILLARY",D5281,REMOVABLE UNILATERAL PARTIAL DENTURE - ONE PIECE CAST METAL (INCLUDING CLASPS AND TEETH),94.82357912081673,1,Present Both in MD and Autoproposal
D5282,"REMOVABLE UNILATERAL PARTIAL DENTURE  ONE PIECE CAST METAL (INCLUDING CLASPS AND TEETH), MAXILLARY",D5213,"MAXILLARY PARTIAL DENTURE - CAST METAL FRAMEWORK WITH RESIN DENTURE BASES (INCLUDING ANY CONVENTIONAL CLASPS, RESTS AND TEETH)",60.42068130096836,,Present in Autoproposal
D5282,"REMOVABLE UNILATERAL PARTIAL DENTURE  ONE PIECE CAST METAL (INCLUDING CLASPS AND TEETH), MAXILLARY",D5225,"MAXILLARY PARTIAL DENTURE - FLEXIBLE BASE (INCLUDING ANY CLASPS, RESTS AND TEETH)",58.734344927558546,,Present in Autoproposal
D5282,"REMOVABLE UNILATERAL PARTIAL DENTURE  ONE PIECE CAST METAL (INCLUDING CLASPS AND TEETH), MAXILLARY",D5223,"IMMEDIATE MAXILLARY PARTIAL DENTURE  CAST METAL FRAMEWORK WITH RESIN DENTURE BASES (INCLUDING ANY CONVENTIONAL CLASPS, RESTS AND TEETH)",58.64189393665744,,Present in Autoproposal
D5282,"REMOVABLE UNILATERAL PARTIAL DENTURE  ONE PIECE CAST METAL (INCLUDING CLASPS AND TEETH), MAXILLARY",D5214,"MANDIBULAR PARTIAL DENTURE - CAST METAL FRAMEWORK WITH RESIN DENTURE BASES (INCLUDING ANY CONVENTIONAL CLASPS, RESTS AND TEETH)",52.795519228100765,,Present in Autoproposal
D5282,"REMOVABLE UNILATERAL PARTIAL DENTURE  ONE PIECE CAST METAL (INCLUDING CLASPS AND TEETH), MAXILLARY",D5224,"IMMEDIATE MANDIBULAR PARTIAL DENTURE  CAST METAL FRAMEWORK WITH RESIN DENTURE BASES (INCLUDING ANY CONVENTIONAL CLASPS, RESTS AND TEETH)",51.235732629046225,,Present in Autoproposal
D5282,"REMOVABLE UNILATERAL PARTIAL DENTURE  ONE PIECE CAST METAL (INCLUDING CLASPS AND TEETH), MAXILLARY",D5221,"IMMEDIATE MAXILLARY PARTIAL DENTURE  RESIN BASE (INCLUDING ANY CONVENTIONAL CLASPS, RESTS AND TEETH)",51.15209910423234,,Present in Autoproposal
D5282,"REMOVABLE UNILATERAL PARTIAL DENTURE  ONE PIECE CAST METAL (INCLUDING CLASPS AND TEETH), MAXILLARY",D5226,"MANDIBULAR PARTIAL DENTURE - FLEXIBLE BASE (INCLUDING ANY CLASPS, RESTS AND TEETH)",48.009697579044456,,Present in Autoproposal
D5282,"REMOVABLE UNILATERAL PARTIAL DENTURE  ONE PIECE CAST METAL (INCLUDING CLASPS AND TEETH), MAXILLARY",D9934,"CLEANING AND INSPECTION OF REMOVABLE PARTIAL DENTURE, MAXILLARY",44.415105810908415,,Present in Autoproposal
D5282,"REMOVABLE UNILATERAL PARTIAL DENTURE  ONE PIECE CAST METAL (INCLUDING CLASPS AND TEETH), MAXILLARY",D5222,"IMMEDIATE MANDIBULAR PARTIAL DENTURE  RESIN BASE (INCLUDING ANY CONVENTIONAL CLASPS, RESTS AND TEETH)",41.7747212446115,,Present in Autoproposal
D5283,"REMOVABLE UNILATERAL PARTIAL DENTURE  ONE PIECE CAST METAL (INCLUDING CLASPS AND TEETH), MANDIBULAR",D5281,REMOVABLE UNILATERAL PARTIAL DENTURE - ONE PIECE CAST METAL (INCLUDING CLASPS AND TEETH),95.12229458951722,1,Present Both in MD and Autoproposal
D5283,"REMOVABLE UNILATERAL PARTIAL DENTURE  ONE PIECE CAST METAL (INCLUDING CLASPS AND TEETH), MANDIBULAR",D5214,"MANDIBULAR PARTIAL DENTURE - CAST METAL FRAMEWORK WITH RESIN DENTURE BASES (INCLUDING ANY CONVENTIONAL CLASPS, RESTS AND TEETH)",60.240181613541836,,Present in Autoproposal
D5283,"REMOVABLE UNILATERAL PARTIAL DENTURE  ONE PIECE CAST METAL (INCLUDING CLASPS AND TEETH), MANDIBULAR",D5224,"IMMEDIATE MANDIBULAR PARTIAL DENTURE  CAST METAL FRAMEWORK WITH RESIN DENTURE BASES (INCLUDING ANY CONVENTIONAL CLASPS, RESTS AND TEETH)",58.46045050417522,,Present in Autoproposal
D5283,"REMOVABLE UNILATERAL PARTIAL DENTURE  ONE PIECE CAST METAL (INCLUDING CLASPS AND TEETH), MANDIBULAR",D5226,"MANDIBULAR PARTIAL DENTURE - FLEXIBLE BASE (INCLUDING ANY CLASPS, RESTS AND TEETH)",58.453947004582766,,Present in Autoproposal
D5283,"REMOVABLE UNILATERAL PARTIAL DENTURE  ONE PIECE CAST METAL (INCLUDING CLASPS AND TEETH), MANDIBULAR",D5213,"MAXILLARY PARTIAL DENTURE - CAST METAL FRAMEWORK WITH RESIN DENTURE BASES (INCLUDING ANY CONVENTIONAL CLASPS, RESTS AND TEETH)",52.864380992945314,,Present in Autoproposal
D5283,"REMOVABLE UNILATERAL PARTIAL DENTURE  ONE PIECE CAST METAL (INCLUDING CLASPS AND TEETH), MANDIBULAR",D5223,"IMMEDIATE MAXILLARY PARTIAL DENTURE  CAST METAL FRAMEWORK WITH RESIN DENTURE BASES (INCLUDING ANY CONVENTIONAL CLASPS, RESTS AND TEETH)",51.30805142320802,,Present in Autoproposal
D5283,"REMOVABLE UNILATERAL PARTIAL DENTURE  ONE PIECE CAST METAL (INCLUDING CLASPS AND TEETH), MANDIBULAR",D5222,"IMMEDIATE MANDIBULAR PARTIAL DENTURE  RESIN BASE (INCLUDING ANY CONVENTIONAL CLASPS, RESTS AND TEETH)",50.86258537128532,,Present in Autoproposal
D5283,"REMOVABLE UNILATERAL PARTIAL DENTURE  ONE PIECE CAST METAL (INCLUDING CLASPS AND TEETH), MANDIBULAR",D5225,"MAXILLARY PARTIAL DENTURE - FLEXIBLE BASE (INCLUDING ANY CLASPS, RESTS AND TEETH)",47.98418715327269,,Present in Autoproposal
D5283,"REMOVABLE UNILATERAL PARTIAL DENTURE  ONE PIECE CAST METAL (INCLUDING CLASPS AND TEETH), MANDIBULAR",D9935,"CLEANING AND INSPECTION OF REMOVABLE PARTIAL DENTURE, MANDIBULAR",43.98719946785,,Present in Autoproposal
D5283,"REMOVABLE UNILATERAL PARTIAL DENTURE  ONE PIECE CAST METAL (INCLUDING CLASPS AND TEETH), MANDIBULAR",D5221,"IMMEDIATE MAXILLARY PARTIAL DENTURE  RESIN BASE (INCLUDING ANY CONVENTIONAL CLASPS, RESTS AND TEETH)",41.789721154250465,,Present in Autoproposal
D7979,NON  SURGICAL SIALOLITHOTOMY,D7980,SURGICAL SIALOLITHOTOMY,91.42096931639071,10,Present in Autoproposal
D7979,NON  SURGICAL SIALOLITHOTOMY,42340,"Sialolithotomy; parotid, extraoral or complicated intraoral",41.34709999193012,,Present in Autoproposal
D7979,NON  SURGICAL SIALOLITHOTOMY,42335,"Sialolithotomy; submandibular (submaxillary), complicated, intraoral",40.474480275070704,,Present in Autoproposal
D7979,NON  SURGICAL SIALOLITHOTOMY,42330,"Sialolithotomy; submandibular (submaxillary), sublingual or parotid, uncomplicated, intraoral",32.88497219218182,,Present in Autoproposal
D7979,NON  SURGICAL SIALOLITHOTOMY,D5982,SURGICAL STENT,27.009281446840728,,Present in Autoproposal
D7979,NON  SURGICAL SIALOLITHOTOMY,A4461,"SURGICAL DRESSING HOLDER, NON-REUSABLE, EACH",25.490459036744706,,Present in Autoproposal
D7979,NON  SURGICAL SIALOLITHOTOMY,44187,"Laparoscopy, surgical; ileostomy or jejunostomy, non-tube",24.63426288637628,,Present in Autoproposal
D7979,NON  SURGICAL SIALOLITHOTOMY,D3331,TREATMENT OF ROOT CANAL OBSTRUCTION; NON-SURGICAL ACCESS,23.628420419338315,,Present in Autoproposal
D7979,NON  SURGICAL SIALOLITHOTOMY,D5988,SURGICAL SPLINT,23.014722442116856,,Present in Autoproposal
D7979,NON  SURGICAL SIALOLITHOTOMY,99025,INITIAL SURGICAL EVALUATION,22.780916599255647,,Present in Autoproposal
D9995,TELEDENTISTRY  SYNCHRONOUS; REAL-TIME ENCOUNTER,76700,"Ultrasound, abdominal, real time with image documentation; complete",29.93004854700757,10,Present in Autoproposal
D9995,TELEDENTISTRY  SYNCHRONOUS; REAL-TIME ENCOUNTER,D9996,TELEDENTISTRY  ASYNCHRONOUS; INFORMATION STORED AND FORWARDED TO DENTIST FOR SUBSEQUENT REVIEW,27.79511647661929,,Present in Autoproposal
D9995,TELEDENTISTRY  SYNCHRONOUS; REAL-TIME ENCOUNTER,76645,"Ultrasound, breast(s) (unilateral or bilateral), real time with image documentation",27.664553055631075,,Present in Autoproposal
D9995,TELEDENTISTRY  SYNCHRONOUS; REAL-TIME ENCOUNTER,76880,"Ultrasound, extremity, nonvascular, real time with image documentation",26.799386798353325,,Present in Autoproposal
D9995,TELEDENTISTRY  SYNCHRONOUS; REAL-TIME ENCOUNTER,76604,"Ultrasound, chest (includes mediastinum), real time with image documentation",26.13272288807299,,Present in Autoproposal
D9995,TELEDENTISTRY  SYNCHRONOUS; REAL-TIME ENCOUNTER,76856,"Ultrasound, pelvic (nonobstetric), real time with image documentation; complete",24.91661624445793,,Present in Autoproposal
D9995,TELEDENTISTRY  SYNCHRONOUS; REAL-TIME ENCOUNTER,76817,"Ultrasound, pregnant uterus, real time with image documentation, transvaginal",23.664471209291193,,Present in Autoproposal
D9995,TELEDENTISTRY  SYNCHRONOUS; REAL-TIME ENCOUNTER,76641,"Ultrasound, breast, unilateral, real time with image documentation, including axilla when performed; complete",23.06901135606156,,Present in Autoproposal
D9995,TELEDENTISTRY  SYNCHRONOUS; REAL-TIME ENCOUNTER,76642,"Ultrasound, breast, unilateral, real time with image documentation, including axilla when performed; limited",22.858469446516743,,Present in Autoproposal
D9995,TELEDENTISTRY  SYNCHRONOUS; REAL-TIME ENCOUNTER,0353T,"Optical coherence tomography of breast, surgical cavity; real-time intraoperative",22.583433612113428,,Present in Autoproposal
E0447,"Portable oxygen contents, liquid, 1 month's supply = 1 unit, prescribed amount at rest or nighttime exceeds 4 liters per minute (lpm)",E0444,"PORTABLE OXYGEN CONTENTS, LIQUID, 1 MONTH'S SUPPLY = 1 UNIT",62.07248797725654,1,Present Both in MD and Autoproposal
E0447,"Portable oxygen contents, liquid, 1 month's supply = 1 unit, prescribed amount at rest or nighttime exceeds 4 liters per minute (lpm)",E0442,"STATIONARY OXYGEN CONTENTS, LIQUID, 1 MONTH'S SUPPLY = 1 UNIT",51.239652116385116,,Present in Autoproposal
E0447,"Portable oxygen contents, liquid, 1 month's supply = 1 unit, prescribed amount at rest or nighttime exceeds 4 liters per minute (lpm)",E0443,"PORTABLE OXYGEN CONTENTS, GASEOUS, 1 MONTH'S SUPPLY = 1 UNIT",49.8358028265991,,Present in Autoproposal
E0447,"Portable oxygen contents, liquid, 1 month's supply = 1 unit, prescribed amount at rest or nighttime exceeds 4 liters per minute (lpm)",E0441,"STATIONARY OXYGEN CONTENTS, GASEOUS, 1 MONTH'S SUPPLY = 1 UNIT",39.57781305225899,,Present in Autoproposal
E0447,"Portable oxygen contents, liquid, 1 month's supply = 1 unit, prescribed amount at rest or nighttime exceeds 4 liters per minute (lpm)",K0742,"PORTABLE OXYGEN CONTENTS, GASEOUS, 1 MONTH'S SUPPLY = 1 UNIT, FOR CLUSTER HEADACHES, FOR INITIAL MONTHS SUPPLY OR TO REPLACE USED CONTENTS",39.355212185895,,Present in Autoproposal
E0447,"Portable oxygen contents, liquid, 1 month's supply = 1 unit, prescribed amount at rest or nighttime exceeds 4 liters per minute (lpm)",S8121,"OXYGEN CONTENTS, LIQUID, 1 UNIT EQUALS 1 POUND",33.12290274657651,,Present in Autoproposal
E0447,"Portable oxygen contents, liquid, 1 month's supply = 1 unit, prescribed amount at rest or nighttime exceeds 4 liters per minute (lpm)",E0433,"PORTABLE LIQUID OXYGEN SYSTEM, RENTAL; HOME LIQUEFIER USED TO FILL PORTABLE LIQUID OXYGEN CONTAINERS, INCLUDES PORTABLE CONTAINERS, REGULATOR, FLOWMETER, HUMIDIFIER, CANNULA OR MASK AND TUBING, WITH OR WITHOUT SUPPLY RESERVOIR AND CONTENTS GAUGE",32.77564338664848,,Present in Autoproposal
E0447,"Portable oxygen contents, liquid, 1 month's supply = 1 unit, prescribed amount at rest or nighttime exceeds 4 liters per minute (lpm)",E0434,"PORTABLE LIQUID OXYGEN SYSTEM, RENTAL; INCLUDES PORTABLE CONTAINER, SUPPLY RESERVOIR, HUMIDIFIER, FLOWMETER, REFILL ADAPTOR, CONTENTS GAUGE, CANNULA OR MASK, AND TUBING",29.982784041834044,,Present in Autoproposal
E0447,"Portable oxygen contents, liquid, 1 month's supply = 1 unit, prescribed amount at rest or nighttime exceeds 4 liters per minute (lpm)",E0435,"PORTABLE LIQUID OXYGEN SYSTEM, PURCHASE; INCLUDES PORTABLE CONTAINER, SUPPLY RESERVOIR, FLOWMETER, HUMIDIFIER, CONTENTS GAUGE, CANNULA OR MASK, TUBING AND REFILL ADAPTOR",29.76636304332323,,Present in Autoproposal
E0447,"Portable oxygen contents, liquid, 1 month's supply = 1 unit, prescribed amount at rest or nighttime exceeds 4 liters per minute (lpm)",S8120,"OXYGEN CONTENTS, GASEOUS, 1 UNIT EQUALS 1 CUBIC FOOT",21.932033825036815,,Present in Autoproposal
E0467,"Home ventilator, multi-function respiratory device, also performs any or all of the additional functions of oxygen concentration, drug nebulization, aspiration, and cough stimulation, includes all accessories, components and supplies for all functions",E0766,"ELECTRICAL STIMULATION DEVICE USED FOR CANCER TREATMENT, INCLUDES ALL ACCESSORIES, ANY TYPE",31.859245070922075,10,Present in Autoproposal
E0467,"Home ventilator, multi-function respiratory device, also performs any or all of the additional functions of oxygen concentration, drug nebulization, aspiration, and cough stimulation, includes all accessories, components and supplies for all functions",A7020,"INTERFACE FOR COUGH STIMULATING DEVICE, INCLUDES ALL COMPONENTS, REPLACEMENT ONLY",31.512213886641007,,Present in Autoproposal
E0467,"Home ventilator, multi-function respiratory device, also performs any or all of the additional functions of oxygen concentration, drug nebulization, aspiration, and cough stimulation, includes all accessories, components and supplies for all functions",E0446,"TOPICAL OXYGEN DELIVERY SYSTEM, NOT OTHERWISE SPECIFIED, INCLUDES ALL SUPPLIES AND ACCESSORIES",30.6841239852096,,Present in Autoproposal
E0467,"Home ventilator, multi-function respiratory device, also performs any or all of the additional functions of oxygen concentration, drug nebulization, aspiration, and cough stimulation, includes all accessories, components and supplies for all functions",E0762,"TRANSCUTANEOUS ELECTRICAL JOINT STIMULATION DEVICE SYSTEM, INCLUDES ALL ACCESSORIES",29.270686861326407,,Present in Autoproposal
E0467,"Home ventilator, multi-function respiratory device, also performs any or all of the additional functions of oxygen concentration, drug nebulization, aspiration, and cough stimulation, includes all accessories, components and supplies for all functions",A9272,"WOUND SUCTION, DISPOSABLE, INCLUDES DRESSING, ALL ACCESSORIES AND COMPONENTS, ANY TYPE, EACH",27.919715998245977,,Present in Autoproposal
E0467,"Home ventilator, multi-function respiratory device, also performs any or all of the additional functions of oxygen concentration, drug nebulization, aspiration, and cough stimulation, includes all accessories, components and supplies for all functions",E0640,"PATIENT LIFT, FIXED SYSTEM, INCLUDES ALL COMPONENTS/ACCESSORIES",27.883890568765857,,Present in Autoproposal
E0467,"Home ventilator, multi-function respiratory device, also performs any or all of the additional functions of oxygen concentration, drug nebulization, aspiration, and cough stimulation, includes all accessories, components and supplies for all functions",L8614,"COCHLEAR DEVICE, INCLUDES ALL INTERNAL AND EXTERNAL COMPONENTS",27.14195419160243,,Present in Autoproposal
E0467,"Home ventilator, multi-function respiratory device, also performs any or all of the additional functions of oxygen concentration, drug nebulization, aspiration, and cough stimulation, includes all accessories, components and supplies for all functions",A8000,"HELMET, PROTECTIVE, SOFT, PREFABRICATED, INCLUDES ALL COMPONENTS AND ACCESSORIES",26.702750781557455,,Present in Autoproposal
E0467,"Home ventilator, multi-function respiratory device, also performs any or all of the additional functions of oxygen concentration, drug nebulization, aspiration, and cough stimulation, includes all accessories, components and supplies for all functions",T1505,"ELECTRONIC MEDICATION COMPLIANCE MANAGEMENT DEVICE, INCLUDES ALL COMPONENTS AND ACCESSORIES, NOT OTHERWISE CLASSIFIED",26.023422901627814,,Present in Autoproposal
E0467,"Home ventilator, multi-function respiratory device, also performs any or all of the additional functions of oxygen concentration, drug nebulization, aspiration, and cough stimulation, includes all accessories, components and supplies for all functions",A8002,"HELMET, PROTECTIVE, SOFT, CUSTOM FABRICATED, INCLUDES ALL COMPONENTS AND ACCESSORIES",25.46343955572613,,Present in Autoproposal
G9890,"Bridge Payment: A one-time payment for the first Medicare Diabetes Prevention Program (MDPP) core session, core maintenance session, or ongoing maintenance session furnished by an MDPP supplier to an MDPP beneficiary during months 1-24 of the MDPP Expanded Model (EM) who has previously received MDPP services from a different MDPP supplier under the MDPP Expanded Model.  A supplier may only receive one bridge payment per MDPP beneficiary.",G9873,First Medicare Diabetes Prevention Program (MDPP) core session was attended by an MDPP beneficiary under the MDPP Expanded Model (EM).  A core session is an MDPP service that: (1)  is furnished by an MDPP supplier during months 1 through 6 of the MDPP services period; (2)  is approximately 1 hour in length; and (3) adheres to a CDC-approved DPP curriculum for core sessions,76.01734262971713,10,Present in Autoproposal
G9890,"Bridge Payment: A one-time payment for the first Medicare Diabetes Prevention Program (MDPP) core session, core maintenance session, or ongoing maintenance session furnished by an MDPP supplier to an MDPP beneficiary during months 1-24 of the MDPP Expanded Model (EM) who has previously received MDPP services from a different MDPP supplier under the MDPP Expanded Model.  A supplier may only receive one bridge payment per MDPP beneficiary.",G9874,Four total Medicare Diabetes Prevention Program (MDPP) core sessions were attended by an MDPP beneficiary under the MDPP Expanded Model (EM).  A core session is an MDPP service that: (1)  is furnished by an MDPP supplier during months 1 through 6 of the MDPP services period; (2)  is approximately 1 hour in length; and (3) adheres to a CDC-approved DPP curriculum for core sessions.,72.88846616763261,,Present in Autoproposal
G9890,"Bridge Payment: A one-time payment for the first Medicare Diabetes Prevention Program (MDPP) core session, core maintenance session, or ongoing maintenance session furnished by an MDPP supplier to an MDPP beneficiary during months 1-24 of the MDPP Expanded Model (EM) who has previously received MDPP services from a different MDPP supplier under the MDPP Expanded Model.  A supplier may only receive one bridge payment per MDPP beneficiary.",G9875,Nine total Medicare Diabetes Prevention Program (MDPP) core sessions were attended by an MDPP beneficiary under the MDPP Expanded Model (EM).  A core session is an MDPP service that: (1)  is furnished by an MDPP supplier during months 1 through 6 of the MDPP services period; (2)  is approximately 1 hour in length; and (3) adheres to a CDC-approved DPP curriculum for core sessions,72.67485209676752,,Present in Autoproposal
G9890,"Bridge Payment: A one-time payment for the first Medicare Diabetes Prevention Program (MDPP) core session, core maintenance session, or ongoing maintenance session furnished by an MDPP supplier to an MDPP beneficiary during months 1-24 of the MDPP Expanded Model (EM) who has previously received MDPP services from a different MDPP supplier under the MDPP Expanded Model.  A supplier may only receive one bridge payment per MDPP beneficiary.",G9878,"Two Medicare Diabetes Prevention Program (MDPP) core maintenance sessions (MS) were attended by an MDPP beneficiary in months (mo) 7-9 under the MDPP Expanded Model (EM).  A core maintenance session is an MDPP service that: (1) is furnished by an MDPP supplier during months 7 through 12 of the MDPP services period; (2) is approximately 1 hour in length; and (3) adheres to a CDC-approved DPP curriculum for maintenance sessions.The beneficiary achieved at least 5% weight loss (WL) from his/her baseline weight, as measured by at least one in-person weight measurement at a core maintenance session in months 7-9.",67.54752346925686,,Present in Autoproposal
G9890,"Bridge Payment: A one-time payment for the first Medicare Diabetes Prevention Program (MDPP) core session, core maintenance session, or ongoing maintenance session furnished by an MDPP supplier to an MDPP beneficiary during months 1-24 of the MDPP Expanded Model (EM) who has previously received MDPP services from a different MDPP supplier under the MDPP Expanded Model.  A supplier may only receive one bridge payment per MDPP beneficiary.",G9876,"Two Medicare Diabetes Prevention Program (MDPP) core maintenance sessions (MS) were attended by an MDPP beneficiary in months (mo) 7-9 under the MDPP Expanded Model (EM).  A core maintenance session is an MDPP service that: (1) is furnished by an MDPP supplier during months 7 through 12 of the MDPP services period; (2) is approximately 1 hour in length; and (3) adheres to a CDC-approved DPP curriculum for maintenance sessions.  The beneficiary did not achieve at least 5% weight loss (WL) from his/her baseline weight, as measured by at least one in-person weight measurement at a core maintenance session in months 7-9.",67.32001931322235,,Present in Autoproposal
G9890,"Bridge Payment: A one-time payment for the first Medicare Diabetes Prevention Program (MDPP) core session, core maintenance session, or ongoing maintenance session furnished by an MDPP supplier to an MDPP beneficiary during months 1-24 of the MDPP Expanded Model (EM) who has previously received MDPP services from a different MDPP supplier under the MDPP Expanded Model.  A supplier may only receive one bridge payment per MDPP beneficiary.",G9879,"Two Medicare Diabetes Prevention Program (MDPP) core maintenance sessions (MS) were attended by an MDPP beneficiary in months (mo) 10-12 under the MDPP Expanded Model (EM).  A core maintenance session is an MDPP service that: (1) is furnished by an MDPP supplier during months 7 through 12 of the MDPP services period; (2) is approximately 1 hour in length; and (3) adheres to a CDC-approved DPP curriculum for maintenance sessions.The beneficiary achieved at least 5% weight loss (WL) from his/her baseline weight, as measured by at least one in-person weight measurement at a core maintenance session in months 10-12",66.11569569698659,,Present in Autoproposal
G9890,"Bridge Payment: A one-time payment for the first Medicare Diabetes Prevention Program (MDPP) core session, core maintenance session, or ongoing maintenance session furnished by an MDPP supplier to an MDPP beneficiary during months 1-24 of the MDPP Expanded Model (EM) who has previously received MDPP services from a different MDPP supplier under the MDPP Expanded Model.  A supplier may only receive one bridge payment per MDPP beneficiary.",G9877,"Two Medicare Diabetes Prevention Program (MDPP) core maintenance sessions (MS) were attended by an MDPP beneficiary in months (mo) 10-12 under the MDPP Expanded Model (EM).  A core maintenance session is an MDPP service that: (1) is furnished by an MDPP supplier during months 7 through 12 of the MDPP services period; (2) is approximately 1 hour in length; and (3) adheres to a CDC-approved DPP curriculum for maintenance sessions. The beneficiary did not achieve at least 5% weight loss (WL) from his/her baseline weight, as measured by at least one in-person weight measurement at a core maintenance session in months 10-12.",65.90230931539037,,Present in Autoproposal
G9890,"Bridge Payment: A one-time payment for the first Medicare Diabetes Prevention Program (MDPP) core session, core maintenance session, or ongoing maintenance session furnished by an MDPP supplier to an MDPP beneficiary during months 1-24 of the MDPP Expanded Model (EM) who has previously received MDPP services from a different MDPP supplier under the MDPP Expanded Model.  A supplier may only receive one bridge payment per MDPP beneficiary.",G9885,"Two Medicare Diabetes Prevention Program (MDPP) ongoing maintenance sessions (MS) were attended by an MDPP beneficiary in months (mo) 22-24 under the MDPP Expanded Model (EM).  An ongoing maintenance session is an MDPP service that: (1) is furnished by an MDPP supplier during months 13 through 24 of the MDPP services period; (2) is approximately 1 hour in length; and (3) adheres to a CDC-approved DPP curriculum for maintenance sessions. The beneficiary maintained at least 5% weight loss (WL) from his/her baseline weight, as measured by at least one in-person weight measurement at an ongoing maintenance session in months 22-24.",64.41825593923909,,Present in Autoproposal
G9890,"Bridge Payment: A one-time payment for the first Medicare Diabetes Prevention Program (MDPP) core session, core maintenance session, or ongoing maintenance session furnished by an MDPP supplier to an MDPP beneficiary during months 1-24 of the MDPP Expanded Model (EM) who has previously received MDPP services from a different MDPP supplier under the MDPP Expanded Model.  A supplier may only receive one bridge payment per MDPP beneficiary.",G9883,"Two Medicare Diabetes Prevention Program (MDPP) ongoing maintenance sessions (MS) were attended by an MDPP beneficiary in months (mo) 16-18 under the MDPP Expanded Model (EM).  An ongoing maintenance session is an MDPP service that: (1) is furnished by an MDPP supplier during months 13 through 24 of the MDPP services period; (2) is approximately 1 hour in length; and (3) adheres to a CDC-approved DPP curriculum for maintenance sessions. The beneficiary maintained at least 5% weight loss (WL) from his/her baseline weight, as measured by at least one in-person weight measurement at an ongoing maintenance session in months 16-18.",63.94039822621635,,Present in Autoproposal
G9890,"Bridge Payment: A one-time payment for the first Medicare Diabetes Prevention Program (MDPP) core session, core maintenance session, or ongoing maintenance session furnished by an MDPP supplier to an MDPP beneficiary during months 1-24 of the MDPP Expanded Model (EM) who has previously received MDPP services from a different MDPP supplier under the MDPP Expanded Model.  A supplier may only receive one bridge payment per MDPP beneficiary.",G9884,"Two Medicare Diabetes Prevention Program (MDPP) ongoing maintenance sessions (MS) were attended by an MDPP beneficiary in months (mo) 19-21 under the MDPP Expanded Model (EM).  An ongoing maintenance session is an MDPP service that: (1) is furnished by an MDPP supplier during months 13 through 24 of the MDPP services period; (2) is approximately 1 hour in length; and (3) adheres to a CDC-approved DPP curriculum for maintenance sessions. The beneficiary maintained at least 5% weight loss (WL) from his/her baseline weight, as measured by at least one in-person weight measurement at an ongoing maintenance session in months 19-21.",63.61643263701345,,Present in Autoproposal
G9899,"SCREENING, DIAGNOSTIC, FILM, DIGITAL OR DIGITAL BREAST TOMOSYNTHESIS (3D) MAMMOGRAPHY RESULTS DOCUMENTED AND REVIEWED",77061,Digital breast tomosynthesis; unilateral,59.06344389711092,3,Present in Autoproposal
G9899,"SCREENING, DIAGNOSTIC, FILM, DIGITAL OR DIGITAL BREAST TOMOSYNTHESIS (3D) MAMMOGRAPHY RESULTS DOCUMENTED AND REVIEWED",77062,Digital breast tomosynthesis; bilateral,58.85316268325319,,Present in Autoproposal
G9899,"SCREENING, DIAGNOSTIC, FILM, DIGITAL OR DIGITAL BREAST TOMOSYNTHESIS (3D) MAMMOGRAPHY RESULTS DOCUMENTED AND REVIEWED",77063,"Screening digital breast tomosynthesis, bilateral (List separately in addition to code for primary procedure)",50.403394419397415,,Present Both in MD and Autoproposal
G9899,"SCREENING, DIAGNOSTIC, FILM, DIGITAL OR DIGITAL BREAST TOMOSYNTHESIS (3D) MAMMOGRAPHY RESULTS DOCUMENTED AND REVIEWED",3014F,Screening mammography results documented and reviewed (PV),49.308444822471245,,Present in Autoproposal
G9899,"SCREENING, DIAGNOSTIC, FILM, DIGITAL OR DIGITAL BREAST TOMOSYNTHESIS (3D) MAMMOGRAPHY RESULTS DOCUMENTED AND REVIEWED",G0279,"Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066)",40.67271736052209,,Present in Autoproposal
G9899,"SCREENING, DIAGNOSTIC, FILM, DIGITAL OR DIGITAL BREAST TOMOSYNTHESIS (3D) MAMMOGRAPHY RESULTS DOCUMENTED AND REVIEWED",G0203,"SCREENING MAMMOGRAPHY, FILM PROCESSED TO PRODUCE DIGITAL IMAGES ANALYZED FOR POTENTIAL ABNORMALITIES, BILATERAL, ALL VIEWS",36.79001490692735,,Present in Autoproposal
G9899,"SCREENING, DIAGNOSTIC, FILM, DIGITAL OR DIGITAL BREAST TOMOSYNTHESIS (3D) MAMMOGRAPHY RESULTS DOCUMENTED AND REVIEWED",G0207,"DIAGNOSTIC MAMMOGRAPHY, FILM PROCESSED TO PRODUCE DIGITAL IMAGE ANALYZED FOR POTENTIAL ABNORMALITIES, UNILATERAL, ALL VIEWS",36.139031767325804,,Present in Autoproposal
G9899,"SCREENING, DIAGNOSTIC, FILM, DIGITAL OR DIGITAL BREAST TOMOSYNTHESIS (3D) MAMMOGRAPHY RESULTS DOCUMENTED AND REVIEWED",G0205,"DIAGNOSTIC MAMMOGRAPHY, FILM PROCESSED TO PRODUCE DIGITAL IMAGE ANALYZED FOR POTENTIAL ABNORMALITIES, BILATERAL, ALL VIEWS",36.10345834449296,,Present in Autoproposal
G9899,"SCREENING, DIAGNOSTIC, FILM, DIGITAL OR DIGITAL BREAST TOMOSYNTHESIS (3D) MAMMOGRAPHY RESULTS DOCUMENTED AND REVIEWED",3015F,Cervical cancer screening results documented and reviewed (PV),35.438108023870946,,Present in Autoproposal
G9899,"SCREENING, DIAGNOSTIC, FILM, DIGITAL OR DIGITAL BREAST TOMOSYNTHESIS (3D) MAMMOGRAPHY RESULTS DOCUMENTED AND REVIEWED",3017F,Colorectal cancer screening results documented and reviewed (PV),34.30527970295348,,Present in Autoproposal
G9900,"SCREENING, DIAGNOSTIC, FILM, DIGITAL OR DIGITAL BREAST TOMOSYNTHESIS (3D) MAMMOGRAPHY RESULTS WERE NOT DOCUMENTED AND REVIEWED, REASON NOT OTHERWISE SPECIFIED",77061,Digital breast tomosynthesis; unilateral,51.98913369817008,3,Present in Autoproposal
G9900,"SCREENING, DIAGNOSTIC, FILM, DIGITAL OR DIGITAL BREAST TOMOSYNTHESIS (3D) MAMMOGRAPHY RESULTS WERE NOT DOCUMENTED AND REVIEWED, REASON NOT OTHERWISE SPECIFIED",77062,Digital breast tomosynthesis; bilateral,51.80403886759252,,Present in Autoproposal
G9900,"SCREENING, DIAGNOSTIC, FILM, DIGITAL OR DIGITAL BREAST TOMOSYNTHESIS (3D) MAMMOGRAPHY RESULTS WERE NOT DOCUMENTED AND REVIEWED, REASON NOT OTHERWISE SPECIFIED",77063,"Screening digital breast tomosynthesis, bilateral (List separately in addition to code for primary procedure)",44.366339624158435,,Present Both in MD and Autoproposal
G9900,"SCREENING, DIAGNOSTIC, FILM, DIGITAL OR DIGITAL BREAST TOMOSYNTHESIS (3D) MAMMOGRAPHY RESULTS WERE NOT DOCUMENTED AND REVIEWED, REASON NOT OTHERWISE SPECIFIED",3014F,Screening mammography results documented and reviewed (PV),43.40253735948663,,Present in Autoproposal
G9900,"SCREENING, DIAGNOSTIC, FILM, DIGITAL OR DIGITAL BREAST TOMOSYNTHESIS (3D) MAMMOGRAPHY RESULTS WERE NOT DOCUMENTED AND REVIEWED, REASON NOT OTHERWISE SPECIFIED",G8884,CLINICIAN DOCUMENTED REASON THAT PATIENT'S BIOPSY RESULTS WERE NOT REVIEWED,42.715891800198776,,Present in Autoproposal
G9900,"SCREENING, DIAGNOSTIC, FILM, DIGITAL OR DIGITAL BREAST TOMOSYNTHESIS (3D) MAMMOGRAPHY RESULTS WERE NOT DOCUMENTED AND REVIEWED, REASON NOT OTHERWISE SPECIFIED",G8701,"REHABILITATION SERVICES WERE NOT ORDERED, REASON NOT OTHERWISE SPECIFIED",37.38128876263893,,Present in Autoproposal
G9900,"SCREENING, DIAGNOSTIC, FILM, DIGITAL OR DIGITAL BREAST TOMOSYNTHESIS (3D) MAMMOGRAPHY RESULTS WERE NOT DOCUMENTED AND REVIEWED, REASON NOT OTHERWISE SPECIFIED",G0279,"Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066)",35.80115213748141,,Present in Autoproposal
G9900,"SCREENING, DIAGNOSTIC, FILM, DIGITAL OR DIGITAL BREAST TOMOSYNTHESIS (3D) MAMMOGRAPHY RESULTS WERE NOT DOCUMENTED AND REVIEWED, REASON NOT OTHERWISE SPECIFIED",L8039,"BREAST PROSTHESIS, NOT OTHERWISE SPECIFIED",35.61116713606477,,Present in Autoproposal
G9900,"SCREENING, DIAGNOSTIC, FILM, DIGITAL OR DIGITAL BREAST TOMOSYNTHESIS (3D) MAMMOGRAPHY RESULTS WERE NOT DOCUMENTED AND REVIEWED, REASON NOT OTHERWISE SPECIFIED",G9918,"FUNCTIONAL STATUS NOT PERFORMED, REASON NOT OTHERWISE SPECIFIED",33.16000898342955,,Present in Autoproposal
G9900,"SCREENING, DIAGNOSTIC, FILM, DIGITAL OR DIGITAL BREAST TOMOSYNTHESIS (3D) MAMMOGRAPHY RESULTS WERE NOT DOCUMENTED AND REVIEWED, REASON NOT OTHERWISE SPECIFIED",G9925,"SAFETY CONCERNS SCREENING NOT PROVIDED, REASON NOT OTHERWISE SPECIFIED",32.93248325707951,,Present in Autoproposal
G9902,PATIENT SCREENED FOR TOBACCO USE AND IDENTIFIED AS A TOBACCO USER,G9903,PATIENT SCREENED FOR TOBACCO USE AND IDENTIFIED AS A TOBACCO NON-USER,97.69451298574084,10,Present in Autoproposal
G9902,PATIENT SCREENED FOR TOBACCO USE AND IDENTIFIED AS A TOBACCO USER,4004F,"Patient screened for tobacco use and received tobacco cessation intervention (counseling, pharmacotherapy, or both), if identified as a tobacco user (PV, CAD)",76.51323117680145,,Present in Autoproposal
G9902,PATIENT SCREENED FOR TOBACCO USE AND IDENTIFIED AS A TOBACCO USER,G9906,PATIENT IDENTIFIED AS A TOBACCO USER RECEIVED TOBACCO CESSATION INTERVENTION (COUNSELING AND/OR PHARMACOTHERAPY),69.49779291013905,,Present in Autoproposal
G9902,PATIENT SCREENED FOR TOBACCO USE AND IDENTIFIED AS A TOBACCO USER,G9908,"PATIENT IDENTIFIED AS TOBACCO USER DID NOT RECEIVE TOBACCO CESSATION INTERVENTION (COUNSELING AND/OR PHARMACOTHERAPY), REASON NOT GIVEN",60.668849456875726,,Present in Autoproposal
G9902,PATIENT SCREENED FOR TOBACCO USE AND IDENTIFIED AS A TOBACCO USER,G9458,"PATIENT DOCUMENTED AS TOBACCO USER AND RECEIVED TOBACCO CESSATION INTERVENTION (MUST INCLUDE AT LEAST ONE OF THE FOLLOWING: ADVICE GIVEN TO QUIT SMOKING OR TOBACCO USE, COUNSELING ON THE BENEFITS OF QUITTING SMOKING OR TOBACCO USE, ASSISTANCE WITH OR REFERRAL TO EXTERNAL SMOKING OR TOBACCO CESSATION SUPPORT PROGRAMS, OR CURRENT ENROLLMENT IN SMOKING OR TOBACCO USE CESSATION PROGRAM) IF IDENTIFIED AS A TOBACCO USER",60.484867389136134,,Present in Autoproposal
G9902,PATIENT SCREENED FOR TOBACCO USE AND IDENTIFIED AS A TOBACCO USER,G9905,"PATIENT NOT SCREENED FOR TOBACCO USE, REASON NOT GIVEN",56.01619570241599,,Present in Autoproposal
G9902,PATIENT SCREENED FOR TOBACCO USE AND IDENTIFIED AS A TOBACCO USER,G8457,CURRENT TOBACCO NON-USER,55.56979420046015,,Present in Autoproposal
G9902,PATIENT SCREENED FOR TOBACCO USE AND IDENTIFIED AS A TOBACCO USER,G9459,CURRENTLY A TOBACCO NON-USER,53.934185133706066,,Present in Autoproposal
G9902,PATIENT SCREENED FOR TOBACCO USE AND IDENTIFIED AS A TOBACCO USER,G9909,"DOCUMENTATION OF MEDICAL REASON(S) FOR NOT  PROVIDING TOBACCO CESSATION INTERVENTION IF IDENTIFIED AS A TOBACCO USER (EG, LIMITED LIFE EXPECTANCY, OTHER MEDICAL REASON)",51.85458492838209,,Present in Autoproposal
G9902,PATIENT SCREENED FOR TOBACCO USE AND IDENTIFIED AS A TOBACCO USER,G9276,DOCUMENTATION THAT PATIENT IS A CURRENT TOBACCO USER,50.615423854932814,,Present in Autoproposal
G9904,"DOCUMENTATION OF MEDICAL REASON(S) FOR NOT SCREENING FOR TOBACCO USE (E.G., LIMITED LIFE EXPECTANCY, OTHER MEDICAL REASON)",G9907,"DOCUMENTATION OF MEDICAL REASON(S) FOR NOT PROVIDING TOBACCO CESSATION INTERVENTION (E.G., LIMITED LIFE EXPECTANCY, OTHER MEDICAL REASON)",81.44848456439358,10,Present in Autoproposal
G9904,"DOCUMENTATION OF MEDICAL REASON(S) FOR NOT SCREENING FOR TOBACCO USE (E.G., LIMITED LIFE EXPECTANCY, OTHER MEDICAL REASON)",G9623,"DOCUMENTATION OF MEDICAL REASON(S) FOR NOT SCREENING FOR UNHEALTHY ALCOHOL USE (E.G., LIMITED LIFE EXPECTANCY, OTHER MEDICAL REASONS)",78.7536430698522,,Present in Autoproposal
G9904,"DOCUMENTATION OF MEDICAL REASON(S) FOR NOT SCREENING FOR TOBACCO USE (E.G., LIMITED LIFE EXPECTANCY, OTHER MEDICAL REASON)",G9909,"DOCUMENTATION OF MEDICAL REASON(S) FOR NOT  PROVIDING TOBACCO CESSATION INTERVENTION IF IDENTIFIED AS A TOBACCO USER (EG, LIMITED LIFE EXPECTANCY, OTHER MEDICAL REASON)",72.66982949951345,,Present in Autoproposal
G9904,"DOCUMENTATION OF MEDICAL REASON(S) FOR NOT SCREENING FOR TOBACCO USE (E.G., LIMITED LIFE EXPECTANCY, OTHER MEDICAL REASON)",G9917,"DOCUMENTATION OF MEDICAL REASON(S) FOR NOT PERFORMING FUNCTIONAL STATUS (E.G., PATIENT IS SEVERELY IMPAIRED AND CAREGIVER KNOWLEDGE IS LIMITED, OTHER MEDICAL REASON)",46.98018396133773,,Present in Autoproposal
G9904,"DOCUMENTATION OF MEDICAL REASON(S) FOR NOT SCREENING FOR TOBACCO USE (E.G., LIMITED LIFE EXPECTANCY, OTHER MEDICAL REASON)",G9384,"DOCUMENTATION OF MEDICAL REASON(S) FOR NOT RECEIVING ANNUAL SCREENING FOR HCV INFECTION (E.G., DECOMPENSATED CIRRHOSIS INDICATING ADVANCED DISEASE [I.E., ASCITES, ESOPHAGEAL VARICEAL BLEEDING, HEPATIC ENCEPHALOPATHY], HEPATOCELLULAR CARCINOMA, WAITLIST FOR ORGAN TRANSPLANT, LIMITED LIFE EXPECTANCY, OTHER MEDICAL REASONS)",44.56846927671954,,Present in Autoproposal
G9904,"DOCUMENTATION OF MEDICAL REASON(S) FOR NOT SCREENING FOR TOBACCO USE (E.G., LIMITED LIFE EXPECTANCY, OTHER MEDICAL REASON)",G9452,"DOCUMENTATION OF MEDICAL REASON(S) FOR NOT RECEIVING ONE-TIME SCREENING FOR HCV INFECTION (E.G., DECOMPENSATED CIRRHOSIS INDICATING ADVANCED DISEASE [IE, ASCITES, ESOPHAGEAL VARICEAL BLEEDING, HEPATIC ENCEPHALOPATHY], HEPATOCELLULAR CARCINOMA, WAITLIST FOR ORGAN TRANSPLANT, LIMITED LIFE EXPECTANCY, OTHER MEDICAL REASONS)",44.247053986384415,,Present in Autoproposal
G9904,"DOCUMENTATION OF MEDICAL REASON(S) FOR NOT SCREENING FOR TOBACCO USE (E.G., LIMITED LIFE EXPECTANCY, OTHER MEDICAL REASON)",G9905,"PATIENT NOT SCREENED FOR TOBACCO USE, REASON NOT GIVEN",43.24865103264629,,Present in Autoproposal
G9904,"DOCUMENTATION OF MEDICAL REASON(S) FOR NOT SCREENING FOR TOBACCO USE (E.G., LIMITED LIFE EXPECTANCY, OTHER MEDICAL REASON)",G8693,"TOBACCO USE NOT ASSESSED, REASON NOT SPECIFIED",42.619328614696684,,Present in Autoproposal
G9904,"DOCUMENTATION OF MEDICAL REASON(S) FOR NOT SCREENING FOR TOBACCO USE (E.G., LIMITED LIFE EXPECTANCY, OTHER MEDICAL REASON)",G9190,"DOCUMENTATION OF MEDICAL REASON(S) FOR NOT PRESCRIBING BETA-BLOCKER THERAPY (EG, ALLERGY, INTOLERANCE, OTHER MEDICAL REASONS)",42.105211520393375,,Present in Autoproposal
G9904,"DOCUMENTATION OF MEDICAL REASON(S) FOR NOT SCREENING FOR TOBACCO USE (E.G., LIMITED LIFE EXPECTANCY, OTHER MEDICAL REASON)",G9975,DOCUMENTATION OF MEDICAL REASON(S) FOR NOT PERFORMING A DILATED MACULAR EXAMINATION,40.76060308281682,,Present in Autoproposal
G9948,PATIENT HAD ANY ADDITIONAL SPINE PROCEDURES PERFORMED ON THE SAME DATE AS THE LUMBAR DISCECTOMY/LAMINOTOMY,G9942,PATIENT HAD ANY ADDITIONAL SPINE PROCEDURES PERFORMED ON THE SAME DATE AS THE LUMBAR DISCECTOMY/LAMINOTOMY,100.0,10,Present in Autoproposal
G9948,PATIENT HAD ANY ADDITIONAL SPINE PROCEDURES PERFORMED ON THE SAME DATE AS THE LUMBAR DISCECTOMY/LAMINOTOMY,00640,"Anesthesia for manipulation of the spine or for closed procedures on the cervical, thoracic or lumbar spine",41.4992656258765,,Present in Autoproposal
G9948,PATIENT HAD ANY ADDITIONAL SPINE PROCEDURES PERFORMED ON THE SAME DATE AS THE LUMBAR DISCECTOMY/LAMINOTOMY,G9945,"PATIENT HAD CANCER, FRACTURE OR INFECTION RELATED TO THE LUMBAR SPINE OR PATIENT HAD IDIOPATHIC OR CONGENITAL SCOLIOSIS",35.86594224180415,,Present in Autoproposal
G9948,PATIENT HAD ANY ADDITIONAL SPINE PROCEDURES PERFORMED ON THE SAME DATE AS THE LUMBAR DISCECTOMY/LAMINOTOMY,G0364,BONE MARROW ASPIRATION PERFORMED WITH BONE MARROW BIOPSY THROUGH THE SAME INCISION ON THE SAME DATE OF SERVICE,34.213336880587605,,Present in Autoproposal
G9948,PATIENT HAD ANY ADDITIONAL SPINE PROCEDURES PERFORMED ON THE SAME DATE AS THE LUMBAR DISCECTOMY/LAMINOTOMY,00604,Anesthesia for procedures on cervical spine and cord; procedures with patient in the sitting position,31.329888562444385,,Present in Autoproposal
G9948,PATIENT HAD ANY ADDITIONAL SPINE PROCEDURES PERFORMED ON THE SAME DATE AS THE LUMBAR DISCECTOMY/LAMINOTOMY,G9822,WOMEN WHO HAD AN ENDOMETRIAL ABLATION PROCEDURE DURING THE YEAR PRIOR TO THE INDEX DATE (EXCLUSIVE OF THE INDEX DATE),30.539502484233484,,Present in Autoproposal
G9948,PATIENT HAD ANY ADDITIONAL SPINE PROCEDURES PERFORMED ON THE SAME DATE AS THE LUMBAR DISCECTOMY/LAMINOTOMY,C2614,"PROBE, PERCUTANEOUS LUMBAR DISCECTOMY",29.689165657882434,,Present in Autoproposal
G9948,PATIENT HAD ANY ADDITIONAL SPINE PROCEDURES PERFORMED ON THE SAME DATE AS THE LUMBAR DISCECTOMY/LAMINOTOMY,22224,"Osteotomy of spine, including discectomy, anterior approach, single vertebral segment; lumbar",29.115408312911338,,Present in Autoproposal
G9948,PATIENT HAD ANY ADDITIONAL SPINE PROCEDURES PERFORMED ON THE SAME DATE AS THE LUMBAR DISCECTOMY/LAMINOTOMY,G9691,PATIENT HAD HOSPICE SERVICES ANY TIME DURING THE MEASUREMENT PERIOD,27.368507182168255,,Present in Autoproposal
G9948,PATIENT HAD ANY ADDITIONAL SPINE PROCEDURES PERFORMED ON THE SAME DATE AS THE LUMBAR DISCECTOMY/LAMINOTOMY,01935,Anesthesia for percutaneous image guided procedures on the spine and spinal cord; diagnostic,26.809373608950803,,Present in Autoproposal
G9949,LEG PAIN WAS NOT MEASURED BY THE VISUAL ANALOG SCALE (VAS) WITHIN THREE MONTHS PREOPERATIVELY AND AT THREE MONTHS (6 TO 20 WEEKS) POSTOPERATIVELY,G9947,LEG PAIN WAS MEASURED BY THE VISUAL ANALOG SCALE (VAS) WITHIN THREE MONTHS PREOPERATIVELY AND AT THREE MONTHS (6 TO 20 WEEKS) POSTOPERATIVELY,99.30036855645594,10,Present in Autoproposal
G9949,LEG PAIN WAS NOT MEASURED BY THE VISUAL ANALOG SCALE (VAS) WITHIN THREE MONTHS PREOPERATIVELY AND AT THREE MONTHS (6 TO 20 WEEKS) POSTOPERATIVELY,G9943,BACK PAIN WAS NOT MEASURED BY THE VISUAL ANALOG SCALE (VAS) WITHIN THREE MONTHS PREOPERATIVELY AND AT THREE MONTHS ( 6 - 20 WEEKS)  POSTOPERATIVELY,96.10767639658705,,Present in Autoproposal
G9949,LEG PAIN WAS NOT MEASURED BY THE VISUAL ANALOG SCALE (VAS) WITHIN THREE MONTHS PREOPERATIVELY AND AT THREE MONTHS (6 TO 20 WEEKS) POSTOPERATIVELY,G9941,BACK PAIN WAS MEASURED BY THE VISUAL ANALOG SCALE (VAS) WITHIN THREE MONTHS PREOPERATIVELY AND AT THREE MONTHS (6 - 20 WEEKS) POSTOPERATIVELY,95.38051372160888,,Present in Autoproposal
G9949,LEG PAIN WAS NOT MEASURED BY THE VISUAL ANALOG SCALE (VAS) WITHIN THREE MONTHS PREOPERATIVELY AND AT THREE MONTHS (6 TO 20 WEEKS) POSTOPERATIVELY,G9946,BACK PAIN WAS NOT MEASURED BY THE VISUAL ANALOG SCALE (VAS) WITHIN THREE MONTHS PREOPERATIVELY AND AT ONE YEAR (9 TO 15 MONTHS) POSTOPERATIVELY,84.99211770913662,,Present in Autoproposal
G9949,LEG PAIN WAS NOT MEASURED BY THE VISUAL ANALOG SCALE (VAS) WITHIN THREE MONTHS PREOPERATIVELY AND AT THREE MONTHS (6 TO 20 WEEKS) POSTOPERATIVELY,G9944,BACK PAIN WAS MEASURED BY THE VISUAL ANALOG SCALE (VAS) WITHIN THREE MONTHS PREOPERATIVELY AND AT ONE YEAR  (9 TO 15 MONTHS) POSTOPERATIVELY,84.17742332390928,,Present in Autoproposal
G9949,LEG PAIN WAS NOT MEASURED BY THE VISUAL ANALOG SCALE (VAS) WITHIN THREE MONTHS PREOPERATIVELY AND AT THREE MONTHS (6 TO 20 WEEKS) POSTOPERATIVELY,E1639,"SCALE, EACH",23.34239342233684,,Present in Autoproposal
G9949,LEG PAIN WAS NOT MEASURED BY THE VISUAL ANALOG SCALE (VAS) WITHIN THREE MONTHS PREOPERATIVELY AND AT THREE MONTHS (6 TO 20 WEEKS) POSTOPERATIVELY,G9563,PATIENTS WHO DID NOT HAVE A FOLLOW-UP EVALUATION CONDUCTED AT LEAST EVERY THREE MONTHS DURING OPIOID THERAPY,22.929229937786214,,Present in Autoproposal
G9949,LEG PAIN WAS NOT MEASURED BY THE VISUAL ANALOG SCALE (VAS) WITHIN THREE MONTHS PREOPERATIVELY AND AT THREE MONTHS (6 TO 20 WEEKS) POSTOPERATIVELY,G9562,PATIENTS WHO HAD A FOLLOW-UP EVALUATION CONDUCTED AT LEAST EVERY THREE MONTHS DURING OPIOID THERAPY,21.838979309484834,,Present in Autoproposal
G9949,LEG PAIN WAS NOT MEASURED BY THE VISUAL ANALOG SCALE (VAS) WITHIN THREE MONTHS PREOPERATIVELY AND AT THREE MONTHS (6 TO 20 WEEKS) POSTOPERATIVELY,G8056,CLINICIAN DOCUMENTED THAT PATIENT WAS NOT AN ELIGIBLE CANDIDATE FOR THE FALLS ASSESSMENT MEASURE WITHIN THE LAST 12 MONTHS,21.66799121393548,,Present in Autoproposal
G9949,LEG PAIN WAS NOT MEASURED BY THE VISUAL ANALOG SCALE (VAS) WITHIN THREE MONTHS PREOPERATIVELY AND AT THREE MONTHS (6 TO 20 WEEKS) POSTOPERATIVELY,G9837,TRASTUZUMAB NOT ADMINISTERED WITHIN 12 MONTHS OF DIAGNOSIS,21.64856296917619,,Present in Autoproposal
G9954,PATIENT EXHIBITS 2 OR MORE RISK FACTORS FOR POST-OPERATIVE VOMITING,4556F,Patient exhibits 3 or more risk factors for post-operative nausea and vomiting (Peri2),85.2844639224171,10,Present in Autoproposal
G9954,PATIENT EXHIBITS 2 OR MORE RISK FACTORS FOR POST-OPERATIVE VOMITING,4557F,Patient does not exhibit 3 or more risk factors for post-operative nausea and vomiting (Peri2),61.44718135504903,,Present in Autoproposal
G9954,PATIENT EXHIBITS 2 OR MORE RISK FACTORS FOR POST-OPERATIVE VOMITING,G8970,NO RISK FACTORS OR ONE MODERATE RISK FACTOR FOR THROMBOEMBOLISM,35.2558473943283,,Present in Autoproposal
G9954,PATIENT EXHIBITS 2 OR MORE RISK FACTORS FOR POST-OPERATIVE VOMITING,G8972,ONE OR MORE HIGH RISK FACTORS FOR THROMBOEMBOLISM OR MORE THAN ONE MODERATE RISK FACTOR FOR THROMBOEMBOLISM,35.119137708623775,,Present in Autoproposal
G9954,PATIENT EXHIBITS 2 OR MORE RISK FACTORS FOR POST-OPERATIVE VOMITING,G9602,PATIENT NOT DISCHARGED TO HOME BY POST-OPERATIVE DAY #7,29.412874187011095,,Present in Autoproposal
G9954,PATIENT EXHIBITS 2 OR MORE RISK FACTORS FOR POST-OPERATIVE VOMITING,G8825,PATIENT NOT DISCHARGED TO HOME BY POST-OPERATIVE DAY #7,29.412874187011095,,Present in Autoproposal
G9954,PATIENT EXHIBITS 2 OR MORE RISK FACTORS FOR POST-OPERATIVE VOMITING,D0171,RE-EVALUATION  POST-OPERATIVE OFFICE VISIT,26.79004589263574,,Present in Autoproposal
G9954,PATIENT EXHIBITS 2 OR MORE RISK FACTORS FOR POST-OPERATIVE VOMITING,3760F,"Patient exhibits dysphagia, weight loss, or impaired nutrition (ALS)",26.585476607660937,,Present in Autoproposal
G9954,PATIENT EXHIBITS 2 OR MORE RISK FACTORS FOR POST-OPERATIVE VOMITING,G8818,PATIENT DISCHARGE TO HOME NO LATER THAN POST-OPERATIVE DAY #7,26.14443481726376,,Present in Autoproposal
G9954,PATIENT EXHIBITS 2 OR MORE RISK FACTORS FOR POST-OPERATIVE VOMITING,G9601,PATIENT DISCHARGE TO HOME NO LATER THAN POST-OPERATIVE DAY #7,26.14443481726376,,Present in Autoproposal
G9955,CASES IN WHICH AN INHALATIONAL ANESTHETIC IS USED ONLY FOR INDUCTION,4554F,Patient received inhalational anesthetic agent (Peri2),38.79510861894671,10,Present in Autoproposal
G9955,CASES IN WHICH AN INHALATIONAL ANESTHETIC IS USED ONLY FOR INDUCTION,4555F,Patient did not receive inhalational anesthetic agent (Peri2),34.1548654675454,,Present in Autoproposal
G9955,CASES IN WHICH AN INHALATIONAL ANESTHETIC IS USED ONLY FOR INDUCTION,93622,Comprehensive electrophysiologic evaluation including insertion and repositioning of multiple electrode catheters with induction or attempted induction of arrhythmia; with left ventricular pacing and recording (List separately in addition to code for primary procedure),19.816166557781077,,Present in Autoproposal
G9955,CASES IN WHICH AN INHALATIONAL ANESTHETIC IS USED ONLY FOR INDUCTION,93624,"Electrophysiologic follow-up study with pacing and recording to test effectiveness of therapy, including induction or attempted induction of arrhythmia",19.58447086163749,,Present in Autoproposal
G9955,CASES IN WHICH AN INHALATIONAL ANESTHETIC IS USED ONLY FOR INDUCTION,93618,Induction of arrhythmia by electrical pacing,17.93999907954008,,Present in Autoproposal
G9955,CASES IN WHICH AN INHALATIONAL ANESTHETIC IS USED ONLY FOR INDUCTION,G9356,ELECTIVE DELIVERY OR EARLY INDUCTION PERFORMED,17.611441579972062,,Present in Autoproposal
G9955,CASES IN WHICH AN INHALATIONAL ANESTHETIC IS USED ONLY FOR INDUCTION,93621,Comprehensive electrophysiologic evaluation including insertion and repositioning of multiple electrode catheters with induction or attempted induction of arrhythmia; with left atrial pacing and recording from coronary sinus or left atrium (List separately in addition to code for primary procedure),17.3916659560549,,Present in Autoproposal
G9955,CASES IN WHICH AN INHALATIONAL ANESTHETIC IS USED ONLY FOR INDUCTION,G9355,ELECTIVE DELIVERY OR EARLY INDUCTION NOT PERFORMED,17.111862677469738,,Present in Autoproposal
G9955,CASES IN WHICH AN INHALATIONAL ANESTHETIC IS USED ONLY FOR INDUCTION,G9657,TRANSFER OF CARE DURING AN ANESTHETIC OR TO THE INTENSIVE CARE UNIT,17.09254331614532,,Present in Autoproposal
G9955,CASES IN WHICH AN INHALATIONAL ANESTHETIC IS USED ONLY FOR INDUCTION,62274,INJECT SPINAL ANESTHETIC,16.80390504058485,,Present in Autoproposal
G9956,PATIENT RECEIVED COMBINATION THERAPY CONSISTING OF AT LEAST TWO PROPHYLACTIC PHARMACOLOGIC ANTI-EMETIC AGENTS OF DIFFERENT CLASSES PREOPERATIVELY AND/OR INTRAOPERATIVELY,G9958,PATIENT DID NOT RECEIVE COMBINATION THERAPY CONSISTING OF AT LEAST TWO PROPHYLACTIC PHARMACOLOGIC ANTI-EMETIC AGENTS OF DIFFERENT CLASSES PREOPERATIVELY AND/OR INTRAOPERATIVELY,91.18258200313022,10,Present in Autoproposal
G9956,PATIENT RECEIVED COMBINATION THERAPY CONSISTING OF AT LEAST TWO PROPHYLACTIC PHARMACOLOGIC ANTI-EMETIC AGENTS OF DIFFERENT CLASSES PREOPERATIVELY AND/OR INTRAOPERATIVELY,G9775,PATIENT RECEIVED AT LEAST 2 PROPHYLACTIC PHARMACOLOGIC ANTI-EMETIC AGENTS OF DIFFERENT CLASSES PREOPERATIVELY AND/OR INTRAOPERATIVELY,87.81136715587428,,Present in Autoproposal
G9956,PATIENT RECEIVED COMBINATION THERAPY CONSISTING OF AT LEAST TWO PROPHYLACTIC PHARMACOLOGIC ANTI-EMETIC AGENTS OF DIFFERENT CLASSES PREOPERATIVELY AND/OR INTRAOPERATIVELY,4558F,Patient received at least 2 prophylactic pharmacologic anti-emetic agents of different classes preoperatively and intraoperatively (Peri2),83.14980332897305,,Present in Autoproposal
G9956,PATIENT RECEIVED COMBINATION THERAPY CONSISTING OF AT LEAST TWO PROPHYLACTIC PHARMACOLOGIC ANTI-EMETIC AGENTS OF DIFFERENT CLASSES PREOPERATIVELY AND/OR INTRAOPERATIVELY,G9957,"DOCUMENTATION OF MEDICAL REASON FOR NOT RECEIVING COMBINATION THERAPY CONSISTING OF AT LEAST TWO PROPHYLACTIC PHARMACOLOGIC ANTI-EMETIC AGENTS OF DIFFERENT CLASSES PREOPERATIVELY AND/OR INTRAOPERATIVELY (E.G., INTOLERANCE OR OTHER MEDICAL REASON)",78.96770283218285,,Present in Autoproposal
G9956,PATIENT RECEIVED COMBINATION THERAPY CONSISTING OF AT LEAST TWO PROPHYLACTIC PHARMACOLOGIC ANTI-EMETIC AGENTS OF DIFFERENT CLASSES PREOPERATIVELY AND/OR INTRAOPERATIVELY,G9777,PATIENT DID NOT RECEIVE AT LEAST 2 PROPHYLACTIC PHARMACOLOGIC ANTI-EMETIC AGENTS OF DIFFERENT CLASSES PREOPERATIVELY AND/OR INTRAOPERATIVELY,77.8262688944104,,Present in Autoproposal
G9956,PATIENT RECEIVED COMBINATION THERAPY CONSISTING OF AT LEAST TWO PROPHYLACTIC PHARMACOLOGIC ANTI-EMETIC AGENTS OF DIFFERENT CLASSES PREOPERATIVELY AND/OR INTRAOPERATIVELY,G9776,"DOCUMENTATION OF MEDICAL REASON FOR NOT RECEIVING AT LEAST 2 PROPHYLACTIC PHARMACOLOGIC ANTI-EMETIC AGENTS OF DIFFERENT CLASSES PREOPERATIVELY AND/OR INTRAOPERATIVELY  (E.G., INTOLERANCE OR OTHER MEDICAL REASON)",65.49960027564431,,Present in Autoproposal
G9956,PATIENT RECEIVED COMBINATION THERAPY CONSISTING OF AT LEAST TWO PROPHYLACTIC PHARMACOLOGIC ANTI-EMETIC AGENTS OF DIFFERENT CLASSES PREOPERATIVELY AND/OR INTRAOPERATIVELY,G9367,AT LEAST TWO DIFFERENT HIGH-RISK MEDICATIONS ORDERED,29.987190635044907,,Present in Autoproposal
G9956,PATIENT RECEIVED COMBINATION THERAPY CONSISTING OF AT LEAST TWO PROPHYLACTIC PHARMACOLOGIC ANTI-EMETIC AGENTS OF DIFFERENT CLASSES PREOPERATIVELY AND/OR INTRAOPERATIVELY,G9368,AT LEAST TWO DIFFERENT HIGH-RISK MEDICATIONS NOT ORDERED,29.317758305800908,,Present in Autoproposal
G9956,PATIENT RECEIVED COMBINATION THERAPY CONSISTING OF AT LEAST TWO PROPHYLACTIC PHARMACOLOGIC ANTI-EMETIC AGENTS OF DIFFERENT CLASSES PREOPERATIVELY AND/OR INTRAOPERATIVELY,G8285,PATIENT NOT DOCUMENTED TO HAVE RECEIVED PHARMACOLOGIC THERAPY,29.168288129750795,,Present in Autoproposal
G9956,PATIENT RECEIVED COMBINATION THERAPY CONSISTING OF AT LEAST TWO PROPHYLACTIC PHARMACOLOGIC ANTI-EMETIC AGENTS OF DIFFERENT CLASSES PREOPERATIVELY AND/OR INTRAOPERATIVELY,77431,Radiation therapy management with complete course of therapy consisting of 1 or 2 fractions only,24.54591581432775,,Present in Autoproposal
G9978,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: A problem focused history; A problem focused examination; and Straightforward medical decision making, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are self limited or minor. Typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9481,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",92.903991907087,1,Present Both in MD and Autoproposal
G9978,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: A problem focused history; A problem focused examination; and Straightforward medical decision making, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are self limited or minor. Typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9486,"Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: a problem focused history; a problem focused examination; straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",91.13512127436326,,Present in Autoproposal
G9978,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: A problem focused history; A problem focused examination; and Straightforward medical decision making, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are self limited or minor. Typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9482,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: an expanded problem focused history; an expanded problem focused examination; straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of low to moderate severity. typically, 20 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",88.26784128768925,,Present in Autoproposal
G9978,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: A problem focused history; A problem focused examination; and Straightforward medical decision making, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are self limited or minor. Typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9483,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a detailed history; a detailed examination; medical decision making of low complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate severity. typically, 30 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",84.98081385372791,,Present in Autoproposal
G9978,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: A problem focused history; A problem focused examination; and Straightforward medical decision making, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are self limited or minor. Typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9487,"Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: an expanded problem focused history; an expanded problem focused examination; medical decision making of low complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of low to moderate severity. typically, 15 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",84.73816610685971,,Present in Autoproposal
G9978,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: A problem focused history; A problem focused examination; and Straightforward medical decision making, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are self limited or minor. Typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9485,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a comprehensive history; a comprehensive examination; medical decision making of high complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 60 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",84.55595495273049,,Present in Autoproposal
G9978,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: A problem focused history; A problem focused examination; and Straightforward medical decision making, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are self limited or minor. Typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9484,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a comprehensive history; a comprehensive examination; medical decision making of moderate complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 45 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",84.27244492448077,,Present in Autoproposal
G9978,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: A problem focused history; A problem focused examination; and Straightforward medical decision making, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are self limited or minor. Typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9489,"Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: a comprehensive history; a comprehensive examination; medical decision making of high complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 40 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",82.82817654574639,,Present in Autoproposal
G9978,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: A problem focused history; A problem focused examination; and Straightforward medical decision making, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are self limited or minor. Typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9488,"Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: a detailed history; a detailed examination; medical decision making of moderate complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 25 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",82.29394944196295,,Present in Autoproposal
G9978,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: A problem focused history; A problem focused examination; and Straightforward medical decision making, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are self limited or minor. Typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",99201,"Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A problem focused history; A problem focused examination; Straightforward medical decision making. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are self limited or minor. Typically, 10 minutes are spent face-to-face with the patient and/or family.",77.71308170364345,,Present in Autoproposal
G9979,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: An expanded problem focused history; An expanded problem focused examination; Straightforward medical decision making, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of low to moderate severity. Typically, 20 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9482,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: an expanded problem focused history; an expanded problem focused examination; straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of low to moderate severity. typically, 20 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",93.14989587045297,1,Present Both in MD and Autoproposal
G9979,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: An expanded problem focused history; An expanded problem focused examination; Straightforward medical decision making, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of low to moderate severity. Typically, 20 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9487,"Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: an expanded problem focused history; an expanded problem focused examination; medical decision making of low complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of low to moderate severity. typically, 15 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",90.18661985869264,,Present in Autoproposal
G9979,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: An expanded problem focused history; An expanded problem focused examination; Straightforward medical decision making, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of low to moderate severity. Typically, 20 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9481,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",88.2751188866387,,Present in Autoproposal
G9979,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: An expanded problem focused history; An expanded problem focused examination; Straightforward medical decision making, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of low to moderate severity. Typically, 20 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9486,"Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: a problem focused history; a problem focused examination; straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",87.42627276526652,,Present in Autoproposal
G9979,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: An expanded problem focused history; An expanded problem focused examination; Straightforward medical decision making, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of low to moderate severity. Typically, 20 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9483,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a detailed history; a detailed examination; medical decision making of low complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate severity. typically, 30 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",84.94462301584043,,Present in Autoproposal
G9979,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: An expanded problem focused history; An expanded problem focused examination; Straightforward medical decision making, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of low to moderate severity. Typically, 20 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9484,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a comprehensive history; a comprehensive examination; medical decision making of moderate complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 45 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",84.47360968479572,,Present in Autoproposal
G9979,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: An expanded problem focused history; An expanded problem focused examination; Straightforward medical decision making, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of low to moderate severity. Typically, 20 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9485,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a comprehensive history; a comprehensive examination; medical decision making of high complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 60 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",84.11087037283107,,Present in Autoproposal
G9979,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: An expanded problem focused history; An expanded problem focused examination; Straightforward medical decision making, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of low to moderate severity. Typically, 20 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9488,"Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: a detailed history; a detailed examination; medical decision making of moderate complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 25 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",83.22311136633967,,Present in Autoproposal
G9979,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: An expanded problem focused history; An expanded problem focused examination; Straightforward medical decision making, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of low to moderate severity. Typically, 20 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9489,"Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: a comprehensive history; a comprehensive examination; medical decision making of high complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 40 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",83.13514650383236,,Present in Autoproposal
G9979,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: An expanded problem focused history; An expanded problem focused examination; Straightforward medical decision making, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of low to moderate severity. Typically, 20 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",99202,"Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: An expanded problem focused history; An expanded problem focused examination; Straightforward medical decision making. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity. Typically, 20 minutes are spent face-to-face with the patient and/or family.",78.62680112298743,,Present in Autoproposal
G9980,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: A detailed history; A detailed examination; Medical decision making of low complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate severity. Typically, 30 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9483,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a detailed history; a detailed examination; medical decision making of low complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate severity. typically, 30 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",92.31471777822713,1,Present Both in MD and Autoproposal
G9980,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: A detailed history; A detailed examination; Medical decision making of low complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate severity. Typically, 30 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9488,"Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: a detailed history; a detailed examination; medical decision making of moderate complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 25 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",89.18307580275918,,Present in Autoproposal
G9980,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: A detailed history; A detailed examination; Medical decision making of low complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate severity. Typically, 30 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9484,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a comprehensive history; a comprehensive examination; medical decision making of moderate complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 45 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",87.64541089420284,,Present in Autoproposal
G9980,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: A detailed history; A detailed examination; Medical decision making of low complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate severity. Typically, 30 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9485,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a comprehensive history; a comprehensive examination; medical decision making of high complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 60 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",87.25644454121803,,Present in Autoproposal
G9980,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: A detailed history; A detailed examination; Medical decision making of low complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate severity. Typically, 30 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9489,"Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: a comprehensive history; a comprehensive examination; medical decision making of high complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 40 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",85.63864582100533,,Present in Autoproposal
G9980,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: A detailed history; A detailed examination; Medical decision making of low complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate severity. Typically, 30 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9481,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",84.3329409218613,,Present in Autoproposal
G9980,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: A detailed history; A detailed examination; Medical decision making of low complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate severity. Typically, 30 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9482,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: an expanded problem focused history; an expanded problem focused examination; straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of low to moderate severity. typically, 20 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",84.29900938730111,,Present in Autoproposal
G9980,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: A detailed history; A detailed examination; Medical decision making of low complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate severity. Typically, 30 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9487,"Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: an expanded problem focused history; an expanded problem focused examination; medical decision making of low complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of low to moderate severity. typically, 15 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",83.29505187415846,,Present in Autoproposal
G9980,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: A detailed history; A detailed examination; Medical decision making of low complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate severity. Typically, 30 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9486,"Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: a problem focused history; a problem focused examination; straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",82.99946465541825,,Present in Autoproposal
G9980,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: A detailed history; A detailed examination; Medical decision making of low complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate severity. Typically, 30 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",99203,"Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A detailed history; A detailed examination; Medical decision making of low complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate severity. Typically, 30 minutes are spent face-to-face with the patient and/or family.",75.72706463481309,,Present in Autoproposal
G9981,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of moderate complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate to high severity. Typically, 45 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9484,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a comprehensive history; a comprehensive examination; medical decision making of moderate complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 45 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",92.43364792458624,1,Present Both in MD and Autoproposal
G9981,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of moderate complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate to high severity. Typically, 45 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9485,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a comprehensive history; a comprehensive examination; medical decision making of high complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 60 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",91.04428198580581,,Present in Autoproposal
G9981,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of moderate complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate to high severity. Typically, 45 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9489,"Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: a comprehensive history; a comprehensive examination; medical decision making of high complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 40 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",89.31019851916544,,Present in Autoproposal
G9981,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of moderate complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate to high severity. Typically, 45 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9483,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a detailed history; a detailed examination; medical decision making of low complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate severity. typically, 30 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",87.71977672686631,,Present in Autoproposal
G9981,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of moderate complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate to high severity. Typically, 45 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9488,"Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: a detailed history; a detailed examination; medical decision making of moderate complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 25 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",87.02906247285563,,Present in Autoproposal
G9981,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of moderate complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate to high severity. Typically, 45 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9482,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: an expanded problem focused history; an expanded problem focused examination; straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of low to moderate severity. typically, 20 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",83.90292323523111,,Present in Autoproposal
G9981,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of moderate complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate to high severity. Typically, 45 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9481,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",83.70093121661907,,Present in Autoproposal
G9981,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of moderate complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate to high severity. Typically, 45 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9487,"Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: an expanded problem focused history; an expanded problem focused examination; medical decision making of low complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of low to moderate severity. typically, 15 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",82.3811646670288,,Present in Autoproposal
G9981,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of moderate complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate to high severity. Typically, 45 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9486,"Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: a problem focused history; a problem focused examination; straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",82.37744831614775,,Present in Autoproposal
G9981,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of moderate complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate to high severity. Typically, 45 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",99204,"Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 45 minutes are spent face-to-face with the patient and/or family.",76.14518566431397,,Present in Autoproposal
G9982,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate to high severity. Typically, 60 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9485,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a comprehensive history; a comprehensive examination; medical decision making of high complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 60 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",92.38613590902008,1,Present Both in MD and Autoproposal
G9982,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate to high severity. Typically, 60 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9484,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a comprehensive history; a comprehensive examination; medical decision making of moderate complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 45 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",91.01344457966916,,Present in Autoproposal
G9982,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate to high severity. Typically, 60 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9489,"Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: a comprehensive history; a comprehensive examination; medical decision making of high complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 40 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",89.88921192281876,,Present in Autoproposal
G9982,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate to high severity. Typically, 60 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9483,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a detailed history; a detailed examination; medical decision making of low complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate severity. typically, 30 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",87.30090082904691,,Present in Autoproposal
G9982,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate to high severity. Typically, 60 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9488,"Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: a detailed history; a detailed examination; medical decision making of moderate complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 25 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",86.46051561699623,,Present in Autoproposal
G9982,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate to high severity. Typically, 60 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9481,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",83.9540730219553,,Present in Autoproposal
G9982,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate to high severity. Typically, 60 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9482,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: an expanded problem focused history; an expanded problem focused examination; straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of low to moderate severity. typically, 20 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",83.51374645297368,,Present in Autoproposal
G9982,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate to high severity. Typically, 60 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9486,"Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: a problem focused history; a problem focused examination; straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",82.62658743183773,,Present in Autoproposal
G9982,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate to high severity. Typically, 60 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9487,"Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: an expanded problem focused history; an expanded problem focused examination; medical decision making of low complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of low to moderate severity. typically, 15 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",82.01432792205922,,Present in Autoproposal
G9982,"Remote in-home visit for the evaluation and management of a new patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate to high severity. Typically, 60 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",99344,"Home visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of high severity. Typically, 60 minutes are spent face-to-face with the patient and/or family.",77.0553196178345,,Present in Autoproposal
G9983,"Remote in-home visit for the evaluation and management of an established patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires at least 2 of the following 3 key components: A problem focused history; A problem focused examination; Straightforward medical decision making, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are self limited or minor. Typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9486,"Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: a problem focused history; a problem focused examination; straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",93.17615625039389,1,Present Both in MD and Autoproposal
G9983,"Remote in-home visit for the evaluation and management of an established patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires at least 2 of the following 3 key components: A problem focused history; A problem focused examination; Straightforward medical decision making, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are self limited or minor. Typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9481,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",91.16195317430798,,Present in Autoproposal
G9983,"Remote in-home visit for the evaluation and management of an established patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires at least 2 of the following 3 key components: A problem focused history; A problem focused examination; Straightforward medical decision making, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are self limited or minor. Typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9487,"Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: an expanded problem focused history; an expanded problem focused examination; medical decision making of low complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of low to moderate severity. typically, 15 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",87.5190049741619,,Present in Autoproposal
G9983,"Remote in-home visit for the evaluation and management of an established patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires at least 2 of the following 3 key components: A problem focused history; A problem focused examination; Straightforward medical decision making, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are self limited or minor. Typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9482,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: an expanded problem focused history; an expanded problem focused examination; straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of low to moderate severity. typically, 20 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",87.44231881982805,,Present in Autoproposal
G9983,"Remote in-home visit for the evaluation and management of an established patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires at least 2 of the following 3 key components: A problem focused history; A problem focused examination; Straightforward medical decision making, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are self limited or minor. Typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9489,"Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: a comprehensive history; a comprehensive examination; medical decision making of high complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 40 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",85.29126881561115,,Present in Autoproposal
G9983,"Remote in-home visit for the evaluation and management of an established patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires at least 2 of the following 3 key components: A problem focused history; A problem focused examination; Straightforward medical decision making, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are self limited or minor. Typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9488,"Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: a detailed history; a detailed examination; medical decision making of moderate complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 25 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",84.74115520189159,,Present in Autoproposal
G9983,"Remote in-home visit for the evaluation and management of an established patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires at least 2 of the following 3 key components: A problem focused history; A problem focused examination; Straightforward medical decision making, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are self limited or minor. Typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9483,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a detailed history; a detailed examination; medical decision making of low complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate severity. typically, 30 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",83.65152416969647,,Present in Autoproposal
G9983,"Remote in-home visit for the evaluation and management of an established patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires at least 2 of the following 3 key components: A problem focused history; A problem focused examination; Straightforward medical decision making, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are self limited or minor. Typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9485,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a comprehensive history; a comprehensive examination; medical decision making of high complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 60 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",83.23331101058643,,Present in Autoproposal
G9983,"Remote in-home visit for the evaluation and management of an established patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires at least 2 of the following 3 key components: A problem focused history; A problem focused examination; Straightforward medical decision making, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are self limited or minor. Typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9484,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a comprehensive history; a comprehensive examination; medical decision making of moderate complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 45 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",82.9542357122338,,Present in Autoproposal
G9983,"Remote in-home visit for the evaluation and management of an established patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires at least 2 of the following 3 key components: A problem focused history; A problem focused examination; Straightforward medical decision making, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are self limited or minor. Typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",99347,"Home visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A problem focused interval history; A problem focused examination; Straightforward medical decision making. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are self limited or minor. Typically, 15 minutes are spent face-to-face with the patient and/or family.",77.64533741028062,,Present in Autoproposal
G9984,"Remote in-home visit for the evaluation and management of an established patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires at least 2 of the following 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9487,"Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: an expanded problem focused history; an expanded problem focused examination; medical decision making of low complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of low to moderate severity. typically, 15 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",93.6946423335344,1,Present Both in MD and Autoproposal
G9984,"Remote in-home visit for the evaluation and management of an established patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires at least 2 of the following 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9482,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: an expanded problem focused history; an expanded problem focused examination; straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of low to moderate severity. typically, 20 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",90.26248218328575,,Present in Autoproposal
G9984,"Remote in-home visit for the evaluation and management of an established patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires at least 2 of the following 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9486,"Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: a problem focused history; a problem focused examination; straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",87.57262903735463,,Present in Autoproposal
G9984,"Remote in-home visit for the evaluation and management of an established patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires at least 2 of the following 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9488,"Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: a detailed history; a detailed examination; medical decision making of moderate complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 25 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",85.39756595404371,,Present in Autoproposal
G9984,"Remote in-home visit for the evaluation and management of an established patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires at least 2 of the following 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9489,"Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: a comprehensive history; a comprehensive examination; medical decision making of high complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 40 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",85.34859269940951,,Present in Autoproposal
G9984,"Remote in-home visit for the evaluation and management of an established patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires at least 2 of the following 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9481,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",84.80545832725677,,Present in Autoproposal
G9984,"Remote in-home visit for the evaluation and management of an established patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires at least 2 of the following 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9483,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a detailed history; a detailed examination; medical decision making of low complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate severity. typically, 30 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",83.98233805110134,,Present in Autoproposal
G9984,"Remote in-home visit for the evaluation and management of an established patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires at least 2 of the following 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9484,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a comprehensive history; a comprehensive examination; medical decision making of moderate complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 45 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",82.99023242605418,,Present in Autoproposal
G9984,"Remote in-home visit for the evaluation and management of an established patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires at least 2 of the following 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9485,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a comprehensive history; a comprehensive examination; medical decision making of high complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 60 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",82.64811899259344,,Present in Autoproposal
G9984,"Remote in-home visit for the evaluation and management of an established patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires at least 2 of the following 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",99348,"Home visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity. Typically, 25 minutes are spent face-to-face with the patient and/or family.",79.45474403525215,,Present in Autoproposal
G9985,"Remote in-home visit for the evaluation and management of an established patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires at least 2 of the following 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9488,"Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: a detailed history; a detailed examination; medical decision making of moderate complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 25 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",92.88761086514639,1,Present Both in MD and Autoproposal
G9985,"Remote in-home visit for the evaluation and management of an established patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires at least 2 of the following 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9483,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a detailed history; a detailed examination; medical decision making of low complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate severity. typically, 30 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",89.39706914517187,,Present in Autoproposal
G9985,"Remote in-home visit for the evaluation and management of an established patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires at least 2 of the following 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9489,"Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: a comprehensive history; a comprehensive examination; medical decision making of high complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 40 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",88.8252261241313,,Present in Autoproposal
G9985,"Remote in-home visit for the evaluation and management of an established patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires at least 2 of the following 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9484,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a comprehensive history; a comprehensive examination; medical decision making of moderate complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 45 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",87.16260191654273,,Present in Autoproposal
G9985,"Remote in-home visit for the evaluation and management of an established patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires at least 2 of the following 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9485,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a comprehensive history; a comprehensive examination; medical decision making of high complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 60 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",86.6217659100448,,Present in Autoproposal
G9985,"Remote in-home visit for the evaluation and management of an established patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires at least 2 of the following 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9487,"Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: an expanded problem focused history; an expanded problem focused examination; medical decision making of low complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of low to moderate severity. typically, 15 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",84.90161698651785,,Present in Autoproposal
G9985,"Remote in-home visit for the evaluation and management of an established patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires at least 2 of the following 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9486,"Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: a problem focused history; a problem focused examination; straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",84.28688283502646,,Present in Autoproposal
G9985,"Remote in-home visit for the evaluation and management of an established patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires at least 2 of the following 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9482,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: an expanded problem focused history; an expanded problem focused examination; straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of low to moderate severity. typically, 20 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",82.78920938134979,,Present in Autoproposal
G9985,"Remote in-home visit for the evaluation and management of an established patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires at least 2 of the following 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9481,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",81.86056400722555,,Present in Autoproposal
G9985,"Remote in-home visit for the evaluation and management of an established patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires at least 2 of the following 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",99214,"Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent face-to-face with the patient and/or family.",76.45673707834383,,Present in Autoproposal
G9986,"Remote in-home visit for the evaluation and management of an established patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires at least 2 of the following 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate to high severity. Typically, 40 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9489,"Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: a comprehensive history; a comprehensive examination; medical decision making of high complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 40 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",92.80107752570605,1,Present Both in MD and Autoproposal
G9986,"Remote in-home visit for the evaluation and management of an established patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires at least 2 of the following 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate to high severity. Typically, 40 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9485,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a comprehensive history; a comprehensive examination; medical decision making of high complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 60 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",90.00314100184485,,Present in Autoproposal
G9986,"Remote in-home visit for the evaluation and management of an established patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires at least 2 of the following 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate to high severity. Typically, 40 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9484,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a comprehensive history; a comprehensive examination; medical decision making of moderate complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 45 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",89.39283182187205,,Present in Autoproposal
G9986,"Remote in-home visit for the evaluation and management of an established patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires at least 2 of the following 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate to high severity. Typically, 40 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9488,"Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: a detailed history; a detailed examination; medical decision making of moderate complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate to high severity. typically, 25 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",88.76964958494597,,Present in Autoproposal
G9986,"Remote in-home visit for the evaluation and management of an established patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires at least 2 of the following 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate to high severity. Typically, 40 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9483,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a detailed history; a detailed examination; medical decision making of low complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of moderate severity. typically, 30 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",85.7867362031638,,Present in Autoproposal
G9986,"Remote in-home visit for the evaluation and management of an established patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires at least 2 of the following 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate to high severity. Typically, 40 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9487,"Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: an expanded problem focused history; an expanded problem focused examination; medical decision making of low complexity, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of low to moderate severity. typically, 15 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",84.79983701038945,,Present in Autoproposal
G9986,"Remote in-home visit for the evaluation and management of an established patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires at least 2 of the following 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate to high severity. Typically, 40 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9486,"Remote in-home visit for the evaluation and management of an established patient for use only in a medicare-approved cms innovation center demonstration project, which requires at least 2 of the following 3 key components: a problem focused history; a problem focused examination; straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",84.78096812992368,,Present in Autoproposal
G9986,"Remote in-home visit for the evaluation and management of an established patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires at least 2 of the following 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate to high severity. Typically, 40 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9482,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: an expanded problem focused history; an expanded problem focused examination; straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are of low to moderate severity. typically, 20 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",82.64882668443781,,Present in Autoproposal
G9986,"Remote in-home visit for the evaluation and management of an established patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires at least 2 of the following 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate to high severity. Typically, 40 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",G9481,"Remote in-home visit for the evaluation and management of a new patient for use only in a medicare-approved cms innovation center demonstration project, which requires these 3 key components: a problem focused history; a problem focused examination; and straightforward medical decision making, furnished in real time using interactive audio and video technology. counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. usually, the presenting problem(s) are self limited or minor. typically, 10 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology",82.34042634816805,,Present in Autoproposal
G9986,"Remote in-home visit for the evaluation and management of an established patient for use only in a Medicare-approved Bundled Payments for Care Improvement Advanced (BPCI Advanced) model episode of care, which requires at least 2 of the following 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity, furnished in real time using interactive audio and video technology.Counseling and coordination of care with other physicians, other qualified health care professionals or agencies are provided consistent with the nature of the problem(s) and the needs of the patient or the family or both. Usually, the presenting problem(s) are of moderate to high severity. Typically, 40 minutes are spent with the patient or family or both via real time, audio and video intercommunications technology.",99215,"Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 40 minutes are spent face-to-face with the patient and/or family.",76.13683700270538,,Present in Autoproposal
G9987,"Bundled Payments for Care Improvement Advanced (BPCI Advanced) model home visit for patient assessment performed by clinical staff for an individual not considered homebound, including, but not necessarily limited to patient assessment of clinical status, safety/fall prevention, functional status/ambulation, medication reconciliation/management, compliance with orders/plan of care, performance of activities of daily living, and ensuring beneficiaryconnections to community and other services; for use only for a BPCI Advanced model episode of care; may not be billed for a 30-day period covered by a transitional care management code.",G9490,"CMS innovation center models, home visit for patient assessment performed by clinical staff for an individual not considered homebound, including, but not necessarily limited to patient assessment of clinical status, safety/fall prevention, functional status/ambulation, medication reconciliation/management, compliance with orders/plan of care, performance of activities of daily living, and ensuring beneficiary connections to community and other services. (for use only in medicare-approved cms innovation center models); may not be billed for a 30 day period covered by a transitional care management code",73.39997140445568,2,Present Both in MD and Autoproposal
G9987,"Bundled Payments for Care Improvement Advanced (BPCI Advanced) model home visit for patient assessment performed by clinical staff for an individual not considered homebound, including, but not necessarily limited to patient assessment of clinical status, safety/fall prevention, functional status/ambulation, medication reconciliation/management, compliance with orders/plan of care, performance of activities of daily living, and ensuring beneficiaryconnections to community and other services; for use only for a BPCI Advanced model episode of care; may not be billed for a 30-day period covered by a transitional care management code.",G9187,"BUNDLED PAYMENTS FOR CARE IMPROVEMENT INITIATIVE HOME VISIT FOR PATIENT ASSESSMENT PERFORMED BY A QUALIFIED HEALTH CARE PROFESSIONAL FOR INDIVIDUALS NOT CONSIDERED HOMEBOUND INCLUDING, BUT NOT LIMITED TO, ASSESSMENT OF SAFETY, FALLS, CLINICAL STATUS, FLUID STATUS, MEDICATION RECONCILIATION/MANAGEMENT, PATIENT COMPLIANCE WITH ORDERS/PLAN OF CARE, PERFORMANCE OF ACTIVITIES OF DAILY LIVING, APPROPRIATENESS OF CARE SETTING; (FOR USE ONLY IN THE MEIDCARE-APPROVED BUNDLED PAYMENTS FOR CARE IMPROVEMENT INITIATIVE); MAY NOT BE BILLED FOR A 30-DAY PERIOD COVERED BY A TRANSITIONAL CARE MANAGEMENT CODE",71.36419696412857,,Present Both in MD and Autoproposal
G9987,"Bundled Payments for Care Improvement Advanced (BPCI Advanced) model home visit for patient assessment performed by clinical staff for an individual not considered homebound, including, but not necessarily limited to patient assessment of clinical status, safety/fall prevention, functional status/ambulation, medication reconciliation/management, compliance with orders/plan of care, performance of activities of daily living, and ensuring beneficiaryconnections to community and other services; for use only for a BPCI Advanced model episode of care; may not be billed for a 30-day period covered by a transitional care management code.",99509,Home visit for assistance with activities of daily living and personal care,29.600495542466692,,Present in Autoproposal
G9987,"Bundled Payments for Care Improvement Advanced (BPCI Advanced) model home visit for patient assessment performed by clinical staff for an individual not considered homebound, including, but not necessarily limited to patient assessment of clinical status, safety/fall prevention, functional status/ambulation, medication reconciliation/management, compliance with orders/plan of care, performance of activities of daily living, and ensuring beneficiaryconnections to community and other services; for use only for a BPCI Advanced model episode of care; may not be billed for a 30-day period covered by a transitional care management code.",94005,"Home ventilator management care plan oversight of a patient (patient not present) in home, domiciliary or rest home (eg, assisted living) requiring review of status, review of laboratories and other studies and revision of orders and respiratory care plan (as appropriate), within a calendar month, 30 minutes or more",28.598650203528024,,Present in Autoproposal
G9987,"Bundled Payments for Care Improvement Advanced (BPCI Advanced) model home visit for patient assessment performed by clinical staff for an individual not considered homebound, including, but not necessarily limited to patient assessment of clinical status, safety/fall prevention, functional status/ambulation, medication reconciliation/management, compliance with orders/plan of care, performance of activities of daily living, and ensuring beneficiaryconnections to community and other services; for use only for a BPCI Advanced model episode of care; may not be billed for a 30-day period covered by a transitional care management code.",S0311,"COMPREHENSIVE MANAGEMENT AND CARE COORDINATION FOR ADVANCED ILLNESS, PER CALENDAR MONTH",28.595173061816435,,Present in Autoproposal
G9987,"Bundled Payments for Care Improvement Advanced (BPCI Advanced) model home visit for patient assessment performed by clinical staff for an individual not considered homebound, including, but not necessarily limited to patient assessment of clinical status, safety/fall prevention, functional status/ambulation, medication reconciliation/management, compliance with orders/plan of care, performance of activities of daily living, and ensuring beneficiaryconnections to community and other services; for use only for a BPCI Advanced model episode of care; may not be billed for a 30-day period covered by a transitional care management code.",G0506,COMPREHENSIVE ASSESSMENT OF AND CARE PLANNING FOR PATIENTS REQUIRING CHRONIC CARE MANAGEMENT SERVICES (LIST SEPARATELY IN ADDITION TO PRIMARY MONTHLY CARE MANAGEMENT SERVICE),28.46274205240241,,Present in Autoproposal
G9987,"Bundled Payments for Care Improvement Advanced (BPCI Advanced) model home visit for patient assessment performed by clinical staff for an individual not considered homebound, including, but not necessarily limited to patient assessment of clinical status, safety/fall prevention, functional status/ambulation, medication reconciliation/management, compliance with orders/plan of care, performance of activities of daily living, and ensuring beneficiaryconnections to community and other services; for use only for a BPCI Advanced model episode of care; may not be billed for a 30-day period covered by a transitional care management code.",G8320,CLINICIAN HAS NOT PROVIDED CARE FOR THE CATARACT PATIENT FOR THE REQUIRED TIME FOR ASSESSMENT OF VISUAL FUNCTIONAL STATUS MEASUREMENT,28.4284872521824,,Present in Autoproposal
G9987,"Bundled Payments for Care Improvement Advanced (BPCI Advanced) model home visit for patient assessment performed by clinical staff for an individual not considered homebound, including, but not necessarily limited to patient assessment of clinical status, safety/fall prevention, functional status/ambulation, medication reconciliation/management, compliance with orders/plan of care, performance of activities of daily living, and ensuring beneficiaryconnections to community and other services; for use only for a BPCI Advanced model episode of care; may not be billed for a 30-day period covered by a transitional care management code.",99502,Home visit for newborn care and assessment,27.889608833210232,,Present in Autoproposal
G9987,"Bundled Payments for Care Improvement Advanced (BPCI Advanced) model home visit for patient assessment performed by clinical staff for an individual not considered homebound, including, but not necessarily limited to patient assessment of clinical status, safety/fall prevention, functional status/ambulation, medication reconciliation/management, compliance with orders/plan of care, performance of activities of daily living, and ensuring beneficiaryconnections to community and other services; for use only for a BPCI Advanced model episode of care; may not be billed for a 30-day period covered by a transitional care management code.",99483,"Assessment of and care planning for a patient with cognitive impairment, requiring an independent historian, in the office or other outpatient, home or domiciliary or rest home, with all of the following required elements: Cognition-focused evaluation including a pertinent history and examination; Medical decision making of moderate or high complexity; Functional assessment (eg, basic and instrumental activities of daily living), including decision-making capacity; Use of standardized instruments for staging of dementia (eg, functional assessment staging test [FAST], clinical dementia rating [CDR]); Medication reconciliation and review for high-risk medications; Evaluation for neuropsychiatric and behavioral symptoms, including depression, including use of standardized screening instrument(s); Evaluation of safety (eg, home), including motor vehicle operation; Identification of caregiver(s), caregiver knowledge, caregiver needs, social supports, and the willingness of caregiver to take on caregiving tasks; Development, updating or revision, or review of an Advance Care Plan; Creation of a written care plan, including initial plans to address any neuropsychiatric symptoms, neuro-cognitive symptoms, functional limitations, and referral to community resources as needed (eg, rehabilitation services, adult day programs, support groups) shared with the patient and/or caregiver with initial education and support. Typically, 50 minutes are spent face-to-face with the patient and/or family or caregiver.",27.415763685819904,,Present in Autoproposal
G9987,"Bundled Payments for Care Improvement Advanced (BPCI Advanced) model home visit for patient assessment performed by clinical staff for an individual not considered homebound, including, but not necessarily limited to patient assessment of clinical status, safety/fall prevention, functional status/ambulation, medication reconciliation/management, compliance with orders/plan of care, performance of activities of daily living, and ensuring beneficiaryconnections to community and other services; for use only for a BPCI Advanced model episode of care; may not be billed for a 30-day period covered by a transitional care management code.",99375,"Supervision of a patient under care of home health agency (patient not present) in home, domiciliary or equivalent environment (eg, Alzheimer's facility) requiring complex and multidisciplinary care modalities involving regular development and/or revision of care plans by that individual, review of subsequent reports of patient status, review of related laboratory and other studies, communication (including telephone calls) for purposes of assessment or care decisions with health care professional(s), family member(s), surrogate decision maker(s) (eg, legal guardian) and/or key caregiver(s) involved in patient's care, integration of new information into the medical treatment plan and/or adjustment of medical therapy, within a calendar month; 30 minutes or more",27.183502977358344,,Present in Autoproposal
J0584,"Injection, burosumab-twza 1 mg",J9267,"INJECTION, PACLITAXEL, 1 MG",52.950885430632866,10,Present in Autoproposal
J0584,"Injection, burosumab-twza 1 mg",J9280,"INJECTION, MITOMYCIN, 5 MG",52.950885430632866,,Present in Autoproposal
J0584,"Injection, burosumab-twza 1 mg",Q2046,"INJECTION, AFLIBERCEPT, 1 MG",52.316794577196156,,Present in Autoproposal
J0584,"Injection, burosumab-twza 1 mg",J0202,"INJECTION, ALEMTUZUMAB, 1 MG",52.316794577196156,,Present in Autoproposal
J0584,"Injection, burosumab-twza 1 mg",J0178,"INJECTION, AFLIBERCEPT, 1 MG",52.316794577196156,,Present in Autoproposal
J0584,"Injection, burosumab-twza 1 mg",J3396,"INJECTION, VERTEPORFIN, 0.1 MG",52.316794577196156,,Present in Autoproposal
J0584,"Injection, burosumab-twza 1 mg",C9261,"INJECTION, USTEKINUMAB, 1 MG",52.316794577196156,,Present in Autoproposal
J0584,"Injection, burosumab-twza 1 mg",J1325,"INJECTION, EPOPROSTENOL, 0.5 MG",52.316794577196156,,Present in Autoproposal
J0584,"Injection, burosumab-twza 1 mg",Q9979,"INJECTION, ALEMTUZUMAB, 1 MG",52.316794577196156,,Present in Autoproposal
J0584,"Injection, burosumab-twza 1 mg",J2505,"INJECTION, PEGFILGRASTIM, 6 MG",51.58259659366726,,Present in Autoproposal
J0841,"Injection, crotalidae immune f(ab')2 (equine), 120 mg",J0716,"INJECTION, CENTRUROIDES IMMUNE F(AB)2, UP TO 120 MILLIGRAMS",52.20590590270686,3,Present in Autoproposal
J0841,"Injection, crotalidae immune f(ab')2 (equine), 120 mg",C9288,"INJECTION, CENTRUROIDES (SCORPION) IMMUNE F(AB)2 (EQUINE), 1 VIAL",50.23337814591608,,Present in Autoproposal
J0841,"Injection, crotalidae immune f(ab')2 (equine), 120 mg",J0840,"INJECTION, CROTALIDAE POLYVALENT IMMUNE FAB (OVINE), UP TO 1 GRAM",34.62858198763841,,Present Both in MD and Autoproposal
J0841,"Injection, crotalidae immune f(ab')2 (equine), 120 mg",C9274,"CROTALIDAE POLYVALENT IMMUNE FAB (OVINE), 1 VIAL",33.283599661666834,,Present in Autoproposal
J0841,"Injection, crotalidae immune f(ab')2 (equine), 120 mg",J2560,"INJECTION, PHENOBARBITAL SODIUM, UP TO 120 MG",31.39062493312027,,Present in Autoproposal
J0841,"Injection, crotalidae immune f(ab')2 (equine), 120 mg",J7504,"LYMPHOCYTE IMMUNE GLOBULIN, ANTITHYMOCYTE GLOBULIN, EQUINE, PARENTERAL, 250 MG",28.883147810306497,,Present in Autoproposal
J0841,"Injection, crotalidae immune f(ab')2 (equine), 120 mg",J1564,"INJECTION, IMMUNE GLOBULIN, INTRAVENOUS, 10 MG",27.730718106939744,,Present in Autoproposal
J0841,"Injection, crotalidae immune f(ab')2 (equine), 120 mg",65850,Trabeculotomy ab externo,24.774624639249385,,Present in Autoproposal
J0841,"Injection, crotalidae immune f(ab')2 (equine), 120 mg",Q9942,"INJECTION, IMMUNE GLOBULIN, INTRAVENOUS, LYOPHILIZED, 10 MG",24.137293332860118,,Present in Autoproposal
J0841,"Injection, crotalidae immune f(ab')2 (equine), 120 mg",86654,"Antibody; encephalitis, Western equine",23.583062294823076,,Present in Autoproposal
J1746,"Injection, ibalizumab-uiyk, 10 mg",J9355,"INJECTION, TRASTUZUMAB, 10 MG",64.79661678099245,10,Present in Autoproposal
J1746,"Injection, ibalizumab-uiyk, 10 mg",J0475,"INJECTION, BACLOFEN, 10 MG",64.79661678099245,,Present in Autoproposal
J1746,"Injection, ibalizumab-uiyk, 10 mg",J9035,"INJECTION, BEVACIZUMAB, 10 MG",64.16889233915315,,Present in Autoproposal
J1746,"Injection, ibalizumab-uiyk, 10 mg",J9181,"INJECTION, ETOPOSIDE, 10 MG",64.16889233915315,,Present in Autoproposal
J1746,"Injection, ibalizumab-uiyk, 10 mg",J9010,"INJECTION, ALEMTUZUMAB, 10 MG",64.16889233915315,,Present in Autoproposal
J1746,"Injection, ibalizumab-uiyk, 10 mg",J0131,"INJECTION, ACETAMINOPHEN, 10 MG",63.43662718836007,,Present in Autoproposal
J1746,"Injection, ibalizumab-uiyk, 10 mg",C9283,"INJECTION, ACETAMINOPHEN, 10 MG",63.43662718836007,,Present in Autoproposal
J1746,"Injection, ibalizumab-uiyk, 10 mg",J9150,"INJECTION, DAUNORUBICIN, 10 MG",63.43662718836007,,Present in Autoproposal
J1746,"Injection, ibalizumab-uiyk, 10 mg",J0128,"INJECTION, ABARELIX, 10 MG",62.55543553025977,,Present in Autoproposal
J1746,"Injection, ibalizumab-uiyk, 10 mg",J1953,"INJECTION, LEVETIRACETAM, 10 MG",62.55543553025977,,Present in Autoproposal
J2186,"Inj., meropenem, vaborbactam",J2185,"INJECTION, MEROPENEM, 100 MG",60.510926256842836,10,Present in Autoproposal
J2186,"Inj., meropenem, vaborbactam",J7625,ALBUTEROL SULFATE .5% INJ,39.48832602379107,,Present in Autoproposal
J2186,"Inj., meropenem, vaborbactam",J7655,ISOETHARINE HCL 1% INJ,39.25260668736333,,Present in Autoproposal
J2186,"Inj., meropenem, vaborbactam",J7653,ISOETHARINE HCL .2%/ INJ,39.25260668736333,,Present in Autoproposal
J2186,"Inj., meropenem, vaborbactam",J2996,ALTEPLASE RECOMBINANT INJ,36.60554413860462,,Present in Autoproposal
J2186,"Inj., meropenem, vaborbactam",J7654,ISOETHARINE HCL .25% INJ,36.07271648744501,,Present in Autoproposal
J2186,"Inj., meropenem, vaborbactam",J7651,ISOETHARINE HCL .125% INJ,34.6357302129482,,Present in Autoproposal
J2186,"Inj., meropenem, vaborbactam",J1770,IRON DEXTRAN 5 CC INJ,34.02594453326004,,Present in Autoproposal
J2186,"Inj., meropenem, vaborbactam",J1760,IRON DEXTRAN 2 CC INJ,34.02594453326004,,Present in Autoproposal
J2186,"Inj., meropenem, vaborbactam",Q3021,PED HEPATITIS B VACCINE INJ,33.95018979817151,,Present in Autoproposal
J2787,"Riboflavin 5'-phosphate, ophthalmic solution, up to 3 mL",84252,Riboflavin (Vitamin B-2),45.905578366214456,4,Present in Autoproposal
J2787,"Riboflavin 5'-phosphate, ophthalmic solution, up to 3 mL",J9175,"INJECTION, ELLIOTTS' B SOLUTION, 1 ML",28.727495006817037,,Present in Autoproposal
J2787,"Riboflavin 5'-phosphate, ophthalmic solution, up to 3 mL",J1710,"INJECTION, HYDROCORTISONE SODIUM PHOSPHATE, UP TO 50 MG",28.53360540515978,,Present in Autoproposal
J2787,"Riboflavin 5'-phosphate, ophthalmic solution, up to 3 mL",J7315,"MITOMYCIN, OPHTHALMIC, 0.2 MG",27.97825384437418,,Present Both in MD and Autoproposal
J2787,"Riboflavin 5'-phosphate, ophthalmic solution, up to 3 mL",Q2002,"INJECTION, ELLIOTTS B SOLUTION, PER ML",27.723392451002095,,Present in Autoproposal
J2787,"Riboflavin 5'-phosphate, ophthalmic solution, up to 3 mL",J1910,"INJECTION, KUTAPRESSIN, UP TO 2 ML",27.001261137706482,,Present in Autoproposal
J2787,"Riboflavin 5'-phosphate, ophthalmic solution, up to 3 mL",J7131,"HYPERTONIC SALINE SOLUTION, 1 ML",26.6341996393354,,Present in Autoproposal
J2787,"Riboflavin 5'-phosphate, ophthalmic solution, up to 3 mL",J2800,"INJECTION, METHOCARBAMOL, UP TO 10 ML",25.22234563572826,,Present in Autoproposal
J2787,"Riboflavin 5'-phosphate, ophthalmic solution, up to 3 mL",J2513,"INJECTION, PENTASTARCH, 10% SOLUTION, 100 ML",24.871175472985758,,Present in Autoproposal
J2787,"Riboflavin 5'-phosphate, ophthalmic solution, up to 3 mL",J2650,"INJECTION, PREDNISOLONE ACETATE, UP TO 1 ML",24.625060229873448,,Present in Autoproposal
J3245,"Injection, tildrakizumab, 1 mg",J9267,"INJECTION, PACLITAXEL, 1 MG",52.950885430632866,10,Present in Autoproposal
J3245,"Injection, tildrakizumab, 1 mg",J9280,"INJECTION, MITOMYCIN, 5 MG",52.950885430632866,,Present in Autoproposal
J3245,"Injection, tildrakizumab, 1 mg",Q2046,"INJECTION, AFLIBERCEPT, 1 MG",52.316794577196156,,Present in Autoproposal
J3245,"Injection, tildrakizumab, 1 mg",J0202,"INJECTION, ALEMTUZUMAB, 1 MG",52.316794577196156,,Present in Autoproposal
J3245,"Injection, tildrakizumab, 1 mg",J0178,"INJECTION, AFLIBERCEPT, 1 MG",52.316794577196156,,Present in Autoproposal
J3245,"Injection, tildrakizumab, 1 mg",J3396,"INJECTION, VERTEPORFIN, 0.1 MG",52.316794577196156,,Present in Autoproposal
J3245,"Injection, tildrakizumab, 1 mg",C9261,"INJECTION, USTEKINUMAB, 1 MG",52.316794577196156,,Present in Autoproposal
J3245,"Injection, tildrakizumab, 1 mg",J1325,"INJECTION, EPOPROSTENOL, 0.5 MG",52.316794577196156,,Present in Autoproposal
J3245,"Injection, tildrakizumab, 1 mg",Q9979,"INJECTION, ALEMTUZUMAB, 1 MG",52.316794577196156,,Present in Autoproposal
J3245,"Injection, tildrakizumab, 1 mg",J2505,"INJECTION, PEGFILGRASTIM, 6 MG",51.58259659366726,,Present in Autoproposal
J3397,"Injection, vestronidase alfa-vjbk, 1 mg",C9478,"INJECTION, SEBELIPASE ALFA, 1 MG",68.83848233233039,2,Present in Autoproposal
J3397,"Injection, vestronidase alfa-vjbk, 1 mg",J1322,"INJECTION, ELOSULFASE ALFA, 1 MG",68.83848233233039,,Present Both in MD and Autoproposal
J3397,"Injection, vestronidase alfa-vjbk, 1 mg",J2840,"INJECTION, SEBELIPASE ALFA, 1 MG",68.83848233233039,,Present in Autoproposal
J3397,"Injection, vestronidase alfa-vjbk, 1 mg",C9014,"INJECTION, CERLIPONASE ALFA, 1 MG",67.39042843760339,,Present in Autoproposal
J3397,"Injection, vestronidase alfa-vjbk, 1 mg",C9234,"INJECTION, ALGLUCOSIDASE ALFA, 10 MG",66.33066745093528,,Present in Autoproposal
J3397,"Injection, vestronidase alfa-vjbk, 1 mg",S0147,"INJECTION, ALGLUCOSIDASE ALFA, 20 MG",64.95443301968733,,Present in Autoproposal
J3397,"Injection, vestronidase alfa-vjbk, 1 mg",C9277,"INJECTION, ALGLUCOSIDASE ALFA (LUMIZYME), 1 MG",57.05207387915048,,Present in Autoproposal
J3397,"Injection, vestronidase alfa-vjbk, 1 mg",J0220,"INJECTION, ALGLUCOSIDASE ALFA, 10 MG, NOT OTHERWISE SPECIFIED",56.15338137897654,,Present in Autoproposal
J3397,"Injection, vestronidase alfa-vjbk, 1 mg",J0221,"INJECTION, ALGLUCOSIDASE ALFA, (LUMIZYME), 10 MG",54.36774506585399,,Present in Autoproposal
J3397,"Injection, vestronidase alfa-vjbk, 1 mg",S0112,"INJECTION, DARBEPOETIN ALFA, 1 MCG",53.03969882978365,,Present in Autoproposal
J3591,Unclassified drug or biological used for esrd on dialysis,J3490,UNCLASSIFIED DRUGS,41.438175261515894,1,Present Both in MD and Autoproposal
J3591,Unclassified drug or biological used for esrd on dialysis,J0884,"INJECTION, ARGATROBAN, 1 MG (FOR ESRD ON DIALYSIS)",37.144642983357905,,Present in Autoproposal
J3591,Unclassified drug or biological used for esrd on dialysis,Q2047,"INJECTION, PEGINESATIDE, 0.1 MG (FOR ESRD ON DIALYSIS)",36.71255772688167,,Present in Autoproposal
J3591,Unclassified drug or biological used for esrd on dialysis,J0890,"INJECTION, PEGINESATIDE, 0.1 MG (FOR ESRD ON DIALYSIS)",36.71255772688167,,Present in Autoproposal
J3591,Unclassified drug or biological used for esrd on dialysis,J0604,"CINACALCET, ORAL, 1 MG, (FOR ESRD ON DIALYSIS)",34.83297240218632,,Present in Autoproposal
J3591,Unclassified drug or biological used for esrd on dialysis,J3590,UNCLASSIFIED BIOLOGICS,33.978398771357085,,Present Both in MD and Autoproposal
J3591,Unclassified drug or biological used for esrd on dialysis,Q4082,"DRUG OR BIOLOGICAL, NOT OTHERWISE CLASSIFIED, PART B DRUG COMPETITIVE ACQUISITION PROGRAM (CAP)",33.71703644232894,,Present in Autoproposal
J3591,Unclassified drug or biological used for esrd on dialysis,C9399,UNCLASSIFIED DRUGS OR BIOLOGICALS,33.538641892224035,,Present in Autoproposal
J3591,Unclassified drug or biological used for esrd on dialysis,J0887,"INJECTION, EPOETIN BETA, 1 MICROGRAM, (FOR ESRD ON DIALYSIS)",32.291831135367126,,Present in Autoproposal
J3591,Unclassified drug or biological used for esrd on dialysis,Q9972,"INJECTION, EPOETIN BETA, 1 MICROGRAM, (FOR ESRD ON DIALYSIS)",32.291831135367126,,Present in Autoproposal
J7177,"Injection, human fibrinogen concentrate (fibryga), 1 mg",J7178,"INJECTION, HUMAN FIBRINOGEN CONCENTRATE, 1 MG",100.0,1,Present Both in MD and Autoproposal
J7177,"Injection, human fibrinogen concentrate (fibryga), 1 mg",Q2045,"INJECTION, HUMAN FIBRINOGEN CONCENTRATE, 1 MG",100.0,,Present in Autoproposal
J7177,"Injection, human fibrinogen concentrate (fibryga), 1 mg",J1680,"INJECTION, HUMAN FIBRINOGEN CONCENTRATE, 100 MG",93.11209387566859,,Present in Autoproposal
J7177,"Injection, human fibrinogen concentrate (fibryga), 1 mg",85385,Fibrinogen; antigen,50.65957374656325,,Present in Autoproposal
J7177,"Injection, human fibrinogen concentrate (fibryga), 1 mg",85384,Fibrinogen; activity,48.92076734125334,,Present in Autoproposal
J7177,"Injection, human fibrinogen concentrate (fibryga), 1 mg",J2724,"INJECTION, PROTEIN C CONCENTRATE, INTRAVENOUS, HUMAN, 10 IU",47.75259560629333,,Present in Autoproposal
J7177,"Injection, human fibrinogen concentrate (fibryga), 1 mg",P9013,UNIT/S BLOOD FIBRINOGEN,46.499973359076044,,Present in Autoproposal
J7177,"Injection, human fibrinogen concentrate (fibryga), 1 mg",J7175,"INJECTION, FACTOR X, (HUMAN), 1 I.U.",37.325556565669444,,Present in Autoproposal
J7177,"Injection, human fibrinogen concentrate (fibryga), 1 mg",C9132,"PROTHROMBIN COMPLEX CONCENTRATE (HUMAN), KCENTRA, PER I.U. OF FACTOR IX ACTIVITY",31.800728612140457,,Present in Autoproposal
J7177,"Injection, human fibrinogen concentrate (fibryga), 1 mg",C1013,"PLATELET CONCENTRATE, LEUKOREDUCED, EACH UNIT",29.102371919042813,,Present in Autoproposal
J7318,"Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg",C9465,"Hyaluronan or derivative, Durolane, for intra-articular injection, per dose",91.88447896056084,1,Present Both in MD and Autoproposal
J7318,"Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg",C9471,"HYALURONAN OR DERIVATIVE, HYMOVIS, FOR INTRA-ARTICULAR INJECTION, 1 MG",72.411129103449,,Present in Autoproposal
J7318,"Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg",J7322,"HYALURONAN OR DERIVATIVE, HYMOVIS, FOR INTRA-ARTICULAR INJECTION, 1 MG",72.411129103449,,Present in Autoproposal
J7318,"Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg",J7328,"HYALURONAN OR DERIVATIVE, GELSYN-3, FOR INTRA-ARTICULAR INJECTION, 0.1 MG",71.62331892428627,,Present in Autoproposal
J7318,"Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg",J7326,"HYALURONAN OR DERIVATIVE, GEL-ONE, FOR INTRA-ARTICULAR INJECTION, PER DOSE",66.92014389690307,,Present in Autoproposal
J7318,"Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg",Q4086,"HYALURONAN OR DERIVATIVE, ORTHOVISC, FOR INTRA-ARTICULAR INJECTION, PER DOSE",65.19560237987906,,Present in Autoproposal
J7318,"Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg",J7324,"HYALURONAN OR DERIVATIVE, ORTHOVISC, FOR INTRA-ARTICULAR INJECTION, PER DOSE",65.19560237987906,,Present in Autoproposal
J7318,"Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg",J7323,"HYALURONAN OR DERIVATIVE, EUFLEXXA, FOR INTRA-ARTICULAR INJECTION, PER DOSE",65.19560237987906,,Present in Autoproposal
J7318,"Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg",Q4084,"HYALURONAN OR DERIVATIVE, SYNVISC, FOR INTRA-ARTICULAR INJECTION, PER DOSE",65.19560237987906,,Present in Autoproposal
J7318,"Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg",Q4085,"HYALURONAN OR DERIVATIVE, EUFLEXXA, FOR INTRA-ARTICULAR INJECTION, PER DOSE",65.19560237987906,,Present in Autoproposal
J7329,"Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg",C9471,"HYALURONAN OR DERIVATIVE, HYMOVIS, FOR INTRA-ARTICULAR INJECTION, 1 MG",85.5614426508772,7,Present in Autoproposal
J7329,"Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg",J7322,"HYALURONAN OR DERIVATIVE, HYMOVIS, FOR INTRA-ARTICULAR INJECTION, 1 MG",85.5614426508772,,Present in Autoproposal
J7329,"Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg",J7328,"HYALURONAN OR DERIVATIVE, GELSYN-3, FOR INTRA-ARTICULAR INJECTION, 0.1 MG",84.63056122009723,,Present in Autoproposal
J7329,"Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg",J7326,"HYALURONAN OR DERIVATIVE, GEL-ONE, FOR INTRA-ARTICULAR INJECTION, PER DOSE",79.07326021726952,,Present in Autoproposal
J7329,"Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg",Q4086,"HYALURONAN OR DERIVATIVE, ORTHOVISC, FOR INTRA-ARTICULAR INJECTION, PER DOSE",77.03553118397267,,Present in Autoproposal
J7329,"Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg",J7324,"HYALURONAN OR DERIVATIVE, ORTHOVISC, FOR INTRA-ARTICULAR INJECTION, PER DOSE",77.03553118397267,,Present in Autoproposal
J7329,"Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg",J7323,"HYALURONAN OR DERIVATIVE, EUFLEXXA, FOR INTRA-ARTICULAR INJECTION, PER DOSE",77.03553118397267,,Present Both in MD and Autoproposal
J7329,"Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg",Q4084,"HYALURONAN OR DERIVATIVE, SYNVISC, FOR INTRA-ARTICULAR INJECTION, PER DOSE",77.03553118397267,,Present in Autoproposal
J7329,"Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg",Q4085,"HYALURONAN OR DERIVATIVE, EUFLEXXA, FOR INTRA-ARTICULAR INJECTION, PER DOSE",77.03553118397267,,Present in Autoproposal
J7329,"Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg",J7319,"HYALURONAN (SODIUM HYALURONATE) OR DERIVATIVE, INTRA-ARTICULAR INJECTION, PER INJECTION",76.33333477452486,,Present in Autoproposal
J9044,"Injection, bortezomib, not otherwise specified, 0.1 mg",J9041,"INJECTION, BORTEZOMIB, 0.1 MG",78.15194045423146,1,Present Both in MD and Autoproposal
J9044,"Injection, bortezomib, not otherwise specified, 0.1 mg",C9207,"INJECTION, BORTEZOMIB, PER 3.5 MG",74.22654997168291,,Present in Autoproposal
J9044,"Injection, bortezomib, not otherwise specified, 0.1 mg",S0115,"BORTEZOMIB, 3.5 MG",73.42914989721392,,Present in Autoproposal
J9044,"Injection, bortezomib, not otherwise specified, 0.1 mg",T5999,"SUPPLY, NOT OTHERWISE SPECIFIED",51.51947654731911,,Present in Autoproposal
J9044,"Injection, bortezomib, not otherwise specified, 0.1 mg",J0833,"INJECTION, COSYNTROPIN, NOT OTHERWISE SPECIFIED, 0.25 MG",50.42589256628636,,Present in Autoproposal
J9044,"Injection, bortezomib, not otherwise specified, 0.1 mg",84591,"Vitamin, not otherwise specified",47.79244301568693,,Present in Autoproposal
J9044,"Injection, bortezomib, not otherwise specified, 0.1 mg",J0220,"INJECTION, ALGLUCOSIDASE ALFA, 10 MG, NOT OTHERWISE SPECIFIED",46.6063499286053,,Present in Autoproposal
J9044,"Injection, bortezomib, not otherwise specified, 0.1 mg",L1499,"SPINAL ORTHOSIS, NOT OTHERWISE SPECIFIED",46.4869874799741,,Present in Autoproposal
J9044,"Injection, bortezomib, not otherwise specified, 0.1 mg",L8039,"BREAST PROSTHESIS, NOT OTHERWISE SPECIFIED",46.31933695344734,,Present in Autoproposal
J9044,"Injection, bortezomib, not otherwise specified, 0.1 mg",J3301,"INJECTION, TRIAMCINOLONE ACETONIDE, NOT OTHERWISE SPECIFIED, 10 MG",45.73676959412902,,Present in Autoproposal
L8608,"Miscellaneous external component, supply or accessory for use with the argus ii retinal prosthesis system",Q0507,MISCELLANEOUS SUPPLY OR ACCESSORY FOR USE WITH AN EXTERNAL VENTRICULAR ASSIST DEVICE,55.485578820708525,9,Present in Autoproposal
L8608,"Miscellaneous external component, supply or accessory for use with the argus ii retinal prosthesis system",Q0505,MISCELLANEOUS SUPPLY OR ACCESSORY FOR USE WITH VENTRICULAR ASSIST DEVICE,52.019229838597504,,Present in Autoproposal
L8608,"Miscellaneous external component, supply or accessory for use with the argus ii retinal prosthesis system",Q0508,MISCELLANEOUS SUPPLY OR ACCESSORY FOR USE WITH AN IMPLANTED VENTRICULAR ASSIST DEVICE,46.311840854538325,,Present in Autoproposal
L8608,"Miscellaneous external component, supply or accessory for use with the argus ii retinal prosthesis system",A9900,"MISCELLANEOUS DME SUPPLY, ACCESSORY, AND/OR SERVICE COMPONENT OF ANOTHER HCPCS CODE",44.28978738530238,,Present in Autoproposal
L8608,"Miscellaneous external component, supply or accessory for use with the argus ii retinal prosthesis system",A4649,SURGICAL SUPPLY; MISCELLANEOUS,44.26942786163532,,Present in Autoproposal
L8608,"Miscellaneous external component, supply or accessory for use with the argus ii retinal prosthesis system",A9999,"MISCELLANEOUS DME SUPPLY OR ACCESSORY, NOT OTHERWISE SPECIFIED",42.110289664309455,,Present in Autoproposal
L8608,"Miscellaneous external component, supply or accessory for use with the argus ii retinal prosthesis system",A4421,OSTOMY SUPPLY; MISCELLANEOUS,41.65217541652233,,Present in Autoproposal
L8608,"Miscellaneous external component, supply or accessory for use with the argus ii retinal prosthesis system",A4335,INCONTINENCE SUPPLY; MISCELLANEOUS,41.09341515411693,,Present in Autoproposal
L8608,"Miscellaneous external component, supply or accessory for use with the argus ii retinal prosthesis system",C1841,"RETINAL PROSTHESIS, INCLUDES ALL INTERNAL AND EXTERNAL COMPONENTS",37.82718184144764,,Present Both in MD and Autoproposal
L8608,"Miscellaneous external component, supply or accessory for use with the argus ii retinal prosthesis system",Q0509,MISCELLANEOUS SUPPLY OR ACCESSORY FOR USE WITH ANY IMPLANTED VENTRICULAR ASSIST DEVICE FOR WHICH PAYMENT WAS NOT MADE UNDER MEDICARE PART A,33.57959627715165,,Present in Autoproposal
L8698,"Miscellaneous component, supply or accessory for use with total artificial heart system",Q0505,MISCELLANEOUS SUPPLY OR ACCESSORY FOR USE WITH VENTRICULAR ASSIST DEVICE,55.9729765086112,3,Present in Autoproposal
L8698,"Miscellaneous component, supply or accessory for use with total artificial heart system",Q0507,MISCELLANEOUS SUPPLY OR ACCESSORY FOR USE WITH AN EXTERNAL VENTRICULAR ASSIST DEVICE,51.255297902805886,,Present in Autoproposal
L8698,"Miscellaneous component, supply or accessory for use with total artificial heart system",Q0508,MISCELLANEOUS SUPPLY OR ACCESSORY FOR USE WITH AN IMPLANTED VENTRICULAR ASSIST DEVICE,49.83179467025157,,Present Both in MD and Autoproposal
L8698,"Miscellaneous component, supply or accessory for use with total artificial heart system",0053T,"Replacement or repair of implantable component or components of total replacement heart system (artificial heart), excluding thoracic unit",48.42995916027682,,Present in Autoproposal
L8698,"Miscellaneous component, supply or accessory for use with total artificial heart system",A9900,"MISCELLANEOUS DME SUPPLY, ACCESSORY, AND/OR SERVICE COMPONENT OF ANOTHER HCPCS CODE",47.65605405117916,,Present in Autoproposal
L8698,"Miscellaneous component, supply or accessory for use with total artificial heart system",A4649,SURGICAL SUPPLY; MISCELLANEOUS,47.63414709208964,,Present in Autoproposal
L8698,"Miscellaneous component, supply or accessory for use with total artificial heart system",33928,Removal and replacement of total replacement heart system (artificial heart),47.24383472802195,,Present in Autoproposal
L8698,"Miscellaneous component, supply or accessory for use with total artificial heart system",33929,Removal of a total replacement heart system (artificial heart) for heart transplantation (List separately in addition to code for primary procedure),45.80918044959119,,Present in Autoproposal
L8698,"Miscellaneous component, supply or accessory for use with total artificial heart system",A9999,"MISCELLANEOUS DME SUPPLY OR ACCESSORY, NOT OTHERWISE SPECIFIED",45.31090255400741,,Present in Autoproposal
L8698,"Miscellaneous component, supply or accessory for use with total artificial heart system",A4421,OSTOMY SUPPLY; MISCELLANEOUS,44.817969111716764,,Present in Autoproposal
L8701,"Powered upper extremity range of motion assist device, elbow, wrist, hand with single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated",E1806,"STATIC PROGRESSIVE STRETCH WRIST DEVICE, FLEXION AND/OR EXTENSION, WITH OR WITHOUT RANGE OF MOTION ADJUSTMENT, INCLUDES ALL COMPONENTS AND ACCESSORIES",42.08844641230135,10,Present in Autoproposal
L8701,"Powered upper extremity range of motion assist device, elbow, wrist, hand with single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated",E1801,"STATIC PROGRESSIVE STRETCH ELBOW DEVICE, EXTENSION AND/OR FLEXION, WITH OR WITHOUT RANGE OF MOTION ADJUSTMENT, INCLUDES ALL COMPONENTS AND ACCESSORIES",41.97728513915647,,Present in Autoproposal
L8701,"Powered upper extremity range of motion assist device, elbow, wrist, hand with single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated",E1841,"STATIC PROGRESSIVE STRETCH SHOULDER DEVICE, WITH OR WITHOUT RANGE OF MOTION ADJUSTMENT, INCLUDES ALL COMPONENTS AND ACCESSORIES",40.012536160340076,,Present in Autoproposal
L8701,"Powered upper extremity range of motion assist device, elbow, wrist, hand with single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated",L3720,"ELBOW ORTHOSIS, DOUBLE UPRIGHT WITH FOREARM/ARM CUFFS, FREE MOTION, CUSTOM FABRICATED",39.501554612587235,,Present in Autoproposal
L8701,"Powered upper extremity range of motion assist device, elbow, wrist, hand with single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated",E1811,"STATIC PROGRESSIVE STRETCH KNEE DEVICE, EXTENSION AND/OR FLEXION, WITH OR WITHOUT RANGE OF MOTION ADJUSTMENT, INCLUDES ALL COMPONENTS AND ACCESSORIES",37.89101788244582,,Present in Autoproposal
L8701,"Powered upper extremity range of motion assist device, elbow, wrist, hand with single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated",E1816,"STATIC PROGRESSIVE STRETCH ANKLE DEVICE, FLEXION AND/OR EXTENSION, WITH OR WITHOUT RANGE OF MOTION ADJUSTMENT, INCLUDES ALL COMPONENTS AND ACCESSORIES",37.61982230238749,,Present in Autoproposal
L8701,"Powered upper extremity range of motion assist device, elbow, wrist, hand with single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated",E1831,"STATIC PROGRESSIVE STRETCH TOE DEVICE, EXTENSION AND/OR FLEXION, WITH OR WITHOUT RANGE OF MOTION ADJUSTMENT, INCLUDES ALL COMPONENTS AND ACCESSORIES",37.291587808277136,,Present in Autoproposal
L8701,"Powered upper extremity range of motion assist device, elbow, wrist, hand with single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated",L3730,"ELBOW ORTHOSIS, DOUBLE UPRIGHT WITH FOREARM/ARM CUFFS, EXTENSION/ FLEXION ASSIST, CUSTOM FABRICATED",37.250850922053715,,Present in Autoproposal
L8701,"Powered upper extremity range of motion assist device, elbow, wrist, hand with single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated",A8002,"HELMET, PROTECTIVE, SOFT, CUSTOM FABRICATED, INCLUDES ALL COMPONENTS AND ACCESSORIES",35.61546304076826,,Present in Autoproposal
L8701,"Powered upper extremity range of motion assist device, elbow, wrist, hand with single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated",L3904,"WRIST HAND FINGER ORTHOSIS, EXTERNAL POWERED, ELECTRIC, CUSTOM FABRICATED",35.53469535772377,,Present Both in MD and Autoproposal
L8702,"Powered upper extremity range of motion assist device, elbow, wrist, hand, finger, single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated",L3904,"WRIST HAND FINGER ORTHOSIS, EXTERNAL POWERED, ELECTRIC, CUSTOM FABRICATED",41.78843889972151,1,Present Both in MD and Autoproposal
L8702,"Powered upper extremity range of motion assist device, elbow, wrist, hand, finger, single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated",E1806,"STATIC PROGRESSIVE STRETCH WRIST DEVICE, FLEXION AND/OR EXTENSION, WITH OR WITHOUT RANGE OF MOTION ADJUSTMENT, INCLUDES ALL COMPONENTS AND ACCESSORIES",40.45323545505165,,Present in Autoproposal
L8702,"Powered upper extremity range of motion assist device, elbow, wrist, hand, finger, single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated",E1801,"STATIC PROGRESSIVE STRETCH ELBOW DEVICE, EXTENSION AND/OR FLEXION, WITH OR WITHOUT RANGE OF MOTION ADJUSTMENT, INCLUDES ALL COMPONENTS AND ACCESSORIES",40.343180767127144,,Present in Autoproposal
L8702,"Powered upper extremity range of motion assist device, elbow, wrist, hand, finger, single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated",E1841,"STATIC PROGRESSIVE STRETCH SHOULDER DEVICE, WITH OR WITHOUT RANGE OF MOTION ADJUSTMENT, INCLUDES ALL COMPONENTS AND ACCESSORIES",38.312319411000715,,Present in Autoproposal
L8702,"Powered upper extremity range of motion assist device, elbow, wrist, hand, finger, single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated",L3720,"ELBOW ORTHOSIS, DOUBLE UPRIGHT WITH FOREARM/ARM CUFFS, FREE MOTION, CUSTOM FABRICATED",37.73815641999423,,Present in Autoproposal
L8702,"Powered upper extremity range of motion assist device, elbow, wrist, hand, finger, single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated",L3902,"WRIST HAND FINGER ORTHOSIS, EXTERNAL POWERED, COMPRESSED GAS, CUSTOM-FABRICATED",36.751784830252085,,Present in Autoproposal
L8702,"Powered upper extremity range of motion assist device, elbow, wrist, hand, finger, single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated",E1811,"STATIC PROGRESSIVE STRETCH KNEE DEVICE, EXTENSION AND/OR FLEXION, WITH OR WITHOUT RANGE OF MOTION ADJUSTMENT, INCLUDES ALL COMPONENTS AND ACCESSORIES",36.321477330483596,,Present in Autoproposal
L8702,"Powered upper extremity range of motion assist device, elbow, wrist, hand, finger, single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated",E1816,"STATIC PROGRESSIVE STRETCH ANKLE DEVICE, FLEXION AND/OR EXTENSION, WITH OR WITHOUT RANGE OF MOTION ADJUSTMENT, INCLUDES ALL COMPONENTS AND ACCESSORIES",36.06151534836488,,Present in Autoproposal
L8702,"Powered upper extremity range of motion assist device, elbow, wrist, hand, finger, single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated",E1831,"STATIC PROGRESSIVE STRETCH TOE DEVICE, EXTENSION AND/OR FLEXION, WITH OR WITHOUT RANGE OF MOTION ADJUSTMENT, INCLUDES ALL COMPONENTS AND ACCESSORIES",35.746877146406334,,Present in Autoproposal
L8702,"Powered upper extremity range of motion assist device, elbow, wrist, hand, finger, single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated",L3730,"ELBOW ORTHOSIS, DOUBLE UPRIGHT WITH FOREARM/ARM CUFFS, EXTENSION/ FLEXION ASSIST, CUSTOM FABRICATED",35.57779677951532,,Present in Autoproposal
Q5105,"Injection, epoetin alfa, biosimilar, (Retacrit) (for esrd on dialysis), 100 units",Q4081,"INJECTION, EPOETIN ALFA, 100 UNITS (FOR ESRD ON DIALYSIS)",89.56841961911378,1,Present Both in MD and Autoproposal
Q5105,"Injection, epoetin alfa, biosimilar, (Retacrit) (for esrd on dialysis), 100 units",Q4055,"INJECTION, EPOETIN ALFA, 1000 UNITS (FOR ESRD ON DIALYSIS)",78.42133490808602,,Present in Autoproposal
Q5105,"Injection, epoetin alfa, biosimilar, (Retacrit) (for esrd on dialysis), 100 units",J0886,"INJECTION, EPOETIN ALFA, 1000 UNITS (FOR ESRD ON DIALYSIS)",78.42133490808602,,Present in Autoproposal
Q5105,"Injection, epoetin alfa, biosimilar, (Retacrit) (for esrd on dialysis), 100 units",J0885,"INJECTION, EPOETIN ALFA, (FOR NON-ESRD USE), 1000 UNITS",64.26751505068272,,Present in Autoproposal
Q5105,"Injection, epoetin alfa, biosimilar, (Retacrit) (for esrd on dialysis), 100 units",Q9972,"INJECTION, EPOETIN BETA, 1 MICROGRAM, (FOR ESRD ON DIALYSIS)",55.81056490192488,,Present in Autoproposal
Q5105,"Injection, epoetin alfa, biosimilar, (Retacrit) (for esrd on dialysis), 100 units",J0887,"INJECTION, EPOETIN BETA, 1 MICROGRAM, (FOR ESRD ON DIALYSIS)",55.81056490192488,,Present in Autoproposal
Q5105,"Injection, epoetin alfa, biosimilar, (Retacrit) (for esrd on dialysis), 100 units",Q4054,"INJECTION, DARBEPOETIN ALFA, 1 MCG (FOR ESRD ON DIALYSIS)",50.183097936735145,,Present in Autoproposal
Q5105,"Injection, epoetin alfa, biosimilar, (Retacrit) (for esrd on dialysis), 100 units",J0882,"INJECTION, DARBEPOETIN ALFA, 1 MICROGRAM (FOR ESRD ON DIALYSIS)",49.119878282653545,,Present in Autoproposal
Q5105,"Injection, epoetin alfa, biosimilar, (Retacrit) (for esrd on dialysis), 100 units",Q0136,"INJECTION, EPOETIN ALPHA, (FOR NON ESRD USE), PER 1000 UNITS",48.32541240597658,,Present in Autoproposal
Q5105,"Injection, epoetin alfa, biosimilar, (Retacrit) (for esrd on dialysis), 100 units",C9271,"INJECTION, VELAGLUCERASE ALFA, 100 UNITS",46.20262023204869,,Present in Autoproposal
Q5106,"Injection, epoetin alfa, biosimilar, (Retacrit) (for non-esrd use), 1000 units",J0885,"INJECTION, EPOETIN ALFA, (FOR NON-ESRD USE), 1000 UNITS",89.55195913600392,1,Present Both in MD and Autoproposal
Q5106,"Injection, epoetin alfa, biosimilar, (Retacrit) (for non-esrd use), 1000 units",J0886,"INJECTION, EPOETIN ALFA, 1000 UNITS (FOR ESRD ON DIALYSIS)",76.12346449418479,,Present in Autoproposal
Q5106,"Injection, epoetin alfa, biosimilar, (Retacrit) (for non-esrd use), 1000 units",Q4055,"INJECTION, EPOETIN ALFA, 1000 UNITS (FOR ESRD ON DIALYSIS)",76.12346449418479,,Present in Autoproposal
Q5106,"Injection, epoetin alfa, biosimilar, (Retacrit) (for non-esrd use), 1000 units",Q0136,"INJECTION, EPOETIN ALPHA, (FOR NON ESRD USE), PER 1000 UNITS",73.18605397494353,,Present in Autoproposal
Q5106,"Injection, epoetin alfa, biosimilar, (Retacrit) (for non-esrd use), 1000 units",Q4081,"INJECTION, EPOETIN ALFA, 100 UNITS (FOR ESRD ON DIALYSIS)",64.2557042545282,,Present in Autoproposal
Q5106,"Injection, epoetin alfa, biosimilar, (Retacrit) (for non-esrd use), 1000 units",J0888,"INJECTION, EPOETIN BETA, 1 MICROGRAM, (FOR NON ESRD USE)",52.293417458775295,,Present in Autoproposal
Q5106,"Injection, epoetin alfa, biosimilar, (Retacrit) (for non-esrd use), 1000 units",Q9973,"INJECTION, EPOETIN BETA, 1 MICROGRAM, (NON-ESRD USE)",50.78530527544651,,Present in Autoproposal
Q5106,"Injection, epoetin alfa, biosimilar, (Retacrit) (for non-esrd use), 1000 units",C1774,"INJECTION, DARBEPOETIN ALFA (FOR NON ESRD USE), PER 1 MCG",45.45993188099874,,Present in Autoproposal
Q5106,"Injection, epoetin alfa, biosimilar, (Retacrit) (for non-esrd use), 1000 units",Q0137,"INJECTION, DARBEPOETIN ALFA, 1 MCG (NON-ESRD USE)",44.913239895842494,,Present in Autoproposal
Q5106,"Injection, epoetin alfa, biosimilar, (Retacrit) (for non-esrd use), 1000 units",J0881,"INJECTION, DARBEPOETIN ALFA, 1 MICROGRAM (NON-ESRD USE)",43.878278564976156,,Present in Autoproposal
Q5108,"Injection, pegfilgrastim-jmdb, biosimilar, (fulphila), 0.5 mg",J2505,"INJECTION, PEGFILGRASTIM, 6 MG",77.08494550584456,1,Present Both in MD and Autoproposal
Q5108,"Injection, pegfilgrastim-jmdb, biosimilar, (fulphila), 0.5 mg",Q4053,"INJECTION, PEGFILGRASTIM, 1 MG",77.08494550584456,,Present in Autoproposal
Q5108,"Injection, pegfilgrastim-jmdb, biosimilar, (fulphila), 0.5 mg",S0135,"INJECTION, PEGFILGRASTIM, 6 MG",77.08494550584456,,Present in Autoproposal
Q5108,"Injection, pegfilgrastim-jmdb, biosimilar, (fulphila), 0.5 mg",C9119,"INJECTION, PEGFILGRASTIM, PER 6 MG SINGLE DOSE VIAL",54.52092587381399,,Present in Autoproposal
Q5108,"Injection, pegfilgrastim-jmdb, biosimilar, (fulphila), 0.5 mg",Q5102,"INJECTION, INFLIXIMAB, BIOSIMILAR, 10 MG",53.30663626715471,,Present in Autoproposal
Q5108,"Injection, pegfilgrastim-jmdb, biosimilar, (fulphila), 0.5 mg",J1745,"INJECTION, INFLIXIMAB, EXCLUDES BIOSIMILAR, 10 MG",47.269193990944494,,Present in Autoproposal
Q5108,"Injection, pegfilgrastim-jmdb, biosimilar, (fulphila), 0.5 mg",Q5103,"Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg",38.30281058484692,,Present in Autoproposal
Q5108,"Injection, pegfilgrastim-jmdb, biosimilar, (fulphila), 0.5 mg",Q5104,"Injection, infliximab-abda, biosimilar, (renflexis), 10 mg",38.30281058484692,,Present in Autoproposal
Q5108,"Injection, pegfilgrastim-jmdb, biosimilar, (fulphila), 0.5 mg",Q5110,"Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram",31.910439927058498,,Present in Autoproposal
Q5108,"Injection, pegfilgrastim-jmdb, biosimilar, (fulphila), 0.5 mg",Q5101,"Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram",31.910439927058498,,Present in Autoproposal
Q5510,"Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram",Q5110,"Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram",100.0,4,Present in Autoproposal
Q5510,"Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram",Q5101,"Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram",53.25108434912522,,Present Both in MD and Autoproposal
Q5510,"Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram",J1447,"INJECTION, TBO-FILGRASTIM, 1 MICROGRAM",46.668719627514875,,Present in Autoproposal
Q5510,"Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram",J1442,"INJECTION, FILGRASTIM (G-CSF), EXCLUDES BIOSIMILARS, 1 MICROGRAM",37.38172422335934,,Present Both in MD and Autoproposal
Q5510,"Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram",Q5102,"INJECTION, INFLIXIMAB, BIOSIMILAR, 10 MG",30.1658094875,,Present in Autoproposal
Q5510,"Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram",J2278,"INJECTION, ZICONOTIDE, 1 MICROGRAM",28.54246380168433,,Present in Autoproposal
Q5510,"Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram",J9039,"INJECTION, BLINATUMOMAB, 1 MICROGRAM",28.093813632936033,,Present in Autoproposal
Q5510,"Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram",J1446,"INJECTION, TBO-FILGRASTIM, 5 MICROGRAMS",27.445462506077707,,Present in Autoproposal
Q5510,"Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram",J1440,"INJECTION, FILGRASTIM (G-CSF), 300 MCG",27.099976898099403,,Present in Autoproposal
Q5510,"Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram",J1745,"INJECTION, INFLIXIMAB, EXCLUDES BIOSIMILAR, 10 MG",26.74926801631824,,Present in Autoproposal
Q9991,"Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg",J0572,"BUPRENORPHINE/NALOXONE, ORAL, LESS THAN OR EQUAL TO 3 MG BUPRENORPHINE",62.300156854799326,10,Present in Autoproposal
Q9991,"Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg",J0573,"BUPRENORPHINE/NALOXONE, ORAL, GREATER THAN 3 MG, BUT LESS THAN OR EQUAL TO 6 MG BUPRENORPHINE",61.26720273348234,,Present in Autoproposal
Q9991,"Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg",J0574,"BUPRENORPHINE/NALOXONE, ORAL, GREATER THAN 6 MG, BUT LESS THAN OR EQUAL TO 10 MG BUPRENORPHINE",60.12591912414567,,Present in Autoproposal
Q9991,"Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg",C9486,"INJECTION, GRANISETRON EXTENDED RELEASE, 0.1 MG",49.03080823323744,,Present in Autoproposal
Q9991,"Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg",J1627,"INJECTION, GRANISETRON, EXTENDED-RELEASE, 0.1 MG",49.03080823323744,,Present in Autoproposal
Q9991,"Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg",80348,Buprenorphine,48.48397039007493,,Present in Autoproposal
Q9991,"Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg",J0401,"INJECTION, ARIPIPRAZOLE, EXTENDED RELEASE, 1 MG",48.33599326160889,,Present in Autoproposal
Q9991,"Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg",J0592,"INJECTION, BUPRENORPHINE HYDROCHLORIDE, 0.1 MG",48.19002642308595,,Present in Autoproposal
Q9991,"Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg",J0571,"BUPRENORPHINE, ORAL, 1 MG",46.206882393692425,,Present in Autoproposal
Q9991,"Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg",J0575,"BUPRENORPHINE/NALOXONE, ORAL, GREATER THAN 10 MG BUPRENORPHINE",46.13880296460884,,Present in Autoproposal
Q9992,"Injection, buprenorphine extended-release (sublocade), greater than 100 mg",J0575,"BUPRENORPHINE/NALOXONE, ORAL, GREATER THAN 10 MG BUPRENORPHINE",56.71645207610672,10,Present in Autoproposal
Q9992,"Injection, buprenorphine extended-release (sublocade), greater than 100 mg",J0573,"BUPRENORPHINE/NALOXONE, ORAL, GREATER THAN 3 MG, BUT LESS THAN OR EQUAL TO 6 MG BUPRENORPHINE",56.26953948819923,,Present in Autoproposal
Q9992,"Injection, buprenorphine extended-release (sublocade), greater than 100 mg",J0574,"BUPRENORPHINE/NALOXONE, ORAL, GREATER THAN 6 MG, BUT LESS THAN OR EQUAL TO 10 MG BUPRENORPHINE",55.221352199444354,,Present in Autoproposal
Q9992,"Injection, buprenorphine extended-release (sublocade), greater than 100 mg",J1627,"INJECTION, GRANISETRON, EXTENDED-RELEASE, 0.1 MG",52.52673131210865,,Present in Autoproposal
Q9992,"Injection, buprenorphine extended-release (sublocade), greater than 100 mg",C9486,"INJECTION, GRANISETRON EXTENDED RELEASE, 0.1 MG",52.52673131210865,,Present in Autoproposal
Q9992,"Injection, buprenorphine extended-release (sublocade), greater than 100 mg",80348,Buprenorphine,51.94090363571276,,Present in Autoproposal
Q9992,"Injection, buprenorphine extended-release (sublocade), greater than 100 mg",J0401,"INJECTION, ARIPIPRAZOLE, EXTENDED RELEASE, 1 MG",51.782375658154265,,Present in Autoproposal
Q9992,"Injection, buprenorphine extended-release (sublocade), greater than 100 mg",J0592,"INJECTION, BUPRENORPHINE HYDROCHLORIDE, 0.1 MG",51.62600130529638,,Present in Autoproposal
Q9992,"Injection, buprenorphine extended-release (sublocade), greater than 100 mg",J0571,"BUPRENORPHINE, ORAL, 1 MG",49.5014580367122,,Present in Autoproposal
Q9992,"Injection, buprenorphine extended-release (sublocade), greater than 100 mg",J0572,"BUPRENORPHINE/NALOXONE, ORAL, LESS THAN OR EQUAL TO 3 MG BUPRENORPHINE",48.72705538532711,,Present in Autoproposal
Q9994,"In-line cartridge containing digestive enzyme(s) for enteral feeding, each",S9300,"NURSING SERVICES AND ALL NECESSARY SUPPLIES FOR HOME ENTERAL FEEDING BY GRAVITY, PER DIEM (ENTERAL FORMULA NOT INCLUDED)",31.563949285734694,10,Present in Autoproposal
Q9994,"In-line cartridge containing digestive enzyme(s) for enteral feeding, each",A4672,"DRAINAGE EXTENSION LINE, STERILE, FOR DIALYSIS, EACH",28.996720160213908,,Present in Autoproposal
Q9994,"In-line cartridge containing digestive enzyme(s) for enteral feeding, each",K0612,"DRAINAGE EXTENSION LINE, STERILE, FOR DIALYSIS, EACH",28.996720160213908,,Present in Autoproposal
Q9994,"In-line cartridge containing digestive enzyme(s) for enteral feeding, each",S9308,"NURSING SERVICES AND ALL NECESSARY SUPPLIES FOR HOME ENTERAL FEEDING BY PUMP, INCLUDING PUMP RENTAL, PER DIEM (ENTERAL FORMULA NOT INCLUDED)",28.866334365366132,,Present in Autoproposal
Q9994,"In-line cartridge containing digestive enzyme(s) for enteral feeding, each",J7304,"CONTRACEPTIVE SUPPLY, HORMONE CONTAINING PATCH, EACH",28.361355939322188,,Present in Autoproposal
Q9994,"In-line cartridge containing digestive enzyme(s) for enteral feeding, each",D5951,FEEDING AID,27.938685573225143,,Present in Autoproposal
Q9994,"In-line cartridge containing digestive enzyme(s) for enteral feeding, each",B4156,"ENTERAL FORMULAE; CATEGORY VI; STANDARDIZED NUTRIENTS, ADMINISTERED THROUGH AN ENTERAL FEEDING TUBE, 100 CALORIES = 1 UNIT",27.264132888668424,,Present in Autoproposal
Q9994,"In-line cartridge containing digestive enzyme(s) for enteral feeding, each",J7303,"CONTRACEPTIVE SUPPLY, HORMONE CONTAINING VAGINAL RING, EACH",26.359696824521215,,Present in Autoproposal
Q9994,"In-line cartridge containing digestive enzyme(s) for enteral feeding, each",B4035,"ENTERAL FEEDING SUPPLY KIT; PUMP FED, PER DAY, INCLUDES BUT NOT LIMITED TO FEEDING/FLUSHING SYRINGE, ADMINISTRATION SET TUBING, DRESSINGS, TAPE",25.250303803633212,,Present in Autoproposal
Q9994,"In-line cartridge containing digestive enzyme(s) for enteral feeding, each",B4151,"ENTERAL FORMULAE; CATEGORY I; NATURAL INTACT PROTEIN/PROTEIN ISOLATES, ADMINISTERED THROUGH AN ENTERAL FEEDING TUBE, 100 CALORIES = 1 UNIT",25.03211501859861,,Present in Autoproposal
Q9995,"Injection, emicizumab-kxwh, 0.5 mg",J9267,"INJECTION, PACLITAXEL, 1 MG",52.950885430632866,10,Present in Autoproposal
Q9995,"Injection, emicizumab-kxwh, 0.5 mg",J9280,"INJECTION, MITOMYCIN, 5 MG",52.950885430632866,,Present in Autoproposal
Q9995,"Injection, emicizumab-kxwh, 0.5 mg",Q2046,"INJECTION, AFLIBERCEPT, 1 MG",52.316794577196156,,Present in Autoproposal
Q9995,"Injection, emicizumab-kxwh, 0.5 mg",J0202,"INJECTION, ALEMTUZUMAB, 1 MG",52.316794577196156,,Present in Autoproposal
Q9995,"Injection, emicizumab-kxwh, 0.5 mg",J0178,"INJECTION, AFLIBERCEPT, 1 MG",52.316794577196156,,Present in Autoproposal
Q9995,"Injection, emicizumab-kxwh, 0.5 mg",J3396,"INJECTION, VERTEPORFIN, 0.1 MG",52.316794577196156,,Present in Autoproposal
Q9995,"Injection, emicizumab-kxwh, 0.5 mg",C9261,"INJECTION, USTEKINUMAB, 1 MG",52.316794577196156,,Present in Autoproposal
Q9995,"Injection, emicizumab-kxwh, 0.5 mg",J1325,"INJECTION, EPOPROSTENOL, 0.5 MG",52.316794577196156,,Present in Autoproposal
Q9995,"Injection, emicizumab-kxwh, 0.5 mg",Q9979,"INJECTION, ALEMTUZUMAB, 1 MG",52.316794577196156,,Present in Autoproposal
Q9995,"Injection, emicizumab-kxwh, 0.5 mg",J2505,"INJECTION, PEGFILGRASTIM, 6 MG",51.58259659366726,,Present in Autoproposal
T4545,"Incontinence product, disposable, penile wrap, each",T4541,"INCONTINENCE PRODUCT, DISPOSABLE UNDERPAD, LARGE, EACH",50.93770517445404,10,Present in Autoproposal
T4545,"Incontinence product, disposable, penile wrap, each",T4542,"INCONTINENCE PRODUCT, DISPOSABLE UNDERPAD, SMALL SIZE, EACH",49.014689287376804,,Present in Autoproposal
T4545,"Incontinence product, disposable, penile wrap, each",E0459,CHEST WRAP,43.084860453742536,,Present in Autoproposal
T4545,"Incontinence product, disposable, penile wrap, each",T4521,"ADULT SIZED DISPOSABLE INCONTINENCE PRODUCT, BRIEF/DIAPER, SMALL, EACH",42.50004487005848,,Present in Autoproposal
T4545,"Incontinence product, disposable, penile wrap, each",T4533,"YOUTH SIZED DISPOSABLE INCONTINENCE PRODUCT, BRIEF/DIAPER, EACH",42.324632243730385,,Present in Autoproposal
T4545,"Incontinence product, disposable, penile wrap, each",T4523,"ADULT SIZED DISPOSABLE INCONTINENCE PRODUCT, BRIEF/DIAPER, LARGE, EACH",41.99560813878407,,Present in Autoproposal
T4545,"Incontinence product, disposable, penile wrap, each",T4522,"ADULT SIZED DISPOSABLE INCONTINENCE PRODUCT, BRIEF/DIAPER, MEDIUM, EACH",41.186054861465905,,Present in Autoproposal
T4545,"Incontinence product, disposable, penile wrap, each",T4530,"PEDIATRIC SIZED DISPOSABLE INCONTINENCE PRODUCT, BRIEF/DIAPER, LARGE SIZE, EACH",40.594642082525965,,Present in Autoproposal
T4545,"Incontinence product, disposable, penile wrap, each",T4524,"ADULT SIZED DISPOSABLE INCONTINENCE PRODUCT, BRIEF/DIAPER, EXTRA LARGE, EACH",39.59725874046276,,Present in Autoproposal
T4545,"Incontinence product, disposable, penile wrap, each",T4529,"PEDIATRIC SIZED DISPOSABLE INCONTINENCE PRODUCT, BRIEF/DIAPER, SMALL/MEDIUM SIZE, EACH",38.29945331034382,,Present in Autoproposal
V5171,"Hearing aid, contralateral routing device, monaural, in the ear (ite)",V5050,"HEARING AID, MONAURAL, IN THE EAR",74.10424778303538,7,Present in Autoproposal
V5171,"Hearing aid, contralateral routing device, monaural, in the ear (ite)",V5256,"HEARING AID, DIGITAL, MONAURAL, ITE",69.84873715707825,,Present in Autoproposal
V5171,"Hearing aid, contralateral routing device, monaural, in the ear (ite)",V5246,"HEARING AID, DIGITALLY PROGRAMMABLE ANALOG, MONAURAL, ITE (IN THE EAR)",68.38534151583038,,Present in Autoproposal
V5171,"Hearing aid, contralateral routing device, monaural, in the ear (ite)",V5060,"HEARING AID, MONAURAL, BEHIND THE EAR",60.78334319631542,,Present in Autoproposal
V5171,"Hearing aid, contralateral routing device, monaural, in the ear (ite)",V5260,"HEARING AID, DIGITAL, BINAURAL, ITE",51.85493834315257,,Present in Autoproposal
V5171,"Hearing aid, contralateral routing device, monaural, in the ear (ite)",V5210,"HEARING AID, BICROS, IN THE EAR",50.69165188278245,,Present in Autoproposal
V5171,"Hearing aid, contralateral routing device, monaural, in the ear (ite)",V5170,"HEARING AID, CROS, IN THE EAR",50.69165188278245,,Present Both in MD and Autoproposal
V5171,"Hearing aid, contralateral routing device, monaural, in the ear (ite)",V5242,"HEARING AID, ANALOG, MONAURAL, CIC (COMPLETELY IN THE EAR CANAL)",49.836670083305876,,Present in Autoproposal
V5171,"Hearing aid, contralateral routing device, monaural, in the ear (ite)",92592,Hearing aid check; monaural,49.735835543373994,,Present in Autoproposal
V5171,"Hearing aid, contralateral routing device, monaural, in the ear (ite)",V5262,"HEARING AID, DISPOSABLE, ANY TYPE, MONAURAL",49.21362220398164,,Present in Autoproposal
V5172,"Hearing aid, contralateral routing device, monaural, in the canal (itc)",V5243,"HEARING AID, ANALOG, MONAURAL, ITC (IN THE CANAL)",79.11391749815448,10,Present in Autoproposal
V5172,"Hearing aid, contralateral routing device, monaural, in the canal (itc)",V5255,"HEARING AID, DIGITAL, MONAURAL, ITC",69.003196086522,,Present in Autoproposal
V5172,"Hearing aid, contralateral routing device, monaural, in the canal (itc)",V5050,"HEARING AID, MONAURAL, IN THE EAR",59.398530362295034,,Present in Autoproposal
V5172,"Hearing aid, contralateral routing device, monaural, in the canal (itc)",V5245,"HEARING AID, DIGITALLY PROGRAMMABLE, ANALOG, MONAURAL, ITC",56.04109955190003,,Present in Autoproposal
V5172,"Hearing aid, contralateral routing device, monaural, in the canal (itc)",V5242,"HEARING AID, ANALOG, MONAURAL, CIC (COMPLETELY IN THE EAR CANAL)",50.81712579295847,,Present in Autoproposal
V5172,"Hearing aid, contralateral routing device, monaural, in the canal (itc)",V5259,"HEARING AID, DIGITAL, BINAURAL, ITC",50.76432299172855,,Present in Autoproposal
V5172,"Hearing aid, contralateral routing device, monaural, in the canal (itc)",92592,Hearing aid check; monaural,49.87865716874194,,Present in Autoproposal
V5172,"Hearing aid, contralateral routing device, monaural, in the canal (itc)",V5262,"HEARING AID, DISPOSABLE, ANY TYPE, MONAURAL",49.35494423942403,,Present in Autoproposal
V5172,"Hearing aid, contralateral routing device, monaural, in the canal (itc)",V5249,"HEARING AID, ANALOG, BINAURAL, ITC",49.29448015273793,,Present in Autoproposal
V5172,"Hearing aid, contralateral routing device, monaural, in the canal (itc)",92590,Hearing aid examination and selection; monaural,48.85108909743355,,Present in Autoproposal
V5181,"Hearing aid, contralateral routing device, monaural, behind the ear (bte)",V5060,"HEARING AID, MONAURAL, BEHIND THE EAR",78.49084989147296,5,Present in Autoproposal
V5181,"Hearing aid, contralateral routing device, monaural, behind the ear (bte)",V5247,"HEARING AID, DIGITALLY PROGRAMMABLE ANALOG, MONAURAL, BTE (BEHIND THE EAR)",72.60240910929951,,Present in Autoproposal
V5181,"Hearing aid, contralateral routing device, monaural, behind the ear (bte)",V5257,"HEARING AID, DIGITAL, MONAURAL, BTE",64.45538599718623,,Present in Autoproposal
V5181,"Hearing aid, contralateral routing device, monaural, behind the ear (bte)",V5050,"HEARING AID, MONAURAL, IN THE EAR",64.38141414905616,,Present in Autoproposal
V5181,"Hearing aid, contralateral routing device, monaural, behind the ear (bte)",V5180,"HEARING AID, CROS, BEHIND THE EAR",59.415456506540096,,Present Both in MD and Autoproposal
V5181,"Hearing aid, contralateral routing device, monaural, behind the ear (bte)",V5220,"HEARING AID, BICROS, BEHIND THE EAR",59.415456506540096,,Present in Autoproposal
V5181,"Hearing aid, contralateral routing device, monaural, behind the ear (bte)",V5261,"HEARING AID, DIGITAL, BINAURAL, BTE",47.850973443540504,,Present in Autoproposal
V5181,"Hearing aid, contralateral routing device, monaural, behind the ear (bte)",92592,Hearing aid check; monaural,45.89549658759845,,Present in Autoproposal
V5181,"Hearing aid, contralateral routing device, monaural, behind the ear (bte)",V5140,"BINAURAL, BEHIND THE EAR",45.544160381249114,,Present in Autoproposal
V5181,"Hearing aid, contralateral routing device, monaural, behind the ear (bte)",V5262,"HEARING AID, DISPOSABLE, ANY TYPE, MONAURAL",45.4136058085609,,Present in Autoproposal
V5211,"Hearing aid, contralateral routing system, binaural, ite/ite",V5260,"HEARING AID, DIGITAL, BINAURAL, ITE",78.51666307196747,10,Present in Autoproposal
V5211,"Hearing aid, contralateral routing system, binaural, ite/ite",V5252,"HEARING AID, DIGITALLY PROGRAMMABLE, BINAURAL, ITE",69.54336566658111,,Present in Autoproposal
V5211,"Hearing aid, contralateral routing system, binaural, ite/ite",V5256,"HEARING AID, DIGITAL, MONAURAL, ITE",63.70129448486055,,Present in Autoproposal
V5211,"Hearing aid, contralateral routing system, binaural, ite/ite",V5246,"HEARING AID, DIGITALLY PROGRAMMABLE ANALOG, MONAURAL, ITE (IN THE EAR)",48.16498278996063,,Present in Autoproposal
V5211,"Hearing aid, contralateral routing system, binaural, ite/ite",92593,Hearing aid check; binaural,40.822910494954456,,Present in Autoproposal
V5211,"Hearing aid, contralateral routing system, binaural, ite/ite",V5263,"HEARING AID, DISPOSABLE, ANY TYPE, BINAURAL",40.39182211165501,,Present in Autoproposal
V5211,"Hearing aid, contralateral routing system, binaural, ite/ite",92591,Hearing aid examination and selection; binaural,39.97715334033478,,Present in Autoproposal
V5211,"Hearing aid, contralateral routing system, binaural, ite/ite",92595,Electroacoustic evaluation for hearing aid; binaural,37.0311739987192,,Present in Autoproposal
V5211,"Hearing aid, contralateral routing system, binaural, ite/ite",V5259,"HEARING AID, DIGITAL, BINAURAL, ITC",36.83777245679357,,Present in Autoproposal
V5211,"Hearing aid, contralateral routing system, binaural, ite/ite",V5258,"HEARING AID, DIGITAL, BINAURAL, CIC",36.83777245679357,,Present in Autoproposal
V5212,"Hearing aid, contralateral routing system, binaural, ite/itc",V5260,"HEARING AID, DIGITAL, BINAURAL, ITE",68.8434121485826,10,Present in Autoproposal
V5212,"Hearing aid, contralateral routing system, binaural, ite/itc",V5259,"HEARING AID, DIGITAL, BINAURAL, ITC",67.80877458639019,,Present in Autoproposal
V5212,"Hearing aid, contralateral routing system, binaural, ite/itc",V5249,"HEARING AID, ANALOG, BINAURAL, ITC",65.84542245495777,,Present in Autoproposal
V5212,"Hearing aid, contralateral routing system, binaural, ite/itc",V5252,"HEARING AID, DIGITALLY PROGRAMMABLE, BINAURAL, ITE",60.97562475873141,,Present in Autoproposal
V5212,"Hearing aid, contralateral routing system, binaural, ite/itc",V5251,"HEARING AID, DIGITALLY PROGRAMMABLE ANALOG, BINAURAL, ITC",55.026621819359264,,Present in Autoproposal
V5212,"Hearing aid, contralateral routing system, binaural, ite/itc",V5256,"HEARING AID, DIGITAL, MONAURAL, ITE",51.158268180384624,,Present in Autoproposal
V5212,"Hearing aid, contralateral routing system, binaural, ite/itc",V5255,"HEARING AID, DIGITAL, MONAURAL, ITC",49.93642191005074,,Present in Autoproposal
V5212,"Hearing aid, contralateral routing system, binaural, ite/itc",92593,Hearing aid check; binaural,48.891086353563026,,Present in Autoproposal
V5212,"Hearing aid, contralateral routing system, binaural, ite/itc",V5263,"HEARING AID, DISPOSABLE, ANY TYPE, BINAURAL",48.37479833983808,,Present in Autoproposal
V5212,"Hearing aid, contralateral routing system, binaural, ite/itc",92591,Hearing aid examination and selection; binaural,47.8781750843931,,Present in Autoproposal
V5213,"Hearing aid, contralateral routing system, binaural, ite/bte",V5260,"HEARING AID, DIGITAL, BINAURAL, ITE",68.34669558501614,10,Present in Autoproposal
V5213,"Hearing aid, contralateral routing system, binaural, ite/bte",V5261,"HEARING AID, DIGITAL, BINAURAL, BTE",68.34669558501614,,Present in Autoproposal
V5213,"Hearing aid, contralateral routing system, binaural, ite/bte",V5252,"HEARING AID, DIGITALLY PROGRAMMABLE, BINAURAL, ITE",60.53567557773925,,Present in Autoproposal
V5213,"Hearing aid, contralateral routing system, binaural, ite/bte",V5253,"HEARING AID, DIGITALLY PROGRAMMABLE, BINAURAL, BTE",60.53567557773925,,Present in Autoproposal
V5213,"Hearing aid, contralateral routing system, binaural, ite/bte",V5256,"HEARING AID, DIGITAL, MONAURAL, ITE",50.789152844937156,,Present in Autoproposal
V5213,"Hearing aid, contralateral routing system, binaural, ite/bte",V5257,"HEARING AID, DIGITAL, MONAURAL, BTE",50.789152844937156,,Present in Autoproposal
V5213,"Hearing aid, contralateral routing system, binaural, ite/bte",92593,Hearing aid check; binaural,48.53832910861184,,Present in Autoproposal
V5213,"Hearing aid, contralateral routing system, binaural, ite/bte",V5263,"HEARING AID, DISPOSABLE, ANY TYPE, BINAURAL",48.025766197986584,,Present in Autoproposal
V5213,"Hearing aid, contralateral routing system, binaural, ite/bte",92591,Hearing aid examination and selection; binaural,47.53272616116969,,Present in Autoproposal
V5213,"Hearing aid, contralateral routing system, binaural, ite/bte",92595,Electroacoustic evaluation for hearing aid; binaural,44.02996476819694,,Present in Autoproposal
V5214,"Hearing aid, contralateral routing system, binaural, itc/itc",V5259,"HEARING AID, DIGITAL, BINAURAL, ITC",78.00284011152829,10,Present in Autoproposal
V5214,"Hearing aid, contralateral routing system, binaural, itc/itc",V5249,"HEARING AID, ANALOG, BINAURAL, ITC",75.74432647041185,,Present in Autoproposal
V5214,"Hearing aid, contralateral routing system, binaural, itc/itc",V5251,"HEARING AID, DIGITALLY PROGRAMMABLE ANALOG, BINAURAL, ITC",63.2990761127027,,Present in Autoproposal
V5214,"Hearing aid, contralateral routing system, binaural, itc/itc",V5255,"HEARING AID, DIGITAL, MONAURAL, ITC",62.71895838202227,,Present in Autoproposal
V5214,"Hearing aid, contralateral routing system, binaural, itc/itc",V5243,"HEARING AID, ANALOG, MONAURAL, ITC (IN THE CANAL)",54.538041149065165,,Present in Autoproposal
V5214,"Hearing aid, contralateral routing system, binaural, itc/itc",V5245,"HEARING AID, DIGITALLY PROGRAMMABLE, ANALOG, MONAURAL, ITC",50.937341888789966,,Present in Autoproposal
V5214,"Hearing aid, contralateral routing system, binaural, itc/itc",92593,Hearing aid check; binaural,41.679521478991674,,Present in Autoproposal
V5214,"Hearing aid, contralateral routing system, binaural, itc/itc",V5263,"HEARING AID, DISPOSABLE, ANY TYPE, BINAURAL",41.23938731625739,,Present in Autoproposal
V5214,"Hearing aid, contralateral routing system, binaural, itc/itc",92591,Hearing aid examination and selection; binaural,40.81601730781459,,Present in Autoproposal
V5214,"Hearing aid, contralateral routing system, binaural, itc/itc",92595,Electroacoustic evaluation for hearing aid; binaural,37.80822076031687,,Present in Autoproposal
V5215,"Hearing aid, contralateral routing system, binaural, itc/bte",V5261,"HEARING AID, DIGITAL, BINAURAL, BTE",68.8434121485826,10,Present in Autoproposal
V5215,"Hearing aid, contralateral routing system, binaural, itc/bte",V5259,"HEARING AID, DIGITAL, BINAURAL, ITC",67.80877458639019,,Present in Autoproposal
V5215,"Hearing aid, contralateral routing system, binaural, itc/bte",V5249,"HEARING AID, ANALOG, BINAURAL, ITC",65.84542245495777,,Present in Autoproposal
V5215,"Hearing aid, contralateral routing system, binaural, itc/bte",V5253,"HEARING AID, DIGITALLY PROGRAMMABLE, BINAURAL, BTE",60.97562475873141,,Present in Autoproposal
V5215,"Hearing aid, contralateral routing system, binaural, itc/bte",V5251,"HEARING AID, DIGITALLY PROGRAMMABLE ANALOG, BINAURAL, ITC",55.026621819359264,,Present in Autoproposal
V5215,"Hearing aid, contralateral routing system, binaural, itc/bte",V5257,"HEARING AID, DIGITAL, MONAURAL, BTE",51.158268180384624,,Present in Autoproposal
V5215,"Hearing aid, contralateral routing system, binaural, itc/bte",V5255,"HEARING AID, DIGITAL, MONAURAL, ITC",49.93642191005074,,Present in Autoproposal
V5215,"Hearing aid, contralateral routing system, binaural, itc/bte",92593,Hearing aid check; binaural,48.891086353563026,,Present in Autoproposal
V5215,"Hearing aid, contralateral routing system, binaural, itc/bte",V5263,"HEARING AID, DISPOSABLE, ANY TYPE, BINAURAL",48.37479833983808,,Present in Autoproposal
V5215,"Hearing aid, contralateral routing system, binaural, itc/bte",92591,Hearing aid examination and selection; binaural,47.8781750843931,,Present in Autoproposal
V5221,"Hearing aid, contralateral routing system, binaural, bte/bte",V5261,"HEARING AID, DIGITAL, BINAURAL, BTE",78.51666307196747,10,Present in Autoproposal
V5221,"Hearing aid, contralateral routing system, binaural, bte/bte",V5253,"HEARING AID, DIGITALLY PROGRAMMABLE, BINAURAL, BTE",69.54336566658111,,Present in Autoproposal
V5221,"Hearing aid, contralateral routing system, binaural, bte/bte",V5257,"HEARING AID, DIGITAL, MONAURAL, BTE",63.70129448486055,,Present in Autoproposal
V5221,"Hearing aid, contralateral routing system, binaural, bte/bte",V5247,"HEARING AID, DIGITALLY PROGRAMMABLE ANALOG, MONAURAL, BTE (BEHIND THE EAR)",45.11513496019391,,Present in Autoproposal
V5221,"Hearing aid, contralateral routing system, binaural, bte/bte",92593,Hearing aid check; binaural,40.822910494954456,,Present in Autoproposal
V5221,"Hearing aid, contralateral routing system, binaural, bte/bte",V5263,"HEARING AID, DISPOSABLE, ANY TYPE, BINAURAL",40.39182211165501,,Present in Autoproposal
V5221,"Hearing aid, contralateral routing system, binaural, bte/bte",92591,Hearing aid examination and selection; binaural,39.97715334033478,,Present in Autoproposal
V5221,"Hearing aid, contralateral routing system, binaural, bte/bte",92595,Electroacoustic evaluation for hearing aid; binaural,37.0311739987192,,Present in Autoproposal
V5221,"Hearing aid, contralateral routing system, binaural, bte/bte",V5259,"HEARING AID, DIGITAL, BINAURAL, ITC",36.83777245679357,,Present in Autoproposal
V5221,"Hearing aid, contralateral routing system, binaural, bte/bte",V5258,"HEARING AID, DIGITAL, BINAURAL, CIC",36.83777245679357,,Present in Autoproposal
A9513,"Lutetium lu 177, dotatate, therapeutic, 1 millicurie",A9587,"GALLIUM GA-68, DOTATATE, DIAGNOSTIC, 0.1 MILLICURIE",55.90972294460703,10,Present in Autoproposal
A9513,"Lutetium lu 177, dotatate, therapeutic, 1 millicurie",A9563,"SODIUM PHOSPHATE P-32, THERAPEUTIC, PER MILLICURIE",38.75785676670249,,Present in Autoproposal
A9513,"Lutetium lu 177, dotatate, therapeutic, 1 millicurie",A9527,"IODINE I-125, SODIUM IODIDE SOLUTION, THERAPEUTIC, PER MILLICURIE",34.15839055817239,,Present in Autoproposal
A9513,"Lutetium lu 177, dotatate, therapeutic, 1 millicurie",A9530,"IODINE I-131 SODIUM IODIDE SOLUTION, THERAPEUTIC, PER MILLICURIE",33.962913453201224,,Present in Autoproposal
A9513,"Lutetium lu 177, dotatate, therapeutic, 1 millicurie",A9517,"IODINE I-131 SODIUM IODIDE CAPSULE(S), THERAPEUTIC, PER MILLICURIE",33.00067980439974,,Present in Autoproposal
A9513,"Lutetium lu 177, dotatate, therapeutic, 1 millicurie",A9534,"SUPPLY OF RADIOPHARMACEUTICAL THERAPEUTIC IMAGING AGENT, I-131 TOSITUMOMAB, PER MILLICURIE",32.940739509752234,,Present in Autoproposal
A9513,"Lutetium lu 177, dotatate, therapeutic, 1 millicurie",A9564,"CHROMIC PHOSPHATE P-32 SUSPENSION, THERAPEUTIC, PER MILLICURIE",32.6671277132207,,Present in Autoproposal
A9513,"Lutetium lu 177, dotatate, therapeutic, 1 millicurie",A9600,"STRONTIUM SR-89 CHLORIDE, THERAPEUTIC, PER MILLICURIE",31.78259691631601,,Present in Autoproposal
A9513,"Lutetium lu 177, dotatate, therapeutic, 1 millicurie",C9405,"SUPPLY OF RADIOPHARMACEUTICAL THERAPEUTIC AGENT, I-131 SODIUM IODIDE SOLUTION, BRAND NAME, PER MILLICURIE",28.075237251168257,,Present in Autoproposal
A9513,"Lutetium lu 177, dotatate, therapeutic, 1 millicurie",A9588,"FLUCICLOVINE F-18, DIAGNOSTIC, 1 MILLICURIE",27.065752260070987,,Present in Autoproposal
A9589,"Instillation, hexaminolevulinate hydrochloride, 100 mg",C9275,"INJECTION, HEXAMINOLEVULINATE HYDROCHLORIDE, 100 MG, PER STUDY DOSE",73.9580366603424,1,Present Both in MD and Autoproposal
A9589,"Instillation, hexaminolevulinate hydrochloride, 100 mg",J2175,"INJECTION, MEPERIDINE HYDROCHLORIDE, PER 100 MG",40.8514318125962,,Present in Autoproposal
A9589,"Instillation, hexaminolevulinate hydrochloride, 100 mg",J1626,"INJECTION, GRANISETRON HYDROCHLORIDE, 100 MCG",33.2604991177221,,Present in Autoproposal
A9589,"Instillation, hexaminolevulinate hydrochloride, 100 mg",J0592,"INJECTION, BUPRENORPHINE HYDROCHLORIDE, 0.1 MG",32.07236610081593,,Present in Autoproposal
A9589,"Instillation, hexaminolevulinate hydrochloride, 100 mg",J1620,"INJECTION, GONADORELIN HYDROCHLORIDE, PER 100 MCG",31.313365995581066,,Present in Autoproposal
A9589,"Instillation, hexaminolevulinate hydrochloride, 100 mg",J1610,"INJECTION, GLUCAGON HYDROCHLORIDE, PER 1 MG",30.93976500953811,,Present in Autoproposal
A9589,"Instillation, hexaminolevulinate hydrochloride, 100 mg",C1167,"INJECTION, EPIRUBICIN HYDROCHLORIDE, 2 MG",30.661041269862917,,Present in Autoproposal
A9589,"Instillation, hexaminolevulinate hydrochloride, 100 mg",S0167,"INJECTION, APOMORPHINE HYDROCHLORIDE, 1 MG",30.177067633047372,,Present in Autoproposal
A9589,"Instillation, hexaminolevulinate hydrochloride, 100 mg",J0364,"INJECTION, APOMORPHINE HYDROCHLORIDE, 1 MG",30.177067633047372,,Present in Autoproposal
A9589,"Instillation, hexaminolevulinate hydrochloride, 100 mg",J9211,"INJECTION, IDARUBICIN HYDROCHLORIDE, 5 MG",30.177067633047372,,Present in Autoproposal
B4105,"In-line cartridge containing digestive enzyme(s) for enteral feeding, each",S9300,"NURSING SERVICES AND ALL NECESSARY SUPPLIES FOR HOME ENTERAL FEEDING BY GRAVITY, PER DIEM (ENTERAL FORMULA NOT INCLUDED)",31.563949285734694,10,Present in Autoproposal
B4105,"In-line cartridge containing digestive enzyme(s) for enteral feeding, each",A4672,"DRAINAGE EXTENSION LINE, STERILE, FOR DIALYSIS, EACH",28.996720160213908,,Present in Autoproposal
B4105,"In-line cartridge containing digestive enzyme(s) for enteral feeding, each",K0612,"DRAINAGE EXTENSION LINE, STERILE, FOR DIALYSIS, EACH",28.996720160213908,,Present in Autoproposal
B4105,"In-line cartridge containing digestive enzyme(s) for enteral feeding, each",S9308,"NURSING SERVICES AND ALL NECESSARY SUPPLIES FOR HOME ENTERAL FEEDING BY PUMP, INCLUDING PUMP RENTAL, PER DIEM (ENTERAL FORMULA NOT INCLUDED)",28.866334365366132,,Present in Autoproposal
B4105,"In-line cartridge containing digestive enzyme(s) for enteral feeding, each",J7304,"CONTRACEPTIVE SUPPLY, HORMONE CONTAINING PATCH, EACH",28.361355939322188,,Present in Autoproposal
B4105,"In-line cartridge containing digestive enzyme(s) for enteral feeding, each",D5951,FEEDING AID,27.938685573225143,,Present in Autoproposal
B4105,"In-line cartridge containing digestive enzyme(s) for enteral feeding, each",B4156,"ENTERAL FORMULAE; CATEGORY VI; STANDARDIZED NUTRIENTS, ADMINISTERED THROUGH AN ENTERAL FEEDING TUBE, 100 CALORIES = 1 UNIT",27.264132888668424,,Present in Autoproposal
B4105,"In-line cartridge containing digestive enzyme(s) for enteral feeding, each",J7303,"CONTRACEPTIVE SUPPLY, HORMONE CONTAINING VAGINAL RING, EACH",26.359696824521215,,Present in Autoproposal
B4105,"In-line cartridge containing digestive enzyme(s) for enteral feeding, each",B4035,"ENTERAL FEEDING SUPPLY KIT; PUMP FED, PER DAY, INCLUDES BUT NOT LIMITED TO FEEDING/FLUSHING SYRINGE, ADMINISTRATION SET TUBING, DRESSINGS, TAPE",25.250303803633212,,Present in Autoproposal
B4105,"In-line cartridge containing digestive enzyme(s) for enteral feeding, each",B4151,"ENTERAL FORMULAE; CATEGORY I; NATURAL INTACT PROTEIN/PROTEIN ISOLATES, ADMINISTERED THROUGH AN ENTERAL FEEDING TUBE, 100 CALORIES = 1 UNIT",25.03211501859861,,Present in Autoproposal
E0953,"WHEELCHAIR ACCESSORY, LATERAL THIGH OR KNEE SUPPORT, ANY TYPE INCLUDING FIXED MOUNTING HARDWARE, EACH",E0953,"WHEELCHAIR ACCESSORY, LATERAL THIGH OR KNEE SUPPORT, ANY TYPE INCLUDING FIXED MOUNTING HARDWARE, EACH",100.00000000000003,3,Present in Autoproposal
E0953,"WHEELCHAIR ACCESSORY, LATERAL THIGH OR KNEE SUPPORT, ANY TYPE INCLUDING FIXED MOUNTING HARDWARE, EACH",E0957,"WHEELCHAIR ACCESSORY, MEDIAL THIGH SUPPORT, ANY TYPE, INCLUDING FIXED MOUNTING HARDWARE, EACH",86.14716156672999,,Present in Autoproposal
E0953,"WHEELCHAIR ACCESSORY, LATERAL THIGH OR KNEE SUPPORT, ANY TYPE INCLUDING FIXED MOUNTING HARDWARE, EACH",E0956,"WHEELCHAIR ACCESSORY, LATERAL TRUNK OR HIP SUPPORT, ANY TYPE, INCLUDING FIXED MOUNTING HARDWARE, EACH",82.72549469475773,,Present Both in MD and Autoproposal
E0953,"WHEELCHAIR ACCESSORY, LATERAL THIGH OR KNEE SUPPORT, ANY TYPE INCLUDING FIXED MOUNTING HARDWARE, EACH",E0955,"WHEELCHAIR ACCESSORY, HEADREST, CUSHIONED, ANY TYPE, INCLUDING FIXED MOUNTING HARDWARE, EACH",61.185079105978865,,Present in Autoproposal
E0953,"WHEELCHAIR ACCESSORY, LATERAL THIGH OR KNEE SUPPORT, ANY TYPE INCLUDING FIXED MOUNTING HARDWARE, EACH",E0960,"WHEELCHAIR ACCESSORY, SHOULDER HARNESS/STRAPS OR CHEST STRAP, INCLUDING ANY TYPE MOUNTING HARDWARE",50.34600599813792,,Present in Autoproposal
E0953,"WHEELCHAIR ACCESSORY, LATERAL THIGH OR KNEE SUPPORT, ANY TYPE INCLUDING FIXED MOUNTING HARDWARE, EACH",E1027,"LATERAL/ANTERIOR SUPPORT, FOR PEDIATRIC WHEELCHAIR, EACH (INCLUDES HARDWARE)",48.79736582859744,,Present in Autoproposal
E0953,"WHEELCHAIR ACCESSORY, LATERAL THIGH OR KNEE SUPPORT, ANY TYPE INCLUDING FIXED MOUNTING HARDWARE, EACH",E2617,"CUSTOM FABRICATED WHEELCHAIR BACK CUSHION, ANY SIZE, INCLUDING ANY TYPE MOUNTING HARDWARE",48.10994935085201,,Present in Autoproposal
E0953,"WHEELCHAIR ACCESSORY, LATERAL THIGH OR KNEE SUPPORT, ANY TYPE INCLUDING FIXED MOUNTING HARDWARE, EACH",K0666,"CUSTOM FABRICATED WHEELCHAIR BACK CUSHION, ANY SIZE, INCLUDING ANY TYPE MOUNTING HARDWARE",48.10994935085201,,Present in Autoproposal
E0953,"WHEELCHAIR ACCESSORY, LATERAL THIGH OR KNEE SUPPORT, ANY TYPE INCLUDING FIXED MOUNTING HARDWARE, EACH",E0954,"WHEELCHAIR ACCESSORY, FOOT BOX, ANY TYPE, INCLUDES ATTACHMENT AND MOUNTING HARDWARE, EACH FOOT",47.941746486380076,,Present in Autoproposal
E0953,"WHEELCHAIR ACCESSORY, LATERAL THIGH OR KNEE SUPPORT, ANY TYPE INCLUDING FIXED MOUNTING HARDWARE, EACH",E2399,"POWER WHEELCHAIR ACCESSORY, NOT OTHERWISE CLASSIFIED INTERFACE, INCLUDING ALL RELATED ELECTRONICS AND ANY TYPE MOUNTING HARDWARE",46.70593275836712,,Present in Autoproposal
J0185,"Injection, aprepitant, 1 mg",C9463,"Injection, aprepitant, 1 mg",100.00000000000003,1,Present Both in MD and Autoproposal
J0185,"Injection, aprepitant, 1 mg",J8501,"APREPITANT, ORAL, 5 MG",83.0696267371327,,Present in Autoproposal
J0185,"Injection, aprepitant, 1 mg",J9267,"INJECTION, PACLITAXEL, 1 MG",26.27069613400331,,Present in Autoproposal
J0185,"Injection, aprepitant, 1 mg",J9280,"INJECTION, MITOMYCIN, 5 MG",26.27069613400331,,Present in Autoproposal
J0185,"Injection, aprepitant, 1 mg",J0202,"INJECTION, ALEMTUZUMAB, 1 MG",25.956102563064647,,Present in Autoproposal
J0185,"Injection, aprepitant, 1 mg",J0178,"INJECTION, AFLIBERCEPT, 1 MG",25.956102563064647,,Present in Autoproposal
J0185,"Injection, aprepitant, 1 mg",J3396,"INJECTION, VERTEPORFIN, 0.1 MG",25.956102563064647,,Present in Autoproposal
J0185,"Injection, aprepitant, 1 mg",C9261,"INJECTION, USTEKINUMAB, 1 MG",25.956102563064647,,Present in Autoproposal
J0185,"Injection, aprepitant, 1 mg",Q2046,"INJECTION, AFLIBERCEPT, 1 MG",25.956102563064647,,Present in Autoproposal
J0185,"Injection, aprepitant, 1 mg",J1325,"INJECTION, EPOPROSTENOL, 0.5 MG",25.956102563064647,,Present in Autoproposal
J0517,"Injection, benralizumab, 1 mg",C9466,"Injection, benralizumab, 1 mg",100.0,1,Present Both in MD and Autoproposal
J0517,"Injection, benralizumab, 1 mg",J9267,"INJECTION, PACLITAXEL, 1 MG",25.48946538832415,,Present in Autoproposal
J0517,"Injection, benralizumab, 1 mg",J9280,"INJECTION, MITOMYCIN, 5 MG",25.48946538832415,,Present in Autoproposal
J0517,"Injection, benralizumab, 1 mg",J0202,"INJECTION, ALEMTUZUMAB, 1 MG",25.184227114586477,,Present in Autoproposal
J0517,"Injection, benralizumab, 1 mg",J0178,"INJECTION, AFLIBERCEPT, 1 MG",25.184227114586477,,Present in Autoproposal
J0517,"Injection, benralizumab, 1 mg",J3396,"INJECTION, VERTEPORFIN, 0.1 MG",25.184227114586477,,Present in Autoproposal
J0517,"Injection, benralizumab, 1 mg",C9261,"INJECTION, USTEKINUMAB, 1 MG",25.184227114586477,,Present in Autoproposal
J0517,"Injection, benralizumab, 1 mg",J1325,"INJECTION, EPOPROSTENOL, 0.5 MG",25.184227114586477,,Present in Autoproposal
J0517,"Injection, benralizumab, 1 mg",Q2046,"INJECTION, AFLIBERCEPT, 1 MG",25.184227114586477,,Present in Autoproposal
J0517,"Injection, benralizumab, 1 mg",Q9979,"INJECTION, ALEMTUZUMAB, 1 MG",25.184227114586477,,Present in Autoproposal
J0567,"Injection, cerliponase alfa, 1 mg",C9014,"INJECTION, CERLIPONASE ALFA, 1 MG",100.00000000000003,1,Present Both in MD and Autoproposal
J0567,"Injection, cerliponase alfa, 1 mg",C9478,"INJECTION, SEBELIPASE ALFA, 1 MG",46.390548173701355,,Present in Autoproposal
J0567,"Injection, cerliponase alfa, 1 mg",J1322,"INJECTION, ELOSULFASE ALFA, 1 MG",46.390548173701355,,Present in Autoproposal
J0567,"Injection, cerliponase alfa, 1 mg",J2840,"INJECTION, SEBELIPASE ALFA, 1 MG",46.390548173701355,,Present in Autoproposal
J0567,"Injection, cerliponase alfa, 1 mg",C9234,"INJECTION, ALGLUCOSIDASE ALFA, 10 MG",44.70052098070722,,Present in Autoproposal
J0567,"Injection, cerliponase alfa, 1 mg",S0147,"INJECTION, ALGLUCOSIDASE ALFA, 20 MG",43.773070701183414,,Present in Autoproposal
J0567,"Injection, cerliponase alfa, 1 mg",C9277,"INJECTION, ALGLUCOSIDASE ALFA (LUMIZYME), 1 MG",38.4476370196975,,Present in Autoproposal
J0567,"Injection, cerliponase alfa, 1 mg",J0220,"INJECTION, ALGLUCOSIDASE ALFA, 10 MG, NOT OTHERWISE SPECIFIED",37.84200429349368,,Present in Autoproposal
J0567,"Injection, cerliponase alfa, 1 mg",J0221,"INJECTION, ALGLUCOSIDASE ALFA, (LUMIZYME), 10 MG",36.63865633174297,,Present in Autoproposal
J0567,"Injection, cerliponase alfa, 1 mg",S0112,"INJECTION, DARBEPOETIN ALFA, 1 MCG",35.743680283405716,,Present in Autoproposal
J0599,"Injection, c-1 esterase inhibitor (human), (haegarda), 10 units",C9251,"INJECTION, C1 ESTERASE INHIBITOR (HUMAN), 10 UNITS",88.09831409958694,10,Present in Autoproposal
J0599,"Injection, c-1 esterase inhibitor (human), (haegarda), 10 units",J0597,"INJECTION, C-1 ESTERASE INHIBITOR (HUMAN), BERINERT, 10 UNITS",85.10157254654143,,Present in Autoproposal
J0599,"Injection, c-1 esterase inhibitor (human), (haegarda), 10 units",C9269,"INJECTION, C-1 ESTERASE INHIBITOR (HUMAN), BERINERT, 10 UNITS",85.10157254654143,,Present in Autoproposal
J0599,"Injection, c-1 esterase inhibitor (human), (haegarda), 10 units",J0598,"INJECTION, C-1 ESTERASE INHIBITOR (HUMAN), CINRYZE, 10 UNITS",84.14902634397725,,Present in Autoproposal
J0599,"Injection, c-1 esterase inhibitor (human), (haegarda), 10 units",C9445,"INJECTION, C-1 ESTERASE INHIBITOR (RECOMBINANT), RUCONEST, 10 UNITS",71.09294481139679,,Present in Autoproposal
J0599,"Injection, c-1 esterase inhibitor (human), (haegarda), 10 units",J0596,"INJECTION, C1 ESTERASE INHIBITOR (RECOMBINANT), RUCONEST, 10 UNITS",64.82959256505981,,Present in Autoproposal
J0599,"Injection, c-1 esterase inhibitor (human), (haegarda), 10 units",J0256,"INJECTION, ALPHA 1 PROTEINASE INHIBITOR (HUMAN), NOT OTHERWISE SPECIFIED, 10 MG",42.812443352148534,,Present in Autoproposal
J0599,"Injection, c-1 esterase inhibitor (human), (haegarda), 10 units",J0257,"INJECTION, ALPHA 1 PROTEINASE INHIBITOR (HUMAN), (GLASSIA), 10 MG",41.346903444950414,,Present in Autoproposal
J0599,"Injection, c-1 esterase inhibitor (human), (haegarda), 10 units",J1786,"INJECTION, IMIGLUCERASE, 10 UNITS",39.75158562595242,,Present in Autoproposal
J0599,"Injection, c-1 esterase inhibitor (human), (haegarda), 10 units",C9293,"INJECTION, GLUCARPIDASE, 10 UNITS",38.30645420129501,,Present in Autoproposal
J1301,"Injection, edaravone, 1 mg",C9493,"INJECTION, EDARAVONE, 1 MG",100.0,1,Present Both in MD and Autoproposal
J1301,"Injection, edaravone, 1 mg",J9280,"INJECTION, MITOMYCIN, 5 MG",25.48946538832415,,Present in Autoproposal
J1301,"Injection, edaravone, 1 mg",J9267,"INJECTION, PACLITAXEL, 1 MG",25.48946538832415,,Present in Autoproposal
J1301,"Injection, edaravone, 1 mg",Q9979,"INJECTION, ALEMTUZUMAB, 1 MG",25.184227114586477,,Present in Autoproposal
J1301,"Injection, edaravone, 1 mg",Q2046,"INJECTION, AFLIBERCEPT, 1 MG",25.184227114586477,,Present in Autoproposal
J1301,"Injection, edaravone, 1 mg",J0202,"INJECTION, ALEMTUZUMAB, 1 MG",25.184227114586477,,Present in Autoproposal
J1301,"Injection, edaravone, 1 mg",J0178,"INJECTION, AFLIBERCEPT, 1 MG",25.184227114586477,,Present in Autoproposal
J1301,"Injection, edaravone, 1 mg",J3396,"INJECTION, VERTEPORFIN, 0.1 MG",25.184227114586477,,Present in Autoproposal
J1301,"Injection, edaravone, 1 mg",C9261,"INJECTION, USTEKINUMAB, 1 MG",25.184227114586477,,Present in Autoproposal
J1301,"Injection, edaravone, 1 mg",J1325,"INJECTION, EPOPROSTENOL, 0.5 MG",25.184227114586477,,Present in Autoproposal
J1454,"Injection, fosnetupitant 235 mg and palonosetron 0.25 mg",Q9978,NETUPITANT 300 MG AND PALONOSETRON 0.5 MG,64.05208411016878,10,Present in Autoproposal
J1454,"Injection, fosnetupitant 235 mg and palonosetron 0.25 mg",J8655,NETUPITANT 300 MG AND PALONOSETRON 0.5 MG,64.05208411016878,,Present in Autoproposal
J1454,"Injection, fosnetupitant 235 mg and palonosetron 0.25 mg",C9448,"NETUPITANT 300 MG AND PALONOSETRON 0.5 MG, ORAL",60.79858330895031,,Present in Autoproposal
J1454,"Injection, fosnetupitant 235 mg and palonosetron 0.25 mg",J2469,"INJECTION, PALONOSETRON HCL, 25 MCG",60.562306701369415,,Present in Autoproposal
J1454,"Injection, fosnetupitant 235 mg and palonosetron 0.25 mg",Q2024,"INJECTION, BEVACIZUMAB, 0. 25 MG",47.22998849294521,,Present in Autoproposal
J1454,"Injection, fosnetupitant 235 mg and palonosetron 0.25 mg",C9257,"INJECTION, BEVACIZUMAB, 0.25 MG",47.22998849294521,,Present in Autoproposal
J1454,"Injection, fosnetupitant 235 mg and palonosetron 0.25 mg",J0695,"INJECTION, CEFTOLOZANE 50 MG AND TAZOBACTAM 25 MG",46.358922349901235,,Present in Autoproposal
J1454,"Injection, fosnetupitant 235 mg and palonosetron 0.25 mg",C9452,"INJECTION, CEFTOLOZANE 50 MG AND TAZOBACTAM 25 MG",46.358922349901235,,Present in Autoproposal
J1454,"Injection, fosnetupitant 235 mg and palonosetron 0.25 mg",S0107,"INJECTION, OMALIZUMAB, 25 MG",46.102051220505544,,Present in Autoproposal
J1454,"Injection, fosnetupitant 235 mg and palonosetron 0.25 mg",J2324,"INJECTION, NESIRITIDE, 0.25 MG",46.102051220505544,,Present in Autoproposal
J1628,"Injection, guselkumab, 1 mg",J9267,"INJECTION, PACLITAXEL, 1 MG",52.950885430632866,10,Present in Autoproposal
J1628,"Injection, guselkumab, 1 mg",J9280,"INJECTION, MITOMYCIN, 5 MG",52.950885430632866,,Present in Autoproposal
J1628,"Injection, guselkumab, 1 mg",Q2046,"INJECTION, AFLIBERCEPT, 1 MG",52.316794577196156,,Present in Autoproposal
J1628,"Injection, guselkumab, 1 mg",J0202,"INJECTION, ALEMTUZUMAB, 1 MG",52.316794577196156,,Present in Autoproposal
J1628,"Injection, guselkumab, 1 mg",J0178,"INJECTION, AFLIBERCEPT, 1 MG",52.316794577196156,,Present in Autoproposal
J1628,"Injection, guselkumab, 1 mg",J3396,"INJECTION, VERTEPORFIN, 0.1 MG",52.316794577196156,,Present in Autoproposal
J1628,"Injection, guselkumab, 1 mg",C9261,"INJECTION, USTEKINUMAB, 1 MG",52.316794577196156,,Present in Autoproposal
J1628,"Injection, guselkumab, 1 mg",J1325,"INJECTION, EPOPROSTENOL, 0.5 MG",52.316794577196156,,Present in Autoproposal
J1628,"Injection, guselkumab, 1 mg",Q9979,"INJECTION, ALEMTUZUMAB, 1 MG",52.316794577196156,,Present in Autoproposal
J1628,"Injection, guselkumab, 1 mg",J2505,"INJECTION, PEGFILGRASTIM, 6 MG",51.58259659366726,,Present in Autoproposal
J2797,"Injection, rolapitant, 0.5 mg",C9464,"Injection, rolapitant, 0.5 mg",100.0,1,Present Both in MD and Autoproposal
J2797,"Injection, rolapitant, 0.5 mg",J8670,"ROLAPITANT, ORAL, 1 MG",82.37358758750706,,Present in Autoproposal
J2797,"Injection, rolapitant, 0.5 mg",Q9981,"ROLAPITANT, ORAL, 1 MG",82.37358758750706,,Present in Autoproposal
J2797,"Injection, rolapitant, 0.5 mg",J9280,"INJECTION, MITOMYCIN, 5 MG",26.8496608620037,,Present in Autoproposal
J2797,"Injection, rolapitant, 0.5 mg",J9267,"INJECTION, PACLITAXEL, 1 MG",26.8496608620037,,Present in Autoproposal
J2797,"Injection, rolapitant, 0.5 mg",C9261,"INJECTION, USTEKINUMAB, 1 MG",26.528134144706826,,Present in Autoproposal
J2797,"Injection, rolapitant, 0.5 mg",Q2046,"INJECTION, AFLIBERCEPT, 1 MG",26.528134144706826,,Present in Autoproposal
J2797,"Injection, rolapitant, 0.5 mg",Q9979,"INJECTION, ALEMTUZUMAB, 1 MG",26.528134144706826,,Present in Autoproposal
J2797,"Injection, rolapitant, 0.5 mg",J1325,"INJECTION, EPOPROSTENOL, 0.5 MG",26.528134144706826,,Present in Autoproposal
J2797,"Injection, rolapitant, 0.5 mg",J3396,"INJECTION, VERTEPORFIN, 0.1 MG",26.528134144706826,,Present in Autoproposal
J3304,"Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg",Q9993,"Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg",100.00000000000003,1,Present Both in MD and Autoproposal
J3304,"Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg",C9469,"Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg",100.00000000000003,,Present in Autoproposal
J3304,"Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg",J3300,"INJECTION, TRIAMCINOLONE ACETONIDE, PRESERVATIVE FREE, 1 MG",72.41697421375433,,Present in Autoproposal
J3304,"Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg",J3301,"INJECTION, TRIAMCINOLONE ACETONIDE, NOT OTHERWISE SPECIFIED, 10 MG",46.85565077991303,,Present in Autoproposal
J3304,"Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg",C9486,"INJECTION, GRANISETRON EXTENDED RELEASE, 0.1 MG",38.715065185756224,,Present in Autoproposal
J3304,"Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg",J1627,"INJECTION, GRANISETRON, EXTENDED-RELEASE, 0.1 MG",38.715065185756224,,Present in Autoproposal
J3304,"Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg",J0401,"INJECTION, ARIPIPRAZOLE, EXTENDED RELEASE, 1 MG",38.166434480125645,,Present in Autoproposal
J3304,"Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg",J2426,"INJECTION, PALIPERIDONE PALMITATE EXTENDED RELEASE, 1 MG",31.223366980555312,,Present in Autoproposal
J3304,"Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg",J3303,"INJECTION, TRIAMCINOLONE HEXACETONIDE, PER 5 MG",30.703845172457545,,Present in Autoproposal
J3304,"Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg",J3302,"INJECTION, TRIAMCINOLONE DIACETATE, PER 5 MG",30.703845172457545,,Present in Autoproposal
J3316,"Injection, triptorelin, extended-release, 3.75 mg",J3315,"INJECTION, TRIPTORELIN PAMOATE, 3.75 MG",67.0061417214346,10,Present in Autoproposal
J3316,"Injection, triptorelin, extended-release, 3.75 mg",C9486,"INJECTION, GRANISETRON EXTENDED RELEASE, 0.1 MG",52.26529875400029,,Present in Autoproposal
J3316,"Injection, triptorelin, extended-release, 3.75 mg",J1627,"INJECTION, GRANISETRON, EXTENDED-RELEASE, 0.1 MG",52.26529875400029,,Present in Autoproposal
J3316,"Injection, triptorelin, extended-release, 3.75 mg",J0401,"INJECTION, ARIPIPRAZOLE, EXTENDED RELEASE, 1 MG",51.524647857564496,,Present in Autoproposal
J3316,"Injection, triptorelin, extended-release, 3.75 mg",J2426,"INJECTION, PALIPERIDONE PALMITATE EXTENDED RELEASE, 1 MG",42.15151377156684,,Present in Autoproposal
J3316,"Injection, triptorelin, extended-release, 3.75 mg",J9600,"INJECTION, PORFIMER SODIUM, 75 MG",33.44411894505548,,Present in Autoproposal
J3316,"Injection, triptorelin, extended-release, 3.75 mg",Q9993,"Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg",33.042910050085716,,Present in Autoproposal
J3316,"Injection, triptorelin, extended-release, 3.75 mg",C9469,"Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg",33.042910050085716,,Present in Autoproposal
J3316,"Injection, triptorelin, extended-release, 3.75 mg",J7508,"TACROLIMUS, EXTENDED RELEASE, (ASTAGRAF XL), ORAL, 0.1 MG",33.00410873100541,,Present in Autoproposal
J3316,"Injection, triptorelin, extended-release, 3.75 mg",J7512,"PREDNISONE, IMMEDIATE RELEASE OR DELAYED RELEASE, ORAL, 1 MG",31.8558208048838,,Present in Autoproposal
J3398,"Injection, voretigene neparvovec-rzyl, 1 billion vector genomes",C1732,"CATHETER, ELECTROPHYSIOLOGY, DIAGNOSTIC/ABLATION, 3D OR VECTOR MAPPING",46.10739657241379,10,Present in Autoproposal
J3398,"Injection, voretigene neparvovec-rzyl, 1 billion vector genomes",C2630,"CATHETER, ELECTROPHYSIOLOGY, DIAGNOSTIC/ABLATION, OTHER THAN 3D OR VECTOR MAPPING, COOL-TIP",37.596392777119206,,Present in Autoproposal
J3398,"Injection, voretigene neparvovec-rzyl, 1 billion vector genomes",C1733,"CATHETER, ELECTROPHYSIOLOGY, DIAGNOSTIC/ABLATION, OTHER THAN 3D OR VECTOR MAPPING, OTHER THAN COOL-TIP",34.27547193251163,,Present in Autoproposal
J3398,"Injection, voretigene neparvovec-rzyl, 1 billion vector genomes",J2353,"INJECTION, OCTREOTIDE, DEPOT FORM FOR INTRAMUSCULAR INJECTION, 1 MG",15.94161590653313,,Present in Autoproposal
J3398,"Injection, voretigene neparvovec-rzyl, 1 billion vector genomes",Q4052,"INJECTION, OCTREOTIDE, DEPOT FORM FOR INTRAMUSCULAR INJECTION, 1 MG",15.94161590653313,,Present in Autoproposal
J3398,"Injection, voretigene neparvovec-rzyl, 1 billion vector genomes",J7175,"INJECTION, FACTOR X, (HUMAN), 1 I.U.",14.858174608317245,,Present in Autoproposal
J3398,"Injection, voretigene neparvovec-rzyl, 1 billion vector genomes",Q0159,ADENOSINE INJECTION,14.80858227995226,,Present in Autoproposal
J3398,"Injection, voretigene neparvovec-rzyl, 1 billion vector genomes",C1101,"CATHETER, PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY GUIDE, MEDTRONIC AVE 5F, 6F, 7F, 8F, 9F ZUMA GUIDE CATHETER, MEDTRONIC AVE Z2 5F, 6F, 7F, 8F, 9F ZUMA GUIDE CATHETER, MEDTRONIC AVE VECTOR GUIDE CATHETER, MEDTRONIC AVE VECTOR X GUIDE CATHETER.   NOTE: ONLY THE MEDTRONIC AVE Z2 ZUMA GUIDE CATHETERS ARE EFFECTIVE OCTOBER 1, 2000.  THE MEDTRONIC AVE ZUMA GUIDE CATHETERS WERE EFFECTIVE AUGUST 1, 2000.",14.637775773216832,,Present in Autoproposal
J3398,"Injection, voretigene neparvovec-rzyl, 1 billion vector genomes",68200,Subconjunctival injection,14.419733076826304,,Present in Autoproposal
J3398,"Injection, voretigene neparvovec-rzyl, 1 billion vector genomes",36299,"Unlisted procedure, vascular injection",14.211178296764784,,Present in Autoproposal
J7170,"Injection, emicizumab-kxwh, 0.5 mg",J9267,"INJECTION, PACLITAXEL, 1 MG",52.950885430632866,10,Present in Autoproposal
J7170,"Injection, emicizumab-kxwh, 0.5 mg",J9280,"INJECTION, MITOMYCIN, 5 MG",52.950885430632866,,Present in Autoproposal
J7170,"Injection, emicizumab-kxwh, 0.5 mg",Q2046,"INJECTION, AFLIBERCEPT, 1 MG",52.316794577196156,,Present in Autoproposal
J7170,"Injection, emicizumab-kxwh, 0.5 mg",J0202,"INJECTION, ALEMTUZUMAB, 1 MG",52.316794577196156,,Present in Autoproposal
J7170,"Injection, emicizumab-kxwh, 0.5 mg",J0178,"INJECTION, AFLIBERCEPT, 1 MG",52.316794577196156,,Present in Autoproposal
J7170,"Injection, emicizumab-kxwh, 0.5 mg",J3396,"INJECTION, VERTEPORFIN, 0.1 MG",52.316794577196156,,Present in Autoproposal
J7170,"Injection, emicizumab-kxwh, 0.5 mg",C9261,"INJECTION, USTEKINUMAB, 1 MG",52.316794577196156,,Present in Autoproposal
J7170,"Injection, emicizumab-kxwh, 0.5 mg",J1325,"INJECTION, EPOPROSTENOL, 0.5 MG",52.316794577196156,,Present in Autoproposal
J7170,"Injection, emicizumab-kxwh, 0.5 mg",Q9979,"INJECTION, ALEMTUZUMAB, 1 MG",52.316794577196156,,Present in Autoproposal
J7170,"Injection, emicizumab-kxwh, 0.5 mg",J2505,"INJECTION, PEGFILGRASTIM, 6 MG",51.58259659366726,,Present in Autoproposal
J7203,"Injection factor ix, (antihemophilic factor, recombinant), glycopegylated, (rebinyn), 1 iu",C9468,"Injection, factor ix (antihemophilic factor, recombinant), glycopegylated, Rebinyn, 1 i.u.",95.19499569277887,1,Present Both in MD and Autoproposal
J7203,"Injection factor ix, (antihemophilic factor, recombinant), glycopegylated, (rebinyn), 1 iu",J7195,"INJECTION, FACTOR IX (ANTIHEMOPHILIC FACTOR, RECOMBINANT) PER IU, NOT OTHERWISE SPECIFIED",73.44934285512039,,Present in Autoproposal
J7203,"Injection factor ix, (antihemophilic factor, recombinant), glycopegylated, (rebinyn), 1 iu",J7200,"INJECTION, FACTOR IX, (ANTIHEMOPHILIC FACTOR, RECOMBINANT), RIXUBIS, PER IU",72.12924331337996,,Present in Autoproposal
J7203,"Injection factor ix, (antihemophilic factor, recombinant), glycopegylated, (rebinyn), 1 iu",C9133,"FACTOR IX (ANTIHEMOPHILIC FACTOR, RECOMBINANT), RIXUBIS, PER I.U.",63.97603599178387,,Present in Autoproposal
J7203,"Injection factor ix, (antihemophilic factor, recombinant), glycopegylated, (rebinyn), 1 iu",C9135,"FACTOR IX (ANTIHEMOPHILIC FACTOR, RECOMBINANT), ALPROLIX, PER I.U.",63.97603599178387,,Present in Autoproposal
J7203,"Injection factor ix, (antihemophilic factor, recombinant), glycopegylated, (rebinyn), 1 iu",Q0160,"FACTOR IX (ANTIHEMOPHILIC FACTOR, PURIFIED, NON-RECOMBINANT) PER I.U.",63.72254167207553,,Present in Autoproposal
J7203,"Injection factor ix, (antihemophilic factor, recombinant), glycopegylated, (rebinyn), 1 iu",J7193,"FACTOR IX (ANTIHEMOPHILIC FACTOR, PURIFIED, NON-RECOMBINANT) PER I.U.",63.72254167207553,,Present in Autoproposal
J7203,"Injection factor ix, (antihemophilic factor, recombinant), glycopegylated, (rebinyn), 1 iu",J7182,"INJECTION, FACTOR VIII, (ANTIHEMOPHILIC FACTOR, RECOMBINANT), (NOVOEIGHT), PER IU",60.176154710173094,,Present in Autoproposal
J7203,"Injection factor ix, (antihemophilic factor, recombinant), glycopegylated, (rebinyn), 1 iu",C9137,"INJECTION, FACTOR VIII (ANTIHEMOPHILIC FACTOR, RECOMBINANT) PEGYLATED, 1 I.U.",55.07668695758164,,Present in Autoproposal
J7203,"Injection factor ix, (antihemophilic factor, recombinant), glycopegylated, (rebinyn), 1 iu",J7207,"INJECTION, FACTOR VIII, (ANTIHEMOPHILIC FACTOR, RECOMBINANT), PEGYLATED, 1 I.U.",55.07668695758164,,Present in Autoproposal
J9057,"Injection, copanlisib, 1 mg",J9267,"INJECTION, PACLITAXEL, 1 MG",52.950885430632866,10,Present in Autoproposal
J9057,"Injection, copanlisib, 1 mg",J9280,"INJECTION, MITOMYCIN, 5 MG",52.950885430632866,,Present in Autoproposal
J9057,"Injection, copanlisib, 1 mg",Q2046,"INJECTION, AFLIBERCEPT, 1 MG",52.316794577196156,,Present in Autoproposal
J9057,"Injection, copanlisib, 1 mg",J0202,"INJECTION, ALEMTUZUMAB, 1 MG",52.316794577196156,,Present in Autoproposal
J9057,"Injection, copanlisib, 1 mg",J0178,"INJECTION, AFLIBERCEPT, 1 MG",52.316794577196156,,Present in Autoproposal
J9057,"Injection, copanlisib, 1 mg",J3396,"INJECTION, VERTEPORFIN, 0.1 MG",52.316794577196156,,Present in Autoproposal
J9057,"Injection, copanlisib, 1 mg",C9261,"INJECTION, USTEKINUMAB, 1 MG",52.316794577196156,,Present in Autoproposal
J9057,"Injection, copanlisib, 1 mg",J1325,"INJECTION, EPOPROSTENOL, 0.5 MG",52.316794577196156,,Present in Autoproposal
J9057,"Injection, copanlisib, 1 mg",Q9979,"INJECTION, ALEMTUZUMAB, 1 MG",52.316794577196156,,Present in Autoproposal
J9057,"Injection, copanlisib, 1 mg",J2505,"INJECTION, PEGFILGRASTIM, 6 MG",51.58259659366726,,Present in Autoproposal
J9153,"Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine",C9024,"INJECTION, LIPOSOMAL, 1 MG DAUNORUBICIN AND 2.27 MG CYTARABINE",100.0,1,Present Both in MD and Autoproposal
J9153,"Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine",J9151,"INJECTION, DAUNORUBICIN CITRATE, LIPOSOMAL FORMULATION, 10 MG",55.9804946269819,,Present in Autoproposal
J9153,"Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine",J9150,"INJECTION, DAUNORUBICIN, 10 MG",55.29631403343911,,Present in Autoproposal
J9153,"Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine",J9100,"INJECTION, CYTARABINE, 100 MG",52.79583338855942,,Present in Autoproposal
J9153,"Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine",J9110,"INJECTION, CYTARABINE, 500 MG",50.931303758227074,,Present in Autoproposal
J9153,"Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine",J9098,"INJECTION, CYTARABINE LIPOSOME, 10 MG",43.15981140099263,,Present in Autoproposal
J9153,"Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine",C1166,"INJECTION, CYTARABINE LIPOSOME, PER 10 MG",41.899812014247715,,Present in Autoproposal
J9153,"Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine",C9424,"DAUNORUBICIN, BRAND NAME, 10 MG",39.08910496929851,,Present in Autoproposal
J9153,"Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine",C9422,"CYTARABINE, BRAND NAME, 100 MG",37.12479714934187,,Present in Autoproposal
J9153,"Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine",Q2050,"INJECTION, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, NOT OTHERWISE SPECIFIED, 10 MG",34.433848219583766,,Present in Autoproposal
J9173,"Injection, durvalumab, 10 mg",C9492,"INJECTION, DURVALUMAB, 10 MG",100.00000000000003,1,Present Both in MD and Autoproposal
J9173,"Injection, durvalumab, 10 mg",J9355,"INJECTION, TRASTUZUMAB, 10 MG",38.82827538024409,,Present in Autoproposal
J9173,"Injection, durvalumab, 10 mg",J0475,"INJECTION, BACLOFEN, 10 MG",38.82827538024409,,Present in Autoproposal
J9173,"Injection, durvalumab, 10 mg",J9035,"INJECTION, BEVACIZUMAB, 10 MG",38.4521221379687,,Present in Autoproposal
J9173,"Injection, durvalumab, 10 mg",J9181,"INJECTION, ETOPOSIDE, 10 MG",38.4521221379687,,Present in Autoproposal
J9173,"Injection, durvalumab, 10 mg",J9010,"INJECTION, ALEMTUZUMAB, 10 MG",38.4521221379687,,Present in Autoproposal
J9173,"Injection, durvalumab, 10 mg",J0131,"INJECTION, ACETAMINOPHEN, 10 MG",38.01332464608036,,Present in Autoproposal
J9173,"Injection, durvalumab, 10 mg",J9150,"INJECTION, DAUNORUBICIN, 10 MG",38.01332464608036,,Present in Autoproposal
J9173,"Injection, durvalumab, 10 mg",C9283,"INJECTION, ACETAMINOPHEN, 10 MG",38.01332464608036,,Present in Autoproposal
J9173,"Injection, durvalumab, 10 mg",J0128,"INJECTION, ABARELIX, 10 MG",37.48528546651737,,Present in Autoproposal
J9229,"Injection, inotuzumab ozogamicin, 0.1 mg",C9028,"INJECTION, INOTUZUMAB OZOGAMICIN, 0.1 MG",100.0,1,Present Both in MD and Autoproposal
J9229,"Injection, inotuzumab ozogamicin, 0.1 mg",J9300,"INJECTION, GEMTUZUMAB OZOGAMICIN, 5 MG",54.80702356925132,,Present in Autoproposal
J9229,"Injection, inotuzumab ozogamicin, 0.1 mg",J9203,"INJECTION, GEMTUZUMAB OZOGAMICIN, 0.1 MG",54.80702356925132,,Present in Autoproposal
J9229,"Injection, inotuzumab ozogamicin, 0.1 mg",C9004,"INJECTION, GEMTUZUMAB OZOGAMICIN, PER 5 MG",53.14518598999152,,Present in Autoproposal
J9229,"Injection, inotuzumab ozogamicin, 0.1 mg",J9267,"INJECTION, PACLITAXEL, 1 MG",19.908939771210726,,Present in Autoproposal
J9229,"Injection, inotuzumab ozogamicin, 0.1 mg",J9280,"INJECTION, MITOMYCIN, 5 MG",19.908939771210726,,Present in Autoproposal
J9229,"Injection, inotuzumab ozogamicin, 0.1 mg",J1325,"INJECTION, EPOPROSTENOL, 0.5 MG",19.670528713343057,,Present in Autoproposal
J9229,"Injection, inotuzumab ozogamicin, 0.1 mg",J0202,"INJECTION, ALEMTUZUMAB, 1 MG",19.670528713343057,,Present in Autoproposal
J9229,"Injection, inotuzumab ozogamicin, 0.1 mg",J0178,"INJECTION, AFLIBERCEPT, 1 MG",19.670528713343057,,Present in Autoproposal
J9229,"Injection, inotuzumab ozogamicin, 0.1 mg",C9261,"INJECTION, USTEKINUMAB, 1 MG",19.670528713343057,,Present in Autoproposal
J9311,"Injection, rituximab 10 mg and hyaluronidase",C9467,"Injection, rituximab and hyaluronidase, 10 mg",100.00000000000003,1,Present Both in MD and Autoproposal
J9311,"Injection, rituximab 10 mg and hyaluronidase",J9310,"INJECTION, RITUXIMAB, 100 MG",64.68242785920626,,Present in Autoproposal
J9311,"Injection, rituximab 10 mg and hyaluronidase",J3470,"INJECTION, HYALURONIDASE, UP TO 150 UNITS",39.975514107092614,,Present in Autoproposal
J9311,"Injection, rituximab 10 mg and hyaluronidase",J3473,"INJECTION, HYALURONIDASE, RECOMBINANT, 1 USP UNIT",37.68018909089773,,Present in Autoproposal
J9311,"Injection, rituximab 10 mg and hyaluronidase",J1575,"INJECTION, IMMUNE GLOBULIN/HYALURONIDASE, (HYQVIA), 100 MG IMMUNEGLOBULIN",34.26752514576792,,Present in Autoproposal
J9311,"Injection, rituximab 10 mg and hyaluronidase",J9355,"INJECTION, TRASTUZUMAB, 10 MG",31.80955936571104,,Present in Autoproposal
J9311,"Injection, rituximab 10 mg and hyaluronidase",J0475,"INJECTION, BACLOFEN, 10 MG",31.80955936571104,,Present in Autoproposal
J9311,"Injection, rituximab 10 mg and hyaluronidase",J9035,"INJECTION, BEVACIZUMAB, 10 MG",31.501400716541372,,Present in Autoproposal
J9311,"Injection, rituximab 10 mg and hyaluronidase",J9181,"INJECTION, ETOPOSIDE, 10 MG",31.501400716541372,,Present in Autoproposal
J9311,"Injection, rituximab 10 mg and hyaluronidase",J9010,"INJECTION, ALEMTUZUMAB, 10 MG",31.501400716541372,,Present in Autoproposal
Q9993,"Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg",Q9993,"Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg",100.00000000000003,2,Present in Autoproposal
Q9993,"Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg",C9469,"Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg",100.00000000000003,,Present Both in MD and Autoproposal
Q9993,"Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg",J3300,"INJECTION, TRIAMCINOLONE ACETONIDE, PRESERVATIVE FREE, 1 MG",72.41697421375433,,Present in Autoproposal
Q9993,"Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg",J3301,"INJECTION, TRIAMCINOLONE ACETONIDE, NOT OTHERWISE SPECIFIED, 10 MG",46.85565077991303,,Present in Autoproposal
Q9993,"Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg",C9486,"INJECTION, GRANISETRON EXTENDED RELEASE, 0.1 MG",38.715065185756224,,Present in Autoproposal
Q9993,"Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg",J1627,"INJECTION, GRANISETRON, EXTENDED-RELEASE, 0.1 MG",38.715065185756224,,Present in Autoproposal
Q9993,"Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg",J0401,"INJECTION, ARIPIPRAZOLE, EXTENDED RELEASE, 1 MG",38.166434480125645,,Present in Autoproposal
Q9993,"Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg",J2426,"INJECTION, PALIPERIDONE PALMITATE EXTENDED RELEASE, 1 MG",31.223366980555312,,Present in Autoproposal
Q9993,"Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg",J3303,"INJECTION, TRIAMCINOLONE HEXACETONIDE, PER 5 MG",30.703845172457545,,Present in Autoproposal
Q9993,"Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg",J3302,"INJECTION, TRIAMCINOLONE DIACETATE, PER 5 MG",30.703845172457545,,Present in Autoproposal
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
,,,,,,
